,title,abstract,authors,link,ID,publication_date,update_date,subject,is_medRxiv
0,Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines,"Recently, the emerged and rapidly spreading SARS-CoV-2 variant of concern (VOC) 501Y.V2 with 10 amino acids in spike protein were found to escape host immunity induced by infection or vaccination. Global concerns have been raised for its potential to affect vaccine efficacy. Here, we evaluated the neutralization activities of two vaccines developed in China against 501Y.V2. One is licensed inactivated vaccine BBIBP-CorV and the other one is recombinant dimeric receptor-binding domain (RBD) vaccine ZF2001. Encouragingly, both vaccines largely preserved neutralizing titres, with slightly reduction, against 501Y.V2 authentic virus compare to their titres against both original SARS-CoV-2 and the currently circulating D614G virus. These data indicated that 501Y.V2 variant will not escape the immunity induced by vaccines targeting whole virus or RBD.",Baoying Huang; Lianpan Dai; Hui Wang; Zhongyu Hu; Wenjie Tan; George F. Gao; Xiaoming Yang,https://biorxiv.org/cgi/content/short/2021.02.01.429069,https://biorxiv.org/cgi/content/short/2021.02.01.429069,2021-02-02,2021-02-02,,False
1,Radius of Gyration as predictor of COVID-19 deaths trend with three-weeks offset,"Total and perimetral lockdowns were the strongest nonpharmaceutical interventions to fight against Covid-19, as well as the with the strongest socioeconomic collateral effects. Lacking a metric to predict the effect of lockdowns in the spreading of COVID-19 with, authorities and decision-makers opted for preventive measures that showed either too strong or not strong enough after a period of two to three weeks, once data about hospitalizations and deaths was available. We present here the radius of gyration as a candidate predictor of the trend in deaths by COVID-19 with an offset of three weeks. Indeed, the radius of gyration aggregates the most relevant microscopic aspects of human mobility into a macroscopic value, very sensitive to temporary trends and local effects, such as lockdowns and mobility restrictions. We use mobile phone data of more than 13 million users in Spain during a period of one year (from January 6th 2020 to January 10th 2021) to compute the users' daily radius of gyration and compare the median value of the population with the evolution of COVID-19 deaths: we find that for all weeks where the radius of gyration is above a critical value (70% of its pre-pandemic score) the number of weekly deaths increases three weeks after. The reverse also stands: for all weeks where the radius of gyration is below the critical value, the number of weekly deaths decreased after three weeks. This observation leads to two conclusions: i) the radius of gyration can be used as a predictor of COVID-19-related deaths; and ii) partial mobility restrictions are as effective as a total lockdown as far the radius of gyration is below this critical value.",Alberto Hernando de Castro; David Mateo; Jordi Bayer; Ignacio Barrios,https://medrxiv.org/cgi/content/short/2021.01.30.21250708,https://medrxiv.org/cgi/content/short/2021.01.30.21250708,2021-02-02,2021-02-02,,True
2,COVID-19 vaccine acceptability and inequity in the United States: Results from a nationally representative survey,"Background At the time of this survey, September 1st, there were roughly 6 million COVID-19 cases and 176,771 deaths in the United States and no federally approved vaccine. The objective of this study was to explore the willingness to accept a COVID-19 vaccine in the United States and describe variability in this acceptability by key racial, ethnic and socio-demographic characteristics. Methods This was a cross-sectional digital survey that sampled participants from a nationally-representative panel maintained by a third party, Dynata. Dynata randomly sampled their database and emailed web-based surveys to United States residents ensuring the sample was matched to US Census estimates for age, race, gender, income, and Census region. Participants were asked how willing or unwilling they would be to: 1) receive a COVID-19 vaccine as soon as it was made publicly available, and 2) receive the influenza vaccine for the upcoming influenza season. Participants could respond with extremely willing, willing, unwilling, or extremely unwilling. For those who reported being unwilling to receive a COVID-19 vaccine, reasons for this hesitancy were captured. All participants were asked about where they obtain vaccine-related information, and which sources they trust most. Univariable and multivariable logistic regressions were conducted to examine the association of all demographic characteristics with willingness to receive COVID-19 vaccine. Findings From September 1st to September 7, 2020, 1592 respondents completed the online survey. Overall, weighted analyses found that only 58.9% of the sample population were either willing or extremely willing to receive a COVID-19 vaccine as soon as it was made publicly available. In comparison, 67.7% of the respondents were willing or extremely willing to take the influenza vaccine. By gender, 66.1% of males and 51.5% of females were willing to receive a COVID-19 vaccine. Males were significantly more willing to receive a COVID-19 vaccine (adjusted odds ratio (OR)=1.98, 95% CI: 1.56, 2.53; p<0.001) than females. Blacks were the least willing racial/ethnic group (48.8%) Blacks, (aOR=0.59, 95%CI: 0.43, 0.80; p<0.001) were significantly less willing, than whites, to receive a COVID-19 vaccine. There were numerous reasons provided for being unwilling to receive a COVID-19 vaccine. The most common reason was concern about the vaccine's safety (36.9%), followed by concerns over its efficacy (19.1%). Interpretation In conclusion, we found that a substantial proportion (41%) of United States residents are unwilling to receive a COVID-19 vaccine as soon as one is made publicly available. We found that vaccine acceptance differs by sub-populations. In addition to sub-group differences in willingness to receive the vaccine, respondents provided a variety of reasons for being unwilling to receive the vaccine, driven by various sources of vaccine information (and misinformation). This compounds the challenge of delivering a safe and efficacious COVID-19 vaccine at a population level to achieve herd immunity. A multi-pronged and targeted communications and outreach effort is likely needed to achieve a high level of immunization coverage.",Dustin G Gibson; Smisha Agarwal; Ankita Meghani; Rupali Limaye; Alain Bernard Labrique,https://medrxiv.org/cgi/content/short/2021.01.29.21250784,https://medrxiv.org/cgi/content/short/2021.01.29.21250784,2021-02-02,2021-02-02,,True
3,Sustainable targeted interventions to mitigate the COVID-19 pandemic: A big data-driven modeling study in Hong Kong,"Background: The nonpharmaceutical interventions (NPIs) for contact suppression have been widely used worldwide, which impose harmful burdens on the population and the local economy. The evaluation of alternative NPIs is needed to confront the pandemic with less disruption. By harnessing human mobility data, we develop an agent-based model that can evaluate the efficacies of NPIs with individualized mobility simulations. Based on the model, we propose the data-driven targeted interventions to mitigate the COVID-19 pandemic in Hong Kong without city-wide NPIs. Methods: We develop a data-driven agent-based model for 7.55 million Hong Kong residents to evaluate the efficacies of various NPIs in the first 80 days of the initial outbreak. The entire territory of Hong Kong has split into 4,905 500mx500m grids. The model can simulate detailed agent interactions based on the demographics data, public facilities and functional buildings, transportation systems, and travel patterns. The general daily human mobility patterns are adopted from Google Community Mobility Report. The scenario without any NPIs is set as the baseline. By simulating the epidemic progression and human movement at the individual level, we proposed model-driven targeted interventions, which focus on the surgical testing and quarantine of only a small portion of regions instead of enforcing NPIs in the whole city. The efficacious of common NPIs and the proposed targeted interventions are evaluated by extensive Monte Carlo simulations. Findings: Without NPIs, we estimate that there are 128,711 total infections (IQR 23,511-70,310) by the end of the 80-day simulation. The proposed targeted intervention averts 95.85% and 94.13% of baseline infections with only 100 (2.04%) and 50 (1.02%) grids being quarantined, respectively. Mild social distancing without testing results in 16,503 total cases (87.18% infections averted), rapid implementation of full lockdown and testing measures (such as the control measure in Mainland China) performs the best, with only 805 infections (99.37% infections averted). Testing-and-quarantining 10%, 20%, 50% of all symptomatic cases with 24-hour/48-hour avert 89.92%/ 87.78%, 95.47%/ 92.42%, and 97.93%/ 95.61% infections, respectively. Interpretation: Big data-driven mobility modeling can inform targeted interventions, which are able to effectively contain the COVID-19 outbreak with much lower disruption of the city. It represents a promising approach to sustainable NPIs to help us revive the economy of the city and the world.",Hanchu ZHOU; Qingpeng Zhang; Zhidong Cao; Helai Huang; Dajun Zeng,https://medrxiv.org/cgi/content/short/2021.01.29.21250786,https://medrxiv.org/cgi/content/short/2021.01.29.21250786,2021-02-02,2021-02-02,,True
4,A Logistic Formula in Biology and Its Application to Deaths by the Third Wave of COVID-19 in Japan,A logistic formula in biology is applied to analyze the third wave of COVID-19 in Japan.,Takesi Saito,https://medrxiv.org/cgi/content/short/2021.01.30.21250827,https://medrxiv.org/cgi/content/short/2021.01.30.21250827,2021-02-02,2021-02-02,,True
5,Emergence of universality in the transmission dynamics of COVID-19,"The complexities involved in modeling the transmission dynamics of COVID-19 has been a major roadblock in achieving predictability in the spread and containment of the disease. In addition to understanding the modes of transmission, the effectiveness of the mitigation methods also needs to be built into any effective model for making such predictions. We show that such complexities can be circumvented by appealing to scaling principles which lead to the emergence of universality in the transmission dynamics of the disease. The ensuing data collapse renders the transmission dynamics largely independent of geopolitical variations, the effectiveness of various mitigation strategies, population demographics, etc. We propose a simple two-parameter model---the Blue Sky model---and show that one class of transmission dynamics can be explained by a solution that lives at the edge of a blue sky bifurcation. In addition, the data collapse leads to an enhanced degree of predictability in the disease spread for several geographical scales which can also be realized in a model-independent manner as we show using a deep neural network. The methodology adopted in this work can potentially be applied to the transmission of other infectious diseases and new universality classes may be found. The predictability in transmission dynamics and the simplicity of our methodology can help in building policies for exit strategies and mitigation methods during a pandemic.",Ayan Paul; Jayanta Kumar Bhattacharjee; Aksay Pal; Sagar Chakraborty,https://medrxiv.org/cgi/content/short/2021.01.29.21250750,https://medrxiv.org/cgi/content/short/2021.01.29.21250750,2021-02-01,2021-02-01,,True
6,Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells,"Background: The SARS-CoV-2 virus that was first identified in Wuhan, China has caused the death of over 2 million people worldwide during the COVID-19 pandemic. Whilst effective vaccines have been developed and vaccination schedules are being rolled out, the identification of safe and inexpensive drugs to slow the replication of SARS-CoV-2 could help thousands of people worldwide whilst awaiting vaccination. Methods: Using SARS-CoV-2 tagged with nano-luciferase (SARS-CoV-2-{Delta}Orf7a-NLuc) we screened a variety of cells under optimised cell culture conditions for their ability to be infected by, and support the replication of, SARS-CoV-2. Electron microscopy was used to demonstrate generation of infectious virus particles. We assessed a library of 1971 FDA-approved drugs for their ability to inhibit or enhance viral replication in Vero (simian kidney cells) but also in the human hepatocyte cell, HUH7. Initial hits were further tested to identify compounds that could suppress viral replication, post-viral infection. Dose response curves were obtained for a shortlist of 9 compounds of interest (COI). Findings: Our SARS-CoV-2-{Delta}Orf7a-NLuc virus was as effective as wild-type SARS-CoV-2 in inducing CPE and replicating in Vero cells. Conventional electron microscopy showed the NLuc-tagged virus to be structurally indistinguishable from the wild-type virus, and both could be identified within the endosomal system of infected cells. SARS-CoV-2-{Delta}Orf7a-NLuc was used in experiments to robustly quantitate virus infection and replication. A wide variety of human cells including lung fibroblasts and epithelial cells were susceptible to infection but were not effective in supporting SARS-CoV-2-{Delta}Orf7a-NLuc replication. In contrast, human kidney epithelial cells and human hepatic cells were particularly susceptible and supported SARS-CoV-2-replication, which is in-line with reported proteinuria and liver damage in patients with COVID-19. Our screening of FDA approved compounds identified 35 COI that inhibited virus infection and replication in either Vero or human cell lines. Nine of these also inhibited SARS-CoV-2 replication when treatment commenced after virus infection. Therapeutics approved for treatment of cancer, malaria, hypertension and viral infection were identified with atovaquone, manidipine, vitamin D3 and ebastine being well tolerated with minimal side effects. Only two COI were consistently found to enhance SARS-CoV-2 replication, aliskiren and lithocholic acid. Interpretation: Re-purposing of safe, well-tolerated FDA-approved drugs that inhibit SARS-CoV-2 replication is an attractive strategy to reduce the risk of COVID-19 infection prior to receiving an effective vaccine. The COI identified here hold potential to contain COVID-19 whilst wide-scale vaccination proceeds. The identification of FDA-approved drugs that enhance SARS-CoV-2 replication in human cells suggests that entry routes into cells can be made more accessible to the virus by certain medications. The information provided in this research paper is for information only and is not meant to be a substitute for advice provided by a doctor or other qualified health care professional.",Adam Pickard; Ben C Calverley; Joan Chang; Richa Garva; Yinhui Lu; Karl E Kadler,https://biorxiv.org/cgi/content/short/2021.01.31.428851,https://biorxiv.org/cgi/content/short/2021.01.31.428851,2021-02-01,2021-02-01,,False
7,"Expression of human ACE2 N-terminal domain, part of the receptor for SARS-CoV-2, in fusion with maltose binding protein, E. coli ribonuclease I and human RNase A","The SARS-CoV-2 viral genome contains a positive-strand single-stranded RNA of ~30 kb. Human ACE2 protein is the receptor for SARS-CoV-2 virus attachment and initiation of infection. We propose to use ribonucleases (RNases) as antiviral agents to destroy the viral genome in vitro. In the virions the RNA is protected by viral capsid proteins, membrane proteins and nucleocapsid proteins. To overcome this protection we set out to construct RNase fusion with human ACE2 receptor N-terminal domain (ACE2NTD). We constructed six proteins expressed in E. coli cells: 1) MBP-ACE2NTD, 2) ACE2NTD-GFP, 3) RNase I (6xHis), 4) RNase III (6xHis), 5) RNase I-ACE2NTD (6xHis), and 6) human RNase A-ACE2NTD150 (6xHis). We evaluated fusion expression in different E. coli strains, partially purified MBP-ACE2NTD protein from the soluble fraction of bacterial cell lysate, and refolded MBP-ACE2NTD protein from inclusion body. The engineered RNase I-ACE2NTD (6xHis) and hRNase A-ACE2NTD (6xHis) fusions are active in cleaving COVID-19 RNA in vitro. The recombinant RNase I (6xHis) and RNase III (6xHis) are active in cleaving RNA and dsRNA in test tube. This study provides a proof-of-concept for construction of fusion protein between human cell receptor and nuclease that may be used to degrade viral nucleic acids in our environment.",Shuang-yong Xu; Alexey Fomenkov; Tien-Hao Chen; Erbay Yigit,https://biorxiv.org/cgi/content/short/2021.01.31.429007,https://biorxiv.org/cgi/content/short/2021.01.31.429007,2021-02-01,2021-02-01,,False
8,Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16,"Capping viral messenger RNAs is essential for efficient translation and prevents their detection by host innate immune responses. For SARS-CoV-2, RNA capping includes 2'-O-methylation of the first ribonucleotide by methyltransferase nsp16 in complex with activator nsp10. The reaction requires substrates, a short RNA and SAM, and is catalyzed by divalent cations, with preference for Mn2+. Crystal structures of nsp16-nsp10 with capped RNAs revealed a critical role of metal ions in stabilizing interactions between ribonucleotides and nsp16, resulting in precise alignment of the substrates for methyl transfer. An aspartate residue that is highly conserved among coronaviruses alters the backbone conformation of the capped RNA in the binding groove. This aspartate is absent in mammalian methyltransferases and is a promising site for designing coronavirus-specific inhibitors.",George Minasov; Monica Rosas-Lemus; Ludmilla Shuvalova; Nicole L. Inniss; Joseph S. Brunzelle; Courtney M. Daczkowski; Paul Hoover; Andrew D Mesecar; Karla J Satchell,https://biorxiv.org/cgi/content/short/2021.01.31.429023,https://biorxiv.org/cgi/content/short/2021.01.31.429023,2021-02-01,2021-02-01,,False
9,Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro,"Development of effective antiviral drugs targeting the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) are urgently needed to combat the coronavirus disease 2019 (COVID-19). Oxysterols, defined as oxidized derivatives of cholesterol, include endogenous (naturally occurring) cholesterol metabolites as well as semi-synthetic oxysterol derivatives. We have previously studied the use of semi-synthetic oxysterol derivatives as drug candidates for inhibition of cancer, fibrosis, and bone regeneration. In this study, we have screened a panel of naturally occurring and semi-synthetic oxysterol derivatives for anti-SARS-CoV-2 activity, using a cell culture infection assay. We show that the natural oxysterols, 7-ketocholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 27-hydroxycholesterol, substantially inhibited SARS-CoV-2 propagation in cultured cells. Among semi-synthetic oxysterols, Oxy186 displayed antiviral activity comparable to natural oxysterols. In addition, related oxysterol analogues Oxy210 and Oxy232 displayed more robust anti-SARS-CoV-2 activities, reducing viral replication more than 90% at 10 microM and 99% at 15 microM, respectively. When orally administered in mice, peak plasma concentrations of Oxy210 fall into a therapeutically relevant range (19 microM), based on the dose-dependent curve for antiviral activity in our cell culture infection assay. Mechanistic studies suggest that Oxy210 reduced replication of SARS-CoV-2 with disrupting the formation of double membrane vesicles (DMVs), intracellular membrane compartments associated with viral replication. Oxy210 also inhibited the replication of hepatitis C virus, another RNA virus whose replication is associated with DMVs, but not the replication of the DMV-independent hepatitis D virus. Our study warrants further evaluation of Oxy210 and Oxy232 as a safe and reliable oral medication, which could help protect vulnerable populations with increased risk developing COVID-19.",Not available,https://biorxiv.org/cgi/content/short/2021.01.31.429001,https://biorxiv.org/cgi/content/short/2021.01.31.429001,2021-02-01,2021-02-01,,False
10,Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.,"Co-circulation of SARS-CoV-2 and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in co-infected patients. The lack of a readily available COVID-19 vaccine has reinforced the importance of influenza vaccine programmes during the COVID-19 pandemic. Live Attenuated Influenza Vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration might influence the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV (QLAIV) was administered to ferrets 3 days pre- or post-SARS-CoV-2 infection. LAIV administration did not exacerbate SARS-CoV-2 disease course or lung pathology with either regimen. Additionally, LAIV administered prior to SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract (URT). We conclude that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding.",Kathryn A Ryan; Katarzyna E Schewe; Jonathan Crowe; Susan A Fotheringham; Yper Hall; Richard Humphreys; Anthony C Marriott; Jemma Paterson; Emma Rayner; Francisco J Salguero; Robert J Watson; Catherine J Whittaker; Miles W Carroll; Oliver Dibben,https://biorxiv.org/cgi/content/short/2021.02.01.429110,https://biorxiv.org/cgi/content/short/2021.02.01.429110,2021-02-01,2021-02-01,,False
11,Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite a lack of an antiviral effect,"In response to the ongoing COVID-19 pandemic, repurposing of drugs for the treatment of SARS-CoV-2 infections is being explored. The FDA-approved HIV protease inhibitor Nelfinavir is one of the drugs that has been reported to inhibit in vitro SARS-CoV2 replication. We here report on the effect of Nelfinavir in the Syrian hamster SARS-CoV-2 infection model. Although treatment of infected hamsters with either 15 mg/kg BID or 50 mg/kg BID Nelfinavir [for four consecutive days, initiated on the day of infection] did not reduce viral RNA loads nor infectious virus titres in the lungs (as compared to the vehicle control at the end of treatment) the drug markedly improved virus-induced lung pathology at doses that were well tolerated. Yet, a massive interstitial infiltration of neutrophils was observed in the lungs of treated (infected and uninfected) animals. The protective effect of Nelfinavir on SARS-CoV-2-induced lung pathology that is unrelated to an antiviral effect warrants further exploration in the context of the treatment of COVID-19.",Caroline S. Foo; Rana Abdelnabi; Suzanne J.F. Kaptein; Xin Zhang; Sebastiaan ter Horst; Raf Mols; Leen Delang; Joana Rocha-Pereira; Lotte Coelmont; Pieter Leyssen; Kai Dallmeier; Valentijn Vergote; Elisabeth Heylen; Laura Vangeel; Arnab K. Chatterjee; Pieter Annaert; Patrick Augustijns; Steven De Jonghe; Dirk Jochmans; Birgit Weynand; Johan Neyts,https://biorxiv.org/cgi/content/short/2021.02.01.429108,https://biorxiv.org/cgi/content/short/2021.02.01.429108,2021-02-01,2021-02-01,,False
12,Environmentally-induced mdig is a major contributor to the severity of COVID-19 through fostering expression of SARS-CoV-2 receptor NRPs and glycan metabolism,"The novel {beta}-coronavirus, SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), has infected more than 101 million people and resulted in 2.2 million death worldwide. Recent epidemiological studies suggested that some environmental factors, such as air pollution, might be the important contributors to the mortality of COVID-19. However, how environmental exposure enhances the severity of COVID-19 remains to be fully understood. In the present report, we provide evidence showing that mdig, a previously reported environmentally-induced oncogene that antagonizes repressive trimethylation of histone proteins, is a master regulator for SARS-CoV-2 receptors neuropilin-1 (NRP1) and NRP2, cathepsins, glycan metabolism and inflammation, key determinants for viral infection and cytokine storm of the patients. Depletion of mdig in bronchial epithelial cells by CRISPR-Cas-9 gene editing resulted in a decreased expression of NRP1, NRP2, cathepsins, and genes involved in protein glycosylation and inflammation, largely due to a substantial enrichment of lysine 9 and/or lysine 27 trimethylation of histone H3 (H3K9me3/H3K27me3) on these genes as determined by ChIP-seq. These data, accordingly, suggest that mdig is a key mediator for the severity of COVID-19 in response to environmental exposure and targeting mdig may be one of the effective strategies in ameliorating the symptom and reducing the mortality of COVID-19.",Fei Chen,https://biorxiv.org/cgi/content/short/2021.01.31.429010,https://biorxiv.org/cgi/content/short/2021.01.31.429010,2021-02-01,2021-02-01,,False
13,Identification of a conserved neutralizing epitope present on spike proteins from highly pathogenic coronaviruses,"Three pathogenic human coronaviruses have emerged, with SARS-2 causing a global pandemic. While therapeutic antibodies targeting the SARS-2 spike currently focus on the poorly conserved receptor-binding domain, targeting essential neutralizing epitopes on the more conserved S2 domain may provide broader protection. We report three antibodies binding epitopes conserved on the pre-fusion MERS, SARS-1 and SARS-2 spike S2 domains. Antibody 3A3 binds a conformational epitope with ~2.5 nM affinity and neutralizes in in vitro SARS-2 cell fusion and pseudovirus assays. Hydrogen-Deuterium exchange mass spectrometry identified residues 980-1006 in the flexible hinge region at the S2 apex as the 3A3 epitope, consistent with binding to natural and engineered spike variants. This location at the spike trimer interface suggests 3A3 prevents the S2 conformational rearrangements required for virus-host cell fusion. This work defines a highly conserved vulnerable site on the SARS-2 S2 domain and may help guide design of pan-protective spike immunogens.",Yimin Huang; Annalee W Nguyen; Ching-Lin Hsieh; Rui Silva; Oladimeji S Olaluwoye; Rebecca Wilen; Tamer S Kaoud; Laura R Azouz; Ahlam N Qerqez; Kevin C Le; amanda L Bohanon; Andrea M DiVenere; Yutong Liu; Dzifa Amengor; Kevin Dalby; Jason S McLellan; Jennifer A Maynard,https://biorxiv.org/cgi/content/short/2021.01.31.428824,https://biorxiv.org/cgi/content/short/2021.01.31.428824,2021-02-01,2021-02-01,,False
14,Nanotraps for the containment and clearance of SARS-CoV-2,"SARS-CoV-2 enters host cells through its viral spike protein binding to angiotensin-converting enzyme 2 (ACE2) receptors on the host cells. Here we show functionalized nanoparticles, termed ""Nanotraps"", completely inhibited SARS-CoV-2 infection by blocking the interaction between the spike protein of SARS-CoV-2 and the ACE2 of host cells. The liposomal-based Nanotrap surfaces were functionalized with either recombinant ACE2 proteins or anti-SARS-CoV-2 neutralizing antibodies and phagocytosis-specific phosphatidylserines. The Nanotraps effectively captured SARS-CoV-2 and completely blocked SARS-CoV-2 infection to ACE2-expressing human cell lines and primary lung cells; the phosphatidylserine triggered subsequent phagocytosis of the virus-bound, biodegradable Nanotraps by macrophages, leading to the clearance of pseudotyped and authentic virus in vitro. Furthermore, the Nanotraps demonstrated excellent biosafety profile in vitro and in vivo. Finally, the Nanotraps inhibited pseudotyped SARS-CoV-2 infection in live human lungs in an ex vivo lung perfusion system. In summary, Nanotraps represent a new nanomedicine for the inhibition of SARS-CoV-2 infection.",Min Chen; Jillian Rosenberg; Xiaolei Cai; Andy Chao Hsuan Lee; Jiuyun Shi; Mindy Nguyen; Thirushan Wignakumar; Vikranth Mirle; Arianna Joy Edobor; John Fung; Jessica Scott Donington; Kumaran Shanmugarajah; Eugene  B. Chang; Glenn Randall; Pablo Penaloza-MacMaster; Bozhi Tian; Maria Lucia Madariaga; Jun Huang,https://biorxiv.org/cgi/content/short/2021.02.01.428871,https://biorxiv.org/cgi/content/short/2021.02.01.428871,2021-02-01,2021-02-01,,False
15,Enhanced immunogenicity of a synthetic DNA vaccine expressing consensus SARS-CoV-2 Spike protein using needle-free immunization,"The ongoing global pandemic of Coronavirus Disease 2019 (COVID-19) calls for an urgent development of effective and safe prophylactic and therapeutic measures. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein is a major immunogenic and protective protein, and plays a crucial role in viral pathogenesis. In this study, we successfully constructed a synthetic codon-optimized DNA-based vaccine as a countermeasure against SARS-CoV-2; denoted as VIU-1005. The design was based on the synthesis of codon-optimized coding sequence for optimal mammalian expression of a consensus full-length S glycoprotein. The successful construction of the vaccine was confirmed by restriction digestion and sequencing, and the protein expression of the S protein was confirmed by western blot and immunofluorescence staining in mammalian cells. The immunogenicity of the vaccine was tested in two mouse models (BALB/c and C57BL/6J). Th1-skewed systemic S-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in both models four weeks post three injections with 100 g of the VIU-1005 vaccine via intramuscular needle injection but not intradermal or subcutaneous routes. Importantly, such immunization induced long-lasting IgG response in mice that lasted for at least 6 months. Interestingly, using a needle-free system, we showed an enhanced immunogenicity of VIU-1005 in which lower doses such as 25-50 g or less number of doses were able to elicit significantly high levels of Th1-biased systemic S-specific IgG antibodies and nAbs via intramuscular immunization compared to needle immunization. Compared to the intradermal needle injection which failed to induce any significant immune response, intradermal needle-free immunization elicited robust Th1-biased humoral response similar to that observed with intramuscular immunization. Furthermore, immunization with VIU-1005 induced potent S-specific cellular response as demonstrated by the significantly high levels of IFN-{gamma}, TNF and IL-2 cytokines production in memory CD8+ and CD4+ T cells in BALB/c mice. Together, our results demonstrate that the synthetic VIU-1005 candidate DNA vaccine is highly immunogenic and capable of inducing long-lasting and Th1-skewed immune response in mice. Furthermore, we show that the use of needle-free system could enhance the immunogenicity and minimize doses needed to induce protective immunity in mice, supporting further preclinical and clinical testing of this candidate vaccine.",Saswan S Alamri; Khalid A Alluhaybi; Rowa Y Alhabbab; Abdullah Algaissi; Sarah Almahboub; Mohamed A Alfaleh; Turki S Abujamel; Wesam Abdulaal; M-Zaki ElAssouli; Rahaf Alharbi; Mazen Hassanain; Anwar M Hashem,https://biorxiv.org/cgi/content/short/2021.02.01.429219,https://biorxiv.org/cgi/content/short/2021.02.01.429219,2021-02-01,2021-02-01,,False
16,In vitro inactivation of SARS-CoV-2 with 0.5% povidone iodine nasal spray (Nasodine) at clinically relevant concentrations and timeframes using tissue culture and PCR based assays,"BACKGROUND: There has been considerable speculation regarding the potential of PVP-I nasal disinfection as an adjunct to other countermeasures during the ongoing SARS-CoV-2 pandemic. Nasodine is a commercial formulation of 0.5% PVP-I that has been evaluated for safety and efficacy in human trials as a treatment for the common cold, including a Phase III trial (ANZCTR: ACTRN12619000764134). This study presents the first report of the in vitro efficacy of this formulation against SARS-CoV-2. METHODS: We conducted in vitro experiments to determine if the PVP-I formulation inactivated SARS-CoV-2 using two independent assays and virus isolates, and incorporating both PCR-based detection and cell culture methods to assess residual virus after exposure to the formulation. RESULTS: Based on cell culture results, the PVP-I formulation was found to rapidly inactivate SARS-CoV-2 isolates in vitro in short timeframes (15 seconds to 15 minutes) consistent with the minimum and maximum potential residence time in the nose. The Nasodine formula was found to be more effective than 0.5% PVP-I in saline. Importantly, it was found that the formulation inactivated culturable virus but had no effect on PCR-detectable viral RNA. CONCLUSIONS: The PVP-I formulation eliminated the viability of SARS-CoV-2 virus with short exposure times consistent with nasal use. PCR alone may not be adequate for viral quantification in nasal PVP-I studies; future studies should incorporate cell culture to assess viral viability. Nasal disinfection with PVP-I may be a useful intervention for newly-diagnosed COVID-19 patients to reduce transmission risk and disease progression to the lower respiratory tract.",Simon P Tucker; Stephen Goodall; Peter Molloy; Justin Julander; Michelle Mendenhall; Peter Friedland,https://biorxiv.org/cgi/content/short/2021.01.31.426979,https://biorxiv.org/cgi/content/short/2021.01.31.426979,2021-02-01,2021-02-01,,False
17,Host PDZ-containing proteins targeted by SARS-Cov-2,"Small linear motif targeting protein interacting domains called PDZ have been identified at the C-terminus of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins E, 3a, and N. Using a high-throughput approach of affinity-profiling against the full human PDZome, we identified sixteen human PDZ binders of SARS-CoV-2 proteins E, 3A and N showing significant interactions with dissociation constants values ranging from 3 M to 82 M. Six of them (TJP1, PTPN13, HTRA1, PARD3, MLLT4, LNX2) are also recognized by SARS-CoV while three (NHERF1, MAST2, RADIL) are specific to SARS-CoV-2 E protein. Most of these SARS-CoV-2 protein partners are involved in cellular junctions/polarity and could be also linked to evasion mechanisms of the immune responses during viral infection. Seven of the PDZ-containing proteins among binders of the SARS-CoV-2 proteins E, 3a or N affect significantly viral replication under knock-down gene expression in infected cells. This PDZ profiling identifying human proteins potentially targeted by SARS-CoV-2 can help to understand the multifactorial severity of COVID19 and to conceive effective anti-coronaviral agents for therapeutic purposes.",Celia Caillet-Saguy; Fabien Durbesson; Veronica V. REZELJ; Gergo Gogl; Quang Dinh Tran; Jean-Claude Twizere; Marco Vignuzzi; Renaud Vincentelli; Nicolas Wolff,https://biorxiv.org/cgi/content/short/2021.02.01.429176,https://biorxiv.org/cgi/content/short/2021.02.01.429176,2021-02-01,2021-02-01,,False
18,Prediction Models for Severe Manifestations and Mortality due to COVID-19: A Rapid Systematic Review,"Background Throughout 2020, the coronavirus disease 2019 (COVID-19) has become a threat to public health on national and global level. There has been an immediate need for research to understand the clinical signs and symptoms of COVID-19 that can help predict deterioration including mechanical ventilation, organ support, and death. Studies thus far have addressed the epidemiology of the disease, common presentations, and susceptibility to acquisition and transmission of the virus; however, an accurate prognostic model for severe manifestations of COVID-19 is still needed because of the limited healthcare resources available. Objective This systematic review aims to evaluate published reports of prediction models for severe illnesses caused COVID-19. Methods Searches were developed by the primary author and a medical librarian using an iterative process of gathering and evaluating terms. Comprehensive strategies, including both index and keyword methods, were devised for PubMed and EMBASE. The data of confirmed COVID-19 patients from randomized control studies, cohort studies, and case-control studies published between January 2020 and July 2020 were retrieved. Studies were independently assessed for risk of bias and applicability using the Prediction Model Risk Of Bias Assessment Tool (PROBAST). We collected study type, setting, sample size, type of validation, and outcome including intubation, ventilation, any other type of organ support, or death. The combination of the prediction model, scoring system, performance of predictive models, and geographic locations were summarized. Results A primary review found 292 articles relevant based on title and abstract. After further review, 246 were excluded based on the defined inclusion and exclusion criteria. Forty-six articles were included in the qualitative analysis. Inter observer agreement on inclusion was 0.86 (95% confidence interval: 0.79 - 0.93). When the PROBAST tool was applied, 44 of the 46 articles were identified to have high or unclear risk of bias, or high or unclear concern for applicability. Two studied reported prediction models, 4C Mortality Score from hospital data and QCOVID from general public data from UK, and were rated as low risk of bias and low concerns for applicability. Conclusion Several prognostic models are reported in the literature, but many of them had concerning risks of biases and applicability. For most of the studies, caution is needed before use, as many of them will require external validation before dissemination. However, two articles were found to have low risk of bias and low applicability can be useful tools.",Jamie Miller; Masafumi Tada; Michihiko Goto; Nicholas M Mohr; Sangil Lee,https://medrxiv.org/cgi/content/short/2021.01.28.21250718,https://medrxiv.org/cgi/content/short/2021.01.28.21250718,2021-02-01,2021-02-01,,True
19,The mobility gap: estimating mobility levels required to control Canada's winter COVID-19 surge,"Background Non-pharmaceutical interventions remain a primary means of suppressing COVID-19 until vaccination coverage is sufficient to achieve herd immunity. We used anonymized smartphone mobility measures in seven Canadian provinces to quantify the mobility level needed to suppress COVID-19 (mobility threshold), and the difference relative to current mobility levels (mobility gap). Methods We conducted a longitudinal study of weekly COVID-19 incidence from March 15, 2020 to January 16, 2021, among provinces with 20 COVID-19 cases in at least 10 weeks. The outcome was weekly growth rate defined as the ratio of current cases compared to the previous week. We examined the effects of average time spent outside the home (non-residential mobility) in the prior three weeks using a lognormal regression model accounting for province, season, and mean temperature. We calculated the COVID-19 mobility threshold and gap. Results Across the 44-week study period, a total of 704,294 persons were infected with COVID-19. Non-residential mobility dropped rapidly in the spring and reached a median of 36% (IQR: 31,40) in April 2020. After adjustment, each 5% increase in non-residential mobility was associated with a 9% increase in the COVID-19 weekly growth rate (ratio=1.09, 95%CI: 1.07,1.12). The mobility gap increased through the fall months, which was associated with increasing case growth. Interpretation Mobility strongly and consistently predicts weekly case growth, and low levels of mobility are needed to control COVID-19 through winter 2021. Mobility measures from anonymized smartphone data can be used to guide the provincial and regional implementation and loosening of physical distancing measures.",Kevin Antoine Brown; Jean-Paul R Soucy; Sarah A Buchan; Shelby L Sturrock; Isha Berry; Nathan M Stall; Peter Juni; Amir Ghasemi; Nicholas Gibb; Derek R MacFadden; Nick Daneman,https://medrxiv.org/cgi/content/short/2021.01.28.21250622,https://medrxiv.org/cgi/content/short/2021.01.28.21250622,2021-02-01,2021-02-01,,True
20,Uncovering Survivorship Bias in Longitudinal Mental Health Surveys,"To our knowledge, survivorship bias in longitudinal mental health survey studies has not been systematically assessed. We therefore assessed potential survivorship bias among 4,039 respondents invited to complete multiple surveys in 2020 for The COVID-19 Outbreak Public Evaluation (COPE) Initiative. Demographic differences in follow-up survey participation included lower retention of younger adults. Adjusting for demographics, individuals who completed only one or two out of four surveys had higher prevalences of anxiety and depression symptoms in April 2020 (e.g., one-survey versus four-survey, anxiety symptoms, aPR=1.30, 95%CI=1.08-1.55, P=0.0045; depression symptoms, aPR=1.43, 95%CI=1.17-1.75, P=0.0005). Among respondents who completed April-2020 and May-2020 surveys, individuals who experienced incident anxiety or depression symptoms significantly higher odds of lower participation in subsequent follow-up surveys (aOR=1.68, 95%CI=1.49-2.48, aOR=1.56, 95%CI=1.15-2.12, respectively, both P<0.005). These findings indicate that longitudinal mental health survey studies may be subject to survivorship bias, which could lead to overly optimistic interpretations of mental health trends.",Mark Ã‰. Czeisler; Joshua F. Wiley; Charles A. Czeisler; Shantha M.W. Rajaratnam; Mark E. Howard,https://medrxiv.org/cgi/content/short/2021.01.28.21250694,https://medrxiv.org/cgi/content/short/2021.01.28.21250694,2021-02-01,2021-02-01,,True
21,Hot days and Covid19 - unusual heat stress for nursing professions in Germany,"Objectives Our aim was to identify whether working during hot days alongside with Covid-19 related personal protective equipment causes heat stress for nursing professionals in Germany. Methods Using an online survey, we assessed the impact of hot weather on nursing staff performing in personal protective equipment. A random selection of nursing staff from hospitals, nursing homes and outpatient care participated in the survey. Results Out of 428 participants, 6.3% were between 16 and 25 years old, 22.8% between 26 and 35 years, 21.9% between 36 and 45 years, 30.5% between 45 and 55 years, 18.2% between 56 and 65 years, and 0.3% were older than 65 years. Out of all participants, 18.2% were male and 82.5% female. The results of the survey showed that 48.3% had more than 20 years of experience in nursing and 46.2% cardiac, pulmonary, or other pre-existing conditions. Work was found exhaustive while working in PPE by 96.5% of the participants, and 93% complained of worse breathing. We found out that 85.8% reported difficulties to focus. Many workplaces turned out to lack adequate heat protection, with distinct differences concerning the amount of prophylactic and heat mitigating measures across institutions. Conclusions Our results clearly show that employers must make more of an effort to provide adequate heat protection for their nursing staff. In order to secure the public health care, there is a need for action, especially in the case of previous conditions of caregivers.",Yvette Jegodka; Lena Lagally; Hanna Mertes; Katharina Deering; Julia Schoierer; Barbara Buchberger; Stephan Bose-O'Reilly,https://medrxiv.org/cgi/content/short/2021.01.29.21250592,https://medrxiv.org/cgi/content/short/2021.01.29.21250592,2021-02-01,2021-02-01,,True
22,"Discrimination of SARS-Cov 2 and arboviruses (DENV, ZIKV and CHIKV) clinical features using machine learning techniques: a fast and inexpensive clinical screening for countries simultaneously affected by both diseases","SARS-Cov-2 (Covid-19) has spread rapidly throughout the world, and especially in tropical countries already affected by outbreaks of arboviruses, such as Dengue, Zika and Chikungunya, and may lead these locations to a collapse of health systems. Thus, the present work aims to develop a methodology using a machine learning algorithm (Support Vector Machine) for the prediction and discrimination of patients affected by Covid-19 and arboviruses (DENV, ZIKV and CHIKV). Clinical data from 204 patients with both Covid-19 and arboviruses obtained from 23 scientific articles and 1 dataset were used. The developed model was able to predict 93.1% of Covid-19 cases and 82.1% of arbovirus cases, with an accuracy of 89.1% and Area under Roc Curve of 95.6%, proving to be effective in prediction and possible screening of these patients, especially those affected by Covid-19, allowing early isolation",Joao Daniel Santos Castro,https://medrxiv.org/cgi/content/short/2021.01.28.21250714,https://medrxiv.org/cgi/content/short/2021.01.28.21250714,2021-02-01,2021-02-01,,True
23,Socioeconomic Disparities and COVID-19 Vaccination Acceptance: Experience from Israel,"COVID-19 vaccination acceptance has a key role in mitigating the pandemic. Concern has been raised that vaccination rates will be limited in demographically defined areas of lower income. Israel rapid vaccination campaign may allow to assess these assumptions in real-world and to devise tools for effectively focusing the vaccination efforts. We analyzed the correlation between COVID-19 vaccination rates, socioeconomic status (SES) and active COVID-19 disease burden. We carried out a nationwide study, based on data provided by Ministry of Health of COVID-19 vaccination rates in all municipalities in Israel up to January 12th, 2021. Municipal Vaccination rates of population older than 60 significantly correlated with the socioeconomic status (r=0.83, 95% confidence interval [0.79 to 0.87]). Finally, we established a novel metric for focusing the vaccination efforts based on % vaccinations and active disease burden. In Israel, a case-model country for COVD-19 vaccinations, vaccination rates were strongly correlated with SES. The study findings demonstrate the need to directly target vaccination acceptance to socio-economically disadvantaged populations and suggest potential tools for policymakers to focus their efforts.",Gil Caspi; Avshalom Dayan; Yael Eshal; Sigal L Taub; Gilad Twig; Uri Shalit; Yair Lewis; Avi Shina; Oren Caspi,https://medrxiv.org/cgi/content/short/2021.01.28.21250716,https://medrxiv.org/cgi/content/short/2021.01.28.21250716,2021-02-01,2021-02-01,,True
24,Standardization of a flow cytometry SARS-CoV-2 serologic test,"The SARS-CoV-2 virus is the causing agent of the coronavirus disease 2019 (COVID-19) pandemic which is responsible for millions of deaths worldwide. The development of the humoral response to the virus has been the subject of intensive research and development. A flow cytometry-based assay using native full-length SARS-CoV-2 Spike protein expressed in 293T cells was recently proposed as a complementary seropositivity determination assay. The aim of our study was to further develop the flow cytometry assay for potential use as a confirmatory test and to standardize its parameters and results for reliable inter-laboratory use. We have optimized the protocol, established the Receiving Operating Characteristic (ROC) curve and tested reproducibility using pre-COVID plasma samples and convalescent, SARS-CoV-2 individual plasma samples. The flow-based assay was simplified and standardized by cultivating the 293T cells in suspension and expressing results in Mean Equivalent Soluble Fluorochrome (MESF) using an internal antibody positive control. The ROC curve was determined with an area under the curve (AUC) of 0.996 and the assay specificity and sensitivity were established at 100% and 97.7% respectively. Reproducibility was good as determined on multiple cytometers, on different days, and with data acquisition as far as 72h post-staining. The optimized and standardized assay could be used as a high throughput confirmation confirmatory assay in flow cytometry laboratories involved in serological testing.",Carl Simard; Jonathan Richard; Renee Bazin; Andres Finzi; Patrick Trepanier,https://medrxiv.org/cgi/content/short/2021.01.29.21250770,https://medrxiv.org/cgi/content/short/2021.01.29.21250770,2021-02-01,2021-02-01,,True
25,Vaccination strategies for minimizing loss of life in Covid-19 in a Europe lacking vaccines,"Background: We aimed at identifying vaccination strategies that minimize loss of life in the Covid-19 pandemic. Covid-19 mainly kills the elderly, but the pandemic is driven by social contacts that are more frequent in the young. Vaccines elicit stronger immune responses per dose in younger persons. As vaccine production is a bottleneck, many countries have adopted a strategy of first vaccinating the elderly and vulnerable, while postponing vaccination of the young. Methods: Based on published age-stratified immunogenicity data of the Moderna mRNA-1273 vaccine, we compared the established 'one dose fits all' approach with tailored strategies: The known differential immunogenicity of vaccine doses in different age groups is exploited to vaccinate the elderly at full dose, while the young receive a reduced dose, amplifying the number of individuals receiving the vaccine early. A modeling approach at European Union scale with population structure, Covid-19 case and death rates similar to Europe in late January 2021 is used. Results: When the elderly were vaccinated preferentially, the pandemic initially continued essentially unchecked, as it was dominantly driven by social contacts in other age groups. Tailored strategies, including regular dosing in the elderly but reduced dose vaccination in the young, multiplied early vaccination counts, and even with some loss in protection degree for the individual person, the protective effect towards stopping the pandemic and protecting lives was enhanced, even for the elderly. Conclusion: Protecting the vulnerable, minimizing overall deaths and stopping the pandemic is best achieved by an adaptive vaccination strategy using an age-tailored vaccine dose.",Patrick Hunziker,https://medrxiv.org/cgi/content/short/2021.01.29.21250747,https://medrxiv.org/cgi/content/short/2021.01.29.21250747,2021-02-01,2021-02-01,,True
26,Early Multidrug Outpatient Treatment of SARS-CoV-2 Infection (COVID-19) and Reduced Mortality Among Nursing Home Residents,"The outbreak of COVID-19 from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread all over the world with tremendous morbidity and mortality in the elderly. In-hospital treatment addresses the multifaceted nature of the illness including viral replication, cytokine storm, and endothelial injury with thrombosis. We identified nine reports of early treatment outcomes in COVID-19 nursing home patients. Multi-drug therapy including hydroxychloroquine with one or more anti-infectives, corticosteroids, and antithrombotic agents can be extended to seniors in the nursing home setting without hospitalization. Data from nine studies found multidrug regimens relying on the use of hydroxychloroquine as well as other agents including doxycycline were associated with a statistically significant and >60% reductions in mortality. Going forward, we theorize and based on the evidence, that early empiric treatment for the elderly with COVID-19 in the nursing home setting (or similar congregated settings with elderly residents/patients) has a genuine probability of success and acceptable safety. This group remains our highest at-risk group and warrants acute treatment focus that will prevent the development and/or worsening of problems associated with COVID-19, most particularly isolation, hospitalization, and death. In fact, with the rapidity and severity of SARS-CoV-2 outbreaks in nursing homes, in-center treatment of patients with acute COVID-19 is possibly the most rational and importantly feasible strategy to reduce the risks of hospitalization and death. If the approach remains wait-and-see and elderly high-risk patients in such congregated nursing room type settings are allowed to worsen with no early treatment, they may be too sick and fragile to benefit from in-hospital therapeutics and are at risk for pulmonary failure, life-ending micro-thrombi of the lungs, kidneys etc. We put forth the notion that the most important factor in this regard, is making available early therapeutic intervention as described here. These drugs include and under supervision by skilled doctors, combination/sequenced ivermectin, hydroxychloroquine, colchicine, azithromycin, doxycycline, bromhexine hydrochloride, and favipiravir (outside the US), along with inhaled steroids such as budesonide and oral steroids including dexamethasone and prednisone, and anti-thrombotic anti-clotting drugs such as heparin). As the clinical trials data on treatments for COVID-19 mature, this early treatment therapeutic option deserves serious, urgent, and sober consideration by the medical establishment and respective decision-makers.",Paul E Alexander; Robin Armstrong; George Fareed; Kulvinder Gill; John Lotus; Ramin Oskoui; Chad Podromomos; Harvey Risch; Howard Tenenbaum; Craig M Wax; Peter A McCullough,https://medrxiv.org/cgi/content/short/2021.01.28.21250706,https://medrxiv.org/cgi/content/short/2021.01.28.21250706,2021-02-01,2021-02-01,,True
27,Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis,"Background Despite the direct viral activity, the pathogenesis of coronavirus disease 2019 (COVID-19) includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore tocilizumab (TCZ), a monoclonal antibody against IL-6 receptors, became considered as a possible therapeutic option. Methods Patients were selected from the SARSTer national database, which included 2332 individuals with COVID-19 and the current study included 825 adult patients with moderate to severe course. The retrospective analysis was performed in 170 patients treated with TCZ and 655 without this medication or any other anti-cytokine therapy. The end-points of treatment effectiveness were a rate of death, need for mechanical ventilation, and clinical improvement. Results Patients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions. The reduced death rate was demonstrated in patients treated with TCZ and baseline IL-6 >100 pg/ml (hazard ratio [HR]: 0.27, 95% confidence interval [CI]:0.10-0.78), or those needing oxygen supplementations who worsened within 7 days of hospitalization (HR: 0.38, 95% CI:0.16-0.88). The best effectiveness of TCZ was achieved in patients with a combination of baseline IL-6>100 pg/ml and either SpO2[&le;]90% (HR for death, mechanical ventilation, and clinical improvement after 21 or 28 days: 0.07, 0.14, 5.53, 5.18 respectively) or requiring oxygen supplementation (HR for death and clinical improvement after 21 or 28 days, 0.18, 2.66, 2.85 respectively). Conclusions Tocilizumab administered for COVID-19 in patients with a baseline concentration of IL-6>100 pg/ml is associated with reduced mortality and faster clinical improvement, particularly if there is a need for oxygen supplementation due to SpO2[&le;]90%.",Robert Flisiak; Jerzy Jaroszewicz; Magdalena Rogalska; Tadeusz Lapinski; Aleksandra Berkan-Kawinska; Beata Bolewska; Magdalena Tudrujek-Zdunek; Dorota Kozielewicz; Marta Rorat; Piotr Leszczynski; Krzysztof Klos; Justyna Kowalska; Pawel Pabjan; Anna Piekarska; Iwona Mozer-Lisewska; Krzysztof Tomasiewicz; Malgorzata Pawlowska; Krzysztof Simon; Joanna Polanska; Dorota Zarebska-Michaluk,https://medrxiv.org/cgi/content/short/2021.01.28.21249932,https://medrxiv.org/cgi/content/short/2021.01.28.21249932,2021-02-01,2021-02-01,,True
28,Modeling the potential impact of indirect transmission on COVID-19 epidemic,"The spread of SARS-CoV-2 through direct transmission (person-to-person) has been the focus of most studies on the dynamics of COVID-19. The efficacy of social distancing and mask usage at reducing the risk of direct transmission of COVID-19 has been studied by many researchers. Little or no attention is given to indirect transmission of the virus through shared items, commonly touch surfaces and door handles. The impact of the persistence of SARS-CoV-2 on hard surfaces and in the environment, on the dynamics of COVID-19 remain largely unknown. Also, the current increase in the number of cases despite the strict non-pharmaceutical interventions suggests a need to study the indirect transmission of COVID-19 while incorporating testing of infected individuals as a preventive measure. Assessing the impact of indirect transmission of the virus may improve our understanding of the overall dynamics of COVID-19. We developed a novel deterministic susceptible-exposedinfected- removed-virus-death compartmental model to study the impact of indirect transmission pathway on the spread of COVID-19, the sources of infection, and prevention/control. We fitted the model to the cumulative number of confirmed cases at episode date in Toronto, Canada using a Markov Chain Monte Carlo optimization algorithm. We studied the effect of indirect transmission on the epidemic peak, peak time, epidemic final size and the effective reproduction number, based on different initial conditions and at different stages. Our findings revealed an increase in cases with indirect transmission. Our work highlights the importance of implementing additional preventive and control measures involving cleaning of surfaces, fumigation, and disinfection to lower the spread of COVID-19, especially in public areas like the grocery stores, malls and so on. We conclude that indirect transmission of SARS-CoV- 2 has a significant effect on the dynamics of COVID-19, and there is need to consider this transmission route for effective mitigation, prevention and control of COVID-19 epidemic.",Jummy Funke David; Sarafa Adewale Iyaniwura; Pei Yuan; Yi Tan; Jude Dzevela Kong; Huaiping Zhu,https://medrxiv.org/cgi/content/short/2021.01.28.20181040,https://medrxiv.org/cgi/content/short/2021.01.28.20181040,2021-02-01,2021-02-01,,True
29,Viral sequencing reveals US healthcare personnel rarely become infected with SARS-CoV-2 through patient contact,"Background Healthcare personnel (HCP) are at increased risk of infection with the severe acute respiratory coronavirus 2019 virus (SARS-CoV-2). Between 12 March 2020 and 10 January 2021, >1,170 HCP tested positive for SARS-CoV-2 at a major academic medical institution in the Upper Midwest of the United States. We aimed to understand the sources of infections in HCP and to evaluate the efficacy of infection control procedures used at this institution to protect HCP from healthcare-associated transmission. Methods In this retrospective case series, we used viral genomics to investigate the likely source of SARS-CoV-2 infection in 96 HCP where epidemiological data alone could not be used to rule out healthcare-associated transmission. We obtained limited epidemiological data through informal interviews and review of the electronic health record. We combined viral sequence data and available epidemiological information to infer the most likely source of HCP infection. Findings We investigated 32 SARS-CoV-2 infection clusters involving 96 HCP, 140 possible patient contacts, and 1 household contact (total n = 237). Of these, 182 sequences met quality standards and were used for downstream analysis. We found the majority of HCP infections could not be linked to a patient or co-worker and therefore likely occurred in the outside community (58/96; 60.4%). We found a smaller percentage could be traced to a coworker (10/96; 10.4%) or were part of a patient-employee cluster (12/96; 12.5%). Strikingly, the smallest proportion of HCP infections could be clearly traced to a patient source (4/96; 4.2%). Interpretation Infection control procedures, consistently followed, offer significant protection to HCP caring for COVID-19 patients in a representative American academic medical institution. Rapid SARS-CoV-2 genome sequencing in healthcare settings can be used retrospectively to reconstruct the likely source of HCP infection when epidemiological data are not available or are inconclusive. Understanding the source of SARS-CoV-2 infection can then be used prospectively to adjust and improve infection control practices and guidelines.",Katarina M Braun; Gage Kahl Moreno; Ashley Buys; Max Bobholz; Molly A Accola; Laura Anderson; William M Rehrauer; David A Baker; Nasia Safdar; Alexander J Lepak; David O'Connor; Thomas Friedrich,https://medrxiv.org/cgi/content/short/2021.01.28.21250421,https://medrxiv.org/cgi/content/short/2021.01.28.21250421,2021-02-01,2021-02-01,,True
30,Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers,"Oral fluid (hereafter saliva) offers a non-invasive sampling method for the detection of SARS-CoV-2 antibodies. However, data comparing performance of salivary tests against commercially-available serologic and neutralizing antibody (nAb) assays are lacking. This study compared the performance of a multiplex salivary SARS-CoV-2 IgG assay targeting antibodies to nucleocapsid (N), receptor binding domain (RBD) and spike (S) antigens to three commercially-available SARS-CoV-2 serology enzyme immunoassays (EIAs) (Ortho Vitros, Euroimmun, and BioRad) and nAb. Paired saliva and plasma samples were collected from 101 eligible COVID-19 convalescent plasma (CCP) donors >14 days since PCR+ confirmed diagnosis. Concordance was evaluated using positive (PPA) and negative (NPA) percent agreement, overall percent agreement (PA), and Cohen kappa coefficient. The range between salivary and plasma EIAs for SARS-CoV-2-specific N was PPA: 54.4-92.1% and NPA: 69.2-91.7%, for RBD was PPA: 89.9-100% and NPA: 50.0-84.6%, and for S was PPA: 50.6-96.6% and NPA: 50.0-100%. Compared to a plasma nAb assay, the multiplex salivary assay PPA ranged from 62.3% (N) and 98.6% (RBD) and NPA ranged from 18.8% (RBD) to 96.9% (S). Combinations of N, RBD, and S and a summary algorithmic index of all three (N/RBD/S) in saliva produced ranges of PPA: 87.6-98.9% and NPA: 50-91.7% with the three EIAs and ranges of PPA: 88.4-98.6% and NPA: 21.9-34.4% with the nAb assay. A multiplex salivary SARS-CoV-2 IgG assay demonstrated comparable performance to three commercially-available plasma EIAs and a nAb assay, and may be a viable alternative to assist in screening CCP donors and monitoring population-based seroprevalence and vaccine antibody response.",Christopher D Heaney; Nora Pisanic; Pranay R Randad; Kate Kruczynski; Tyrone Howard; Xianming Zhu; Kirsten Littlefield; Eshan Patel; Ruchee Shrestha; Oliver Laeyendecker; Shmuel Shoham; David J Sullivan; Kelly Gebo; Daniel Hanley; Andrew Redd; Thomas Quinn; Arturo Casadevall; Jonathan M Zenilman; Andrew Pekosz; Evan M Bloch; Aaron AR Tobian,https://medrxiv.org/cgi/content/short/2021.01.28.21250717,https://medrxiv.org/cgi/content/short/2021.01.28.21250717,2021-02-01,2021-02-01,,True
31,Significance of SARS-CoV-2 Specific Antibody Testing during COVID-19 Vaccine Allocation,"Objective: To assess the value of using SARS-CoV-2 specific antibody testing to prioritize the vaccination of susceptible individuals as part of a COVID-19 vaccine distribution plan when vaccine supply is limited. Methods: A compartmental model was used to simulate COVID-19 spread when considering diagnosis, isolation, and vaccination of a cohort of 1 million individuals. The scenarios modeled represented 4 pandemic severity scenarios and various times when the vaccine becomes available during the pandemic. Eligible individuals have a probability p of receiving antibody testing prior to vaccination (p = 0, 0.25, 0.5, 0.75, and 1). The value of serology testing was evaluated by comparing the infection attack rate, peak infections, peak day, and deaths. Results: The use of antibody testing to prioritize the allocation of limited vaccines reduces infection attack rates and deaths. The size of the reduction depends on when the vaccine becomes available relative to the infection peak day. The largest reduction in cases and deaths occurs when the vaccine is deployed before and close to the infection peak day. The reduction in the number of cases and deaths diminishes as vaccine deployment is delayed and moves closer to the peak day. Conclusions: Antibody testing as part of the vaccination plan is an effective method to maximize the benefit of a COVID-19 vaccine. Decision-makers need to consider relative timing between the infection peak day and when the vaccine becomes available.",Akane B Fujimoto; Inci Yildirim; Pinar Keskinocak,https://medrxiv.org/cgi/content/short/2021.01.28.21250721,https://medrxiv.org/cgi/content/short/2021.01.28.21250721,2021-02-01,2021-02-01,,True
32,Targeting TGF-b pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19,"Our COVID-19 drug candidate ARTIVeda/PulmoHeal is a novel gelatin capsule formulation of the Artemisia extract Ayurveda for oral delivery of TGF-b targeting anti-malaria phytomedicine Artemisinin with documented anti-inflammatory and anti-SARS-CoV-2 activity. Here we report the safety and efficacy of ARTIVeda in adult COVID-19 patients with symptomatic mild-moderate COVID-19, who were treated in a randomized, open-label Phase IV study in Bangalore, Karnataka, India (Clinical Trials Registry India identifier: CTRI/2020/09/028044). ARTIVeda showed a very favorable safety profile, and the only ARTIVeda-related adverse events were transient mild rash and mild hypertension. Notably, ARTIVeda, when added to the SOC, accelerated the recovery of patients with mild-moderate COVID-19. While all patients were symptomatic at baseline (WHO score = 2-4), 31 of 39 (79.5%) of patients treated with ARTIVeda plus SOC became asymptomatic (WHO score = 1) by the end of the 5-day therapy, including 10 of 10 patients with severe dry cough 7 of 7 patients with severe fever. By comparison, 12 of 21 control patients (57.1%) treated with SOC alone became asymptomatic on day 5 (P=0.028, Fishers exact test). This clinical benefit was particularly evident when the treatment outcomes of hospitalized COVID-19 patients (WHO score = 4) treated with SOC alone versus SOC plus ARTIVeda were compared. The median time to becoming asymptomatic was only 5 days for the SOC plus ARTIVeda group (N=18) but 14 days for the SOC alone group (N=10) (P=0.004, Log-rank test). These data provide clinical proof of concept that targeting the TGF-b pathway with ARTIVeda may contribute to a faster recovery of patients with mild-moderate COVID-19 when administered early in the course of their disease.",Vuong Trieu; Saran Saund; Prashant Rahate; Viljay Barge; Sunil Nalk; Hitesh Windlass; Fatih Uckun,https://medrxiv.org/cgi/content/short/2021.01.24.21250418,https://medrxiv.org/cgi/content/short/2021.01.24.21250418,2021-02-01,2021-02-01,,True
33,Age significantly influences the sensitivity of SARS-CoV-2 rapid antibody assays,"BACKGROUND Point of care serological assays are a promising tool in COVID-19 diagnostics but do have limitations. This study evaluated the sensitivity of five rapid antibody assays and explored factors influencing their sensitivity to detect SARS-CoV-2-specific IgG and IgM antibodies. METHODS Finger-prick blood samples from 102 participants, within two to six weeks of PCR-confirmed COVID-19 diagnosis, were tested for IgG and IgM on five rapid serological assays. The assay sensitivities were compared, and patient factors evaluated in order to investigate potential associations with assay sensitivity. RESULTS Sensitivity ranged from 36% to 69% for IgG and 13% to 67% for IgM. Age was the only factor significantly influencing the likelihood of a detectable IgG or IgM response. Individuals aged 40 years and older had an increased likelihood of a detectable IgG or IgM antibody response by rapid antibody assay. CONCLUSION Rapid serological assays demonstrate significant variability when used in a real-world clinical context. There may be limitations in their use for COVID-19 diagnosis amongst the young.",Natalie Irwin; Lyle Murray; Benjamin Ozynski; Guy A Richards; Graham Paget; Jacqui Venturas; Ismail Kalla; Nina Diana; Adam Mahomed; Jarrod Zamparini,https://medrxiv.org/cgi/content/short/2021.01.28.21250675,https://medrxiv.org/cgi/content/short/2021.01.28.21250675,2021-02-01,2021-02-01,,True
34,Effect of RBD (Y453F) mutation in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity.,"Background: Infection with receptor binding domain (RBD) mutant (Y453F) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from farmed minks is known to widely spread among humans. Methods: We investigated the characteristics of SARS-CoV-2 RBD Y453F mutant using three-dimensional structural analysis. We investigated the effect of the RBD Y453F mutant of SARS-CoV-2 on neutralizing antibodies in serum derived from Corona virus Disease 2019 (COVID-19) positive patients. Results: Our studies suggest that virus variants with RBD Y453F mutation partially escaped detection by four neutralizing monoclonal antibodies and neutralizing antibodies in serum. Conclusions: Consequently, raising a concern that infection of SARS-CoV-2 mutants that cause serious symptoms in humans may spread globally.",Takuma Hayashi; Nobuo Yaegashi; Ikuo Konishi,https://medrxiv.org/cgi/content/short/2021.01.28.21250577,https://medrxiv.org/cgi/content/short/2021.01.28.21250577,2021-02-01,2021-02-01,,True
35,Resource Allocation for Different Types of Vaccines against COVID-19: Tradeoffs and Synergies between Efficacy and Reach,"Objective: During the COVID-19 pandemic, multiple vaccine candidates were developed in record time. The primary decision for a vaccine-ordering decision-maker then becomes how to allocate limited resources between different types of vaccines. One may expect that available resources should be favored towards a vaccine with high efficacy if it can be distributed as widely as any other vaccine. However, if a high efficacy vaccine consumes more resources than a vaccine with lower efficacy due to distributional challenges, the decision is no longer trivial as a widespread vaccination is necessary to reach herd immunity. Methods: We adapt a Susceptible-Infected-Recovered-Deceased (SIR-D) model with vaccination and simulate the level of infection attack rate (IAR) under different resource consumption ratios between two vaccine types with different resource allocation decisions. Results: We find that when there are limited resources, allocating resources entirely to a vaccine with high efficacy that becomes available earlier than a vaccine with lower efficacy that becomes available later does not always lead to a lower IAR, particularly if the former can immunize less than a range of 5.9% to 6.4% of the population (with the selected study parameters) before the latter becomes available. Sensitivity analyses show that this result stays robust under different efficacy levels for the higher efficacy vaccine. Conclusions: Our results show that the reach of a vaccine to be distributed widely under limited resources is a key factor to achieve low IAR levels, even though the vaccine may be of higher efficacy and may become available earlier than others. Manufacturing a novel vaccine lacking a fully developed suitable infrastructure for its effective distribution and storage may impact the potential benefits of the immunization program. Understanding the tradeoffs between efficacy and reach is critical for resource allocation decisions between different vaccine types to maximize the improvement in health outcomes.",Daniel Kim; Pelin Pekgun; Inci Yildirim; Pinar Keskinocak,https://medrxiv.org/cgi/content/short/2021.01.28.21250713,https://medrxiv.org/cgi/content/short/2021.01.28.21250713,2021-02-01,2021-02-01,,True
36,PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern,"With the emergence of SARS-CoV-2 variants that may increase transmissibility and/or cause escape from immune responses1-3, there is an urgent need for the targeted surveillance of circulating lineages. It was found that the B.1.1.7 (also 501Y.V1) variant first detected in the UK4,5 could be serendipitously detected by the ThermoFisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike {Delta}69-70, would cause a 'spike gene target failure' (SGTF) result. However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern that lack spike {Delta}69-70, such as B.1.351 (also 501Y.V2) detected in South Africa6 and P.1 (also 501Y.V3) recently detected in Brazil7. We identified a deletion in the ORF1a gene (ORF1a {Delta}3675-3677) in all three variants, which has not yet been widely detected in other SARS-CoV-2 lineages. Using ORF1a {Delta}3675-3677 as the primary target and spike {Delta}69-70 to differentiate, we designed and validated an open source PCR assay to detect SARS-CoV-2 variants of concern8. Our assay can be rapidly deployed in laboratories around the world to enhance surveillance for the local emergence spread of B.1.1.7, B.1.351, and P.1.",Chantal BF Vogels; Mallery Breban; Tara Alpert; Mary E Petrone; Anne E Watkins; Emma Hodcroft; Christopher E Mason; Gaurav Khullar; Joel T Dudley; Matthew J Mackay; Jianhui Wang; Chen Liu; Pei Hui; Steven Murphy; Caleb Neal; Eva Laszlo; Marie L Landry; Anthony Muyombwe; Randy Downing; Jafar Razeq; Richard A Neher; Joseph R Fauver; Nathan D Grubaugh,https://medrxiv.org/cgi/content/short/2021.01.28.21250486,https://medrxiv.org/cgi/content/short/2021.01.28.21250486,2021-02-01,2021-02-01,,True
37,Differences in detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic college students and children.,"Limitations in timely testing for SARS-CoV-2 drive the need for new approaches in suspected COVID-19 disease. We queried whether viral load (VL) in the upper airways at presentation could improve the management and diagnosis of patients. This study was conducted in a 9 hospital system in Allegheny County, Pennsylvania between March 1- August 31 2020. Viral load was determined by PCR assays for patients presenting to the Emergency Departments (ED), community pediatrics practices and college health service. We found that for the ED patients, VL did not vary substantially between those admitted and not. VL was relatively equivalent across ages, except for the under 25 age groups that tended to present with higher loads. To determine if rapid antigen testing (RAT) could aid diagnosis in certain populations, we compared BD Veritor and Quidel Sofia to SOC PCR-based tests. The antigen assay provided a disease-detection sensitivity of >90% in a selection of 32 positive students and was modeled to have an 80% sensitivity in all positive students. In the outpatient pediatric population, the antigen assay detected 70% of PCR-positives. Extrapolating these findings to viral loads in older hospitalized patients, a minority would be detected by RAT (40%). Higher loads did correlate with death, though the prognostic value was marginal (ROC AUC of only 0.66). VL did not distinguish between those needing mechanical ventilation and routine inpatients. We conclude that VL in upper airways, while not prognostic for disease management, may aid in selecting proper testing methodologies for certain patient populations.",Juan Luis Gomez Marti; Jamie Gribschaw; Melissa McCullough; Abbie Mallon; Jamie Acero; Amy Kinzler; Jamie Godesky; Kelly Heidenreich; Jennifer Iagnemma; Marian Vanek; A William Pasculle; Tung Phan; Alejandro Hoberman; John V Williams; Stephanie Mitchell; Alan Wells,https://medrxiv.org/cgi/content/short/2021.01.28.21250365,https://medrxiv.org/cgi/content/short/2021.01.28.21250365,2021-02-01,2021-02-01,,True
38,12-lead Electrocardiogram in Hospitalized COVID 19 Patients,"COVID-19 pandemic resulted in considerable morbidity and mortality. We analyzed 345 Electrocardiograms of 100 COVID-19 patients admitted to our tertiary care center in Detroit, during the initial month of Covid-19. Findings were correlated with mortality, cardiac injury and inflammatory markers. Our cohort included 61% males and 77% African Americans. The median age and BMI were 66 years (57-74) and 31 kg/m2 (26.1-39), respectively. We observed atrial arrhythmias in 29% of the patients (17% new onset), First degree heart block in 12%, ST-T segment changes in 17%, S1Q3T3 pattern in 19%, premature ventricular complexes in 23%, premature atrial complexes in 13%, Q waves in 27%, T wave inversion in 42% of the cases. While presence of premature atrial complexes or left atrial abnormality correlated with mortality (P = 0.02 & 0.03, respectively), other findings did not show significant correlation in this small cohort of patients.",Mohamed Shokr; Omar Chehab; Mustafa Ajam; Manmohan Singh; Said Ashraf; John Dawdy; Mohit Pahuja; Vivek Reddy; Ahmed Subahi; M. Chadi Alraies; Luis Afonso; Randy Lieberman,https://medrxiv.org/cgi/content/short/2021.01.29.21250407,https://medrxiv.org/cgi/content/short/2021.01.29.21250407,2021-02-01,2021-02-01,,True
39,Application of a 27-protein candidate cardiovascular surrogate endpoint to track risk ascendancy and resolution in COVID-19.,"Background: There is an urgent need for tools allowing the early prognosis and subsequent monitoring of individuals with heterogeneous COVID-19 disease trajectories. Pre-existing cardiovascular (CV) disease is a leading risk factor for COVID-19 susceptibility and poor outcomes, and cardiac involvement is prevalent in COVID-19 patients both during the acute phase as well as in convalescence. The utility of traditional CV risk biomarkers in mild COVID-19 disease or across disease course is poorly understood. We sought to determine if a previously validated 27-protein predictor of CV outcomes served a purpose in COVID-19. Methods: The 27-protein test of residual CV (RCV) risk was applied without modification to n=860 plasma samples from hospitalized and non-hospitalized SARS-CoV-2 infected individuals at disease presentation from three independent cohorts to predict COVID-19 severity and mortality. The same test was applied to an additional n=991 longitudinal samples to assess sensitivity to change in CV risk throughout the course of infection into convalescence. Results: In each independent cohort, RCV predictions were significantly related to maximal subsequent COVID-19 severity and to mortality. At the baseline blood draw, the mean protein-predicted likelihood of an event in subjects who died during the study period ranged from 88-99% while it ranged from 8-36% in subjects who were not admitted to hospital. Additionally, the test outperformed existing risk predictors based on commonly used laboratory chemistry values or presence of comorbidities. Application of the RCV test to sequential samples showed dramatic increases in risk during the first few days of infection followed by risk reduction in the survivors; a period of catastrophically high cardiovascular risk (above 50%) typically lasted 8-12 days and had not resolved to normal levels in most people within that timescale. Conclusions: The finding that a 27-protein candidate CV surrogate endpoint developed in multi-morbid patients prior to the pandemic is both prognostic and acutely sensitive to the adverse effects of COVID-19 suggests that this disease activates the same biologic risk-related mechanisms. The test may be useful for monitoring recovery and drug response.",Clare Paterson; Yolanda Hagar; Michael A Hinterberg; Alexander W Charney; Diane M Del Valle; Michael R Filbin; Sacha Gnjatic; Jason D Goldman; Nir Hacohen; James R Heath; Rainer Hillenbrand; Lori L Jennings; Seunghee Kim-Schulze; Andrew T Magis; Miriam Merad; Konstantinos Mouskas; Nicole W Simons; Stephen A Williams,https://medrxiv.org/cgi/content/short/2021.01.28.21250129,https://medrxiv.org/cgi/content/short/2021.01.28.21250129,2021-02-01,2021-02-01,,True
40,High variability in transmission of SARS-CoV-2 within households and implications for control,"Background. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a high risk of transmission in close-contact indoor settings, which may include households. Prior studies have found a wide range of household secondary attack rates and may contain biases due to simplifying assumptions about transmission variability and test accuracy. Methods. We compiled serological SARS-CoV-2 antibody test data and prior PCR test reporting from members of more than 9000 Utah households. We paired these data with a probabilistic model of household importation and transmission. We calculated a maximum likelihood estimate of the importation probability, mean and variability of household transmission probability, and sensitivity and specificity of test data. Given our household transmission estimates, we estimated the threshold of non-household transmission required for epidemic growth in the population. Results. We estimated that individuals in our study households had a 0.38% (95% CI 0.30% - 0.48%) chance of acquiring SARS-CoV-2 infection outside their household. Our household secondary attack rate estimate was 35% (26% - 47%), substantially higher than the crude estimate of 15% unadjusted for imperfect serological test specificity and other factors. We found evidence for high variability in individual transmissibility, with higher probability of no transmissions or many transmissions compared to standard models. With household transmission at our estimates, the average number of non-household transmissions per case must be kept below 0.40 (0.32 - 0.51) to avoid continued growth of the Utah epidemic. Conclusions. Our findings suggest that crude estimates of household secondary attack rate based on serology data without accounting for false positive tests may underestimate the true average transmissibility, even when test specificity is high. Our finding of potential high variability (overdispersion) in transmissibility of infected individuals is consistent with characterizing SARS-CoV-2 transmission being largely driven by superspreading from a minority of infected individuals. Mitigation efforts targeting large households and other locations where many people congregate indoors might curb continued spread of the virus.",Damon J.A. Toth; Alexander B. Beams; Lindsay T. Keegan; Yue Zhang; Tom Greene; Brian Orleans; Nathan Seegert; Adam Looney; Stephen C. Alder; Matthew H. Samore,https://medrxiv.org/cgi/content/short/2021.01.29.20248797,https://medrxiv.org/cgi/content/short/2021.01.29.20248797,2021-02-01,2021-02-01,,True
41,Correlation of SARS-CoV-2 serology and clinical phenotype amongst hospitalised children in a tertiary children's hospital in India,"Introduction: Children usually present with minimal or no symptoms of SARS-CoV-2 infection. Antibody responses to SARS-CoV-2 in children from low- and middle-income countries (LMIC) have not been well described. We describe the prevalence of anti SARS-CoV-2 antibodies and clinical phenotype of seropositive children admitted to a tertiary children's hospital in South India. Methods: To determine the seropositivity and describe the clinical characteristics of SARS-CoV-2 infection amongst hospitalised children, we performed a prospective clinical data collection and blood sampling of children admitted to Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India over 4 months of the COVID-19 pandemic. In seropositive children, we compared antibody titres between children with and without PIMS-TS. Results: Of 463 children, 91 (19.6%) were seropositive. The median (range) age of seropositive children was 5 years (1 month - 17 years). Clinical presentation was consistent with Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) in 48% (44/91) of seropositive children. The median (range) antibody titre was 54.8 (11.1-170.9) AU/ml among all seropositive children. The median antibody titre among the children with PIMS-TS (60.3 AU/mL) was significantly (p=0.01) higher when compared to the children without PIM-TS (54.8 AU/mL). Conclusion: We describe the antibody responses to SARS-CoV-2 amongst hospitalised children in a LMIC tertiary children's hospital. Almost half of the seropositive children had PIMS-TS. Antibody levels may be helpful in the diagnosis and disease stratification of PIMS-TS.",Aishwarya Venkataraman; Balasubramanian S; Sulochana Putilibai; Lakshan Raj S; Sumanth Amperayani; Senthilnathan S; Anand Manoharan; Arokia Sophi; Amutha R; Kalaimaran Sadasivam; Anu Goenka; Ramanan A V,https://medrxiv.org/cgi/content/short/2021.01.29.21250660,https://medrxiv.org/cgi/content/short/2021.01.29.21250660,2021-02-01,2021-02-01,,True
42,Increasing but inadequate intention to receive Covid-19 vaccination over the first 50 days of impact of the more infectious variant and roll-out of vaccination in UK: indicators for public health messaging,"Objectives To inform critical public health messaging by determining how changes in Covid-19 vaccine hesitancy, attitudes to the priorities for administration, the emergence of new variants and availability of vaccines may affect the trajectory and achievement of herd immunity. Methods >9,000 respondents in an ongoing cross-sectional participatory longitudinal epidemiology study (LoC-19, n=18,581) completed a questionnaire within their personal electronic health record in the week reporting first effective Covid-19 vaccines, and then again after widespread publicity of the increased transmissibility of a new variant (November 13th and December 31st 2020 respectively). Questions covered willingness to receive Covid-19 vaccination and attitudes to prioritisation. Descriptive statistics, unadjusted and adjusted odds ratios (ORs) and natural language processing of free-text responses are reported, and how changes over the first 50 days of both vaccination roll-out and new-variant impact modelling of anticipated transmission rates and the likelihood and time to herd immunity. Findings Compared with the week reporting the first efficacious vaccine there was a 15% increase in acceptance of Covid-19 vaccination, attributable in one third to the impact of the new variant, with 75% of respondents ""shielding"" -- staying at home and not leaving unless essential -- regardless of health status or tier rules. 12.5% of respondents plan to change their behaviour two weeks after completing vaccination compared with 45% intending to do so only when cases have reduced to a low level. Despite the increase from 71% to 86% over this critical 50-day period, modelling of planned uptake of vaccination remains below that required for rapid effective herd immunity -- now estimated to be 90 percent in the presence of a new variant escalating R0 to levels requiring further lockdowns. To inform the public messaging essential therefore to improve uptake, age and female gender were, respectively, strongly positively and negatively associated with wanting a vaccine. 22.7% disagreed with the prioritisation list, though 70.3% were against being able to expedite vaccination through payment. Teachers (988, 12.6%) and Black, Asian and Minority Ethnic (BAME) (837, 10.7%) groups were most cited by respondents for prioritisation. Interpretation In this sample, the growing impact of personal choice among the increasingly informed public highlights a decrease in Covid-19 vaccine hesitancy over time, with news of a new variant motivating increased willingness for vaccination but at levels below what may be required for effective herd immunity. We identify public preferences for next-in-line priorities, headed by teachers and BAME groups, consideration of which will help build trust and community engagement critical for maximising compliance with not only the vaccination programme but also all other public health measures.",Patrik Bachtiger; Alexander Adamson; William A Maclean; Jennifer K Quint; Nicholas S Peters,https://medrxiv.org/cgi/content/short/2021.01.30.21250083,https://medrxiv.org/cgi/content/short/2021.01.30.21250083,2021-02-01,2021-02-01,,True
43,Relative humidity predicts day-to-day variations in COVID-19 cases in the city of Buenos Aires,"Possible links between the transmission of COVID-19 and meteorology have been investigated by comparing positive cases across geographical regions. Little is known, however, about the degree to which meteorological conditions drive the daily dynamics of COVID-19 spread at a given location. The main limitation is that individual waves of the disease are typically abrupt and eventful, making correlations somewhat anecdotal. In contrast, we here present a long-term case study for the city of Buenos Aires, which has suffered a single prolonged wave of spread during 2020, with most significant changes in policy and population behavior taking place before the main local outbreak. We found that humidity plays a prominent role in modulating the variation of COVID-19 positive cases through a negative-slope linear relationship, with an optimal lag of 9 days between the meteorological observation and the positive case report. This relationship is specific to winter months, when relative humidity predicts up to half of the variance in positive cases. Our results provide a tool to anticipate local surges in COVID-19 cases after events of low humidity. More generally, they add to accumulating evidence pointing to dry air as an important driver of global COVID-19 transmission.",Andrea L Pineda Rojas; Sandra M Cordo; Ramiro I Saurral; Jose L Jimenez; Linsey C Marr; Emilio Kropff,https://medrxiv.org/cgi/content/short/2021.01.29.21250789,https://medrxiv.org/cgi/content/short/2021.01.29.21250789,2021-02-01,2021-02-01,,True
44,COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout,"Background: The Kingdom of Saudi Arabia (KSA) was the fourth country in the world to authorize the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine, which it rolled out on December 17, 2020 and first targeted at healthcare workers (HCWs). This study assesses vaccine uptake among this group during the first month of its availability. Methods: A national cross-sectional, pilot-validated, self-administered survey was conducted among HCWs in the KSA between December 27, 2020 and January 3, 2021. The survey included sociodemographic details, previous contact with COVID-19 patients, previous infection with COVID-19, receiving (or registering with the Ministry of Health website to receive) the COVID-19 vaccine, sources of HCWs information on vaccines, awareness of emerging variants of concern, and anxiety level using the 7 item Generalized Anxiety Disorder assessment. A descriptive bivariate analysis and multivariate logistic binary regression analysis were performed. The primary evaluated outcome was vaccine uptake. Results: Of the 1,058 participants who completed the survey, 704 (66.5%) were female, and 626 (59.2%) were nurses. Of all the respondents, 352 (33.27%) were enrolled to receive or had already received the vaccine, while 706 (66.73%) had not registered. In a bivariate analysis, not enrolling for vaccination was more likely in females than males (78.5% vs. 21.5%, P < 0.001), HCWs between the ages of 20 and 40 years than those > 40 years (70.4% vs. 29.6%, P = 0.005), Saudi HCWs than expatriates (78% vs 22%, P < 0.001), and among HCWs who used social media as a source of information than those who did not (69.8% vs. 38.6%, P < 0.001) . In a multivariate analysis, independent factors for not enrolling to receive the vaccine included being female (aOR = 0.287, 95%CI = 0.206, 0.401, P < 0.001), being less than 40 years of age (aOR = 1.021, 95%CI = 1.002,1.040, P = 0.032), and using social media as a source of information (aOR = 0.207, 95%CI = 0.132,1.354, P = 0.001 ). Factors associated with uptake were being a Saudi national (aOR = 1.918, 95%CI = 1.363,2.698, P < 0.001), working in an intensive care unit (aOR = 1.495, 95%CI = 1.083,2.063, P = 0.014), and working at a university hospital (aOR = 1.867, 95%CI = 1.380,2.525, P < 0.001). Conclusions: A low level of vaccine uptake was observed especially in female HCWs, those younger than 40 years old, and those who used social media as their source of vaccine information. This survey provides important information for public health authorities in order to scale up vaccination campaigns targeting these HCWs to increase vaccine enrollment and uptake.",Mazin Barry; Mohamad-Hani Temsah; Fadi Aljamaan; Basema Saddik; Ayman Al-Eyadhy; Shelaweeh Alanazi; Nurah Alamro; Abdullah Alhuzaimi; Ali Alhaboob; Fahad Alsohime; Ali Alaraj; Rabih Halwani; Amr Jamal; Omar Temsah; Fahad Alzamil; Ali Alsomialy; Jaffar Al-Tawfiq,https://medrxiv.org/cgi/content/short/2021.01.29.21250749,https://medrxiv.org/cgi/content/short/2021.01.29.21250749,2021-02-01,2021-02-01,,True
45,COVID-19 Prevention Beliefs and Practices in College Students,"Background: As college students in the United States return to university campuses, it is important to understand their beliefs and practices on coronavirus disease 2019 (COVID-19) prevention. Purpose: To assess beliefs and practices regarding COVID-19 prevention among college students in the United States Methods: An online, self-administered survey was developed that collected information on COVID-19 preventative practice and beliefs. Survey responses were collected between July 13, 2020 and July 31, 2020. Results: A total of 4,834 college students participated in the survey with a response rate of 22.9%. Compared to males, more female college students practiced COVID-19 preventative measures, including always wearing masks or face coverings in public (52% vs. 44%, p<0.001) and always or often observing social distancing (70% vs. 63%, p<0.001). In contrast to students from larger population areas, fewer college students from rural areas reported practicing prevention measures, such as always wearing a mask (24% rural v. 45% towns vs. 55% cities, p<0.001) and always social distancing (20% rural vs. 21% towns vs. 29% cities, p<0.001). Additionally, more students from rural areas have become much less worried about personally contracting COVID-19 over the last 3 months when compared to students from towns and cities (21% vs. 16% vs. 11%, p<0.001). Fewer white college students compared to other racial groups thought it was very important to wear masks (55% white vs. 76% Black vs. 82% Asian vs. 63% American Indian or Alaskan native (AIAN) & Native Hawaiian or Other Pacific Islander (NHOPI) , p<0.001) and very important to practice social distancing (29% white vs. 50% Black vs. 53% Asian vs. 36% AIAN/NHOPI, p <0.001). Compared to Non-Hispanic students, more Hispanic students thought it was very important to practice preventative measures, including wearing a mask (71% vs. 58%, p<0.001), social distancing (37% vs. 32%, p=0.017), and good hand hygiene (77% vs. 67%, p=0.013). Conclusion: COVID-19 prevention beliefs and practices differ between sexes, the size of town one lives, race, and ethnicity. In general, female students followed Center for Disease Control and Prevention (CDC) COVID-19 prevention guidelines more closely than male students. Students who reside in areas of larger populations have more strict COVID-19 prevention beliefs and practices than students from areas with smaller populations. Asian and Black/African American students adhered closer to CDC COVID-19 prevention guidelines and had stronger beliefs for infection prevention measures than white or AIAN/NHOPI students. Hispanic/Latino students were more stringent in COVID-19 prevention beliefs and practices than non-Hispanic/Latino students.",Caitlyn Cassimatis; Liga Kreitner; Abdoulie Njai; Emily Leary; Aaron D Gray,https://medrxiv.org/cgi/content/short/2021.01.29.21250794,https://medrxiv.org/cgi/content/short/2021.01.29.21250794,2021-02-01,2021-02-01,,True
46,How best do we engage the general population in testing for COVID-19?,"The UK Scientific Advisory Group for Emergencies (SAGE) emphasises the need for high levels of engagement with communities and individuals to ensure the effectiveness of any COVID-19 testing programme. A novel pilot health surveillance programme to assess the feasibility of weekly mass RT-LAMP testing for the SARS-CoV-2 virus using saliva samples collected at home was developed and piloted by the University of Southampton and Southampton City Council. Rapid qualitative evaluation was conducted to explore experiences of those who took part in the programme, of those who declined and of those in the educational and healthcare organisations involved in the pilot testing who were responsible for roll-out. This included 77 interviews and 20 focus groups with 223 staff, students, pupils and household members from four schools, one university, and one community healthcare NHS trust. Conversations revealed that high levels of communication, trust and convenience were necessary to ensure public engagement with the programme. This suggests community leaders and stakeholder organisations should be involved throughout programme development and implementation to optimise these features of the testing. Participants and stakeholders motivations, challenges and concerns need to be understood and these insights used to modify the programme in a continuous, real-time process to ensure and sustain engagement with testing over the extended period necessary.",Daniella Watson; Natalia Laverty Baralle; Jawahr Alagil; Krithika Anil; Sandy Ciccognani; Rachel Dewar-Haggart; Sarah Fearn; Julia Groot; Kathryn Knowles; Claire Meagher; Carmel McGrath; Sarah Muir; Jo Musgrove; Kate Glyn-Owen; Kath Woods-Townsend; Andrew Mortimore; Paul Roderick; Janis Baird; Hazel Inskip; Keith Godfrey; Mary Barker,https://medrxiv.org/cgi/content/short/2021.01.29.21250730,https://medrxiv.org/cgi/content/short/2021.01.29.21250730,2021-02-01,2021-02-01,,True
47,Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial,"Background COVID-19 patients have severe lung injury. The USWD could play a supportive role in relieving lung injury and enhance clinical recovery. Methods and findings The design was a single-center, evaluator blinded; 2-arm parallel design superiority randomized controlled clinical trial. Moderate and severe coronavirus-2 (SARS-CoV-2) positive patients with acute respiratory syndrome, Fifty patients were randomized (USWD, 25; control, 25) between February 18/2020 and April 20/2020. There were male 22 (44.0%) and female 28 (56.0%) with mean (SD) age 53(10.69). Time to clinical recovery (USWD 36.84 vs control 43.56, P = 0.03) was significantly shortened with a between-group difference of 6.72 days. The median SIRS score at day 28 was 0 (0-1) in the USWD group, while 0 (0-2) in the control group ( P = 0.011), and the seven-point scale at day 28 showed significant improvement in the USWD group (P = 0.003). While the rate of RNA negative conversion at day 7 (2/25 vs 7/25, p=0.054), day 14 (14/25 vs 18/25 p=0.239), day 21 (22/25 vs 18/25 p=0.279), and day 28 (25/25 vs 22/25 p=0.730) did not show statistical significance. Similarly, no significant differences were observed in the AI-assisted CT analysis. No treatment-associated adverse events or worsening of pulmonary fibrosis were found. Conclusions Among the 50 moderate and severe COVID-19 patients, the USWD as an adjunctive therapy to standard therapy could shorten the recovery course and enhance clinical improvement without aggravating pulmonary fibrosis. However, the study did not report statistical significance in the negative conversion rates of SARS-CoV-2 nucleic acid due to the small sample size and early termination, the findings of this study are limited.",liangjiang huang; qian li; Shah Zulfiqar Ali Sayed; Nasb Mohammad; bin chen; MPhil Ali Iftikhar; Lingfeng Xie; Jifa Hu; hong chen,https://medrxiv.org/cgi/content/short/2021.01.28.21250163,https://medrxiv.org/cgi/content/short/2021.01.28.21250163,2021-02-01,2021-02-01,,True
48,Updated SARS-CoV-2 Single Nucleotide Variants and Mortality Association,"Since its outbreak in December 2019, COVID-19 has caused 100,5844,555 cases and 2,167,313 deaths as of Jan 27, 2021. Comparing our previous study of SARS-CoV-2 single nucleotide variants (SNVs) before June 2020, we found out that the SNV clustering had changed considerably since June 2020. Apart from that the group SNVs represented by two non-synonymous mutations A23403G (S: D614G) and C14408T (ORF1ab: P4715L) became dominant and carried by over 95% genomes, a few emerging groups of SNVs were recognized with sharply increased monthly occurrence ratios up to 70% in November 2020. Further investigation revealed that several SNVs were strongly associated with the mortality, but they presented distinct distribution in specific countries, e.g., Brazil, USA, Saudi Arabia, India, and Italy. SNVs including G25088T, T25A, G29861T and G29864A were adopted in a regularized logistic regression model to predict the mortality status in Brazil with the AUC of 0.84. Protein structure analysis showed that the emerging subgroups of non-synonymous SNVs and those mortality-related ones in Brazil were located on protein surface area. The clashes in protein structure introduced by these mutations might in turn affect virus pathogenesis through conformation changes, leading to the difference in transmission and virulence. Particularly, we found that SNVs tended to occur in intrinsic disordered regions (IDRs) of Spike (S) and ORF1ab, suggesting a critical role of SNVs in protein IDRs to determine protein folding and immune evasion.",Shuyi Fang; Sheng Liu; Jikui Shen; Alex Z Lu; Yucheng Zhang; Kailing Li; Juli Liu; Lei Yang; Chang-Deng Hu; Jun Wan,https://medrxiv.org/cgi/content/short/2021.01.29.21250757,https://medrxiv.org/cgi/content/short/2021.01.29.21250757,2021-02-01,2021-02-01,,True
49,Estimating the COVID-19 Prevalence in Spain with Indirect Reporting via Open Surveys,"During the initial phases of the COVID-19 pandemic, accurate tracking has proven unfeasible. Initial estimation methods pointed towards case numbers that were much higher than officially reported. In the CoronaSurveys project, we have been addressing this issue using open online surveys with indirect reporting. We compare our estimates with the results of a serology study for Spain, obtaining high correlations (R squared 0.89). In our view, these results strongly support the idea of using open surveys with indirect reporting as a method to broadly sense the progress of a pandemic.",Augusto Garcia-Agundez; Oluwasegun Ojo; Harold Hernandez; Carlos Baquero; Davide Frey; Chryssis Georgiou; Mathieu Goessens; Rosa Lillo; Raquel Menezes; Nicolas Nicolaou; Antonio Ortega; Efstathios Stavrakis; Antonio Fernandez Anta,https://medrxiv.org/cgi/content/short/2021.01.29.20248125,https://medrxiv.org/cgi/content/short/2021.01.29.20248125,2021-02-01,2021-02-01,,True
50,Discontinuation of isolation for persons with COVID-19: Is 10 days really safe?,"Background. The detection of SARS-CoV-2 RNA by real-time polymerase chain reaction (PCR) in respiratory samples from COVID-19 patients is not a direct indication of the presence of viable viruses. The isolation of SARS-CoV-2 in cell culture system however, can acts as surrogate marker of infectiousness. Cell culture based studies performed mostly with hospitalized and moderate/severe COVID-19 claims that no replication competent virus is found after 9 days of the symptoms onset in respiratory samples. Therefore, it is now recommended 10 days isolation before patient discharge. Methods. We cell-cultured 29 SARS-COV-2 RT-PCR positive respiratory samples at the 10th day after the illness in Vero E6 cells. After two passages, cytopathic effect and cycle threshold (CT) lower than the obtained in the original sample were used to determine positivity. Findings. We found viable particles in (7/29) 24% of samples tested. The positivity in cell culture was strongly associated (p<0.0001) to the low cycle thresholds in clinical samples (Ct <21). Conclusion. This data adds important knowledge to the current protocols for de-isolation of patients with non-hospitalized mild COVID-19.",Alvina Clara Felix; Anderson Vincente de Paula; Andreia C Ribeiro; Francini C da Silva; Marta Inemami; Angela A Costa; Cibele OD Leal; Walter M Figueiredo; Claudio S Pannuti; Camila M Romano,https://medrxiv.org/cgi/content/short/2021.01.29.21250753,https://medrxiv.org/cgi/content/short/2021.01.29.21250753,2021-02-01,2021-02-01,,True
51,A mathematical model to estimate percentage secondary infections from margin of error of diagnostic sensitivity: Useful tool for regulatory agencies to assess the risk of propagation due to false negative outcome of diagnostics,"False negative outcome of a diagnosis is one the major reasons for the dissemination of the diseases with high risk of propagation. Diagnostic sensitivity and the margin of error determine the false negative outcome of the diagnosis. A mathematical model had been developed to estimate the mean % secondary infections based on the margin of error of diagnostic sensitivity, % prevalence and R0 value. This model recommends a diagnostic test with diagnostic sensitivity [&ge;] 96% and at least 92% lower bound limit of the 95% CI or [&le;] 4% margin of error for a highly infectious diseases like COVID-19 to curb the secondary transmission of the infection due to false negative cases. Positive relationship was found between mean % secondary infection and margin of error of sensitivity suggesting greater the margin of error of a diagnostic test sensitivity, higher the number of secondary infections in a population due to false negative cases. Negative correlation was found between number of COVID-19 test kits (>90% sensitivity) with regulatory approval and margin of error (R= -0.92, p=0.023) suggesting lesser the margin of error of a diagnostic test, higher the chances of getting approved by the regulatory agencies.However, there are no specific regulatory standards available for margin of error of the diagnostic sensitivity of COVID-19 diagnostic tests. Highly infectious disease such as COVID-19, certainly need specific regulatory standards on margin of error or 95% CI of the diagnostic sensitivity to curb the dissemination of the disease due to false negative cases and our model can be used to set the standards such as sensitivity, margin of error or lower bound limit of 95% CI.",Azhahianambi Palavesam; Karthik Kumaragurubaran; Aravindh Babu R Parthiban; Senthilkumar TMA; Balachandran Chidambaram; Dhinakar Raj Gopal,https://medrxiv.org/cgi/content/short/2021.01.29.21250804,https://medrxiv.org/cgi/content/short/2021.01.29.21250804,2021-02-01,2021-02-01,,True
52,MOATAI-VIR - an AI algorithm that predicts severe adverse events and molecular features for COVID-19's complications,"Following SARS-CoV-2 infection, some COVID-19 patients experience severe adverse events caused by pathogenic host responses. To treat these complications, their underlying etiology must be identified. Thus, a novel AI-based methodology, MOATAI-VIR, which predicts disease-protein-pathway relationships for 22 clinical manifestations attributed to COVID-19 was developed. SARS-CoV-2 interacting human proteins and GWAS identified respiratory failure associated risk genes provide the input from which the mode-of-action (MOA) proteins/pathways of the resulting disease comorbidities are predicted. These comorbidities are then mapped to their clinical manifestations. Three uncharacterized manifestation categories are found: neoplasms, mental and behavioral disorders, and congenital malformations, deformations, and chromosomal abnormalities. The prevalence of neoplasms suggests a possible association between COVID-19 and cancer, whether by shared molecular mechanisms between oncogenesis and viral replication, or perhaps, SARS-CoV-2 is an oncovirus. To assess the molecular basis of each manifestation, the proteins shared across each group of comorbidities were prioritized and subject to global pathway analysis. From these most frequent pathways, the molecular features associated with hallmark COVID-19 phenotypes, such as loss of sense of smell/taste, unusual neurological symptoms, cytokine storm, and blood clots were explored. Results of MOATAI-VIR are available for academic users at: http://pwp.gatech.edu/cssb/MOATAI-VIR/.",Courtney Alexandra Astore; Hongyi Zhou; Joshy Jacob; Jeffrey Skolnick,https://medrxiv.org/cgi/content/short/2021.01.29.21250712,https://medrxiv.org/cgi/content/short/2021.01.29.21250712,2021-02-01,2021-02-01,,True
53,Retinol Depletion in Severe COVID-19,"Background and Purpose: Vitamin A is depleted during infections. Vitamin A has been used successfully in measles, RSV, and AIDS patients and is an effective vaccine adjuvant. In this study, low retinol levels were found in patients with severe COVID-19. Retinoid signaling impairment in COVID-19 disrupts Type-I interferon synthesis. Material and Method: Two groups were formed in the study. The patient group consisted of 27 (Group 1) severe COVID-19 patients hospitalized in the intensive care unit with respiratory failure, and the control group consisted of 23 (Group 2) patients without COVID-19 symptoms. Serum retinol levels were analyzed by ELIZA and HPLC in both groups. Findings: Retinol levels were found to be significantly lower in the patient group (P <0.001). There was no difference in retinol between two different age groups in the patient group (P> 0.05). There was no significant difference in retinol between men and women (P> 0.05). Comorbidity did not affect serum retinol levels (P >0.05). Conclusion: Serum retinol levels were low in patients with severe COVID-19. Drugs preventing retinol excretion were not stopped in the patient group. Some patients took vitamin A externally. Despite this, retinol was low in COVID-19 patients. Retinol depletion impairs Type-I interferon synthesis by impairing retinoid signaling. Retinoid signaling may be the main pathogenetic disorder in COVID-19. This pathogenesis can serve as a guide for adjuvants, drug targets, and candidate drugs. Retinol, retinoic acid derivatives, and some CYP450 inhibitors may work on COVID-19.",Aziz Rodan Sarohan; Hakan Akelma; Esref Arac; Ozgur Aslan,https://medrxiv.org/cgi/content/short/2021.01.30.21250844,https://medrxiv.org/cgi/content/short/2021.01.30.21250844,2021-02-01,2021-02-01,,True
54,Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA preparation method,"Current conventional detection of SARS-CoV-2 involves collection of a patient sample with a nasopharyngeal swab, storage of the swab during transport in a viral transport medium, extraction of RNA, and quantitative reverse transcription PCR (RT-qPCR). We developed a simplified and novel preparation method using a Chelex resin that obviates RNA extraction during viral testing. Direct detection RT-qPCR and digital-droplet PCR was compared to the current conventional method with RNA extraction for simulated samples and patient specimens. The heat-treatment in the presence of Chelex markedly improved detection sensitivity as compared to heat alone, and lack of RNA extraction shortens the overall diagnostic workflow. Furthermore, the initial sample heating step inactivates SARS-CoV-2 infectivity, thus improving workflow safety. This fast RNA preparation and detection method is versatile for a variety of samples, safe for testing personnel, and suitable for standard clinical collection and testing on high throughput platforms.",Bin Guan; Karen M Frank; Jose O Maldonado; Margaret Beach; Eileen Pelayo; Blake M Warner; Robert B Hufnagel,https://medrxiv.org/cgi/content/short/2021.01.29.21250790,https://medrxiv.org/cgi/content/short/2021.01.29.21250790,2021-02-01,2021-02-01,,True
55,Differential Cytokine Signatures of SARS-CoV-2 and Influenza Infection Highlight Key Differences in Pathobiology,"Background: Several inflammatory cytokines are upregulated in severe COVID-19. We compared cytokines in COVID-19 versus influenza in order to define differentiating features of the inflammatory response to these pathogens and their association with severe disease. Because elevated body mass index (BMI) is a known risk factor for severe COVID-19, we examined the relationship of BMI to cytokines associated with severe disease. Methods: Thirty-seven cytokines and chemokines were measured in plasma from 145 patients with COVID-19, 57 patients with influenza, and 30 healthy controls. Controlling for BMI, age, and sex, differences in cytokines between groups were determined by linear regression and random forest prediction was utilized to determine the cytokines most important in distinguishing severe COVID-19 and influenza. Mediation analysis was utilized to identify cytokines that mediate the effect of BMI on disease severity. Results: IL-18, IL-1{beta}, IL-6, and TNF- were significantly increased in COVID-19 versus influenza patients while GM-CSF, IFN-{gamma}, IFN-{lambda}1, IL-10, IL-15, and MCP-2 were significantly elevated in the influenza group. In subgroup analysis based on disease severity, IL-18, IL-6, and TNF- were elevated in severe COVID-19, but not severe influenza. Random forest analysis identified high IL-6 and low IFN-{lambda}1 levels as the most distinct between severe COVID-19 and severe influenza. Finally, IL-1RA was identified as a potential mediator of the effects of BMI on COVID-19 severity. Conclusions: These findings point to activation of fundamentally different innate immune pathways in SARS-CoV-2 and influenza infection, and emphasize drivers of severe COVID-19 to focus both mechanistic and therapeutic investigations.",Andrew H Karaba; Weiqiang Zhou; Leon L Hsieh; Alexis Figueroa; Guido Massaccesi; Richard E Rothman; Katherine ZJ Fenstermacher; Lauren Sauer; Kathryn Shaw-Saliba; Paul W Blair; Sherry Leung; Russell Wesson; Nada Alachkar; Ramy El-Diwany; Hongkai Ji; Andrea L Cox,https://medrxiv.org/cgi/content/short/2021.01.29.21250317,https://medrxiv.org/cgi/content/short/2021.01.29.21250317,2021-02-01,2021-02-01,,True
56,Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2,"Coronavirus disease 2019 (COVID-19) vaccine shortages have led some experts and countries to consider untested dosing regimens. We studied antibody responses to a single dose of the Pfizer-BioNTech or Moderna vaccines in healthcare workers (HCW) with laboratory-confirmed COVID-19 infection and compared to them to antibody responses of HCW who were IgG negative to SARS-CoV-2 spike protein. HCW with prior COVID-19 showed clear secondary antibody responses to vaccination with IgG spike binding titers rapidly increasing by 7 days and peaking by days 10 and 14 post-vaccination. At all time points tested, HCW with prior COVID-19 infection showed statistically significant higher antibody titers of binding and functional antibody compared to HCW without prior COVID-19 infection (p<.0001for each of the time points tested). In times of vaccine shortage, and until correlates of protection are identified, our findings preliminarily suggest the following strategy as more evidence-based: a) a single dose of vaccine for patients already having had laboratory-confirmed COVID-19; and b) patients who have had laboratory-confirmed COVID-19 can be placed lower on the vaccination priority list.",Saman Saadat; Zahra Rikhtegaran-Tehrani; James Logue; Michelle Newman; Matthew B Frieman; Anthony D. Harris; Mohammad M. Sajadi,https://medrxiv.org/cgi/content/short/2021.01.30.21250843,https://medrxiv.org/cgi/content/short/2021.01.30.21250843,2021-02-01,2021-02-01,,True
57,Diagnostic accuracy of PanbioTM rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2,"Background Antigen-detecting rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 offer new opportunities for testing in the context of the COVID-19 pandemic. Nasopharyngeal swabs (NPS) are the reference sample type, but oropharyngeal swabs (OPS) may be a more acceptable sample type in some patients. Methods We conducted a prospective study in a single screening center to assess the diagnostic performance of the PanbioTM COVID-19 Ag Rapid Test (Abbott) on OPS compared with reverse-transcription quantitative PCR (RT-qPCR) using NPS. Results 402 outpatients were enrolled in a COVID-19 screening center, of whom 168 (41.8%) had a positive RT-qPCR test. The oropharyngeal Ag-RDT sensitivity compared to nasopharyngeal RT-qPCR was 81% (95%CI: 74.2-86.6). Two false positives were noted out of the 234 RT-qPCR negative individuals, which resulted in a specificity of 99.1% (95%CI: 96.9-99.9) for the RDT. For cycle threshold values [&le;] 26.7 ([&ge;] 1E6 SARS-CoV-2 genomes copies/mL, a presumed cut-off for infectious virus), 96.3% sensitivity (95%CI: 90.7-99.0%) was obtained with the Ag-RDT using OPS. Interpretation Based on our findings, the diagnostic performance of the PanbioTM Covid-19 RDT with OPS samples meet the criteria required by the WHO for Ag-RDTs (sensitivity [&ge;] 80% and specificity [&ge;] 97%).",Marie-Therese Ngo Nsoga; Ilona Kronig; Francisco Javier Perez Rodriguez; Pascale Sattonnet-Roche; Diogo Da Silva; Javan Helbling; Jilian A Sacks; Margaretha de Vos; Erik Boehm; AngÃ¨le Gayet- Ageron; Alice Berger; FrÃ©dÃ©rique Jacquerioz-Bausch; FranÃ§ois Chappuis; Laurent Kaiser; Manuel Schibler; Adriana Renzoni; Isabella Eckerle,https://medrxiv.org/cgi/content/short/2021.01.30.21250314,https://medrxiv.org/cgi/content/short/2021.01.30.21250314,2021-02-01,2021-02-01,,True
58,Under what circumstances could vaccination offset the harm from a more transmissible variant of SARS-COV-2 in NYC? Trade-offs regarding prioritization and speed of vaccination.,"Introduction New York City (NYC) was a global epicenter of COVID-19. Vaccines against COVID-19 became available in December 2020 with limited supply, resulting in the need for policies regarding prioritization. The next month, SARS-CoV-2 variants were detected that were more transmissible but still vaccine-susceptible, raising scrutiny of these policies. In particular, prioritization of higher-risk people could prevent more deaths per dose of vaccine administered but could also delay herd immunity if the prioritization introduced bottlenecks that lowered vaccination speed (the number of doses that could be delivered per day). We used mathematical modeling to examine the trade-off between prioritization and the vaccination speed. Methods A stochastic, discrete-time susceptible-exposed-infected-recovered (SEIR) model with age- and comorbidity-adjusted COVID-19 outcomes (infections, hospitalizations, and deaths by July 1, 2021) was used to examine the trade-off between vaccination speed and whether or not vaccination was prioritized to individuals age 65+ and ""essential workers,"" defined as including first responders and healthcare, transit, education, and public safety workers. The model was calibrated to COVID-19 hospital admissions, hospital census, ICU census, and deaths in NYC. Vaccination speed was assumed to be 10,000 doses per day starting December 15th, 2020 targeting healthcare workers and nursing home populations, and to subsequently expand at alternative starting times and speeds. We compared COVID-outcomes across alternative expansion starting times (January 15th, January 21st, or February 1st) and speeds (20,000, 30,000, 50,000, 100,000, 150,000, or 200,000 doses per day for the first dose), as well as alternative prioritization options (""yes"" versus ""no"" prioritization of essential workers and people age 65+). Model projections were produced with and without considering the emergence of a SARS-COV-2 variant with 56% greater transmissibility over January and February, 2021. Results In the absence of a COVID-19 vaccine, the emergence of the more transmissible variant would triple the peak in infections, hospitalizations, and deaths and more than double cumulative infections, hospitalizations, and deaths. To offset the harm from the more transmissible variant would require reaching a vaccination speed of at least 100,000 doses per day by January 15th or 150,000 per day by January 21st. Prioritizing people ages 65+ and essential workers increased the number of lives saved per vaccine dose delivered: with the emergence of a more transmissible variant, 8,000 deaths could be averted by delivering 115,000 doses per day without prioritization or 71,000 doses per day with prioritization. If prioritization were to cause a bottleneck in vaccination speed, more lives would be saved with prioritization only if the bottleneck reduced vaccination speed by less than one-third of the maximum vaccine delivery capacity. These trade-offs between vaccination speed and prioritization were robust over a wide range of delivery capacity. Conclusions The emergence of a more transmissible variant of SARS-CoV-2 has the potential to triple the 2021 epidemic peak and more than double the 2021 COVID-19 burden in NYC. Vaccination could only offset the harm of the more transmissible variant if high speed were achieved in mid- to late January. Prioritization of COVID-19 vaccines to higher-risk populations saves more lives only if it does not create an excessive vaccine delivery bottleneck.",Hae-Young Kim; Anna Bershteyn; Jessica McGillen; R. Scott Braithwaite,https://medrxiv.org/cgi/content/short/2021.01.29.21250710,https://medrxiv.org/cgi/content/short/2021.01.29.21250710,2021-02-01,2021-02-01,,True
59,Genetically predicted serum vitamin D and COVID-19: a Mendelian randomization study,"Objectives: To investigate causality of the association of serum vitamin D with the risk and severity of COVID-19 infection. Design: Two-sample Mendelian randomization study. Setting: Summary data from genome-wide analyses in the population-based UK Biobank and SUNLIGHT Consortium, applied to meta-analyzed results of genome-wide analyses in the COVID-19 Host Genetics Initiative. Participants: 17,965 COVID-19 cases including 11,085 laboratory or physician confirmed cases, 7,885 hospitalized cases, and 4,336 severe respiratory cases, and 1,370,547 controls, primarily of European ancestry. Exposures: Genetically predicted variation in serum vitamin D status, based on genome-wide significant single nucleotide polymorphisms (SNPs) associated with serum vitamin D or risk of vitamin D deficiency/insufficiency. Main outcome measures: Susceptibility to and severity of COVID-19 infection, including severe respiratory infection and hospitalization. Results: Mendelian randomization analysis, powered to detect moderate effects comparable to those seen in observational studies, provided little to no evidence for an effect of genetically predicted serum vitamin D on susceptibility to or severity of COVID-19 infection. Using SNPs in loci related to vitamin D metabolism as proxies for serum vitamin D concentration, the odds ratio for a standard deviation increase in serum vitamin D was 1.04 (95% confidence interval 0.92 to 1.18) for any COVID-19 infection versus population controls, 1.05 (0.84-1.31) for hospitalized COVID-19 versus population controls, 0.96 (0.64 to 1.43) for severe respiratory COVID-19 versus population controls, 1.15 (0.99 to 1.35) for COVID-19 positive versus COVID-19 negative, and 1.44 (0.75 to 2.78) for hospitalized COVID-19 versus non-hospitalized COVID-19. Results were similar in analyses that used all SNPs with genome-wide significant associations with serum vitamin D (i.e., including SNPs in loci with no known relationship to vitamin D metabolism) and in analyses using SNPs with genome-wide significant associations with risk of vitamin D deficiency or insufficiency. Conclusions: These findings suggest that genetically predicted differences in long-term vitamin D nutritional status do not causally affect susceptibility to and severity of COVID-19 infection, and that associations observed in previous studies may have been driven by confounding. These results do not exclude the possibility of low-magnitude causal effects, nor do they preclude potential causal effects of acute responses to therapeutic doses of vitamin D. Future directions include extension of this work to non-European ancestry populations, and high-risk populations, for example persons with comorbid disease.",Bonnie K Patchen; Andrew G Clark; Nathan M Gaddis; Dana B Hancock; Patricia A Cassano,https://medrxiv.org/cgi/content/short/2021.01.29.21250759,https://medrxiv.org/cgi/content/short/2021.01.29.21250759,2021-02-01,2021-02-01,,True
60,Identification of B.1.346 lineage of SARS-CoV-2 in Japan: Genomic evidence of re-entry of Clade 20C,"Objectives Whole SARS-CoV-2 genome sequencing from COVID-19 patients is useful for infection control and regional trends evaluation. We report a lineage data collected from hospitals in the Kanto region of Japan. Methods We performed whole genome sequencing in specimens of 198 COVID-19 patients at 13 collaborating hospitals in the Kanto region. Phylogenetic analysis and fingerprinting of the nucleotide substitutions underwent to differentiate and classify the viral lineages. Results More than 90% of the strains belonged to Clade 20B and two lineages (B.1.1.284 and B.1.1.214) have been detected predominantly in the Kanto region. However, one sample from a COVID-19 patient in November 2020, belonged to the B.1.346 lineage of Clade 20C, which has been prevalent in western United States. The patient had no history of overseas travel and no contact with anyone who had travelled abroad, suggesting that this strain appeared likely to have been imported from western United States, across the strict quarantine barrier. Conclusion B.1.1.284 and B.1.1.214 have been identified predominantly in the Kanto region and B.1.346 of clade 20C in one patient was probably imported from western United States. These results illustrate that a decentralized network of hospitals can be significantly advantageous for monitoring regional molecular epidemiologic trends.",Abe Kodai; Shimura Takako; Takenouchi Toshiki; Iwasaki Yuka; Ishizu Hirotsugu; Uwamino Yoshifumi; Uno Shunsuke; Gotoh Jun; Tachikawa Natsuo; Takeuchi Yuriko; Katayama Junpei; Nozaki Hiroyuki; Fujii Susumu; Seki Shikou; Nakamura Morio; Uda Kazuhiro; Misumi Takahiko; Ishihara Jun; Yamada Kenichiro; Kanai Toshio; Murai Shinji; Araki Kazuhiro; Ebihara Tamotsu; Shiomi Haruhiko; Hasegawa Naoki; Amagai Masayuki; Kitagawa Yuko; Suematsu Makoto; Kosaki Kenjiro,https://medrxiv.org/cgi/content/short/2021.01.29.21250798,https://medrxiv.org/cgi/content/short/2021.01.29.21250798,2021-02-01,2021-02-01,,True
61,Aerosol emission from the respiratory tract: an analysis of relative risks from oxygen delivery systems,"Background: Risk of aerosolisation of SARS-CoV-2 directly informs organisation of acute healthcare and PPE guidance. Continuous positive airways pressure (CPAP) and high-flow nasal oxygen (HFNO) are widely used modes of oxygen delivery and respiratory support for patients with severe COVID-19, with both considered as high risk aerosol generating procedures. However, there are limited high quality experimental data characterising aerosolisation during oxygen delivery and respiratory support. Methods: Healthy volunteers were recruited to breathe, speak, and cough in ultra-clean, laminar flow theatres followed by using oxygen and respiratory support systems. Aerosol emission was measured using two discrete methodologies, simultaneously. Hospitalised patients with COVID-19 were also recruited and had aerosol emissions measured during breathing, speaking, and coughing. Findings: In healthy volunteers (n = 25 subjects; 531 measures), CPAP (with exhalation port filter) produced less aerosols than breathing, speaking and coughing (even with large >50L/m facemask leaks). HFNO did emit aerosols, but the majority of these particles were generated from the HFNO machine, not the patient. HFNO-generated particles were small (<1 micron), passing from the machine through the patient and to the detector without coalescence with respiratory aerosol, thereby unlikely to carry viral particles. Coughing was associated with the highest aerosol emissions with a peak concentration at least 10 times greater the mean concentration generated from speaking or breathing. Hospitalised patients with COVID-19 (n = 8 subjects; 56 measures) had similar size distributions to healthy volunteers. Interpretation: In healthy volunteers, CPAP is associated with less aerosol emission than breathing, speaking or coughing. Aerosol emission from the respiratory tract does not appear to be increased by HFNO. Although direct comparisons are complex, cough appears to generate significant aerosols in a size range compatible with airborne transmission of SARS-CoV-2. As a consequence, the risk of SARS-CoV-2 aerosolisation is likely to be high in all areas where patients with Covid-19 are coughing. Guidance on personal protective equipment policy should reflect these updated risks. Funding: NIHR-UKRI Rapid COVID call (COV003), Wellcome Trust GW4-CAT Doctoral Training Scheme (FH), MRC CARP Fellowship(JD, MR/T005114/1). Natural Environment Research Council grant (BB, NE/P018459/1)",Fergus W Hamilton; Florence Gregson; David T Arnold; Sadiyah Sheikh; Kirsty Ward; Jules Brown; Ed Moran; Carrie White; Anna Morley; - AERATOR Group; Bryan R Bzdek; Jonathan Reid; Nick Maskell; James W Dodd,https://medrxiv.org/cgi/content/short/2021.01.29.21250552,https://medrxiv.org/cgi/content/short/2021.01.29.21250552,2021-02-01,2021-02-01,,True
62,Impact of public sentiments on the transmission of COVID-19 across a geographical gradient,"COVID-19 is a respiratory disease caused by a recently discovered, novel coronavirus, SARS-COV2. The disease has led to over 81 million confirmed cases of COVID-19, with close to 2 million deaths. In the current social climate, the risk of COVID-19 infection is driven by individual and public perception of risk and sentiments. A number of factors influences public perception, including an individual's belief system, prior knowledge about a disease and information about a disease. In this paper, we develop a model for COVID-19 using a system of ordinary differential equations following the natural history of the infection. The model uniquely incorporates social behavioral aspects such as quarantine and quarantine violation. The model is further driven by people's sentiments (positive and negative) which accounts for the influence of disinformation. People's sentiments were obtained by parsing through and analyzing COVID-19 related tweets from Twitter, a social media platform across six countries. Our results show that our model incorporating public sentiments is able to capture the trend in the trajectory of the epidemic curve of the reported cases. Furthermore, our results show that positive public sentiments reduce disease burden in the community. Our results also show that quarantine violation and early discharge of the infected population amplifies the disease burden on the community. Hence, it is important to account for public sentiment and individual social behavior in epidemic models developed to study diseases like COVID-19.",Folashade Agusto; Eric Numfor; Srinivasan Karthik; Enahoro Iboi; Alexander Fulk; Jarron M. Saint Onge; Townsend Peterson,https://medrxiv.org/cgi/content/short/2021.01.29.21250655,https://medrxiv.org/cgi/content/short/2021.01.29.21250655,2021-02-01,2021-02-01,,True
63,Testing out of quarantine,"Since SARS-CoV-2 emerged, a 14-day quarantine has been recommended based on COVID-19's incubation period. Using an RT-PCR or rapid antigen test to ""test out"" of quarantine is a frequently proposed strategy to shorten duration without increasing risk. We calculated the probability that infected individuals test negative for SARS-CoV-2 on a particular day post-infection and remain symptom free for some period of time. We estimate that an infected individual has a 20.1% chance (95% CI 9.8-32.6) of testing RT-PCR negative on day five post-infection and remaining asymptomatic until day seven. We also show that the added information a test provides decreases as we move further from the test date, hence a less sensitive test that returns rapid results is often preferable to a more sensitive test with a delay.",Lucy D'Agostino McGowan; Elizabeth C. Lee; Kyra H. Grantz; Lauren Kucirka; Emily S. Gurley; Justin Lessler,https://medrxiv.org/cgi/content/short/2021.01.29.21250764,https://medrxiv.org/cgi/content/short/2021.01.29.21250764,2021-02-01,2021-02-01,,True
64,Predicting Prognosis in COVID-19 Patients using Machine Learning and Readily Available Clinical Data,"Rationale Prognostic tools for aiding in the treatment of hospitalized COVID-19 patients could help improve outcome by identifying patients at higher or lower risk of severe disease. Objectives The study objective was to develop models to stratify patients by risk of severe outcomes during COVID-19 hospitalization using readily available information at hospital admission. Methods Hierarchical ensemble classification models were trained on a set of 229 patients hospitalized with COVID-19 to predict severe outcomes, including ICU admission, development of ARDS, or intubation, using easily attainable attributes including basic patient characteristics, vital signs at admission, and basic lab results collected at time of presentation. Each test stratifies patients into groups of increasing risk. An additional cohort of 330 patients was used for blinded, independent validation. Shapley value analysis evaluated which attributes contributed most to the models' predictions of risk. Measurements and Main Results Test performance was assessed using precision (positive predictive value) and recall (sensitivity) of the final risk groups. All test cut-offs were fixed prior to blinded validation. In both development and validation, the tests achieved precision in the lowest risk groups near or above 0.9. The proportion of patients with severe outcomes significantly increased across increasing risk groups. While the importance of attributes varied by test and patient, CRP, LDH, and D-dimer were often found to be important in the assignment of risk label. Conclusions Risk of severe outcomes for patients hospitalized with COVID-19 infection can be assessed using machine learning-based models based",Thomas W Campbell; Melissa P Wilson; Heinrich Roder; Samantha MaWhinney; Robert W Georgantas III; Laura K Maguire; Joanna Roder; Kristine M Erlandson,https://medrxiv.org/cgi/content/short/2021.01.29.21250762,https://medrxiv.org/cgi/content/short/2021.01.29.21250762,2021-02-01,2021-02-01,,True
65,"""This is really like waiting for war and this is not good"" - Intertwining between pandemic experiences, and the development of professional action of healthcare professionals in critical care at the beginning of the COVID-19 pandemic in Germany: a qualitative study","Objectives Healthcare professionals (HCPs) are facing remarkable challenges in their daily work since the outbreak of the COVID-19 pandemic. Being well prepared is crucial for dealing with such a pandemic. The aim of our study was to explore HCPs' subjective perspectives on their professional action and coping strategies in critical care during the preparation and coping phase after the outbreak of the COVID-19 pandemic in Germany. Design Together with HCPs working in critical care, we collaboratively designed an interview study based on an ethnomethodological approach. We performed semi-structured qualitative interviews via telephone or video call and analysed the data based on grounded theory. Setting Our research interest was focused on HCPs (qualified nurses, physicians, medical students) working in critical care during the first wave of the COVID-19 pandemic in Germany between April and July 2020. Participants Our sample consisted of 39 HCPs (19 nurses, 17 physicians, three medical students, 18/39 female) from ten German federal states. All participants were involved in the acute care of COVID-19 infected patients in hospitals and had a mean professional experience of 14.8{+/-}10.1 years, 15 participants held a management position (e.g. senior physician or head nurse). We recruited participants via personal contacts and snowballing. Results Initial and focused coding resulted in seven categories: Creating structural measures, handling operational changes, dealing with personal protective equipment, building up knowledge and skills, managing information, perceiving peer support and experiencing emotions. Conclusions Professional action and subjectively perceived preparedness (professional and emotional) interacted with each other. Their interrelation was not static, but rather dynamic and ambiguous according to the situation. The findings of our study can be beneficial in developing guidelines, policy interventions or personnel and work practice strategies.",Madlen Hoerold; Karl Philipp Drewitz; Vreni Brunnthaler; Julia Piel; Magdalena Rohr; Ilona Hrudey; Claudia Hasenpusch; Angela Ulrich; Niklas Otto; Susanne Brandstetter; Christian Apfelbacher,https://medrxiv.org/cgi/content/short/2021.01.29.21250626,https://medrxiv.org/cgi/content/short/2021.01.29.21250626,2021-02-01,2021-02-01,,True
66,Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study,"Background: SARS-CoV-2 antibody tests are used for population surveillance and might have a future role in individual risk assessment. Lateral flow immunoassays (LFIAs) can deliver results rapidly and at scale, but have widely varying accuracy. Methods: In a laboratory setting, we performed head-to-head comparisons of four LFIAs: the Rapid Test Consortium AbC-19TM Rapid Test, OrientGene COVID IgG/IgM Rapid Test Cassette, SureScreen COVID-19 Rapid Test Cassette, and Biomerica COVID-19 IgG/IgM Rapid Test. We analysed blood samples from 2,847 key workers and 1,995 pre-pandemic blood donors with all four devices. Findings: We observed a clear trade-off between sensitivity and specificity: the IgG band of the SureScreen device and the AbC-19TM device had higher specificities but OrientGene and Biomerica higher sensitivities. Based on analysis of pre-pandemic samples, SureScreen IgG band had the highest specificity (98.9%, 95% confidence interval 98.3 to 99.3%), which translated to the highest positive predictive value across any pre-test probability: for example, 95.1% (95%CI 92.6, 96.8%) at 20% pre-test probability. All four devices showed higher sensitivity at higher antibody concentrations (spectrum effects), but the extent of this varied by device. Interpretation: The estimates of sensitivity and specificity can be used to adjust for test error rates when using these devices to estimate the prevalence of antibody. If tests were used to determine whether an individual has SARS-CoV-2 antibodies, in an example scenario in which 20% of individuals have antibodies we estimate around 5% of positive results on the most specific device would be false positives. Funding: Public Health England.",Hayley E Jones; Ranya Mulchandani; Sian Taylor-Phillips; A E Ades; Justin Shute; Keith Perry; Nastassya Chandra; Tim Brooks; Andre Charlett; Matthew Hickman; Isabel Oliver; Stephen Kaptoge; John Danesh; Emanuele Di Angelantonio; - COMPARE Study investigators; - EDSAB-HOME investigators; David H WYLLIE,https://medrxiv.org/cgi/content/short/2021.01.30.21250777,https://medrxiv.org/cgi/content/short/2021.01.30.21250777,2021-02-01,2021-02-01,,True
67,COVID-19 Hospitalizations in Five California Hospitals,"Importance: Characterization of a diverse cohort hospitalized with COVID-19 in a health care system in California is needed to further understand the impact of SARS-CoV-2 and improve patient outcomes. Objectives: To investigate the characteristics of patients hospitalized with COVID-19 and assess factors associated with poor outcomes. Design: Patient-level retrospective cohort study Setting: University of California five academic hospitals. Participants: Patients [&ge;]18 years old with a confirmed test result for SAR-CoV-2 virus hospitalized at five UC hospitals. Exposure: Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive results on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring hospital admission. Main Outcomes and Measures: Admission to the intensive care unit, death during hospitalization, and the composite of both outcomes. Results: Outcomes were assessed for 4,730 patients who were discharged or died during a hospitalization. A total of 846 patients were treated at UC Davis, 1,564 UC Irvine, 1,283 UC Los Angeles, 471 UC San Diego, and 566 UC San Francisco. More than 20% of patients were [&ge;]75 years of age (75-84: 12.3%, [&ge;]85: 10.5%), male (56.5%), Hispanic/Latino (45.7%), and Asian (10.3%). The most common comorbidities were hypertension (35.2%), cardiac disease (33.3%), and diabetes (24.0%). The ICU admission rate was 25.2% (1194/4730), with 7.0% (329/4730) in-hospital mortality. Among patients admitted to the ICU, 18.8% (225/1194) died; 2.9% (104/3536) died without ICU admission. The rate of the composite outcome (ICU admission and/or death) was 27.4% (1,298/4,730). While controlling for comorbidities, patients of age 75-84 (OR 1.47, 95% CI: 1.11-1.93) and 85-59 (OR 1.39, 95% CI: 1.04-1.87) were more likely to experience a composite outcome than 18-34 year-olds. Males (OR 1.39, 95% CI: 1.21-1.59), and patients identifying as Hispanic/Latino (OR 1.35, 95% CI: 1.14-1.61), and Asian (OR 1.43, 95% CI: 1.23-1.82), were also more likely to experience a composite outcome than White. Patients with 5 or more comorbidities were exceedingly likely to experience a composite outcome (OR 2.74, 95% CI: 2.32-3.25). Conclusions: Males, older patients, those with pre-existing comorbidities, and those identifying as Hispanic/Latino or Asian experienced an increased risk of ICU admission and/or death.",Miriam Nuno; Yury Garcia; Ganesh Rajasekar; Diego Pinheiro; Alec J Schmidt,https://medrxiv.org/cgi/content/short/2021.01.29.21250788,https://medrxiv.org/cgi/content/short/2021.01.29.21250788,2021-02-01,2021-02-01,,True
68,Strategies for vaccination against SARS-CoV-2 to efficiently bring R<1,"With limited availability of vaccines, an efficient use of the limited supply of vaccines in order to achieve herd immunity will be an important tool to combat the wide-spread prevalence of COVID-19. Here, we propose a targeted vaccination approach (EHR) that provides a significant reduction in the necessary number of doses needed achieve herd immunity compared to age-prioritized and random selection vaccination schemes. Using high-fidelity individual-based computer simulations with Oslo, Norway as an example, we find that for a community reproductive number in a setting where R=1.4 without population immunity, the EHR method reaches herd immunity at only 15% of the population vaccinated, whereas the common age-prioritized approach needs 40%. With R=1.9 in the absence of immunity, EHR needs 30% and age-prioritized needs 52%.",Andre Voigt; Stig William Omholt; Eivind Almaas,https://medrxiv.org/cgi/content/short/2021.01.30.21250828,https://medrxiv.org/cgi/content/short/2021.01.30.21250828,2021-02-01,2021-02-01,,True
69,COVID-19 spread and Weather in U.S. states: a cross-correlative study on summer-autumn 2020.,"An effect of weather on sars-cov-2 transmission is regularly proposed as a putative cause of unexplained fluctuations of covid-19 new cases, but clear data supporting this hypothesis remains to be presented. Here I measured longitudinal time-series correlations between outdoor temperature, humidity and covid-19 reproduction number (Rt) in the 50 U.S. states (+DC). In order to mitigate the confounding influence of varying social restriction measures, the analysis spans a 5-month period during summer and autumn 2020 when restrictions were comparatively lower and more stable. I used a cross-covariance approach to account for a variable delay between infection and case report. For a delay near 11 days, most U.S. states exhibited a negative correlation between outdoor temperature and Rt, as well as between absolute humidity and Rt (mean r = -0.35). In 21 states, the correlation was strong (r < -0.5). Individual state data are presented, and associations between cold and/or dry weather episodes and short-term new case surges are proposed. After identifying potential confounding factors, I discuss 3 possible causal mechanisms that could explain a correlation between outdoor weather and indoor disease transmission: behavioral adaptations to cold weather, respiratory tract temperature, and the importing of outdoor absolute humidity to indoor spaces.",Emmanuel de Margerie,https://medrxiv.org/cgi/content/short/2021.01.29.21250793,https://medrxiv.org/cgi/content/short/2021.01.29.21250793,2021-02-01,2021-02-01,,True
70,Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in The Washington Metropolitan Area as of October 2020,"The estimated SARS-CoV-2 seroprevalence in children was found to be 9.46% for the Washington Metropolitan area. Hispanic/Latinx individuals were found to have higher odds of seropositivity. While chronic medical conditions were not associated with having antibodies, previous fever and body aches were predictive symptoms.",Burak Bahar; Joelle N Simpson; Cara Biddle; Andrew Campbell; Jeffrey S Dome; Roberta L DeBiasi; Catriona Mowbray; Stefanie Marguilies; Adrienne Sherman; Jacqueline Reuben; Meghan Delaney,https://medrxiv.org/cgi/content/short/2021.01.30.21250830,https://medrxiv.org/cgi/content/short/2021.01.30.21250830,2021-02-01,2021-02-01,,True
71,Understanding soaring coronavirus cases and the effect of contagion policies in the UK,"The number of new daily SARS-CoV-2 infections is frantically rising in almost every country of the EU. The phenomenological explanation offered is a new mutation of the virus, first identified in the UK. We use publicly available data in combination with a controlled SIR model, which captures the effects of preventive measures on the active cases, to show that the current wave of infections is consistent with a single transmission rate. This suggests that the new SARS-CoV-2 variant is as transmissible as previous strains. Our findings indicate that the relaxation of preventive measures is closely related with the ongoing surge in cases. We simulate the effects of new restrictions and vaccination campaigns in 2021, demonstrating that lockdown policies are not fully effective to flatten the curve. For effective mitigation, it is critical that the public keeps on high alert until vaccination reaches a critical threshold.",Miguel A Duran-Olivencia; Serafim Kalliadasis,https://medrxiv.org/cgi/content/short/2021.01.30.21250822,https://medrxiv.org/cgi/content/short/2021.01.30.21250822,2021-02-01,2021-02-01,,True
72,Impact of COVID-19 restrictions on the postpartum experience of women living in Eastern Canada: A mixed method cohort study,"OBJECTIVES: To (1) compare changes in self-efficacy, social support, postpartum anxiety and postpartum depression in Canadian women collected before (Cohort 1) and during the COVID-19 pandemic (Cohort 2); (2) explore the women felt related to having a newborn during the pandemic; and (3) explore ways that women coped. METHODS: Prior to the pandemic (October 1, 2019-January 1, 2020), an online survey was conducted with women had given birth within the past six months in one of the three Eastern Canadian Maritime provinces (Cohort 1). A second, similar survey was conducted between August 1, 2020 and October 31, 2020 (Cohort 2) during a period of provincial pandemic response to COVID-19. RESULTS: For Cohort 1, 561 women completed the survey and 335 women in Cohort 2. Cohorts were similar in terms of age of women, parity, and age of newborn. There were no significant differences for self-efficacy, social support, postpartum anxiety, and depression between the cohorts. Difficulties that women reported as a result of COVID-19 restrictions included lack of support from family and friends, fear of COVID-19 exposure, feeling isolated and uncertain, negative impact on perinatal care experience, and hospital restrictions. Having support from partners and families, in-person/virtual support, as well as self-care and the low prevalence of COVID-19 during the summer of 2020 helped women cope. CONCLUSION: While there was no significant difference in pre-pandemic and during pandemic psychosocial outcomes, there were still challenges and negative impacts that women identified. Consideration of vulnerable populations is important when making public health recommendations.",Justine Dol; Brianna Richardson; Megan Aston; Douglas McMillan; Gail Tomblin Murphy; Marsha Campbell-Yeo,https://medrxiv.org/cgi/content/short/2021.01.30.21250555,https://medrxiv.org/cgi/content/short/2021.01.30.21250555,2021-02-01,2021-02-01,,True
73,Prognosis and hematological findings in patients with COVID-19 in an Amazonian population of Peru,"Objective: This study examined the laboratory results of COVID-19 patients from a hospital in the Peruvian Amazon and their clinical prognosis. Methods: An analytical cross-sectional study was carried out whose purpose was to identify the laboratory tests of patients with COVID-19 and mortality in a hospital in Ucayali, Peru during the period from March 13 to May 9, 2020, selecting a total of 127 with Covid-19. Mean and the standard deviation was described for age, leukocytes, neutrophils, platelets, RDW-SD; median and interquartile range for the variables lymphocyte, RN / L, fibrinogen, CRP, D-dimer, DHL, hematocrit, monocytes, eosinophils. Results: No differences were observed in this population regarding death and sex (OR: 1.31; 95% CI 0.92 to 1.87), however, it was observed that, for each one-year increase, the probability of death increased by 4% (PR: 1.04, 95% CI 1.03 to 1.05). The IRR (Incidence Risk Ratio) analysis for the numerical variables showed results strongly associated with hematological values such as Leukocytes (scaled by 2500 units) (IRR: 1.08, 95% CI 1.03 to 1.13), neutrophils (scaled by 2500 units) (IRR: 1.08; 95% CI 1.03 to 1.13), on the contrary, it is observed that the increase of 1000 units in lymphocytes, the probability of dying decreased by 48% (IRR: 0.52; 95% CI 0.38 to 071). Conclusion: Parameters such as leukocytes and neutrophils were statistically much higher in patients who died.",Sebastian Iglesias-Osores; Arturo Rafael-Heredia; Eric Ricardo Rojas-Tello; Washington A. Ortiz-Uribe; Walter Leveau-Bartra; Orison Armando Leveau-Bartra; Miguel Alcantara-Mimbela; Lizbeth M. Cordova-Rojas; Elmer Lopez-Lopez; Virgilio E. Failoc-Rojas,https://medrxiv.org/cgi/content/short/2021.01.31.21250859,https://medrxiv.org/cgi/content/short/2021.01.31.21250859,2021-02-01,2021-02-01,,True
74,Immuno-fibrotic drivers of impaired lung function in post-COVID-19 syndrome,"Subjects recovering from COVID-19 frequently experience persistent respiratory ailments; however, little is known about the underlying biology that directs lung recovery and its relation to COVID-19 severity. We performed a cohort study of subjects with lingering symptoms after COVID-19, collecting clinical data, pulmonary function tests, and plasma for multiplex biomarker profiling. Sixty-one subjects were enrolled across two academic medical centers at a median of 9 weeks post-COVID-19: n=13 (21%) mild/non-hospitalized, n=30 (49%) hospitalized/noncritical, and n=18 (30%) hospitalized/ICU. Dyspnea (69%) and cough (58%) were common. Pulmonary function at follow-up declined as acute COVID-19 severity increased (P<0.05), but did not correlate with symptoms. Partial least-squares discriminant analysis of biomarkers clustered subjects by COVID-19 severity. Lipocalin 2 (LCN2), matrix metalloproteinase-7 (MMP-7), and hepatocyte growth factor (HGF) were significantly higher in ICU subjects (P<0.05), and inversely correlated with pulmonary function (P<0.05). These host response profiles reflecting neutrophil activation, fibrosis signaling, and alveolar repair, respectively, may be novel therapeutic or prognostic targets in post-COVID-19 syndrome.",Hyung J. Chun; Elias Coutavas; Alexander Pine; Alfred I. Lee; Vanessa Yu; Marcus Shallow; Coral X. Giovacchini; Anne Mathews; Brian Stephenson; Loretta G. Que; Patty J. Lee; Bryan D. Kraft,https://medrxiv.org/cgi/content/short/2021.01.31.21250870,https://medrxiv.org/cgi/content/short/2021.01.31.21250870,2021-02-01,2021-02-01,,True
75,Persistent COVID-19 symptoms minimally impact the development of SARS-CoV-2 specific cellular immunity,"SARS-CoV-2 represents an unprecedented public health challenge with many unknowns remaining regarding the factors that impact viral pathogenicity and the development of immunity after infection. While the majority of SARS-CoV-2 infected individuals with mild-to-moderate COVID-19 resolve their infection with few complications, a significant number of individuals experienced prolonged symptoms lasting for weeks after initial diagnosis. Persistent viral infections are commonly accompanied by immunologic dysregulation, especially within the cellular immune compartment. However, it is unclear if persistent mild-to-moderate COVID-19 impacts the development of virus-specific cellular immunity. To this end, we analyzed the development of SARS-CoV-2 specific cellular immunity in convalescent COVID-19 patients who experienced eight days or fewer of COVID-19 symptoms, or symptoms persisting for 18 days or more. We observed that the duration of COVID-19 symptoms minimally impacts the magnitude, antigen specificity, and transcriptional profile of SARS-CoV-2 specific cellular immunity within both the CD4+ and CD8+ T cell compartments. Furthermore, we observed that reactivity against the structural N protein from SARS-CoV-2 in convalescent COVID-19 patients correlates with the amount of reactivity against the seasonal human coronaviruses 229E and NL63. These results provide additional insight into the complex processes that regulate the development of cellular immunity against SARS-CoV-2 and related human coronaviruses",HengSheng Fang; Adam D Wegman; Kianna Ripich; Heather Friberg; Jeffrey Currier; Stephen J Thomas; Timothy P Endy; Adam Waickman,https://medrxiv.org/cgi/content/short/2021.01.29.21250771,https://medrxiv.org/cgi/content/short/2021.01.29.21250771,2021-02-01,2021-02-01,,True
76,Using time use diaries to track changing behavior across successive stages of COVID-19 social restrictions,"We present analyses of 24-hour time use diary records of the UK populations activities, their social context and their location, collected in real time from four successive waves of representative UK samples, both before, and during, the current COVID-19 pandemic. We show changes in behavioral response to social restrictions at three time-points during the pandemic, including across two nationwide lockdowns. Comparing samples across the four waves, we find evidence of substantial changes in the populations activities, locations and social interactions, which may be interpreted as direct responses to changes in regulations. One of our main motivations was to compare risk-related behavior across the first and second lockdowns. We find suggestive evidence that the second lockdown (recorded late November 2020) was less strictly adhered to than the first (recorded May-June 2020). Holding constant gender, age and social grade, the population spent on average 32 more minutes per day in high risk activities in late November 2020 than in first lockdown. Disaggregating by gender and age group, the difference was found to be statistically significant for all groups, with the exception of those aged 55 and over.",Jonathan Gershuny; Oriel Sullivan; Almudena Sevilla; Margarita Vega-Rapun; Francesca Foliano; Juana Lamote de Grignon; Teresa Harms; Pierre Walthery,https://medrxiv.org/cgi/content/short/2021.01.29.21250766,https://medrxiv.org/cgi/content/short/2021.01.29.21250766,2021-02-01,2021-02-01,,True
77,Minimizing loss of life in Covid-19 in a 100 day period in the U.S.A. by age-tailored dosing and distribution of a limited vaccine supply,"Background: We aimed at minimizing loss of lives in the Covid-19 pandemic in the USA by identifying optimal vaccination strategies during a 100-day period. While lethality is highest in the elderly, transmission and case numbers are highest in the young. Due to limited vaccine availability, a strategy of first vaccinating the elderly is widely used. Vaccines elicit enhanced immune responses in younger persons compared to the elderly, but even in the latter, mRNA vaccines are effective, implying that in the young, lower vaccine doses might suffice for protection, thereby increasing the number of persons that can be vaccinated. Methods: Using published immunogenicity data of the Moderna mRNA-1273 vaccine, we examined the value of tailored-dose vaccination strategies, using a modeling approach that incorporates age-related vaccine immunogenicity, social contact patterns, population structure, Covid-19 case and death rates in the U.S. in late January 2021. Reduced dose vaccination in the young multiplies the number of individuals vaccinated early. Results: Age-tailored dosing strategies led to faster case reduction and thereby shortened the pandemic, reducing the delay to reaching <100'000/day from 64 to 30 days and avoiding 25'000 deaths within 100 days in the USA. While regular vaccination of the elderly can continue, the main protection of the elderly resulted from stopping the pandemic by vaccinating a large number of young persons by age-adapted dosing. Conclusion: Rapid reduction of Covid-19 case and death rate in the U.S. can be best achieved by using highly effective vaccines in an age-tailored dosing regimen. Protecting the vulnerable is most effectively achieved by dose tailored vaccination of all population segments, while an 'elderly first' approach costs more lives, even in the elderly.",Patrick Hunziker,https://medrxiv.org/cgi/content/short/2021.01.30.21250834,https://medrxiv.org/cgi/content/short/2021.01.30.21250834,2021-02-01,2021-02-01,,True
78,Emergence of first strains of Sars-CoV-2 lineage B.1.1.7 in Romania,"United Kingdom reported the emergence of a new and highly transmissible SARS-CoV-2 variant B.1.1.7. that rapidly spread to other contries. The impact of this new mutation that occurs in the S protein, on infectivity, virulence and current vaccine effectiveness is still under evaluation. We have identified the first cases of the B.1.1.7 variant in samples collected from Romanian patients, of which one was traced to the UK region where the new variant was originally sequenced. Mutations in the Nsp3 protein, N844S and D455N and L15F in Orf3a were also detected, indicating common ancestry with UK strains as well as remote connections with strains from Nagasaki, Japan. These results indicate, for the first time, the presence and characteristics of the new variant B.1.1.7 in Romania and underscore the need for increased genomic sequencing in confirmed COVID-19 patients.",Andrei Lobiuc; Mihai Dimian; Olga Sturdza; Roxana Filip; Mihai Covasa,https://medrxiv.org/cgi/content/short/2021.01.29.21250643,https://medrxiv.org/cgi/content/short/2021.01.29.21250643,2021-02-01,2021-02-01,,True
79,Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine,"As COVID-19 vaccines are getting rolled out, an important question is arising: Should individuals who already had a SARS-CoV-2 infection receive one or two shots of the currently authorized mRNA vaccines. In this short report, we are providing evidence that the antibody response to the first vaccine dose in individuals with pre-existing immunity is equal to or even exceeds the titers found in naive individuals after the second dose. We also show that the reactogenicity is significantly higher in individuals who already have been infected with SARS-CoV-2 in the past. Changing the policy to give these individuals only one dose of vaccine would not negatively impact on their antibody titers, spare them from unnecessary pain and free up many urgently needed vaccine doses.",Florian Krammer; Komal Srivastava; - PARIS team; Viviana Simon,https://medrxiv.org/cgi/content/short/2021.01.29.21250653,https://medrxiv.org/cgi/content/short/2021.01.29.21250653,2021-02-01,2021-02-01,,True
80,"Structural basis of fitness of emerging SARS-COV-2 variants and considerations for screening, testing and surveillance strategy to contain their threat.","While emergence of new SAS-COV-2 variants is posing grave challenge to efforts to deal with the COVID-19 pandemic, the structural and molecular basis of their fitness remain poorly understood. We performed in silico analysis of structures of two most frequent SARS-COV-2 mutations, namely, N501Y and E484K, to identify plausible basis of their fitness over the original strain. The analysis suggested that the N501Y mutation is associated with strengthening of intra- as well as intermolecular H-bond in the hACE2 receptor-spike protein complex, which could result in increased affinity and, therefore, higher infectivity. While E484K mutation did not seem to directly affect the binding with hACE2 receptor, it disrupted H-bonding and salt-bridge interaction associated with binding with neutralizing antibody, which could affect chance of re-infection, disease outcome. Survey of several other mutations showing reduction in antibody-mediated neutralization also revealed that similar disruption of H-bonding or salt-bridge or Van der Waals interaction might explain their phenotype. Analysis of GESS database indicated that N501Y, EK484 as well as these other mutations existed since March-April, 2020, might have evolved independently across the world and may keep accumulating, which could affect efficacy of vaccination and antibody-based therapies. Our analysis also indicated that these may spread in spite of current travel restrictions focused on few countries and evolve indigenously warranting intensification of surveillance for emerging mutations among all travellers as well as people in their dwelling zones. Meta-analysis of existing literature showed that repeat testing of travellers, contacts and others under scrutiny 7-11 days after the initial RT-PCR test may significantly help to contain the spread of emerging variants by catching false negative results. In addition, existing evidence calls for development of strain-specific tests, escalated sequencing and broadening the scope of surveillance including in hospitals and animal farms to contain the threat of emerging variants.",Sk Ramiz Islam; Debasish Prusty; Soumen Kanti Manna,https://medrxiv.org/cgi/content/short/2021.01.28.21250666,https://medrxiv.org/cgi/content/short/2021.01.28.21250666,2021-01-31,2021-01-31,,True
81,How well do face masks protect the wearer compared to public perceptions?,"Introduction There is a growing body of evidence to support the wearing of face masks to reduce spread of infectious respiratory pathogens, including SARS-CoV-2. However, the literature exploring the effectiveness of homemade fabric face masks is still in its infancy. Developing an evidence base is an important step to ensure that public policy is evidence based and truly effective. Methods Two methodologies were used in this study: quantitative fit testing of various face masks to indicate their effectiveness and a survey of 710 US residents about their perceptions of face mask effectiveness. N95, surgical and two fabric face masks were tested on an individual twenty five times each using a TSI 8038+ machine. Our survey was distributed by Qualtrics XM, asking participants to estimate the effectiveness of N95, surgical and fabric face masks. Results and Discussion Our results indicate that fabric face masks blocked between 62.6% and 87.1% of fine particles, whereas surgical masks protected against an average of 78.2% of fine particles. N95 masks blocked 99.6% of fine particles. Survey respondents tended to underestimate the effectiveness of masks, especially fabric masks. Together these results suggest that fabric masks may be a useful tool in the battle against the COVID-19 pandemic and that increasing public awareness of the effectiveness of fabric masks may help in this endeavour.",Eugenia O'Kelly; Anmol Arora; James Ward; P John Clarkson,https://medrxiv.org/cgi/content/short/2021.01.27.21250645,https://medrxiv.org/cgi/content/short/2021.01.27.21250645,2021-01-31,2021-01-31,,True
82,High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19,"Since the outset of the COVID-19 pandemic, increasing evidence suggests that the innate immune responses play an important role in the disease development. A dysregulated inflammatory state has been proposed as key driver of clinical complications in COVID-19, with a potential detrimental role of granulocytes. However, a comprehensive phenotypic description of circulating granulocytes in SARS-CoV-2-infected patients is lacking. In this study, we used high-dimensional flow cytometry for granulocyte immunophenotyping in peripheral blood collected from COVID-19 patients during acute and convalescent phases. Severe COVID-19 was associated with increased levels of both mature and immature neutrophils, and decreased counts of eosinophils and basophils. Distinct immunotypes were evident in COVID-19 patients, with altered expression of several receptors involved in activation, adhesion and migration of granulocytes (e.g. CD62L, CD11a/b, CD69, CD63, CXCR4). Paired sampling revealed recovery and phenotypic restoration of the granulocytic signature in the convalescent phase. The identified granulocyte immunotypes correlated with distinct sets of soluble inflammatory markers supporting pathophysiologic relevance. Furthermore, clinical features, including multi-organ dysfunction and respiratory function, could be predicted using combined laboratory measurements and immunophenotyping. This study provides a comprehensive granulocyte characterization in COVID-19 and reveals specific immunotypes with potential predictive value for key clinical features associated with COVID-19.",Magda Lourda; Majda Dzidic; Laura Hertwig; Helena Bergsten; Laura M Palma Medina; Egle Kvedaraite; Jagadeeswara Rao Muvva; Jean-Baptiste Gorin; Martin Cornillet; Johanna Emgard; Kirsten Moll; Marina Garcia; Kimia T Maleki; Jonas Klingstrom; Jakob Michaelsson; Malin Flodstrom-Tullberg; Susanna Brighenti; Marcus Buggert; Jenny Mjosberg; Karl-Johan Malmberg; Johan K Sandberg; Jan-Inge Henter; Elin Folkesson; Sara Gredmark-Russ; Anders Sonnerborg; Lars I Eriksson; Olav Rooyackers; Soo Aleman; Kristoffer Stralin; Hans-Gustaf Ljunggren; Niklas K Bjorkstrom; Mattias Svensson; Andrea Ponzetta; Anna Norrby-Teglund; Benedict J Chambers; - Karolinska KI/K COVID-19 Study Group,https://medrxiv.org/cgi/content/short/2021.01.27.21250591,https://medrxiv.org/cgi/content/short/2021.01.27.21250591,2021-01-31,2021-01-31,,True
83,Modeling the asymptomatic prevalence of SARS-CoV-2 epidemic in Italy and the ISTAT survey,"objectives: August 3rd, 2020, the Italian National Institute of Statistics (ISTAT) presented preliminary results of seroprevalence survey on the percentage of individuals affected by Covid-19. The survey aims to define (within the entire population of Italy) the portion of individuals that developed an antibody response against SARS-CoV-2. For the first time one has an estimate of the asymptomatic infected population and the possibility to acknowledge its potential role in the infection spread in Italy, one of the most affected areas in Europe. The information obtained allow a particularly sensitive validation of epidemiological models which include the asymptomatic class. methods: The present study is devoted to the construction of a model able to simulate, in a systematic way, the asymptomatic group whose relevance in the, SARS-CoV-2 epidemic, has been recently investigated and discussed. The investigation involves the description of the first epidemic outbreak in Italy as well as the predictive analysis of the ongoing second wave. In particular the possible correction to the data of the serological tests because of their sensitivity and specificity. results: The model: taken as an example of the models presently used, satisfactory reproduces the data of the ISTAT survey showing a relevant predictive power and relegating in a secondary position models which do not include, in the simulation, the presence of asymptomatic groups. The corrections due to the serological test sensitivity (in particular those ones depending on the symptoms onset) make the comparison between data and models less accurate. conclusions: The predictions of the model confirm a relevant presence of asymptomatic individuals also during the second pandemic wave in Italy. The ratio of reported to unreported cases is predicted to be roughly 1:4. A more detailed knowledge of the results of the survey could allow to correct, in a relevant way, the data by means of the experimental evidences on the antibodies sensibility. The model analyses of the vaccination strategies, confirms the relevance of a massive administration with the beginning of the year to arrive at the end of the infection within August 2021.",Marco Claudio Traini; Carla Caponi; Riccardo Ferrari; Giuseppe Vittorio De Socio,https://medrxiv.org/cgi/content/short/2021.01.27.21250597,https://medrxiv.org/cgi/content/short/2021.01.27.21250597,2021-01-31,2021-01-31,,True
84,Neighbourhood-level risk factors of COVID-19 incidence and mortality,"Background Racialized and low income communities face disproportionally high rates of coronavirus 2019 (COVID-19) infection and death. However, data on inequities in COVID-19 across granular categories of socio-demographic characteristics is more sparse. Methods Neighbourhood-level counts of COVID-19 cases and deaths in Ontario, Canada recorded as of July 28th, 2020 were extracted from provincial and local reportable infectious disease surveillance systems. Associations between COVID-19 incidence and mortality and 18 neighbourhood-level measures of immigration, race, housing and socio-economic characteristics were estimated with Poisson generalized linear mixed models. Housing characteristic variables were subsequently added to models to explore if housing may have a confounding influence on the relationships between immigration, race, and socio-economic status and COVID-19 incidence. Results There were large inequities in COVID-19 incidence and mortality across the socio-demographic variables examined. Neighbourhoods having a higher proportion immigrants, racialized populations, large households and low socio-economic status were associated with COVID-19 risk. Adjusting for housing characteristics, especially unsuitably crowded housing, attenuated COVID-19 risks. However persistent risk remained for neighbourhoods having high proportions of immigrants, racialized populations, and proportion of Black, Latin American, and South Asian residents. Conclusions Socio-demographic factors account for some of the neighbourhood-level differences in COVID-19 across Ontario. Housing characteristics account for a portion, but not all, of the excess burden of COVID-19 experienced by immigrant, racialized, low income and low education populations.",Trevor van Ingen; Kevin A Brown; Sarah A Buchan; Samantha Akingbola; Nick Daneman; Brendan T Smith,https://medrxiv.org/cgi/content/short/2021.01.27.21250618,https://medrxiv.org/cgi/content/short/2021.01.27.21250618,2021-01-31,2021-01-31,,True
85,Forecasting virus outbreaks with social media data via neural ordinary differential equations,"In the midst of the covid-19 pandemic, social media data collected in real time has the potential of being an early indicator of a new epidemic wave. This possibility is explored here by using a neural ordinary differential equation (neural ODE) that is trained to predict virus outbreaks for a geographic region. It learns from multivariate time series of signals obtained from a novel set of massive online surveys about COVID-19 symptoms. Once trained, the neural ODE is able to capture the dynamics of the interlinked local signals and accurately predict the number of new infections up to two months in advance. Moreover, it can estimate the future effects of changes in the number of infected at a given time, which can be associated with the flow of people entering or leaving a given region or, for instance, with a local vaccination campaign. This work gives compelling preliminary evidence for the predictive power of widely distributed social media surveys for public health application",Matias NuÃ±ez; Nadia Barreiro; Rafael Barrio; Christopher Rackauckas,https://medrxiv.org/cgi/content/short/2021.01.27.21250642,https://medrxiv.org/cgi/content/short/2021.01.27.21250642,2021-01-31,2021-01-31,,True
86,Mitigation policies and vaccination in the COVID-19 pandemic: a modelling study,"The perspective of vaccination to protect human population from infection of SARS-CoV-2 virus has great potential to control the pandemic. Nevertheless, vaccine planning requires phased introduction with age groups, health workers, and vulnerable people. We developed a mathematical model capable of capturing the dynamics of the SARS-CoV-2 dissemination aligned with social distancing, isolation measures, and vaccination. The city of Rio de Janeiro provides a case study to analyze possible scenarios including non--pharmaceutical interventions and vaccination in the epidemic scenario. Our results shows that a combination of different policies such as case isolation and social distancing are more effective for mitigating the epidemics. Furthermore, these policies will still be necessary in a phased vaccination program. Therefore, health surveillance activities should be maintained along with vaccination planning in scheduled groups until a large vaccinated coverage is reached.",Naiara C.M. Valiati; Daniel A.M. Villela,https://medrxiv.org/cgi/content/short/2021.01.27.21250651,https://medrxiv.org/cgi/content/short/2021.01.27.21250651,2021-01-31,2021-01-31,,True
87,"Impact of age, gender, ethnicity and prior disease status on immunogenicity following administration of a single dose of the BNT162b2 mRNA Covid-19 Vaccine: real-world evidence from Israeli healthcare workers, December-January 2020","The Pfizer Covid-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We described immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, gender, ethnicity and prior COVID19 infection. Immunogenicity was similar by gender and ethnicity but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naive individuals regardless of the presence of detectable IgG antibodies pre-vaccination.",Kamal Abu Jabal; Hila Ben-Amram; Karine Beiruti; Yunis Batheesh; Christian Sussan; Salman Zarka; Michael Edelstein,https://medrxiv.org/cgi/content/short/2021.01.27.21250567,https://medrxiv.org/cgi/content/short/2021.01.27.21250567,2021-01-31,2021-01-31,,True
88,SARS-CoV-2 Seroepidemiology in Children and Adolescents,"Background: Pediatric SARS-CoV-2 data remain limited and seropositivity rates in children were reported as <1% early in the pandemic. Seroepidemiologic evaluation of SARS-CoV-2 in children in a major metropolitan region of the United States was performed.Methods: Children and adolescents [&le;] 19 years were enrolled in a cross-sectional, observational study of SARS-CoV-2 seroprevalence from July-October 2020 in Northern Virginia, United States. Demographic, health, and COVID-19 exposure information was collected, and blood was analyzed for SARS-CoV-2 spike protein total antibody. Risk factors associated with SARS-CoV-2 seropositivity were analyzed. Orthogonal antibody testing was performed, and samples were evaluated for responses to different antigens. Results: In 1038 children, the anti-SARS-CoV-2 total antibody positivity rate was 8.5%. After multivariate logistic regression, significant risk factors included Hispanic ethnicity, public or absent insurance, a history of COVID-19 symptoms, exposure to person with COVID-19, a household member positive for SARS-CoV-2 and multi-family or apartment dwelling without a private entrance. 66% of seropositive children had no symptoms of COVID-19. Orthogonal antibody testing with a receptor binding domain specific antigen revealed a high concordance of 80.5%. Children also demonstrated a robust immune response to the nucleocapsid antigen. Conclusions: A much higher burden of SARS-CoV-2 infection, as determined by seropositivity, was found in children than previously reported. This was also higher compared to adults in the same region at a similar time. Contrary to prior reports, we determined children shoulder a significant burden of COVID-19 infection. The role of pediatric infection and transmission must be considered in COVID-19 mitigation strategies including vaccination.",Rebecca E Levorson; Erica Christian; Brett Hunter; Jasdeep Sayal; Jiayang Sun; Scott A Bruce; Stephanie Garofalo; Matthew Southerland; Svetlana Ho; Shira Levy; Christopher Defillipi; Lilian Peake; Frederick C Place; Suchitra K Hourigan,https://medrxiv.org/cgi/content/short/2021.01.28.21250466,https://medrxiv.org/cgi/content/short/2021.01.28.21250466,2021-01-31,2021-01-31,,True
89,REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021,"In early January 2021, England entered its third national lockdown of the COVID-19 pandemic to reduce numbers of deaths and pressure on healthcare services, while rapidly rolling out vaccination to healthcare workers and those most at risk of severe disease and death. REACT-1 is a survey of SARS-CoV-2 prevalence in the community in England, based on repeated cross-sectional samples of the population. Between 6th and 22nd January 2021, out of 167,642 results, 2,282 were positive giving a weighted national prevalence of infection of 1.57% (95% CI, 1.49%, 1.66%). The R number nationally over this period was estimated at 0.98 (0.92, 1.04). Prevalence remained high throughout, but with suggestion of a decline at the end of the study period. The average national trend masked regional heterogeneity, with robustly decreasing prevalence in one region (South West) and increasing prevalence in another (East Midlands). Overall prevalence at regional level was highest in London at 2.83% (2.53%, 3.16%). Although prevalence nationally was highest in the low-risk 18 to 24 year old group at 2.44% (1.96%, 3.03%), it was also high in those over 65 years who are most at risk, at 0.93% (0.82%, 1.05%). Large household size, living in a deprived neighbourhood, and Black and Asian ethnicity were all associated with higher levels of infections compared to smaller households, less deprived neighbourhoods and other ethnicities. Healthcare and care home workers, and other key workers, were more likely to test positive compared to other workers. If sustained lower prevalence is not achieved rapidly in England, pressure on healthcare services and numbers of COVID-19 deaths will remain unacceptably high.",Steven Riley; Oliver Eales; Caroline E. Walters; Haowei Wang; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,https://medrxiv.org/cgi/content/short/2021.01.28.21250606,https://medrxiv.org/cgi/content/short/2021.01.28.21250606,2021-01-31,2021-01-31,,True
90,Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States,"Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who have not previously been diagnosed with COVID-19. Individuals with characteristics that reflect the US population (n = 11,382) and who had not previously been diagnosed with COVID-19 were selected by quota sampling from 241,424 volunteers (ClinicalTrials.gov NCT04334954). Enrolled participants provided medical, geographic, demographic, and socioeconomic information and 9,028 blood samples. The majority (88.7%) of samples were collected between May 10th and July 31st, 2020. Samples were analyzed via ELISA for anti-Spike and anti-RBD antibodies. Estimation of seroprevalence was performed by using a weighted analysis to reflect the US population. We detected an undiagnosed seropositivity rate of 4.6% (95% CI: 2.6 - 6.5%). There was distinct regional variability, with heightened seropositivity in locations of early outbreaks. Subgroup analysis demonstrated that the highest estimated undiagnosed seropositivity within groups was detected in younger participants (ages 18-45, 5.9%), females (5.5%), Black/African American (14.2%), Hispanic (6.1%), and Urban residents (5.3%), and lower undiagnosed seropositivity in those with chronic diseases. During the first wave of infection over the spring/summer of 2020 an estimate of 4.6% of adults had a prior undiagnosed SARS-CoV-2 infection. These data indicate that there were 4.8 (95% CI: 2.8-6.8) undiagnosed cases for every diagnosed case of COVID-19 during this same time period in the United States, and an estimated 16.8 million undiagnosed cases by mid-July 2020.",Heather Kalish; Carleen Klumpp-Thomas; Sally Hunsberger; Holly Ann Baus; Michael P Fay; Nalyn Siripong; Jing Wang; Jennifer Hicks; Jennifer Mehalko; Jameson Travers; Matthew Drew; Kyle Pauly; Jacquelyn Spathies; Tran Ngo; Kenneth M Adusei; Maria Karkanitsa; Jennifer A Croker; Yan Li; Barry I Graubard; Lindsay Czajkowski; Olivia Belliveau; Cheryl Chairez; Kelly Snead; Peter Frank; Anandakumar Shunmugavel; Alison Han; Luca T Giurgea; Luz Angela Rosas; Rachel Bean; Rani Athota; Adriana Cervantes-Medina; Monica Gouzoulis; Brittany Heffelfinger; Shannon Valenti; Rocco Caldararo; Michelle M Kolberg; Andrew Kelly; Reid Simon; Saifullah Shafiq; Vanessa Wall; Susan Reed; Eric W Ford; Ravi Lokwani; John-Paul Denson; Simon Messing; Sam G Michael; William Gillette; Robert P Kimberly; Steven E Reis; Matthew D Hall; Dominic Esposito; Matthew J Memoli; Kaitlyn Sadtler,https://medrxiv.org/cgi/content/short/2021.01.27.21250570,https://medrxiv.org/cgi/content/short/2021.01.27.21250570,2021-01-31,2021-01-31,,True
91,Point-of-Care CRISPR-Cas-Assisted SARS-CoV-2 Detection in an Automated and Mobile Droplet Magnetofluidic Device,"In the fight against COVID-19, there remains unmet needs in developing point-of-care (POC) diagnostic testing tools that can rapidly and sensitively detect the causative SARS-CoV-2 virus to control disease transmission and improve patient management. Although recent CRISPR-Cas-assisted SARS-CoV-2 detection assays (such as DETECTR and SHERLOCK) are viewed as transformative solutions for POC diagnostic testing, their lack of simple sample processing and full integration within an automated and portable device hamper their potential for POC use. We report herein POC-CRISPR - a new single-step CRISPR-Cas-assisted assay that is coupled to droplet magnetofluidics (DM) - that leverages simple magnetic concentration and transport of nucleic acid-binding magnetic beads to accomplish sample preparation and assay automation. By further adapting the assay into a fully integrated thermoplastic cartridge within a palm-sized mobile device, POC-CRISPR was able to detect 1 genome equivalent (GE)/L SARS-CoV-2 RNA from a sample volume of 100 L in 30 min. Moreover, when evaluated with unprocessed clinical nasopharyngeal (NP) swab eluates, POC-CRISPR identified SARS-CoV-2 positive samples in as short as 20 min and achieved full concordance with standard RT-qPCR.",Fan-En Chen; Pei-Wei Lee; Joon Soo Park; Alexander Y. Trick; Liben Chen; Kushagra Shah; Kuangwen Hsieh; Tza-Huei Wang,https://medrxiv.org/cgi/content/short/2021.01.27.21250564,https://medrxiv.org/cgi/content/short/2021.01.27.21250564,2021-01-31,2021-01-31,,True
92,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,"Background: Estimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for a better evaluation of the virus spread and monitoring the progress of the COVID-19 pandemic in a population. In the Kingdom of Saudi Arabia (KSA), SARS-CoV-2 seroprevalence has been reported in specific regions, but an extensive nationwide study has not been reported. Here, we report a nationwide study to determine the prevalence of SARS-CoV-2 in the population of KSA during the pandemic, using serum samples from healthy blood donors, non-COVID patients and healthcare workers (HCWs) in six different regions of the kingdom, with addition samples from COVID-19 patients. Methods: A total of 11703 serum samples were collected from different regions of the KSA including; 5395 samples from residual healthy blood donors (D); 5877 samples from non-COVID patients collected through residual sera at clinical biochemistry labs from non-COVID patients (P); and 400 samples from consented HCWs. To determine the seroprevalence of SARS-CoV-2, all serum samples, in addition to positive control sera from RT-PCR confirmed COVID-19 patients, were subjected to in-house ELISA with a sample pooling strategy, which was further validated by testing individual samples that make up some of the pools, with a statistical estimation method to report seroprevalence estimates Results: Overall (combining D and P groups) seroprevalence estimate was around 11% in Saudi Arabia; and was 5.1% (Riyadh), 1.5% (Jazan), 18.4% (Qassim), 20.8% (Hail), 14.7% (ER; Alahsa), and 18.8% in Makkah. Makkah samples were only D group and had a rate of 24.4% and 12.8% in the cities of Makkah and Jeddah, respectively. The seroprevalence in Saudi Arabia across the sampled areas would be 12 times the COVID-19 infection rate. Among HCWs, 7.5% (4.95-10.16 CI 95%) had reactive antibodies to SARS-CoV-2 without reporting any previously confirmed infection. This was higher in HCWs with hypertension. The study also presents the demographics and prevalence of co-morbidities in HCWs and subset of non-COVID-19 population. Interpretation: Our study estimates the overall national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions.",Naif Khalaf Alharbi; Suliman Alghnam; Abdullah Algaissi; Hind Albalawi; Mohammed W Alenazi; Areeb M Albargawi; Abdullah G Alharbi; Abdulaziz Alhazmi; Ali Al Qarni; Ali Alfarhan; Hossam M. Zowawi; Hind Alhatmi; Jahad Alghamdi; Fayhan Alroqi; Yaseen M. Arabi; Anwar M. Hashem; Mohammed Bosaeed; Omar Aldibasi,https://medrxiv.org/cgi/content/short/2021.01.28.21250598,https://medrxiv.org/cgi/content/short/2021.01.28.21250598,2021-01-31,2021-01-31,,True
93,Evidence for SARS-CoV-2 Spike Protein in the Urine of COVID-19 patients,"SARS-CoV-2 infection has so far affected over 42 million people worldwide, causing over 1.1 million deaths. With the large majority of SARS-CoV-2 infected individuals being asymptomatic, major concerns have been raised about possible long-term consequences of the infection. We developed an antigen capture assay to detect SARS-CoV-2 spike protein in urine samples from COVID-19 patients whose diagnosis was confirmed by PCR from nasopharyngeal swabs (NP-PCR+). The study used a collection of 233 urine samples from 132 participants from Yale New Haven Hospital and the Childrens Hospital of Philadelphia obtained during the pandemic (106 NP-PCR+ and 26 NP-PCR-) as well as a collection of 20 urine samples from 20 individuals collected before the pandemic. Our analysis identified 23 out of 91 (25%) NP-PCR+ adult participants with SARS-CoV-2 spike S1 protein in urine (Ur-S+). Interestingly, although all NP-PCR+ children were Ur-S-, 1 NP-PCR- child was found to be positive for spike protein in urine. Of the 23 Ur-S+ adults, only 1 individual showed detectable viral RNA in urine. Our analysis further showed that 24% and 21% of NP-PCR+ adults have high levels of albumin and cystatin C in urine, respectively. Among individuals with albuminuria (>0.3 mg/mg of creatinine) statistical correlation could be found between albumin and spike protein in urine. Together, our data showed that 1 of 4 of SARS-CoV-2 infected individuals develop renal abnormalities such as albuminuria. Awareness about the long-term impact of these findings is warranted.",Santosh George; Anasuya Chattopadhyay Pal; Jacqueline Gagnon; Sushma Timalsina; Pallavi Singh; Pratap Vydyam; Muhammad Munshi; Joy E Chiu; Isaline Renard; Christina A Harden; Isabel M Ott; Anne E Watkins; Chantal B F Vogels; Peiwen Lu; Maria Tokuyama; Arvind Venkataraman; Arnau Casanovas-Massana; Anne L Wyllie; Veena Rao; Melissa Campbell; Shelli F Farhadian; Nathan D Grubaugh; Charles S Dela Cruz; Albert I Ko; Amalia Berna Perez; Elikplim H Akaho; Dennis G Moledina; Jeffrey Testani; Audrey R John; Michel Ledizet; Choukri Ben Mamoun,https://medrxiv.org/cgi/content/short/2021.01.27.21250637,https://medrxiv.org/cgi/content/short/2021.01.27.21250637,2021-01-31,2021-01-31,,True
94,Serosurveillance of SARS CoV 2 among the healthcare workers of a tertiary care teaching institution in Central Kerala during the post lockdown phase,"Background. Kerala was the first state to have the confirmed case of COVID 19 in the country and it was first confirmed in Thrissur district on 30 January 2020.Our institute being in the heart of the city had to take adequate measures to mitigate the spread and treat the required patients by keeping its staff safe & healthy. The hallmark of COVID 19 infection is high infectivity, pre symptomatic transmission and asymptomatic prevalence which could result in high cumulative numbers of infections, hospitalizations, and deaths. Kerala was the first state to confirm community transmission in July 2020.Health care workers being in the forefront in the war against COVID19 are very prone in acquiring the infection and are possible to be asymptomatic sources for cluster formation. Knowing the development of immunity as shown by the presence of anti COV2 antibodies in the population contributes to the epidemiological understanding of the disease. The intent of the study is to do an antibody testing in our hospital to find the serosurveillance of SARS CoV 2 among the healthcare workers in our hospital. Aim: To estimate the seropositivity of SARS CoV 2 among the healthcare workers at Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, six months after revoking the lockdown Methodology: A cross sectional study among the health care workers of the medical college. Multistage Sampling was done with the hospital block as the first stage and departments as the second stage. In the final stage of sampling the test individuals were selected on a first come first served basis after the antibody test availability was declared open and free for all staff. A consent form and a Google form were given to all staff who volunteered for participating in the study. Each consented participant recruited into the investigation completed a questionnaire which covers details regarding demographics, exposure history, Residence & travel. Blood sample was collected and Anti SARS COV2 IgG antibody testing which targets the Spike Protein 1(SP1) was done using the VITROS chemiluminescence platform (Orthoclinical diagnostics, USA). Sampling & testing ranged over a time frame from September 5th to December 15th, 2020 Results: Jubilee Mission Medical College has 2785 working staff at the time of study. A total of 423 staff consented and their samples were tested. 37 staff members tested positive for COVID 19 antibody, yielding an overall prevalence of 8.75% (95% CI, 6.23 to 11.86). 86.5 % (32/37) of them were having a history of COVID-19 Antigen / RT PCR Positivity. We identified a statistically significant linear trend (p value =0.00001), between seropositivity and the degree of severity of COVID 19. Among the various factors which increase the risk of seroconversion, history of undergoing quarantine (p value < 0.001), contact with a confirmed case (p value = 0.002), contact with a caregiver for COVID 19 (p value =0.001) and history of Upper respiratory symptoms (p value =0.001), were found to be significantly associated with positive serology. Conclusions: The overall seropositivity in the current study was found to be 8.75% which is comparable to seroprevalence studies conducted in the United States and Wuhan in China. The pattern of seropositivity across the different category of health workers observed in the present study showed a higher prevalence among nurses. This result is also in agreement with a recent published report from united states. Various measures advised by the national and state health authorities were adequately adhered to. Keeping track of the pattern of development of immunity in the community is part of understanding the illness and forecasting the spread. For the tested HCW, it will boost up morale by ending uncertainty. For the hospital administration it will help in decision making about relative focusing of interventions on patients in general and HCWs. By knowing the immunity status of HCWs, the Institution will be able to contribute authentically to the development of intervention strategies and guidelines from time to time, besides following the available guidelines. Being an educational institution, it is obligatory to train all the elements of care delivery to the future generation of health care workers. Getting experienced from a small but relevant sample was expected to facilitate larger community study envisaged in peripheral areas Jubilee served",Aboobacker Mohamed Rafi; Maglin Monica Lisa Joseph Tomy; Ronnie Thomas; Chithra Valsan; U G Unnikrishnan; Susheela J Innah; Praveenlal Kuttichira,https://medrxiv.org/cgi/content/short/2021.01.27.21250502,https://medrxiv.org/cgi/content/short/2021.01.27.21250502,2021-01-31,2021-01-31,,True
95,SARS-CoV-2 antigen rapid diagnostic test enhanced with silver amplification technology,"Rapid diagnosis of COVID-19 is essential for instituting measures to prevent viral spread. SARS-CoV-2 antigen rapid diagnostic test (Ag-RDT) based on lateral flow immunochromatography assay (LFIA) principle can visually indicate the presence of SARS-CoV-2 antigens as a band. Ag-RDT is clinically promising as a point-of-care testing because it can give results in a short time without the need for special equipment. Although various antigen capture LFIAs are now available for rapid diagnosis for SARS-CoV-2 infection, they face the problems of low sensitivity. We have previously developed highly specific monoclonal antibodies (mAb) against SARS-CoV-2 nucleocapsid protein (NP) and in this study, we have employed these mAbs to develop a new LFIA that can detect SARS-CoV-2 NP in nasopharyngeal swab samples with higher sensitivity by combining them with silver amplification technology. We also compared the performance of our Ag-RDT against the commercially available Ag-RDTs using clinical samples to find that our newly developed LFIA performed best among tested, highlighting the superiority of silver amplification technology.",Kei Miyakawa; Rikako Funabashi; Yutaro Yamaoka; Sundararaj Stanleyraj Jeremiah; Junichi Katada; Atsuhiko Wada; Toshiki Takei; Kohei Shimizu; Hiroki Ozawa; Chiharu Kawakami; Shuzo Usuku; Nobuko Tanaka; Etsuko Yamazaki; Hideaki Shimizu; Nobuhiko Okabe; Hideki Hasegawa; Akihide Ryo,https://medrxiv.org/cgi/content/short/2021.01.27.21250659,https://medrxiv.org/cgi/content/short/2021.01.27.21250659,2021-01-31,2021-01-31,,True
96,Awake prone positioning and oxygen therapy in patients with COVID-19: The APRONOX study,"Purpose: The awake prone position (PP) strategy for patients with acute respiratory distress syndrome (ARDS) is a safe, simple, and cost-effective technique used to improve hypoxemia. We aimed to evaluate the relationship between awake PP (AP) and endotracheal intubation in patients with coronavirus disease (COVID-19). Methods: In this retrospective, multicentre observational study conducted between 1 May and 12 June 2020 in 27 hospitals in Mexico and Ecuador, non-intubated patients with COVID-19 managed with AP or awake supine positioning (AS) were included to evaluate intubation and mortality risk in AP patients through logistic regression models; multivariable adjustment, propensity score analyses, and E-values were calculated to limit confounding. A CART model with cross-validation was also built. This study was registered at https://clinicaltrials.gov/ct2/show/NCT04407468 Results: 827 non-intubated patients with COVID-19 in the AP (n=505) and AS (n=322) groups were included for analysis. Less patients in the AP group required endotracheal intubation (23.6% vs 40.4%) or died (20% vs 37.9%). AP was a protective factor for intubation even after multivariable adjustment (OR=0.39, 95%CI:0.28-0.56, p<0.0001, E-value=2.01), which prevailed after propensity score analysis (OR=0.32, 95%CI:0.21-0.49, p<0.0001, E-value=2.21), and mortality (adjusted OR=0.38, 95%CI:0.25-0.57, p<0.0001, E-value=1.98). The main variables associated with PP failure in AP patients were age, lower SpO2/FiO2, and management with a non-rebreather mask. In the CART model, only two variables were used: SpO2/FiO2 (F 97.7, p<0.001) and PP (X2 50.5, p<0.001), with an overall percentage of 75.2%. Conclusion: PP in awake hospitalised patients with COVID-19 is associated with a lower risk of intubation and mortality.",Orlando Ruben Perez-Nieto; Diego Escarraman-Martinez; Manuel Alberto Guerrero-Gutierrez; Eder Ivan Zamarron-Lopez; Javier Mancilla-Galindo; Ashuin Kammar-Garcia; Miguel Angel Martinez-Camacho; Ernesto Deloya-Tomas; Jesus Salvador Sanchez-Diaz; Luis Alberto Macias-Garcia; Raul Soriano-Orozco; Gabriel Cruz-Sanchez; Jose David Salmeron-Gonzalez; Marco Antonio Toledo-Rivera; Ivette Mata-Maqueda; Luis Antonio Morgado-Villasenor; Jenner Jose Martinez-Mazariegos; Raymundo Flores Ramirez; Jose Luis Medina-Estrada; Silvio Antonio Ã‘amendys-Silva; - APRONOX Group,https://medrxiv.org/cgi/content/short/2021.01.27.21250631,https://medrxiv.org/cgi/content/short/2021.01.27.21250631,2021-01-31,2021-01-31,,True
97,Title: Health and Healthcare Variables Associated with Italy's Excess Mortality during the First Wave of the COVID-19 pandemic: An Ecological Study.,"Background: Healthcare factors have strongly influenced the propagation of COVID-19. The present study aims to examine whether excess mortality during the first phase of the COVID-19 outbreak in Italy was associated with health, healthcare, demographic, and socioeconomic indicators measured at a provincial level. Methods: The present ecological study concerns the raw number of deaths from Jan. 1 to Apr. 30, 2020 and the mean number of deaths in the same months of 2015 to 2019, per province. Information on socioeconomic factors and healthcare settings were extracted from the most recently updated databases on the ISTAT website. Two multilevel, multivariate models were constructed to test whether excess mortality was associated with the indicators across 107 provinces in Italy. Results: On linear multilevel, multivariate analysis, AIDS mortality rate (p-value <0.05) correlates positively with excess mortality, while a higher density of General Practitioners (number of GPs per 1,000 population) is associated with lower excess mortality (p-value <0.05). After controlling for the diffusion of COVID-19 in each province, the significance of GP density increases (p-value <0.001) and the rate of hospitalization in long-term care wards is positively associated (p-value <0.05) with excess mortality. Conclusion: Some health and healthcare variables are strongly associated with excess mortality caused by COVID-19 in Italy and should be considered to implement mitigation policies and increase healthcare resilience.",Alessandra Buja; Matteo Paganini; Riccardo Fusinato; Silvia Cocchio; Manuela Scioni; Vincenzo Rebba; Vincenzo Baldo; Giovanna Boccuzzo,https://medrxiv.org/cgi/content/short/2021.01.28.21250669,https://medrxiv.org/cgi/content/short/2021.01.28.21250669,2021-01-31,2021-01-31,,True
98,A control framework to optimize public health policies in the course of the COVID-19 pandemic,"The SARS-CoV-2 pandemic triggered substantial economic and social disruptions. Mitigation policies varied across countries based on resources, political conditions, and human behavior. In the absence of widespread vaccination able to induce herd immunity, strategies to coexist with the virus while minimizing risks of surges are paramount, which should work in parallel with reopening societies. To support these strategies, we present a predictive control system coupled with a nonlinear model able to optimize the level of policies to stop epidemic growth. We applied this system to study the unfolding of COVID-19 in Bahia, Brazil, also assessing the effects of varying population compliance. We show the importance of finely tuning the levels of enforced measures to achieve SARS-CoV-2 containment, with periodic interventions emerging as an optimal control strategy in the long-term.",Igor M. L. Pataro; Juliane F. Oliveira; Marcelo M. Morato; Alan A. S. Amad; Pablo I. P. Ramos; Felipe A. C. Pereira; Mateus S. Silva; Daniel C. P. Jorge; Roberto F. S. Andrade; Mauricio L. Barreto; Marcus Americano da Costa,https://medrxiv.org/cgi/content/short/2021.01.28.21250692,https://medrxiv.org/cgi/content/short/2021.01.28.21250692,2021-01-31,2021-01-31,,True
99,Racial and Ethnic Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: An Analysis of 45 States and the District of Columbia,"The coronavirus disease 2019 (COVID-19) epidemic in the United States has disproportionately impacted communities of color across the country. Focusing on COVID-19-attributable mortality, we expand upon a national comparative analysis of years of potential life lost (YPLL) attributable to COVID-19 by race/ethnicity (Bassett et al., 2020), estimating percentages of total YPLL for non-Hispanic Whites, non-Hispanic Blacks, Hispanics, non-Hispanic Asians, and non-Hispanic American Indian or Alaska Natives, contrasting them with their respective percent population shares, as well as age-adjusted YPLL rate ratios - anchoring comparisons to non-Hispanic Whites - in each of 45 states and the District of Columbia using data from the National Center for Health Statistics as of December 30, 2020. Using a novel Monte Carlo simulation procedure to quantify estimation uncertainty, our results reveal substantial racial/ethnic disparities in COVID-19-attributable YPLL across states, with a prevailing pattern of non-Hispanic Blacks and Hispanics experiencing disproportionately high and non-Hispanic Whites experiencing disproportionately low COVID-19-attributable YPLL. Furthermore, observed disparities are generally more pronounced when measuring mortality in terms of YPLL compared to death counts, reflecting the greater intensity of the disparities at younger ages. We also find substantial state-to-state variability in the magnitudes of the estimated racial/ethnic disparities, suggesting that they are driven in large part by social determinants of health whose degree of association with race/ethnicity varies by state.",Jay J Xu; Jarvis T Chen; Thomas R Belin; Ronald S Brookmeyer; Marc A Suchard; Christina M Ramirez,https://medrxiv.org/cgi/content/short/2021.01.28.21249411,https://medrxiv.org/cgi/content/short/2021.01.28.21249411,2021-01-31,2021-01-31,,True
100,"Surveillance-to-Diagnostic Testing Program for Asymptomatic SARS-CoV-2 Infections on a Large, Urban Campus - Georgia Institute of Technology, Fall 2020","A SARS-CoV-2 testing program combining pooled saliva sample surveillance leading to diagnosis and intervention surveyed over 112,000 samples from 18,029 students, staff and faculty, as part of integrative efforts to mitigate transmission at the Georgia Institute of Technology in Fall 2020. Cumulatively, 1,508 individuals were confirmed diagnostically. The surveillance strategy, including focused intensification of testing given case clusters, was effective in disrupting transmission following rapid case increases upon entry in August 2020, and again in November 2020. Owing to broad adoption by the campus community, the program protected higher risk staff while allowing some normalization of research activities.",Greg C Gibson; Joshua S Weitz; Michael P. Shannon; Benjamin Holton; Anton Bryksin; Brian Liu; Sandra Bramblett; Julianne Williamson; Michael Farrell; Alexander Ortiz; Chaouki T. Abdallah; AndrÃ©s GarcÃ­a,https://medrxiv.org/cgi/content/short/2021.01.28.21250700,https://medrxiv.org/cgi/content/short/2021.01.28.21250700,2021-01-31,2021-01-31,,True
101,Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii,"Recombinant production of viral proteins can be used to produce vaccine antigens or reagents to identify antibodies in patient serum. Minimally, these proteins must be correctly folded and have appropriate post-translation modifications. Here we report the production of the SARS-CoV-2 spike protein Receptor Binding Domain (RBD) in the green algae Chlamydomonas. RBD fused to a fluorescent reporter protein accumulates as an intact protein when targeted for ER-Golgi retention or secreted from the cell, while a chloroplast localized version is truncated, lacking the amino terminus. The ER-retained RBD fusion protein was able to bind the human ACE2 receptor, the host target of SARS-CoV-2, and was specifically out-competed by mammalian cell-produced recombinant RBD, suggesting that the algae produced proteins are sufficiently post-translationally modified to act as authentic SARS-CoV-2 antigens. Because algae can be grown at large scale very inexpensively, this recombinant protein may be a low cost alternative to other expression platforms.",Anthony J Berndt; Tressa N Smalley; Bijie Ren; Amr Badary; Ashley Sproles; Francis Fields; Yasin Torres-Tiji; Vanessa Heredia; Stephen P Mayfield,https://biorxiv.org/cgi/content/short/2021.01.29.428890,https://biorxiv.org/cgi/content/short/2021.01.29.428890,2021-01-30,2021-01-30,,False
102,SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques,"The first COVID-19 vaccines have recently gained authorization for emergency use.1,2 At this moment, limited knowledge on duration of immunity and efficacy of these vaccines is available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short lived,3,4 and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection.5 Here we model the relationship between immunogenicity and protective efficacy of a series of Ad26 vectors encoding stabilized variants of the SARS-CoV-2 Spike (S) protein in rhesus macaques6,7,8 and validate the analyses by challenging macaques 6 months after immunization with the Ad26.COV2.S vaccine candidate that has been selected for clinical development. We find that Ad26.COV2.S confers durable protection against replication of SARS-CoV-2 in the lungs that is predicted by the levels of S-binding and neutralizing antibodies. These results suggest that Ad26.COV2.S could confer durable protection in humans and that immunological correlates of protection may enable the prediction of durability of protection.",Ramon Roozendaal; Laura Solforosi; Daniel Stieh; Jan Serroyen; Roel Straetemans; Frank Wegmann; Sietske K. Rosendahl Huber; Joan E. M. van der Lubbe; Jenny Hendriks; Mathieu le Gars; Liesbeth Dekking; Dominika N. Czapska-Casey; Nuria Guimera; Sarah Janssen; Sarah Tete; Abishek Chandrashekar; Noe Mercado; Jingyou Yu; Wouter Koudstaal; Jerry Sadoff; Dan H. Barouch; Hanneke Schuitemaker; Roland Zahn,https://biorxiv.org/cgi/content/short/2021.01.30.428921,https://biorxiv.org/cgi/content/short/2021.01.30.428921,2021-01-30,2021-01-30,,False
103,A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19,"The development of effective countermeasures against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent vesicular stomatitis virus (VSV) vaccine vector that expresses the S1 subunit of SARS-CoV-2 spike protein. We used golden Syrian hamsters as animal model of severe COVID-19 to test the efficacy of the ConVac vaccine. A single vaccine dose elicited high levels of SARS-CoV-2 specific binding and neutralizing antibodies; following intranasal challenge with SARS-CoV-2, animals were protected from weight loss and viral replication in the lungs. No enhanced pathology was observed in vaccinated animals upon challenge, but some inflammation was still detected. The data indicate rapid control of SARS-CoV-2 replication by the S1-based VSV-vectored SARS-CoV-2 ConVac vaccine.",Delphine C. Malherbe; Drishya Kurup; Christoph Wirblich; Adam J. Ronk; Chad Mire; Natalia Kuzmina; Noor Shaik; Sivakumar Periasamy; Matthew A. Hyde; Julie M. Williams; Pei-Yong Shi; Matthias J Schnell; Alexander Bukreyev,https://biorxiv.org/cgi/content/short/2021.01.29.428442,https://biorxiv.org/cgi/content/short/2021.01.29.428442,2021-01-30,2021-01-30,,False
104,Development and external validation of prognostic models for COVID-19 to support risk stratification in secondary care,"Objectives Existing UK prognostic models for patients admitted to hospital with COVID-19 are limited by reliance on comorbidities, which are under-recorded in secondary care, and lack of imaging data among the candidate predictors. Our aims were to develop and externally validate novel prognostic models for adverse outcomes (death, intensive therapy unit (ITU) admission) in UK secondary care; and externally validate the existing 4C score. Design Candidate predictors included demographic variables, symptoms, physiological measures, imaging, laboratory tests. Final models used logistic regression with stepwise selection. Setting Model development was performed in data from University Hospitals Birmingham (UHB). External validation was performed in the CovidCollab dataset. Participants Patients with COVID-19 admitted to UHB January-August 2020 were included. Main outcome measures Death and ITU admission within 28 days of admission. Results 1040 patients with COVID-19 were included in the derivation cohort; 288 (28%) died and 183 (18%) were admitted to ITU within 28 days of admission. Area under the receiver operating curve (AUROC) for mortality was 0.791 (95%CI 0.761-0.822) in UHB and 0.767 (95%CI 0.754-0.780) in CovidCollab; AUROC for ITU admission was 0.906 (95%CI 0.883-0.929) in UHB and 0.811 (95%CI 0.795-0.828) in CovidCollab. Models showed good calibration. Addition of comorbidities to candidate predictors did not improve model performance. AUROC for the 4C score in the UHB dataset was 0.754 (95%CI 0.721-0.786). Conclusions The novel prognostic models showed good discrimination and calibration in derivation and external validation datasets, and outperformed the existing 4C score. The models can be integrated into electronic medical records systems to calculate each individual patients probability of death or ITU admission at the time of hospital admission. Implementation of the models and clinical utility should be evaluated.",Nicola J Adderley; Thomas Taverner; Malcolm Price; Christopher Sainsbury; David Greenwood; Joht Singh Chandan; Yemisi Takwoingi; Rashan Haniffa; Isaac Hosier; Carly Welch; Dhruv Parekh; Suzy Gallier; Krishna M Gokhale; Alastair K Denniston; Elizabeth Sapey; Krishnarajah Nirantharakumar,https://medrxiv.org/cgi/content/short/2021.01.25.21249942,https://medrxiv.org/cgi/content/short/2021.01.25.21249942,2021-01-30,2021-01-30,,True
105,Longitudinal analyses reveal age-specific immune correlates of COVID-19 severity,"Severe COVID-19 disproportionately impacts older individuals and those with comorbidities. It is estimated that approximately 80% of COVID-19 deaths are observed among individuals >65 years of age. However, the immunological underpinnings of severe COVID-19 in the aged have yet to be defined. This study captures the longitudinal immune response to SARS-CoV-2 infection in a cohort of young and aged patients with varying disease severity. Phenotypic transcriptional and functional examination of the peripheral mononuclear cells revealed age-, time, and disease severity-specific adaptations. Gene expression signatures within memory B cells suggest qualitative differences in the antibody responses in aged patients with severe disease. Examination of T cells showed profound lymphopenia, that worsened over time and correlated with lower levels of plasma cytokines important for T cell survival in aged patients with severe disease. Single cell RNA sequencing revealed augmented signatures of activation, exhaustion, cytotoxicity, and type-I interferon signaling in memory T cells and NK cells. Although hallmarks of a cytokine storm were evident in both groups, older individuals exhibited elevated levels of chemokines that mobilize inflammatory myeloid cells, notably in those who succumbed to disease. Correspondingly, we observed a re-distribution of DC and monocytes with severe disease that was accompanied by a rewiring towards a more regulatory phenotype. Several of these critical changes, such as the reduction of surface HLA-DR on myeloid cells, were reversed in young but not aged patients over time. In summary, the data presented here provide novel insights into the impact of aging on the host response to SARS-CoV2 infection.",Sloan A. Lewis; Suhas Sureshchandra; Michael Z. Zulu; Brianna Doratt; Amanda Pinski; Micaila Curtis; Allen Jankeel; Izabela Ibraim; Nicholas Rhoades; Xiwen Jiang; Delia Tifrea; Frank Zaldivar; Weining Shen; Robert Edwards; Daniel Chow; Dan Cooper; Alpesh Amin; Ilhem Messaoudi,https://medrxiv.org/cgi/content/short/2021.01.25.21250189,https://medrxiv.org/cgi/content/short/2021.01.25.21250189,2021-01-30,2021-01-30,,True
106,Impact of Prior Infection on Protection and Transmission of SARS-CoV-2 in Golden Hamsters,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 100 million confirmed human infections, and 2 million more deaths globally since its emergence in the end of 2019. Several studies have shown that prior infection provided protective immunity against SARS-CoV-2 in non-human primate models. However, the effect of prior infection on blocking SARS-CoV-2 transmission is not clear. Here, we evaluated the impact of prior infection on protection and transmission of the SARS-CoV-2 virus in golden hamsters. Our results showed that prior infection provided protective immunity against SARS-CoV-2 re-challenge, but it was not sterizing immunity. The transmission experiment results showed that SARS-CoV-2 was efficiently transmitted from naive hamsters to prior infected hamsters by direct contact and airborne route, but not by indirect contact. Further, the virus was efficiently transmitted from prior infected hamsters to naive hamsters by direct contact, but not by airborne route and indirect contact. Surprisingly, the virus can be transmitted between prior infected hamsters by direct contact during a short period of early infection. Taken together, our study demonstrated that prior infected hamsters with good immunity can still be naturally re-infected, and the virus can be transmitted between prior infected hamsters and the naive through different transmission routes, implying the potential possibility of human re-infection and the risk of virus transmission between prior infected population and the healthy. Our study will help to calculate the herd immunity threshold more accurately, make more reasonable public health decisions, formulate an optimized population vaccination program, as well as aid the implementation of appropriate public health and social measures to control COVID-19.",Not available,https://biorxiv.org/cgi/content/short/2021.01.30.428920,https://biorxiv.org/cgi/content/short/2021.01.30.428920,2021-01-30,2021-01-30,,False
107,Timing of elective tracheotomy and duration of mechanical ventilation amongst patients admitted to intensive care with severe COVID-19: a multicentre prospective cohort study,"Background: The COVID-19 pandemic has strained intensive care unit (ICU) resources. Tracheotomy is the most common surgery performed on ICU patients and can affect the duration of ICU care. We studied the association between when tracheotomy occurs and ICU stay length, mortality, and intraoperative and postoperative complications. Methods: Multicentre prospective cohort including all COVID-19 patients admitted to ICUs in 36 hospitals in Spain who received invasive mechanical ventilation and tracheotomy between 11 March and 20 July 2020. We used a target emulation trial framework to study the causal effects of early (7 to 10 days post-intubation) versus late (>10 days) tracheotomy on time from tracheotomy to weaning, postoperative mortality, and tracheotomy complications. Cause-specific Cox models were used for the first two outcomes and Poisson regression for the third, all adjusted for potential confounders. Findings: We included 696 patients, of whom 142 (20.4%) received early tracheotomy. Using late tracheotomy as the reference group, multivariable cause-specific analysis showed that early tracheotomy was associated with faster post-tracheotomy weaning (hazard ratio (HR) [95% confidence interval (CI)]: 1.28 [1.01 to 1.61]) without differences in mortality (HR [95% CI]: 0.94 [0.65 to 1.36]) or intraoperative or postoperative complications (adjusted rate ratio [95% CI]: 0.56 [0.23 to 1.38] and 1.31 [0.89 to 1.93], respectively). Interpretation: Early tracheotomy reduced post-tracheotomy weaning time, resulting in fewer mechanical ventilation days and shorter ICU stays, without changing complication or mortality rates. These results support early tracheotomy for COVID-19 patients when clinically indicated.",Albert Prats-Uribe; Marc Tobed; Jose Miguel Villacampa; Adriana Aguero; Clara Garcia-Bastida; Jose Ignacio Tato; Laura Rodriganez; Victoria Duque-Holguera; Estefania Hernandez-Garcia; Daniel Poletti; Gabriela Simonetti; Vanessa Villarraga; Carla Meler-Claramonte; Carla Merma-Linares; Alvaro Sanchez Barrueco; Carlos M Chiesa-Estomba; Maria Casasayas; Pablo Parente-Arias; Pedro Castro; DANIEL PRIETO-ALHAMBRA; Isabel Vilaseca; Francesc-Xavier Aviles-Jurado; - TraqueoCOVID SEORL Group,https://medrxiv.org/cgi/content/short/2021.01.22.21249651,https://medrxiv.org/cgi/content/short/2021.01.22.21249651,2021-01-30,2021-01-30,,True
108,Post-Mendelian genetic model in COVID-19,"Host genetics is an emerging theme in COVID-19 and few common polymorphisms and some rare variants have been identified, either by GWAS or candidate gene approach, respectively. However, an organic model is still missing. Here, we propose a new model that takes into account common and rare germline variants applied in a cohort of 1,300 Italian SARS-CoV-2 positive individuals. Ordered logistic regression of clinical WHO grading on sex and age was used to obtain a binary phenotypic classification. Genetic variability from WES was synthesized in several boolean representations differentiated according to allele frequencies and genotype effect. LASSO logistic regression was used for extracting relevant genes. We defined about 100 common driver polymorphisms corresponding to classical -threshold model-. Extracted genes were demonstrated to be gender specific. Stochastic rare more penetrant events on about additional 100 extracted genes, when occurred in a medium or severe background (common within the family), simulate Mendelian inheritance in 14% of subjects (having only 1 mutation) or oligogenic inheritance (in 10% having 2 mutations, in 11% having 3 mutations, etc). The combined effect of common and rare results can be described as an integrated polygenic score computed as: (nseverity-nmildness) +F (mseverity-mmildness) where n is the number of common driver genes, m is the number of driver rare variants and F is a factor for appropriately weighing the more powerful rare variants. We called the model -post-Mendelian-. The model well describes the cohort, and patients are clustered in severe or mild by the integrated polygenic scores, the F factor being calibrated around 2, with a prediction capacity of 65% in males and 70% in females. In conclusion, this is the first comprehensive model interpreting host genetics in a holistic post-Mendelian manner. Further validations are needed in order to consolidate and refine the model which however holds true in thousands of SARS-CoV-2 Italian subjects.",Nicola Picchiotti; Elisa Benetti; Chiara Fallerini; Sergio Daga; Margherita Baldassarri; Francesca Fava; Kristina Zguro; Floriana Valentino; Gabriella Doddato; Annarita Giliberti; Rossella Tita; Sara Amitrano; Mirella Bruttini; Laura Di Sarno; Nicola Iuso; Diana Alaverdian; Giada Beligni; Susanna Croci; Ilaria Meloni; Anna Maria Pinto; Chiara Gabbi; Stefano Ceri; Antonio Esposito; Pietro Pinoli; Francis P. Crawley; Elisa Frullanti; Francesca Mari; - GEN-COVID Multicenter Study; Marco Gori; Alessandra Renieri; Simone Furini,https://medrxiv.org/cgi/content/short/2021.01.27.21250593,https://medrxiv.org/cgi/content/short/2021.01.27.21250593,2021-01-29,2021-01-29,,True
109,Disentangling the association of hydroxychloroquine treatment with mortality in Covid-19 hospitalized patients through Hierarchical Clustering,"The efficacy of hydroxychloroquine (HCQ) in treating SARS-CoV-2 infection is harshly debated, with observational and intervention studies reporting contrasting results. To clarify the role of HCQ in Covid-19 patients, we carried out a retrospective observational study of 4,396 unselected patients hospitalized for Covid-19 in Italy (February-May 2020). Patients characteristics were collected at entry, including age, sex, obesity, smoking status, blood parameters, history of diabetes, cancer, cardiovascular and chronic pulmonary diseases and medications in use. These were used to identify subtypes of patients with similar characteristics through hierarchical clustering based on Gower distance. Using multivariable Cox regressions, these clusters were then tested for association with mortality and modification of effect by treatment with HCQ. We identified two clusters, one of 3,913 younger patients with lower circulating inflammation levels and better renal function, and one of 483 generally older and more comorbid subjects, more prevalently men and smokers. The latter group was at increased death risk adjusted by HCQ (HR[CI95%] = 3.80[3.08-4.67]), while HCQ showed an independent inverse association (0.51[0.43-0.61]), as well as a significant influence of cluster*HCQ interaction (p<0.001). This was driven by a differential association of HCQ with mortality between the high (0.89[0.65-1.22]) and the low risk cluster (0.46[0.39-0.54]). These effects survived adjustments for additional medications in use and were concordant with associations with disease severity and outcome. These findings suggest a particularly beneficial effect of HCQ within low risk Covid-19 patients and may contribute clarifying the current controversy on HCQ efficacy in Covid-19 treatment.",Augusto Di Castelnuovo; Alessandro Gialluisi; - The COVID-19 RISK and Treatments (CORIST) Collaboration; Licia Iacoviello,https://medrxiv.org/cgi/content/short/2021.01.27.21250238,https://medrxiv.org/cgi/content/short/2021.01.27.21250238,2021-01-29,2021-01-29,,True
110,Lumipulse G SARS-CoV-2 Ag Assay Evaluation for SARS-CoV-2 Antigen Detection Using 594 Nasopharyngeal Swab Samples from Different Testing Groups,"Compared to RT-PCR, lower performance of antigen detection assays, including the Lumipulse G SARS-CoV-2 Ag assay, may depend on specific testing scenarios. We tested 594 nasopharyngeal swab samples from individuals with COVID-19 (RT-PCR cycle threshold [Ct] values [&le;]40) or non-COVID-19 (Ct values [&le;]40) diagnoses. RT-PCR positive samples were assigned to diagnostic, screening, or monitoring groups of testing. With a limit of detection of 1.2 x 104 SARS-CoV-2 RNA copies/ml, Lumipulse showed positive percent agreement (PPA) of 79.9% (155/194) and negative percent agreement of 99.3% (397/400), whereas PPAs were 100% for samples with Ct values of <18 or 18-<25 and 92.5% for samples with Ct values of 25-<30. By three groups, Lumipulse showed PPA of 87.0% (60/69), 81.1% (43/53), or 72.2% (52/72), respectively, whereas PPA was 100% for samples with Ct values of <18 or 18-<25, and was 94.4%, 80.0%, or 100% for samples with Ct values of 25-<30, respectively. RT-PCR positive samples were also tested for SARS-CoV-2 subgenomic RNA and, by three groups, testing showed that PPA was 63.8% (44/69), 62.3% (33/53), or 33.3% (24/72), respectively. PPAs dropped to 55.6%, 20.0%, or 41.7% for samples with Ct values of 25-<30, respectively. All 101 samples with a subgenomic RNA positive result had a Lumipulse assays antigen positive result, whereas only 54 (58.1%) of remaining 93 samples had a Lumipulse assays antigen positive result. In conclusion, Lumipulse assay was highly sensitive in samples with low RT-PCR Ct values, implying repeated testing to reduce consequences of false-negative results.",Giulia Menchinelli; Licia Bordi; Flora Marzialiotti; Ivana Palucci; Maria R. Capobianchi; Giuseppe Sberna; Eleonora Lalle; Lucio Romano; Giulia De Angelis; Simona Marchetti; Maurizio Sanguinetti; Paola Cattani; Brunella Posteraro,https://medrxiv.org/cgi/content/short/2021.01.26.21250533,https://medrxiv.org/cgi/content/short/2021.01.26.21250533,2021-01-29,2021-01-29,,True
111,THE AIRBORNE CONTAGIOUSNESS OF RESPIRATORY VIRUSES: A COMPARATIVE ANALYSIS AND IMPLICATIONS FOR MITIGATION,"Background: The infectious emission rate is a critical input parameter for airborne contagion models, but data are limited due to reliance on estimates from chance superspreading events. A predictive estimation approach for the quanta emission rate (ERq) was recently proposed for SARS-CoV-2 using the droplet volume concentration of various expiratory activities. This study assesses the strength of the approach and uses novel predictive estimates of ERq to compare the contagiousness of respiratory pathogens. Methods: We applied the predictive approach to SARS-CoV-1, SARS-CoV-2, MERS, measles virus, adenovirus, rhinovirus, coxsackievirus, seasonal influenza virus and Mycobacterium tuberculosis (TB) and compared ERq estimates to values reported in literature. We calculated infection risk in a prototypical classroom and barracks to assess the relative ability of ventilation to mitigate airborne transmission. Results: Our median standing and speaking ERq estimate for SARS-CoV-2 (2.6 quanta hour (h)-1) is similar to active, untreated TB (3.1 h-1), higher than seasonal influenza (0.17 quanta h-1), and lower than measles virus (15 quanta h-1). We calculated event reproduction numbers above 1 for SARS-CoV-2, measles virus, and untreated TB in both the classroom and barracks for an activity level of standing and speaking at low, medium and high ventilation rates of 2.3, 6.6 and 14 liters per second per person, respectively. Conclusions: Our predictive ERq estimates are consistent with the range of values reported over decades of research. In congregate settings, current ventilation standards are unlikely to control the spread of viruses with upper quartile ERq values above 10 quanta h-1, such as SARS-CoV-2, indicating the need for additional control measures.",Alex Mikszewski; Luca Stabile; Giorgio Buonanno; Lidia Morawska,https://medrxiv.org/cgi/content/short/2021.01.26.21250580,https://medrxiv.org/cgi/content/short/2021.01.26.21250580,2021-01-29,2021-01-29,,True
112,Evaluation of spike protein antigens for SARS-CoV-2 serology,"Background: Spike protein domains are being used in various serology-based assays to detect prior exposure to SARS-CoV-2 virus. However, there has been limited comparison of human antibody titers against various spike protein antigens among COVID-19 infected patients. Methods: We compared four spike proteins (RBD, S1, S2 and a stabilized spike trimer (ST)) representing commonly used antigens for their reactivity to human IgG antibodies using indirect ELISA in serum from COVID-19 patients and pre-2020 samples. ST ELISA was also compared against the EUROIMMUN IgG ELISA test. Further, we estimated time appropriate IgG and IgA seropositivity rates in COVID-19 patients using a panel of sera samples collected longitudinally from the day of onset of symptoms (DOS). Results: Among the four spike antigens tested, the ST demonstrated the highest sensitivity (86.2%; 95% CI: 77.8-91.7%), while all four antigens showed high specificity to COVID-19 sera (94.7-96.8%). 13.8% (13/94) of the samples did not show seroconversion in any of the four antigen-based assays. In a double-blinded head-to-head comparison, ST based IgG ELISA displayed a better sensitivity (87.5%, 95%CI: 76.4-93.8%) than the EUROIMMUN IgG ELISA (67.9%, 95% CI: 54.8-78.6%). Further, in ST-based assays, we found 48% and 50% seroconversion in the first six days (from DOS) for IgG and IgA antibodies, respectively, which increased to 84% (IgG) and 85% (IgA) for samples collected [&ge;]22 days DOS. Conclusions: Comparison of spike antigens demonstrates that spike trimer protein is a superior option as an ELISA antigen for COVID-19 serology.",Suraj Jagtap; Ratnasri K; Priyanka Valloly; Rakhi Sharma; Satyaghosh Maurya; Anushree Gaigore; Chitra Ardhya; Dayanand S. Biligi; Bapu Koundinya Desiraju; Uma Chandra Mouli Natchu; Deepak Kumar Saini; Rahul Roy,https://medrxiv.org/cgi/content/short/2021.01.27.21250382,https://medrxiv.org/cgi/content/short/2021.01.27.21250382,2021-01-29,2021-01-29,,True
113,"SARS-CoV-2 infection and transmission in school settings during the second wave in Berlin, Germany: a cross-sectional study","Background: School attendance during the SARS-CoV-2 pandemic is intensely debated. Modelling studies suggest that school closures contribute to community transmission reduction. However, data among school-attending students and staff are scarce. In November 2020, we examined SARS-CoV-2 infections and seroreactivity in 24 randomly selected school classes and connected households in Berlin, Germany. Methods: Students and school staff were examined, oro-nasopharyngeal swabs and blood samples collected, and SARS-CoV-2 infection and IgG antibodies detected by RT-PCR and ELISA. Household members performed self-swabs. Individual and institutional infection prevention and control measures were assessed. Classes with SARS-CoV-2 infection and connected household members were re-tested after one week. Findings: 1119 participants were examined, including 177 primary and 175 secondary school students, 142 staff, and 625 household members. Participants reported mainly cold symptoms (19.4%). SARS-CoV-2 infection occurred in eight of 24 classes affecting each 1-2 individuals. Infection prevalence was 2.7% (95%CI, 1.2-5.0%; 9/338), 1.4% (0.2-5.1%; 2/140), and 2.3% (1.3-3.8%; 14/611) among students, staff and household members, respectively, including quarantined persons. Six of nine infected students were asymptomatic. Prevalence increased with inconsistent facemask use in school, way to school on foot, and case-contacts outside school. IgG antibodies were detected in 2.0% (0.8-4.1%; 7/347), 1.4% (0.2-5.0%; 2/141) and 1.4% (0.6-2.7%; 8/576), respectively. For three of nine households with infection(s) detected at cross-sectional assessment, origin in school seemed possible. After one week, no school-related, secondary infections appeared in affected classes; the attack rate in connected households was 1.1%. Interpretation: These data suggest that school attendance under preventive measures is feasible, provided their rigorous implementation. In balancing threats and benefits of open versus closed schools during the pandemic, parents and society need to consider possible spill-overs into their households. Deeper insight is needed into the infection risks due to being a schoolchild as compared to attending school. Funding: Senate of Berlin.",Stefanie Theuring; Marlene Thielecke; Welmoed van Loon; Franziska Hommes; Claudia Huelso; Annkathrin von der Haar; Jennifer Koerner; Michael Schmidt; Falko Boehringer; Marcus A. Mall; Alexander Rosen; Christof von Kalle; Valerie Kirchberger; Tobias Kurth; Joachim Seybold; Frank P Mockenhaupt; - BECOSS Study Group,https://medrxiv.org/cgi/content/short/2021.01.27.21250517,https://medrxiv.org/cgi/content/short/2021.01.27.21250517,2021-01-29,2021-01-29,,True
114,The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.,"One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are being rolled out under emergency use authorizations. It is of great concern that newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can escape antibody-mediated protection induced by previous infection or vaccination through mutations in the spike protein. The glutamate (E) to Lysine (K) substitution at position 484 (E484K) in the receptor binding domain (RBD) of the spike protein is present in the rapidly spreading variants of concern belonging to the B.1.351 and P.1 lineages. We performed in vitro microneutralization assays with both the USA-WA1/2020 virus and a recombinant (r)SARS-CoV-2 virus that is identical to USA-WA1/2020 except for the E484K mutation introduced in the spike RBD. We selected 34 sera from study participants based on their SARS-CoV-2 spike ELISA antibody titer (negative [N=4] versus weak [N=8], moderate [N=11] or strong positive [N=11]). In addition, we included sera from five individuals who received two doses of the Pfizer SARS-CoV-2 vaccine BNT162b2. Serum neutralization efficiency was lower against the E484K rSARS-CoV-2 (vaccination samples: 3.4 fold; convalescent low IgG: 2.4 fold, moderate IgG: 4.2 fold and high IgG: 2.6 fold) compared to USA-WA1/2020. For some of the convalescent donor sera with low or moderate IgG against the SARS-CoV-2 spike, the drop in neutralization efficiency resulted in neutralization ID50 values similar to negative control samples, with low or even absence of neutralization of the E484K rSARS-CoV-2. However, human sera with high neutralization titers against the USA-WA1/2020 strain were still able to neutralize the E484K rSARS-CoV-2. Therefore, it is important to aim for the highest titers possible induced by vaccination to enhance protection against newly emerging SARS-CoV-2 variants. Two vaccine doses may be needed for induction of high antibody titers against SARS-CoV-2. Postponing the second vaccination is suggested by some public health authorities in order to provide more individuals with a primer vaccination. Our data suggests that this may leave vaccinees less protected against newly emerging variants.",Sonia Jangra; Chengjin Ye; Raveen Rathnasinghe; Daniel Stadlbauer; - Personalized Virology Initiative (PVI) Study Group; Florian Krammer; Viviana Simon; Luis Martinez-Sobrido; Adolfo Garcia-Sastre; Michael Schotsaert,https://medrxiv.org/cgi/content/short/2021.01.26.21250543,https://medrxiv.org/cgi/content/short/2021.01.26.21250543,2021-01-29,2021-01-29,,True
115,Covid-19 positive test cycle threshold trends predict covid-19 mortality in Rhode Island,"The cycle thresholds (Cts) at which reverse transcriptase polymerase chain reaction (rtPCR) tests for covid-19 become positive are intimately associated with both viral load, and covid-19 infectiousness (i.e. ability to culture live virus). Clinical data indicate lower Cts, and hence larger viral loads, independently predict greater covid-19 mortality when patients are hospitalized for symptomatic covid-19 pneumonia. We merged public covid-19 mortality data from the Rhode Island Department of Health with a de-identified dataset of n=5036 positive rtPCR test Cts from the Rhode Island Department of Health State Laboratory to explore the potential relationship between positive covid-19 test Ct distribution trends, and covid-19 mortality in the state of Rhode Island, from March through early to mid-June, 2020. Mean daily covid-19 positive test Ct data were compiled, and 7-day rolling average covid-19 mortality was offset by 21-days, given the lag between infection and death. We divided the Ct data into three strata, >32, 28-32, and <28, which were operationally defined as not infectious, maybe infectious, and infectious, respectively. Between late March and June, mean daily Ct values rose linearly (R-squared=0.789) so that by early June, as the covid-19 pandemic ebbed in severity, all means reached the noninfectious (Ct >32) range. Most notably, this May-June trend for Cts was accompanied by a marked, steady decline in Rhode Island daily covid-19 mortality. Our results suggest that monitoring, and public reporting of mean population covid-19 test Cts over time is warranted to gauge the vacillations of covid-19 outbreak severity, including covid-19 mortality trends.",Andrew Bostom; Charles B. Eaton; Todd Kenyon,https://medrxiv.org/cgi/content/short/2021.01.26.21250557,https://medrxiv.org/cgi/content/short/2021.01.26.21250557,2021-01-29,2021-01-29,,True
116,SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study,"Background: The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subsequent infection among seropositive young adults was studied prospectively. Methods: The study population comprised 3,249 predominantly male, 18-20-year-old Marine recruits. Upon arrival at a Marine-supervised two-week quarantine, participants were assessed for baseline SARS-CoV-2 IgG seropositivity, defined as a 1:150 dilution or greater on receptor binding domain and full-length spike protein enzyme-linked immunosorbent (ELISA) assays. SARS-CoV-2 infection was assessed by PCR at initiation, middle and end of the quarantine. After appropriate exclusions, including participants with a positive PCR during quarantine, we performed three biweekly PCR tests in both seropositive and in seronegative groups once recruits left quarantine and entered basic training and baseline neutralizing antibody titers on all subsequently infected seropositive and selected seropositive uninfected participants. Findings: Among 189 seropositive participants, 19 (10.1%) had at least one positive PCR test for SARS-CoV-2 during the six-week follow-up (1.1 cases per person-year). In contrast, 1,079 (48.0%) of the 2,247 seronegative participants tested positive (6.2 cases per person-year). The incidence rate ratio was 0.18 (95% CI 0.11-0.28, p<0.00001). Among seropositive recruits, infection was associated with lower baseline full-length spike protein IgG titers (p<0.0001). Compared with seronegative recruits, seropositive recruits had about 10-fold lower viral loads (ORF1ab gene, p<0.005), and trended towards shorter duration of PCR positivity (p=0.18) and more frequent asymptomatic infections (p=0.13). Among seropositive participants, baseline neutralizing titers were detected in 45 of 54 (83.3%) uninfected and in 6 of 19 (31.6%) infected participants during the 6 weeks of observation (ID50 difference p<.0001). Interpretation: Seropositive young adults had about one-fifth the risk of subsequent infection compared with seronegative individuals. Although antibodies induced by initial infection are largely protective, they do not guarantee effective SARS-CoV-2 neutralization activity or immunity against subsequent infection. These findings may be relevant for optimization of mass vaccination strategies.","Andrew G Letizia; Yongchao Ge; Sindhu Vangeti; Carl Goforth; Dawn L Weir; Natalia A Kuzmina; Hua Wei Chen; Dan Ewing; Alessandra Soares-Schanoski; Mary-Catherine George; William D Graham; Franca Jones; Preeti Bharaj; Rhonda A Lizewski; Stephen A Lizewski; Jan Marayag; Nada Marjanovic,; Clare Miller; Sagie Mofsowitz; Venugopalan D Nair; Edgar Nunez; Danielle M Parent; Chad K Porter; Ernesto Santa Ana; Megan Schilling; Daniel Stadlbauer; Victor Sugiharto; Michael S Termini; Peifang Sun; Russell P Tracy; Florian Krammer; Alexander Bukreyev; Ramos Irene; Stuart C Sealfon",https://medrxiv.org/cgi/content/short/2021.01.26.21250535,https://medrxiv.org/cgi/content/short/2021.01.26.21250535,2021-01-29,2021-01-29,,True
117,Stringency of the containment measures in response to COVID-19 inversely correlates with the overall disease occurrence over the epidemic wave,"Non-pharmaceutical interventions (NPIs) were the only viable choice to mitigate or suppress transmission of COVID-19 in the absence of efficient and safe vaccines. Moreover, the importance of some NPIs is likely to remain in the future, at least in specific settings, in which the limited vaccination coverage and the high rate of contacts would enable further disease transmission. Nonetheless, the benefits of NPIs have been questioned with respect to their effectiveness and societal costs. In this study of 28 European countries during the first wave of epidemic we demonstrate a significant inverse correlation between the stringency of adopted containment measures and cumulative incidences of the confirmed COVID-19 cases. Our results indicate that early implementation of the stringent containment measures prior to detection of the first confirmed case, and rapid ramp-up of containment stringency after the first case was diagnosed, were instrumental for lowering the number of COVID-19 cases during the epidemic wave. The impact of delayed adoption of containment measures could not be fully attenuated by later adoption of even more stringent community containment.",Roman Mezencev; Cyril Klement,https://medrxiv.org/cgi/content/short/2021.01.26.21250501,https://medrxiv.org/cgi/content/short/2021.01.26.21250501,2021-01-29,2021-01-29,,True
118,Reduction of respiratory syncytial virus burden of disease observed in primary care diagnosis of children under 5 years old during the COVID-19 pandemic: a time-series analysis using routinely collected data from primary care electronic health records in Catalonia (Spain).,"Background: Great reductions of respiratory syncytial virus (RSV) in children were observed during the 2020 Southern hemisphere winter. Aim: To describe trends of RSV related disease in children in the Northern hemisphere and to propose a low cost clinical surveillance system based on primary care electronic health records (EHR). Methods: Time series analysis of RSV-related disease and virus laboratory-confirmations in children under 5 years old from 1 September 2009 to 16 January 2021. We collected RSV diagnoses from primary care EHR in Catalonia (Spain). We compared the trend of RSV in the season 2020-2021 with that in the previous seasons. We estimated the expected RSV cases with data from 2009 to 2018 using a time series regression adjusted by seasonality. We used the same method to estimate the expected RSV laboratory-confirmations as a sensitivity analysis. Results: In previous seasons, RSV-related disease peaks in Catalonia during the weeks 52 and 53. However in the 2020-2021 period, we observed a reduction of 87.6% (95% CI: 82.7% to 90.3%) in RSV-related disease from october 2020 compared to the expected. Only 1 RSV case was laboratory-confirmed during the 2020-2021 season until mid-January. Conclusions: We observed a nearly absence of RSV-related disease and laboratory-confirmations during the weeks when RSV usually peaks in Catalonia. The use of primary care EHR could be a low-cost surveillance system to monitorize trends of RSV the coming months.",Ermengol Coma; Jorgina Vila; Leonardo MÃ©ndez-Boo; AndrÃ©s AntÃ³n; NÃºria Mora; Francesc Fina; Mireia FÃ bregas; Manuel Medina,https://medrxiv.org/cgi/content/short/2021.01.27.21250063,https://medrxiv.org/cgi/content/short/2021.01.27.21250063,2021-01-29,2021-01-29,,True
119,Risk perception of COVID-19 and its socioeconomic correlates in the United States: A social media analysis,"Social media analysis provides a new approach to monitoring and understanding risk perceptions regarding COVID-19 over time. Our current understandings of risk perceptions regarding COVID-19 do not disentangle the three dimensions of risk perceptions (perceived susceptibility, perceived severity, and negative emotion) over a long enough timeframe to cover different pandemic phases. The impact of social determinants of health factors on COVID-19-related risk perceptions over time is also not clear. To address these two knowledge gaps, we extracted tweets regarding COVID-19-related risk perceptions and developed index indicators for three dimensions of risk perceptions based on over 297 million geotagged tweets posted by over 3.5 million Twitter users from January to October 2020 in the United States. We also examined correlations between index indicator scores and county-level social determinants of health factors. The three domains of risk perceptions demonstrate different trajectories. Perceived severity kept climbing throughout the whole study period. Perceived susceptibility and negative emotion declined and remained stable at a lower level after peaking on March 11 (WHO named COVID-19 a global pandemic). Attention on risk perceptions was not exactly in accordance with epidemic trends of COVID-19 (cases, deaths). Users from socioeconomically vulnerable counties showed lower attention on perceived severity and susceptibility of COVID-19 than those from wealthier counties. Examination of trends in tweets regarding the multiple domains of risk perceptions throughout stages of the COVID-19 pandemic can help policy makers frame in-time, tailored, and appropriate responses to prevent viral spread and encourage preventive behavior uptake in United States.",Shan Qiao; Zhenlong Li; Chen Liang; Xiaoming Li; Caroline Ann Rudisill,https://medrxiv.org/cgi/content/short/2021.01.27.21250654,https://medrxiv.org/cgi/content/short/2021.01.27.21250654,2021-01-29,2021-01-29,,True
120,"Depression Symptoms during the COVID-19 Pandemic among Well-Educated, Employed Adults with Low Infection Risks","Levels and distributions of depression symptoms 8-10 months after the onset of the COVID-19 pandemic are reported in a population of faculty, staff, and students at Duke University who faced minimal infection and economic disruption due to the pandemic. Almost 5,000 respondents age 18-81 years who completed the 20-item Center for Epidemiological Studies-Depression (CES-D) battery reported high rates of depression symptoms with more than 40% reporting levels that indicate risk of moderate depression and 25% indicating risk of severe depression. There is a very steep age gradient with the highest levels reported by the youngest respondents of whom over 40% are at risk of severe depression. Symptoms are worse among those who report the demands of work often interfere with family responsibilities but these pressures neither explain the high reported rates nor the steep age gradient. Severe depression risks are highest among students. High levels of depression symptoms during the pandemic appear to be persistent and not confined to those at greatest risk of infection or economic insecurity.",Duncan Thomas; Tyson Brown; Donald H Taylor Jr.; Ralph Lawton; Victoria K Lee; Menna Mburi; Michelle Wong; Rachel Kranton,https://medrxiv.org/cgi/content/short/2021.01.26.21250558,https://medrxiv.org/cgi/content/short/2021.01.26.21250558,2021-01-29,2021-01-29,,True
121,Multinational Prevalence of Neurological Phenotypes in Patients Hospitalized with COVID-19,"OBJECTIVE: Neurological complications can worsen outcomes in COVID-19. We defined the prevalence of a wide range of neurological conditions among patients hospitalized with COVID-19 in geographically diverse multinational populations. METHODS: Using electronic health record (EHR) data from 348 participating hospitals across 6 countries and 3 continents between January and September 2020, we performed a cross-sectional study of hospitalized adult and pediatric patients with a positive SARS-CoV-2 reverse transcription polymerase chain reaction test, both with and without severe COVID-19. We assessed the frequency of each disease category and 3-character International Classification of Disease (ICD) code of neurological diseases by countries, sites, time before and after admission for COVID-19, and COVID-19 severity. RESULTS: Among the 35,177 hospitalized patients with SARS-CoV-2 infection, there was increased prevalence of disorders of consciousness (5.8%, 95% confidence interval [CI]: 3.7%-7.8%, pFDR<.001) and unspecified disorders of the brain (8.1%, 95%CI: 5.7%-10.5%, pFDR<.001), compared to pre-admission prevalence. During hospitalization, patients who experienced severe COVID-19 status had 22% (95%CI: 19%-25%) increase in the relative risk (RR) of disorders of consciousness, 24% (95%CI: 13%-35%) increase in other cerebrovascular diseases, 34% (95%CI: 20%-50%) increase in nontraumatic intracranial hemorrhage, 37% (95%CI: 17%-60%) increase in encephalitis and/or myelitis, and 72% (95%CI: 67%-77%) increase in myopathy compared to those who never experienced severe disease. INTERPRETATION: Using an international network and common EHR data elements, we highlight an increase in the prevalence of central and peripheral neurological phenotypes in patients hospitalized with SARS-CoV-2 infection, particularly among those with severe disease.",Trang T Le; Alba GutiÃ©rrez-SacristÃ¡n; Jiyeon Son; Chuan Hong; Andrew M South; Brett K Beaulieu-Jones; Ne Hooi Will Loh; Yuan Luo; Michele Morris; Kee Yuan Ngiam; Lav P Patel; Malarkodi J Samayamuthu; Emily Schriver; Amelia LM Tan; Jason Moore; Tianxi Cai; Gilbert S. Omenn; Paul Avillach; Isaac S Kohane; - The Consortium for Clinical Characterization of COVID-19 by EHR (4CE); Shyam Visweswaran; Danielle L Mowery; Zongqi Xia,https://medrxiv.org/cgi/content/short/2021.01.27.21249817,https://medrxiv.org/cgi/content/short/2021.01.27.21249817,2021-01-29,2021-01-29,,True
122,Is vitamin D deficiency associated with the COVID-19 epidemic in Europe?,"Objective: COVID-19 has emerged as a global pandemic, affecting nearly 80 million people from 218 countries as of December 2020. At the same time, vitamin D deficiency seems to be prevalent among COVID-19 patients. Hence, the association between the prevalence of vitamin D deficiency and COVID-19 infection and mortality among European countries was examined. Design: A case series and recent literature review study Settings: Information on prevalence of vitamin D deficiency in each country was retrieved through literature searching on PubMed database. As of December, 23rd 2020, COVID-19 infections and mortalities per million population were extracted from the Worldometer website, whereas the latitude of each country was taken from the CSGNetwork website. The association between both vitamin D deficiency and COVID-19 infection and mortality were explored using correlation coefficients and scatterplots. Participants: European Countries-Populations Results: The range of prevalence of vitamin D deficiency among European countries was 6.9-75.1%, with most countries facing more than 50% of vitamin D deficiency among their population. Significant positive correlations were observed between COVID-19 infections (r=0.82; p<0.001) and mortalities (r=0.53; p=0.05) per million population with the prevalence of vitamin D deficiency. Most of the high latitude countries showed lower rates of COVID-19 infections and mortalities compared to middle latitude countries. Conclusion: Prevalence of vitamin D deficiency was significantly associated with both infection and mortality rate of COVID-19 among European countries. Thus, it is an important parameter to be considered when implementing preventive measures to mitigate the mortality rate of COVID-19.",Dimitra Rafailia Bakaloudi; Michail Chourdakis,https://medrxiv.org/cgi/content/short/2021.01.28.21250673,https://medrxiv.org/cgi/content/short/2021.01.28.21250673,2021-01-29,2021-01-29,,True
123,"Ownership and COVID-19 in care homes for older people: A living systematic review of outbreaks, infections, and mortalities","Background: The adult social care sector is being increasingly outsourced to for-profit providers, but the impacts of privatisation on service quality and resident outcomes are unclear. During the COVID-19 pandemic, for-profit providers have been accused of failing their residents by prioritising profits over care, prevention, and caution, which has been reported to result in a higher prevalence of COVID-19 infections and deaths in for-profit care homes. Although many of these reports are anecdotal or based on news reports, there is a growing body of academic research investigating ownership variation across COVID-19 outcomes, which has not been systematically appraised and synthesised. Objectives: To identify, appraise, and synthesise the available research on ownership variation in COVID-19 outcomes (outbreaks, infections, deaths, shortage of personal protective equipment (PPE) and staff) across for-profit, public, and non-profit care homes for older people, and to update our findings as new research becomes available. Design: Living systematic review. Methods: This review was prospectively registered with Prospero (CRD42020218673). We searched 17 databases and performed forward and backward citation tracking of all included studies. Search results were screened and reviewed in duplicate. Risk of bias (RoB) was assessed in duplicate according to the COSMOS-E guidance. The results were synthesised according to RoB, model adjustment, and country context and visualised using harvest plots. Results: Twenty-eight studies across five countries were included, with 75% of included studies conducted in the Unites States. For-profit ownership was not consistently associated with a higher probability of COVID-19 outbreaks across included studies. However, there was compelling evidence of worse COVID-19 outcomes following an outbreak; with for-profit care homes having higher rates of accumulative infections and deaths. For-profit providers were also associated with shortages in PPE, which may have contributed to the higher incidence of infections and deaths. Chain affiliation was often found to be correlated with higher risk of outbreaks, but not consistently associated with an elevated number of deaths and infections. Private equity ownership was not consistently associated with worse COVID-19 outcomes. Conclusion: For-profit status was a consistent risk factor for higher cumulative COVID-19 infections and deaths. Thus, ownership among providers may be a key modifiable factor which can be regulated to improve health outcomes in vulnerable populations and reduce health disparities. This review will be updated as new research becomes published, which may change the conclusion of our synthesis.",Anders M Bach-Mortensen; Ben Verboom; Michelle Degli Esposti,https://medrxiv.org/cgi/content/short/2021.01.28.21250547,https://medrxiv.org/cgi/content/short/2021.01.28.21250547,2021-01-29,2021-01-29,,True
124,More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis,"COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers. This systematic review and meta-analysis aims to identify studies assessing long-term effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. All articles with original data for detecting long-term COVID-19 published before 1st of January 2021 and with a minimum of 100 patients were included. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. Heterogeneity was assessed using I2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. The follow-up time ranged from 15 to 110 days post-viral infection. The age of the study participants ranged between 17 and 87 years. It was estimated that 80% (95% CI 65-92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). All meta-analyses showed medium (n=2) to high heterogeneity (n=13). In order to have a better understanding, future studies need to stratify by sex, age, previous comorbidities, severity of COVID-19 (ranging from asymptomatic to severe), and duration of each symptom. From the clinical perspective, multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.",Sandra Lopez-Leon; Talia Wegman-Ostrosky; Carol Perelman; Rosalinda Sepulveda; Paulina A Rebolledo; Angelica Cuapio; Sonia Villapol,https://medrxiv.org/cgi/content/short/2021.01.27.21250617,https://medrxiv.org/cgi/content/short/2021.01.27.21250617,2021-01-29,2021-01-29,,True
125,Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19,"We evaluated diagnostic accuracy of the Innova SARS-CoV-2 Antigen Rapid Qualitative Test compared to SARS-CoV-2 RT-PCR from nasopharyngeal swabs in adult admissions who met the COVID-19 case definition at a busy acute hospital in the UK. We found the Innova SARS-CoV-2 Antigen Rapid Qualitative Test had a good specificity in patients with symptoms of COVID-19 presenting to hospital. The Innova LFA can be used to rapidly identify COVID-19 cases amongst hospital admissions meeting the COVID-19 case definition, allowing patients to be allocated to COVID-19 cohort areas.",Hamish Houston; Ankur Gupta-Wright; Edward Toke-Bjolgerud; James Biggin-Lamming; Laurence John,https://medrxiv.org/cgi/content/short/2021.01.27.21250428,https://medrxiv.org/cgi/content/short/2021.01.27.21250428,2021-01-29,2021-01-29,,True
126,First detection and report of SARS-CoV-2 Spike protein N501Y mutations in Oklahoma USA,"We describe the detection of SARS-CoV-2 (VOC )B.1.1.7 lineage in Oklahoma, USA. Various mutations in the S gene and ORF8 with similarity to the genome of B.1.1.7 lineage were detected in 4 of the 6 genomes sequenced and reported here. The sequences have been made available in GISAID. Presence of novel lineages indicate the need for frequent whole genome sequencing to better understand pathogen dynamics in different geographical locations.",Sai Narayanan; Girish Patil; Sunil More; Jeremiah T Saliki; Anil Kaul; Akhilesh Ramachandran,https://medrxiv.org/cgi/content/short/2021.01.26.21250584,https://medrxiv.org/cgi/content/short/2021.01.26.21250584,2021-01-29,2021-01-29,,True
127,A systematic review and meta-analysis on the safety and efficacy of tocilizumab in the management of COVID-19,"Background: This systematic review and meta-analysis was aimed to evaluate the therapeutic benefits and safety of tocilizumab (TCZ) in treating severe coronavirus disease 2019 (COVID-19) and associated health complications. Methods: The electronic search was performed using PubMed, Scopus, CENTRAL (Cochrane Central Register of Controlled Trials (RCTs), and Google scholar databases to identify the retrospective observational reports. The studies published from 01 January 2020 to 30th September 2020 involving comparison of TCZ group with SOC/control treatment group were included. The studies included in this work involve RT-PCR confirmed cases of COVID-19 (Population), having tocilizumab and corresponding SOC/control as interventions (Intervention), comparison between tocilizumab versus SOC/control (Comparison) for the parameter of interest. Mortality, incidences of ICU admission, need of mechanical ventilation (MV), length of stay in the hospital (LOS), and length of stay in the ICU (LOS-ICU), and the incidences of super-infection, bacteraemia, fugleman, pneumonia, and pulmonary thrombosis were evaluated as the primary outcomes. The comparison will be between TCZ versus standard of care (SOC)/placebo. Results: Based on the inclusion criteria there were 24 retrospective studies involving 5686 subjects were included. The outcomes of the meta-analysis have revealed that the TCZ has reduced the mortality (Mantel-Haenszel (M-H), random effects risk difference (RE-RD) of -0.11 (-0.18 to -0.04), at 95% CI, p = 0.001, I2 = 88%) and increased the incidences of super-infections (M-H, RE-Risk ratio (RR) of 1.49 (1.13 to 1.96) at 95% CI, p=0.004, I2 = 47%). However, there is no significant difference in ICU admissions rate (M-H, RE-RD of -0.06 (-0.23 to 0.12) at 95% CI, p=0.54, I2 = 93%), need of MV (M-H, RE-RD of 0.00 (-0.06 to 0.07) at 95% CI, p=0.96, I2 = 74%), LOS (Inverse variance (IV): -2.86 (-0.91 to 3.38) at 95% CI, p=0.37, I2 = 100%), LOS-ICU (IV: -3.93 (-12.35 to 4.48) at 95% CI, p=0.36, I2 = 100%), and incidences of pulmonary thrombosis (M-H, fixed effect odds ratio (FE-OR) of 1.01 (0.45 to 2.26) at 95% CI, p=0.99, I2 = 0%) compared to SOC/control. Conclusion: This meta-analysis was performed using retrospective clinical reports on the use of tocilizumab in COVID-19 and based on the outcomes of the meta-analysis we can conclude that administration of TCZ would reduce the risk of mortality, and however there is no much difference observed between the TCZ and SOC/control groups in other parameters such as ICU admission rate, need of mechanical ventilation and length of hospital stay (ICU and Non-ICU). On the other hand, TCZ treated subjects possess higher chances of super-infections and pneumonia compared with SOC/control group. However, there is a need for multi-centric randomized trials to determine the potential therapeutic role of TCZ in mitigating COVID-19 and associated health complications.",Gollapalle Lakshminarayanashastry Viswanatha; CH K V L S N Anjana Male; Hanumanthappa Shylaja,https://medrxiv.org/cgi/content/short/2021.01.27.21250599,https://medrxiv.org/cgi/content/short/2021.01.27.21250599,2021-01-29,2021-01-29,,True
128,Duration of SARS-CoV-2 Sero-Positivity in a Large Longitudinal Sero-Surveillance Cohort: The COVID-19 Community Research Partnership,"Background: Estimating population prevalence and incidence of prior SARS-CoV-2 infection is essential to formulate public health recommendations concerning the COVID-19 pandemic. However, interpreting estimates based on sero-surveillance requires an understanding of the duration of elevated antibodies following SARS-CoV-2 infection, especially in the large number of people with pauci-symptomatic or asymptomatic disease. Methods: We examined >30,000 serology assays for SARS-CoV-2 specific IgG and IgM assays acquired longitudinally in 11,468 adults between April and November 2020 in the COVID-19 Community Research Partnership. Findings: Among participants with serologic evidence for infection but few or no symptoms or clinical disease, roughly 50% sero-reverted in 30 days of their initial positive test. Sero-reversion occurred more quickly for IgM than IgG and for antibodies targeting nucleocapsid protein compared with spike proteins, but was not associated with age, sex, race/ethnicity, or healthcare worker status. Interpretation: The short duration of antibody response suggests that the true population prevalence of prior SARS-CoV-2 infection may be significantly higher than presumed based on earlier sero-surveillance studies. The impact of the large number of minimally symptomatic COVID-19 cases with only a brief antibody response on population immunity remains to be determined.",David M Herrington; - The COVID-19 Community Research Partnership Study Group,https://medrxiv.org/cgi/content/short/2021.01.27.21250615,https://medrxiv.org/cgi/content/short/2021.01.27.21250615,2021-01-29,2021-01-29,,True
129,SARS-CoV-2 in Ivory Coast: serosurveillance survey among mines workers,"Background: Eight months after the detection of the first COVID-19 case in Africa, 1,262,476 cases have been reported in African countries compared to 72 million worldwide. The real burden of SARS-CoV-2 infection in West Africa is not clearly defined. The aim of the study was to evaluate the seroprevalence of SARS-CoV-2 in half of the 3,380 workers of several mining companies operating in two mines in the Ivory Coast and having its headquarters in the economic capital Abidjan. Methods: From 15th July to 13th October 2020, a voluntary serological test campaign was performed in the 3 sites where the companies operate: two mines, and the headquarters in Abidjan.We performed a COVID-PRESTO rapid test for the detection of IgG and IgM on capillary blood. A multivariate analysis was performed to identify independent sociodemographic characteristics associated with a higher SARS-CoV-2 seroprevalence rate. Results: A total of 1,687 subjects were tested. 91% were male (n= 1,536) and mean age was 37 years old. The overall crude seroprevalence rate was 25.1% (n=422), but differing significantly between different sites, rising from 13.6% (11.2%-16.1%) in mine A to 34.4% (31.1%-37.7%) in mine B and 34.7% (26.2%-43.2%) in Abidjan. Non-resident workers in mines had a significantly lower prevalence rate than those living full-time in mines. Seroprevalence was 26.5% in natives of the Ivory Coast, while people coming from countries other than Africa were less likely to be SARS-CoV-2 seropositive. Among the 422 positive subjects, 74 reported mild symptoms in the three previous months and one was hospitalized for a severe COVID-19 infection. Conclusion: The prevalence of SARS-CoV-2 infection among mine workers in Ivory Coast is high. The low morbidity observed has probably led to an underestimation of the burden of this infection in West Africa. The high prevalence reported in subjects living in Abidjan, who have not any close contact with mine workers, may be indicative of the real seroprevalence in the Ivory Coast capital.",Jean- Marie Milleliri; Daouda Coulibaly; Blaise Nyobe; Jean-Loup Rey; Franck Lamontagne; Laurent Hocqueloux; Susanna Giache; Antoine Valery; thierry prazuck,https://medrxiv.org/cgi/content/short/2021.01.27.21249186,https://medrxiv.org/cgi/content/short/2021.01.27.21249186,2021-01-29,2021-01-29,,True
130,Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care,"Aim: We aimed to assess the risk for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in a large cohort of healthcare workers (HCWs). Methods: From May 11 until June 11, 2020, 3,981 HCWs at a large Swedish Emergency Care hospital provided serum samples and questionnaire data. Exposure was measured by assaying IgG antibodies to SARS-CoV-2. Results: The total seroprevalence was 17.7% and increased during the study period. Among the seropositive HCWs, 10.5% had been entirely asymptomatic. Participants who worked with COVID-19 patients had higher odds for seropositivity: ORadj 1.96 (95% CI 1.59-2.42). HCWs from three of the departments managing COVID-19 patients had significantly higher seroprevalences, whereas the prevalence among HCWs from the Intensive Care Unit (also managing COVID-19 patients) was significantly lower. Conclusion: HCWs in contact with SARS-CoV-2 infected patients had a variable, but on average higher, likelihood for SARS-CoV-2 infections.",Susanna Klevebro; Fuad Bahram; Miriam K Elfstrom; Ulrika Hellberg; Sophia Hober; Simon K Merid; Inger Kull; Peter Nilsson; Per Tornvall; Gang Wang; Kalle Conneryd-Lundgren; Sari Ponzer; Joakim Dillner; Erik Melen,https://medrxiv.org/cgi/content/short/2021.01.28.21250664,https://medrxiv.org/cgi/content/short/2021.01.28.21250664,2021-01-29,2021-01-29,,True
131,"HLA-A*11:01:01:01, HLA*C*12:02:02:01-HLA-B*52:01:02:02, age and sex are associated with severity of Japanese COVID-19 with respiratory failure","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19) was announced as an outbreak by the World Health Organization (WHO) in January 2020 and as a pandemic in March 2020. The majority of infected individuals have experienced no or only mild symptoms, ranging from fully asymptomatic cases to mild pneumonic disease. However, a minority of infected individuals develop severe respiratory symptoms. The objective of this study was to identify susceptible HLA alleles and clinical markers for the early identification of severe COVID-19 among hospitalized COVID-19 patients. A total of 137 patients with mild COVID-19 (mCOVID-19) and 53 patients with severe COVID-19 (sCOVID-19) were recruited from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan for the period of February-August 2020. High-resolution sequencing-based typing for eight HLA genes was performed using next-generation sequencing. In the HLA association studies, HLA-A*11:01:01:01 [Pc = 0.013, OR = 2.26 (1.27-3.91)] and HLA-C*12:02:02:01-HLA-B*52:01:01:02 [Pc = 0.020, OR = 2.25 (1.24-3.92)] were found to be significantly associated with the severity of COVID-19. After multivariate analysis controlling for other confounding factors and comorbidities, HLA-A*11:01:01:01 [P = 3.34E-03, OR = 3.41 (1.50-7.73)], age at diagnosis [P = 1.29E-02, OR = 1.04 (1.01-1.07)] and sex at birth [P = 8.88E-03, OR = 2.92 (1.31-6.54)] remained significant. Early identification of potential sCOVID-19 could help clinicians prioritize medical utility and significantly decrease mortality from COVID-19.",Seik-Soon Khor; Yosuke Omae; Nao Nishida; Masaya Sugiyama; Noriko Kinoshita; Tetsuya Suzuki; Michiyo Suzuki; Satoshi Suzuki; Shinyu Izumi; Masayuki Hojo; Norio Ohmagari; Masashi Mizokami; Katsushi Tokunaga,https://medrxiv.org/cgi/content/short/2021.01.26.21250349,https://medrxiv.org/cgi/content/short/2021.01.26.21250349,2021-01-29,2021-01-29,,True
132,A Rapid and Low-Cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-Based RT-qPCR,"Background: The new SARS-CoV-2 variant VUI (202012/01), identified recently in the United Kingdom (UK), exhibits a higher transmissibility rate compared to other variants, and a reproductive number 0.4 higher. In the UK, scientists were able to identify the increase of this new variant through the rise of false negative results for the spike (S) target using a three-target RT-PCR assay (TaqPath kit). Methods: To control and study the current coronavirus pandemic, it is important to develop a rapid and low-cost molecular test to identify the aforementioned variant. In this work, we designed primer sets specific to SARS-CoV-2 variant VUI (202012/01) to be used by SYBR Green-based RT-PCR. These primers were specifically designed to confirm the deletion mutations {Delta}69/{Delta}70 in the spike and the {Delta}106/{Delta}107/{Delta}108 in the NSP6 gene. We studied 20 samples from positive patients, 16 samples displayed an S-negative profile (negative for S target and positive for N and ORF1ab targets) and four samples with S, N and ORF1ab positive profile. Results: Our results emphasized that all S-negative samples harbored the mutations {Delta}69/{Delta}70 and {Delta}106/{Delta}107/{Delta}108. This protocol could be used as a second test to confirm the diagnosis in patients who were already positive to COVID-19 but showed false negative results for S-gene. Conclusions: This technique may allow to identify patients carrying the VUI (202012/01) variant or a closely related variant, in case of shortage in sequencing.",Fadi Abdel-Sater; Mahmoud Younes; Hassan Nassar; Paul Nguewa; Kassem Hamze,https://medrxiv.org/cgi/content/short/2021.01.27.21250048,https://medrxiv.org/cgi/content/short/2021.01.27.21250048,2021-01-29,2021-01-29,,True
133,A prediction model for COVID-19 prevalence based on demographic and healthcare parameters in Iran,"Coronavirus Disease 2019 (COVID-19) pandemic has become the greatest threat to global health in only a matter of months. Iran struggling with COVID-19 coincidence with Nowruz vacations has led to horrendous consequences for both people and the public health workforce. Modeling approaches have been proved to be highly advantageous in taking appropriate actions in the early stages of the pandemic. To this date, no study has been conducted to model COVID-19 to investigate the impact of disease factors, especially after travel restrictions in Iran. In this study, we exploited the opportunities that Artificial neural networks offer to investigate contributing factors of early-stage coronavirus spread via generating a model to predict daily confirmed cases in Iran. We collected publicly available data of confirmed cases in 24 provinces from April 4, 2020, to May 2, 2020, with a list of explanatory factors. The factors were checked separately for any linear associations and to train and validate a multilayer perceptron network. The accuracy of the models was evaluated, the R2 scores were 0.842 for population distribution, 0.822 for health index, and 0.864 for the population in the provinces. Our results suggest the significant impact of the mentioned factors on disease spread in the time of travel restrictions when the vacation ended. Accordingly, this information can be implicated in assessing the risk of epidemics and future policy makings in this area.",parimah Sadat Emadi Safavi; Karim Rahimian; Alireza Doustmohammadi; Mahla Safari Dastjerdei; Ahmadreza Rasouli; Javad Zahiri,https://medrxiv.org/cgi/content/short/2021.01.27.21250551,https://medrxiv.org/cgi/content/short/2021.01.27.21250551,2021-01-29,2021-01-29,,True
134,The World Mortality Dataset: Tracking excess mortality across countries during the COVID-19 pandemic,"Comparing the impact of the COVID-19 pandemic between countries or across time is difficult because the reported numbers of cases and deaths can be strongly affected by testing capacity and reporting policy. Excess mortality, defined as the increase in all-cause mortality relative to the recent average, is widely considered as a more objective indicator of the COVID-19 death toll. However, there has been no central, frequently-updated repository of the all-cause mortality data across countries. To fill this gap, we have collected weekly, monthly, or quarterly all-cause mortality data from 77 countries, openly available as the regularly-updated World Mortality Dataset. We used this dataset to compute the excess mortality in each country during the COVID-19 pandemic. We found that in the worst-affected countries the annual mortality increased by over 50%, while in several other countries it decreased by over 5%, presumably due to lockdown measures decreasing the non-COVID mortality. Moreover, we found that while some countries have been reporting the COVID-19 deaths very accurately, many countries have been underreporting their COVID-19 deaths by an order of magnitude or more. Averaging across the entire dataset suggests that the world's COVID-19 death toll may be at least 1.6 times higher than the reported number of confirmed deaths.",Ariel Karlinsky; Dmitry Kobak,https://medrxiv.org/cgi/content/short/2021.01.27.21250604,https://medrxiv.org/cgi/content/short/2021.01.27.21250604,2021-01-29,2021-01-29,,True
135,Beyond the new normal: assessing the feasibility of vaccine-based elimination of SARS-CoV-2,"As the COVID-19 pandemic drags into its second year, there is hope on the horizon, in the form of SARS-CoV-2 vaccines which promise disease elimination and a return to pre-pandemic normalcy. In this study we critically examine the basis for that hope, using an epidemiological modeling framework to establish the link between vaccine characteristics and effectiveness in bringing an end to this unprecedented public health crisis. Our findings suggest that vaccines that do not prevent infection will allow extensive endemic SARS-CoV-2 spread upon a return to pre-pandemic social and economic conditions. Vaccines that only reduce symptomatic COVID-19 or mortality will fail to mitigate serious COVID-19 mortality risks, particularly in the over-65 population, likely resulting in hundreds of thousands of US deaths on a yearly basis. Our modeling points to the possibility of complete SARS-CoV-2 elimination with high population-level compliance and a vaccine that is highly effective at reducing SARS-CoV-2 infection. Notably, vaccine-mediated reduction of transmission is critical for elimination, and in order for partially-effective vaccines to play a positive role in SARS-CoV-2 elimination, other stackable (complementary) interventions must be deployed simultaneously.",Madison Stoddard; Sharanya Sarkar; Ryan P. Nolan; Douglas E White; Laura White; Natasha S Hochberg; Arijit Chakravarty,https://medrxiv.org/cgi/content/short/2021.01.27.20240309,https://medrxiv.org/cgi/content/short/2021.01.27.20240309,2021-01-29,2021-01-29,,True
136,Evaluation of COVID-19 vaccination strategies with a delayed second dose,"COVID-19 vaccines currently approved in the United States require two doses, administered three to four weeks apart. Constraints in vaccine supply and distribution capacity, together with the rise of COVID-19 cases and hospitalizations, have sparked a policy debate on whether to vaccinate more individuals with the first dose of available vaccines and delay the second dose, or to continue with the recommended two-dose series as tested in clinical trials. We developed an agent-based model of COVID-19 transmission to compare the impact of these two vaccination strategies, while varying the temporal waning of vaccine efficacy against disease following the first dose, vaccine efficacy against infection, and the level of pre-existing immunity in the population. Our results show that for Moderna vaccines with 80% efficacy following the first dose, a delay of 9-12 weeks could enhance the program effectiveness and prevent additional infections, hospitalizations, and deaths, compared to a 4-week interval between the doses. However, for Pfizer-BioNTech vaccines with demonstrated efficacy of 52% after the first dose, there was no clear advantage for delaying the second dose beyond the 3-week tested schedule, unless the efficacy of the first dose did not wane over time. Our findings underscore the importance of quantifying the durability of vaccine-induced protection after the first dose as well as vaccine efficacy against infection in order to determine the optimal time interval between the two doses.",Seyed M. Moghadas; Thomas N. Vilches; Kevin Zhang; Shokoofeh Nourbakhsh; Pratha Sah; Meagan C. Fitzpatrick; Alison P. Galvani,https://medrxiv.org/cgi/content/short/2021.01.27.21250619,https://medrxiv.org/cgi/content/short/2021.01.27.21250619,2021-01-29,2021-01-29,,True
137,"The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-infection and transmissibility","The new SARS-CoV-2 variant B.1.1.7 was identified in December 2020 in the South-East of England, and rapidly increased in frequency and geographic spread. While there is some evidence for increased transmissibility of this variant, it is not known if the new variant presents with variation in symptoms or disease course, or if previously infected individuals may become reinfected with the new variant. Using longitudinal symptom and test reports of 36,920 users of the Covid Symptom Study app testing positive for COVID-19 between 28 September and 27 December 2020, we examined the association between the regional proportion of B.1.1.7 and reported symptoms, disease course, rates of reinfection, and transmissibility. We found no evidence for changes in reported symptoms, disease severity and disease duration associated with B.1.1.7. We found a likely reinfection rate of around 0.7% (95% CI 0.6-0.8), but no evidence that this was higher compared to older strains. We found an increase in R(t) by a factor of 1.35 (95% CI 1.02-1.69). Despite this, we found that regional and national lockdowns have reduced R(t) below 1 in regions with very high proportions of B.1.1.7.",Mark S Graham; Carole H Sudre; Anna May; Michela Antonelli; Benjamin Murray; Thomas Varsavsky; Kerstin Klaser; Liane Dos Santos Canas; Erika Molteni; Marc Modat; David Alden Drew; Long Alden Nguyen; Lorenzo Polidori; Somesh Selvachandran; Christina Hu; Joan Capdevila Pujol; - The COVID-19 Genomics UK (COG-UK) consortium; Alexander Hammers; Andrew T Chan; Jonathan Wolf; Timothy Spector; Claire Steves; Sebastien Ourselin,https://medrxiv.org/cgi/content/short/2021.01.28.21250680,https://medrxiv.org/cgi/content/short/2021.01.28.21250680,2021-01-29,2021-01-29,,True
138,COVID-19 mortality: positive correlation with cloudiness and sunlight but no correlation with latitude in Europe,"We systematically investigated an ongoing debate about the possible correlation between SARS-CoV-2 (COVID-19) epidemiological outcomes and solar exposure in European countries, in the period of March - August 2020. For each country, we correlated its mortality data with solar insolation (watt/square metre) and objective sky cloudiness (as cloud fraction) derived from satellite weather data. We found a positive correlation between the monthly mortality rate and the overall cloudiness in that month (Pearson's r(35)=.779, P<.001; linear model fitting the data, adjusted R2 =0.59). In Europe, in colder months, approximately 34% to 58% of the variance in COVID-19 mortality/million appears to be predicted by the cloudiness fraction of the sky, except in August in which only ~15% of the variance was explained. The data show a low, negative correlation between the mortality rate with the overall insolation received by the country area in that entire month (Pearson's r(35)=-0.622, P<.001). Additionally, we did not find any statistically significant correlation between the mortality and the latitude of the countries when the ""latitude of a country"" was precisely defined as the average landmass location (country centroid). The unexpected correlation found between cloudiness and mortality could perhaps be explained by the following: 1) heavy cloudiness is linked with colder outdoor surfaces, which might aid virus survival; 2) reduced evaporation rate; 3) moderate pollution may be linked to both cloudiness and mortality; and 4) large-scale behavioural changes due to cloudiness (which perhaps drives people to spend more time indoors and thus facilitates indoor contamination).",Secil Omer; Adrian Iftime; Victor Andrei Burcea,https://medrxiv.org/cgi/content/short/2021.01.27.21250658,https://medrxiv.org/cgi/content/short/2021.01.27.21250658,2021-01-29,2021-01-29,,True
139,The Experience of Two Independent Schools with In-Person Learning During the COVID-19 Pandemic,"BACKGROUND In 2020, U.S schools closed due to SARS-CoV-2 but their role in transmission was unknown. In fall 2020, national guidance for reopening omitted testing or screening recommendations. We report the experience of 2 large independent K-12 schools (School-A and School-B) that implemented an array of SARS-CoV-2 mitigation strategies that included periodic universal testing. METHODS SARS-CoV-2 was identified through periodic universal PCR testing, self-reporting of tests conducted outside school, and contact tracing. Schools implemented behavioral and structural mitigation measures, including mandatory masks, classroom disinfecting, and social distancing. RESULTS Over the fall semester, School-A identified 112 cases in 2320 students and staff; School-B identified 25 cases (2.0%) in 1200 students and staff. Most cases were asymptomatic and none required hospitalization. Of 69 traceable introductions, 63(91%) were not associated with school-based transmission, 59 cases (54%) occurred in the 2 weeks post-Thanksgiving. In 6/7 clusters, clear noncompliance with mitigation protocols was found. The largest outbreak had 28 identified cases and was traced to an off-campus party. There was no transmission from students to staff. CONCLUSIONS Although school-age children can contract and transmit SARS-CoV-2, rates of COVID-19 infection related to in-person education were significantly lower than those in the surrounding community. However, social activities among students outside of school undermined those measures and should be discouraged, perhaps with behavioral contracts, to ensure the safety of school communities. In addition, introduction risks were highest following extended school breaks. These risks may be mitigated with voluntary quarantines and surveillance testing prior to re-opening.",Darria Long Gillespie; Lauren Ancel Meyers; Michael Lachmann; Stephen C Redd; Jonathan M Zenilman,https://medrxiv.org/cgi/content/short/2021.01.26.21250065,https://medrxiv.org/cgi/content/short/2021.01.26.21250065,2021-01-29,2021-01-29,,True
140,Induction of labour during the COVID-19 pandemic: a national survey of impact on practice in the UK,"Background Induction of labour (IOL) is one of the most commonly performed interventions in maternity care, with outpatient cervical ripening increasingly offered as an option for women undergoing IOL. The COVID-19 pandemic has changed the context of practice and the option of returning home for cervical ripening may now assume greater significance. This work aimed to examine whether and how the COVID-19 pandemic has changed practice around IOL in the UK. Method We used an online questionnaire to survey senior obstetricians and midwives at all 156 UK NHS Trusts and Boards that currently offer maternity services. Responses were analysed to produce descriptive statistics, with free text responses analysed using a conventional content analysis approach. Findings Responses were received from 92 of 156 UK Trusts and Boards, a 59% response rate. Many Trusts and Boards reported no change to their IOL practice, however 23% reported change in methods used for cervical ripening; 28% a change in criteria for home cervical ripening; 28% stated that more women were returning home during cervical ripening; and 24% noted changes to womens response to recommendations for IOL. Much of the change was reported as happening in response to attempts to minimise hospital attendance and restrictions on birth partners accompanying women. Conclusions The pandemic has changed practice around induction of labour, although this varied significantly between NHS Trusts and Boards. There is a lack of formal evidence to support decision-making around outpatient cervical ripening: the basis on which changes were implemented and what evidence was used to inform decisions is not clear.",Mairi Harkness; Cassandra Yuill; Helen Cheyne; Sarah Stock; Christine McCourt,https://medrxiv.org/cgi/content/short/2021.01.27.21250521,https://medrxiv.org/cgi/content/short/2021.01.27.21250521,2021-01-29,2021-01-29,,True
141,The prevalence of olfactory dysfunction and its associated factors in patients with COVID-19 infection,"Objective To determine the prevalence of olfactory dysfunctions, mainly, anosmia and to identify its associated factors in patients with COVID-19 infection. Study design A hospital-based prospective observational cohort study Setting A COVID dedicated hospital, Square Hospitals Ltd., Dhaka, Bangladesh. Methods We collected patients information including laboratory-confirmed COVID-19 test results. We used Pearson Chi-square test and logistic regression model to assess the associations between demographic and clinical characteristics and olfactory outcomes. Results Out of 600 COVID-19 positive patients, 38.7% were diagnosed with olfactory dysfunction. Our analyses showed that patients age, smoking status, cough, dyspnea, sore throat, asthenia, and nausea or vomiting were significantly associated with the anosmia. We observed the risk of developing anosmia was greater in younger patients than in older patients, and this risk decreased as age increased [odds ratio (OR) range for different age groups: 1.26 to 1.08]. Smoking patients were 1.73 times more likely to experience anosmia than non-smoking patients [OR=1.73, 95% confidence interval (CI) = 1.01-2.98]. In addition, patients complained asthenia had a significantly double risk of developing the anosmia [OR = 1.96, CI = 1.23-3.06]. Conclusions Our study shows that about 39% of patients diagnosed with olfactory dysfunction. Patients age, smoking status, and asthenia are significantly positively associated with the anosmia. Since anosmia can be a significant marker for the diagnosis of COVID-19, we suggest regular screening of olfactory dysfunction in patients with early symptoms of COVID-19, particularly younger patients, smoker, and complained asthenia.",Md. Mehedi Hasan; Naima Ahmed Tamanna; Mohammad Nasimul Jamal; Md. Jamal Uddin,https://medrxiv.org/cgi/content/short/2021.01.27.21250153,https://medrxiv.org/cgi/content/short/2021.01.27.21250153,2021-01-29,2021-01-29,,True
142,Self-Reported Mask Wearing Greatly Exceeds Directly Observed Use: Urgent Need for Policy Intervention in Kenya,"Background Many countries in sub-Saharan Africa have so far avoided large outbreaks of COVID-19, perhaps due to the strict lockdown measures that were imposed early in the pandemic. Yet the harsh socio-economic consequences of the lockdowns have led many governments to ease the restrictions in favor of less stringent mitigation strategies. In the absence of concrete plans for widespread vaccination, masks remain one of the few tools available to low-income populations to avoid the spread of SARS-CoV-2 for the foreseeable future. Methods We compare mask use data collected through self-reports from phone surveys and direct observations in public spaces from population-representative samples in Ugunja subcounty, a rural setting in Western Kenya. We examine mask use in different situations and compare mask use by gender, age, location, and the riskiness of the activity Findings We assess mask use data from 1,960 phone survey respondents and 9,549 direct observations. While only 12% of people admitted in phone interviews to not wearing a mask in public, 90% of people we observed did not have a mask visible (77.7% difference, 95% CI 0.742, 0.802). Self-reported mask use was significantly higher than observed mask use in all scenarios (i.e. in the village, in the market, on public transportation). Interpretation We find limited compliance with the national government mask mandate in Kenya using directly observed data, but high rates of self-reported mask use. This vast gap suggests that people are aware that mask use is socially desirable, but in practice they do not adopt this behavior. Focusing public policy efforts on improving adoption of mask use via education and behavioral interventions may be needed to improve compliance. Funding Weiss Family Foundation, International Growth Centre",Aleksandra Jakubowski; Dennis Egger; Carolyne Nekesa; Layna Lowe; Michael Walker; Edward Miguel,https://medrxiv.org/cgi/content/short/2021.01.27.21250487,https://medrxiv.org/cgi/content/short/2021.01.27.21250487,2021-01-29,2021-01-29,,True
143,Passing the Test: A model-based analysis of safe school-reopening strategies,"Background. The COVID-19 pandemic has induced historic educational disruptions. In December 2020, at least two-thirds of US public school students were not attending full-time in-person education. The Biden Administration has expressed that reopening schools is a priority. Objective. To compare risks of SARS-COV-2 transmission in schools across different school-based prevention strategies and levels of community transmission. Design. We developed an agent-based network model to simulate transmission in elementary and high school communities, including home, school, and inter-household interactions. Setting. We parameterized school structure based on average US classrooms, with elementary schools of 638 students and high schools of 1,451 students. We varied daily community incidence from 1 to 100 cases per 100,000 population. Patients (or Participants). We simulated students, faculty/staff, and adult household members. Interventions. We evaluated isolation of symptomatic individuals, quarantine of an infected individual's contacts, reduced class sizes, alternative schedules, staff vaccination, and weekly asymptomatic screening. Measurements. We projected transmission among students, staff and families during one month following introduction of a single infection into a school. We also calculated the number of infections expected for a typical 8-week quarter, contingent on community incidence rate. Results. School transmission risk varies according to student age and community incidence and is substantially reduced with effective, consistent mitigation measures. Nevertheless, when transmission occurs, it may be difficult to detect without regular, frequent testing due to the subclinical nature of most infections in children. Teacher vaccination can reduce transmission to staff, while asymptomatic screening both improves understanding of local circumstances and reduces transmission, facilitating five-day schedules at full classroom capacity. Limitations. There is uncertainty about susceptibility and infectiousness of children and low precision regarding the effectiveness of specific prevention measures, particularly with emergence of new variants. Conclusion. With controlled community transmission and moderate school-based prevention measures, elementary schools can open with few in-school transmissions, while high schools require more intensive mitigation. Asymptomatic screening can both reduce transmission and provide useful information for decision-makers.",Alyssa M Bilinski; Joshua A Salomon; John Giardina; Andrea Ciaranello; Meagan Fitzpatrick,https://medrxiv.org/cgi/content/short/2021.01.27.21250388,https://medrxiv.org/cgi/content/short/2021.01.27.21250388,2021-01-29,2021-01-29,,True
144,Sequencing Data of North American SARS-CoV-2 Isolates Shows Widespread Complex Variants,"Several new variants of the SARS-CoV-2 have been isolated in the United States, Mexico, and Canada. Many of the variants contain single variants of functional significance (e.g. S: N501Y increases transmissibility). To study the occurrence and co-circulation of these variants, we have developed an easy-to-use dashboard at https://janieslab.github.io/sars-cov-2.html. We created a multiple sequence alignment workflow and processing script to generate a variant dataset, which populates this dashboard. We then use the features of the dashboard, such as visualization of the single and complex nucleotide variants geospatially and in a color-coded matrix format. Users also interact with the dashboard to filter the underlying data to regions of interest and or variants of interest. The user can export reports based on the desired filters, which we intend to be used for regionally specific pandemic response. We find in Genbank, an isolate from Massachusetts containing [(S: Q677H), (ORF3a: Q57H), (M: A85S), (N: D377Y)] collected on September 11, 2020. Moreover, we find that many viral isolates bear a marker of increased transmissibility (S: N501Y) in linkage with at least one variant of concern isolated from Ohio also range across the Untied States and stretch from British Columbia, Canada to Mexico. When we analyze co-circulation of more complex variant constellations with (S: N501Y), we note that the Upper Midwest and Northeast United States contain these isolates. In summary, the viral variants that have raised concern in a few US States in recent reports are widespread. Based on the increase in the proportion of variant viruses being sampled and some empirical evidence in the United Kingdom, South Africa, and Ohio, these variants are likely to lead to increased transmission of SARS-CoV-2 across North America in the coming months.",Colby T Ford; Rachel Scott; Denis Jacob Machado; Daniel Janies,https://medrxiv.org/cgi/content/short/2021.01.27.21250648,https://medrxiv.org/cgi/content/short/2021.01.27.21250648,2021-01-29,2021-01-29,,True
145,The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence,"Background BNT162b2 vaccines showed high efficacy against COVID-19 in a randomized controlled phase-III trial. A vaccine effectiveness evaluation in real life settings is urgently needed, especially given the global disease surge. Hence, we assessed the short-term effectiveness of the first dose of BNT162b2-vaccine against SARS-CoV-2 infection. Given the BNT162b2 Phase-III results, we hypothesized that the cumulative incidence of SARS-CoV-2 infection among vaccinees will decline after 12 days following immunization compared to the incidence during the preceding days. Methods We conducted a retrospective cohort study using data from 2.6 million-member state-mandated health provider in Israel. Study population consisted of all members aged 16 or above years who were vaccinated with BNT162b2-vaccine between December/19/2020 and January/15/2021. We collected information regarding medical history and positive SARS-CoV-2 polymerase chain reaction test from days after first dose to January/17/2021. Daily and cumulative infection rates in days 13-24 were compared to days 1-12 after first dose using Kaplan-Meier survival analysis and generalized linear models. Findings Data of 503,875 individuals (mean age 59.7 years SD=14.7, 47.8% males) were analyzed, of whom 351,897 had 13-24 days of follow-up. The cumulative incidence of SARS-CoV-2 infection was 0.57% (n=2484) during days 1-12 and 0.27% (n=614) in days 13-24. A 51.4% relative risk reduction (RRR) was calculated in weighted-average daily incidence of SARS-CoV-2 infection from 43.41-per-100,000(SE=12.07) in days 1-12 to 21.08-per-100,000(SE=6.16) in days 13-24 following immunization. The decrement in incidence was evident from day 18 after first dose. Similar RRRs were calculated in individuals aged 60 or above (44.5%), younger individuals (50.2%), females (50.0%) and males (52.1%). Findings were similar in sub-populations and patients with various comorbidities. Conclusions We demonstrated an effectiveness of 51% of BNT162b2 vaccine against SARS-CoV-2 infection 13-24 days after immunization with the first dose. Immunization with the second dose should be continued to attain the anticipated protection.",Gabriel Chodcik; Lilac Tene; Tal Patalon; Sivan Gazit; Amir Ben-Tov; Dani Cohen; Khitam Muhsen,https://medrxiv.org/cgi/content/short/2021.01.27.21250612,https://medrxiv.org/cgi/content/short/2021.01.27.21250612,2021-01-29,2021-01-29,,True
146,SARS-CoV-2 antigenemia/viremia masks seroconversion in a COVID-19 patient,"Immune responses against SARS-CoV-2 have been vigorously analyzed. It has been proposed that a subset of mild or asymptomatic cases with undetectable antibodies may clear the virus in a T-cell cytotoxic-dependent manner, albeit recent data revealed the importance of B-cells in that regard. We hypothesized that underdiagnosed antigenemia/viremia may conceal humoral response possibly through immunocomplex formation. We report the first case of late-onset seroconversion detected following decline in antigenemia/viremia levels. Consequently, classification of at least a subset of COVID-19 cases as non-responders might not represent a true immunobiological phenomenon, rather reflect antibody masking due to prolonged antigenemia/viremia.",Vassilis G Gorgoulis,https://medrxiv.org/cgi/content/short/2021.01.26.21250561,https://medrxiv.org/cgi/content/short/2021.01.26.21250561,2021-01-29,2021-01-29,,True
147,The successful use of volunteers to enhance NHS Test and Trace contact tracing of in-patients with Covid-19: a Pilot Study,"Contact tracing in the UK for Covid-19 is performed by NHS Test and Trace (NHSTT) via telephone or email. This study estimates how many patients who have been admitted to hospital are not reached by NHSTT and the number of their contacts who were not advised to self-isolate. Medical Student volunteers conducted face to face interviews with patients diagnosed with Covid-19 on an infectious diseases ward. Data on their close contacts were sent to NHSTT. 20 cases were enrolled. 13(65%) did not engage with NHSTT, 4(20%) because they had no positive PCR, 9(45%) because of severity of illness, language or intellectual difficulties. 49 close contacts were identified of whom 33(67%) were from cases who had not engaged with NHSTT. Backwards contacts tracing information was collected from 11(55%) cases and 8(40%) gave detailed information. These data suggest that NHSTT fails to engage nearly two thirds of Covid-19 in-patients and fails to advise two thirds of their close contacts to self isolate. Volunteers used face to face interviews to overcome false negative tests, illness and communication problems to identify both close contacts and data on sources of infection.",Rachel Foster; Bing Jones; Abigail Reynolds; Andzelika Duda; Carey Carey; Jack Czauderna; Alex Westran,https://medrxiv.org/cgi/content/short/2021.01.28.21250096,https://medrxiv.org/cgi/content/short/2021.01.28.21250096,2021-01-29,2021-01-29,,True
148,New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19,"Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. We developed three different protein arrays to measure hallmark IgG autoantibodies associated with Connective Tissue Diseases (CTDs), Anti-Cytokine Antibodies (ACA), and anti-viral antibody responses in 147 hospitalized COVID-19 patients in three different centers. Autoantibodies were identified in approximately 50% of patients, but in <15% of healthy controls. When present, autoantibodies largely targeted autoantigens associated with rare disorders such as myositis, systemic sclerosis and CTD overlap syndromes. Anti-nuclear antibodies (ANA) were observed in [~]25% of patients. Patients with autoantibodies tended to demonstrate one or a few specificities whereas ACA were even more prevalent, and patients often had antibodies to multiple cytokines. Rare patients were identified with IgG antibodies against angiotensin converting enzyme-2 (ACE-2). A subset of autoantibodies and ACA developed de novo following SARS-CoV-2 infection while others were transient. Autoantibodies tracked with longitudinal development of IgG antibodies that recognized SARS-CoV-2 structural proteins such as S1, S2, M, N and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. COVID-19 patients with one or more autoantibodies tended to have higher levels of antibodies against SARS-CoV-2 Nonstructural Protein 1 (NSP1) and Methyltransferase (ME). We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.",Sarah Esther Chang; Allan Feng; Wenzhao Meng; Sokratis Apostolidis; Elisabeth Mack; Maja Artandi; Linda Barman; Kate Bennett; Saborni Chakraborty; Iris Chang; Peggie Cheung; Sharon Chinthrajah; Shaurya Dhingra; Evan Do; Amanda Finck; Andrew Gaano; Reinhard Gessner; Heather M. Giannini; Joyce Gonzalez; Sarah Greib; Margrit Guendisch; Alex Ren Hsu; Alex Kuo; Monali Manohar; Rong Mao; Indira Neeli; Andreas Neubauer; Oluwatosin Oniyide; Abigail Elizabeth Powell; Rajan Puri; Harald Renz; Jeffrey M. Schapiro; Payton Anders Weidenbacher; Rich Wittman; Neera Ahuja; Ho-Ryun Chung; Prasanna Jagannathan; Judith James; Peter S. Kim; Nuala J. Meyer; Kari Christine Nadeau; Marko Radic; William H. Robinson; Upinder Singh; Taia T. Wang; E. John Wherry; Chrysanthi Skevaki; Eline T. Luning Prak; Paul J Utz,https://medrxiv.org/cgi/content/short/2021.01.27.21250559,https://medrxiv.org/cgi/content/short/2021.01.27.21250559,2021-01-29,2021-01-29,,True
149,Association of COVID-19 incidence with objectively and subjectively measured mental health proxies in the Austrian Football League: an epidemiological study,"Objective We aimed to explore the association of COVID-19 incidence with mental health in 225 team and staff members of five professional Austrian Football clubs captured by objective (location variance) or subjective (self-reported sleep quality, level of recovery, perceived risk of infection) mental health proxies. Methods Data collected during the implementation of a novel monitoring concept to enable safe continuation of professional Football during the COVID-19 pandemic were matched with Austrian COVID-19 incidence data and smartphone collected location data (time-period June 17th to July 31st, 2020). Multivariable linear regression models explored the association of COVID-19 incidence, defined as daily novel or active cases of COVID-19, with the objective and subjective health proxies while adjusting for the occurrence of one COVID-19 case in a staff member in one of the clubs, team status (i.e. player vs staff) and game days. Results Data from 115 participants were analysed. An increasing number of novel COVID-19 cases was significantly associated with deteriorating sleep quality (B 0.48, 95% CI 0.05; 1.00) but with none of the other mental health proxies. An increasing number of active COVID-19 cases was significantly associated with an increase in perceived infection risk (B 0.04, 95% CI 0.00; 0.07) and location variance (B 0.28, 95% CI 0.06; 0.49). Conclusion The adverse association of an increasing COVID-19 incidence with mental health in professional Footballers and staff members became obvious particularly in subjectively measured mental health. During the ongoing pandemic, targeted mental care should be included in the daily routines of this population.",Antje van der Zee-Neuen; Alexander Seymer; Dagmar Schaffler-Schaden; Juergen Herfert; James O Brien; Tim Johansson; Patrick Kutschar; Stephan Ludwig; Thomas Stoeggl; David Keeley; Maria Flamm; Juergen Osterbrink,https://medrxiv.org/cgi/content/short/2021.01.27.21250527,https://medrxiv.org/cgi/content/short/2021.01.27.21250527,2021-01-29,2021-01-29,,True
150,The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization,"SARS-CoV-2 transmission from humans to animals has been reported for many domesticated species, including cats, dogs and minks. Identification of novel spike gene mutations appearing in minks has raised major concerns about potential immune evasion and challenges for the global vaccine strategy. The genetic variant, known as ""cluster-five"", arose among farmed minks in Denmark and resulted in a complete shutdown of the worlds largest mink production. However, the functional properties of this new variant are not established. Here we present functional data on the Y453F cluster-five receptor-binding domain (RBD) and show that it does not decrease established humoral immunity or affect the neutralizing response in a vaccine model based on wild-type RBD or spike. However, it binds the human ACE-2 receptor with a four-fold higher affinity suggesting an enhanced transmission capacity and a possible challenge for viral control.",Rafael Bayarri-Olmos; Anne Rosbjerg; Laust Bruun Johnsen; Charlotte Helgstrand; Theresa Bak-Thomsen; Peter Garred; Mikkel-Ole Skjoedt,https://biorxiv.org/cgi/content/short/2021.01.29.428834,https://biorxiv.org/cgi/content/short/2021.01.29.428834,2021-01-29,2021-01-29,,False
151,Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce superior immune responses than single dose vaccine regimens in mice,"Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccination with a self-amplifying RNA (saRNA) vaccine and an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2. We demonstrate that antibody responses are higher in two dose heterologous vaccination regimens than single dose regimens, with high titre neutralising antibodies induced. Importantly, the cellular immune response after a heterologous regimen is dominated by cytotoxic T cells and Th1+ CD4 T cells which is superior to the response induced in homologous vaccination regimens in mice.",Alexandra J Spencer; Paul F McKay; Sandra Belij-Rammerstorfer; Marta Ulaszewska; Cameron D Bissett; Kai Hu; Karnyart Samnuan; Hannah R Sharpe; Daniel Wright; Ciaran Gilbride; Adam Truby; Elizabeth R Allen; Sarah C Gilbert; Robin J Shattock; Teresa Lambe,https://biorxiv.org/cgi/content/short/2021.01.28.428665,https://biorxiv.org/cgi/content/short/2021.01.28.428665,2021-01-29,2021-01-29,,False
152,Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of COVID-19 pandemic, enters host cells via the interaction of its Receptor-Binding Domain (RBD) of Spike protein with host Angiotensin-Converting Enzyme 2 (ACE2). Therefore, RBD is a promising vaccine target to induce protective immunity against SARS-CoV-2 infection. In this study, we report the development of RBD protein-based vaccine candidate against SARS-CoV-2 using self-assembling H. pylori-bullfrog ferritin nanoparticles as an antigen delivery. RBD-ferritin protein purified from mammalian cells efficiently assembled into 24-mer nanoparticles. 16-20 months-old ferrets were vaccinated with RBD-ferritin nanoparticles (RBD-nanoparticles) by intramuscular or intranasal inoculation. All vaccinated ferrets with RBD-nanoparticles produced potent neutralizing antibodies against SARS-CoV-2. Strikingly, vaccinated ferrets demonstrated efficient protection from SARS-CoV-2 challenge, showing no fever, body weight loss and clinical symptoms. Furthermore, vaccinated ferrets showed rapid clearance of infectious viruses in nasal washes and lungs as well as viral RNA in respiratory organs. This study demonstrates the Spike RBD-nanoparticle as an effective protein vaccine candidate against SARS-CoV-2.",Young-Il Kim; Dokyun Kim; Kwang-Min Yu; Hogyu David Seo; Shin-Ae Lee; Mark Anthony B. Casel; Seung-Gyu Jang; Stephanie Kim; WooRam Jung; Chih-Jen Lai; Young Ki Choi; Jae U. Jung,https://biorxiv.org/cgi/content/short/2021.01.28.428743,https://biorxiv.org/cgi/content/short/2021.01.28.428743,2021-01-29,2021-01-29,,False
153,Recombination and low-diversity confound homoplasy-based methods to detect the effect of SARS-CoV-2 mutations on viral transmissibility,"The SARS-CoV-2 variant carrying the Spike protein mutation G614 was first detected in late January 2020 and within a few months became the dominant form globally. In the months that followed, many studies, both in vitro and in animal models, showed that variants carrying this mutation were more infectious and more readily transmitted than the ancestral Wuhan form. Here we investigate why a recently published study by van Dorp et al. failed to detect such higher transmissibility of the G614 variant using homoplasy-based methods. We show that both low diversity and recombination confound the methods utilized by van Dorp et al. and significantly decrease their sensitivity. Furthermore, though they claim no evidence of recombination in their dataset, we and several other studies identify a subset of the sequences as recombinants, possibly enough to affect their statistic adversely.",Elena E. Giorgi; Tanmoy Bhattacharya; Will M. Fischer; Hyejin Yoon; Werner Abfalterer; Bette Korber,https://biorxiv.org/cgi/content/short/2021.01.29.428535,https://biorxiv.org/cgi/content/short/2021.01.29.428535,2021-01-29,2021-01-29,,False
154,Information retrieval in an infodemic: the case of COVID-19 publications,"In the context of searching for COVID-19 related scientific literature, we present an information retrieval methodology for effectively finding relevant publications for different information needs. We discuss different components of our architecture consisting of traditional information retrieval models, as well as modern neural natural language processing algorithms. We present recipes to better adapt these components to the case of an infodemic, where, from one hand, the number of publications has an exponential growth and, from the other hand, the topics of interest evolve as the pandemic progresses. The methodology was evaluated in the TREC-COVID challenge, achieving competitive results with top ranking teams participating in the competition. In retrospect to this challenge, we provide additional insights with further useful impacts.",Not available,https://biorxiv.org/cgi/content/short/2021.01.29.428847,https://biorxiv.org/cgi/content/short/2021.01.29.428847,2021-01-29,2021-01-29,,False
155,The evolutionary making of SARS-CoV-2,"Covid-19 is the most devastating pandemic of the past 100 years. A zoonotic transfer presumably at a wildlife market introduced the causative virus, SARS-CoV-2 (sarbecovirus; beta-coronavirus), to humans in late 2019. Meanwhile, the mechanistic details of the infection process have been largely elucidated, and structural models explain binding of the virial spike to the human cell surface receptor ACE2. Yet, the evolutionary trajectory that gave rise to this pathogen is poorly understood. Here we scan SARS-CoV-2 protein sequences in-silico for innovations along the evolutionary lineage starting with the last common ancestor of coronaviruses. Substantial differences in the sets of proteins encoded by SARS-CoV-2 and viruses outside sarbecovirus, and in their domain architectures, indicate divergent functional demands. By contrast, sarbecoviruses themselves are almost fully conserved at these levels of resolution. However, profiling spike evolution on the sub-domain level using predicted linear epitopes reveals that this protein was gradually reshaped within sarbecovirus. The only epitope that is private to SARS-CoV-2 overlaps with the furin cleavage site. This lends phylogenetic support to the hypothesis that a change in strategy facilitated the zoonotic transfer of SARS-CoV-2 and its success as a human pathogen. Upon furin cleavage, spike switches from a ""stealth mode"" where immunodominant ACE2 binding epitopes are largely hidden to an ""attack mode"" where these epitopes are exposed. The resulting reinforcement of ACE2 binding extends the window of opportunity for cell entry. SARS-CoV-2 variants fine-tuning this mode switch will be particularly threatening as they optimize immune evasion.",Ruben Iruegas LÃ³pez; Julian Dosch; Mateusz Sikora; Gerhard Hummer; Roberto Covino; Ingo Ebersberger,https://biorxiv.org/cgi/content/short/2021.01.29.428808,https://biorxiv.org/cgi/content/short/2021.01.29.428808,2021-01-29,2021-01-29,,False
156,"The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial","BackgroundAlthough several therapies have been evaluated for treatment of COVID-19, the morbidity and mortality in COVID-19 are still significant, and the need for safe and effective drugs remains high even after launch of vaccine programs.

MethodsWe conducted a double-blind, randomized, placebo-controlled trial with the novel oral angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients with C-reactive protein 50-150 mg/L but not needing mechanical ventilation. Patients were randomly assigned to oral C21 (100 mg twice daily) or placebo for 7 days in addition to standard of care, including glucocorticoids and remdesivir.

Results106 patients underwent randomization (51 in the C21 group and 55 in the placebo group). At day 14 after start of treatment, the proportion of patients still requiring supplemental oxygen was significantly reduced by 90% in the C21 group compared to the placebo group (p=0.003). Moreover, fewer patients required mechanical ventilation (one C21 patient and four placebo patients), and C21 was associated with a numerical reduction in the mortality rate (one and three deaths in the C21 and placebo group, respectively). Treatment with C21 was safe and well tolerated.

ConclusionsAs studied in hospitalized COVID-19 patients, C21 on top of standard of care led to a clinically beneficial improvement in respiratory function compared to placebo, paving the way for a pivotal randomised controlled trial.

This study is registered at ClinicalTrials.gov with identifier NCT04452435.",Goran Tornling; Rohit Batta; Joanna Porter; Thomas Bengtsson; Kartikeya Parmar; Reema Kashiva; Anne Kartine Cohrt; Kate Westergaard; Anders Hallberg; Carl-Johan Dalsgaard; Johan Raud,https://medrxiv.org/cgi/content/short/2021.01.26.21250511,https://medrxiv.org/cgi/content/short/2021.01.26.21250511,2021-01-28,2021-01-28,,True
157,"Individual factors underlie temperature variation in sickness and in health: influence of age, BMI and genetic factors in a multi-cohort study","IntroductionAgeing affects immune function resulting in aberrant fever response to infection. We assess the effects of biological variables on basal temperature and temperature in COVID-19 infection, proposing an updated temperature threshold for older adults.

MethodsParticipants:

O_LIUnaffected twin volunteers: 1089 adult TwinsUK participants.
C_LIO_LILondon hospitalised COVID-19+: 520 adults with emergency admission.
C_LIO_LIBirmingham hospitalised COVID-19+: 757 adults with emergency admission.
C_LIO_LICommunity-based COVID-19+: 3972 adults self-reporting a positive test using the COVID Symptom Study mobile application.
C_LI

AnalysisHeritability assessed using saturated and univariate ACE models; Linear mixed-effect and multivariable linear regression analysing associations between temperature, age, sex and BMI; multivariable logistic regression analysing associations between fever ([&ge;]37.8{degrees}C) and age; receiver operating characteristic (ROC) analysis to identify temperature threshold for adults [&ge;] 65 years.

ResultsAmong unaffected volunteers, lower BMI (p=0.001), and older age (p<0.001) associated with lower basal temperature. Basal temperature showed a heritability of 47% (95% Confidence Interval 18-57%).

In COVID-19+ participants, increasing age associated with lower temperatures in cohorts (c) and (d) (p<0.001). For each additional year of age, participants were 1% less likely to demonstrate a fever (OR 0.99; p<0.001).

Combining healthy and COVID-19+ participants, a temperature of 37.4{degrees}C in adults [&ge;]65 years had similar sensitivity and specificity to 37.8{degrees}C in adults <65 years for discriminating fever in COVID-19.

ConclusionsAgeing affects temperature in health and acute infection. Significant heritability indicates biological factors contribute to temperature regulation.

Our observations indicate a lower threshold (37.4{degrees}C) should be considered for assessing fever in older adults.

Key PointsO_LIOlder adults, particularly those with lower BMI, have a lower basal temperature and a lower temperature in response to infection
C_LIO_LIBasal temperature is heritable, suggesting biological factors underlying temperature regulation
C_LIO_LIOur findings support a lower temperature threshold of 37.4{degrees}C for identifying possible COVID-19 infection in older adults
C_LIO_LIThis has implications for case detection, surveillance and isolation and could be incorporated into observation assessment
C_LI",Rose S. Penfold; Maria Beatrice Zazzara; Marc F. Ã–sterdahl; - GSTT CovidCollaborative; Carly Welch; Mary Ni Lochlainn; Maxim Freidin; Ruth C.E. Bowyer; Ellen E.J. Thompson; Michela Antonelli; Yu Xian Rachel Tan; Carole Sudre; Marc Modat; Benjamin Murray; Jonathan Wolf; Sebastien Ourselin; Tonny Veenith; Janet M. Lord; Claire J. Steves,https://medrxiv.org/cgi/content/short/2021.01.26.21250480,https://medrxiv.org/cgi/content/short/2021.01.26.21250480,2021-01-28,2021-01-28,,True
158,Immune response to SARS-CoV-2 in the nasal mucosa in children and adults,"RationaleDespite similar viral load and infectivity rates between children and adults infected with SARS-CoV-2, children rarely develop severe illness. Differences in the host response to the virus at the primary infection site are among the proposed mechanisms.

ObjectivesTo investigate the host response to SARS-CoV-2, respiratory syncytial virus (RSV), and influenza virus (IV) in the nasal mucosa in children and adults.

MethodsClinical outcomes and gene expression in the nasal mucosa were analyzed in 36 children hospitalized with SARS-CoV-2 infection, 24 children with RSV infection, 9 children with IV infection, 16 adults with mild to moderate SARS-CoV-2 infection, and 7 healthy pediatric and 13 healthy adult controls.

ResultsIn both children and adults, infection with SARS-CoV-2 leads to an interferon response in the nasal mucosa. The magnitude of the interferon response correlated with the abundance of viral reads and was comparable between symptomatic children and adults infected with SARS-CoV-2 and symptomatic children infected with RSV and IV. Cell type deconvolution identified an increased abundance of immune cells in the samples from children and adults with a viral infection. Expression of ACE2 and TMPRSS2 - key entry factors for SARS-CoV-2 - did not correlate with age or presence or absence of viral infection.

ConclusionsOur findings support the hypothesis that differences in the immune response to SARS-CoV-2 determine disease severity, independent of viral load and interferon response at the primary infection primary site.",Clarissa M Koch; Andrew D Prigge; Kishore R Anekalla; Avani Shukla; Hanh Chi Do-Umehara; Leah Setar; Jairo Chavez; Hiam Abdala-Valencia; Yuliya Politanska; Nikolay S Markov; Grant R Hahn; Taylor Heald-Sargent; L Nelson Sanchez-Pinto; William J Muller; Alexander V Misharin; Karen M Ridge; Bria M Coates,https://medrxiv.org/cgi/content/short/2021.01.26.21250269,https://medrxiv.org/cgi/content/short/2021.01.26.21250269,2021-01-28,2021-01-28,,True
159,Trajectories of Hypoxemia & Respiratory System Mechanics of COVID-19 ARDS in the NorthCARDS dataset,"RationaleThe preliminary reports of COVID Acute Respiratory Distress Syndrome (COVIDARDS) suggest the existence of a subset of patients with higher lung compliance despite profound hypoxemia. Understanding heterogeneity seen in patients with COVIDARDS and comparing to non-COVIDARDS may inform tailored treatments.

ObjectivesTo describe the trajectories of hypoxemia and respiratory compliance in COVIDARDS and associations with outcomes.

MethodsA multidisciplinary team of frontline clinicians and data scientists created the Northwell COVIDARDS dataset (NorthCARDS) leveraging over 11,542 COVID-19 hospital admissions. Data was summarized to describe differences based on clinically meaningful categories of lung compliance, and compared to non-COVIDARDS reports. A sophisticated method of extrapolating PaO2 from SpO2, as well estimating FiO2 from non invasive oxygen delivery devices were utilized to create meaningful trends of derived PaO2 to FiO2 (P/F).

Measurements and Main ResultsOf the 1595 COVIDARDS patients in the NorthCARDS dataset, there were 538 (34{middle dot}6%) who had very low lung compliance (<20ml/cmH2O), 982 (63{middle dot}2%) with low-normal compliance (20-50ml/cmH2O), and 34 (2{middle dot}2%) with high lung compliance (>50ml/cmH2O). The very low compliance group had double the median time to intubation compared to the low-normal group (107 hours(IQR 26{middle dot}3, 238{middle dot}3) vs. 37{middle dot}9 hours(IQR 4{middle dot}8, 90{middle dot}7)). Oxygenation trends have improved in all groups after a nadir immediately post intubation. The P/F ratio improved from a mean of 109 to 155, with the very low compliance group showing a smaller improvement compared to low compliance group. The derived P/F trends closely correlated with blood gas analysis driven P/F trends, except immediately post intubation were the trends diverge as illustrated in the image. Overall, 67{middle dot}5% (n=1049) of the patients died during the hospitalization. In comparison to non-COVIDARDS reports, there were less patients in the high compliance category (2.2%vs.12%, compliance [&ge;]50mL/cmH20), and more patients with P/F [&le;] 150 (57{middle dot}8% vs. 45.6%). No correlation was apparent between lung compliance and P/F ratio. The Oxygenation Index was similar, (11{middle dot}12(SD 5{middle dot}67)vs.12{middle dot}8(SD 10{middle dot}8)).

ConclusionsHeterogeneity in lung compliance is seen in COVIDARDS, without apparent correlation to degree of hypoxemia. Notably, time to intubation was greater in the very low lung compliance category. Understanding ARDS patient heterogeneity must include consideration of treatment patterns in addition to trajectories of change in patient-level data and demographics.",Daniel Jafari; Amir Gandomi-Sereshki; Alex Makhnevich; Michael Qiu; Daniel M Rolston; Eric P Gottesman; Adey Tsegaye; Paul H Mayo; Molly E Stewart; Meng Zhang; Negin Hajizadeh,https://medrxiv.org/cgi/content/short/2021.01.26.21250492,https://medrxiv.org/cgi/content/short/2021.01.26.21250492,2021-01-28,2021-01-28,,True
160,Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19,"Although T cells are likely players in SARS-CoV-2 immunity, little is known about the phenotypic features of SARS-CoV-2-specific T cells associated with recovery from severe COVID-19. We analyzed T cells from longitudinal specimens of 34 COVID-19 patients with severities ranging from mild (outpatient) to critical culminating in death. Relative to patients that succumbed, individuals that recovered from severe COVID-19 harbored elevated and increasing numbers of SARS-CoV-2-specific T cells capable of homeostatic proliferation. In contrast, fatal COVID-19 displayed elevated numbers of SARS-CoV-2-specific regulatory T cells and a time-dependent escalation in activated bystander CXCR4+ T cells. Together with the demonstration of increased proportions of inflammatory CXCR4+ T cells in the lungs of severe COVID-19 patients, these results support a model whereby lung-homing T cells activated through bystander effects contribute to immunopathology, while a robust, non-suppressive SARS-CoV-2-specific T cell response limits pathogenesis and promotes recovery from severe COVID-19.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC=""FIGDIR/small/21250054v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (91K):
org.highwire.dtl.DTLVardef@193d721org.highwire.dtl.DTLVardef@110bf84org.highwire.dtl.DTLVardef@8d8d4dorg.highwire.dtl.DTLVardef@137c2b8_HPS_FORMAT_FIGEXP  M_FIG C_FIG HIGHLIGHTSO_LIDysfunctional spike-specific T cells are characteristic of severe COVID-19
C_LIO_LISpike-specific CD127+ Th1 cells are increased in survivors of severe COVID-19
C_LIO_LISpike-specific Tregs and IL6+ CD8+ T cells are increased in fatal COVID-19
C_LIO_LIEscalation of activated lung-homing CXCR4+ T cells associates with fatal COVID-19
C_LI

BRIEF SUMMARYBy conducting CyTOF on total and SARS-CoV-2-specific T cells from longitudinal specimens spanning the entire spectrum of COVID-19 diseases, Neidleman et al. demonstrate that spike-specific Th1 cells capable of IL7-dependent homeostatic proliferation predict survival from severe COVID-19, while Tregs and IL6+ CD8+ T cells recognizing spike predict fatal outcome. Fatal COVID-19 is characterized by escalating activation of bystander CXCR4+ T cells in the lungs. Boosting SARS-CoV-2-specific CD4+ T effector responses while diminishing CXCR4-mediated homing may help recovery from severe disease.",Jason Neidleman; Xiaoyu Luo; Ashley F. George; Matthew McGregor; Junkai Yang; Cassandra Yun; Victoria Murray; Gurjot Gill; Warner C. Greene; Joshua Vasquez; Sulggi Lee; Eliver Ghosn; Kara Lynch; Nadia R. Roan,https://medrxiv.org/cgi/content/short/2021.01.22.21250054,https://medrxiv.org/cgi/content/short/2021.01.22.21250054,2021-01-28,2021-01-28,,True
161,Genome-scale metabolic modeling reveals SARS-CoV-2-induced host metabolic reprogramming and identifies metabolic antiviral targets,"Tremendous progress has been made to control the COVID-19 pandemic, including the development and approval of vaccines as well as the drug remdesivir, which inhibits the SARS-CoV-2 virus that causes COVID-19. However, remdesivir confers only mild benefits to a subset of patients, and additional effective therapeutic options are needed. Drug repurposing and drug combinations may represent practical strategies to address these urgent unmet medical needs. Viruses, including coronaviruses, are known to hijack the host metabolism to facilitate their own proliferation, making targeting host metabolism a promising antiviral approach. Here, we describe an integrated analysis of 12 published in vitro and human patient gene expression datasets on SARS-CoV-2 infection using genome-scale metabolic modeling (GEM). We find that SARS-CoV-2 infection can induce recurrent and complicated metabolic reprogramming spanning a wide range of metabolic pathways. We next applied the GEM-based metabolic transformation algorithm (MTA) to predict anti-SARS-CoV-2 targets that counteract the virus-induced metabolic changes. These predictions are enriched for validated targets from various published experimental drug and genetic screens. Further analyzing the RNA-sequencing data of remdesivir-treated Vero E6 cell samples that we generated, we predicted metabolic targets that act in combination with remdesivir. These predictions are enriched for previously reported synergistic drugs with remdesivir. Since our predictions are based in part on human patient data, they are likely to be clinically relevant. We provide our top high-confidence candidate targets for their evaluation in further studies, demonstrating host metabolism-targeting as a promising antiviral strategy.",Kuoyuan Cheng; Laura Riva; Sanju Sinha; Lipika Ray Pal; Nishanth Ulhas Nair; Laura Martin-Sancho; Sumit K. Chanda; Eytan Ruppin,https://biorxiv.org/cgi/content/short/2021.01.27.428543,https://biorxiv.org/cgi/content/short/2021.01.27.428543,2021-01-28,2021-01-28,,False
162,SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines,"The SARS-CoV-2 Spike glycoprotein mediates virus entry and is a major target for neutralizing antibodies. All current vaccines are based on the ancestral Spike with the goal of generating a protective neutralizing antibody response. Several novel SARS-CoV-2 variants with multiple Spike mutations have emerged, and their rapid spread and potential for immune escape have raised concerns. One of these variants, first identified in the United Kingdom, B.1.1.7 (also called VUI202012/01), contains eight Spike mutations with potential to impact antibody therapy, vaccine efficacy and risk of reinfection. Here we employed a lentivirus-based pseudovirus assay to show that variant B.1.1.7 remains sensitive to neutralization, albeit at moderately reduced levels (~2-fold), by serum samples from convalescent individuals and recipients of two different vaccines based on ancestral Spike: mRNA-1273 (Moderna), and protein nanoparticle NVX-CoV2373 (Novavax). Some monoclonal antibodies to the receptor binding domain (RBD) of Spike were less effective against the variant while others were largely unaffected. These findings indicate that B.1.1.7 is not a neutralization escape variant that would be a major concern for current vaccines, or for an increased risk of reinfection.",Not available,https://biorxiv.org/cgi/content/short/2021.01.27.428516,https://biorxiv.org/cgi/content/short/2021.01.27.428516,2021-01-28,2021-01-28,,False
163,Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein,"Patients who recover from SARS-CoV-2 infections produce antibodies and antigen-specific T cells against multiple viral proteins. Here, an unbiased interrogation of the anti-viral memory B cell repertoire of convalescent patients has been performed by generating large, stable hybridoma libraries and screening thousands of monoclonal antibodies to identify specific, high-affinity immunoglobulins (Igs) directed at distinct viral components. As expected, a significant number of antibodies were directed at the Spike (S) protein, a majority of which recognized the full-length protein. These full-length Spike specific antibodies included a group of somatically hypermutated IgMs. Further, all but one of the six COVID-19 convalescent patients produced class-switched antibodies to a soluble form of the receptor-binding domain (RBD) of S protein. Functional properties of anti-Spike antibodies were confirmed in a pseudovirus neutralization assay. Importantly, more than half of all of the antibodies generated were directed at non-S viral proteins, including structural nucleocapsid (N) and membrane (M) proteins, as well as auxiliary open reading frame-encoded (ORF) proteins. The antibodies were generally characterized as having variable levels of somatic hypermutations (SHM) in all Ig classes and sub-types, and a diversity of VL and VH gene usage. These findings demonstrated that an unbiased, function-based approach towards interrogating the COVID-19 patient memory B cell response may have distinct advantages relative to genomics-based approaches when identifying highly effective anti-viral antibodies directed at SARS-CoV-2.",Jillian M DiMuzio; Baron C Heimbach; Raymond J Howanski; John P Dowling; Nirja B Patel; Noeleya Henriquez; Chris Nicolescu; Mitchell Nath; Antonio Polley; Jamie L Bingaman; Todd Smith; Benjamin C Harman; Matthew K Robinson; Michael J Morin; Pavel A Nikitin,https://biorxiv.org/cgi/content/short/2021.01.27.428534,https://biorxiv.org/cgi/content/short/2021.01.27.428534,2021-01-28,2021-01-28,,False
164,D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Viral Transmission via Enhanced Furin-mediated Spike Cleavage,"Since the D614G substitution in the spike (S) of SARS-CoV-2 emerged, the variant strain underwent rapid expansion to become the most abundant strain worldwide. Therefore, this substitution may provide an advantage of viral spreading. To explore the mechanism, we analyzed 18 viral isolates containing S proteins with either G614 or D614. Both the virus titer and syncytial phenotype were significantly increased in S-G614 than in S-D614 isolates. We further showed increased cleavage of S at the furin substrate site, a key event that promotes syncytium, in S-G614 isolates. These functions of the D614G substitution were validated in cells expressing S protein. The effect on syncytium was abolished by furin inhibitor treatment and mutation of the furin-cleavage site, suggesting its dependence on cleavage by furin. Our study provides a mechanistic explanation for the increased transmissibility of S-G614 containing SARS-CoV-2 through enhanced furin-mediated S cleavage, which increases membrane fusion and virus infectivity.",Ya-Wen Cheng; Tai-Ling Chao; Chiao-Ling Li; Sheng-Han Wang; Han-Chieh Kao; Ya-Min Tsai; Hurng-Yi Wang; Chi-Ling Hsieh; Pei-Jer Chen; Sui-Yuan Chang; Shiou-Hwei Yeh,https://biorxiv.org/cgi/content/short/2021.01.27.428541,https://biorxiv.org/cgi/content/short/2021.01.27.428541,2021-01-28,2021-01-28,,False
165,Early therapy with remdesivir and antibody combinations improves COVID-19 disease in mice,"Improving the standard of clinical care for coronavirus disease 2019 (COVID-19) is a global health priority. Small molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAb) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of COVID-19. However, the efficacy of single agent therapies has not been comprehensively defined over the time course of infection and it is not known if combination RDV/mAb will improve outcomes over single agent therapies. In kinetic studies in a mouse-adapted SARS-CoV-2 pathogenesis model, we show that single-agent therapies exert potent antiviral effects even when initiated relatively late after infection, but their efficacy is diminished as a function of time. RDV and a cocktail of two mAbs in combination provided improved outcomes compared to single agents alone extending the therapeutic window of intervention with less weight loss, decreased virus lung titers, reduced acute lung injury, and improved pulmonary function. Overall, we demonstrate that direct-acting antivirals combined with potent mAb can improve outcomes over single agents alone in animal models of COVID-19 thus providing a rationale for the coupling of therapies with disparate modalities to extend the therapeutic window of treatment.",David Martinez; Alexandra Schaefer; Sarah R. Leist; Kendra Gully; Joy Feng; Elaine Bunyan; Danielle Porter; Tomas Cihlar; Stephanie Montgomery; Ralph S. Baric; Michel C. Nussenzweig; Timothy P. Sheahan,https://biorxiv.org/cgi/content/short/2021.01.27.428478,https://biorxiv.org/cgi/content/short/2021.01.27.428478,2021-01-28,2021-01-28,,False
166,Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2,"Biochemical phenotypes are major indexes for protein structure and function characterization. They are determined, at least in part, by the intrinsic physicochemical properties of amino acids and may be reflected in the protein three-dimensional structure. Modeling mutational effects on biochemical phenotypes is a critical step for understanding protein function and disease mechanism as well as enabling drug discovery. Deep Mutational Scanning (DMS) experiments have been performed on SARS-CoV-2s spike receptor binding domain and the human ACE2 zinc-binding peptidase domain - both central players in viral infection and evolution and antibody evasion - quantifying how mutations impact binding affinity and protein expression. Here, we modeled biochemical phenotypes from massively parallel assays, using convolutional neural networks trained on protein sequence mutations in the virus and human host. We found that neural networks are significantly predictive of binding affinity, protein expression, and antibody escape, learning complex interactions and higher-order features that are difficult to capture with conventional methods from structural biology. Integrating the intrinsic physicochemical properties of amino acids, including hydrophobicity, solvent-accessible surface area, and long-range non-bonded energy per atom, significantly improved prediction (empirical p<0.01) though there was such a strong dependence on the sequence data alone to yield reasonably good prediction. We observed concordance of the DMS data and our neural network predictions with an independent study on intermolecular interactions from molecular dynamics (multiple 500 ns or 1 s all-atom) simulations of the spike protein-ACE2 interface, with critical implications for the use of deep learning to dissect molecular mechanisms. The mutation- or genetically-determined component of a biochemical phenotype estimated from the neural networks has improved causal inference properties relative to the original phenotype and can facilitate crucial insights into disease pathophysiology and therapeutic design.",Bo Wang; Eric R Gamazon,https://biorxiv.org/cgi/content/short/2021.01.28.428521,https://biorxiv.org/cgi/content/short/2021.01.28.428521,2021-01-28,2021-01-28,,False
167,Coronavirus associated molecular mimicry common to SARS-CoV-2 peptide,"Relationship of COVID-19 and immunity is complex and can involve autoimmune reactions through molecular mimicry. We investigated autoimmunity related pathological mechanisms involving molecular mimicry that are common to certain coronaviruses, including SARS-CoV-2, by means of a selected peptide sequence (CFLGYFCTCYFGLFC). Accordingly, coronavirus-associated sequences that are homologous to that 15mer sequence in the SARS-CoV-2 proteome are attained first. Then, homologous human and coronavirus sequences are obtained, wherein the coronavirus sequences are homologous to the 15mer SARS-CoV-2 peptide. All the identified query-subject sequences contained at least 7 residue matches in the aligned regions. Finally, parts of those coronavirus and host sequences, which are predicted to have high affinity to the same human leukocyte antigen (HLA) alleles as that of the SARS-CoV-2 sequence, are selected among the query and subject epitope-pairs that were both (predicted to be) strongly binding to the same HLA alleles. The proteins or the protein regions with those predicted epitopes include, but not limited to, immunoglobulin heavy chain junction regions, phospholipid phosphatase-related protein type 2, slit homolog 2 protein, and CRB1 isoform I precursor. These proteins are potentially associated with certain pathologies, but especially the possible CRB1 related coronavirus pathogenicity could be furthered by autoimmunity risk in HLA*A24:02 serotypes. Overall, results imply autoimmunity risk in COVID-19 patients with HLA*A02:01 and HLA*A24:02 serotypes in general, through molecular mimicry. This is also common to other coronaviruses than SARS-CoV-2. These results are indicative at the current stage, they need to be validated. Yet, they can pave the way to autoimmunity treatment options to be used in COVID-19 and its associated diseases.",Yekbun Adiguzel,https://biorxiv.org/cgi/content/short/2021.01.28.428642,https://biorxiv.org/cgi/content/short/2021.01.28.428642,2021-01-28,2021-01-28,,False
168,Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail,"The SARS-CoV-2 pandemic has led to an urgent need to understand the molecular basis for immune recognition of SARS-CoV-2 spike (S) glycoprotein antigenic sites. To define the genetic and structural basis for SARS-CoV-2 neutralization, we determined the structures of two human monoclonal antibodies COV2-2196 and COV2-21301, which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor binding domain (RBD) of SARS-CoV-2. COV2-2196 forms an ""aromatic cage"" at the heavy/light chain interface using germline-encoded residues in complementarity determining regions (CDRs) 2 and 3 of the heavy chain and CDRs 1 and 3 of the light chain. These structural features explain why highly similar antibodies (public clonotypes) have been isolated from multiple individuals1-4. The structure of COV2-2130 reveals that an unusually long LCDR1 and HCDR3 make interactions with the opposite face of the RBD from that of COV2-2196. Using deep mutational scanning and neutralization escape selection experiments, we comprehensively mapped the critical residues of both antibodies and identified positions of concern for possible viral escape. Nonetheless, both COV2-2196 and COV2130 showed strong neutralizing activity against SARS-CoV-2 strain with recent variations of concern including E484K, N501Y, and D614G substitutions. These studies reveal germline-encoded antibody features enabling recognition of the RBD and demonstrate the activity of a cocktail like AZD7442 in preventing escape from emerging variant viruses.",Jinhui Dong; Seth Zost; Allison Greaney; Tyler N Starr; Adam S Dingens; Elaine C Chen; Rita Chen; Brett Case; Rachel Sutton; Pavlo Gilchuk; Jessica Rodriguez; Erica Armstrong; Christopher Gainza; Rachel Nargi; Elad Binshtein; Xuping Xie; Xianwen Zhang; Pei-Yong Shi; James Logue; Stuart Weston; Marisa McGrath; Matthew Frieman; Tyler Brady; Kevin Tuffy; Helen Bright; Yueh-Ming Loo; Patrick McvTamney; Mark Esser; Robert Carnahan; Michael Diamond; Jesse Bloom; James E Crowe Jr.,https://biorxiv.org/cgi/content/short/2021.01.27.428529,https://biorxiv.org/cgi/content/short/2021.01.27.428529,2021-01-28,2021-01-28,,False
169,Spike mutations decrease SARS-CoV-2 sensitivity to neutralizing antibodies but not ACE2-Ig in vitro,"Spontaneous and selection-pressure-driven evolution of SARS-CoV-2 has started to pose more challenges to controlling the pandemic. Here, we first investigated cross-species receptor usage of multiple SARS-CoV-2 variants that emerged during the pandemic. We found that, in contrast to an early isolate WHU01, the circulating variants B.1.1.7/501Y.V1, B.1.351/501Y.V2, and P.1/501Y.V3 were able to use rat and mouse Ace2 orthologs as entry receptors, suggesting that rats and mice might be able to harbor and spread these variants. We then evaluated in vitro sensitivity of these variants to three therapeutic antibodies in clinics (etesevimab/LY-CoV016, casirivimab/REGN10933, and imdevimab/REGN10987) and an ACE2-Ig variant we developed recently. We found that all the tested SARS-CoV-2 variants showed reduced sensitivity to at least one of the tested antibodies but slightly increased sensitivity to the ACE2-Ig protein. These data demonstrate that the ACE2-Ig is a good drug candidate against SARS-CoV-2 variants that emerge over the course of the pandemic.",Weitong Yao; Yifei Wang; Danting Ma; Xiaojuan Tang; Haimin Wang; Chao Li; Hua Lin; Yujun Li; Guocai Zhong,https://biorxiv.org/cgi/content/short/2021.01.27.428353,https://biorxiv.org/cgi/content/short/2021.01.27.428353,2021-01-28,2021-01-28,,False
170,"A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses","The SARS-CoV-2 pandemic and the vaccination effort that is ongoing has created an unmet need for accessible, affordable, flexible and precise platforms for monitoring the induction, specificity and maintenance of virus-specific immune responses. Herein we validate a multiplex (Luminex-based) assay capable of detecting SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type (e.g. plasma, serum, saliva or blood spots). The well-established precision of Luminex-based assays provides the ability to follow changes in antibody levels over time to many antigens, including multiple permutations of the most common SARS-CoV-2 antigens. This platform can easily measure antibodies known to correlate with neutralization activity as well as multiple non-SARS-CoV-2 antigens such as vaccines (e.g. Tetanus toxoid) or those from frequently encountered agents (influenza), which serve as stable reference points for quantifying the changing SARS-specific responses. All of the antigens utilized in our study can be made in-house, many in E. coli using readily available plasmids. Commercially sourced antigens may also be incorporated and newly available antigen variants can be rapidly produced and integrated, making the platform adaptable to the evolving viral strains in this pandemic.

Brief SummaryA multi-antigen assay for monitoring SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type was developed.",Huifeng Shen; David Forgacs; Digantkumar Chapla; Kelley W Moreman; Lance Wells; Sarah A Hamer; Stephen M Tompkins; Ted M Ross; Nadine Rouphael; Srilatha Edupuganti; Matthew H Collins; Rick Tarleton,https://medrxiv.org/cgi/content/short/2021.01.20.21249279,https://medrxiv.org/cgi/content/short/2021.01.20.21249279,2021-01-27,2021-01-27,,True
171,The Association Between Hypoglycemic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis,"BackgroundDuring the current Coronavirus Disease 2019 (COVID-19) pandemic, diabetic patients face disproportionately more. Anti-inflammatory effects of hypoglycemic agents have been reported, and their beneficial or harmful effects in patients with diabetes and COVID-19 remain controversial.

PurposeThis study was performed to clarify this association.

Data SourcesRelevant literature was searched on China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, Chinese periodical service platform VIP Database, Sinomed (China Biology Medicine, CBM), MedRxiv, PubMed, ScienceDirect, Web of Science, Ovid Databases (LWW), Springer Link, Wiley Online Library, Oxford Academic, Nature Press Group, Cochrane Library and BMJ Evidence-Based Medicine up to November 14, 2020.

Study SelectionOnly observational studies of hypoglycemic agents vs. drugs or therapy without hypoglycemic agents in adult diabetic patients with COVID-19 were included.

Data ExtractionData of death and poor composite outcomes were extracted.

Data SynthesisThe pooled effects were calculated using the fixed-effects or random-effects models based on heterogeneity assessment.

LimitationMost studies were retrospective cohort studies with relative weak capability to verify causality.

ConclusionHome use of metformin might be beneficial in decreasing mortality in diabetic patients infected with SARS-CoV-2. There is insufficient evidence to conclude that metformin and other hypoglycemic agents are associated with poor composite outcomes. More prospective studies, especially RCTs are needed.

Registration-PROSPEROCRD42020221951.",Tiantia Han; Shaodi Ma; Chenyu Sun; Huimei Zhang; Guangbo Qu; Yue Chen; Ce Cheng; Eric L. Chen; Mubashir Ayaz Ahmed; Keun Young Kim; Reveena Manem; Mengshi Chen; Zhichun Guo; Hongru Yang; Yue Yan; Qin Zhou,https://medrxiv.org/cgi/content/short/2021.01.26.21250506,https://medrxiv.org/cgi/content/short/2021.01.26.21250506,2021-01-27,2021-01-27,,True
172,COVID-19-related disruptions to routine vaccination services in India: perspectives from pediatricians,"Background and ObjectiveThe COVID-19 pandemic has led to disruptions to routine immunization programs in India and around the world, setting the stage for potentially serious outbreaks of vaccine-preventable diseases.

MethodsWe surveyed pediatric healthcare providers in India in 2 rounds in April-June and September 2020 to understand how COVID-19 control measures may have impacted routine vaccination.

ResultsRespondents were predominantly pediatricians working in primary, secondary or tertiary healthcare centers, across 21 Indian states and two union territories. Among the 424 (survey 1) and 141 (survey 2) respondents, 33.4% and 7.8%, respectively, reported near complete suspension of vaccination services due to COVID-19. A 50% or greater drop in vaccination services was reported by 83.1% of respondents in June, followed by 32.6% four months later, indicating slow recovery of services. By September 2020, 83.6% were aware of updated guidelines on safe provision of immunization services, although awareness of specific catch-up vaccination plans was low, and 76.6% expressed concern about a vaccine coverage gap that could potentially lead to increased non-COVID-19 illnesses and deaths.

ConclusionsPandemic-related disruptions to vaccination services were reported by pediatricians across India. Concerted efforts are needed from governing and academic groups to ensure that routine immunization and catch-up programs are implemented during this pandemic, which can sustain gains in vaccination coverage and provide a robust blueprint for the national roll-out of the COVID-19 vaccine.",Anita Shet; Baldeep Dhaliwal; Preetika Banerjee; Kelly Carr; Andrea DeLuca; Carl Britto; Rajeev Seth; Bakul Parekh; GV Basavaraj; Digant Shastri; Piyush Gupta,https://medrxiv.org/cgi/content/short/2021.01.25.21250040,https://medrxiv.org/cgi/content/short/2021.01.25.21250040,2021-01-27,2021-01-27,,True
173,"Impact of COVID-19 on education, health and lifestyle behaviour of Brazilian urology residents","ObjectivesTo evaluate the impact of COVID-19 on clinical and surgical practice, educational activities, health and lifestyle behavior of Brazilian urology residents.

Materials and MethodsA web-based survey was sent to 468 Brazilian urology residents from postgraduate years (PGY) 3 to 5 to collect data on clinical practice and training after 4 months of COVID-19. We also assessed health-related and behavior changes, rate of infection by SARS-CoV-2, deployment to the front line of COVID-19, residents concerns, and access to personal protective equipment (PPE).

ResultsMassive reductions in elective and emergency patient consultations, diagnostic procedures and surgeries were reported across the country, affecting PGY 3 to 5 alike. Most in-person educational activities were abolished. The median damage to the urological training expected for 2020 was 6.0 [3.4 -7.7], on a scale from 0 to 10, with senior residents estimating a greater damage (P< 0.001). Educational interventions developed included online case-based discussions, subspeciality conferences and lectures, and grand rounds. Most senior residents favored extending residency to compensate for training loss and most younger residents favored no additional training (p< 0.001). Modifications in health and lifestyle included weight gain (43.8%), reduced physical activity (68.6%), increased alcoholic intake (44.9%) and cigarette consumption (53.6%), worsening of sexual life (25.2%) and feelings of sadness or depression (48,2%). Almost half were summoned to work on the COVID-19 front-line and 24.4% had COVID-19. Most residents had inadequate training to deal with COVID-19 patients and most reported a shortage of PPE. Residents concerns included the risk of contaminating family members, being away from residency program, developing severe COVID-19 and overloading colleagues.

ConclusionsCOVID-19 had a massive impact in Brazilian urology residents training, health and lifestyle behavior, which may reflect what happened in other medical specialties. Studies should confirm these findings to help developing strategies to mitigate residents losses.",Jose A Prezotti Sr.; Joao Victor T Henriques Sr.; Luciano Favorito; Alfredo F Canalini Sr.; Marcos G Machado Sr.; Thulio Bosi Sr.; Akemi M Barbosa; Julyana Moromizato; Karin Anzolch; Roni Fernandes; Fransber Rodrigues; Carlos Henrique Bellucci; Caroline Santos Silva; Antonio Carlos Lima Pompeo; Jose de Bessa Jr.; Cristiano M Gomes,https://medrxiv.org/cgi/content/short/2021.01.26.21250518,https://medrxiv.org/cgi/content/short/2021.01.26.21250518,2021-01-27,2021-01-27,,True
174,"U.S. Public Views about COVID-19 ""Immunity Passports""","ImportanceDiscovery of effective vaccines and increased confidence that infection confers extended protection against COVID-19 have renewed discussion of using immunity certificates or ""passports"" to selectively reduce ongoing public health restrictions.

ObjectiveTo determine public views regarding government and private conferral of immunity privileges.

Design and SettingU.S. national on-line survey fielded in June 2020. Participants were randomly asked about either government ""passports"" or private ""certificates"" for COVID-19 immunity.

ParticipantsU.S. adults from a standing panel maintained for academic research, selected to approximate national demographics.

Main Outcomes/MeasuresLevel of support/opposition to immunity privileges, and whether views vary based on: government vs. private adoption; demographics; political affiliation or views; or various COVID19-related attitudes and experiences.

ResultsOf 1315 respondents, 45.2% supported immunity privileges, with slightly more favoring private certificates than government passports (48.1% vs 42.6%, p=0.04). Support was greater for using passports or certificates to enable returns to high-risk jobs or attendance at large recreational events than for returning to work generally. Levels of support did not vary significantly according to age groups, socioeconomic or employment status, urbanicity, political affiliation or views, or whether the respondent had chronic disease(s). However, estimates from adjusted analyses showed less support among women (Odds Ratio, 0.64; 95% Confidence Interval, 0.51 to 0.80), and among Hispanics (0.56; 0.40 to 0.78) and other minorities (0.58; 0.40 to 0.85) compared with whites, but not among blacks (0.83; 0.60 to 1.15). Opposition was much lower among those who personally wanted a passport or certificate (24.4%) and much higher among those who believed this would harm the social fabric of their community (77.1%).

Conclusions and RelevancePublic views are divided on either government or private use of immunity certificates, but these views do not vary along usual political lines or by characteristics that indicate individual vulnerability to infection. Social consensus on the desirability of an immunity privileges programs may be difficult to achieve.

Key PointsO_ST_ABSQuestionC_ST_ABSWhat are the publics views on government or private use of immunity ""passports"" to selectively lift COVID-19 restrictions?

FindingsViews are divided and do not vary substantially according to political views or many demographic factors. Support is greater among men but lower among Hispanics and those who believe that immunity privileges would harm the social fabric of society.

MeaningSocial consensus will be difficult to achieve on the appropriateness of immunity privileges.",Mark A Hall; David M. Studdert,https://medrxiv.org/cgi/content/short/2021.01.26.21250184,https://medrxiv.org/cgi/content/short/2021.01.26.21250184,2021-01-27,2021-01-27,,True
175,The King's College London Coronavirus Health and Experiences of Colleagues at King's Study: SARS-CoV-2 antibody response in a higher education sample,"ObjectiveTo assess the feasibility of home antibody testing as part of large-scale study, the Kings College London Coronavirus Health and Experiences of Colleagues at Kings (KCL CHECK).

MethodsParticipants of the KCL CHECK study were sent a SureScreen Diagnostics COVID-19 IgG/IgM Rapid Test Cassette to complete at home in June 2020 (phase 1) and September 2020 (phase 2). Participants were asked to upload a test result image to a study website. Test result images and sociodemographic information were analysed by the research team.

ResultsA total of n=2716 participants enrolled in the KCL CHECK study, with n=2003 (73.7%) and n=1825 (69.3%) consenting and responding to phase 1 and 2. Of these, n=1882 (93.9%; phase 1) and n=1675 (91.8%; phase 2) returned a valid result. n=123 (6.5%; phase 1) and n=91 (5.4%; phase 2) tested positive for SARS-CoV-2 antibodies. A total of n=1488 participants provided a result in both phases, with n=57 (3.8%) testing positive for SARS- CoV-2 antibodies across both phases, suggesting a reduction in the number of positive antibody results over time. Initial comparisons showed variation by age group, gender and clinical role.

ConclusionsOur study highlights the feasibility of rapid, repeated and low-cost SARS-CoV-2 serological testing without the need for face-to-face contact.

What is already known about this subject?Higher education institutions have a duty of care to minimise the spread and transmission of COVID-19 in its campuses, and among staff and students. The reopening of higher education buildings and campuses has brought about a mass movement of students, academics and support staff from across the UK. Serological antibody studies can assist by highlighting groups of people and behaviours associated with high risk of COVID-19.

What are the new findings?We report a framework for SARS-CoV-2 serological antibody testing in an occupational group of postgraduate research students and current members of staff at Kings College London. Over two phases of data collection, 6.5% (phase 1) and 5.4% (phase 2) tested positive for SARS-CoV-2 antibodies, with only 3.8% testing positive for antibodies in both phases, suggesting a reduction in positive antibody results over time.

How might this impact on policy or clinical practice in the foreseeable future?Our study highlights the feasibility of rapidly deploying low-cost and repeatable SARS-CoV-2 serological testing, without the need for face-to-face contact, to support the higher education system of the UK.",Daniel Leightley Dr; Valentina Vitiello Dr; Alice Wickersham Ms; Katrina A.S. Davis Dr; Gabriella Bergin-Cartwright Ms; Grace Lavelle Dr; Sharon A.M. Stevelink Dr; Matthew Hotopf Prof; Reza Razavi Prof,https://medrxiv.org/cgi/content/short/2021.01.26.21249744,https://medrxiv.org/cgi/content/short/2021.01.26.21249744,2021-01-27,2021-01-27,,True
176,Lack of trust and social media echo chambers predict COVID-19 vaccine hesitancy,"As COVID-19 vaccines are rolled out across the world, there are growing concerns about the role that trust, belief in conspiracy theories and spread of misinformation through social media impact vaccine hesitancy. We use a nationally representative survey of 1,476 adults in the UK between December 12 to 18, 2020 and five focus groups conducted in the same period. Trust is a core predictor, with distrust in vaccines in general and mistrust in government raising vaccine hesitancy. Trust in health institutions and experts and perceived personal threat are vital, with focus groups revealing that COVID-19 vaccine hesitancy is driven by a misunderstanding of herd immunity as providing protection, fear of rapid vaccine development and side effects, belief the virus is man- made and related to population control. Particularly those who obtain information from relatively unregulated social media sources such as YouTube that have recommendations tailored by watch history are less likely to be willing to become vaccinated. Those who hold general conspiratorial beliefs are less willing to be vaccinated. Since an increasing number of individuals use social media for gathering health information, interventions require action from governments, health officials and social media companies. More attention needs to help people understand their own risks, unpack complex concepts and fill knowledge voids.",Will Jennings; Gerry Stoker; Hannah Willis; Viktor Valgardsson; Jenn Gaskell; Daniel Devine; Lawrence Mckay; Melinda C Mills,https://medrxiv.org/cgi/content/short/2021.01.26.21250246,https://medrxiv.org/cgi/content/short/2021.01.26.21250246,2021-01-27,2021-01-27,,True
177,Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis,"BackgroundTo assess the outcomes of ivermectin in ambulatory and hospitalized patients with COVID-19.

MethodsFive databases and websites for preprints were searched until January 2021 for randomized controlled trials (RCTs) and retrospective cohorts assessing ivermectin versus control in ambulatory and hospitalized participants. The primary outcome was overall mortality. Secondary outcome was recovered patients. For meta-analysis, random-effects and inverse variance meta-analyses with logarithmic transformation were performed. ROBINS-I for cohort studies, and the Cochrane Risk of Bias 2.0 tool for trials were used. The strength of evidence was assessed using GRADE.

ResultsAfter the selection, twelve studies (five retrospective cohort studies, six randomized clinical trials and one case series), were included. In total, 7412 participants were reported, the mean age was 47.5 (SD 9.5) years, and 4283 (58%) were male. Ivermectin was not associated with reduced mortality (logRR: 0.89, 95% CI 0.09 to 1.70, p = 0.04, I2= 84.7%), or reduced patient recovery (logRR 5.52, 95% CI -24.36 to 35.4, p = 0.51, I2 = 92.6%). All studies had a high risk of bias, and showed a very low certainty of the evidence.

ConclusionsThere insufficient certainty and quality of evidence to recommend the use of ivermectin to prevent or treat ambulatory or hospitalized patients with COVID-19.",Alex Castaneda-Sabogal; Diego Chambergo-Michilot; Carlos J. Toro-Huamanchumo; Christian Silva-Rengifo; Jose Gonzales-Zamora; Joshuan J. Barboza,https://medrxiv.org/cgi/content/short/2021.01.26.21250420,https://medrxiv.org/cgi/content/short/2021.01.26.21250420,2021-01-27,2021-01-27,,True
178,Association between COVID-19 mortality and population level health and socioeconomic indicators,"With the availability of multiple COVID-19 vaccines and the predicted shortages in supply for the near future, it is necessary to allocate vaccines in a manner that minimizes severe outcomes. To date, vaccination strategies in the US have focused on individual characteristics such as age and occupation. In this study, we assess the utility of population-level health and socioeconomic indicators as additional criteria for geographical allocation of vaccines. Using spatial autoregressive models, we demonstrate that 43% of the variability in COVID-19 mortality in US counties can be explained by health/socioeconomic factors, adjusting for case rates. Of the indicators considered, prevalence of chronic kidney disease and proportion of population living in nursing homes were found to have the strongest association. In the context of vaccine rollout globally, our findings indicate that national and subnational estimates of burden of disease could be useful for minimizing COVID-19 mortality.",Sasikiran Kandula; Jeffrey Shaman,https://medrxiv.org/cgi/content/short/2021.01.25.21250468,https://medrxiv.org/cgi/content/short/2021.01.25.21250468,2021-01-27,2021-01-27,,True
179,Fallow time determination in dentistry using aerosol measurement.,"AimTo calculate fallow time (FT) required following dental aerosol generating procedures (AGPs) in both a dental hospital (mechanically ventilated) and primary care (non-mechanically ventilated). Secondary outcomes were to identify spread and persistence of aerosol in open clinics compared to closed surgeries (mechanically ventilated environment), and identify if extra-oral scavenging (EOS) reduces production of aerosol and FT.

MethodsIn vitro simulation of fast handpiece (FHP) cavity preparations using a manikin was conducted in a mechanically and non-mechanically ventilated environment using Optical Particle Sizer and NanoScan at baseline, during the procedure and fallow period.

ResultsAGPs carried out in the non-mechanically, non-ventilated environment failed to achieve baseline particle levels after one hour. In contrast, when windows were opened after AGP, there was an immediate reduction in all particle sizes.

In mechanically ventilated environments the baseline levels of particles were very low and particle count returned to baseline within 10 minutes following AGP. There was no detectable difference between particles in mechanically ventilated open bays and closed surgeries.

The effect of the EOS was greater in non-mechanically ventilated environment on reducing the particle count; additionally, it also reduced the spikes in particle counts in mechanically ventilated environments.

ConclusionHigh-efficiency particulate air filtered mechanical ventilation along with mitigating factors (high-volume suction) resulted in reduction of FT (10 minutes). Non-ventilated rooms failed to reach baseline level even after one hour of FT. There was no difference in particle counts in open bay or closed surgeries in mechanically ventilated settings. The use of an EOS device can reduce the particulate spikes during procedures in both mechanical and non-mechanical environments.

This study confirms that AGPs are not recommended in dental surgeries where no ventilation is possible. No difference was demonstrated in FT required in open bays and closed surgeries in mechanically ventilated settings.

Clinical significanceAGPs should not be carried out in surgeries where ventilation is not possible. Mechanical ventilation for AGPs should be gold standard; where not available or practical then the use of natural ventilation with EOS helps reduce FT. AGPs can be carried out in open bay environment with a minimum of 6 air changes per hour of mechanical ventilation. Four-handed dentistry with high-volume suction and saliva ejector are essential mitigating factors during AGPs.",Shakeel Shahdad Professor; Annika Hindocha Dr; Tulsi Patel Dr; Neil Cagney Dr; Jens-Dominik Mueller Dr; Amine Koched Dr; Noha Seoudi Dr; Claire Morgan Dr; Padhraig Fleming Dr; Ahmed Din Dr,https://medrxiv.org/cgi/content/short/2021.01.26.21250482,https://medrxiv.org/cgi/content/short/2021.01.26.21250482,2021-01-27,2021-01-27,,True
180,"Water, sanitation, and hygiene practices and challenges during the COVID-19 pandemic: a cross-sectional study in rural Odisha, India","Water, sanitation, and hygiene (WASH) practices emerged as a critical component to controlling and preventing the spread of the COVID-19 pandemic. We conducted 131 semi-structured phone interviews with households in rural Odisha, India to understand behavior changes made in WASH practices as a result of the pandemic and challenges that would prevent best practices. Interviews were conducted from May-July 2020 with 73 heads of household, 37 caregivers of children less than five years old, and 21 members of village water and sanitation committees in villages with community-level piped water and high levels of latrine ownership. The majority of respondents (86%, N=104) reported a change in their handwashing practice due to COVID-19 or the related government lockdown, typically describing an increase in handwashing frequency, more thorough washing method, and/or use of soap. These improved handwashing practices remained in place a few months after the pandemic began and were often described as a new consistent practice after additional daily actions (such as returning home), suggesting new habit formation. Few participants (13%) reported barriers to handwashing. Some respondents also detailed improvements in other WASH behaviors including village-level cleaning of water tanks and/or treatment of piped water (48% of villages), household water treatment and storage (17% of respondents), and household cleaning (41% of respondents). However, there was minimal change in latrine use and child feces management practices as a result of the pandemic. We provide detailed thematic summaries of qualitative responses to allow for richer insights into these WASH behavior changes, or lack thereof, during the pandemic. The results also highlight the importance of ensuring communities have adequate WASH infrastructure to enable the practice of safe behaviors and strengthen resilience during a large-scale health crisis.",Valerie Bauza; Gloria D. Sclar; Alokananda Bisoyi; Fiona Majorin; Apurva Ghugey; Thomas Clasen,https://medrxiv.org/cgi/content/short/2021.01.26.21250274,https://medrxiv.org/cgi/content/short/2021.01.26.21250274,2021-01-27,2021-01-27,,True
181,Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19,"BackgroundEvidence suggests the role of an inflammatory storm in COVID-19 complications. Colchicine is an orally administered, anti-inflammatory medication beneficial in gout, pericarditis and coronary disease.

MethodsWe performed a randomized, double-blind trial involving non-hospitalized patients with COVID-19 diagnosed by polymerase chain reaction (PCR) testing or clinical criteria. The patients were randomly assigned to receive colchicine (0.5 mg twice daily for 3 days and once daily thereafter) or placebo for 30 days. The primary efficacy endpoint was the composite of death or hospitalization for COVID-19.

ResultsA total of 4488 patients were enrolled. The primary endpoint occurred in 4.7% of the patients in the colchicine group and 5.8% of those in the placebo group (odds ratio, 0.79; 95.1% confidence interval (CI), 0.61 to 1.03; P=0.08). Among the 4159 patients with PCR-confirmed COVID-19, the primary endpoint occurred in 4.6% and 6.0% of patients in the colchicine and placebo groups, respectively (odds ratio, 0.75; 95% CI, 0.57 to 0.99; P=0.04). In these patients with PCR-confirmed COVID-19, the odds ratios were 0.75 (95% CI, 0.57 to 0.99) for hospitalization due to COVID-19, 0.50 (95% CI, 0.23 to 1.07) for mechanical ventilation, and 0.56 (95% CI, 0.19 to 1.66) for death. Serious adverse events were reported in 4.9% and 6.3% in the colchicine and placebo groups (P=0.05); pneumonia occurred in 2.9% and 4.1% of patients (P=0.02). Diarrhea was reported in 13.7% and 7.3% in the colchicine and placebo groups (P<0.0001).

ConclusionAmong non-hospitalized patients with COVID-19, colchicine reduces the composite rate of death or hospitalization. (COLCORONA ClinicalTrials.gov number: NCT04322682)",Jean-Claude Tardif; Nadia Bouabdallaoui; Philippe L L'Allier; Daniel Gaudet; Binita Shah; Michael H Pillinger; Jose Lopez-Sendon; Protasio da Luz; Lucie Verret; Sylvia Audet; Jocelyn Dupuis; Andre Y Denault; Martin Pelletier; Philippe A Tessier; Sarah Samson; Denis Fortin; Jean-Daniel Tardif; David Busseuil; Elisabeth Goulet; Chantal Lacoste; Anick Dubois; Avni Y Joshi; David D Waters; Priscilla Hsue; Norman E Lepor; Frederic Lesage; Nicolas Sainturet; Eve Roy-Clavel; Zohar Bassevitch; Andreas Orfanos; Jean C Gregoire; Lambert Busque; Christian Lavallee; Pierre-Olivier Hetu; Jean-Sebastien Paquette; Sylvie Levesque; Marieve Cossette; Anna Nozza; Malorie Chabot-Blanchet; Marie-Pierre Dube; Marie-Claude Guertin; Guy Boivin,https://medrxiv.org/cgi/content/short/2021.01.26.21250494,https://medrxiv.org/cgi/content/short/2021.01.26.21250494,2021-01-27,2021-01-27,,True
182,Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques,"We previously reported that a single immunization with an adenovirus serotype 26 (Ad26) vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against SARS-CoV-2 challenge. In this study, we evaluated the immunogenicity and protective efficacy of reduced doses of Ad26.COV2.S. 30 rhesus macaques were immunized once with 1x1011, 5x1010, 1.125x1010, or 2x109 vp Ad26.COV2.S or sham and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes. Vaccine doses as low as 2x109 vp provided robust protection in bronchoalveolar lavage, whereas doses of 1.125x1010 vp were required for protection in nasal swabs. Activated memory B cells as well as binding and neutralizing antibody titers following vaccination correlated with protective efficacy. At suboptimal vaccine doses, viral breakthrough was observed but did not show evidence of virologic, immunologic, histopathologic, or clinical enhancement of disease compared with sham controls. These data demonstrate that a single immunization with a relatively low dose of Ad26.COV2.S effectively protected against SARS-CoV-2 challenge in rhesus macaques. Moreover, our findings show that a higher vaccine dose may be required for protection in the upper respiratory tract compared with the lower respiratory tract.",Xuan He; Abishek Chandrashekar; Roland C. Zahn; Frank Wegmann; Jingyou Yu; Noe B. Mercado; Katherine McMahan; Amanda J. Martinot; Cesar Piedra-Mora; Sidney Beecy; Sarah Ducat; Ronnie Chamanza; Sietske Rosendahl Huber; Leslie van der Fits; Erica N. Borducchi; Michelle Lifton; Jinyan Liu; Felix Nampanya; Shivani Patel; Lauren Peter; Lisa H. Tostanoski; Laurent Pessaint; Alex Van Ry; Brad Finneyfrock; Jason Velasco; Elyse Teow; Renita Brown; Anthony Cook; Hanne Andersen; Mark G. Lewis; Hanneke Schuitemaker; Dan H. Barouch,https://biorxiv.org/cgi/content/short/2021.01.27.428380,https://biorxiv.org/cgi/content/short/2021.01.27.428380,2021-01-27,2021-01-27,,False
183,Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model,"The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the defining global health emergency of this century. GC-376 is a Mpro inhibitor with antiviral activity against SARS-CoV-2 in vitro. Using the K18-hACE2 mouse model, the in vivo antiviral efficacy of GC-376 against SARS-CoV-2 was evaluated. GC-376 treatment was not toxic in K18-hACE2 mice and produced milder tissue lesions, reduced viral loads, fewer presence of viral antigen, and reduced inflammation in comparison to vehicle-treated controls, most notably in the brain in mice challenged with a low virus dose. Although GC-376 was not sufficient to improve neither clinical symptoms nor survival, it did show a positive effect against SARS-CoV-2 in vivo. This study supports the notion that the K18-hACE2 mouse model is suitable to study antiviral therapies against SARS-CoV-2, and GC-376 represents a promising lead candidate for further development to treat SARS-CoV-2 infection.",C. Joaquin Caceres; Stivalis Cardenas-Garcia; Silvia Carnaccini; Brittany Seibert; Daniela S Rajao; Jun Wang; Daniel R Perez,https://biorxiv.org/cgi/content/short/2021.01.27.428428,https://biorxiv.org/cgi/content/short/2021.01.27.428428,2021-01-27,2021-01-27,,False
184,Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain,"Since the COVID-19 pandemic onset, the antibody response to SARS-CoV-2 has been extensively characterized. Antibodies to the receptor binding domain (RBD) on the spike protein are frequently encoded by IGHV3-53/3-66 with a short CDR H3. Germline-encoded sequence motifs in CDRs H1 and H2 play a major role, but whether any common motifs are present in CDR H3, which is often critical for binding specificity, have not been elucidated. Here, we identify two public clonotypes of IGHV3-53/3-66 RBD antibodies with a 9-residue CDR H3 that pair with different light chains. Distinct sequence motifs on CDR H3 are present in the two public clonotypes that appear to be related to differential light chain pairing. Additionally, we show that Y58F is a common somatic hypermutation that results in increased binding affinity of IGHV3-53/3-66 RBD antibodies with a short CDR H3. Overall, our results advance fundamental understanding of the antibody response to SARS-CoV-2.",Timothy J.C. Tan; Meng Yuan; Kaylee Kuzelka; Gilberto C. Padron; Jacob R. Beal; Xin Chen; Yiquan Wang; Joel Rivera-Cardona; Xueyong Zhu; Beth M. Stadtmueller; Christopher B. Brooke; Ian A. Wilson; Nicholas C. Wu,https://biorxiv.org/cgi/content/short/2021.01.26.428356,https://biorxiv.org/cgi/content/short/2021.01.26.428356,2021-01-27,2021-01-27,,False
185,"Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera","We engineered three SARS-CoV-2 viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion+N501Y+D614G from UK; and E484K+N501Y+D614G from SA. Neutralization geometric mean titers (GMTs) of twenty BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses.",Xuping Xie; Yang Liu; Jianying Liu; Xianwen Zhang; Jing Zou; Camila R. Fontes-Garfias; Hongjie Xia; Kena A. Swanson; Mark Cutler; David Cooper; Vineet D Menachery; Scott Weaver; Philip Dormitzer; Pei-Yong Shi,https://biorxiv.org/cgi/content/short/2021.01.27.427998,https://biorxiv.org/cgi/content/short/2021.01.27.427998,2021-01-27,2021-01-27,,False
186,An Updated Investigation Prior To COVID-19 Vaccination Program In Indonesia: Full-Length Genome Mutation Analysis Of SARS-CoV-2,"IntroductionIndonesia kick-started the big project of COVID-19 vaccination program in January 2021 by employed vaccine to the president of Indonesia. The outbreak and rapid transmission of COVID-19 have endangered the global health and economy. This study aimed to investigate the full-length genome mutation analysis of 166 Indonesian SARS-CoV-2 isolates as 12 January 2021.

MethodsAll data of isolates was extracted from the Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV database. CoVsurver was employed to investigate the full-length genome mutation analysis of all isolates. Furthermore, this study also focused on the unlocking of mutation in Indonesian SARS-CoV-2 isolates S protein. WIV04 isolate that was originated from Wuhan, China was used as a virus reference according to CoVsurver default. All data was visualized using GraphPad Prism software, PyMOL, and BioRender.

ResultsThis study result showed that a full-length genome mutation analysis of 166 Indonesian SARS-CoV-2 isolates was successfully discovered. Every single mutation in S protein was described and then visualised by employing BioRender. Furthermore, it also found that D614G mutation appeared in 103 Indonesian SARS-CoV-2 isolates.

ConclusionTo sum up, this study helps to observe the spread of the COVID-19 transmission. However, it would like to propose that the epidemiological surveillance and genomics studies might be improved on COVID-19 pandemic in Indonesia.",Reviany V. Nidom; Setyarina Indrasari; Irine Normalina; Astria N. Nidom; Balqis Afifah; Lestari Dewi; Andra Kusuma Putra; Arif Nur Muhammad Ansori; Muhammad Khaliim Jati Kusala; Mohammad Yusuf Alamudi; Chairul Anwar Nidom,https://biorxiv.org/cgi/content/short/2021.01.26.426655,https://biorxiv.org/cgi/content/short/2021.01.26.426655,2021-01-27,2021-01-27,,False
187,Zinc supplement augments the suppressive effects of repurposed drugs of NF-kappa B inhibitor on ACE2 expression in human lung cell lines in vitro.,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a vast number of infections and fatalities worldwide. As the development and safety validation of effective vaccines are ongoing, drug repurposing is most efficient approach to search FDA approved agents against coronavirus disease 2019 (COVID-19). In the present study, we found that endogenous ACE2 expressions could be detected in H322M and Calu-3 cell lines, as well as their ACE2 mRNA and protein expressions were suppressed by pyrrolidine dithiocarbamate (PDTC), a NF-kappa B inhibitor, in dose- and time-dependent manners. Moreover, N-acetyl-cysteine (NAC) pretreatment reversed PDTC-induced ACE2 suppression, as well as the combined treatment of hydrogen peroxide and knockdown of p50 subunit of NF-kappa B by siRNA reduced ACE2 expression in H322M cells. In addition, anthelmintic drug triclabendazole and antiprotozoal drug emetine, repurposed drugs of NF-kappa B inhibitor, also inhibited ACE2 mRNA and protein expressions in H322M cells. Moreover, zinc supplement augmented the suppressive effects of triclabendazole and emetine on ACE2 suppression in H322M and Calu-3 cells. Taken together, these results indicate that ACE2 expression is modulated by reactive oxygen species (ROS) and NF-kappa B signal in human lung cell lines, and zinc combination with triclabendazole or emetine has the clinical potential for the prevention and treatment of COVID-19.",Ming Cheng Lee; Yin-Kai Chen; Yih-Jen Hsu; Bor-Ru Lin,https://biorxiv.org/cgi/content/short/2021.01.27.428372,https://biorxiv.org/cgi/content/short/2021.01.27.428372,2021-01-27,2021-01-27,,False
188,E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil,"The COVID-19 pandemic caused by SARS-CoV-2 has affected millions of people since its beginning in 2019. The propagation of new lineages and the discovery of key mechanisms adopted by the virus to overlap the immune system are central topics for the entire public health policies, research and disease management. Since the second semester 2020, the mutation E484K has been progressively found in the Brazilian territory, composing different lineages over time. It brought multiple concerns related to the risk of reinfection and the effectiveness of new preventive and treatment strategies due to the possibility of escaping from neutralizing antibodies. To better characterize the current scenario we performed genomic and phylogenetic analyses of the E484K mutated genomes sequenced from Brazilian samples in 2020. From October, 2020, 43.9% of the sequenced genomes present the E484K mutation, which was identified in three different lineages (P1, P2 and B.1.1.33) in four Brazilian regions. We also evaluated the presence of E484K associated mutations and identified selective pressures acting on the spike protein, leading us to some insights about adaptive and purifying selection driving the virus evolution.",Patricia Aline Grohs Ferrareze; Vinicius Bonetti Franceschi; Amanda de Menezes Mayer; Gabriel Dickin Caldana; Ricardo Ariel Zimerman; Claudia Elizabeth Thompson,https://biorxiv.org/cgi/content/short/2021.01.27.426895,https://biorxiv.org/cgi/content/short/2021.01.27.426895,2021-01-27,2021-01-27,,False
189,Lysosomal-Immune Axis Is Associated with COVID 19 Disease Severity: Insights from Patient Single Cell Data,"SARS-COV-2 has become a leading cause of illness, hospitalizations, and deaths worldwide yet heterogeneity in disease morbidity remains a conundrum. In this study, we analyzed publicly available single-cell RNA-seq data from 75076 cells sequenced from clinically staged COVID-19 patients using a network approach and identified lysosomal-immune axis as a factor significantly associated with disease severity. Our results suggest modulation of lysosomal-immune pathways may present a novel drug-targeting strategy to attenuate SARS-Cov-2 infections.",Rahul Pande; Erin Teeple; Weixiao Huang; Katherine W. Klinger; Deepak Rajpal; Dinesh Kumar,https://biorxiv.org/cgi/content/short/2021.01.27.428394,https://biorxiv.org/cgi/content/short/2021.01.27.428394,2021-01-27,2021-01-27,,False
190,Computational Analysis of Protein Stability and Allosteric Interaction Networks in Distinct Conformational Forms of the SARS-CoV-2 Spike D614G Mutant: Reconciling Functional Mechanisms through Allosteric Model of Spike Regulation,"Structural and biochemical studies SARS-CoV-2 spike mutants with the enhanced infectivity have attracted significant attention and offered several mechanisms to explain the experimental data. The development of a unified view and a working model which is consistent with the diverse experimental data is an important focal point of the current work. In this study, we used an integrative computational approach to examine molecular mechanisms underlying functional effects of the D614G mutation by exploring atomistic modeling of the SARS-CoV-2 spike proteins as allosteric regulatory machines. We combined coarse-grained simulations, protein stability and dynamic fluctuation communication analysis along with network-based community analysis to simulate structures of the native and mutant SARS-CoV-2 spike proteins in different functional states. The results demonstrated that the D614 position anchors a key regulatory cluster that dictates functional transitions between open and closed states. Using molecular simulations and mutational sensitivity analysis of the SARS-CoV-2 spike proteins we showed that the D614G mutation can improve stability of the spike protein in both closed and open forms, but shifting thermodynamic preferences towards the open mutant form. The results offer support to the reduced shedding mechanism of S1 domain as a driver of the increased infectivity triggered by the D614G mutation. Through distance fluctuations communication analysis, we probed stability and allosteric communication propensities of protein residues in the native and mutant SARS-CoV-2 spike proteins, providing evidence that the D614G mutation can enhance long-range signaling of the allosteric spike engine. By employing network community analysis of the SARS-CoV-2 spike proteins, our results revealed that the D614G mutation can promote the increased number of stable communities and allosteric hub centers in the open form by reorganizing and enhancing the stability of the S1-S2 inter-domain interactions and restricting mobility of the S1 regions. This study provides atomistic-based view of the allosteric interactions and communications in the SARS-CoV-2 spike proteins, suggesting that the D614G mutation can exert its primary effect through allosterically induced changes on stability and communications in the residue interaction networks.",Gennady Verkhivker; Steve Agajanian; Deniz Oztas; Grace Gupta,https://biorxiv.org/cgi/content/short/2021.01.26.428331,https://biorxiv.org/cgi/content/short/2021.01.26.428331,2021-01-27,2021-01-27,,False
191,Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes,"The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demands unprecedented attention. We report four X-ray crystal structures of three synthetic nanobodies (sybodies) (Sb16, Sb45 and Sb68) bind to the receptor-binding domain (RBD) of SARS-CoV-2: binary complexes of Sb16-RBD and Sb45-RBD; a ternary complex of Sb45-RBD-Sb68; and Sb16 unliganded. Sb16 and Sb45 bind the RBD at the ACE2 interface, positioning their CDR2 and CDR3 loops diametrically. Sb16 reveals a large CDR2 shift when binding the RBD. Sb68 interacts peripherally at the ACE2 interface; steric clashes with glycans explain its mechanism of viral neutralization. Superposing these structures onto trimeric spike (S) protein models indicates these sybodies bind conformations of the mature S protein differently, which may aid therapeutic design.

One Sentence SummaryX-ray structures of synthetic nanobodies complexed with the receptor-binding domain of the spike protein of SARS-CoV-2 reveal details of CDR loop interactions in recognition of distinct epitopic sites.",Not available,https://biorxiv.org/cgi/content/short/2021.01.27.428466,https://biorxiv.org/cgi/content/short/2021.01.27.428466,2021-01-27,2021-01-27,,False
192,SARS-CoV-2 emerging complexity,"The novel SARS_CoV-2 virus, prone to variation when interacting with spatially extended ecosystems and within hosts1 can be considered a complex dynamic system2. Therefore, it behaves creating several space-time manifestations of its dynamics. However, these physical manifestations in nature have not yet been fully disclosed or understood. Here we show 4-3 and 2-D space-time patterns of rate of infected individuals on a global scale, giving quantitative measures of transitions between different dynamical behaviour. By slicing the spatio-temporal patterns, we found manifestations of the virus behaviour such as cluster formation and bifurcations. Furthermore, by analysing the morphogenesis processes by entropy, we have been able to detect the virus phase transitions, typical of adaptive biological systems3. Our results for the first time describe the virus patterning behaviour processes all over the world, giving for them quantitative measures. We know that the outcomes of this work are still partial and more advanced analyses of the virus behaviour in nature are necessary. However, we think that the set of methods implemented can provide significant advantages to better analyse the viral behaviour in the approach of system biology4, thus expanding knowledge and improving pandemic problem solving.",Francesca Bertacchini; Eleonora Bilotta; Pietro  S. Pantano,https://biorxiv.org/cgi/content/short/2021.01.27.428384,https://biorxiv.org/cgi/content/short/2021.01.27.428384,2021-01-27,2021-01-27,,False
193,Do examinations prepare students for higher education? A lesson from the Covid-19 lockdown.,"The COVID-19 pandemic caused severe disruption to education in the UK in 2020, with most of the school teaching moving online and national school examinations being cancelled. This was particularly disruptive for those taking end of school examinations in preparation for higher education. Biological science courses require students to absorb a lot of new vocabulary and concepts, with examinations traditionally focusing on content recall rather than reasoning. Students who had entered university in September 2019 were compared with those arriving in September 2020 with respect to their knowledge of bioscience vocabulary and understanding of key concepts. Results showed no significant difference between those who had gone through the examination process in 2019 relative to those who had not, in 2020. This suggests the cramming of information for examinations has no detectable effect on the knowledge and understanding of biology that students take with them to university.",Harriet L Jones; Valentina Zini; Jon R Green; John R Prendergast; Jon Scott,https://biorxiv.org/cgi/content/short/2021.01.26.428208,https://biorxiv.org/cgi/content/short/2021.01.26.428208,2021-01-27,2021-01-27,,False
194,Evaluation of six commercial SARS-CoV-2 Enzyme-Linked Immunosorbent assays for clinical testing and serosurveillance.,"BackgroundSerological testing for SARS-CoV-2 complements nucleic acid tests for patient diagnosis and enables monitoring of population susceptibility to inform the COVID-19 pandemic response. As we move into the era of vaccines, the detection of neutralising antibody will become increasingly important. Many serological tests have been developed under emergency use authorization, but their reliability remains unclear.

MethodsWe evaluated the performance of six commercially-available Enzyme-linked Immunosorbent Assays (ELISAs), including a surrogate virus neutralization test, for detection of SARS-CoV-2 immunoglobulins (IgA, IgM, IgG), total or neutralising antibodies and a subset of results were compared to microneutralisation.

ResultsFor sera collected > 14 days post-symptom onset the Wantai total Ab performed best with highest sensitivity 100% (95% confidence interval: 94.6-100) followed by 93.1% for Euroimmun NCP-IgG,93.1% for GenScript Surrogate Virus Neutralization Test, 90.3% for Euroimmun S1-IgG, 88.9% for Euroimmun S1-IgA and 83.3% for Wantai IgM. Specificity for the best performing assay was 99.5% and for the lowest 97.1%.

ConclusionWantai ELISA, detecting total immunoglobulins against SARS-CoV-2 receptor binding domain, had the best performance. Antibody target, timing and longevity of the immune response, and the objectives of testing should be considered in test choice. ELISAs should be used within a confirmatory testing algorithm to ensure reliable results. ELISAs provide high quality results, with flexibility for test numbers without the need for manufacturer specific analyzers.",Suellen R Nicholson; Theo Karapanagiotidis; Arseniy Khvorov; Celia Douros; Francesca Mordant; Katherine Bond; Deborah A Williamson; Damian Francis John Purcell; Sharon Lewin; Sheena Sullivan; Kanta Subbarao; Mike Catton,https://medrxiv.org/cgi/content/short/2021.01.21.21250249,https://medrxiv.org/cgi/content/short/2021.01.21.21250249,2021-01-26,2021-01-26,,True
195,SARS-CoV-2 recruits a haem metabolite to evade antibody immunity,"The coronaviral spike is the dominant viral antigen and the target of neutralizing antibodies. We show that SARS-CoV-2 spike binds biliverdin and bilirubin, the tetrapyrrole products of haem metabolism, with nanomolar affinity. Using cryo-electron microscopy and X-ray crystallography we mapped the tetrapyrrole interaction pocket to a deep cleft on the spike N-terminal domain (NTD). At physiological concentrations, biliverdin significantly dampened the reactivity of SARS-CoV-2 spike with immune sera and inhibited a subset of neutralizing antibodies. Access to the tetrapyrrole-sensitive epitope is gated by a flexible loop on the distal face of the NTD. Accompanied by profound conformational changes in the NTD, antibody binding requires relocation of the gating loop, which folds into the cleft vacated by the metabolite. Our results indicate that the virus co-opts the haem metabolite for the evasion of humoral immunity via allosteric shielding of a sensitive epitope and demonstrate the remarkable structural plasticity of the NTD.",Annachiara Rosa; Valerie E Pye; Carl Graham; Luke Muir; Jeffrey Seow; Kevin W Ng; Nicola J Cook; Chloe Rees-Spear; Eleanor Parker; Mariana Silva dos Santos; Carolina Rosadas; Alberto Susana; Hefin Rhys; Andrea Nans; Laura Masino; Chloe Roustan; Evangelos Christodoulou; Rachel Ulferts; Antoni Wrobel; Charlotte-Eve Short; Michael Fertleman; Rogier W Sanders; Judith Heaney; Moira Spyer; Svend Kjaer; Andy Riddell; Michael H Malim; Rupert Beale; James I MacRae; Graham P Taylor; Eleni Nastouli; Marit J van Gils; Peter B Rosenthal; Massimo Pizzato; Myra O McClure; Richard S Tedder; George Kassiotis; Laura E McCoy; Katie J Doores; Peter Cherepanov,https://medrxiv.org/cgi/content/short/2021.01.21.21249203,https://medrxiv.org/cgi/content/short/2021.01.21.21249203,2021-01-26,2021-01-26,,True
196,Genomic insights into early SARS-CoV-2 strains isolated in Reunion Island,"The relative isolation of many island communities provides some protection from the COVID-19 pandemic, as imported cases can be limited and traced effectively. Until recently, this was true for the population of the French overseas department, Reunion Island, where only limited numbers of autochthonous cases were observed prior to August 2020. Since the report of the first case of COVID-19, contact tracing has been carried out for each new case identified in Reunion Island to identify transmission and clusters. To contribute to the public health response and understand the diffusion of SARS-Cov-2 strains in Reunion Island, we established in-house genome sequencing capability in Reunion using Oxford nanopore technology (MinION) as an inexpensive option for genomic typing of SARS-CoV-2 lineages on the island, and cross-validated typing results between viral isolation methods and different sequencing technologies. The results of our work during the early phase of the epidemics are presented herein.

Article Summary LineThe COVID-19 pandemic has had an unprecedented impact on the global community. Here we provide epidemiological and genomic details of the early stages of the pandemic on Reunion Island.",David A Wilkinson; Camille Lebarbenchon; Celestine Atyame; Sarah Hafsia; Marie-Christine Jaffar-Bandjee; Luce Menudier; Sebastien Tanaka; Olivier Meilhac; Patrick Mavingui,https://medrxiv.org/cgi/content/short/2021.01.21.21249623,https://medrxiv.org/cgi/content/short/2021.01.21.21249623,2021-01-26,2021-01-26,,True
197,The usefulness of a quantitative olfactory test for the detection of COVID-19.,"BackgroundDuring the COVID-19 pandemic, olfactory dysfunction (anosmia or hyposmia) has been reported by many patients and recognized as a prevalent and early symptom of infection. This finding has been associated with viral-induced olfactory neuron dysfunction rather than the nasal congestion typically found in cold- or flu-like states. In literature, the prevalence of anosmia varies from 15% to 85%, and the studies, in general, were based on the subjective evaluation of patients self-reports of loss of smell (yes or no question). In the present study, we quantitatively evaluated olfactory dysfunction and the prevalence of fever in symptomatic patients suspected of having COVID-19 using a scratch-and-sniff olfactory test and infrared temperature testing with RT-PCR as the gold-standard comparator method to diagnose COVID-19 infection.

MethodsOutpatients had their forehead temperature checked with an infrared non-contact thermometer (temperature guns). After that, they received two olfactory smell identification test (SIT) cards (u-Smell-it; CT, USA) that each had 5 scent windows and were asked to scratch with a pencil and sniff each of the 10 small circles containing the microencapsulated fragrances and mark the best option on a response card. Nasopharyngeal swabs were then collected for Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) to determine if the patients were positive or negative for COVID-19 infection. We considered the number of  hits (correct answers) [&le;] 5 as positive for loss of smell (LOS) in the olfactory test; [&ge;] 6 hits was considered negative for LOS (i.e. normal olfactory function). All data were analyzed using Excel and Matlab software.

ResultsIn the present study, 165 patients were eligible for the olfactory test and nasopharyngeal swab collection RT-PCR. Five patients were excluded because of inconclusive PCR results (n=2) and missing data (n=3). A total of 160 patients completed all the protocols. The RT-PCR positivity rate for COVID-19 was 27.5% (n=44), and PCR+ patients scored significantly worse in the olfactory test (5.5{+/-}3.5) compared to RT-PCR-patients (8.2{+/-}1.8, p<0.001). 0/44 PCR+ patients presented with a fever ([&ge;]37.8{degrees}C). In contrast an olfactory SIT had a specificity of 94.8% (95% CI, 89.1 - 98.1), sensitivity of 47.7% (95% CI, 32.7 - 63.3), accuracy of 0.82 (95% CI, 0.75 - 0.87), positive predictive value of 77.8% (95% CI, 59.6 - 88.8), negative predictive value of 82.7% (85% CI, 78.7 - 86.7), and odds ratio of 16.7.

ConclusionOur results suggest that temperature checking failed to detect COVID-19 infection, while an olfactory test may be useful to help identify COVID-19 infection in symptomatic patients.",Marcos Adriano Lessa; Stella M R Cotta-Pereira; Frederico A Ferreira; Terezinha Marta Pereira Pinto Castineira; Rafael de Mello Galiez; Debora Souza Faffe; Isabela de Carvalho Leitao; Diana Mariani; Erica Ramos dos Santos Nascimento; Flavia Soares Lessa; Isabela Brasil Succi; Carlos Eduardo Pedreira,https://medrxiv.org/cgi/content/short/2021.01.20.21250173,https://medrxiv.org/cgi/content/short/2021.01.20.21250173,2021-01-26,2021-01-26,,True
198,Comparison study of commercial COVID-19 RT-PCR kits propose an approach to evaluate their performances,"With the increasing number of COVID-19 cases in Indonesia, scalable and high-throughput diagnostic testing is essential nationwide. Currently, RT-PCR has been the preferred method of viral detection and many manufacturers offer commercial kits for routine clinical diagnostics. In response to the incoming of various kits, there is a need to assess their performance and compatibility of use in clinical laboratories. Kit characteristics impact the testing workflow of these laboratories and some factors can render a kit to perform sub-optimally, leading to false results that are misleading for public safety. Here, we evaluated six commercial kits that are predominantly distributed to appointed testing facilities across Indonesia. Their performance was assessed based on their ease of use, availability, robustness and accuracy for scalable testing in a manual set-up. Our findings demonstrated that all six kits are suitable for use in routine diagnostics, but their considerations for use may vary according to different use-cases. To better guide considerations in procurement of kits, our study provided a systematic approach for laboratories to assess the performance of new incoming kits.",Hana Krismawati; Caroline Mahendra; Annabelle Hartanto; Muhammad Fajri Rokhmad; Semuel Sandi; Astrid Irwanto,https://medrxiv.org/cgi/content/short/2021.01.20.21250143,https://medrxiv.org/cgi/content/short/2021.01.20.21250143,2021-01-26,2021-01-26,,True
199,Model-driven mitigation measures for reopening schools during the COVID-19 pandemic,"Reopening schools is an urgent priority as the COVID-19 pandemic drags on throughout much of the world. To explore the risks associated with returning to in-person learning and the value of mitigation measures in a school setting, we use the stochastic, network-based SEIRS+ epidemiological modeling platform to simulate SARS-CoV-2 transmission in schools. Because children and adolescents differ both in disease susceptibility and in patterns of social interaction, we use distinct models of SARS-CoV-2 transmission for primary and secondary school settings. We find that a number of mitigation measures may prove useful, particularly when community prevalence is low. Student cohorting, in which students are divided into two separate populations that attend in-person classes on alternating schedules, can reduce both the likelihood and the size of outbreaks. Proactive testing of teachers and staff once or twice a week can help catch introductions early, before they spread widely through the school. Especially in secondary schools, once- or twice-weekly testing amongst students should also be considered to further reduce the likelihood of a large outbreak amongst the full population. Vaccinating teachers and staff protects these individuals and may also have a disproportionate protective effect on the outbreak potential in primary and secondary schools when vaccines block SARS-CoV-2 transmission in addition to symptoms. Other mitigation strategies - including mask-wearing, social distancing, and increased ventilation - remain a crucial component of any reopening plan.",Ryan Seamus McGee; Julian R. Homburger; Hannah E. Williams; Carl T. Bergstrom; Alicia Y. Zhou,https://medrxiv.org/cgi/content/short/2021.01.22.21250282,https://medrxiv.org/cgi/content/short/2021.01.22.21250282,2021-01-26,2021-01-26,,True
200,A 3D CNN Classification Model for Accurate Diagnosis of Coronavirus Disease 2019 using Computed Tomography Images,"The coronavirus disease (COVID-19) has been spreading rapidly around the world. As of August 25, 2020, 23.719 million people have been infected in many countries. The cumulative death toll exceeds 812,000. Early detection of COVID-19 is essential to provide patients with appropriate medical care and protect uninfected people. Leveraging a large computed tomography (CT) database from 1,112 patients provided by China Consortium of Chest CT Image Investigation (CC-CCII), we investigated multiple solutions in detecting COVID-19 and distinguished it from other common pneumonia (CP) and normal controls. We also compared the performance of different models for complete and segmented CT slices. In particular, we studied the effects of CT-superimposition depths into volumes on the performance of our models. The results show that the optimal model can identify the COVID-19 slices with 99.76% accuracy (99.96% recall, 99.35% precision and 99.65% F1-score). The overall performance for three-way classification obtained 99.24% accuracy and the area under the receiver operating characteristic curve (AUROC) of 0.9986. To the best of our knowledge, our method achieves the highest accuracy and recall with the largest public available COVID-19 CT dataset. Our model can help radiologists and physicians perform rapid diagnosis, especially when the healthcare system is overloaded.",Yifan Li; Xuan Pei; Yandong Guo,https://medrxiv.org/cgi/content/short/2021.01.21.21249999,https://medrxiv.org/cgi/content/short/2021.01.21.21249999,2021-01-26,2021-01-26,,True
201,Data Driven High Resolution Modeling and Spatial Analyses of the COVID-19 Pandemic in Germany,"The SARS-CoV-2 virus has spread around the world with over 90 million infections to date, and currently many countries are fighting the second wave of infections. With neither sufficient vaccination capacity nor effective medication, non-pharmaceutical interventions (NPIs) remain the measure of choice. However, NPIs place a great burden on society, the mental health of individuals, and economics. Therefore the cost/benefit ratio must be carefully balanced and a target-oriented small-scale implementation of these NPIs could help achieve this balance. To this end, we introduce a modified SEIR-class compartment model and parametrize it locally for all 412 districts of Germany. The NPIs are modeled at district level by time varying contact rates. This high spatial resolution makes it possible to apply geostatistical methods to analyse the spatial patterns of the pandemic in Germany and to compare the results of different spatial resolutions. We find that the modified SEIR model can successfully be fitted to the COVID-19 cases in German districts, states, and also nationwide. We propose the correlation length as a further measure, besides the weekly incidence rates, to describe the current situation of the epidemic.",Lennart Sch&uumller; Justin M. Calabrese; Sabine Attinger,https://medrxiv.org/cgi/content/short/2021.01.21.21250215,https://medrxiv.org/cgi/content/short/2021.01.21.21250215,2021-01-26,2021-01-26,,True
202,Management of conductive deafness from Otitis Media with Effusion (known as glue ear) in children using bone conduction headsets when grommet operations were unavailable during COVID-19.,"BackgroundOtitis Media with Effusion (OME) causing hearing impairments affects [~]1 in 10 children starting school in UK/ Europe. 80% have at least one episode with most having conductive hearing loss. Studies showed children with OME hear better with bone conducting headsets. During COVID-19 we investigated whether children with deafness secondary OME, without access to audiology or grommet surgery, could be aided with bone conduction kits and the HearGlueEar app.

MethodsStarting July 2020, during COVID-19, children aged 3-11 years with OME and on a grommet waiting list were invited to a single arm, prospective study. They received the kit, instructions and HearGlueEar app by post. By 3 weeks parents were asked to charge and pair the devices, attend a remote consultation and complete an OMQ-14 questionnaire. Remote follow-up lasted 3 months. Outcomes: ability to use the equipment, complete the questionnaire about childs hearing and behaviour before and with the equipment, declining grommet surgery or where deafness resolved, and give opinion about the intervention.

Findings26 children enrolled. Families used the kit at home and school. Most found remote consultations positive and convenient. OMQ-14 responses were 90% positive. Comments were: ""Other people have said, wow his speech is clearer."", ""It is making a real difference at home."", ""He said over and over again, ""I can hear everybody, wow, wow, wow."", ""It is no exaggeration to say this has made an astronomical improvement to his quality of life"". One child reported ""I can hear my best friend again"". ""She is getting on really well with the headphones - pairing them with the iPad at home is simply brilliant."" Three families continued with the headset to avoid grommets.

InterpretationPosting a bone conduction kit, HearGlueEar app and remote consultation is effective support for children with deafness secondary to OME.

FundingNone",Tamsin Mary Holland Brown; Isobel Fitzgerald OConnor; Jessica Bewick; Colin Morley,https://medrxiv.org/cgi/content/short/2021.01.21.21249496,https://medrxiv.org/cgi/content/short/2021.01.21.21249496,2021-01-26,2021-01-26,,True
203,Rule of thumb in human intelligence for assessing the COVID-19 outbreak in Japan,"BackgroundThe COVID-19 outbreak in Japan exhibited its third peak at the end of 2020. Mathematical modelling and developed AI cannot explain several peaks in a single year.

ObjectThis study was conducted to evaluate a rule of thumb for prediction from past wave experiences.

MethodWe rescaled the number of newly infected patients as 100% at the peak and checked similarities among waves. Then we extrapolated the courses of the third and later waves.

ResultsResults show some similarity around the second and the third waves. Based on this similarity, we expected the bottom of the third wave will show 2131 newly positive patients including asymptomatic patients at around the end of February, 2021.

Discussion and ConclusionWe can infer the course of the third wave from similarity with the second wave. Mathematical modelling has been unable to do it, even when AI was used for prediction. Performance of the rule of thumb used with human intelligence might be superior to that of AI under these circumstances.",Junko Kurita; Tamie Sugawara; Yasushi Ohkusa,https://medrxiv.org/cgi/content/short/2021.01.20.21250204,https://medrxiv.org/cgi/content/short/2021.01.20.21250204,2021-01-26,2021-01-26,,True
204,Willingness to volunteer of medical students during the COVID-19 pandemic: Assessment at a tertiary care hospital in India,"Background and ObjectivesThe involvement of medical students in strategies to control COVID-19 might be considered to cope with the shortage of healthcare workers. This study aims at assessing the level of knowledge about COVID-19, willingness to volunteer, potential areas of involvement and reasons for deterrence towards volunteering among medical students.

MethodsA cross-sectional study was conducted among undergraduate medical students of a tertiary care teaching hospital in New Delhi. A web-based questionnaire was used to elicit demographic information, knowledge of COVID-19, willingness to volunteer and reasons for deterrence for working during COVID-19 pandemic and self-declared knowledge in six domains.

ResultsA total of 292 students participated in the study with a mean age of 19.9{+/-}3.1 years. The mean (S.D.) knowledge score of COVID-19 was 6.9 (1.1) (maximum score 10). Knowledge score was significantly different among preclinical (6.5), paraclinical (7.18), and clinical groups (7.03). Almost three fourth (75.3%) participants were willing to volunteer in COVID-19 pandemic, though 67.8% had not received any training in emergency medicine or public health crisis management. Willingness to work was maximum in areas of social work and indirect patient care (62.3% each). Lack of personal protective equipment was cited as a highly deterrent factor for volunteering (62.7%) followed by fear of transmitting the infection to family (45.9%), fear of causing harm to the patient (34.2%), and absence of treatment (22.2%).

Interpretation & conclusionsMajority of the students were willing to volunteer even though they had not received adequate training. Students may serve as an auxiliary force during the pandemic, especially in the non-clinical setting.",Manraj Singh Sra; Amulya Gupta; Abhishek Jaiswal; Kapil Yadav; Anil Goswami; Kiran Goswami,https://medrxiv.org/cgi/content/short/2021.01.22.21250302,https://medrxiv.org/cgi/content/short/2021.01.22.21250302,2021-01-26,2021-01-26,,True
205,Role of FYVE and Coiled-Coil Domain Autophagy Adaptor 1 in severity of COVID-19 infection: from GWAS hit to therapeutic hypothesis,"Coronaviruses remodel intracellular membranes to form specialized viral replication compartments, such as double-membrane vesicles where viral RNA genome replication takes place. Understanding the factors affecting host response is instrumental to design of therapeutics to prevent or ameliorate the course of infection.

As part of explorative tests in hospitalized patients with confirmed COVID-19 infection participating in ODYSSEY trial, we obtained samples for whole genome sequencing analysis as well as for viral genome sequencing. Based on our data, we confirm one of the strongest severity susceptibility locus thus far reported in association with severe COVID-19: 3p21.31 locus with lead variant rs73064425. We further examine the associated region. Interestingly based on LD analysis we report 3 coding mutations within one gene in the region of FYVE and Coiled-Coil Domain Autophagy Adaptor 1 (FYCO1). We specifically focus on the role of FYCO1 modifiers and gain-of-function variants. We report the associations between the region and clinical characteristics in this severe set of COVID-19 patients.

We next analyzed expression profiles of FYCO1 across all 466 compounds tested. We selected only those results that showed a significant reduction of expression of FYCO1. The most significant candidate was indomethacin - an anti-inflammatory that could potentially downregulate FYCO1. We hypothesize that via its direct effects on efficiency of viral egress, it may serve as a potent therapeutic decreasing the replication and infectivity of the virus. Clinical studies will be needed to examine the therapeutic utility of indomethacin and other compounds downregulating FYCO1 in COVID-19 infection and other strains of betacoronaviruses.",Sandra Paulina Smieszek; Mihael H Polymeropoulos,https://medrxiv.org/cgi/content/short/2021.01.22.21250070,https://medrxiv.org/cgi/content/short/2021.01.22.21250070,2021-01-26,2021-01-26,,True
206,The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient - a case study,"BackgroundImmunocompromised patients show prolonged shedding of SARS-CoV-2 in nasopharyngeal swabs. We report a case of a prolonged persistence of viable SARS-CoV-2 associated with clinical relapses of COVID-19 in a lymphoma patient.

MethodsNasopharyngeal swabs and blood samples were tested for SARS-CoV-2 by Real time-PCR (RT-PCR). On five positive nasopharyngeal swabs, we performed viral culture and next generation sequencing. We analysed the patients adaptive and innate immunity to characterize T and NK cell subsets.

FindingsSARS-CoV-2 RT-PCR on nasopharyngeal swabs samples remained positive with cycle threshold mean values of 22 {+/-} 1{middle dot}3 for over 8 months. All five performed viral cultures were positive and genomic analysis confirmed a persistent infection with the same strain. Viremia resulted positive in three out of four COVID-19 clinical relapses and cleared each time after remdesivir treatment. T and NK cells dynamic was different in aviremic and viremic samples and no SARS-CoV-2 specific antibodies were detected throughout the disease course.

InterpretationIn our patient, SARS-CoV-2 persisted with proven infectivity for over eight months. Viremia was associated with COVID-19 relapses and remdesivir treatment was effective in viremia clearance and symptoms remission, although it was unable to clear the virus from the upper respiratory airways. During the viremic phase, we observed a low frequency of terminal effector CD8+ T lymphocytes in peripheral blood that are probably recruited in inflammatory tissue for viral eradication. In addition we found a high level of NK cells repertoire perturbation with a relevant involvement during SARS-CoV-2 viremia.

FundingNone.",Chiara Sepulcri Jr.; Chiara Dentone Sr.; Malgorzata Mikulska Sr.; Bianca Bruzzone Sr.; Alessia Lai Sr.; Daniela Fenoglio Sr.; Federica Bozzano Sr.; Annalisa Bergna Jr.; Alessia Parodi Sr.; Tiziana Altosole Jr.; Emanuele Delfino Sr.; Giulia Bartalucci Sr.; Andrea Orsi Sr.; Antonio Di Biagio Sr.; Gianguglielmo Zehender Sr.; Filippo Ballerini Sr.; Stefano Bonora Sr.; Raffaele De Palma Sr.; Guido Silvestri Sr.; Andrea De Maria Sr.; Matteo Bassetti Sr.,https://medrxiv.org/cgi/content/short/2021.01.23.21249554,https://medrxiv.org/cgi/content/short/2021.01.23.21249554,2021-01-26,2021-01-26,,True
207,Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay,"BackgroundSARS-CoV-2 surrogate neutralization assays that bypass the need for viral culture offer substantial advantages regarding throughput and cost. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript) is the first such commercially available assay, detecting antibodies that block RBD/ACE-2 interaction. We aimed to evaluate cPass to inform its use and assess its added value compared to anti-RBD ELISA assays.

MethodsSerum reference panels were used to compare cPass to plaque-reduction neutralization test (PRNT) and a pseudotyped lentiviral neutralization assay for detection of neutralizing antibodies. We assessed the correlation of cPass with an ELISA detecting anti-RBD IgG, IgM, and IgA antibodies at a single timepoint and across intervals from onset of symptoms of SARS-CoV-2 infection.

ResultsCompared to PRNT-50%, cPass had 100% sensitivity (95%CI 82-100) and 95% specificity (76-100). Sensitivity was also very high compared to the pseudotyped lentiviral neutralization assay, but specificity was lower, ranging from 17-70%. Highest agreement between cPass and ELISA was for anti-RBD IgG (r=0.851 at 0-6 weeks; r=0.798 at > 6 weeks). Anti-RBD IgG diagnostic accuracy for detection of neutralizing antibodies was essentially identical to that of cPass.

ConclusionsThe added value of cPass compared to an IgG anti-RBD ELISA was not supported by these results.",Jesse Papenburg; Matthew P Cheng; Rachel Corsini; Chelsea Caya; Emelissa J Mendoza; Kathy J Manguiat; Heidi Wood; Michael Drebot; Gerasimos Zaharatos; RenÃ©e Bazin; Guillaume Beaudoin-BussiÃ¨res; JÃ©rÃ©mie PrÃ©vost; AndrÃ©s Finzi; Momar Ndao; Cedric P Yansouni,https://medrxiv.org/cgi/content/short/2021.01.23.21250325,https://medrxiv.org/cgi/content/short/2021.01.23.21250325,2021-01-26,2021-01-26,,True
208,Seroprevalence and attainment of herd immunity against SARS CoV-2: A modelling study,"Objective: The present study is aims to predict the likelihood of and likely time required to attain herd immunity against COVID-19 in New Delhi due to natural infection. Method: An ODE based mathematical model was constructed by extending the classical SEIR model to predict the seroprevalence rate in Delhi. We estimated the parameter values for Delhi using available data (reported cases and the seroprevalence rate) and used them for future prediction. We also attempted to capture the changes in the seroprevalence rate with different possibilities of reinfection. Results: Maximum seroprevalence rate obtained through our model is 31.65% and also a reduction in the seroprevalence rate was observed for the upcoming one month (month of January, 2021) due to the reduced transmission rate. After increasing the transmission rate to the value same as the third wave in New Delhi, we obtained a maximum value of 54.96%. This maximum value significantly decreased with the reduction in the reinfection possibilities. Also, a little impact of the duration of persistence of antibodies, 180 vs 105 days, was observed on the maximum seroprevalence. Conclusion: This modelling study suggests that natural infection alone, as gauged by serial sero-surveys, will not result in attainment of herd immunity in the state of Delhi.",Abhijit Paul; Harshith B Kadnur; Animesh Ray; Samrat Chatterjee; Naveet Wig,https://medrxiv.org/cgi/content/short/2021.01.22.21250328,https://medrxiv.org/cgi/content/short/2021.01.22.21250328,2021-01-26,2021-01-26,,True
209,ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections,"We report Accurate SARS-CoV-2 genome Reconstruction (ACoRE), an amplicon-based viral genome sequencing workflow for the complete and accurate reconstruction of SARS-CoV-2 sequences from clinical samples, including suboptimal ones that would usually be excluded even if unique and irreplaceable. We demonstrated the utility of the approach by achieving complete genome reconstruction and the identification of false-positive variants in >170 clinical samples, thus avoiding the generation of inaccurate and/or incomplete sequences. Most importantly, ACoRE was crucial to identify the correct viral strain responsible of a relapse case, that would be otherwise mis-classified as a re-infection due to missing or incorrect variant identification by a standard workflow.",Luca Marcolungo; Cristina Beltrami; Chiara Degli Esposti; Giulia Lopatriello; Chiara Piubelli; Antonio Mori; Elena Pomari; Michela Deiana; Salvatore Scarso; Zeno Bisoffi; Valentina Grosso; Emanuela Cosentino; Simone Maestri; Denise Lavezzari; Barbara Iadarola; Marta Paterno; Elena Segala; Barbara Giovannone; Martina Gallinaro; Marzia Rossato; Massimo Delledonne,https://medrxiv.org/cgi/content/short/2021.01.22.21250285,https://medrxiv.org/cgi/content/short/2021.01.22.21250285,2021-01-26,2021-01-26,,True
210,Extraction of Viral Nucleic Acids with Carbon Nanotubes Increases SARS-CoV-2 RT-qPCR Detection Sensitivity,"The global SARS-CoV-2 coronavirus pandemic has led to a surging demand for rapid and efficient viral infection diagnostic tests, generating a supply shortage in diagnostic test consumables including nucleic acid extraction kits. Here, we develop a modular method for high-yield extraction of viral single-stranded nucleic acids by using  capture ssDNA sequences attached to carbon nanotubes. Target SARS-CoV-2 viral RNA can be captured by ssDNA-nanotube constructs via hybridization and separated from the liquid phase in a single-tube system with minimal chemical reagents, for downstream quantitative reverse transcription polymerase chain reaction (RT-qPCR) detection. This nanotube-based extraction method enables 100% extraction yield of target SARS-CoV-2 RNA from phosphate buffered saline in comparison to [~]20% extraction yield when instead using a commercial silica-column kit. Notably, carbon nanotubes enable extraction of nucleic acids directly from 50% human saliva, bypassing the need for further biofluid purification and avoiding the use of DNA/RNA extraction kits. Carbon nanotube-based extraction of viral nucleic acids facilitates high-yield and high-sensitivity identification of viral nucleic acids such as the SARS-CoV-2 viral genome with reduced reliance on reagents affected by supply chain obstacles.



O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=133 SRC=""FIGDIR/small/20224675v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (25K):
org.highwire.dtl.DTLVardef@e835c3org.highwire.dtl.DTLVardef@121cc0aorg.highwire.dtl.DTLVardef@1dabebforg.highwire.dtl.DTLVardef@2126f8_HPS_FORMAT_FIGEXP  M_FIG C_FIG",Sanghwa Jeong; Eduardo G Grandio; Nicole Navarro; Rebecca L Pinals; Francis Ledesma; Darwin Yang; Markita P Landry,https://medrxiv.org/cgi/content/short/2021.01.22.20224675,https://medrxiv.org/cgi/content/short/2021.01.22.20224675,2021-01-26,2021-01-26,,True
211,"Weekly SARS-CoV-2 sentinel in primary schools, kindergartens and nurseries, June to November 2020, Germany","A 12-week sentinel programme monitored SARS-CoV-2 in primary schools, kindergartens and nurseries. Out of 3169 oropharyngeal swabs, only two tested positive on rRT-PCR while general incidence rates were surging. Thus, children attending respective institutions are not significantly contributing to the pandemic spread when appropriate infection control measures are in place.",Martin Hoch; Sebastian Vogel; Laura Kolberg; Elisabeth Dick; Volker Fingerle; Ute Eberle; Nikolaus Ackermann; Andreas Sing; Johannes Huebner; Anita Rack-Hoch; Tilmann Schober; Ulrich von Both,https://medrxiv.org/cgi/content/short/2021.01.22.21249971,https://medrxiv.org/cgi/content/short/2021.01.22.21249971,2021-01-26,2021-01-26,,True
212,Oral ulcers of COVID-19 patients: a scoping review protocol,"ObjectiveThis scoping review aims to systematically identify the types, characteristics, and possible pathophysiologic etiologies of the oral ulcers that emerge in COVID-19 patients.

IntroductionThe oral cavity is a vulnerable niche for the most diverse microbial ecosystem in the human body; therefore, it presents a wide array of mucocutaneous complications that could indicate various acute and chronic conditions. The COVID-19-related oral conditions, including oral ulcers, had been widely debated as direct manifestations or indirect complications of the SARS-CoV-2 infection. According to a preliminary search of PROSPERO, MEDLINE, the Cochrane Database of Systematic Reviews and the JBI Evidence Synthesis, there is no published nor registered scoping review concerned with the oral ulcers of COVID-19 patients.

Inclusion criteriaThe review will include studies included COVID-19 patients whose infection had been confirmed by RT-PCR testing regardless of infection severity and clinical course. Only the studies that reported COVID-19 patients with oral ulcers.

MethodsA three-phase search strategy will be carried out: an initial limited search, a full electronic search, and hand search using the reference lists of all included records. The main bibliographic databases of published literature will include MEDLINE (PubMed), Cochrane COVID-19 Study Register, EMBASE via Ovid, and Scopus. All identified records will be managed using EndNote 9.2, and the titles and abstracts will be screened against the inclusion criteria before the full text of all potentially relevant studies will be examined. The data will be presented in tabular form, rating maps, and narrative summary.

RegistrationThis protocol had been pre-registered in Open Science Framework (OSF) Registries.[1]",Abanoub Riad; Julien Issa; Veronika Chuchmova; Esraa Gomaa; Andrea Pokorna; Jitka Klugarova; Miloslav Klugar,https://medrxiv.org/cgi/content/short/2021.01.22.21250326,https://medrxiv.org/cgi/content/short/2021.01.22.21250326,2021-01-26,2021-01-26,,True
213,Analysis of the number of deaths in Brazil between 2003 and 2020 and possible inferences about the COVID-19 pandemic and history of other diseases,"This work explores data on the number of deaths in Brazil since the beginning of the historical series of IBGE, 2003, together with data for the period 2015-2020 of the Transparency Portal. The graphs for total deaths, deaths from violence and deaths in hospitals are discussed. The relationship between them leads to conclusions about the real dimension of the effect of COVID-19 in Brazilian society during the year 2020 and its relative importance to other diseases that had a lesser impact. Hypotheses are also made about the number of deaths in future years.",Lilian P Sosman; Andres Reinaldo Rodriguez Papa,https://medrxiv.org/cgi/content/short/2021.01.23.21250374,https://medrxiv.org/cgi/content/short/2021.01.23.21250374,2021-01-26,2021-01-26,,True
214,Projected spread of COVID-19's second wave in South Africa under different levels of lockdown,"South Africa is currently experiencing a second wave of resurgence in COVID-19 infection. In this modelling study, we use a Bayesian compartmental model to project possible spread of the second wave of COVID-19 in South Africa under various levels of lockdown restrictions. Our model suggests that strict lockdown restrictions will have to be in place up to the end of March 2021 before cases can drop to levels observed, in September to early November 2020, after the first wave. On the one hand, extended lockdown restrictions have negative consequences - albeit effective, they are not sustainable over extended periods. On the other hand, short lockdown restrictions over a few weeks will not have a lasting effect on the spread of the disease. Lockdown restrictions need to be supplemented with increased rapid testing, palliative support for the vulnerable, and implementations of other non-pharmaceutical interventions (NPIs) such as mask mandate. These multifaceted approaches could help keep cases under control until vaccines are widely available.",Elisha B Are; Caroline B Colijn,https://medrxiv.org/cgi/content/short/2021.01.22.21250308,https://medrxiv.org/cgi/content/short/2021.01.22.21250308,2021-01-26,2021-01-26,,True
215,Estimating COVID-19 Cases on University Campuses Prior To Semester,"For many institutions of higher learning, the beginning of each semester is marked by a significant migration of young adults into the area. In the midst of the COVID19 pandemic, this presents an opportunity for active cases to be introduced into a community. Prior to the Fall 2020 semester, Colorado State University researchers combined student home locations with recent case counts compiled by the New York Times to assign a probability to each individual of arriving with COVID19. These probabilities were combined to estimate that there would be 7.8 new cases among the on-campus population. Comprehensive testing of arriving students revealed 7 new cases, which validated the approach. The procedure was repeated to explore what could happen if students had returned to campus after Fall break. The estimate of 48 cases corroborated the Universitys early decision to transition to fully remote learning after break.",Alex Fout; Jude Bayham; Margaret J Gutilla; Bailey K Fosdick; Heather Pidcoke; Michael Kirby; Peter Jan van Leeuwen; Chuck Anderson,https://medrxiv.org/cgi/content/short/2021.01.22.21250120,https://medrxiv.org/cgi/content/short/2021.01.22.21250120,2021-01-26,2021-01-26,,True
216,Preliminary Evidence on Long COVID in children,"There is increasing evidence that adult patients diagnosed with acute COVID-19 suffer from Long COVID initially described in Italy.

To date, data on Long COVID in children are lacking.

We assessed persistent symptoms in pediatric patients previously diagnosed with COVID-19. More than a half reported at least one persisting symptom even after 120 days since COVID-19, with 42.6% being impaired by these symptoms during daily activities. Symptoms like fatigue, muscle and joint pain, headache, insomnia, respiratory problems and palpitations were particularly frequent, as also described in adults.

The evidence that COVID-19 can have long-term impact children as well, including those with asymptomatic/paucisymptomatic COVID-19, highlight the need for pediatricians, mental health experts and policy makers of implementing measures to reduce impact of the pandemic on childs health.",danilo buonsenso; Daniel Munblit; Cristina De Rose; Dario Sinatti; Antonia Ricchiuto; Angelo Carfi; Piero Valentini,https://medrxiv.org/cgi/content/short/2021.01.23.21250375,https://medrxiv.org/cgi/content/short/2021.01.23.21250375,2021-01-26,2021-01-26,,True
217,Longevity of SARS-CoV-2 immune responses in haemodialysis patients and protection against reinfection,"BackgroundPatients with end stage kidney disease (ESKD) receiving in-centre haemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, ICHD patients frequently develop serological evidence of infection, even with asymptomatic disease. The aim of this study is to investigate the durability and functionality of immune responses to SARS-CoV-2 infection in ICHD patients.

MethodsThree hundred and fifty-six ICHD patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection. Patients were screened for nucleocapsid protein (anti-NP) and receptor binding domain (anti-RBD) antibodies. Patients who became seronegative at 6 months were investigated for SARS-CoV-2 specific T-cell responses.

ResultsOne hundred and twenty-nine (36.2%) patients had detectable antibody to anti-NP at Time 0, of which 127 (98.4%) also had detectable anti-RBD. At 6 months, of 111 patients tested, 71(64.0%) and 97 (87.4%) remained anti-NP and anti-RBD seropositive respectively, p<0.001. For patients who retained antibody, both anti-NP and anti-RBD levels reduced significantly after 6 months. Ten patients who were anti-NP and anti-RBD seropositive at Time 0, had no detectable antibody at 6 months; of which 8 were found to have SARS-CoV-2 antigen specific T cell responses.

Independent of antibody status at 6 months, patients with baseline positive SARS-CoV-2 serology were significantly less likely to have PCR confirmed infection over the following 6 months.

ConclusionsICHD patients mount durable immune responses 6 months post SARS-CoV-2 infection, with <3% of patients showing no evidence of humoral or cellular immunity. These immune responses are associated with a reduced risk of subsequent reinfection.

SIGNIFICANCE STATEMENTFollowing infection with SARS-CoV-2, patients with end stage kidney disease (ESKD) frequently develop serological evidence of infection, even with asymptomatic disease. Patients with ESKD receiving in-centre haemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. What is not known is how durable the serological responses in ESKD patients are or whether evidence of prior immune responses protect patients from reinfection. In this study of 356 ICHD patients, at 6 months following the detection of SARS-CoV-2 antibodies, fewer than 3% of patients lacked evidence of either humoral or cellular immunity. Furthermore, patients with serological evidence of infection had a significantly lower risk of being diagnosed with subsequent infection or  reinfection, suggesting functional immune protection.",Candice L Clarke; Maria Prendecki; Amrita Dhutia; Claire Edwards; Virginia Prout; Liz Lightstone; Eleanor Parker; Federica Marchesin; Megan Griffith; Rawya Charif; Graham Pickard; Alison Cox; Myra McClure; Richard Tedder; Paul Randell; Louise Greathead; Mary Guckian; Stephen P McAdoo; Peter Kelleher; Michelle Willicombe,https://medrxiv.org/cgi/content/short/2021.01.22.21249865,https://medrxiv.org/cgi/content/short/2021.01.22.21249865,2021-01-26,2021-01-26,,True
218,"Assessment of the knowledge, preferences and concern regarding the prospective COVID- 19 vaccine among adults residing in New Delhi, India-A cross-sectional study.","BackgroundUnderstanding the perception and concerns of people about COVID-19 vaccine in developing and populous country like India will help in understanding demand for the vaccine and further tailoring out public health information and education activities before the launch of the vaccine. The study was carried out to assess the present state of knowledge people have about the probable vaccine for COVID-19, to know the preferences of respondents about this vaccine and to learn the expectations and apprehensions of people about features of this prospective COVID-19 vaccine residing in the capital city of India.

MethodsThis cross-sectional study was conducted amongst the residents of Delhi, India from July-October 2020. Both offline and online interview method was used to collect date from 513 participants representing various occupational strata. Data was collected on socio demographic variable, vaccine acceptance and concerns regarding COVID-19 vaccine.

ResultsAmong the study population 79.5% said they will take the vaccine while 8.8% said they were not going to take the vaccine and remaining 11.7% had not yet decided about it. Most of them(78.8%),believed that vaccine would be available to public next year but at the same time half(50.1%) of them believe that it may not be in sufficient amount for everyone to get. More than 50% were willing to pay for the vaccine and 72% felt vaccine should first be given to health workers and high risk group.

ConclusionThe following study has helped to understand the percentage of people who are hesitant to take the vaccine and also the concerns regarding the vaccine. Also since half of the population is willing to pay for the vaccine, a strategical approach considering the various economical classes of people could be applied in a developing country like India.",Farzana Islam; Rashmi Agarwalla; Meely Panda; Yasir Alvi; Vishal Singh; Arup Debroy; Arindam Ray; Amruta Vadnerkar; Shraddha Uttekar,https://medrxiv.org/cgi/content/short/2021.01.23.21250164,https://medrxiv.org/cgi/content/short/2021.01.23.21250164,2021-01-26,2021-01-26,,True
219,Pooled Sample Testing for SARS-CoV-2,"We tested an operationally efficient way to pool samples on a rapid, point-of-care PCR device and examined the limit of detection of SARS-CoV-2 for various pool sizes. Pooled testing maintained testing performance similar to individual sample PCR testing, offering the potential for scalable rapid testing at lower cost with less supplies.",Bethany L Hyde; Ethan Berke; Prat Verma,https://medrxiv.org/cgi/content/short/2021.01.22.21250339,https://medrxiv.org/cgi/content/short/2021.01.22.21250339,2021-01-26,2021-01-26,,True
220,CovidArray: a microarray-based assay with high sensitivity for the detection of SARS-CoV-2 in nasopharyngeal swabs,"BackgroundA new coronavirus (SARS-CoV-2) caused the current Covid-19 epidemic. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is used as the gold standard for clinical detection of SARS-CoV-2. Under ideal conditions RT-qPCR Covid-19 assays have analytical sensitivity and specificity greater than 95%. However, when the sample panel is enlarged including asymptomatic individuals, the sensitivity decreases and false-negative are reported. Moreover, RT-qPCR requires up to 3-6 hours with most of the time involved in RNA extraction from swab samples.

MethodsWe introduce CovidArray, a microarray-based assay, to detect SARS-CoV-2 markers N1 and N2 in the nasopharyngeal swabs. The method is based on solid phase hybridization of fluorescently labelled amplicons upon RNA extraction and reverse transcription. This approach combines the physical-optical properties of the silicon substrate with the surface chemistry used to coat the substrate to obtain a diagnostic tool of great sensitivity. Furthermore, we used an innovative approach, RNAGEM, to extract and purify viral RNA in less than 15 minutes. To validate the CovidArray results, we exploited the high sensitivity of the droplet digital PCR (ddPCR) technique.

ResultWe correctly assigned 12 nasopharyngeal swabs, previously analyzed by RT-qPCR. Thanks to the CovidArray sensitivity that matches that of the ddPCR, we were able to identify a false-negative sample.

ConclusionsCovidArray is the first DNA microarray-based assay to detect viral genes in the swabs. Its high sensitivity and the innovative viral RNA extraction by RNAGEM allows to reduce both the amount of false negative results and the total analysis time to about 2 hours.",Francesco Damin; Silvia Galbiati; Stella Gagliardi; Cristina Cereda; Francesca Dragoni; Claudio Fenizia; Valeria Savasi; Laura Sola; Marcella Chiari,https://medrxiv.org/cgi/content/short/2021.01.21.21250281,https://medrxiv.org/cgi/content/short/2021.01.21.21250281,2021-01-26,2021-01-26,,True
221,"Chinese medicine (Q-14) in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open label, Randomised Controlled Trial","OBJECTIVETo evaluate the efficacy and safety of Chinese medicine (Q-14) plus standard care compared with standard care alone in adult with coronavirus disease 2019 (COVID-19).

Study DESIGNSingle-center, open label, randomised controlled trial.

SETTINGWuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020.

PARTICIPANTS204 patients with laboratory confirmed COVID-19 were randomised in to treatment group and control group, which was 102 patients each group.

INTERVENTIONSIn treatment group, Q-14 was administrated at 10g (granules), twice daily for 14 days and plus standard care. In control group, patients were given standard care alone for 14 days.

MAIN OUTCOME MEASUREThe primary outcome was conversion time of SARS-CoV-2 viral assay. Adverse events were analyzed in the safety population.

RESULTSAmong 204 patients, 195 were analyzed according to the intention to treat principle. There were 149 patients (71 vs. 78 in treatment group and control group respectively) turning to negative via SARS-CoV-2 viral assay. No statistically significance showed in conversion time between treatment group and control group (FAS: Median (IQR): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank: 67.92 vs. 81.44; P=0.051.). Time to recovery of fever was shorter in treatment group as compared in control group. The disappearance rate of symptom in cough, fatigue, chest discomfort was significantly higher in treatment group. In chest computed tomography (Chest CT) examinations, overall evaluation of chest CT examination after treatment compared with baseline showed more patients improved in treatment group .There were no significant differences in the other outcomes.

CONCLUSIONAdministration of Q-14 on standard care for COVID-19 was useful for improvement of symptoms (such as fever, cough, fatigue and chest discomfort), while did not result in a significantly higher probability of negative conversion of SARS-CoV-2 viral assay. No serious adverse events were reported.

TRIAL REGISTRATIONChiCTR2000030288",Jia Liu; Wei Yang; Yue Liu; Cheng Lv; Lianguo Ruan; Chen Zhao; Ruili Huo; Xin Shen; Qing Miao; Wenliang Lv; Hao Li; Huaxin Shi; Lijie Hu; Zhixu Yang; Li Zhang; Bing Wang; Guoju Dong; Yongyue Xian; Bin Li; Zhenqi Zhou; Chunyan Xu; Yingying Chen; Yongjun Bian; Jing Guo; Jinliang Yang; Jian Wang; Wensheng Qi; Suping Chen; Yang Chen; Bei Yan; Wei Wang; Jing Li; Xiaolei Xie; Ming Xu; Jianxin Jiang; Gang Wang; Xiaodong Cong; Haoning Zhu; Jiaheng Shi; Luxing Leng; Dongxu Li; Lanping Guo; Luqi Huang,https://medrxiv.org/cgi/content/short/2021.01.25.21249417,https://medrxiv.org/cgi/content/short/2021.01.25.21249417,2021-01-26,2021-01-26,,True
222,Two original observations concerning bacterial infections in COVID-19 patients hospitalized in intensive care units during the first wave of the epidemic in France,"Among 197 COVID-19 patients hospitalized in ICU, 88 (44.7%) experienced at least one bacterial infection, with pneumonia (39.1%) and bloodstream infections (15,7%) being the most frequent. Unusual findings include frequent suspicion of bacterial translocations originating from the digestive tract as well as bacterial persistence in the lungs despite adequate therapy.",Camille d'Humieres; Juliette Patrier; Brice Lortat-Jacob; Alexy Tran-dinh; Lotfi Chemali; Naouale Maataoui; Emilie Rondinaud; Etienne Ruppe; Charles Burdet; Stephane Ruckly; Philippe Montravers; Jean-Francois Timsit; Laurence Armand-Lefevre,https://medrxiv.org/cgi/content/short/2021.01.22.21250287,https://medrxiv.org/cgi/content/short/2021.01.22.21250287,2021-01-26,2021-01-26,,True
223,Ultrasensitive measurement of both SARS-CoV2 RNA and serology from saliva,"Tests for COVID-19 generally measure SARS-CoV2 viral RNA from nasal swabs or antibodies against the virus from blood. It has been shown, however, that both viral particles and antibodies against those particles are present in saliva, which is more accessible than both swabs and blood. We present methods for highly sensitive measurements of both viral RNA and serology from the same saliva sample. We developed an efficient saliva RNA extraction method and combined it with an ultrasensitive serology test based on Single Molecule Array (Simoa) technology. We apply our test to the saliva of patients who presented to the hospital with COVID-19 symptoms, some of whom tested positive with a conventional RT-qPCR nasopharyngeal swab test. We demonstrate that combining viral RNA detection by RT-qPCR with serology identifies more patients as infected than either method alone. Our results suggest the utility of combining viral RNA and serology testing from saliva, a single easily accessible biofluid.",Dmitry Ter-Ovanesyan; Tal Gilboa; Roey Lazarovits; Alexandra Rosenthal; Xu G Yu; Jonathan Z Li; George M Church; David R Walt,https://medrxiv.org/cgi/content/short/2021.01.25.21249679,https://medrxiv.org/cgi/content/short/2021.01.25.21249679,2021-01-26,2021-01-26,,True
224,SARS-CoV-2 RNA screening in routine pathology specimens,"Virus detection methods are important to cope with the SARS-CoV-2 pandemics. Apart from the lung, SARS-CoV-2 was detected in multiple organs in severe cases. Less is known on organ tropism in patients developing mild or no symptoms, and some of such patients might be missed in symptom-indicated swab testing.

Here we tested and validated several approaches and selected the most reliable RT-PCR protocol for the detection of SARS-CoV-2 RNA in patients routine diagnostic formalin-fixed and paraffin-embedded (FFPE) specimens available in pathology, to assess a) organ tropism in samples from COVID-19-positive patients, b) unrecognized cases in selected tissues from negative or not-tested patients during a pandemic peak, and c) retrospectively, pre-pandemic lung samples.

We identified SARS-CoV-2 RNA in four samples from confirmed COVID-19 patients, in two gastric biopsies, one colon resection, and one pleural effusion specimen, while all other specimens, particularly from patients with mild COVID-19 disease course, were negative. In the pandemic peak cohort, we identified one previously unrecognized COVID-19 case in tonsillectomy samples. All pre-pandemic lung samples were negative.

In conclusion, SARS-CoV-2 RNA detection in FFPE pathology specimens can potentially improve surveillance of COVID-19, allow retrospective studies, and advance our understanding of SARS-CoV-2 organ tropism and effects.",Saskia E von Stillfried; Sophia Villwock; Roman D Buelow; Sonja Djudjaj; Eva M Buhl; Angela Maurer; Nadina Ortiz-Bruechle; Peter Celec; Barbara M Klinkhammer; Dickson WL Wong; Claudio Cacchi; Till Braunschweig; Ruth Knuechel; Edgar Dahl; Peter Boor,https://medrxiv.org/cgi/content/short/2021.01.25.21250082,https://medrxiv.org/cgi/content/short/2021.01.25.21250082,2021-01-26,2021-01-26,,True
225,"Genomic Epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul, Brazil","Brazil is the third country most affected by Covid-19 pandemic. In spite of this, viral evolution in municipality resolution is poorly understood in Brazil and it is crucial to understand the epidemiology of viral spread. We identified four main circulating lineages in Esteio (Southern Brazil) and their relationship with global, national and regional lineages using phylogenetics and phylodynamics inferences from 21 SARS-CoV-2 genome sequences. We provided a comprehensive view of viral mutations from a time- and age-representative sampling from May to October 2020, in Esteio (RS, Brazil), highlighting two frequent mutations in Spike glycoprotein (D614G and V1176F), an emergent mutation (E484K) in Spike Receptor Binding Domain (RBD) characteristic of the South African lineage B.1.351, and the adjacent replacement of 2 amino acids in Nucleocapsid phosphoprotein (R203K and G204R). A significant viral diversity was evidenced with the identification of 80 different SNPs. The E484K replacement was found in two genomes (9.5%) from samples obtained in mid-October, which is to our best knowledge the earliest description of E484K harboring SARS-CoV-2 in South Brazil. This mutation identified in a small municipality from the RS state demonstrates that it was probably widely distributed in the Brazilian territory, but went unnoticed so far by the lack of genomic surveillance in Brazil. The introduction of E484K mutants shows temporal correlation with later increases in new cases in our state. Importantly, since it has been associated with immune evasion and enhanced interaction with hACE-2, lineages containing this substitution must be the subject of intense surveillance. Our date demonstrates multiple introductions of the most prevalent lineages (B.1.1.33 and B.1.1.248) and the major role of community transmission in viral spreading and the establishment of Brazilian lineages. This represents an important contribution to the epidemiology of SARS-CoV-2.",Vinicius Bonetti Franceschi; Gabriel Dickin Caldana; Amanda de Menezes Mayer; Gabriela Bettella Cybis; Carla Andretta Moreira Neves; Patricia Aline Grohs Ferrareze; Meriane Demoliner; Paula Rodrigues de Almeida; Juliana Schons Gularte; Alana Witt Hansen; Matheus Nunes Weber; Juliane Deise Fleck; Ricardo Ariel Zimerman; Livia Kmetzsch; Fernando Rosado Spilki; Claudia Elizabeth Thompson,https://medrxiv.org/cgi/content/short/2021.01.21.21249906,https://medrxiv.org/cgi/content/short/2021.01.21.21249906,2021-01-26,2021-01-26,,True
226,Magnitude and timing of the antiviral response determine SARS-CoV-2 replication early in infection,"The interferon response is a potent antiviral defense mechanism, but its effectiveness depends on its timing relative to viral replication. Here, we report viral replication and host response kinetics in patients at the start of SARS-CoV-2 infection and explore the impact of these kinetics experimentally. In both longitudinal patient nasopharyngeal samples and airway epithelial organoids, we found that SARS-CoV-2 initially replicated exponentially with a doubling time of [~]6hr, and induced interferon stimulated genes (ISGs) with delayed timing relative to viral replication. Prior exposure to rhinovirus increased ISG levels and blocked SARS-CoV-2 replication. Conversely, inhibiting ISG induction abrogated interference by rhinovirus and enhanced SARS-CoV-2 replication rate. These results demonstrate the importance of initial interferon-mediated defenses in determining the extent to which SARS-CoV-2 can replicate at the start of infection and indicate that biological variables that alter the airway interferon response, including heterologous induction of innate immunity by other viruses, could profoundly impact SARS-CoV-2 susceptibility and transmission.",Nagarjuna R. Cheemarla; Timothy A. Watkins; Valia T. Mihaylova; Bao Wang; Dejian Zhao; Guilin Wang; Marie L. Landry; Ellen F. Foxman,https://medrxiv.org/cgi/content/short/2021.01.22.21249812,https://medrxiv.org/cgi/content/short/2021.01.22.21249812,2021-01-26,2021-01-26,,True
227,Dynamic change and clinical relevance of post-infectious SARS-CoV-2 antibody responses.,"BackgroundAlthough reports suggest that most individuals with COVID-19 develop detectable antibodies post infection, the kinetics, durability, and relative differences between IgM and IgG responses beyond the first few weeks after symptom onset remain poorly understood.

MethodsWithin a large, well-phenotyped, diverse, prospective cohort of subjects with and without SARS-CoV-2 PCR-confirmed infection and historical controls derived from cohorts with high prevalence of viral coinfections and samples taken during prior flu seasons, we measured SARS-CoV-2 serological responses (both IgG and IgM) using commercially available assays. We calculated sensitivity and specificity, relationship with disease severity and mapped the kinetics of antibody responses over time using generalised additive models.

ResultsWe analysed 1,001 samples from 752 subjects, 327 with confirmed SARS-CoV-2 (29.7% with severe disease) spanning a period of 90 days from symptom onset. Sensitivity was lower (44.1-47.1%) early (<10 days) after symptom onset but increased to >80% after 10 days. IgM positivity increased earlier than IgG-targeted assays but positivity peaked between day 32 and 38 post onset of symptoms and declined thereafter, a dynamic that was confirmed when antibody levels were analysed, with more rapid decline observed with IgM. Early (<10 days) IgM but not IgG levels were significantly higher in those who subsequently developed severe disease (signal / cut-off 4.20 (0.75-17.93) versus 1.07 (0.21-5.46), P=0.048).

ConclusionsThis study suggests that post-infectious antibody responses in those with confirmed COVID-19 begin to decline relatively early post infection and suggests a potential role for higher IgM levels early in infection predicting subsequent disease severity.",Patrick WG Mallon; Willard Tinago; Alejandro Garcia Leon; Kathleen McCann; Grace Kenny; Padraig McGettrick; Sandra Green; Rosanna Inzitiari; Aoife Cotter; Stefano Savinelli; Eoin R Feeney; Peter Doran,https://medrxiv.org/cgi/content/short/2021.01.24.20248381,https://medrxiv.org/cgi/content/short/2021.01.24.20248381,2021-01-26,2021-01-26,,True
228,A High-throughput Microsphere-based Immunoassay of Anti-SARS-CoV-2 IgM Testing for COVID-19 Diagnostics,"The pandemic of novel coronavirus disease COVID-19 is rapidly expanding across the world. A positive result of antibody tests suggests that the individual has potentially been exposed to SARS-CoV-2, thus allowing to identify asymptomatic infections and determine the seroprevalence in a given population. The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgM antibody detection on the Luminex MAGPIX platform. Clinical agreement studies were performed in 42 COVID-19 patient serum samples and 162 negative donor serum/plasma samples. Positive percent agreement (PPA) was 42.86% (95% CI: 9.90% to 81.59%), 71.43% (95% CI: 29.04% to 96.33%), and 28.57% (95% CI: 13.22% to 48.67%) for samples collected on 0-7 days, 8-14 days, and 2-8 weeks from symptom onset, respectively. Negative Percent Agreement (NPA) was 97.53% (95% CI: 93.80% to 99.32%). There was no cross-reactivity with the SARS-CoV-2 IgG antibody Hemoglobin (200 mg/dL), bilirubin (2 mg/dL), triglyceride (250 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. In conclusion, an anti-SARS-CoV-2 IgM antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up the anti-SARS-CoV-2 IgM testing.",Dayu Zhang; Tianyang Xu; Eric Chu; Aiguo Zhang; Jinwei Du; Michael Sha,https://medrxiv.org/cgi/content/short/2021.01.22.20249050,https://medrxiv.org/cgi/content/short/2021.01.22.20249050,2021-01-26,2021-01-26,,True
229,Assessment of The Relationship of REMS and MEWS Scores with Prognosis in Patients Diagnosed with Covid-19 Admitted to the Emergency Department,"AimWith the rapid and global increase in COVID-19 cases, it is becoming important to identify patients with a risk of mortality and patients that need hospitalization. The aim of this study is to try to predict the mortality rate of COVID patients admitted to the emergency department with rapid scoring systems such as REMS and MEWS and their clinical termination in the emergency department at the end of the first month.

MethodWe have designed this study to be a single-centered, prospective and an observational study. A total of 392 patients diagnosed with COVID-19, who were admitted to the emergency department in a 1-month period, were included in the study. REMS and MEWS scores were calculated for each case. Demographic data of patients, clinical outcomes such as discharge, service hospitalization, ICU hospitalization, and first-month mortality were analysed based on these scores. ROC curves were analysed to determine the cut-off value with the help of which REMS and MEWS scores can predict 1-month mortality and hospitalization.

ResultsOut of the 392 patients included in the study, the 43.4% (n=170) were female and 56.6% (n=222) were male. The average age of our patients was 48.98{+/-}19.49 years. The 1-month mortality rate of our patients was 4.3% (n=17). At the end of the first month, the mortality of patients with a comorbid disease was higher than those who did not (p<0.01). The average of the REMS score was higher in patients with an average mortality of (7.24{+/-}3.77) than in patients without it (2.87{+/-}3.09), and there was a statistically significant difference between them (p<0.01). Similarly, the average of the MEWS score was higher in patients with an average mortality of (2.76{+/-}1.86) than in patients without it (1.65{+/-}1.35), and there was a statistically significant difference (p<0.01). The REMS score of patients admitted to the service was higher than that of patients discharged (p<0.01). When the REMS score was determined as 3 cut-off value in ROC analysis, service hospitalization was 5 times higher in patients with a REMS score of 3 and above than in those who were discharged (OR: 1:5.022 95% CI: 3.088-8.168)). REMS and MEWS scores were also higher in ICU patients than in discharged patients (p<0.01).

ConclusionIn predicting the 1-month mortality of ER patients diagnosed with COVID-19, REMS and MEWS scoring systems can be useful and guiding in determining the patients who need hospitalization for emergency physicians. The use of these scoring systems in emergency departments can help predict the clinical outcomes of patients at the time of the initial evaluation, and can also be a practical method of predicting the prognosis of the patients.",Behlul Bas; Mucahit Senturk; Tugce Nur Burnaz; Kubilay Timur; Asim Kalkan,https://medrxiv.org/cgi/content/short/2021.01.24.21250384,https://medrxiv.org/cgi/content/short/2021.01.24.21250384,2021-01-26,2021-01-26,,True
230,"Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates","We aimed to estimate, albeit crudely and provisionally, national, regional, and global proportions of respective populations that have been infected with SARS-CoV-2, and to assess infection morbidity and mortality rates, factoring both documented and undocumented infections. The estimates were generated by applying mathematical models to 159 countries and territories. The percentage of the worlds population that has been infected as of 31 December 2020 was estimated at 12.56% (95% CI: 11.17-14.05%). It was lowest in the Western Pacific Region at 0.66% (95% CI: 0.59-0.75%) and highest in the Americas at 41.92% (95% CI: 37.95-46.09%). The global infection fatality rate was 10.73 (95% CI: 10.21-11.29) per 10,000 infections. Globally per 1,000 infections, the infection acute-care bed hospitalization rate was 19.22 (95% CI: 18.73-19.51), the infection ICU bed hospitalization rate was 4.14 (95% CI: 4.10-4.18), the infection severity rate was 6.27 (95% CI: 6.18-6.37), and the infection criticality rate was 2.26 (95% CI: 2.24-2.28). If left unchecked with no interventions, the pandemic would eventually cause 8.18 million (95% CI: 7.30-9.18) deaths, 163.67 million (95% CI: 148.12-179.51) acute-care hospitalizations, 33.01 million (95% CI: 30.52-35.70) ICU hospitalizations, 50.23 million (95% CI: 46.24-54.67) severe cases, and 17.62 million (95% CI: 16.36-18.97) critical cases. The global population remains far below the herd immunity threshold and at risk of repeated waves of infection. Global epidemiology reveals immense regional variation in infection exposure and morbidity and mortality rates.",Houssein H. Ayoub; Ghina R. Mumtaz; Shaheen Seedat; Monia Makhoul; Hiam Chemaitelly; Laith J Abu-Raddad,https://medrxiv.org/cgi/content/short/2021.01.24.21250396,https://medrxiv.org/cgi/content/short/2021.01.24.21250396,2021-01-26,2021-01-26,,True
231,"Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million patients using OpenSAFELY.","BackgroundOn December 8th 2020, NHS England administered the first COVID-19 vaccination as part of an ambitious vaccination programme during a global health emergency.

AimsTo develop a framework for detailed near-real-time monitoring of COVID-19 vaccine roll-out; to describe trends and variation in coverage by geographic area, and between key clinical and demographic patient groups.

MethodsWorking on behalf of NHS England we used routine clinical data from 23.4 million patients to conduct a retrospective cohort study of comprehensive electronic health record data in NHS England, using the OpenSAFELY-TPP platform which covers approximately 40% of the general population in England with weekly data updates. We developed algorithms to identify key demographic and clinical sub-groups within this population and generated descriptive statistics on proportion of eligible patients receiving the vaccine among key Joint Committee on Vaccination and Immunisation (JCVI) target groups.

ResultsBetween December 8th and January 13th 961,580 people out of 23.4m in our dataset received a COVID-19 vaccine. Of 1,160,062 patients aged 80 or over and not living in a care home (currently targeted by JCVI) 476,375 had been vaccinated in total (41.1%). We observed a substantial divergence in vaccination by ethnicity within this group (White 42.5% vaccinated, Black 20.5%) and across rankings of deprivation (least deprived 44.7%, most deprived 37.9%). Patients with pre-existing medical conditions were equally likely, or more likely, to have received a vaccine across most co-morbidity groups with two exceptions: severe mental illness (30.3% vaccinated) and learning disability (28.1%). We identify substantial variation in vaccination among the over-80s between Sustainability and Transformation Partnerships (STPs; Range 12%-74%); lower vaccination rates among ethnic minority and deprived groups was observed in most but not all STPs. In the 70-79 age cohort 74,108 people (3.6%) had been vaccinated. 378,921 vaccine recipients under 70 and not identifiably resident in a care home were presumed to be health or social care workers; 32,174 recipients were identified as older aged care home residents (33.2% coverage). Of all those vaccinated, 169,472 had received a second dose (17.6%).

ConclusionsThe NHS in England has rapidly delivered mass vaccination. We were able to deploy a data monitoring framework across small clinical subgroups using linked patient-level NHS data on 23.4 million people with very short delays from vaccine administration to completed analysis. Targeted activity may be needed to address lower vaccination rates observed among certain key groups: ethnic minorities, people living in areas of higher deprivation, and those with severe mental illness or learning disabilities. However we note that this data is only from the first preliminary weeks of the vaccination programme. Variation in vaccination coverage between groups and regions will have many complex drivers, the figures presented in this manuscript require thoughtful interpretation to support a rapidly evolving NHS vaccination campaign; we are sharing local level data with national and regional NHS teams on request.",Brian MacKenna; Helen J Curtis; Caroline E Morton; Peter Inglesby; Alex J Walker; Jessica Morley; Amir Mehrkar; Sebastian CJ Bacon; George Hickman; Christopher Bates; Richard Croker; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan Bhaskaran; Anna Schultze; Christopher T Rentsch; Elizabeth J Williamson; William J Hulme; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; Ian J Douglas; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre,https://medrxiv.org/cgi/content/short/2021.01.25.21250356,https://medrxiv.org/cgi/content/short/2021.01.25.21250356,2021-01-26,2021-01-26,,True
232,Factors influencing nursing students' intention to accept COVID-19 vaccination - A pooled analysis of seven countries,"Experiencing the second wave of COVID-19 pandemic, high vaccination coverage by a safe and effective vaccine globally would be a great achievement. Acceptance of vaccination by healthcare students is an important issue as they have a key role as future professionals in educating patients, informing and guiding them to the right clinical decision. The aim of this study was to explore the intention of nursing students to get vaccinated for SARS-CoV-2 infection and the factors acting either as motivators or barriers towards vaccination. A multicenter cross-sectional study was conducted in 7 countries (Greece, Albania, Cyprus, Spain, Italy, Czech Republic and Kosovo) through a web survey. In total 2249 undergraduate nursing students participated. Forty three point eight percent of students agreed to accept a safe and effective COVID-19 vaccine, while the acceptance was higher among Italian students. The factors for intention to get vaccinated were male gender (p=0.008), no working experience in healthcare facilities during the pandemic (p=0.001), vaccination for influenza in 2019 and 2020 (p<0.001), trust in doctors (p<0.001), governments and experts (p=0.012), high level of knowledge (p<0.001) and fear of COVID-19 (p<0.001). Understanding of factors that influence students decision to accept COVID-19 vaccination could increase the acceptance rate contributing to a management of the pandemic.

HighlightsO_LILess than half of the sample intended to accept COVID-19 vaccination
C_LIO_LIFactors that influenced nursing students to get vaccinated against COVID-19 were male gender, no working experience in healthcare facilities during the pandemic, vaccination for influenza in 2019 and 2020, trust in doctors, governments and experts, high level of knowledge and fear of COVID-19.
C_LI",Evridiki Patelarou; Petros Galanis; Enkeleint A Mechili; Agathi Argyriadi; Alexandros Argyriadis; Evanthia Asimakopoulou; Stiliana Brokaj; Jorgjia Bucaj; Juan Manuel Carmona-Torres; Ana Isabel Cobo-Cuenca; Jakub Dolezel; Stefano Finotto; Darja Jarosov; Athina Kalokairinou; Daniela Mecugni; Velide Pulomenaj; Aurela Saliaj; Idriz Sopjani; Majlinda Zahaj; Athina Patelarou,https://medrxiv.org/cgi/content/short/2021.01.22.21250321,https://medrxiv.org/cgi/content/short/2021.01.22.21250321,2021-01-26,2021-01-26,,True
233,Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD) have increased levels of plasma inflammatory mediators upregulated in severe COVID-19,"BackgroundRespiratory diseases such as chronic obstructive pulmonary disease (COPD) have been associated with increased risk of severe SARS-CoV-2 infection, but the mechanisms and putative immune pathways are unclear. Besides, increased levels of several immune mediators in patients with severe coronavirus disease 19 (COVID-19) have been reported.

ObjectiveTo perform an immunoproteomic profiling of dysregulated plasma proteins in patients with asthma and COPD and to evaluate their relationship with biomarkers of severe COVID-19.

Methods92 protein biomarkers were quantified in 315 plasma samples from adult subjects (age 40-90 years) including 118 asthmatics, 99 COPD patients and 98 healthy controls, that have been recruited in two reference pneumology clinics in Colombia before the beginning of the COVID-19 pandemic.

ResultsForty-one plasma proteins showed differences between patients and controls. Asthmatic patients have increased levels in IL-6 and CCL3 while COPD patients have a broader systemic inflammatory dysregulation driven by HGF, OPG, and several chemokines (CXCL9, CXCL10, CXCL11, CX3CL1, CXCL1, MCP-3, MCP-4, CCL3, CCL4 and CCL11). Functional annotation revealed their enrichment in chemokine signaling pathways related with response to viral infections. Some of these proteins were found up-regulated upon SARS-Cov-2 infection of Calu-3 cells. Also, HPG, CXCL9, CXCL10, IL-6, MCP-3, TNF and EN-RAGE have been found increased in patients with severe COVID-19. HGF, the most significant protein in this study as well as its correlated proteins could be associated with the increased risk of severe COVID-19 in COPD patients.

ConclusionsAsthma and COPD patients have altered plasma levels of proteins that have been found associated with increased risk of severe COVID-19. The reasons for sharing these profiles with this infection are unknown, but our study suggest that adult patients with asthma and COPD have a systemic dysregulation in chemokine networks that could make them more susceptible to severe COVID-19.",Nathalie Acevedo; Jose Miguel Escamilla-Gil; Hector Espinoza; Ronald Regino; Jonathan Ramirez; Lucila Florez De Arco; Rodolfo Dennis; Carlos Torres-Duque; Luis Caraballo,https://medrxiv.org/cgi/content/short/2021.01.23.21250370,https://medrxiv.org/cgi/content/short/2021.01.23.21250370,2021-01-26,2021-01-26,,True
234,Contamination of air and surfaces in workplaces with SARS-CoV-2 virus: a systematic review,"ObjectivesThis systematic review aimed to evaluate the evidence for air and surface contamination of workplace environments with SARS-CoV-2 RNA and the quality of the methods used to identify actions necessary to improve the quality of the data.

MethodsWe searched Web of Science and Google Scholar until 24th December 2020 for relevant articles and extracted data on methodology and results.

ResultsThe vast majority of data come from healthcare settings, with typically around 6 % of samples having detectable concentrations of SARS-CoV-2 RNA and almost none of the samples collected had viable virus. There were a wide variety of methods used to measure airborne virus, although surface sampling was generally undertaken using nylon flocked swabs. Overall, the quality of the measurements was poor. Only a small number of studies reported the airborne concentration of SARS-CoV-2 virus RNA, mostly just reporting the detectable concentration values without reference to the detection limit. Imputing the geometric mean air concentration assuming the limit of detection was the lowest reported value, suggests typical concentrations in health care settings may be around 0.01 SARS-CoV-2 virus RNA copies/m3. Data on surface virus loading per unit area were mostly unavailable.

ConclusionThe reliability of the reported data is uncertain. The methods used for measuring SARS-CoV-2 and other respiratory viruses in work environments should be standardised to facilitate more consistent interpretation of contamination and to help reliably estimate worker exposure.

Key messagesO_LIWhat is already known about this subject?
O_LILow level contamination of air and surfaces in hospitals with SARS-CoV-2 RNA have been reported during the Covid-19 pandemic.
C_LIO_LILimited data have published from non-healthcare settings.
C_LI
C_LIO_LIWhat are the new findings?
O_LITypically, around 6% of air and surface samples in hospitals were positive for SARS-COV-2 RNA, although there is very limited data for non-healthcare settings.
C_LIO_LIThe quality of the available measurement studies is generally poor, with little consistency in the sampling and analytical methods used.
C_LIO_LIFew studies report the concentration of SARS-CoV-2 in air or as surface loading of virus RNA, and very few studies have reported culture of the virus.
C_LIO_LIThe best estimate of typical air concentrations in health care settings is around 0.01 SARS-CoV-2 virus RNA copies/m3
C_LI
C_LIO_LIHow might this impact on policy or clinical practice in the foreseeable future?
O_LIThere should be concerted efforts to standardise the methods used for measuring SARS-CoV-2 and other respiratory viruses in work environments.
C_LI
C_LI",John Cherrie; Mark Cherrie; Alice Davis; David Holmes; Sean Semple; Susanne Steinle; Ewan MacDonald; Ginny Moore; Miranda Loh,https://medrxiv.org/cgi/content/short/2021.01.25.21250233,https://medrxiv.org/cgi/content/short/2021.01.25.21250233,2021-01-26,2021-01-26,,True
235,Impulse dispersion of aerosols during playing wind instruments,"Musical activities especially singing and playing wind instruments have been singled out as potentially high-risk activities for transmission of SARS CoV-2, because of a higher rate of aerosol production and emission. Playing wind instruments can produce condensation water, droplets of saliva, and aerosol particles, which hover and convectional spread in the environmental air and can be potentially infectious.

The aim of this study is to investigate the primary impulse dispersion of aerosols during playing different wind instruments in comparison to breathing and speaking. Nine professional musicians (3 trumpeters, 3 cross flutists and 3 clarinetists) of the Bavarian Symphony Orchestra performed the main theme of Ludwig van Beethoven s 9th symphony, 4th movement in different pitches and loudness. Thereby, the inhaled air volume was marked with small aerosol particles produced with a commercial e-cigarette. The expelled aerosol cloud was recorded by cameras from different perspectives. Afterwards, the dimensions and dynamics of the aerosol cloud was measured by segmenting the video footage at every time point.

Overall, the cross flutes produced the largest dispersion at the end of task of up to maximum distances of 1.88 m in front direction. Thereby it was observed an expulsion of aerosol in different directions: upwards and downwards at the mouthpiece, at the end of the instrument and along the cross flute at the key plane. In comparison, the maximum impulse dispersion generated by the trumpets and clarinets were lower in frontal and lateral direction (1.2 m and 1.0 m in front-direction). The expulsion to the sides was also lower. Consequently, a distance of 3 m to the front and to the sides of 2 m for the cross flutes in an orchestral formation is proposed, for trumpets and clarinets a safety distance of 2 m to the front and 1.5 m between instrumentalists are recommendable.",Sophia Gantner; Matthias Echternach; Reinhard Veltrup; Caroline Westphalen; Marie Christine Koeberlein; Liudmila Kuranova; Gregor Peters; Bernhard Jakubass; Tobias Benthaus; Michael Doellinger; Stefan Kniesburges,https://medrxiv.org/cgi/content/short/2021.01.25.20248984,https://medrxiv.org/cgi/content/short/2021.01.25.20248984,2021-01-26,2021-01-26,,True
236,Novel COVID-19 phenotype definitions reveal phenotypically distinct patterns of genetic association and protective effects,"INTRODUCTION PARAGRAPHMultiple large COVID-19 genome-wide association studies (GWAS) have identified reproducible genetic associations indicating that some infection susceptibility and severity risk is heritable.1-5 Most of these studies ascertained COVID-19 cases in medical clinics and hospitals, which can lead to an overrepresentation of cases with severe outcomes, such as hospitalization, intensive care unit admission, or ventilation. Here, we demonstrate the utility and validity of deep phenotyping with self-reported outcomes in a population with a large proportion of mild and subclinical cases. Using these data, we defined eight different phenotypes related to COVID-19 outcomes: four that align with previously studied COVID-19 definitions and four novel definitions that focus on susceptibility given exposure, mild clinical manifestations, and an aggregate score of symptom severity. We assessed replication of 13 previously identified COVID-19 genetic associations with all eight phenotypes and found distinct patterns of association, most notably related to the chr3/SLC6A20/LZTFL1 and chr9/ABO regions. We then performed a discovery GWAS, which suggested some novel phenotypes may better capture protective associations and also identified a novel association in chr11/GALNT18 that reproduced in two fully independent populations.",Genevieve H.L. Roberts; Raghavendran Partha; Brooke Rhead; Spencer C. Knight; Danny S. Park; Marie V. Coignet; Miao Zhang; Nathan Berkowitz; David A. Turrisini; Michael Gaddis; Shannon R. McCurdy; Milos Pavlovic; Luong Ruiz; Yambazi Banda; Ke Bi; Robert Burton; Marjan Champine; Ross Curtis; Karen Delgado; Abby Drokhlyansky; Ashley Elrick; Cat Foo; Jialiang Gu; Heather Harris; Shea King; Christine Maldonado; Evan McCartney-Melstad; Patty Miller; Keith Noto; Jingwen Pei; Jenna Petersen; Chodon Sass; Alisa Sedghifar; Andrey Smelter; Sarah South; Barry Starr; Cecily Vaughn; Yong Wang; Asher K. Haug Baltzell; Harendra Guturu; Ahna R. Girshick; Kristin A. Rand; Eurie L. Hong; Catherine A. Ball,https://medrxiv.org/cgi/content/short/2021.01.24.21250324,https://medrxiv.org/cgi/content/short/2021.01.24.21250324,2021-01-26,2021-01-26,,True
237,Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis,"BackgroundSeveral studies have reported that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can directly infect endothelial cells, and endothelial dysfunction is often found in severe cases of coronavirus disease 2019 (COVID-19). To better understand the pathological mechanisms underlying endothelial dysfunction in COVID-19-associated coagulopathy, we conducted a systematic review and meta-analysis to assess biomarkers of endothelial cells in patients with COVID-19.

MethodsA literature search was conducted on online databases for observational studies evaluating biomarkers of endothelial dysfunction and composite poor outcomes in COVID-19 patients.

ResultsA total of 1187 patients from 17 studies were included in this analysis. The estimated pooled means for von Willebrand Factor (VWF) antigen levels in COVID-19 patients was higher compared to healthy control (306.42 [95% confidence interval (CI) 291.37-321.48], p<0.001; I2:86%), with the highest VWF antigen levels was found in deceased COVID-19 patients (448.57 [95% CI 407.20-489.93], p<0.001; I2:0%). Meta-analysis showed that higher plasma levels of VWF antigen, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 antigen (PAI-1) antigen, and soluble thrombomodulin (sTM) were associated with composite poor outcome in COVID-19 patients ([standardized mean difference (SMD) 0.74 [0.33-1.16], p<0.001; I2:80.4%], [SMD 0.55 [0.19-0.92], p=0.003; I2:6.4%], [SMD 0.33 [0.04-0.62], p=0.025; I2:7.9%], and [SMD 0.55 [0.10-0.99], p=0.015; I2:23.6%], respectively).

ConclusionThe estimated pooled means shows increased levels of VWF antigen in COVID-19 patients. Several biomarkers of endothelial dysfunction, including VFW antigen, t-PA, PAI-1, and sTM, are significantly associated with increased composite poor outcome in patients with COVID-19.

PROSPERO registration numberCRD42021228821",Andrianto Andrianto; Makhyan Jibril Al-Farabi; Ricardo Adrian Nugraha; Bagas Adhimurda Marsudi; Yusuf Azmi,https://medrxiv.org/cgi/content/short/2021.01.24.21250389,https://medrxiv.org/cgi/content/short/2021.01.24.21250389,2021-01-26,2021-01-26,,True
238,Non-Congruent SARS-CoV-2 Waves in England,"Examination of the chronology, location and size of waves of SARS-CoV-2 infection across England could shed light on the inter-play between the 1st and the 2nd Waves. From mid-October onwards such an analysis becomes increasingly difficult due to the emergence of a new strain (VOC-202012/01) and in light of the differential implementation of lockdown measures and tiers. Therefore, we sought to examine trends and correlations in virus prevalence and covid-related deaths spanning the start of the UK pandemic in March 2020 through to early November 2020 - i.e., including the first growth period of the 2nd Wave. We found striking regional relationships between the 1st and the 2nd Wave that are difficult to explain other than by involving some role for changing levels of immunity in the population affecting the progression of the pandemic.",Anthony J Brookes; Allyson Pollock; Danny Dorling,https://medrxiv.org/cgi/content/short/2021.01.25.21250440,https://medrxiv.org/cgi/content/short/2021.01.25.21250440,2021-01-26,2021-01-26,,True
239,Identification of COVID-19 Subtypes Based on Immunogenomic Profiling,"Although previous studies have shown that the host immune response is crucial in determining clinical outcomes in COVID-19 patients, the association between host immune signatures and COVID-19 patient outcomes remains unclear. Based on the enrichment levels of 11 immune signatures (eight immune-inciting and three immune-inhibiting signatures) in leukocytes of 100 COVID-19 patients, we identified three COVID-19 subtypes: Im-C1, Im-C2, and Im-C3, by clustering analysis. Im-C1 had the lowest immune-inciting signatures and high immune-inhibiting signatures. Im-C2 had medium immune-inciting signatures and high immune-inhibiting signatures. Im-C3 had the highest immune-inciting signatures while the lowest immune-inhibiting signatures. Im-C3 and Im-C1 displayed the best and worst clinical outcomes, respectively, suggesting that antiviral immune responses alleviated the severity of COVID-19 patients. We further demonstrated that the adaptive immune response had a stronger impact on COVID-19 outcomes than the innate immune response. The patients in Im-C3 were younger than those in Im-C1, indicating that younger persons have stronger antiviral immune responses than older persons. Nevertheless, we did not observe a significant association between sex and immune responses in COVID-19 patients. In addition, we found that the type II IFN response signature was an adverse prognostic factor for COVID-19. Our identification of COVID-19 immune subtypes has potential clinical implications for the management of COVID-19 patients.",Qiushi Feng; Xiaosheng Wang,https://medrxiv.org/cgi/content/short/2021.01.24.21250387,https://medrxiv.org/cgi/content/short/2021.01.24.21250387,2021-01-26,2021-01-26,,True
240,ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients,"RationaleMacrophage activation syndrome (MAS) and complex immune dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19.

ObjectiveTo investigate the outcome of personalized immunotherapy in critical COVID-19.

MethodsIn this open-label prospective trial, 102 patients with SOFA (sequential organ failure assessment) score [&ge;]2 or ARDS by SARS-CoV-2 were screened for MAS (ferritin more than 4420 ng/ml) and CID (ferritin [&le;]4420 ng/ml and low expression of HLA-DR on CD14-monocytes). Patients with MAS and CID with increased aminotransferases were assigned to intravenous anakinra; those with CID and normal aminotransferases to tocilizumab. The primary outcome was at least 25% decrease of SOFA score and/or 50% increase of respiratory ratio by day 8; 28-day mortality, change of SOFA score by day 28; serum biomarkers and cytokine production by mononuclear cells were secondary endpoints.

Measurements and Main ResultsThe primary study endpoint was met in 58.3% of anakinra-treated patients and in 33.3% of tocilizumab-treated patients (odds ratio 3.11; 95% CIs 1.29-7.73; P: 0.011). No differences were found in mortality and in SOFA score changes. By day 4, ferritin was decreased among anakinra-treated patients; interleukin (IL)-6, soluble urokinase plasminogen activator receptor (suPAR) and the expression of HLA-DR were increased among tocilizumab-treated patients. Anakinra increased capacity of mononuclear cells to produce IL-6. Survivors by day 28 who received anakinra were distributed to scales of the WHO clinical progression of lower severity. Greater incidence of secondary infections was found with tocilizumab treatment.

ConclusionsBiomarkers may guide favourable anakinra responses in critically ill patients with COVID-19.

Trial RegistrationClinicalTrials.gov, NCT04339712",Eleni Karakike; George N Dalekos; Ioannis Koutsodimitropoulos; Maria Saridaki; Chryssa Pourzitaki; Georgios Papathanakos; Antigone Kotsaki; Stamatios Chalvatzis; Vasiliki Dimakopoulou; Nikolaos Vechlidis; Elisabeth Paramythiotou; Christina Avgoustou; Aikaterini Ioakeimidou; Elli Kouriannidi; Apostolos Komnos; Evangelia Neou; Nikoletta Rovina; Eleni Stefanatou; Haralampos Milionis; George Nikolaidis; Antonia Koutsoukou; Georgia Damoraki; George Dimopoulos; Vassileios Zoumpos; Jesper Eugen-Olsen; Karolina Akinosoglou; Nikolaos K Gatselis; Vasilios Koulouras; Eleni Gkeka; Nikolaos Markou; Mihai G Netea; Evangelos J Giamarellos-Bourboulis,https://medrxiv.org/cgi/content/short/2021.01.20.21250182,https://medrxiv.org/cgi/content/short/2021.01.20.21250182,2021-01-26,2021-01-26,,True
241,Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?,"BackgroundHydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause Torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patients who received hydroxychloroquine with or without azithromycin.

MethodsThis was a retrospective cohort study. 172 patients with COVID-19 included, hospitalized at hospitals of Babol University of Medical Sciences between March 5, 2020, and April 3, 2020. Patients were divided into two groups: hydroxychloroquine alone and hydroxychloroquine with azithromycin. Electrocardiograms were used for outcome assessment.

Results83.1% of patients received hydroxychloroquine plus azithromycin vs 16.9% of patients who received only hydroxychloroquine. The mean age of patients was 59.2 {+/-} 15.4. The mean of post-treatment QTc interval in the monotherapy group was shorter than the mean of post-treatment QTc interval in the combination therapy group but it had no significant statistical difference (462.5 {+/-} 43.1 milliseconds vs 464.3 {+/-} 59.1 milliseconds; P = 0.488). Generally, 22.1% of patients had a prolonged QTc interval after treatment. Male gender, or baseline QTc [&ge;] 450 milliseconds, or high-risk Tisdale score increased the likelihood of prolonged QTc interval. Due to QTc prolongation, 14 patients did not continue therapy after 4 days.

ConclusionHospitalized patients treated with hydroxychloroquine with or without azithromycin, had no significant difference in prolongation of QT interval and outcome. But the number of patients with prolonged QT intervals in this study emphasizes careful cardiac monitoring during therapy; especially in high-risk patients.",Seyed Parsa Eftekhar; Sohrab Kazemi; Mohammad Barary; Mostafa Javanian; Soheil Ebrahimpour; Naghmeh Ziaei,https://medrxiv.org/cgi/content/short/2021.01.16.21249941,https://medrxiv.org/cgi/content/short/2021.01.16.21249941,2021-01-26,2021-01-26,,True
242,Molecular epidemiology of SARS-CoV-2 - a regional to global perspective,"BackgroundAfter a year of the global SARS-CoV-2 pandemic, a highly dynamic genetic diversity is surfacing. Among nearly 1000 reported virus lineages, dominant lineages such as B.1.1.7 or B.1.351 attract media attention with questions regarding vaccine efficiency and transmission potential. In response to the pandemic, the Jena University Hospital began sequencing SARS-CoV-2 samples in Thuringia in early 2020.

MethodsViral RNA was sequenced in tiled amplicons using Nanopore sequencing. Subsequently, bioinformatic workflows were used to process the generated data. As a genomic background, 9,642 representative SARS-CoV-2 genomes (1,917 of German origin) were extracted from more than 300.000 genomes.

ResultsIn a comprehensive bioinformatics analysis, we have set Thuringian isolates in the German, European and global context. In Thuringia, a largely rural German region without an international airport and a population density below the German average, we discovered many of the common ""EU lineages"". German samples are scattered across eight major clades, and Thuringian samples occupy four of them.

ConclusionThe rapid emergence and spread of novel variants are of great concern as these lineages could transmit more efficiently, evade current vaccine efforts or undermine diagnostic test accuracy. To anticipate and mitigate these threats, a continuous molecular surveillance is essential.

Key messagesO_LIBioinformatics analysis of 1,917, 4,251, and 3,474 SARS-CoV-2 genomes from Germany, the EU (except Germany), and non-EU, respectively, subsampled from more than 300,000 public genomes and placed in the context of Thuringian sequences
C_LIO_LIConstant antigenic drift for SARS-CoV-2 and no clear pattern or clustering is visible in Thuringia based on the current number of samples
C_LIO_LICurrently over 100 described lineages are identified in Germany and only a subset (9) are detected in Thuringia so far, most likely due to genetic undersampling
C_LIO_LIFrom a national perspective, it is likely that high-frequency lineages, which are currently spreading throughout Europe, will eventually also reach Thuringia
C_LIO_LISystematic and dense molecular surveillance via whole-genome sequencing is needed to detect concerning new lineages early, limit spread and adjust vaccines if necessary
C_LI",Christian Brandt; Riccardo Spott; Martin Hoelzer; Denis Kuehnert; Stephan Fuchs; Mara Lohde; Mike Marquet; Adrian Viehweger; Dagmar Rimek; Mathias Pletz,https://medrxiv.org/cgi/content/short/2021.01.25.21250447,https://medrxiv.org/cgi/content/short/2021.01.25.21250447,2021-01-26,2021-01-26,,True
243,"Post-Disease Divergence in SARS-CoV-2 RNA Detection between Nasopharyngeal, Anterior Nares and Saliva/Oral Fluid Specimens - Significant Implications for Policy & Public Health","BackgroundPatients have been shown to shed SARS-CoV-2 viral RNA in nasopharyngeal (NP) specimens for over 100 days after resolution of clinical disease (1, 2). How this relates to anterior nares and oral fluid specimens has not previously been investigated.

MethodsWe prospectively collected oral fluid, anterior nares, NP swab and serum specimens from 1,326 individuals at 2 ""drive-through"" testing locations. The Curative SARS-CoV-2 Assay (Curative Assay)(3) on oral fluid and anterior nares specimens was compared to the EURORealTime SARS-CoV-2 Assay (EuroRT Assay)(4) on anterior nares and NP specimens. Viral culture and IgG serology were used to assess infectious potential and stage of disease.

Additionally we investigated differences in viral RNA detection between specimen types, both early (< 21 days) and late (> 21 days) in SARS-CoV-2 infection, by using an employee surveillance program with daily SARS-CoV-2 testing to precisely determine infection date, even without symptoms. We prospectively collected oral fluid, anterior nares and NP swab specimens from 165 subjects with early infections and 22 subjects with late infections. Specimens were tested using the Curative Assay with the ""high-sensitivity"" Hologic Aptima SARS-CoV-2 Assay (Hologic Assay)(5) on an NP swab used as the comparator. Late infection specimens were also tested with EuroRT and Zymo Quick SARS-CoV-2 rRT-PCR Kit (Zymo) (6) Assays.

ResultsThe ""drive-through"" study showed similar sensitivities of oral fluid and anterior nares specimens on the Curative Assay to anterior nares specimens tested with the EuroRT Assay. However NP specimens tested with the same EuroRT assay produced 20-30% more positives. Incorporating viral culture and serology data to exclude NP RT-PCR positives that are not infectious or late in the course of disease showed a Positive Percent Agreement (PPA) for of 98.2% and 96.2% and Negative Percent Agreement (NPA) of 97.6% and 98.1% for anterior nares and oral fluid specimens, respectively.

Within 21 days of infection, the Curative Assay showed a PPA and NPA of 100% and 100%, respectively for oral fluid; of 100% and 99% respectively for anterior nares; and of 98.2% and 99.0%, respectively in nasopharyngeal specimens compared to an NP specimen on the Hologic Assay. 29 positives were asymptomatic and showed 100% PPA and 100% NPA for all specimen types. After 21 days from infection onset, significant divergence between NP and other specimen types occurred on all 4 assays. Out of 22 paired sample sets, 18, 13, 8 and 4 NP specimens were positive on the Curative, Zymo, Hologic and EuroRT assays, respectively, compared to only 3, 2, 0 and 1 positive anterior nares specimens. Only one oral fluid sample was positive in both the Curative and Zymo assays.

ConclusionsWe used a unique population to show significant divergence between NP specimens and anterior nares or oral fluid specimens >21 days from SARS-CoV-2 infection, which appears to be biological variation and is independent of assay used. This has significant public health implications for the use of NP specimens in community testing programs and policy implications for evaluation of novel specimen types and tests where the use of NP swabs as a comparator may say more about the study population than the assay or specimen type to be evaluated and may unnecessarily limit access to testing.",Fred Turner; Amy VandenBerg; Vladimir I Slepnev; Suzana Car; Rita E Starritt; Michael V Seger; Noah Kojima; Nina Nirema; Lauren Lopez; Matthew Brobeck; Sarah K August; Alejandra Orosco; Fred Hertlein; Arthur M Baca,https://medrxiv.org/cgi/content/short/2021.01.26.21250523,https://medrxiv.org/cgi/content/short/2021.01.26.21250523,2021-01-26,2021-01-26,,True
244,High infection attack rates of SARS-CoV-2 in Dutch households revealed by dense sampling,"BackgroundIndoor environments are considered a main setting for transmission of SARS-CoV-2. Households in particular present a close-contact environment with high probability of transmission between persons of different ages and with different roles in society.

MethodsComplete households with a laboratory-confirmed SARS-CoV-2 positive case in the Netherlands (March-May 2020) were included. At least three home visits were performed during 4-6 week of follow-up, collecting naso- and oropharyngeal swabs, oral fluid, faeces and blood samples for molecular and serological analyses of all household members. Symptoms were recorded from two weeks before the first visit up to the last visit. Secondary attack rates (SAR) were estimated with logistic regression. A transmission model was used to assess transmission routes in the household.

ResultsA total of 55 households with 187 household contacts were included. In 17 households no transmission took place, and in 11 households all persons were infected. Estimated SARs were high, ranging from 35% (95%CI: 24%-46%) in children to 51% (95%CI: 39%-63%) in adults. Estimated transmission rates in the household were high, with reduced susceptibility of children compared to adolescents and adults (0.67; 95%CI: 0.40-1.1).

ConclusionEstimated SARs were higher than reported in earlier household studies, presumably owing to a dense sampling protocol. Children were shown to be less susceptible than adults, but the estimated SAR in children was still high. Our results reinforce the role of households as main multiplier of SARS-CoV-2 infection in the population.

Key pointsWe analyze data from a SARS-CoV-2 household study and find higher secondary attack rates than reported earlier. We argue that this is due to a dense sampling strategy that includes sampling at multiple time points and of multiple anatomical sites.",Daphne F.M. Reukers; Michiel van Boven; Adam Meijer; Nynke Rots; Chantal Reusken; Inge Roof; Arianne B. van Gageldonk-Lafeber; Wim van der Hoek; Susan van den Hof,https://medrxiv.org/cgi/content/short/2021.01.26.21250512,https://medrxiv.org/cgi/content/short/2021.01.26.21250512,2021-01-26,2021-01-26,,True
245,Adaptive immunity to human coronaviruses is widespread but low in magnitude,"Endemic human coronaviruses (hCoV) circulate worldwide but cause minimal mortality. Although seroconversion to hCoV is near ubiquitous during childhood, little is known about hCoV-specific T cell memory in adults. We quantified CD4 T cell and antibody responses to hCoV spike antigens in 42 SARS-CoV-2 uninfected individuals. T cell responses were widespread within conventional memory and cTFH compartments but did not correlate with IgG titres. SARS-CoV-2 cross-reactive T cells were observed in 48% of participants and correlated with HKU1 memory. hCoV-specific T cells exhibited a CCR6+ central memory phenotype in the blood, but were enriched for frequency and CXCR3 expression in human lung draining lymph nodes. Overall, hCoV-specific humoral and cellular memory are independently maintained, with a shared phenotype existing among coronavirus-specific CD4 T cells. This understanding of endemic coronavirus immunity provides insight into the homeostatic maintenance of immune responses that are likely to be critical components of protection against SARS-CoV-2.",Hyon-Xhi Tan; Wen Shi Lee; Kathleen M Wragg; Christina Nelson; Robyn Esterbauer; Hannah G Kelly; Thakshila Amarasena; Robert M Jones; Graham Starkey; Bao Zhong Wang; Osamu Yoshino; Thomas Tiang; M Lindsay Grayson; Helen Opdam; Angela Vago; - The Austin Liver Transplant Perfusionist Group; Laura K Mackay; Claire L Gordon; Adam K Wheatley; Stephen J Kent; Jennifer A Juno,https://medrxiv.org/cgi/content/short/2021.01.24.21250074,https://medrxiv.org/cgi/content/short/2021.01.24.21250074,2021-01-26,2021-01-26,,True
246,Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data,"Designing public health responses to outbreaks requires close monitoring of population-level health indicators in real-time. Thus, an accurate estimation of the epidemic curve is critical. We propose an approach to reconstruct epidemic curves in near real time. We apply this approach to characterize the early SARS-CoV-2 outbreak in two Spanish regions between March and April 2020.

We address two data collection problems that affected the reliability of the available real-time epidemiological data, namely, the frequent missing information documenting when a patient first experienced symptoms, and the frequent retrospective revision of historical information (including right censoring). This is done by using a novel back-calculating procedure based on imputing patients dates of symptom onset from reported cases, according to a dynamically-estimated ""backward"" reporting delay conditional distribution, and adjusting for right censoring using an existing package, NobBS, to estimate in real time (nowcast) cases by date of symptom onset. This process allows us to obtain an approximation of the time-varying reproduction number (Rt) in real-time.

At each step, we evaluate how different assumptions affect the recovered epidemiological events and compare the proposed approach to the alternative procedure of merely using curves of case counts, by report day, to characterize the time-evolution of the outbreak. Finally, we assess how these real-time estimates compare with subsequently documented epidemiological information that is considered more reliable and complete that became available later in time. Our approach may help improve accuracy, quantify uncertainty, and evaluate frequently unstated assumptions when recovering the epidemic curves from limited data obtained from public health surveillance systems in other locations.",Pablo Martinez de Salazar; Fred Lu; James A Hay; Diana Gomez-Barroso; Pablo Fernandez-Navarro; Elena Vanessa Martinez; Jenaro Astray-Mochales; Rocio Amillategui; Ana Garcia-Fulgueiras; Maria Dolores Chirlaque; Alonso Sanchez-Migallon; Amparo Larrauri; Maria Jose Sierra; Marc Lipsitch; Fernando Simon; Mauricio Santillana; Miguel Hernan,https://medrxiv.org/cgi/content/short/2021.01.25.20230094,https://medrxiv.org/cgi/content/short/2021.01.25.20230094,2021-01-26,2021-01-26,,True
247,COVID-19 Test Positivity Rate as a marker for hospital overload,"The use of antigen tests for the diagnosis of COVID-19 in Italy has risen sharply in autumn 2020. Although, Italian regions like Alto Adige, Veneto, Toscana, Lazio, Piemonte and Marche did a large use of these tests for screening and surveillance purposes or for implementing diagnosis protocols, in addition to molecular tests, they were not reported in the statistics in the last months of 2020. As a consequence of this situation the test positivity rate (TPR) index, defined as the number of new positive cases divided by the number of tests, has lost in accuracy. Only in the recent days, starting from the 15th of January 2021, antigen tests have become part of the statistics for all the Italian regions. Despite the lack of data, we have noticed that TPR has a strong correlation with the number of patients admitted in hospitals, and that TPR peaks in general precede the peaks of hospitalized people which occur on average about 15 days later.

In this paper, we have deepened this intuition, analysing the TPR course and its relationship with the number of hospitalized people. To conduct the study we have defined a novel version of the TPR index which takes into account the number of tests done with respect to the population (considering both molecular and antigen tests), the number of infected individuals, and the number of patients healed. Successively, starting from a limited set of data which were made available in November 2020, we have reconstructed the antigen tests time series of four Italian regions, and we computed the TPR index for them.

The results show that TPR peaks precede peaks of hospitalized people in both the first and the second phases of the pandemic in Italy, provided that antigen tests are considered. Moreover, the TPR index trend, can be used to deduct important information on the course of the epidemic, and on the impact of COVID-19 in the health care system, which can be monitored in advance.",Mauro Gaspari,https://medrxiv.org/cgi/content/short/2021.01.26.21249544,https://medrxiv.org/cgi/content/short/2021.01.26.21249544,2021-01-26,2021-01-26,,True
248,"Super-Spreaders Out, Super-Spreading In: The Effects of Infectiousness Heterogeneity and Lockdowns on Herd Immunity","Recently, [8] has proposed that heterogeneity of infectiousness (and susceptibility) across individuals in infectious diseases, plays a major role in affecting the Herd Immunity Thresh-old (HIT). Such heterogeneity has been observed in COVID-19 and is recognized as overdis-persion (or ""super-spreading""). The model of [8] suggests that super-spreaders contribute significantly to the effective reproduction factor, R, and that they are likely to get infected and immune early in the process. Consequently, under R0 {approx} 3 (attributed to COVID-19), the Herd Immunity Threshold (HIT) is as low as 5%, in contrast to 67% according to the traditional models [1, 2, 4, 10].

This work follows up on [8] and proposes that heterogeneity of infectiousness (susceptibility) has two ""faces"" whose mix affects dramatically the HIT: (1) Personal-Trait-, and (2) Event-Based-Infectiousness (Susceptibility). The former is a personal trait of specific individuals (super-spreaders) and is nullified once those individuals are immune (as in [8]). The latter is event-based (e.g cultural super-spreading events) and remains effective throughout the process, even after the super-spreaders immune. We extend [8]s model to account for these two factors, analyze it and conclude that the HIT is very sensitive to the mix between (1) and (2), and under R0 {approx} 3 it can vary between 5% and 67%. Preliminary data from COVID-19 suggests that herd immunity is not reached at 5%.

We address operational aspects and analyze the effects of lockdown strategies on the spread of a disease. We find that herd immunity (and HIT) is very sensitive to the lock-down type. While some lockdowns affect positively the disease blocking and increase herd immunity, others have adverse effects and reduce the herd immunity.",Jhonatan Tavori; Hanoch Levy,https://medrxiv.org/cgi/content/short/2021.01.23.21250242,https://medrxiv.org/cgi/content/short/2021.01.23.21250242,2021-01-26,2021-01-26,,True
249,ARE GEOGRAPHIC FACTORS ASSOCIATED WITH POORER OUTCOMES IN PATIENTS DIAGNOSED WITH COVID-19?,"BackgroundThe prognosis of patients with COVID-19, with older age and comorbidities, is associated with a more severe course and higher fatality rates but no analysis has yet included factors related to the geographical area/municipality in which the affected patients live. So the objective of this study is to analyse the prognosis of patients with COVID-19 in terms of sex, age, comorbidities, and geographic variables.

MethodsA retrospective cohort of 6286 patients diagnosed with COVID-19 was analysed, considering demographic data, previous comorbidities and geographic variables. The main study variables were hospital admission, Intensive Care Unit (ICU) admission and death due to worsening symptoms; and the secondary variables were sex, age, comorbidities and geographic variables (size of the area of residence, distance to the hospital and the driving time to the hospital). A comparison analysis and a multivariate Cox model were performed.

ResultsThe multivariate Cox model showed that women had a better prognosis in any type of analysed prognosis. Most of the comorbidities studied were related to a poorer prognosis except for dementia, which is related to lower admissions and higher mortality. Suburban areas were associated with greater mortality and with less hospital or ICU admission. Distance to the hospital was also associated with hospital admission.

ConclusionsFactors such as type of municipality and distance to hospital act as social health determinants. This fact must be taken account in order to stablish specifics prevention measures and treatment protocols.",Rosa Magallon-Botaya Sr.; Barbara Olivan-Blazquez; Karen Ramirez-Cervantes; Fatima Lopez-Mendez; Marc Casajuana-Closas; Eva Andres-Esteban,https://medrxiv.org/cgi/content/short/2021.01.25.21250404,https://medrxiv.org/cgi/content/short/2021.01.25.21250404,2021-01-26,2021-01-26,,True
250,A cross-sectional survey of the workplace factors contributing to symptoms of anxiety and depression among nurses and physicians during the first wave of COVID-19 pandemic in two US healthcare systems,"BackgroundAnxiety and depression among physicians and nurses during COVID-19 pandemic in the USA is not well described and its modifiable causes poorly understood.

MethodsWe conducted a cross-sectional survey of symptoms of anxiety and depression (Hospital Anxiety and Depression Scale) among physicians and nurses in two US healthcare systems June-Sept 2020. We ascertained features of work as well as its perceptions and associated concerns in relation to risk of anxiety and depression, while controlling for health history via regression and path analyses.

ResultsAbout a third of 684 nurses and 185 physicians surveyed showed symptoms of anxiety or depression, the excess was particularly prominent in nurses. Belief in having been infected was a dominant cause of anxiety and depression, more related to history of symptoms of pneumonia, then the contact with infected patients. Having confidence in competent use and access to personal protective equipment, maintaining usual working hours and being surrounded by colleagues who were both sufficient in numbers and not stressed, was protective. Having support of immediate family and religious communities lessened anxiety and depression after accounting for other factors. Involvement in aerosol-generating procedures with infected patients was linked with lower depression in nurses but higher among physicians. Likewise, the setting of recent patient encounters affected risk differently for physicians and nurses.

ConclusionsOur findings may help develop mitigation measures and underscore the need to help nurses and physicians bear the psychological burden of COVID-19 pandemic and similar events in the future.",Igor Burstyn; Karyn Holt,https://medrxiv.org/cgi/content/short/2021.01.25.21250315,https://medrxiv.org/cgi/content/short/2021.01.25.21250315,2021-01-26,2021-01-26,,True
251,SARS-CoV-2 infection in pregnancy is associated with robust inflammatory response at the maternal-fetal interface,"Pregnant women appear to be at increased risk for severe outcomes associated with COVID-19, but the pathophysiology underlying this increased morbidity and its potential impact on the developing fetus is not well understood. In this study of pregnant women with and without COVID-19, we assessed viral and immune dynamics at the placenta during maternal SARS-CoV-2 infection. Amongst uninfected women, ACE2 was detected by immunohistochemistry in syncytiotrophoblast cells of the normal placenta during early pregnancy but was rarely seen in healthy placentas at full term. Term placentas from women infected with SARS-CoV-2, however, displayed a significant increase in ACE2 levels. Using immortalized cell lines and primary isolated placental cells, we determined the vulnerability of various placental cell types to direct infection by SARS-CoV-2 in vitro. Yet, despite the susceptibility of placental cells to SARS-CoV-2 infection, viral RNA was detected in the placentas of only a subset ([~]13%) of women in this cohort. Through single cell transcriptomic analyses, we found that the maternal-fetal interface of SARS-CoV-2-infected women exhibited markers associated with pregnancy complications, such as preeclampsia, and robust immune responses, including increased activation of placental NK and T cells and increased expression of interferon-related genes. Overall, this study suggests that SARS-CoV-2 is associated with immune activation at the maternal-fetal interface even in the absence of detectable local viral invasion. While this likely represents a protective mechanism shielding the placenta from infection, inflammatory changes in the placenta may also contribute to poor pregnancy outcomes and thus warrant further investigation.",Alice Lu-Culligan; Arun R. Chavan; Pavithra Vijayakumar; Lina Irshaid; Edward M. Courchaine; Kristin M. Milano; Zhonghua Tang; Scott D. Pope; Eric Song; Chantal B. F. Vogels; William J. Lu-Culligan; Katherine H. Campbell; Arnau Casanovas-Massana; Santos Bermejo; Jessica M. Toothaker; Hannah J. Lee; Feimei Liu; Wade Schulz; John Fournier; M. Catherine Muenker; Adam J. Moore; - Yale IMPACT Team; Liza Konnikova; Karla M. Neugebauer; Aaron Ring; Nathan D. Grubaugh; Albert I. Ko; Raffaella Morotti; Seth Guller; Harvey J. Kliman; Akiko Iwasaki; Shelli F. Farhadian,https://medrxiv.org/cgi/content/short/2021.01.25.21250452,https://medrxiv.org/cgi/content/short/2021.01.25.21250452,2021-01-26,2021-01-26,,True
252,Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis,"IntroductionThe novel coronavirus (COVID-19), caused by SARS-CoV-2, showed various prevalence and case-fatality rates (CFR) among patients with different pre-existing chronic conditions. End-stage renal disease (ESRD) patients with renal replacement therapy (RRT) might have a higher prevalence and CFR due to reduced immune function from uremia and kidney tropism of SARS-CoV-2, but there was no systematic study on the infection and mortality of the SARS-CoV-2 infection in ESRD patients who are on RRT.

MethodsWe searched five electronic databases and performed a systematic review and meta-analysis up to June 30, 2020, to evaluate the prevalence and case fatality rate (CFR) of the COVID-19 infection among ESRD patients with RRT. The global COVID-19 data were retrieved from the international database on June 30, 2020, for estimating the prevalence and CFR of the general population as referencing points.

ResultsOf 3,272 potential studies, 34 were eligible studies consisted of 1,944 COVID-19 confirmed cases in 21,873 ESRD patients with RRT from 12 countries in four WHO regions. The overall pooled prevalence in ESRD patients with RRT was 3.10% [95% confidence interval (CI) 1.25-5.72] which was higher than referencing 0.14% global average prevalence. The overall estimated CFR of COVID-19 in ESRD patients with RRT was 18.06% (95%CI 14.09- 22.32) which was higher than the global average at 4.98%.

ConclusionsThis meta-analysis suggested high COVID-19 prevalence and CFR in ESRD patients with RRT. ESRD patients with RRT should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.

Author summaryChronic kidney disease (CKD) was associated with increasing severity and mortality of COVID-19. End-stage renal disease (ESRD) patients were at the terminal stage of CKD and had reduced immune function due to uremia. Additionally, ESRD patients with kidney transplantation had a diminished immune system from immunosuppressive agents. Kidneys might be the secondary target of SARS-CoV-2 after the respiratory tract regardless of the previous history of kidney disease, preferably the glomerulus, which was associated with the richness of some specific protein-coding genes in the kidney. The overall pooled prevalence in ESRD patients with renal replacement therapy was approximately 22 times of the referencing global average prevalence. The overall estimated case fatality rate of COVID-19 in ESRD patients with renal replacement therapy was approximately 3.6 times the global average. ESRD patients with renal replacement therapy had high COVID-19 prevalence and case fatality rate. We suggested that ESRD patients with renal replacement therapy should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.",Tanawin Nopsopon; Jathurong Kittrakulrat; Kullaya Takkavatakarn; Thanee Eiamsitrakoon; Talerngsak Kanjanabuch; Krit Pongpirul,https://medrxiv.org/cgi/content/short/2021.01.25.21250454,https://medrxiv.org/cgi/content/short/2021.01.25.21250454,2021-01-26,2021-01-26,,True
253,Logistic advantage of two-step screening strategy for SARS-CoV-2 at airport quarantine,"BackgroundAirport quarantine is required to reduce the risk of entry of travelers infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, it is challenging for both high accuracy and rapid turn-around time to coexist in testing; polymerase chain reaction (PCR) is time-consuming with high accuracy, while antigen testing is rapid with less accuracy.

Methods88,924 (93.2%) of 95,457 arrivals at three international airports in Japan were tested for SARS-CoV-2 using self-collected saliva by a screening strategy with initial chemiluminescent enzyme immunoassay (CLEIA) followed by confirmatory nucleic acid amplification tests (NAAT) only for intermediate range antigen concentrations.

Results254 (0.27%) persons were found to be SARS-CoV-2 antigen positive ([&ge;] 4.0 pg/mL) by CLEIA. NAAT was required for confirmatory testing in 513 (0.54%) persons with intermediate antigen concentrations (0.67-4.0 pg/mL) whereby the virus was detected in 34 (6.6%) persons. This two-step strategy dramatically reduced the utilization of NAAT to approximately one out of every 200 test subjects.

Estimated performance of this strategy did not show significant increase in false negatives as compared to performing NAAT in all subjects. Further reduction in imported cases may be achieved by post-screening quarantine.

ConclusionsPoint of care testing by quantitative CLEIA using self-collected saliva is less labor-intensive and yields results rapidly, thus suitable as an initial screening test. Reserving NAAT for CLEIA indeterminate cases may prevent compromising accuracy while significantly improving the logistics of administering mass-screening at large venues.",Isao Yokota; Peter Y Shane; Takanori Teshima,https://medrxiv.org/cgi/content/short/2021.01.25.21250509,https://medrxiv.org/cgi/content/short/2021.01.25.21250509,2021-01-26,2021-01-26,,True
254,Emergence and fast spread of B.1.1.7 lineage in Lebanon.,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a rapid spread emerging disease. Recently, a new variant of this virus called SARS-CoV-2 VOC 202012/01 (or B.1.1.7 lineage), described in the United Kingdom (UK), has become highly prevalent in several countries. Its rate of transmission has been estimated to be greatly higher. B.1.1.7 lineage harbors 23 mutations co-existed for the first time in the same variant. Herein, we are interested only by the deletion mutation {Delta}H69/{Delta}V70 in the spike protein.

In the UK they were able to identify the increase of this new variant through the increase in the false negative result for the spike target of a three-target RT-PCR assay from Thermo Fisher Scientific (TaqPath kit). Later, the manufacturer announced that this false negative result is because of the deletion {Delta}H69/{Delta}V70 in the area targeted by the TaqPath Kit. Furthermore, The European CDC recommended that the use of this kit help to track the new variant.

Genome sequencing is the gold method to confirm the new variant, but observational studies provide also stronger evidence if similar models are observed in multiple countries, especially when randomized studies are not possible. In Lebanon, the highest number of confirmed cases were reported in first week of 2021. In the present study, we show the emergence and the fast spreading of the new variant in Lebanon and a relationship between SARS-CoV-2 transmission intensity and the frequency of the new variant during the first twelve days of January.",mahmoud younes; kassem hamze; hassan nassar; mohammad makki; Mayssa Ghaddar; paul Nguewa; fadi abdel sater,https://medrxiv.org/cgi/content/short/2021.01.25.21249974,https://medrxiv.org/cgi/content/short/2021.01.25.21249974,2021-01-26,2021-01-26,,True
255,Estimation of the SARS-CoV-2 infection fatality rate in Germany,"Assessing the infection fatality rate (IFR) of SARS-CoV-2 is one of the most controversial issues during the pandemic. Due to asymptomatic or mild courses of COVID-19, many infections remain undetected. Reported case fatality rates - COVID-19-associated deaths divided by number of detected infections - are therefore poor estimates of the IFR. Endogenous changes of the population at risk of a SARS-CoV-2 infection, changing test practices and an improved understanding of the pathogenesis of COVID-19 further exacerbate the estimation of the IFR. Here, we propose a strategy to estimate the IFR of SARS-CoV-2 in Germany that combines official data on reported cases and fatalities supplied by the Robert Koch Institute (RKI) with data from seroepidemiological studies in two infection hotspots, the Austrian town Ischgl and the German municipality Gangelt, respectively. For this purpose, we use the law of total probability to derive an approximate formula for the IFR that is based on a set of assumptions regarding data quality and test specificity and sensitivity. The resulting estimate of the IFR in Germany of 0.83% (95% CI: [0.69%; 0.98%]) that is based on a combination of the RKI and Ischgl data is notably higher than the IFR estimate reported in the Gangelt study (0.36% [0.29%; 0.45%]). It is closer to the consolidated estimate based on a meta-analysis (0.68% [0.53%; 0.82%]), where the difference can be explained by Germanys disadvantageous age structure. As a result of virus mutations, vaccination strategies, and improved therapy, a re-estimation of the IFR will eventually be mandated; the proposed method is able to account for such developments.",Thomas Dimpfl; Jantje SÃ¶nksen; Ingo Bechmann; Joachim Grammig,https://medrxiv.org/cgi/content/short/2021.01.26.21250507,https://medrxiv.org/cgi/content/short/2021.01.26.21250507,2021-01-26,2021-01-26,,True
256,Community structured model for vaccine strategies to control COVID19 spread: a mathematical study,"Efforts to mitigate the COVID-19 pandemic have relied heavily on non-pharmaceutical interventions (NPIs), including physical distancing, hand hygiene, and mask-wearing. However, an effective vaccine is essential to containing the spread of the virus. The first doses were distributed at the end of 2020, but the efficacy, period of immunity it will provide, and percentage of coverage still remain unclear. We developed a compartment model to examine different vaccine strategies for controlling the spread of COVID-19. Our framework accounts for testing rates, test-turnaround times, and vaccination waning immunity. Using reported case data from the city of Toronto, Canada between Mar-Dec, 2020 we defined epidemic phases of infection using contact rates, which depend on individuals duration of time spent within the household, workplace/school, or community settings, as well as the probability of transmission upon contact. We investigated the impact of vaccine distribution by comparing different permutations of waning immunity, vaccine coverage and efficacy throughout various stages of NPIs relaxation in terms of cases, deaths, and household transmission, as measured using the basic reproduction number (R0). We observed that widespread vaccine coverage substantially reduced the number of cases and deaths. In order for NPIs to be relaxed 8 months after vaccine distribution, infection spread can be kept under control with either 60% vaccine coverage, no waning immunity, and 70% efficacy, or with 60% coverage with a 12-month waning immunity and 90% vaccine efficacy. Widespread virus resurgence can result when the immunity wanes under 3 months and/or when NPIs are relaxed in concomitance with vaccine distribution. In addition to vaccination, our analysis of R0 showed that the basic reproduction number is reduced by decreasing the tests turnaround time and transmission in the household. While we found that household transmission can decrease following the introduction of a vaccine, public health efforts to reduce test turnaround times remain important for virus containment. Our findings suggest that vaccinating two-thirds of the population with a vaccine that is at least 70% effective may be sufficient for controlling COVID-19 spread, as long as NPIs are not immediately relaxed.",Elena Aruffo; Pei Yuan; Yi Tan; Evgenia Gatov; Effie Gournis; Sarah Collier; Nick Ogden; Jacques B&eacutelair; Huaiping Zhu,https://medrxiv.org/cgi/content/short/2021.01.25.21250505,https://medrxiv.org/cgi/content/short/2021.01.25.21250505,2021-01-26,2021-01-26,,True
257,"Health impact of routine immunisation service disruptions and mass vaccination campaign suspensions caused by the COVID-19 pandemic: Multimodel comparative analysis of disruption scenarios for measles, meningococcal A, and yellow fever vaccination in 10 low- and lower middle-income countries","BackgroundChildhood immunisation services have been disrupted by the COVID-19 pandemic. WHO recommends considering outbreak risk using epidemiological criteria when deciding whether to conduct preventive vaccination campaigns during the pandemic.

MethodsWe used 2-3 models per infection to estimate the health impact of 50% reduced routine vaccination coverage in 2020 and delay of campaign vaccination from 2020 to 2021 for measles vaccination in Bangladesh, Chad, Ethiopia, Kenya, Nigeria, and South Sudan, for meningococcal A vaccination in Burkina Faso, Chad, Niger, and Nigeria, and for yellow fever vaccination in the Democratic Republic of Congo, Ghana, and Nigeria. Our counterfactual comparative scenario was sustaining immunisation services at coverage projections made prior to COVID-19 (i.e. without any disruption).

FindingsReduced routine vaccination coverage in 2020 without catch-up vaccination may lead to an increase in measles and yellow fever disease burden in the modelled countries. Delaying planned campaigns in Ethiopia and Nigeria by a year may significantly increased the risk of measles outbreaks (both countries did complete their SIAS planned for 2020). For yellow fever vaccination, delay in campaigns leads to a potential disease burden rise of >1 death per 100,000 people until the campaigns are implemented. For meningococcal A vaccination, short term disruptions in 2020 are unlikely to have a significant impact due to the persistence of direct and indirect benefits from past introductory campaigns of the 1 to 29-year-old population, bolstered by inclusion of the vaccine into the routine immunisation schedule accompanied by further catch-up campaigns.

InterpretationThe impact of COVID-19-related disruption to vaccination programs varies between infections and countries. Planning and implementation of campaigns should consider country and infection-specific epidemiological factors and local immunity gaps worsened by the COVID-19 pandemic when prioritising vaccines and strategies for catch-up vaccination.

FundingBill & Melinda Gates Foundation and Gavi, the Vaccine Alliance

Research in contextO_ST_ABSEvidence before the studyC_ST_ABSWe searched PubMed for (COVID-19 OR coronavirus OR SARS-CoV-2) AND (child health intervention OR vaccin* or immuni*) AND (disruption OR suspension OR reduction) AND (indirect effect OR health impact) on January 14, 2021, with no language restrictions. We found 178 articles of which 13 articles were relevant. Six articles reported some empirical data on immunization disruption in Bangladesh, Japan, Kenya, Nigeria, Pakistan, Saudi Arabia, South Africa, Spain and Italy, and a survey study focussed on immunization disruption in low and middle-income countries. One article proposed using the WHO health systems framework to assess the effects of COVID-19 on immunisation programmes in South Africa, another study on leveraging systems thinking and implementation science to improve immunization system performance in Africa, and two studies were review articles. One modelling study focused on the indirect effects, including reduction in routine immunisation services, of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries. Another modelling study focused on a benefit-risk analysis of routine childhood immunisation during the COVID-19 pandemic in Africa. We also found one other study in the grey literature that analysed the impact on SARS-CoV-2 infections as a result of fixed-post and door-to-door vaccination campaigns targeted at children under five years of age in an Ethiopia-like setting.

Added value of this studyWe estimated the increase in cases and deaths caused by the disruption to immunisation services leading to outbreaks for measles, meningococcal A and yellow fever in 10 countries. The reduction in routine immunisation coverage among under-immunised cohorts of children has enhanced the risk of outbreaks which cannot be averted without catch-up vaccination. This can lead to an increase of 9.89% (0.91 additional deaths per 100,000 individuals, or 48,000 in total) across the three diseases from 2020 to 2030 in the countries considered. Results vary by infection and country, but generally most excess deaths are due to measles. Postponing campaign immunisation may not have a detrimental short-term health impact if campaign immunisation is implemented ahead of future outbreaks caused by these immunity gaps.

Implications of the available evidenceThe COVID-19 pandemic has caused significant disruptions to routine services and vaccination campaigns and resulted in immunity gaps with potential to cause outbreaks in the affected populations. The short-term and long-term health impact differ between measles, meningococcal A and yellow fever vaccination and by countries based on the local epidemiological situation. Thereby, catch-up vaccination should be planned by considering the heterogeneity in population susceptibility across different countries to measles, meningococcal A and yellow fever outbreaks and implemented in time to prevent these outbreaks. The study findings can inform risk-benefit trade-off discussions around the timing of campaigns.",Katy Gaythorpe; Kaja Abbas; John Huber; Andromachi Karachaliou; Niket Thakkar; Kim Woodruff; Xiang Li; Susy Echeverria-Londono; - VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease; Matthew Ferrari; Michael L Jackson; Kevin McCarthy; Alex Perkins; Caroline Trotter; Mark Jit,https://medrxiv.org/cgi/content/short/2021.01.25.21250489,https://medrxiv.org/cgi/content/short/2021.01.25.21250489,2021-01-26,2021-01-26,,True
258,Impact of social restrictions during the COVID-19 pandemic on the physical activity levels of older adults: an analysis of the CHARIOT COVID-19 Rapid Response Study,"Rationale and ObjectivesPhysical inactivity is more common in older adults, is associated with social isolation and loneliness, and contributes to increased morbidity and mortality. We examined the effect of social restrictions, implemented to reduce transmission of COVID-19 in the UK (lockdown), on physical activity (PA) levels of older adults, and the demographic, lifestyle and social predictors of this change.

MethodsCognitively healthy adults aged over 50 years from the Cognitive Health in Ageing Register for Investigational and Observational Trials (CHARIOT) cohort were invited to complete a survey of demographic and lifestyle details, social factors, mood, and frailty. Retrospective (pre-lockdown) and current (post-lockdown) PA were captured by the International Physical Activity Questionnaire (IPAQ) short form.

Results6,219 adults aged 50 to 92 years completed the survey during the period of April - July 2020. Mean PA significantly reduced following lockdown, from 3,519 Metabolic Equivalent of Task (MET) minutes/week to 3,185 MET minutes/week (p<0.001). Multivariable linear regression models showed that: those who were divorced or single (240 [95% CI: 120, 360] MET minutes/week less); living alone (277 [95% CI: 152, 402] MET minutes/week less); and reported feeling lonely often (306 [95% CI: 60, 552] MET minutes/week less); were doing less PA after lockdown than those married, co-habiting and not reporting loneliness, respectively.

Conclusions and ImplicationsMarkers of social isolation and loneliness were associated with a reduction in PA following lockdown in the UK. Interventions to improve PA in older adults should take account of social and community factors.",David Salman; Thomas Beaney; Catherine Robb; Celeste A. de Jager Loots; Parthenia Giannakopoulou; Chi Udeh-Momoh; Sara Ahmadi-Abhari; Azeem Majeed; Lefkos T Middleton; Alison H McGregor,https://medrxiv.org/cgi/content/short/2021.01.26.21250520,https://medrxiv.org/cgi/content/short/2021.01.26.21250520,2021-01-26,2021-01-26,,True
259,"Elevated HScore is Associated with Poor Clinical Outcomes in COVID-19, Even in the Absence of Secondary Hemophagocytic Lymphohistiocytosis.","IntroductionPatients with Coronavirus Disease 2019 (COVID-19) frequently experience a hyperinflammatory syndrome, that leads to unfavorable outcomes. This condition resembles Secondary Hemophagocytic Lymphohistiocytosis (sHLH) described in neoplastic, rheumatic and other infectious diseases. However, it has not been prospectively studied on these patients. A scoring system (HScore) has been validated for sHLH, and recently proposed to evaluate hyperinflammation in COVID-19.

Methods143 patients aged [&ge;]18 years admitted because of COVID-19 were enrolled in a prospective, single-center, cohort study. HScore was calculated within the 72 hours since admission. The incidence of sHLH during hospitalization was evaluated. Additionally, the relationship between HScore [&ge;]130 points and either the requirement of mechanical ventilation or 60-days mortality was explored.

ResultsThe median age of enrolled patients was 57 (21-100), and 63.6% were male. The median HScore was 96 (33-169). One patient was diagnosed with sHLH (incidence 0,7%), due to a HScore of 169. After adjusting for age, sex, comorbidities and obesity, HScore [&ge;]130 was independently associated with the composite clinical outcome (HR 2.13, p=0.022).

ConclusionsHLH is not frequent among COVID-19 patients. HScore can efficiently predict the risk for poor outcomes.",Rafael Benavente; Camila PeÃ±a M.D.; Allyson Cid M.D.; NicolÃ¡s Cabello M.D.; Pablo Bustamante M.D.; Marco Ãlvarez M.D.; Elizabeth HenrÃ­quez M.D.; AndrÃ©s Soto M.D.; Ã‰rika Rubilar M.D.,https://medrxiv.org/cgi/content/short/2021.01.26.21249335,https://medrxiv.org/cgi/content/short/2021.01.26.21249335,2021-01-26,2021-01-26,,True
260,Home-based management of COVID-19 by identification of low-risk features,"BackgroundCovid-19 is a triphasic disorder characterized by a viral phase lasting 7-10 days from onset of symptoms. In approximately 20% it is followed by a second stage heralded by elevation of pro- inflammatory markers such as ferritin, IL-6, CRP, LDH and D-dimers. We hypothesized that those with few abnormalities would have a low risk for progression to respiratory insufficiency and hence could be monitored at home without treatment.

MethodsInclusion criteria included Covid infection, age >21, Oxygen saturation >90%. To be observed without treatment, patients could have no more than 1 of the following: CRP > 10 mg/dL, high LDH, ferritin > 500 ng/ml, D-dimer > 1 mg/L, IL-6 > 10 pg/ml, absolute lymphocyte count <1,000, Oxygen saturation <94%, or CT chest evidence of pneumonia. Primary endpoint was progression to respiratory failure and secondary endpoints was 28-day survival.

ResultsOf 208 entered, 132 were low-risk and hence were monitored without therapy. None progressed to respiratory failure or died.

ConclusionsWe have shown that our approach can identify cases who can safely be observed without treatment, thus avoiding expensive, potentially toxic therapies, and circumventing unnecessary, costly hospitalizations. These results support our hypothesis that applying our criteria, 64% of Covid-19 cases can be monitored as outpatients without therapy.

What is already known about this subjectO_LICOVID-19 is a triphasic disorder first typified by an infectious or viral phase that lasts from the first onset of symptoms until 7-10 days later. This is followed by a second phase considered as the inflammatory stage, characterized initially by the appearance of lung infiltrates which is followed in some cases by hypoxemia.
C_LIO_LIApproximately 80% of patients never proceed to the second phase but currently there is no reliable and objective method to accurately predict those that are cured spontaneously without any treatment and who could be managed at home.
C_LI

What this study addsO_LIWe have developed an approach, based essentially on blood-based inflammatory markers which identifies low-risk cases that do not require therapy and can be managed at home. This method showed an excellent correlation with clinical outcome and has encouraging financial and psychological effects.
C_LIO_LIOf 208 patients, 132, fulfilled criteria for low-risk disease that justified monitoring at home without therapy and none of these developed respiratory failure or any other significant complication.
C_LIO_LIIncluded in this low-risk group were many cases with comorbidities, with COVID-19 pneumonia, as well as patients older than 65 and with more than two symptoms at presentation. These characteristics would usually portend an unfavourable prognosis, yet all these patients had an excellent outcome.
C_LI",Fernando Cabanillas; Javier Morales; Jorge Bertran-Pasarell; Ricardo Fernandez; Jose G. Conde; Yaimara Hernandez-Silva; Idalia Liboy,https://medrxiv.org/cgi/content/short/2021.01.25.21249684,https://medrxiv.org/cgi/content/short/2021.01.25.21249684,2021-01-26,2021-01-26,,True
261,Colder and drier winter conditions are associated with greater SARS-CoV-2 transmission: a regional study of the first epidemic wave in north-west hemisphere countries.,"Higher transmissibility of SARS-CoV-2 in cold and dry weather conditions has been hypothesized since the onset of the COVID-19 pandemic but the level of epidemiological evidence remains low.

During the first wave of the pandemic, Spain, Italy, France, Portugal, Canada and USA presented an early spread, a heavy COVID-19 burden, and low initial public health response until lockdowns. In a context when testing was limited, we calculated the basic reproduction number (R0) in 63 regions from the growth in regional death counts. After adjusting for population density, early spread of the epidemic, and age structure, temperature and humidity were negatively associated to SARS-CoV-2 transmissibility. A reduction of mean absolute humidity by 1g/m3 was associated with a 0.15-unit increase of R0. Below 10{degrees}C, a temperature reduction of 1{degrees}C was associated with a 0.16-unit increase of R0.

Our results confirm a dependency of SARS-CoV-2 transmissibility to weather conditions in the absence of control measures during the first wave. The transition from summer-to winter-like conditions likely contributed to the intensification of the second wave in north-west hemisphere countries. Adjustments of the levels of social mobility restrictions need to account for increased SARS-CoV-2 transmissibility in winter conditions.",Jordi Landier; Juliette Paireau; Stanislas Rebaudet; Eva Legendre; Laurent Le Hot; Arnaud Fontanet; SIMON CAUCHEMEZ; Jean Gaudart,https://medrxiv.org/cgi/content/short/2021.01.26.21250475,https://medrxiv.org/cgi/content/short/2021.01.26.21250475,2021-01-26,2021-01-26,,True
262,"Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), initially originated in China in year 2019 and spread rapidly across the globe within 5 months, causing over 96 million cases of infection and over 2 million deaths. Huge efforts were undertaken to bring the COVID-19 vaccines in clinical development, so that it can be made available at the earliest, if found to be efficacious in the trials. We developed a candidate vaccine ZyCoV-D comprising of a DNA plasmid vector carrying the gene encoding the spike protein (S) of the SARS-CoV-2 virus. The S protein of the virus includes the receptor binding domain (RBD), responsible for binding to the human angiotensin converting enzyme (ACE-2) receptor. The DNA plasmid construct was transformed into E. coli cells for large scale production. The immunogenicity potential of the plasmid DNA has been evaluated in mice, guinea pig, and rabbit models by intradermal route at 25, 100 and 500g dose. Based on the animal studies proof-of-concept has been established and preclinical toxicology (PCT) studies were conducted in rat and rabbit model. Preliminary animal study demonstrates that the candidate DNA vaccine induces antibody response including neutralizing antibodies against SARS-CoV-2 and also provided Th-1 response as evidenced by elevated IFN-{gamma} levels.",Ayan Dey; Chozhavel Rajanathan TM; Harish Chandra; Hari PR Pericherla; Sanjeev Kumar; Huzaifa S Choonia; Mayank Bajpai; Arun K Singh; Anuradha Sinha; Gurwinder Saini; Parth Dalal; Sarosh Vandriwala; Mohammed A Raheem; Rupesh D Divate; Neelam L Navlani; Vibhuti Sharma; Aashini Parikh; Siva Prasath; Sankar Rao; Kapil Maithal,https://biorxiv.org/cgi/content/short/2021.01.26.428240,https://biorxiv.org/cgi/content/short/2021.01.26.428240,2021-01-26,2021-01-26,,False
263,A novel SARS-CoV-2 related coronavirus in bats from Cambodia,"Knowledge of the origin and reservoir of the coronavirus responsible for the ongoing COVID-19 pandemic is still fragmentary. To date, the closest relatives to SARS-CoV-2 have been detected in Rhinolophus bats sampled in the Yunnan province, China. Here we describe the identification of SARS-CoV-2 related coronaviruses in two Rhinolophus shameli bats sampled in Cambodia in 2010. Metagenomic sequencing identified nearly identical viruses sharing 92.6% nucleotide identity with SARS-CoV-2. Most genomic regions are closely related to SARS-CoV-2, with the exception of a small region corresponding to the spike N terminal domain. The discovery of these viruses in a bat species not found in China indicates that SARS-CoV-2 related viruses have a much wider geographic distribution than previously understood, and suggests that Southeast Asia represents a key area to consider in the ongoing search for the origins of SARS-CoV-2, and in future surveillance for coronaviruses.",Vibol Hul; Deborah Delaune; Erik A. Karlsson; Alexandre Hassanin; Putita Ou Tey; Artem Baidaliuk; Fabiana Gambaro; Vuong Tan Tu; Lucy Keatts; Jonna Mazet; Christine Johnson; Philippe Buchy; Philippe Dussart; Tracey Goldstein; Etienne Simon-Loriere; Veasna Duong,https://biorxiv.org/cgi/content/short/2021.01.26.428212,https://biorxiv.org/cgi/content/short/2021.01.26.428212,2021-01-26,2021-01-26,,False
264,Variant and mutation analysis of SARS-CoV-2 genomes isolated from the Kingdom of Bahrain,"The challenges imposed by the ongoing outbreak of severe acute respiratory syndrome coronavirus-2 affects every aspect of our modern world, ranging from our health to our socio-economic needs. Our existence highly depends on the vaccines availability, which demands in-depth research of the available strains and their mutations. In this work, we have analyzed all the available SERS-CoV2 genomes isolated from the Kingdom of Bahrain in terms of their variance and origin analysis. We have predicted various known and unique mutations in the SERS-CoV2 isolated from Bahrain. The complexity of the phylogenetic tree and dot plot representation of the strains mentioned above with other isolates of Asia indicates the versatility and multiple origins of Bahrains SERS-CoV2 isolates. We have also identified two high impact spike mutations from these strains which increase the virulence of SARS-CoV2. Our research could have a high impact on vaccine development and distinguishes the source of SERS-CoV2 in the Kingdom of Bahrain.",Khalid M bindayna; Abdel Halim Deifalla; Hicham Ezzat Mohammed Mokbel,https://biorxiv.org/cgi/content/short/2021.01.25.428191,https://biorxiv.org/cgi/content/short/2021.01.25.428191,2021-01-26,2021-01-26,,False
265,Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization,"The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization1,2, with more in the pipeline3-6. Furthermore, multiple vaccine constructs have shown promise7, including two with ~95% protective efficacy against Covid-198,9. However, these interventions were directed toward the initial SARS-CoV-2 that emerged in 2019. Considerable viral evolution has occurred since, including variants with a D614G mutation10 that have become dominant. Viruses with this mutation alone do not appear to be antigenically distinct, however11. Recent emergence of new SARS-CoV-2 variants B.1.1.7 in the UK12 and B.1.351 in South Africa13 is of concern because of their purported ease of transmission and extensive mutations in the spike protein. We now report that B.1.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of spike and relatively resistant to a number of mAbs to the receptor-binding domain (RBD). It is modestly more resistant to convalescent plasma (~3 fold) and vaccinee sera (~2 fold). Findings on B.1.351 are more worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely due to an E484K mutation, although some mAb combinations retain activity. Moreover, B.1.351 is markedly more resistant to neutralization by convalescent plasma (~11-33 fold) and vaccinee sera (~6.5-8.6 fold). B.1.351 and emergent variants14,15 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.",Pengfei Wang; Liu Lihong; Sho Iketani; Yang Luo; Yicheng Guo; Maple Wang; Jian Yu; Baoshan Zhang; Peter D Kwong; Barney S Graham; John R Mascola; Jennifer Y Chang; Michael T Yin; Magdalena E Sobieszczyk; Christos A Kyratsous; Lawrence Shapiro; Zizhang Sheng; Manoj S Nair; Yaoxing Huang; David D Ho,https://biorxiv.org/cgi/content/short/2021.01.25.428137,https://biorxiv.org/cgi/content/short/2021.01.25.428137,2021-01-26,2021-01-26,,False
266,A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques,"The deployment of a vaccine that limits transmission and disease likely will be required to end the Coronavirus Disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally-administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S) in the upper and lower respiratory tract of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged one month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induced neutralizing antibodies and T cell responses and limited or prevented infection in the upper and lower respiratory tract after SARS-CoV-2 challenge. As this single intranasal dose vaccine confers protection against SARS-CoV-2 in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans.",Ahmed O Hassan; Friederike Feldmann; Haiyan Zhao; David T Curiel; Atsushi Okumura; Tsing-Lee Tang-Huau; James Brett Case; Kimberly Meade-White; Julie Callison; Jamie Lovaglio; Patrick W Hanley; Dana P Scott; Daved H. Fremont; Heinz Feldmann; Michael S. Diamond,https://biorxiv.org/cgi/content/short/2021.01.26.428251,https://biorxiv.org/cgi/content/short/2021.01.26.428251,2021-01-26,2021-01-26,,False
267,Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum,"We performed the plaque reduction neutralization test (PRNT50) using sera collected from the 26 recipients of BBV152/COVAXIN against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape.",Gajanan N Sapkal; Pragya Yadav; Raches Ella; Gururaj Deshpande; Rima Sahay; Nivedita Gupta; V Krishna Mohan; Priya Abraham; Samiran Panda; Balram Bhargava,https://biorxiv.org/cgi/content/short/2021.01.26.426986,https://biorxiv.org/cgi/content/short/2021.01.26.426986,2021-01-26,2021-01-26,,False
268,Computational Investigation of Increased Virulence and Pathogenesis of SARS-CoV-2 Lineage B.1.1.7,"New variants of SARS-CoV-2 are being reported worldwide. More specifically, the variants reported in South Africa (501Y.V2) and United Kingdom (B.1.1.7) were found to be more contagious than the wild type. There are also speculations that the variants might evade the host immune responses induced by currently available vaccines and develop resistance to drugs under consideration. The first step of viral infection in COVID-19, occurs through the interaction of receptor binding domain (RBD) of the spike protein with peptidase domain of the human ACE-2 (hACE-2) receptor. So, possibly the mutations in the RBD domain of spike protein in the new variants could modulate the protein-protein interaction with hACE-2 receptor leading to the increased virulence. In this study, we aim to get molecular level understanding into the mechanism behind the increased infection rate due to such mutations in these variants. We have computationally studied the interaction of the spike protein in both wild-type and B.1.1.7 variant with hACE-2 receptor using combined molecular dynamics and binding free energy calculations using molecular mechanics-Generalized Born surface area (MM-GBSA) approach. The binding free energies computed using configurations from minimization run and low temperature simulation show that mutant variant of spike protein has increased binding affinity for hACE-2 receptor (i.e. {Delta}{Delta}G(N501Y,A570D) is in the range -20.4 to -21.4 kcal/mol)The residue-wise decomposition analysis and intermolecular hydrogen bond analysis evidenced that the N501Y mutation has increased interaction between RBD of spike protein with ACE-2 receptor. We have also carried out calculations using density functional theory and the results evidenced the increased interaction between three pairs of residues (TYR449 (spike)-ASP38 (ACE-2), TYR453-HIE34 and TYR501-LYS353) in the variant that could be attributed to its increased virulence. The free energies of wild-type and mutant variants of the spike protein computed from MM-GBSA approach suggests that latter variant is stable by about -10.4 kcal/mol when compared to wild type suggesting that it will be retained in the evolution due to increased stability. We demonstrate that with the use of the state-of-the art of computational approaches, we can in advance predict the more virulent nature of variants of SARS-CoV-2 and alert the world health-care system.",Murugan Arul Natarajan; Prashanth S. Javali; Chitra Jeyaraj Pandian; Muhammad Akhtar Ali; Vaibhav Srivastava; Jeyakanthan Jeyaraman,https://biorxiv.org/cgi/content/short/2021.01.25.428190,https://biorxiv.org/cgi/content/short/2021.01.25.428190,2021-01-26,2021-01-26,,False
269,Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2,"A detailed understanding of antibody-based SARS-CoV-2 immunity has critical implications for overcoming the COVID-19 pandemic and for informing on vaccination strategies. In this study, we evaluated the dynamics of the SARS-CoV-2 antibody response in a cohort of 963 recovered individuals over a period of 10 months. Investigating a total of 2,146 samples, we detected an initial SARS-CoV-2 antibody response in 94.4% of individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of recovered patients demonstrated exceptional SARS-CoV-2 neutralizing activity, defining them as  elite neutralizers. These individuals also possessed effective cross-neutralizing IgG antibodies to SARS-CoV-1 without any known prior exposure to this virus. By applying multivariate statistical modeling, we found that sero-reactivity, age, time since disease onset, and fever are key factors predicting SARS-CoV-2 neutralizing activity in mild courses of COVID-19. Investigating longevity of the antibody response, we detected loss of anti-spike reactivity in 13% of individuals 10 months after infection. Moreover, neutralizing activity had an initial half-life of 6.7 weeks in serum versus 30.8 weeks in purified IgG samples indicating the presence of a more stable and long-term memory IgG B cell repertoire in the majority of individuals recovered from COVID-19. Our results demonstrate a broad spectrum of the initial SARS-CoV-2 neutralizing antibody response depending on clinical characteristics, with antibodies being maintained in the majority of individuals for the first 10 months after mild course of COVID-19.",Kanika Vanshylla; Veronica Di Cristianziano; Franziska Kleipass; Felix Dewald; Philipp Schommers; Lutz Gieselmann; Henning Gruell; Maike Schlotz; Meryem S Ercanoglu; Ricarda Stumpf; Petra Mayer; Eva Heger; Wibke Johannis; Carola Horn; Isabelle Suarez; Norma Jung; Susanne Salomon; Kirsten Eberhardt; Gerd Faetkenheuer; Nico Pfeifer; Ralf Eggeling; Max Augustin; Clara Lehmann; Florian Klein,https://biorxiv.org/cgi/content/short/2021.01.26.428207,https://biorxiv.org/cgi/content/short/2021.01.26.428207,2021-01-26,2021-01-26,,False
270,40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations,"A one-step reverse transcription and real-time PCR (RT-qPCR) test was developed for rapid screening (40 minutes) of the Spike N501Y and HV69-70del mutations in SARS-CoV-2 positive samples. The test also targets a conserved region of SARS-CoV-2 Orf1ab as an internal control. The samples containing both the N501Y and HV69-70del mutations are concluded as VOC-202012/01 positive. Samples suspected to be positive for B.1.351 or P.1 are the N501Y positive and HV69-70del negative cases. Limit of detection (LOD) of the kit for Orf1ab target is 500 copies/mL, while that of the N501, Y501 and HV69-70del targets are 5000 copies/mL. The developed assay was applied to 165 clinical samples containing SARS-CoV-2 from 32 different lineages. The SARS-CoV-2 lineages were determined via the next-generation sequencing (NGS). The RT-qPCR results were in 100% agreement with the NGS results that 19 samples were N501Y and HV69-70del positive, 10 samples were N501Y positive and HV69-70del negative, 1 sample was N501Y negative and HV69-70del positive, and 135 samples were N501Y and HV69-70del negative. All the VOC-202012/01 positive samples were detected in people who have traveled from England to Turkey. The RT-qPCR test and the Sanger sequencing was further applied to 1000 SARS-CoV-2 positive clinical samples collected in Jan2021 from the 81 different provinces of Turkey. The RT-qPCR results were in 100% agreement with the Sanger sequencing results that 32 samples were N501Y positive and HV69-70del negative, 4 samples were N501Y negative and HV69-70del positive, 964 samples were N501Y and HV69-70del negative. The specificity of the 40 minutes RT-qPCR assay relative to the sequencing-based technologies is 100%. The developed assay is an advantageous tool for timely and representative estimation of the N501Y positive variants prevalence because it allows testing a much higher portion of the SARS-CoV-2 positives in much lower time compared to the sequencing-based technologies.",Gulay Korukluoglu; Mustafa Kolukirik; Fatma Bayrakdar; Gozde Girgin Ozgumus; Ayse Basak Altas; Yasemin Cosgun; Canan Zohre Ketre Kolukirik,https://biorxiv.org/cgi/content/short/2021.01.26.428302,https://biorxiv.org/cgi/content/short/2021.01.26.428302,2021-01-26,2021-01-26,,False
271,Variability in codon usage in Coronaviruses is mainly driven by mutational bias and selective constraints on CpG dinucleotide,"The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third virus within the Orthocoronavirinae causing an emergent infectious disease in humans, the ongoing coronavirus disease 2019 pandemic (COVID-19). Due to the high zoonotic potential of these viruses, it is critical to unravel their evolutionary history of host species shift, adaptation and emergence. Only such knowledge can guide virus discovery, surveillance and research efforts to identify viruses posing a pandemic risk in humans. We present a comprehensive analysis of the composition and codon usage bias of the 82 Orthocoronavirinae members, infecting 47 different avian and mammalian hosts. Our results clearly establish that synonymous codon usage varies widely among viruses and is only weakly dependent on the type of host they infect. Instead, we identify mutational bias towards AT-enrichment and selection against CpG dinucleotides as the main factors responsible of the codon usage bias variation. Further insight on the mutational equilibrium within Orthocoronavirinae revealed that most coronavirus genomes are close to their neutral equilibrium, the exception is the three recently-infecting human coronaviruses, which lie further away from the mutational equilibrium than their endemic human coronavirus counterparts. Finally, our results suggest that while replicating in humans SARS-CoV-2 is slowly becoming AT-richer, likely until attaining a new mutational equilibrium.",Josquin Daron; Ignacio G. Bravo,https://biorxiv.org/cgi/content/short/2021.01.26.428296,https://biorxiv.org/cgi/content/short/2021.01.26.428296,2021-01-26,2021-01-26,,False
272,A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients with Mild-to-Moderate COVID-19,"Innovative strategies are required to manage COVID-19 in the communities. Back to Roots was a collaborative, community-based pilot intervention project in the British Asian community. To assess the efficacy and safety of Ayurveda intervention in relieving symptoms of mild-to-moderate COVID-19, a community based participatory research framework was used. Prospectively 28 patients were enrolled with confirmed COVID-19 clinical stages of mild-to-moderate COVID-19, symptomatic, and between 20 to 70{square}years of age. Routine management was followed by all patients managing at home, additionally patents taking Ayurveda intervention for 14 consecutive days. The efficacy and safety of Ayurveda intervention were evaluated. There were suggestions of Ayurvedas advantage in improved symptoms relief, clinical recovery in 7 days. However, a control group was not included but data triangulations from separate usual care found the difference statistically significant. Ayurveda intervention may potentially have a beneficial effect on patients with COVID{square}19, especially for those with mild to moderate symptoms. A further definitive large{square}scale clinical trial is necessary.",Vishwesh Kulkarni; Neha Sharma; Dipa Modi; Abhimanyu Kumar; Jaydeep Joshi; Nagamani Krishnamurthy,https://medrxiv.org/cgi/content/short/2021.01.20.21250198,https://medrxiv.org/cgi/content/short/2021.01.20.21250198,2021-01-26,2021-01-26,,True
273,Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma,"New SARS-CoV-2 variants with mutations in the spike glycoprotein have arisen independently at multiple locations and may have functional significance. The combination of mutations in the 501Y.V2 variant first detected in South Africa include the N501Y, K417N, and E484K mutations in the receptor binding domain (RBD) as well as mutations in the N-terminal domain (NTD). Here we address whether the 501Y.V2 variant could escape the neutralizing antibody response elicited by natural infection with earlier variants. We were the first to outgrow two variants of 501Y.V2 from South Africa, designated 501Y.V2.HV001 and 501Y.V2.HVdF002. We examined the neutralizing effect of convalescent plasma collected from six adults hospitalized with COVID-19 using a microneutralization assay with live (authentic) virus. Whole genome sequencing of the infecting virus of the plasma donors confirmed the absence of the spike mutations which characterize 501Y.V2. We infected with 501Y.V2.HV001 and 501Y.V2.HVdF002 and compared plasma neutralization to first wave virus which contained the D614G mutation but no RBD or NTD mutations. We observed that neutralization of the 501Y.V2 variants was strongly attenuated, with IC50 6 to 200-fold higher relative to first wave virus. The degree of attenuation varied between participants and included a knockout of neutralization activity. This observation indicates that 501Y.V2 may escape the neutralizing antibody response elicited by prior natural infection. It raises a concern of potential reduced protection against re-infection and by vaccines designed to target the spike protein of earlier SARS-CoV-2 variants.",Sandile Cele; Inbal Gazy; Laurelle Jackson; Shi-Hsia Hwa; Houriiyah Tegally; Gila Lustig; Jennifer Giandhari; Sureshnee Pillay; Eduan Wilkinson; Yeshnee Naidoo; Farina Karim; Yashica Ganga; Khadija Khan; Alejandro B. Balazs; Bernadett I. Gosnell; Willem Hanekom; Mahomed-Yunus S. Moosa; Richard J. Lessells; Tulio de Oliveira; Alex Sigal,https://medrxiv.org/cgi/content/short/2021.01.26.21250224,https://medrxiv.org/cgi/content/short/2021.01.26.21250224,2021-01-26,2021-01-26,,True
274,SARS-CoV-2 Airborne Surveillance Using Non-Powered Cold Traps,"BackgroundCOVID-19 pandemic is a worldwide challenge requiring efficient containment strategies. High-throughput SARS-CoV-2 testing and legal restrictions are not effective in order to get the current outbreak under control. Emerging SARS-CoV-2 variants with a higher transmissibility require efficient strategies for early detection and surveillance.

MethodsSARS-CoV-2 RNA levels were determined by quantitative RT-PCR in aerosols collected by non-powered cold traps. SARS-CoV-2 spreading kinetics and indoor hotspots could be identified in isolation units and at public places within a high-endemic area. These included an outpatient endoscopy facility, a concert hall, and a shopping mall.

ResultsIndoor COVID-19 hotspots were found in non-ventilated areas and in zones that are predisposed to a buoyancy (chimney) effect. SARS-CoV-2 RNA in those aerosols reached concentrations of 105 copies/mL. Extensive outdoor air ventilation reliably eliminates SARS-CoV-2 aerosol contamination.

ConclusionsThe method presented herein could predict SARS-CoV-2 indoor hotspots and may help to characterize SARS-CoV-2 spreading kinetics. Moreover, it can be used for the surveillance of emerging SARS-CoV-2 variants. Due to low costs and easy handling, the procedure might enable efficient algorithms for COVID-19 prevention and screening.",Sven G. Gehrke; Claudia Foerderer; Wolfgang Stremmel,https://medrxiv.org/cgi/content/short/2021.01.19.21250064,https://medrxiv.org/cgi/content/short/2021.01.19.21250064,2021-01-26,2021-01-26,,True
275,High density lipoprotein cholesterol and risk of subsequent COVID-19 hospitalisation: the UK Biobank study,"IntroductionWhile unfavourable changes in High Density Lipoprotein (HDL)-cholesterol appear to be a consequence of COVID-19, the reverse has been little-studied. Our objective was to test whether HDL-cholesterol within the normal range is associated with subsequent COVID-19 hospitalisation.

DesignWe examined 317,306 participants in the prospective UK Biobank study with complete data on HDL-cholesterol and covariates at baseline (2006-2010). Follow-up for COVID-19 status was via hospitalisation records in England (16th March and 31st May 2020). Death certificates for the period 1st March to 30th September 2020 with an underlying cause denoted as COVID-19 (emergency ICD-10 code U07.1) were also utilised.

ResultsLower COVID-19 hospitalisation risk was apparent in people with higher level of HDL-cholesterol, adjusting for factors including health behaviours, inflammatory markers, and socio-economic status. The association appeared to be linear so that for each 0.2 mmol/L increase in HDL-cholesterol, the odds ratio for COVID-19 hospitalisation was 0.91 (95% confidence interval: 0.86, 0.96). A similar pattern of association was apparent when deaths from COVID-19 was the outcome of interest.

ConclusionsAdequately high levels of HDL-cholesterol are associated with a lower risk of severe COVID-19.",Camille Lassale; Mark Hamer; Alvaro Hernaez; Catharine R Gale; George David Batty,https://medrxiv.org/cgi/content/short/2021.01.20.21250152,https://medrxiv.org/cgi/content/short/2021.01.20.21250152,2021-01-26,2021-01-26,,True
276,Contact patterns before and during the UK's Autumn 2020 COVID-19 lockdown among university students and staff,"IntroductionContact patterns are an important determinant of infection transmission. CONQUEST (COroNavirus QUESTionnaire) is an online survey of contacts for University of Bristol (UoB) staff and students. Results from 23/06/2020-24/11/2020 are used to investigate contact patterns among staff/students throughout various UK COVID-19 guidance periods.

MethodsResponses captured self-reported contacts on the previous day, with COVID-19 guidance periods split: post-first lockdown (23/06/2020-03/07/2020), relaxed guidance period (04/07/2020-13/09/2020), ""rule-of-six"" period (14/09/2020-04/11/2020), and the second lockdown (05/11/2020-25/11/2020).

Results722 staff (4199 responses) (mean household size: 2.6) and 738 students (1906 responses) (mean household size: 4.5) were included in the study. For staff, median contacts on the previous day were higher in the relaxed guidance and ""rule-of-six"" periods (3) than the post-lockdown and second lockdown periods (2). Mean contacts were higher during these two middle periods (4-6 per week) than the post-lockdown and second lockdown periods (~3). Mean contacts dropped between the last two periods (5.4 to 3.3), driven by a mean reduction in contacts in non-home/university locations (2.9 to 1.2).

Few students responded until October. After 05/10/2020, the median was 2 and the mean was around 6-7 each week, until the second lockdown when it dropped to [~]4. Mean number of contacts dropped between the last two periods (6.3 to 4.0) driven by a reduction in all contact types, including UoB contacts (3.5 to 2.5).

DiscussionThe mean and median number of contacts for UoB staff and students were low compared to pre-COVID-19 studies throughout the survey period and lowest during the second lockdown.",Adam Trickey; Emily J Nixon; Hannah Christensen; Adam Finn; Amy C Thomas; Caroline Relton; Clara Montgomery; Gibran Hemani; Jane Metz; Josephine G Walker; Katy Turner; Rachel Kwiatkowska; Sarah Sauchelli; Leon Danon; Ellen Brooks-Pollock,https://medrxiv.org/cgi/content/short/2021.01.19.21250097,https://medrxiv.org/cgi/content/short/2021.01.19.21250097,2021-01-26,2021-01-26,,True
277,"Integrating Operant and Cognitive Behavioral Economics to Inform Infectious Disease Response: Prevention, Testing, and Vaccination in the COVID-19 Pandemic","The role of human behavior to thwart transmission of infectious diseases like COVID-19 is evident. Yet, many areas of psychological and behavioral science are limited in the ability to mobilize to address exponential spread or provide easily translatable findings for policymakers. Here we describe how integrating methods from operant and cognitive approaches to behavioral economics can provide robust policy relevant data. Adapting well validated methods from behavioral economic discounting and demand frameworks, we evaluate in four crowdsourced samples (total N = 1,366) behavioral mechanisms underlying engagement in preventive health behaviors. We find that people are more likely to social distance when specified activities are framed as high risk, that describing delay until testing (rather than delay until results) increases testing likelihood, and that framing vaccine safety in a positive valence improves vaccine acceptance. These findings collectively emphasize the flexibility of methods from diverse areas of behavioral science for informing public health crisis management.",Justin C Strickland; Derek D Reed; Steven R Hursh; Lindsay P Schwartz; Rachel NS Foster; Brett W Gelino; Robert S LeComte; Fernanda S Oda; Allyson R Salzer; Tadd D Schneider; Lauren Dayton; Carl Latkin; Matthew Johnson,https://medrxiv.org/cgi/content/short/2021.01.20.21250195,https://medrxiv.org/cgi/content/short/2021.01.20.21250195,2021-01-26,2021-01-26,,True
278,Impact of COVID-19 Pandemic on Inpatient Rehabilitation and the Original Infection Control Measures for Rehabilitation Team,"ObjectiveThis study aimed to investigate the impact of the coronavirus disease 2019 (COVID-19) pandemic on inpatient rehabilitation, and to determine the effectiveness of the original infection control measures implemented for the rehabilitation team.

MethodsIn this single-center, retrospective, observational study, we calculated multiple rehabilitation indices of patients discharged from our rehabilitation ward between February 28 and May 25, 2020 when Hokkaido was initially affected by COVID-19, and compared them with those calculated during the same period in 2019. Fishers exact test and the Mann-Whitney U test were used for statistical analysis. We also verified the impact of implementing the original infection control measures for the rehabilitation team on preventing nosocomial infections.

ResultsA total of 93 patients (47 of 2020 group, 46 of 2019 group) were included. The median age was 87 and 88 years, respectively, with no differences in age, sex, and main disease between the groups. Training time per day in the ward in 2020 was significantly lower than that in 2019 (p = 0.013). No significant differences were found in the qualitative evaluation indices of Functional Independence Measure (FIM) score at admission, FIM gain, length of ward stay, FIM efficiency, and rate of discharge to home. None of the patients or staff members had confirmed COVID-19 during the study period.

ConclusionsEarly COVID-19 pandemic in Hokkaido affected the quantitative index for inpatient rehabilitation but not the qualitative indices. No symptomatic nosocomial COVID-19 infections were observed with our infection control measures.",Yukimasa Igawa; Takahiro Sugimoto; Hiromasa Horimoto; Yusuke Moriya; Masaki Okada; Yasuyuki Yamada,https://medrxiv.org/cgi/content/short/2021.01.20.21250145,https://medrxiv.org/cgi/content/short/2021.01.20.21250145,2021-01-26,2021-01-26,,True
279,"Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil","Emergence of novel SARS-CoV-2 lineages are under the spotlight of the media, scientific community and governments. Recent reports of novel variants in the United Kingdom, South Africa and Brazil (B.1.1.28-E484K) have raised intense interest because of a possible higher transmission rate or resistance to the novel vaccines. Nevertheless, the spread of B.1.1.28 (E484K) and other variants in Brazil is still unknown. In this work, we investigated the population structure and genomic complexity of SARS-CoV-2 in Rio Grande do Sul, the southernmost state in Brazil. Most samples sequenced belonged to the B.1.1.28 (E484K) lineage, demonstrating its widespread dispersion. We were the first to identify two independent events of co-infection caused by the occurrence of B.1.1.28 (E484K) with either B.1.1.248 or B.1.91 lineages. Also, clustering analysis revealed the occurrence of a novel cluster of samples circulating in the state (named VUI-NP13L) characterized by 12 lineage-defining mutations. In light of the evidence for E484K dispersion, co-infection and emergence of VUI-NP13L in Rio Grande do Sul, we reaffirm the importance of establishing strict and effective social distancing measures to counter the spread of potentially more hazardous SARS-CoV-2 strains.

HighlightsO_LIThe novel variant B.1.1.28 (E484K) previously described in Rio de Janeiro is currently spread across the southernmost state of Brazil;
C_LIO_LIThe novel variant VUI-NP13L was also identified by causing a local outbreak in Rio Grande do Sul;
C_LIO_LIB.1.1.28 (E484K) is able to establish successful coinfection events co-occurring simultaneously with different lineages of SARS-CoV-2.
C_LI",Ronaldo da Silva Francisco Junior; L. Felipe Benites; Alessandra P Lamarca; Luiz Gonzaga P de Almeida; Alana Witt Hansen; Juliana Schons Gularte; Meriane Demoliner; Alexandra L Gerber; Ana Paula de C Guimaraes; Ana Karolina Eisen Antunes; Fagner Henrique Heldt; Larissa Mallmann; Bruna Hermann; Ana Luiza Ziulkosk; Vyctoria Goes; Karoline Schallenberger; Micheli Fillipi; Francini Pereira; Matheus Nunes Weber; Paula Rodrigues de Almeida; Juliane Deise Fleck; Ana Tereza Ribeiro de Vasconcelos; Fernando Rosado Spilki,https://medrxiv.org/cgi/content/short/2021.01.21.21249764,https://medrxiv.org/cgi/content/short/2021.01.21.21249764,2021-01-26,2021-01-26,,True
280,mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants,"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide. The Moderna mRNA-1273 vaccine has demonstrated ~94% efficacy in a Phase 3 study and has been approved under Emergency Use Authorization. The emergence of SARS-CoV-2 variants with mutations in the spike protein, most recently circulating isolates from the United Kingdom (B.1.1.7) and Republic of South Africa (B.1.351), has led to lower neutralization from convalescent serum by pseudovirus neutralization (PsVN) assays and resistance to certain monoclonal antibodies. Here, using two orthogonal VSV and lentivirus PsVN assays expressing spike variants of 20E (EU1), 20A.EU2, D614G-N439, mink cluster 5, B.1.1.7, and B.1.351 variants, we assessed the neutralizing capacity of sera from human subjects or non-human primates (NHPs) that received mRNA-1273. No significant impact on neutralization against the B.1.1.7 variant was detected in either case, however reduced neutralization was measured against the mutations present in B.1.351. Geometric mean titer (GMT) of human sera from clinical trial participants in VSV PsVN assay using D614G spike was 1/1852. VSV pseudoviruses with spike containing K417N-E484K-N501Y-D614G and full B.1.351 mutations resulted in 2.7 and 6.4-fold GMT reduction, respectively, when compared to the D614G VSV pseudovirus. Importantly, the VSV PsVN GMT of these human sera to the full B.1.351 spike variant was still 1/290, with all evaluated sera able to fully neutralize. Similarly, sera from NHPs immunized with 30 or 100g of mRNA-1273 had VSV PsVN GMTs of ~ 1/323 or 1/404, respectively, against the full B.1.351 spike variant with a ~ 5 to 10-fold reduction compared to D614G. Individual mutations that are characteristic of the B.1.1.7 and B.1.351 variants had a similar impact on neutralization when tested in VSV or in lentivirus PsVN assays. Despite the observed decreases, the GMT of VSV PsVN titers in human vaccinee sera against the B.1.351 variant remained at ~1/300. Taken together these data demonstrate reduced but still significant neutralization against the full B.1.351 variant following mRNA-1273 vaccination.",Not available,https://biorxiv.org/cgi/content/short/2021.01.25.427948,https://biorxiv.org/cgi/content/short/2021.01.25.427948,2021-01-25,2021-01-25,,False
281,An effect of the COVID-19 pandemic: significantly more complicated appendicitis due to delayed presentation of patients!,"AIMS OF THE STUDYThe novel coronavirus pandemic has affected emergency department consultations for surgical pathologies. The aim of our study was to compare the number of acute appendicitis cases and the proportion of complicated appendicitis before and during the COVID-19 pandemic.

METHODSWe retrospectively analyzed all data collected from a multi-center database of patients presenting to the emergency department for acute appendicitis during the COVID-19 pandemic from March 12 to June 6, 2020, and compared these data with those from the same periods in 2017, 2018, and 2019. The number of acute appendicitis cases, proportion of complicated appendicitis, and pre- and postoperative patient characteristics were evaluated.

RESULTSA total of 306 patients were included in this evaluation. Sixty-five patients presented during the 2020 COVID-19 pandemic lockdown (group A), and 241 patients in previous years (group B: 2017-2019). The number of consultations for acute appendicitis decreased by almost 20 percent during the pandemic compared with previous periods, with a significant increase in complicated appendicitis (52% in group A versus 20% in group B, p < 0,001.). Comparing the two groups, significant differences were also noted in the duration of symptoms (symptoms > 48h in 61% and 26%, p < 0,001), the intervention time (77 vs 61 minutes, p = 0,002), length of hospital stay (hospitalization of > 2 days in 63% and 32%, p < 0.001) and duration of antibiotic treatment (antibiotics > 3 days in 36% and 24% p = 0.001).

CONCLUSIONSThe COVID-19 pandemic resulted in a decreased number of consultations for acute appendicitis, with a higher proportion of complicated appendicitis, most likely due to patient delay in consulting the emergency department at symptom onset. Patients and general practitioners should be aware of this problem to avoid a time delay from initial symptoms to consultation.",Marie Burgard; Floryn Cherbanyk; Konstantinos Nassiopoulos; Sonaz Malekzadeh; Francois Pugin; Bernhard Egger,https://medrxiv.org/cgi/content/short/2021.01.23.21250358,https://medrxiv.org/cgi/content/short/2021.01.23.21250358,2021-01-25,2021-01-25,,True
282,Mask adherence and rate of COVID-19 across the United States,"Mask wearing has been advocated by public health officials as a way to reduce the spread of COVID-19. In the United States, policies on mask wearing have varied from state to state over the course of the pandemic. Even as more and more government leaders encourage or even mandate mask wearing, many citizens still resist the notion. Our research examines mask-wearing policy and adherence in association with COVID-19 case rates. We used state-level data on mask-wearing policy for the general public and on proportion of residents who stated they always wear masks in public. For all 50 states and the District of Columbia (DC), these data were abstracted by month for AprilSeptember 2020 to measure their impact on COVID-19 rates in the subsequent month (MayOctober 2020). Monthly COVID-19 case rates (number of cases per capita over two weeks) >200 per 100,000 residents were considered high. Fourteen of the 15 states with no mask-wearing policy for the general public reported a high COVID-19 rate. Of the 8 states with at least 75% mask adherence, none reported a high COVID-19 rate. States with the lowest levels of mask adherence were most likely to have high COVID-19 rates in the subsequent month, independent of mask policy or demographic factors. Our analysis suggests high adherence to mask wearing could be a key factor in reducing the spread of COVID-19. This association between high mask adherence and reduced COVID-19 rates should influence policy makers and public health officials to focus on ways to improve mask adherence across the population in order to mitigate the spread of COVID-19.",Charlie B Fischer; Nedghie Adrien; Jeremiah J Silguero; Julianne J Hopper; Abir I Chowdhury; Martha M Werler,https://medrxiv.org/cgi/content/short/2021.01.18.21250029,https://medrxiv.org/cgi/content/short/2021.01.18.21250029,2021-01-25,2021-01-25,,True
283,"Association between clinical characteristics and laboratory findings with outcome of hospitalized COVID-19 patients, a report from northeast of Iran","Coronavirus disease 2019 (COVID-19) was first discovered in December 2019 in China and has rapidly spread worldwide. Clinical characteristics, laboratory findings, and their association with the outcome of patients with COVID-19 can be decisive in management and early diagnosis. Data were obtained retrospectively from medical records of 397 hospitalized COVID-19 patients between February and May 2020 in Imam Reza hospital, northeast of Iran. Clinical and laboratory features were evaluated among survivors and non-survivors. The correlation between variables and duration of hospitalization and admission to the Intensive Care Unit (ICU) was determined. Male sex, age, hospitalization duration, and admission to ICU were significantly related to mortality rate. Headache was a more common feature in patients who survived (p = 0.017). It was also related to a shorter stay in the hospital (p = 0.032) as opposed to patients who experienced chest pain (p = 0.033). Decreased levels of consciousness and dyspnea were statistically more frequent in non-survivors (p = 0.003 and p = 0.011, respectively). Baseline white blood cell count (WBC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were significantly higher in non-survivors (p < 0.001). Patients with higher WBC and CRP levels were more likely to be admitted to ICU (p = 0.009 and p = 0.001, respectively). Evaluating clinical and laboratory features can help clinicians find ways for risk stratifying patients and even make predictive tools. Chest pain, decreased level of consciousness, dyspnea, and increased CRP and WBC levels seem to be the most potent predictors of severe prognosis.",Sahar Sobhani; Reihaneh Aryan; Elham Kalantari; Salman Soltani; Nafise Malek; Parisa Pirzadeh; Amir Yarahmadi; Atena Aghaee,https://medrxiv.org/cgi/content/short/2021.01.23.21250359,https://medrxiv.org/cgi/content/short/2021.01.23.21250359,2021-01-25,2021-01-25,,True
284,Harnessing testing strategies and public health measures to avert COVID-19 outbreaks during ocean cruises,"To ensure the safe operation of schools, workplaces, nursing homes, and other businesses during COVID-19 pandemic there is an urgent need to develop cost-effective public health strategies. Here we focus on the cruise industry which was hit early by the COVID-19 pandemic, with more than 40 cruise ships reporting COVID-19 infections. We apply mathematical modeling to assess the impact of testing strategies together with social distancing protocols on the spread of the novel coronavirus during ocean cruises using an individual-level stochastic model of the transmission dynamics of COVID-19. We model the contact network, the potential importation of cases arising during shore excursions, the temporal course of infectivity at the individual level, the effects of social distancing strategies, different testing scenarios characterized by the tests sensitivity profile, and the testing frequency. Our findings indicate that PCR testing at embarkation and daily testing of all individuals aboard, together with increased social distancing and other public health measures, should allow for rapid detection and isolation of COVID-19 infections and dramatically reducing the probability of onboard COVID-19 community spread. In contrast, relying only on PCR testing at embarkation would not be sufficient to avert outbreaks, even when implementing substantial levels of social distancing measures.",Gerardo Chowell; Sushma Dahal; Raquel Bono; Kenji Mizumoto,https://medrxiv.org/cgi/content/short/2021.01.24.21250408,https://medrxiv.org/cgi/content/short/2021.01.24.21250408,2021-01-25,2021-01-25,,True
285,Detection of SARS-CoV-2 infection by rapid antigen test in comparison with RT-PCR in a public setting,"BackgroundRapid and accurate detection of SARS-CoV-2 infection is essential in limiting the spread of infection during the ongoing COVID-19 pandemic. The aim of this study was to determine the accuracy of the STANDARD Q COVID-19 Ag test (SD BIOSENSOR) by comparison with RT-PCR in a public setting.

MethodIndividuals aged 18 years or older who had booked an appointment for a RT-PCR test on December 26-31, 2020 at a public test center in Copenhagen, Denmark, were invited to participate. An oropharyngeal swab was collected for RT-PCR analysis, immediately followed by a nasopharyngeal swab examined by the STANDARD Q COVID-19 Ag test (SD BIOSENSOR). Sensitivity, specificity, positive and negative predictive values of the antigen test were calculated with test results from RT-PCR as reference.

ResultsOverall, 4697 individuals were included (female n=2456, 53.3%; mean age: 44.7 years, SD: 16.9 years); 196 individuals were tested twice or more. Among 4811 paired conclusive test results from the RT-PCR and antigen tests, 221 (4.6%) RT-PCR tests were positive. The overall sensitivity and specificity of the antigen test were 69.7% and 99.5%, the positive and negative predictive values were 87.0% and 98.5%. Ct values were significantly higher among individuals with false negative antigen tests compared to true positives.

ConclusionThe sensitivity, specificity, and predictive values found indicate that the STANDARD Q COVID-19 Ag is a good supplement to RT-PCR testing.",Kathrine Kronberg Jakobsen; Jakob Schmidt Jensen; Tobias Todsen; Freddy Lippert; Cyril Jean-Marie Martel; Mads Klokker; Christian von Buchwald,https://medrxiv.org/cgi/content/short/2021.01.22.21250042,https://medrxiv.org/cgi/content/short/2021.01.22.21250042,2021-01-25,2021-01-25,,True
286,"Distinct Autoimmune Antibody Signatures Between Hospitalized Acute COVID-19 Patients, SARS-CoV-2 Convalescent Individuals, and Unexposed Pre-Pandemic Controls","Increasing evidence suggests that autoimmunity may play a role in the pathophysiology of SARS-CoV-2 infection during both the acute and  long COVID phases of disease. However, an assessment of autoimmune antibodies in convalescent SARS-CoV-2 patients has not yet been reported.

MethodologyWe compared the levels of 18 different IgG autoantibodies (AABs) between four groups: (1) unexposed pre-pandemic subjects from the general population (n = 29); (2) individuals hospitalized with acute moderate-severe COVID-19 (n = 20); (3) convalescent SARS-COV-2-infected subjects with asymptomatic to mild viral symptoms during the acute phase with samples obtained between 1.8 and 7.3 months after infection (n = 9); and (4) unexposed pre-pandemic subjects with systemic lupus erythematous (SLE) (n = 6). Total IgG and IgA levels were also measured from subjects in groups 1-3 to assess non-specific pan-B cell activation.

ResultsAs expected, in multivariate analysis, AABs were detected at much higher odds in SLE subjects (5 of 6, 83%) compared to non-SLE pre-pandemic controls (11 of 29, 38%) [odds ratio (OR) 19.4,95% CI, 2.0 - 557.0, p = 0.03]. AAB detection (percentage of subjects with one or more autoantibodies) was higher in SARS-CoV-2 infected convalescent subjects (7 of 9, 78%) [OR 17.4, 95% CI, 2.0 - 287.4, p = 0.02] and subjects with acute COVID-19 (12 of 20, 60%) compared with non-SLE pre-pandemic controls, but was not statistically significant among the latter [OR 1.8,95% CI, 0.6 - 8.1, p = 0.23]. Within the convalescent subject group, AABs were detected in 5/5 with reported persistent symptoms and 2/4 without continued symptoms (p = 0.17). The multivariate computational algorithm Partial Least Squares Determinant Analysis (PLSDA) was used to determine if distinct AAB signatures distinguish subject groups 1-3. Of the 18 autoantibodies measured, anti-Beta 2-Glycoprotein, anti-Proteinase 3-ANCA, anti-Mi-2 and anti-PM/Scl-100 defined the convalescent group; anti-Proteinase 3-ANCA, anti-Mi-2, anti-Jo-1 and anti-RNP/SM defined acute COVID-19 subjects; and anti-Proteinase 3-ANCA, anti-Mi-2, anti-Jo-1, anti-Beta 2-Glycoprotein distinguished unexposed controls. The AABs defining SARS-COV-2 infected from pre-pandemic subjects are widely associated with myopathies, vasculitis, and antiphospholipid syndromes, conditions with some similarities to COVID-19. Compared to pre-pandemic non-SLE controls, subjects with acute COVID-19 had higher total IgG concentration (p-value=0.006) but convalescent subjects did not (p-value=0.08); no differences in total IgA levels were found between groups.

ConclusionsOur findings support existing studies suggesting induction of immune responses to self-epitopes during acute, severe COVID-19 with evidence of general B cell hyperactivation. Also, the preponderance of AAB positivity among convalescent individuals up to seven months after infection indicates potential initiation or proliferation, and then persistence of self-reactive immunity without severe initial disease. These results underscore the importance of further investigation of autoimmunity during SARS-CoV-2 infection and its role in the onset and persistence of post-acute sequelae of COVID-19.",Nahid Bhadelia; Anna Belkina; Alex Olson; Thomas Winter; Patricia Urick; Nina Lin; Ian Rifkin; Yachana Kataria; Rachel Yuen; Manish Sagar; Jennifer Cappione,https://medrxiv.org/cgi/content/short/2021.01.21.21249176,https://medrxiv.org/cgi/content/short/2021.01.21.21249176,2021-01-25,2021-01-25,,True
287,An interactive COVID-19 virus Mutation Tracker (CovMT) with a particular focus on critical mutations in the Receptor Binding Domain (RBD) region of the Spike protein,"Almost one year has passed since the appearance of SARS-CoV-2, causing the COVID-19 pandemic. The number of confirmed SARS-Cov-2 cases worldwide has now reached [~]92 million, with 2 million reported deaths (https://covid19.who.int). Nearly 400,000 SARS-Cov-2 genomes were sequenced from COVID-19 samples and added to public resources such as GISAID (https://gisaid.org). With the vaccines becoming available or entering trials (https://covid19.trackvaccines.org), it is vital to keep track of mutations in the genome of SARS-CoV-2, especially in the Spike proteins Receptor Binding Domain (RBD) region, which could have a potential impact on disease severity and treatment strategies.1-3 In the wake of a recent increase in cases with a potentially more infective RBD mutation (N501Y) in the United Kingdom, countries worldwide are concerned about the spread of this or similar variants. Impressive sampling and timely increase in sequencing efforts related to COVID-19 in the United Kingdom (UK) helped detect and monitor the spread of the new N501Y variant. Similar sequencing efforts are needed in other countries for timely tracking of this or different variants. To track geographic sequencing efforts and mutations, with a particular focus on RBD region of the Spike protein, we present our daily updated COVID-19 virus Mutation Tracker system, see https://www.cbrc.kaust.edu.sa/covmt.",Intikhab Alam; Aleksandar Radovanovic; Roberto Incitti; Allan Kamau; Muhammed Alarawi; Esam I. Azhar; Takashi Gojobori,https://medrxiv.org/cgi/content/short/2021.01.22.21249716,https://medrxiv.org/cgi/content/short/2021.01.22.21249716,2021-01-25,2021-01-25,,True
288,Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients,"BackgroundReports of persistent symptoms after hospitalization with COVID-19 have raised concern of a ""long COVID"" syndrome. This study aimed at characterizing acute and persistent symptoms in non- hospitalized patients with polymerase chain reaction (PCR) confirmed COVID-19.

MethodsCohort study of 445 non-hospitalized participants identified via the Danish Civil Registration System with a SARS-CoV-2-positive PCR-test and available biobank samples for genetic analyses. Participants received a digital questionnaire on demographics and COVID-19-related symptoms. Persistent symptoms: symptoms >four weeks (in sensitivity analyses >12 weeks).

Results445 participants were included, of whom 34% were asymptomatic. Most common acute symptoms were fatigue, headache, and sneezing, while fatigue and reduced smell and taste were reported as most severe. Persistent symptoms, most commonly fatigue and memory and concentration difficulties, were reported by 36% of 198 symptomatic participants with follow-up >four weeks. Risk factors for persistent symptoms included female sex (women 44% vs. men 24%, odds ratio 2.7, 95%CI:1.4-5.1, p=0.003) and BMI (odds ratio 1.1, 95%CI:1.0-1.2, p=0.001).

ConclusionAmong non-hospitalized PCR-confirmed COVID-19 patients one third were asymptomatic while one third of symptomatic participants had persistent symptoms illustrating the heterogeneity of disease presentation. These findings should be considered in future health care planning and policy making related to COVID-19.",Sofie Bliddal; Karina Banasik; Ole Birger Pedersen; Ioanna Nissen; Lisa Cantwell; Michael Schwinn; Morten Tulstrup; David Westergaard; Henrik Ullum; Soren Brunak; Niels Tommerup; Bjarke Feenstra; Frank Geller; Sisse Rye Ostrowski; Kirsten Groenbaek; Claus Henrik Nielsen; Susanne Dam Nielsen; Ulla Feldt-Rasmussen,https://medrxiv.org/cgi/content/short/2021.01.22.21249945,https://medrxiv.org/cgi/content/short/2021.01.22.21249945,2021-01-25,2021-01-25,,True
289,SARS-CoV-2 Control on a Large Urban College Campus Without Mass Testing,"ObjectiveA small percentage of universities and colleges conduct mass SARS-CoV-2 testing. However, universal testing is resource-intensive, strains national testing capacity, and false negative tests can encourage unsafe behaviors.

ParticipantsA large urban university campus.

MethodsVirus control centered on three pillars: mitigation, containment, and communication, with testing of symptomatic and a random subset of asymptomatic students.

ResultsRandom surveillance testing demonstrated a prevalence among asymptomatic students of 0.4% throughout the term. There were two surges in cases that were contained by enhanced mitigation and communication combined with targeted testing. Cumulative cases totaled 445 for the term, most resulting from unsafe undergraduate student behavior and among students living off-campus. A case rate of 232/10,000 undergraduates equaled or surpassed several peer institutions that conducted mass testing.

ConclusionsAn emphasis on behavioral mitigation and communication can control virus transmission on a large urban campus combined with a limited and targeted testing strategy.",Christopher P O'Donnell; Katherine Brownlee; Elise Martin; Joe Suyama; Steven Middle Name(s)/Initial(s) Albert; Steven Anderson; Sai H Bhatte; Kenyon Bonner; Chad Burton; Micaela F Corn; Heather Eng; Bethany J Flage; Jay Frerotte; Goundappa K Balasubramani; Catherine L Haggerty; Joel Haight; Lee H Harrison; Amy Hartman; Thomas Hitter; Wendy C King; Kate Ledger; Jane W Marsh; Margaret C McDonald; Bethany R Miga; Kimberly D Moses; Anne W Newman; Meg Ringler; Mark S Roberts; Terrie Sax; Anantha Shekhar; Matthew Sterne; Tyler J Tenney; Marian Vanek; Alan Wells; Sally Wenzel; John V Williams,https://medrxiv.org/cgi/content/short/2021.01.21.21249825,https://medrxiv.org/cgi/content/short/2021.01.21.21249825,2021-01-25,2021-01-25,,True
290,"COVID-19 Diagnostic Testing For All - Using Non-Dilutive Saliva Sample Collection, Stabilization and Ambient Transport Devices","COVID-19 testing is not accessible for millions during this pandemic despite our best efforts. Without greatly expanded testing of asymptomatic individuals, contact tracing and subsequent isolation of spreaders remains as a means for control. In an effort to increase RT-PCR assay testing for the presence of the novel beta-coronavirus SARS-CoV-2 as well as improve sample collection safety, GenTegra LLC has introduced two products for saliva collection and viral RNA stabilization: GTR-STM (GenTegra Saliva Transport Medium) and GTR-STMdk (GenTegra Saliva Transport Medium Direct to PCR). Both products contain a proprietary formulation based on GenTegras novel ""Active Chemical Protection"" (ACP) technology that gives non-dilutive, error-free saliva sample collection using RNA stabilization chemicals already dried in the collection tube.

GTR-STM can be used for safer saliva-based sample collection at home (or at a test site). Following saliva collection, the sample-containing GTR-STM can be kept at ambient temperature during shipment to an authorized CLIA lab for analysis. SARS-CoV-2 viral RNA in GTR-STM is stable for over a month at ambient temperature, easily surviving the longest transit times from home to lab. GTR-STM enhances patient comfort, convenience, compliance and reduces infectious virus exposure to essential medical and lab professionals.

Alternatively, the GTR-STMdk direct-into-PCR product can be used to improve lab throughput and reduce reagent costs for saliva sample collection and testing at any lab site with access to refrigeration. GTR-STMdk reduces lab process time by 25% and reagent costs by 30% compared to other approaches. Since GTR-STMdk retains SARS-CoV-2 viral RNA stability for three days at ambient temperature, it is optimized for lab test site rather than at home saliva collection. SARS-COV-2 viral RNA levels as low as 0.4 genome equivalents/uL are detected in saliva samples using GTR-STMdk. The increased sensitivity of SARS-CoV-2 detection can expand COVID-19 testing to include asymptomatic individuals using pooled saliva.

One Sentence SummaryGTR-STM and Direct-into-PCR GTR-STMdk offer substantive improvements in SARS-CoV-2 viral RNA stability, safety, and RT-PCR process efficiency for COVID-19 testing by using a non-dilutive saliva sample collection system for individuals at home or onsite respectively.",Yuan Jin Carrington; Justin Orlino; Alejandro Romero; Jessica Rochelle Gustin; Mahssa Rezaei; Elizabeth Green; Summer Linn Rose; Ramani A. Aiyer; Shanavaz Nasarabadi,https://medrxiv.org/cgi/content/short/2021.01.20.20243782,https://medrxiv.org/cgi/content/short/2021.01.20.20243782,2021-01-25,2021-01-25,,True
291,High-altitude is associated with better short-term survival in critically ill COVID-19 patients admitted to the ICU,"BackgroundThe novel human coronavirus, SARS-CoV-2, has affected at least 218 countries worldwide. Some geographical and environmental factors are positively associated with a better or worse prognosis concerning COVID-19 disease and with lower or higher SARS-CoV-2 transmission. High altitude exposure has been associated with lower SARS-CoV-2 attack rates; nevertheless, the role of chronic high-altitude exposure on the clinical outcome of critically ill COVID-19 patients has not been studied.

ObjectiveTo compare the clinical course and outcomes of critically ill patients with COVID-19 hospitalized in two intensive care units (ICU) located at low and high altitude.

Exposure and OutcomeTo explore the effect of two different elevations (10 m vs 2,850 m above sea level) on COVID-19 clinical outcome and survival.

MethodsA prospective cohort, two-center study in confirmed COVID-19 adult patients admitted to a low altitude (Sea level) and high altitude (2,850 m) ICU units in Ecuador was conducted. Two hundred and thirty confirmed COVID-19 patients were enrolled from March 15th to July 15th, 2020. Sociodemographic, clinical, laboratory and imaging parameters including supportive therapies, pharmacological treatments and medical complications were reported and compared between the low and high-altitude groups.

ResultsThe median age of all the patients was 60 years, 64.8% were men and 35.2% were women. A total of 105 (45.7%) patients had at least one underlying comorbidity, the most frequent being chronic diseases, such as hypertension (33.5%), diabetes (16.5%), and chronic kidney failure (5.7%). The APACHE II scale at 72 hours was especially higher in the low-altitude group with a median of 18 points (IQR: 9.5-24.0), compared to 9 points (IQR: 5.0-22.0) obtained in the group of high altitude. There is evidence of a difference in survival in favor of the high-altitude group (p = 0.006), the median survival being 39 days, compared to 21 days in the low altitude group.

ConclusionThere has been a substantial improvement in survival amongst people admitted to the high-altitude critical care unit. High altitude living was associated with improved survival, especially among patients with no comorbidities. COVID-19 patients admitted to the high-altitude ICU unit have improved severity-of-disease classification system scores at 72 hours and reported better respiratory and ventilatory profiles than the low altitude group.",Pablo R Morocho Jaramillo; Katherine Simbana-Rivera; Javier V Velastegui Silva; Lenin Gomez-Barreno; Ana Ventimilla Campoverde; Juan F Novillo Cevallos; Washington Almache Guanoquiza; Silvio Cedeno Guevara; Luis G Imba Castro; Nelson A Moran Puerta; Alex Guayta Valladares; Alex Lister; Esteban Ortiz-Prado,https://medrxiv.org/cgi/content/short/2021.01.22.21249811,https://medrxiv.org/cgi/content/short/2021.01.22.21249811,2021-01-25,2021-01-25,,True
292,Numbers of close contacts of individuals infected with SARS-CoV-2 and their association with government intervention strategies.,"BackgroundContact tracing is conducted with the primary purpose of interrupting transmission from individuals who are likely to be infectious to others. Secondary analyses of data on the numbers of close contacts of confirmed cases could also: provide an early signal of increases in contact patterns that might precede larger than expected case numbers; evaluate the impact of government interventions on the number of contacts of confirmed cases; or provide data information on contact rates between age cohorts for the purpose of epidemiological modelling.

MethodsWe analysed data from 140,204 contacts of 39861 cases in Ireland from 1st May to 1st December 2020. Only  close contacts were included in the analysis. A close contact was defined as any individual who had had > 15 minutes face-to-face (<2 m) contact with a case; any household contact; or any individual sharing a closed space for longer than 2 hours, in any setting.

ResultsThe number of contacts per case was overdispersed, the mean varied considerably over time, and was temporally associated with government interventions. Negative binomial regression models highlighted greater numbers of contacts within specific population demographics, after correcting for temporal associations. Separate segmented regression models of the number of cases over time and the average number of contacts per case indicated that a breakpoint indicating a rapid decrease in the number of contacts per case in October 2020 preceded a breakpoint indicating a reduction in the number of cases by 11 days.

DiscussionThese data were collected for a specific purpose and therefore any inferences must be made with caution. The data are representative of contact rates of cases, and not of the overall population. However, the data may be a more accurate indicator of the likely degree of onward transmission than might be the case if a random sample of the population were taken. Furthermore, since we analysed only the number of close contacts, the total number of contacts per case would have been higher. Nevertheless, this analysis provides useful information for monitoring the impact of government interventions on the number of contacts; for helping pre-empt increases or decreases in case numbers, and for triangulating assumptions regarding the contact mixing rates between different age cohorts for epidemiological modelling.",Conor G McAloon; Patrick Wall; Francis Butler; Mary Codd; Eamonn Gormley; Cathal Walsh; Jim Duggan; T Brendan Murphy; Philip Nolan; Breda Smyth; Katie O'Brien; Conor Teljeur; Martin J Green; Kieran Culhane; Claire Buckley; Jennifer Martin; Sarah Doyle; Ciara Carroll; Simon J More,https://medrxiv.org/cgi/content/short/2021.01.20.21250109,https://medrxiv.org/cgi/content/short/2021.01.20.21250109,2021-01-25,2021-01-25,,True
293,On mobility trends analysis of COVID-19 dissemination in Mexico City,"This work presents a forecast of the spread of the new coronavirus in Mexico City based on a mathematical model with metapopulation structure by using Bayesian Statistics inspired in a data-driven approach. The mobility of humans on a daily basis in Mexico City is mathematically represented by a origin-destination matrix using the open mobility data from Google and a Transportation Mexican Survey. This matrix, is incorporated in a compartmental model. We calibrate the model against borough-level incidence data collected between February 27, 2020 and October 27, 2020 using Bayesian inference to estimate critical epidemiological characteristics associated with the coronavirus spread. Since working with metapopulation models lead to rather high computational time consume, we do a clustering analysis based on mobility trends in order to work on these clusters of borough separately instead of taken all the boroughs together at once. This clustering analysis could be implemented in smaller or lager scale in different part of the world. In addition, this clustering analysis is divided in the phases that the government of Mexico City has set up to restrict the individuals movement in the city. Also, we calculate the reproductive number in Mexico City using the next generation operator method and the inferred model parameters. The analysis of mobility trends can be helpful in public health decisions.",Kernel Prieto; Maria Chavez-Hernandez; Jhoana Patricia Romero-Leiton,https://medrxiv.org/cgi/content/short/2021.01.24.21250406,https://medrxiv.org/cgi/content/short/2021.01.24.21250406,2021-01-25,2021-01-25,,True
294,Predictive power of SARS-CoV-2 wastewater surveillance for diverse populations across a large geographical range,"The COVID-19 pandemic has exacerbated the disparities in healthcare delivery in the US. Many communities had, and continue to have, limited access to COVID-19 testing, making it difficult to track the spread and impact of COVID-19 in early days of the outbreak. To address this issue we monitored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA at the population-level using municipal wastewater influent from 19 cities across the state of Minnesota during the COVID-19 outbreak in Summer 2020. Viral RNA was detected in wastewater continually for 20-weeks for cities ranging in populations from 500 to >1, 000, 000. Using a novel indexing method, we were able to compare the relative levels of SARS-CoV-2 RNA for each city during this sampling period. Our data showed that viral RNA trends appeared to precede clinically confirmed cases across the state by several days. Lag analysis of statewide trends confirmed that wastewater SARS-CoV-2 RNA levels preceded new clinical cases by 15-17 days. At the regional level, new clinical cases lagged behind wastewater viral RNA anywhere from 4- 20 days. Our data illustrates the advantages of monitoring at the population-level to detect outbreaks. Additionally, by tracking infections with this unbiased approach, resources can be directed to the most impacted communities before the need outpaces the capacity of local healthcare systems.",Richard G Melvin; Nabiha Chaudhry; Onimitein Georgewill; Rebecca Freese; Glenn E Simmons Jr.,https://medrxiv.org/cgi/content/short/2021.01.23.21250376,https://medrxiv.org/cgi/content/short/2021.01.23.21250376,2021-01-25,2021-01-25,,True
295,Determinants of the incidence and mortality rates of COVID-19 during the first six months of the pandemic; A cross-country study,"COVID-19 pandemic raises an extraordinary challenge to the healthcare systems globally. The governments are taking key measures to constrain the corresponding health, social, and economic impacts, however, these measures vary depending on the nature of the crisis and country-specific circumstances.

ObjectivesConsidering different incidence and mortality rates across different countries, we aimed at explaining variance of these variables by performing accurate and precise multivariate analysis with aid of suitable predictors, accordingly, the model would proactively guide the governmental responses to the crisis.

MethodsUsing linear and exponential time series analysis, this research aimed at studying the incidence and mortality rates of COVID-19 in 18 countries during the first six months of the pandemic, and further utilize multivariate techniques to explain the variance in monthly exponential growth rates of cases and deaths with aid of a set of different predictors: the recorded Google mobility trends towards six categories of places, daily average temperature, daily humidity, and key socioeconomic attributes of each country.

ResultsThe analysis showed that changes in mobility trends were the most significant predictors of the incidence and mortality rates, temperature and humidity were also significant but to a much lesser extent, on the other hand, the socioeconomic attributes did not contribute significantly to explaining different incidence and mortality rates across countries.

ConclusionChanges in mobility trends across countries dramatically affected the incidence and mortality rates across different countries, thus, it might be used as a proxy measure of contact frequency.",Noha Asem; Ahmed Mohamed Ramadan; Mohamed Hassany; Ramy Mohamed Ghazy; Mohamed Abdallah; Eman Gamal; Shimaa Hassan; Nehal Kamal; Hala Zaid,https://medrxiv.org/cgi/content/short/2021.01.21.21250226,https://medrxiv.org/cgi/content/short/2021.01.21.21250226,2021-01-25,2021-01-25,,True
296,"Social, economic, and environmental factors influencing the basic reproduction number of COVID-19 across countries","ObjectiveTo assess whether the basic reproduction number (R0) of COVID-19 is different across countries and what national-level demographic, social, and environmental factors characterize initial vulnerability to the virus.

MethodsWe fit logistic growth curves to reported daily case numbers, up to the first epidemic peak. This fitting estimates R0. We then use a generalized additive model to discern the effects, and include 5 random effect covariates to account for potential differences in testing and reporting that can bias the estimated R0.

FindingsWe found that the mean R0 is 1.70 (S.D. 0.57), with a range between 1.10 (Ghana) and 3.52 (South Korea). We identified four factors-population between 20-34 years old (youth), population residing in urban agglomerates over 1 million (city), social media use to organize offline action (social media), and GINI income inequality-as having strong relationships with R0. An intermediate level of youth and GINI inequality are associated with high R0, while high city population and high social media use are associated with high R0. Environmental and climate factors were not found to have strong relationships with R0.

ConclusionStudies that aim to measure the effectiveness of interventions should account for the intrinsic differences between populations.",Jude Dzevela Kong; Edward Tekwa; Sarah Gignoux-Wolfsohn,https://medrxiv.org/cgi/content/short/2021.01.24.21250416,https://medrxiv.org/cgi/content/short/2021.01.24.21250416,2021-01-25,2021-01-25,,True
297,Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform,"BackgroundPatients with COVID-19 are thought to be at higher risk of cardiometabolic and pulmonary complications, but quantification of that risk is limited. We aimed to describe the overall burden of these complications in survivors of severe COVID-19.

MethodsWorking on behalf of NHS England we used data from the OpenSAFELY platform linking primary care records to death certificate and hospital data. We constructed two cohorts: a COVID-19 cohort consisting of patients discharged following hospitalisation with COVID-19, and a comparison population of patients discharged following hospitalisation with pneumonia in 2019. Outcomes included DVT, PE, ischaemic stroke, MI, heart failure, AKI and new type 2 diabetes diagnosis. Outcome rates from hospital discharge were measured in each cohort, stratified by patient demographics and 30-day period. We fitted Cox regression models to estimate crude and age/sex adjusted hazard ratios comparing outcome rates between the two cohorts.

ResultsAmongst the population of 31,569 patients discharged following hospitalisation with COVID-19, the highest rates were observed for heart failure (199.3; 95% CI: 191.8 - 207.1) and AKI (154.5; 95% CI: 147.9 - 161.4). Rates of DVT, heart failure, ischaemic stroke, MI, PE and diabetes were high over the four months post discharge, especially in the first month. Patterns were broadly similar to those seen in patients discharged with pneumonia but somewhat higher in the COVID-19 population for stroke (adj-HR 1.78; 95% CI: 1.53 - 2.08), PE (adj-HR 1.38; 95% CI: 1.21 - 1.58), MI (adj-HR 1.46; 95% CI: 1.20 - 1.76), AKI (adj-HR 1.27; 95% CI: 1.19 - 1.36) and T2DM (adj-HR 1.28; 95% CI: 1.08 - 1.50).

ConclusionsIn this descriptive study of survivors of severe COVID-19, rates of the measured outcomes are at least as high, though in some cases slightly higher, than in patients discharged after hospitalisation with pneumonia. Further work is needed to identify what characteristics of COVID-19 patients put them at highest risk of adverse events.",John Tazare; Alex J Walker; Laurie Tomlinson; George Hickman; Christopher T Rentsch; Elizabeth J Williamson; Krishnan Bhaskaran; David Evans; Kevin Wing; Rohini Mathur; Angel YS Wong; Anna Schultze; Sebastian CJ Bacon; Christopher Bates; Caroline E Morton; Helen J Curtis; Emily Nightingale; Helen I McDonald; Amir Mehrkar; Peter Inglesby; Brian MacKenna; Jonathan Cockburn; William J Hulme; Charlotte Warren-Gash; Ketaki Bhate; Emma Powell; Any Mulick; Harriet Forbes; Caroline Minassian; Richard Croker; John Parry; Frank Hester; Sam Harper; Rosalind M Eggo; Stephen JW Evans; Liam Smeeth; Ian J Douglas; Ben Goldacre,https://medrxiv.org/cgi/content/short/2021.01.22.21250304,https://medrxiv.org/cgi/content/short/2021.01.22.21250304,2021-01-25,2021-01-25,,True
298,Using Non-Pharmaceutical Interventions and High Isolation of Asymptomatic Carriers to Contain the Spread of SARS-CoV-2 in Nursing Homes,"ObjectiveUsing a pandemic influenza model modified for COVID-19, this study investigated the degree of control over pre-symptomatic transmission that common non-pharmaceutical interventions (NPIs) would require to reduce the spread in long-term care facilities.

MethodsWe created a stochastic compartmental SEIR model with Poisson-distributed transition states that compared the effect of R0, common NPIs, and isolation rates of pre-symptomatic carriers primarily on attack rate, peak cases, and timing in a 200-resident nursing home. Model sensitivity was assessed with 1st order Sobol indices.

ResultsThe most rigorous NPIs decreased the peak number of infections by 4.3 and delayed the peak by 9.7 days in the absence of pre-symptomatic controls. Reductions in attack rate were not likely, even with rigorous application of all defined NPIs, unless pre-symptomatic carriers were identified and isolated at rates exceeding 76%. Attack rate was most sensitive to the pre-symptomatic isolation rate (Sobol index > 0.7) and secondarily to R0.

ConclusionsCommon NPIs delayed and reduced epidemic peaks. Reducing attack rates ultimately required efficient isolation of pre-symptomatic cases, including rapid antigen tests on a nearly daily basis. This must be accounted for in testing and contact tracing plans for group living settings.",Alec J Schmidt; Yury Garcia; Diego Pinheiro; Tom Reichert; Miriam Nuno,https://medrxiv.org/cgi/content/short/2021.01.22.21249308,https://medrxiv.org/cgi/content/short/2021.01.22.21249308,2021-01-25,2021-01-25,,True
299,Tracking the mental health of home-carers during the first COVID-19 national lockdown: evidence from a nationally representative UK survey,"BackgroundUnpaid carers who look after another member of their household (home-carers) have poorer mental health than the general population. The first COVID-19 national lockdown led to an increasing reliance on home-carers and we investigate the short and longer-term impact of lockdown on their mental health.

MethodsData from 9,737 adult participants (aged 16+) from the UK Household Longitudinal Study (Understanding Society) were used to explore changes in 12-item General Health Questionnaire (GHQ-12) score between (a) pre-pandemic (2019) and early lockdown (April 2020) and (b) early and later (July 2020) lockdown.

ResultsGHQ-12 scores among home-carers were higher pre-lockdown and increased more than for non-carers from 2019 to April 2020 with further increases for home-carers compared with non-carers between April and July. Compared with respondents caring for a spouse/partner, those caring for a child under 18 had a particularly marked increase in GHQ-12 score between 2019 and April, as did those caring for someone with learning difficulties. Home-carers of children under 18 improved from April to July while those caring for adult children saw a marked worsening of their mental health. Home-carers with greater care burden saw larger increases in GHQ-12 score from 2019 to April and from April to July, and increases through both periods were greater for home-carers who had formal help prior to lockdown but then lost it.

ConclusionsThe mental health of home-carers deteriorated more during lockdown than non-carers. Policies that reinstate support for them and their care-recipients will benefit the health of both vulnerable groups.

What is already known on this topicO_LICarers have poorer mental health than the general population.
C_LIO_LIAmong carers who live with the care recipient (home-carers), some subgroups have poorer mental health than others: female versus male; those who provide more hours of care and have been caring for longer; spousal carers compared with those caring for children (including adult), parents, or other relationships; those caring for individuals whose impairment results in behavioural disturbances, than those who care for individuals with physical or long-term health conditions.
C_LI

What this study addsO_LIIn a large representative UK survey, the decline in mental health during lockdown was greater among home-carers than for the general population, and stayed poorer through to July, even as the general populations mental health recovered slightly.
C_LIO_LICompared with respondents who were caring for a spouse/partner, those caring for a child under 18 had a particularly marked increase in GHQ-12 score between 2019 and April while those caring for an adult child experienced a substantial decline in their mental health between the beginning and end of the first lockdown (April to July).
C_LIO_LIThe increase in GHQ-12 in April from 2019 was highest among those caring for someone with a learning disability and lowest for those caring for someone with a problem related to old age.
C_LIO_LIHome-carers who had a greater care burden, in terms of hours of care provided, or lost formal support during lockdown, had poorer mental health.
C_LI",Elise Whitley; Kelly Reeve; Michaela Benzeval,https://medrxiv.org/cgi/content/short/2021.01.25.21250437,https://medrxiv.org/cgi/content/short/2021.01.25.21250437,2021-01-25,2021-01-25,,True
300,An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: national validation cohort study in England,"BackgroundTo externally validate a risk prediction algorithm (QCovid) to estimate mortality outcomes from COVID-19 in adults in England.

MethodsPopulation-based cohort study using the ONS Public Health Linked Data Asset, a cohort based on the 2011 Census linked to Hospital Episode Statistics, the General Practice Extraction Service Data for pandemic planning and research, radiotherapy and systemic chemotherapy records. The primary outcome was time to COVID-19 death, defined as confirmed or suspected COVID-19 death as per death certification. Two time periods were used: (a) 24th January to 30th April 2020; and (b) 1st May to 28th July 2020. We evaluated the performance of the QCovid algorithms using measures of discrimination and calibration for each validation time period.

FindingsThe study comprises 34,897,648 adults aged 19-100 years resident in England. There were 26,985 COVID-19 deaths during the first time-period and 13,177 during the second. The algorithms had good calibration in the validation cohort in both time periods with close correspondence of observed and predicted risks. They explained 77.1% (95% CI: 76.9% to 77.4%) of the variation in time to death in men in the first time-period (R2); the D statistic was 3.76 (95% CI: 3.73 to 3.79); Harrells C was 0.935 (0.933 to 0.937). Similar results were obtained for women, and in the second time-period. In the top 5% of patients with the highest predicted risks of death, the sensitivity for identifying deaths in the first time period was 65.9% for men and 71.7% for women. People in the top 20% of predicted risks of death accounted for 90.8% of all COVID-19 deaths for men and 93.0% for women.

InterpretationThe QCovid population-based risk algorithm performed well, showing very high levels of discrimination for COVID-19 deaths in men and women for both time periods. It has the potential to be dynamically updated as the pandemic evolves and therefore, has potential use in guiding national policy.

FundingNational Institute of Health Research

RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSPublic policy measures and clinical risk assessment relevant to COVID-19 need to be aided by rigorously developed and validated risk prediction models. A recent living systematic review of published risk prediction models for COVID-19 found most models are subject to a high risk of bias with optimistic reported performance, raising concern that these models may be unreliable when applied in practice. A population-based risk prediction model, QCovid risk prediction algorithm, has recently been developed to identify adults at high risk of serious COVID-19 outcomes, which overcome many of the limitations of previous tools.

Added value of this studyCommissioned by the Chief Medical Officer for England, we validated the novel clinical risk prediction model (QCovid) to identify risks of short-term severe outcomes due to COVID-19. We used national linked datasets from general practice, death registry and hospital episode data for a population-representative sample of over 34 million adults. The risk models have excellent discrimination in men and women (Harrells C statistic>0.9) and are well calibrated. QCovid represents a new, evidence-based opportunity for population risk-stratification.

Implications of all the available evidenceQCovid has the potential to support public health policy, from enabling shared decision making between clinicians and patients in relation to health and work risks, to targeted recruitment for clinical trials, and prioritisation of vaccination, for example.",Vahe Nafilyan; Ben Humberstone; Nisha Metha; Ian Diamond; Luke Lorenzi; Piotr Pawelek; Ryan Schofield; Jasper Morgan; Paul Brown; Ronan Lyons; Aziz Sheikh; Julia Hippisley-Cox,https://medrxiv.org/cgi/content/short/2021.01.22.21249968,https://medrxiv.org/cgi/content/short/2021.01.22.21249968,2021-01-25,2021-01-25,,True
301,Using an Ecological and Biological Framing for an Anti-racist Covid-19 Approach,"In the United States and the United Kingdom COVID-19 has disproportionately affected Black, Indigenous and People of Colour (BIPOC) and Black, Asian and Minority Ethnic (BAME) people respectively. Multiple studies identify environmental factors such as overcrowded housing and poor workplace conditions as contributing factors for the disproportionate COVID-19 rates amongst BAME and BIPOC communities. This paper will show that to fully understand the phenomenon, both an ecological and biological approach is needed. An ecological approach highlights how a persons habitat and the experiences within it mediate their susceptibility to disease. Moreover, to understand how this mediation works, this paper will use allostatic load as a biological pathway to link a person to their habitat and the poor health outcomes that contributed to COVID-19 susceptibility. In introducing this new approach, the paper will serve as an anti-racist framework for understanding how COVID-19 affected BAME and BIPOC communities. It is anti-racist by centring poor health outcomes on the habitats people are forced to live in due to structural racism rather than the physiology of a persons race or ethnicity. This is important in order to avoid similar crises in the future and to improve the health of marginalised communities.",Araceli Camargo; Elahi Hossain; Sarah Aliko; Daniel Akinola-Odusola; Josh Artus; Ilan Kelman,https://medrxiv.org/cgi/content/short/2021.01.24.21250397,https://medrxiv.org/cgi/content/short/2021.01.24.21250397,2021-01-25,2021-01-25,,True
302,Existence of SARS-CoV-2 RNA on ambient particulate matter samples: A nationwide study in Turkey,"Coronavirus disease 2019 (COVID-19) is caused by the SARS-CoV-2 virus and has been affecting the world since the end of 2019. Turkey is severely affected with the first case being reported on March 11th 2020. Ambient particulate matter (PM) samples in various size ranges were collected from 13 sites including urban and urban background locations and hospital gardens in 10 cities across Turkey between the 13th of May and the 14th of June, 2020 to investigate a possible presence of SARS-CoV-2 RNA on ambient PM. A total of 155 daily samples (TSP, n=80; PM2.5, n=33; PM2.5-10, n=23; PM10, n=19; and 6 size segregated, n=48) were collected using various samplers in each city. The N1 gene and RdRP gene expressions were analyzed for the presence of SARS-CoV-2 as suggested by the Centers for Disease Control and Prevention (CDC). According to RT-PCR and 3D-RT-PCR analysis, dual RdRP and N1 gene positivity were detected in 20 (9.8 %) of the samples. The highest percentage of virus detection on PM samples was from hospital gardens in Tekirda[g], Zonguldak, and [I]stanbul--especially in PM2.5 mode. Samples collected from two urban sites were also positive. Findings of this study have suggested that SARS-CoV-2 may be transported by ambient particles especially at sites close to the infection hot-spots. However, whether this has an impact on the spread of the virus infection remains to be determined.

Significance StatementAlthough there are several studies reporting the existence of SARS-CoV-2 in indoor aerosols is established, it remains unclear whether the virus is transported by ambient atmospheric particles. The presence of the SARS-CoV-2 RNA in ambient particles collected from characteristic sites within various size ranges was investigated, and positive results were found in urban sites especially around Turkish hospitals. In this context, this study offers a new discussion on the transmission of the virus via ambient particles.",Ozgecan Kayalar; Akif Ari; Gizem Babuscu; Nur Konyalilar; Ozlem Dogan; Fusun Can; Ulku Alver Sahin; Eftade Gaga; Levent Kuzu; Pelin Ari; Mustafa Odabasi; Yucel Tasdemir; Siddik Cindoruk; Fatma Esen; Egemen Sakin; Burak Caliskan; Lokman Tecer; Merve Ficici; Ahmet Altin; Burcu Onat; Coskun Ayvaz; Burcu Uzun; Arslan Saral; Tuncay Dogeroglu; Semra Malkoc; Ozlem Uzmez; Fatma Kunt; Senar Aydin; Melik Kara; Baris Yaman; Guray Dogan; Bihter Olgun; Ebru Dokumaci; Gulen Gullu; Elif Uzunpinar; Hasan Bayram,https://medrxiv.org/cgi/content/short/2021.01.24.21250391,https://medrxiv.org/cgi/content/short/2021.01.24.21250391,2021-01-25,2021-01-25,,True
303,Launching a saliva-based SARS-CoV-2 surveillance testing program on a university campus,"Regular surveillance testing of asymptomatic individuals for SARS-CoV-2 has played a vital role in SARS-CoV-2 outbreak prevention on college and university campuses. Here we describe the voluntary saliva testing program instituted at the University of California, Berkeley during an early period of the SARS-CoV-2 pandemic in 2020. The program was administered as a research study ahead of clinical implementation, enabling us to launch surveillance testing while continuing to optimize the assay. Results of both the testing protocol itself and the study participants experience show how the program succeeded in providing routine, robust testing capable of contributing to outbreak prevention within a campus community and offer strategies for encouraging participation and a sense of civic responsibility.",Alexander J. Ehrenberg; Erica A. Moehle; Cara E. Brook; Andrew H. Doudna Cate; Lea B. Witkowsky; Rohan Sachdeva; Ariana Hirsh; Kerrie Barry; Jennifer R. Hamilton; Enrique Lin-Shiao; Shana McDevitt; Luis Valentin-Alvarado; Kaitlyn N. Letourneau; Lauren Hunter; Amanda Keller; Kathleen Pestal; Phillip A. Frankino; Andrew Murley; Divya Nandakumar; Elizabeth C. Stahl; Connor Tsuchida; Holly K. Gildea; Andrew G. Murdock; Megan L. Hochstrasser; Elizabeth O'Brien; Alison Ciling; Alexandra Tsitsiklis; Kurtresha Worden; Claire Dugast-Darzacq; Stephanie G. Hays; Colin C. Barber; Riley McGarrigle; Emily Lam; David Ensminger; Lucie Bardet; Carolyn Sherry; - IGI SARS-CoV-2 Testing Consortium; Anna Harte; Guy Nicolette; Petros Giannikopoulos; Dirk Hockemeyer; Maya Petersen; Fyodor D. Urnov; Bradley R. Ringeisen; Mike Boots; Jennifer A. Doudna,https://medrxiv.org/cgi/content/short/2021.01.24.21250385,https://medrxiv.org/cgi/content/short/2021.01.24.21250385,2021-01-25,2021-01-25,,True
304,Analytical and clinical evaluation of antibody tests for SARS-CoV-2 serosurveillance studies used in Finland in 2020,"BackgroundSensitive and highly specific antibody tests are critical for detection of SARS-CoV-2 antibodies especially in populations where seroprevalence is low.

AimTo set up, optimize and evaluate the analytical and clinical performance of a new in-house microsphere immunoassay for measurement of IgG antibodies to SARS-CoV-2 nucleoprotein for assessment of population seroprevalence in Finland.

MethodsWe set up a new in-house microsphere immunoassay (FMIA) with SARS-CoV-2 nucleoprotein and optimized its analytical performance. For evaluation of clinical performance, we tested sera collected in a well-characterized cohort of PCR positive-confirmed SARS-CoV-2 patients (n=89) with mostly mild symptoms, and before the COVID-19 pandemic (n=402), for nucleoprotein specific IgG concentrations by FMIA and a commercial chemiluminescent immunoassay and for neutralizing antibodies by the microneutralization test.

ResultsThe analytical performance of FMIA was established in terms of sensitivity, linearity and precision. FMIA discriminated between COVID-19 patient and control samples with high specificity (100%) and sensitivity (100%). We generated FMIA seropositivity cut-offs, 0.46 and 1.71 U/ml, for low- and high-seroprevalence settings, respectively. In addition, we obtained high level of agreement between FMIA results and results by the microneutralization test.

ConclusionThe fluorescent microsphere immunoassay showed excellent analytical and clinical performance and is well suited for serosurveillance studies of SARS-CoV-2. However, to optimize analytical sensitivity and clinical specificity of the assay, different seropositivity thresholds depending on the intended use of the assay and the target population, may be needed.",Nina EkstrÃ¶m; Camilla Virta; Anu Haveri; TimothÃ©e Dub; Lotta Hagberg; Anna Solastie; Pamela Ã–sterlund; Terhi Vihervaara; Iris Erlund; Hanna Nohynek; Merit Melin,https://medrxiv.org/cgi/content/short/2021.01.21.21250207,https://medrxiv.org/cgi/content/short/2021.01.21.21250207,2021-01-25,2021-01-25,,True
305,SARS-CoV-2 seroprevalence among healthcare workers in general hospitals and clinics in Japan,"Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. However, little is known about the prevalence of COVID-19 among healthcare workers in Japan. We aimed to examine the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among 2,160 healthcare workers in general hospitals and clinics in Japan. The prevalence of SARS-CoV-2 immunoglobulin G was 1.2% in August and October 2020, which is relatively higher than that in the general population in Japan. Because of the higher risk of COVID-19 infection, healthcare workers should be the top priority for further social support and vaccination against SARS-CoV-2.",Tatsuya Yoshihara; Kazuya Ito; Masayoshi Zaitsu; Eunhee Chung; Izumi Aoyagi; Ryoichi Kaji; Tomomi Tsuru; Takuma Yonemura; Koji Yamaguchi; Shinichi Nakayama; Yosuke Tanaka; Nobuo Yurino; Hideki Koyanagi; Shunji Matsuki; Ryuji Urae; Shin Irie,https://medrxiv.org/cgi/content/short/2021.01.23.21249922,https://medrxiv.org/cgi/content/short/2021.01.23.21249922,2021-01-25,2021-01-25,,True
306,Prediction of In-hospital Mortality among Adults with COVID-19 Infection,"Prediction of mortality from COVID-19 infection might help triage patients to hospitalization and intensive care. To estimate the risk of inpatient mortality, we analyzed the data of 13,190 adult patients in the New York City Health + Hospitals system admitted for COVID-19 infection from March 1 to June 30, 2020. They had a mean age 58 years, 40% were Latinx, 29% Black, 9% White and 22% of other races/ethnicities and 2,875 died. We used Machine learning (Gradient Boosted Decision Trees; XGBoost) to select predictors of inpatient mortality from demographics, vital signs and lab tests results from initial encounters. XGBoost identified O2 saturation, systolic and diastolic blood pressure, pulse rate, respiratory rate, age, and BUN with an Area Under the Receiver Operating Characteristics Curve = 94%. We applied CART to find cut-points in these variables, logistic regression to calculate odds-ratios for those categories, and assigned points to the categories to develop a score. A score = 0 indicates a 0.8% (95% confidence interval, 0.5 - 1.0%) risk of dying and [&ge;] 12 points indicates a 98% (97-99%) risk, and other scores have intermediate risks. We translated the models into an online calculator for the probability of mortality with 95% confidence intervals (as pictured):



O_FIG O_LINKSMALLFIG WIDTH=138 HEIGHT=200 SRC=""FIGDIR/small/21249953v2_ufig1.gif"" ALT=""Figure 1"">
View larger version (31K):
org.highwire.dtl.DTLVardef@109228forg.highwire.dtl.DTLVardef@bbe826org.highwire.dtl.DTLVardef@8652a9org.highwire.dtl.DTLVardef@9d04b3_HPS_FORMAT_FIGEXP  M_FIG C_FIG danielevanslab.shinyapps.io/COVID_mortality/",Daniel S Evans; Kyoung Min Kim; Xiaqing Jiang; Jessica Jacobson; Warren Browner; Steven R Cummings,https://medrxiv.org/cgi/content/short/2021.01.22.21249953,https://medrxiv.org/cgi/content/short/2021.01.22.21249953,2021-01-25,2021-01-25,,True
307,Do Not Attempt Resuscitation (DNAR) status in people with suspected COVID-19: Secondary analysis of the PRIEST observational cohort study,"BackgroundCardiac arrest is common in people admitted with suspected COVID-19 and has a poor prognosis. Do Not Attempt Resuscitation (DNAR) orders can reduce the risk of futile resuscitation attempts but have raised ethical concerns.

ObjectivesWe aimed to describe the characteristics and outcomes of adults admitted to hospital with suspected COVID-19 according to their DNAR status and identify factors associated with an early DNAR decision.

MethodsWe undertook a secondary analysis of 13977 adults admitted to hospital with suspected COVID-19 and included in the Pandemic Respiratory Infection Emergency System Triage (PRIEST) study. We recorded presenting characteristics and outcomes (death or organ support) up to 30 days. We categorised patients as early DNAR (occurring before or on the day of admission) or late/no DNAR (no DNAR or occurring after the day of admission). We undertook descriptive analysis comparing these groups and multivariable analysis to identify independent predictors of early DNAR.

ResultsWe excluded 1249 with missing DNAR data, and identified 3929/12748 (31%) with an early DNAR decision. They had higher mortality (40.7% v 13.1%) and lower use of any organ support (11.6% v 15.7%), but received a range of organ support interventions, with some being used at rates comparable to those with late or no DNAR (e.g. non-invasive ventilation 4.4% v 3.5%). On multivariable analysis, older age (p<0.001), active malignancy (p<0.001), chronic lung disease (p<0.001), limited performance status (p<0.001), and abnormal physiological variables were associated with increased recording of early DNAR. Asian ethnicity was associated with reduced recording of early DNAR (p=0.001).

ConclusionsEarly DNAR decisions were associated with recognised predictors of adverse outcome, and were also associated with Asian ethnicity. Most people with an early DNAR decision survived to 30 days and many received potentially life-saving interventions.

RegistrationISRCTN registry, ISRCTN28342533, http://www.isrctn.com/ISRCTN28342533",Laura Sutton; Steve Goodacre; Benjamin Thomas; Sarah Connelly,https://medrxiv.org/cgi/content/short/2021.01.23.21249978,https://medrxiv.org/cgi/content/short/2021.01.23.21249978,2021-01-25,2021-01-25,,True
308,Prevalent comorbidities among young and underprivileged: Death portrait of COVID-19 among 235 555 hospitalized patients in Brazil,"BackgroundCOVID-19 has been alarmingly spreading worldwide, with Brazil ranking third in total number of cases and second in deaths. Being a continental country, which comprises many ethnic groups and an engrained social inequality, the pandemic evidenced this heterogeneous discrepancy. We aimed to estimate the impact of associated risk factors, isolated or combined, on COVID-19 severeness, detecting specific epidemiological profiles for multiple age ranges in hospitalized Brazilians.

MethodsIn this large retrospective cohort study, we used open-access data from the Ministry of Health of Brazil with COVID-19 confirmed hospitalized patients annotated in SRAG system between February and August 2020, a total of 235555 entries. The association of COVID-19 death with socio-demographic and clinical characteristics was analysed and presented as odds ratios adjusted by confounding co-variables. We also presented marginal mean aOR values for high-order interactions either by or not another fixed level or condition. We kept all other variables in the multivariate logistic models in their mean values or equal proportions.

FindingsYounger individuals with one or more comorbidities had an adjusted odds ratio up to four-fold compared to those without it, in the same age interval. Younger diabetic patients either self-declared as brown ethnicity (aOR 5{middle dot}58, 95% CI 4{middle dot}97-6{middle dot}25; p<0{middle dot}0001) or with some other associated comorbidities, mainly chronic hematologic disease (21{middle dot}09, 13{middle dot}64-32{middle dot}6; p<0{middle dot}0001) and obesity (aOR 21{middle dot}7, 95% CI not calculated; p<0{middle dot}0001), resulted in outstanding death risk. Age over 60, particularly over 90 (28{middle dot}91, 24{middle dot}5-34{middle dot}11; p<0.001), usage of invasive ventilatory support (16{middle dot}23, 14{middle dot}05-18{middle dot}75; p<0{middle dot}001), admission to intensive care units (3{middle dot}14, 2{middle dot}82-3{middle dot}48; p<0{middle dot}001), multiple respiratory symptoms (3{middle dot}24, 2{middle dot}79-3{middle dot}75; p<0{middle dot}0001), black ethnicity (1{middle dot}78, 1{middle dot}52-2{middle dot}07; p<0{middle dot}05), and diagnosis previous to hospitalization (1{middle dot}32, 1{middle dot}19-1{middle dot}47; p<0{middle dot}05) were associated with higher death odds. As protective factors, with roughly one third less death risk, we found hospitalization duration of (4, 7] days and illness onset to hospitalization over 6 days.

InterpretationWe found evidence for increased COVID-19 risk in two distinct groups: younger patients with prevalent comorbidities, especially in brown ethnicity, and patients with black ethnicity. We speculate that the pro-inflammatory synergism of COVID-19 and comorbidities, promoting an overproduction of cytokines, is partially the cause of higher mortality in this young group. Brazilian black and brown are underprivileged populations, with structural social inequality, limited healthcare access and, thus, remarkable disease vulnerability. Our study supplies essential data to patient stratification upon admission, optimizing hospital management, and to guide public policy determinations, including group prioritization for COVID-19 vaccination in Brazil.

FundingNone.

O_TEXTBOXResearch in context

Evidence before this studyCOVID-19 is still very active, having spread to over two hundred countries and caused more than one million deaths worldwide. Its current situation requires large-scale studies to assess the impact of preexisting comorbidities, symptoms, and socioeconomic issues regarding mortality rate, especially where lack of control is evident. We searched PubMed, Google Scholar, medRxiv, and bioRxiv on Dec 12, 2020, for studies published in English or Brazilian Portuguese, estimating the impact of several risk factors in COVID-19 prognosis. We used the search terms ""Brazil"" or ""risk factors"" or ""ethnicity"" or ""cohort"" or ""diabetes mellitus"" or ""mortality"" or ""symptoms"" or ""comorbidities"", and related synonyms, combined with ""SARS-CoV-2"" or ""COVID-19"". Many pre-existing conditions have shown to directly impact patient prognosis, out of which cancer, chronic kidney disease, chronic obstructive pulmonary disease, cardiovascular disease, obesity, and diabetes, among others, are well established in SARS-CoV-2 infection severeness. Some studies reported an increased death risk for non-white Brazilians, but no large scale cohort analyzing the impact of one or more associated risk factors in younger Brazilians patients were found.

Added value of this studyWe found that the impact of having one or two or more risk factors on mortality are progressively higher in ages (60, 80], (40, 60], (20, 40], and (0, 20], compared with people of the same age interval without comorbidities. We also found that young brown individuals with diabetes, as well as black ethnicity on its own, are population subgroups at remarkably higher risk for severe COVID-19 in Brazil. Furthermore, advanced age, usage of ventilatory support, admission to intensive care units, multiple respiratory symptoms, and diagnosis previous to hospitalization were associated with higher death odds. As protective factors, we found hospitalization duration of (4, 7] days and illness onset to hospitalization over 6 days.

Implications of all the available evidenceWe identified multiple epidemiological profiles associated with death risk in different age ranges in Brazilian COVID-19 hospitalized patients. These findings unveil that a large part of Brazilian working-age population is at a higher risk for SARS-CoV-2 death, a neglected situation that is further exacerbating inequalities, leading to a striking sociodemographic and economic impact. We hope that our analysis aids patient risk stratification, hospital management optimization, and public policy determination, including prioritization for COVID-19 vaccination in Brazil.

C_TEXTBOX",Eduardo Pietre Sr.; Gabriel Pessanha Amorim; Maria Fernanda Bittencourt; Marcelo Ribeiro-Alves Sr.; Mariana Acquarone,https://medrxiv.org/cgi/content/short/2021.01.22.21250346,https://medrxiv.org/cgi/content/short/2021.01.22.21250346,2021-01-25,2021-01-25,,True
309,Mental health and wellbeing amongst people with informal caring responsibilities across different time points during the COVID-19 pandemic: A population-based propensity score matching analysis,"AimsDue to a prolonged period of national and regional lockdown measures during the coronavirus (COVID-19) pandemic, there has been an increase reliance on informal care and a consequent increase in care intensity for informal carers. In light of this, the current study compared the experiences of carers and non-carers on various mental health and wellbeing measures across 5 key time points during the pandemic.

MethodsData analysed were from the UCL COVID -19 Social Study. Our study focused on 5 time points in England: (i) the first national lockdown (March-April 2020; N=12,053); (ii) the beginning of lockdown rules easing (May 2020; N=24,374); (iii) further easing (July 2020; N=21,395); (iv) new COVID-19 restrictions (September 2020; N=4,792); and (v) the three-tier system restrictions (October 2020; N=4,526). We considered 5 mental health and wellbeing measures-depression, anxiety, loneliness, life satisfaction and sense of worthwhile. Propensity score matching were applied for the analyses.

ResultsWe found that informal carers experienced higher levels of depressive symptoms and anxiety than non-carers across all time points. During the first national lockdown, carers also experienced a higher sense of life being worthwhile. No association was found between informal caring responsibilities and levels of loneliness and life satisfaction.

ConclusionGiven that carers are an essential national health care support, especially during a pandemic, it is crucial to integrate carers needs into healthcare planning and delivery. These results highlight there is a pressing need to provide adequate and targeted mental health support for carers during and following this pandemic.",Hei Wan Mak; Feifei Bu; Daisy Fancourt,https://medrxiv.org/cgi/content/short/2021.01.21.21250045,https://medrxiv.org/cgi/content/short/2021.01.21.21250045,2021-01-25,2021-01-25,,True
310,High-throughput sequencing of SARS-CoV-2 in wastewater provides insights into circulating variants,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from a zoonotic spill-over event and has led to a global pandemic. The public health response has been predominantly informed by surveillance of symptomatic individuals and contact tracing, with quarantine, and other preventive measures have then been applied to mitigate further spread. Non-traditional methods of surveillance such as genomic epidemiology and wastewater-based epidemiology (WBE) have also been leveraged during this pandemic. Genomic epidemiology uses high-throughput sequencing of SARS-CoV-2 genomes to inform local and international transmission events, as well as the diversity of circulating variants. WBE uses wastewater to analyse community spread, as it is known that SARS-CoV-2 is shed through bodily excretions. Since both symptomatic and asymptomatic individuals contribute to wastewater inputs, we hypothesized that the resultant pooled sample of population-wide excreta can provide a more comprehensive picture of SARS-CoV-2 genomic diversity circulating in a community than clinical testing and sequencing alone. In this study, we analysed 91 wastewater samples from 11 states in the USA, where the majority of samples represent Maricopa County, Arizona (USA). With the objective of assessing the viral diversity at a population scale, we undertook a single-nucleotide variant (SNV) analysis on data from 52 samples with >90% SARS-CoV-2 genome coverage of sequence reads, and compared these SNVs with those detected in genomes sequenced from clinical patients. We identified 7973 SNVs, of which 5680 were ""novel"" SNVs that had not yet been identified in the global clinical-derived data as of 17th June 2020 (the day after our last wastewater sampling date). However, between 17th of June 2020 and 20th November 2020, almost half of the SNVs have since been detected in clinical-derived data. Using the combination of SNVs present in each sample, we identified the more probable lineages present in that sample and compared them to lineages observed in North America prior to our sampling dates. The wastewater-derived SARS-CoV-2 sequence data indicates there were more lineages circulating across the sampled communities than represented in the clinical-derived data. Principal coordinate analyses identified patterns in population structure based on genetic variation within the sequenced samples, with clear trends associated with increased diversity likely due to a higher number of infected individuals relative to the sampling dates. We demonstrate that genetic correlation analysis combined with SNVs analysis using wastewater sampling can provide a comprehensive snapshot of the SARS-CoV-2 genetic population structure circulating within a community, which might not be observed if relying solely on clinical cases.",Rafaela S. Fontenele; Simona Kraberger; James Hadfield; Erin M. Driver; Devin Bowes; LaRinda A. Holland; Temitope O.C. Faleye; Sangeet Adhikari; Rahul Kumar; Rosa Inchausti; Wydale K. Holmes; Stephanie Deitrick; Philip Brown; Darrell Duty; Ted Smith; Aruni Bhatnagar; Ray A. Yeager II; Rochelle H. Holm; Natalia Hoogesteijn von Reitzenstein; Elliott Wheeler; Kevin Dixon; Tim Constantine; Melissa A. Wilson; Efrem S. Lim; Xiaofang Jiang; Rolf U. Halden; Matthew Scotch; Arvind Varsani,https://medrxiv.org/cgi/content/short/2021.01.22.21250320,https://medrxiv.org/cgi/content/short/2021.01.22.21250320,2021-01-25,2021-01-25,,True
311,Ubiquitin ligase RIPLET mediates polyubiquitination of RIG-I and LGP2 and regulates the innate immune responses to SARS-CoV-2 infection,"RIG-I, a cytoplasmic viral RNA sensor, is crucial for innate antiviral immune responses; however, there are controversies about RIG-Is regulatory mechanism by several ubiquitin ligases and LGP2. Our genetic study revealed that the RIPLET ubiquitin ligase was a general activating factor for RIG-I signaling, whereas another ubiquitin ligase, TRIM25, activated RIG-I in a cell-type-specific manner. These RIPLET and TRIM25 functions were modulated by accessory factors, such as ZCCH3C and NLRP12. Interestingly, we found an additional role of RIPLET in innate immune responses. RIPLET induced delayed polyubiquitination of LGP, resulting in the attenuation of excessive cytokine expression at the late phase. Moreover, RIPLET was involved in the innate immune responses against SARS-CoV-2 infection, a cause of the recent COVID-19 pandemic. Our data indicate that RIPLET fine-tunes innate immune responses via polyubiquitination of RIG-I and LGP2 against virus infection, including SARS-CoV-2.",Takahisa Kouwaki; Tasuku Nishimura; Guanming Wang; Reiko Nakagawa; Hiroyuki Oshiumi,https://biorxiv.org/cgi/content/short/2021.01.25.428042,https://biorxiv.org/cgi/content/short/2021.01.25.428042,2021-01-25,2021-01-25,,False
312,A multiscale model suggests that a moderately weak inhibition of SARS-CoV-2 replication by type I IFN could accelerate the clearance of the virus,"AO_SCPLOWBSTRACTC_SCPLOWSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible RNA virus that emerged in China at the end of 2019 and caused a large global outbreak. The interaction between SARS-CoV-2 and the immune response is complex because it is regulated by various processes taking part at the intracellular, tissue, and host levels. To gain a better understanding of the pathogenesis and progression of COVID-19, we formulate a multiscale model that integrate the main mechanisms which regulate the immune response to SARS-CoV-2 across multiple scales. The model describes the effect of type I interferon on the replication of SARS-CoV-2 inside cells. At the tissue level, we simulate the interactions between infected cells and immune cells using a hybrid agent-based representation. At the same time, we model the dynamics of virus spread and adaptive immune response in the host organism. After model validation, we demonstrate that a moderately weak inhibition of virus replication by type I IFN could elicit a strong adaptive immune response which accelerates the clearance of the virus. Furthermore, numerical simulations suggest that the deficiency of lymphocytes and not dendritic cells could lead to unfavourable outcomes in the elderly population.",Anass Bouchnita; Alexey Tokarev; Vitaly Volpert,https://biorxiv.org/cgi/content/short/2021.01.25.427896,https://biorxiv.org/cgi/content/short/2021.01.25.427896,2021-01-25,2021-01-25,,False
313,Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine,"Multiple successful vaccines against SARS-CoV-2 are urgently needed to address the ongoing Covid-19 pandemic. In the present work, we describe a subunit vaccine based on the SARS-CoV-2 spike protein co-administered with CpG adjuvant. To enhance the immunogenicity of our formulation, both antigen and adjuvant were encapsulated with our proprietary artificial cell membrane (ACM) polymersome technology. Structurally, ACM polymersomes are self-assembling nanoscale vesicles made up of an amphiphilic block copolymer comprising of polybutadiene-b-polyethylene glycol and a cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane. Functionally, ACM polymersomes serve as delivery vehicles that are efficiently taken up by dendritic cells, which are key initiators of the adaptive immune response. Two doses of our formulation elicit robust neutralizing titers in C57BL/6 mice that persist at least 40 days. Furthermore, we confirm the presence of memory CD4+ and CD8+ T cells that produce Th1 cytokines. This study is an important step towards the development of an efficacious vaccine in humans.",Jian Hang Lam; Amit Kumar Khan; Thomas Andrew Cornell; Regine Josefine Dress; Teck Wan Chia; Wen Wang William Yeow; Nur Khairiah Mohd-Ismail; Shrinivas Venkatraman; Kim Tien Ng; Yee-Joo Tan; Danielle E. Anderson; Florent Ginhoux; Madhavan Nallani,https://biorxiv.org/cgi/content/short/2021.01.24.427729,https://biorxiv.org/cgi/content/short/2021.01.24.427729,2021-01-25,2021-01-25,,False
314,"Effect of mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion function","The SARS-CoV-2 spike protein (S) is the sole viral protein responsible for both viral binding to a host cell and the membrane fusion event needed for cell entry. In addition to facilitating fusion needed for viral entry, S can also drive cell-cell fusion, a pathogenic effect observed in the lungs of SARS-CoV-2 infected patients. While several studies have investigated S requirements involved in viral particle entry, examination of S stability and factors involved in S cell-cell fusion remain limited. We demonstrate that S must be processed at the S1/S2 border in order to mediate cell-cell fusion, and that mutations at potential cleavage sites within the S2 subunit alter S processing at the S1/S2 border, thus preventing cell-cell fusion. We also identify residues within the internal fusion peptide and the cytoplasmic tail that modulate S cell-cell fusion. Additionally, we examine S stability and protein cleavage kinetics in a variety of mammalian cell lines, including a bat cell line related to the likely reservoir species for SARS-CoV-2, and provide evidence that proteolytic processing alters the stability of the S trimer. This work therefore offers insight into S stability, proteolytic processing, and factors that mediate S cell-cell fusion, all of which help give a more comprehensive understanding of this highly sought-after therapeutic target.",Chelsea T. Barrett; Hadley E. Neal; Kearstin Edmonds; Carole L. Moncman; Rachel Thompson; Jean M. Branttie; Kerri Beth Boggs; Cheng-Yu Wu; Daisy W. Leung; Rebecca Ellis Dutch,https://biorxiv.org/cgi/content/short/2021.01.24.428007,https://biorxiv.org/cgi/content/short/2021.01.24.428007,2021-01-25,2021-01-25,,False
315,Lost in translation: codon optimization inactivates SARS-CoV-2 RdRp,"RNA-dependent RNA polymerase (RdRp) is a primary target for antivirals. We report that Nsp12, a catalytic subunit of SARS-CoV-2 RdRp, produces an inactive enzyme when codon-optimized for bacterial expression. We also show that accessory subunits, NTPs, and translation by slow ribosomes partially rescue Nsp12. Our findings have implications for functional studies and identification of novel inhibitors of RdRp and for rational design of other biotechnologically and medically important expression systems.",Bing Wang; Vladimir Svetlov; Evgeny Nudler; Irina Artsimovitch,https://biorxiv.org/cgi/content/short/2021.01.24.428004,https://biorxiv.org/cgi/content/short/2021.01.24.428004,2021-01-25,2021-01-25,,False
316,Molecular Dynamics Reveals the Effects of Temperature on Critical SARS-CoV-2 Proteins,"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a newly identified RNA virus that causes the serious infection Coronavirus Disease 2019 (COVID-19). The incidence of COVID-19 is still increasing worldwide despite the summer heat and cool winter. However, little is known about seasonal stability of SARS-CoV-2. Herein, we employ Molecular Dynamics (MD) simulations to explore the effect of temperature on four critical SARS-CoV-2 proteins. Our work demonstrates that the spike Receptor Binding Domain (RBD), Main protease (Mpro), and nonstructural protein 3 (macro X) possesses extreme thermos-stability when subjected to temperature variations rendering them attractive drug targets. Furthermore, our findings suggest that these four proteins are well adapted to habitable temperatures on earth and are largely insensitive to cold and warm climates. Furthermore, we report that the critical residues in SARS-CoV-2 RBD were less responsive to temperature variations as compared to the critical residues in SARS-CoV. As such, extreme summer and winter climates, and the transition between the two seasons, are expected to have a negligible effect on the stability of SARS-CoV-2 which will marginally suppress transmission rates until effective therapeutics are available world-wide.",Paul Morgan; Chih-Wen Shu,https://biorxiv.org/cgi/content/short/2021.01.24.427990,https://biorxiv.org/cgi/content/short/2021.01.24.427990,2021-01-25,2021-01-25,,False
317,mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge,"The mRNA-1273 vaccine was recently determined to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interim Phase 3 results. Human studies, however, cannot provide the controlled response to infection and complex immunological insight that are only possible with preclinical studies. Hamsters are the only model that reliably exhibit more severe SARS-CoV-2 disease similar to hospitalized patients, making them pertinent for vaccine evaluation. We demonstrate that prime or prime-boost administration of mRNA-1273 in hamsters elicited robust neutralizing antibodies, ameliorated weight loss, suppressed SARS-CoV-2 replication in the airways, and better protected against disease at the highest prime-boost dose. Unlike in mice and non-human primates, mRNA-1273- mediated immunity was non-sterilizing and coincided with an anamnestic response. Single-cell RNA sequencing of lung tissue permitted high resolution analysis which is not possible in vaccinated humans. mRNA-1273 prevented inflammatory cell infiltration and the reduction of lymphocyte proportions, but enabled antiviral responses conducive to lung homeostasis. Surprisingly, infection triggered transcriptome programs in some types of immune cells from vaccinated hamsters that were shared, albeit attenuated, with mock-vaccinated hamsters. Our results support the use of mRNA-1273 in a two-dose schedule and provides insight into the potential responses within the lungs of vaccinated humans who are exposed to SARS-CoV-2.",Not available,https://biorxiv.org/cgi/content/short/2021.01.25.428136,https://biorxiv.org/cgi/content/short/2021.01.25.428136,2021-01-25,2021-01-25,,False
318,Profiling transcription factor sub-networks in type I interferon signaling and in response to SARS-CoV-2 infection,"Type I interferons (IFN /{beta}) play a central role in innate immunity to respiratory viruses, including coronaviruses. Genetic defects in type I interferon signaling were reported in a significant proportion of critically ill CoOVID-19 patients. Extensive studies on interferon-induced intracellular signal transduction pathways led to the elucidation of the Jak-Stat pathway. Furthermore, advances in gene expression profiling by microarrays have revealed that type I interferon rapidly induced multiple transcription factor mRNA levels. In this study, transcription factor profiling in the transcriptome was used to gain novel insights into the role of inducible transcription factors in response to type I interferon signaling in immune cells and in lung epithelial cells after SARS-CoV-2 infection. Modeling the interferon-inducible transcription factor mRNA data in terms of distinct sub-networks based on biological functions such as antiviral response, immune modulation, and cell growth revealed enrichment of specific transcription factors in mouse and human immune cells. The evolutionarily conserved core type I interferon gene expression consists of the inducible transcriptional factor mRNA of the antiviral response sub-network and enriched in granulocytes. Analysis of the type I interferon-inducible transcription factor sub-networks as distinct protein-protein interaction pathways revealed insights into the role of critical hubs in signaling. Interrogation of multiple microarray datasets revealed that SARS-CoV-2 induced high levels of IFN-beta and interferon-inducible transcription factor mRNA in human lung epithelial cells. Transcription factor mRNA of the three major sub-networks regulating antiviral, immune modulation, and cell growth were differentially regulated in human lung epithelial cell lines after SARS-CoV-2 infection and in the tissue samples of COVID-19 patients. A subset of type I interferon-inducible transcription factors and inflammatory mediators were specifically enriched in the lungs and neutrophils of Covid-19 patients. The emerging complex picture of type I IFN transcriptional regulation consists of a rapid transcriptional switch mediated by the Jak-Stat cascade and a graded output of the inducible transcription factor activation that enables temporal regulation of gene expression.",Ramana Chilakamarti,https://biorxiv.org/cgi/content/short/2021.01.25.428122,https://biorxiv.org/cgi/content/short/2021.01.25.428122,2021-01-25,2021-01-25,,False
319,Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset,"Functional and lasting immune responses to the novel coronavirus (SARS-CoV-2) are currently under intense investigation as antibody titers in plasma have been shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we sought to determine the presence of SARS-CoV-2-specific memory B cells in COVID-19 convalescent patients. In this study, we report on the evolution of the overall humoral immune responses on 101 blood samples obtained from 32 COVID-19 convalescent patients between 16 and 233 days post-symptom onset. Our observations indicate that anti-Spike and anti-RBD IgM in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity in convalescent plasma declines rapidly compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells, which increase over time, and the number of IgG+ memory B cells which remain stable thereafter for up to 8 months after symptoms onset. With the recent approval of highly effective vaccines for COVID-19, data on the persistence of immune responses are of central importance. Even though overall circulating SARS-CoV-2 Spike-specific antibodies contract over time during convalescence, we demonstrate that RBD-specific B cells increase and persist up to 8 months post symptom onset. We also observe modest increases in RBD-specific IgG+ memory B cells and importantly, detectable IgG and sustained Fc-effector activity in plasma over the 8-month period. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for the prevention of secondary infections, vaccine efficacy and herd immunity against COVID-19.",Sai Priya Anand; Jeremie Prevost; Manon Nayrac; Guillaume Beaudoin-Bussieres; Mehdi Benlarbi; Romain Gasser; Nathalie Brassard; Annemarie Laumaea; Shang Yu Gong; Catherine Bourassa; Elsa Brunet-Ratnasingham; Halima Medjahed; Gabrielle Gendron-Lepage; Guillaume Goyette; Laurie Gokool; Chantal Morrisseau; Philippe Begin; Valerie Martel-Laferriere; Cecile Tremblay; Jonathan Richard; Renee Bazin; Ralf Duerr; Daniel E Kaufmann; Andres Finzi,https://biorxiv.org/cgi/content/short/2021.01.25.428097,https://biorxiv.org/cgi/content/short/2021.01.25.428097,2021-01-25,2021-01-25,,False
320,SARS-CoV-2 receptor binding mutations and antibody mediated immunity.,"SARS-CoV-2 mutations can impact infectivity, viral load, and overall morbidity/mortality during infection. In this analysis, we look at the mutational landscape of the SARS-CoV-2 receptor binding domain, a structure that is antigenic and allows for viral binding to the host. We analyze 104193 GISAID sequences acquired on October 15th, 2020 with a majority of sequences (96%) containing point mutations. We report high frequency mutations with improved binding affinity to ACE2 including S477N, N439K, V367F, and N501Y and address the potential impact of RBD mutations on antibody binding. The high frequency S477N mutation is present in 6.7% of all SARS-CoV-2 sequences, co-occurs with D614G, and is currently present in 14 countries. To address RBD-antibody interactions we take a subset of human derived antibodies and define their interacting residues using PDBsum. Our analysis shows that adaptive immunity against SARS-CoV-2 enlists broad coverage of the RBD suggesting that antibody mediated immunity should be sufficient to resolve infection in the presence of RBD point mutations that conserve structure.",Marios Mejdani; Kiandokht Haddadi; Chester Pham; Radhakrishnan Mahadevan,https://biorxiv.org/cgi/content/short/2021.01.25.427846,https://biorxiv.org/cgi/content/short/2021.01.25.427846,2021-01-25,2021-01-25,,False
321,The CXCR6/CXCL16 axis links inflamm-aging to disease severity in COVID-19 patients,"Advancing age and chronic health conditions, significant risk factors for severe COVID-19, are associated with a pro-inflammatory state, termed inflamm-aging. CXCR6+ T cells are known to traffic to the lung and have been reported to increase with age. The ligand of CXCR6, CXCL16, is constitutively expressed in the lung and upregulated during inflammatory responses and the CXCR6/CXCL16 axis is associated with severe lung disease and pneumonia. Genome-wide association studies have also recently identified 3p21.31, encompassing the CXCR6 gene, as a susceptibility locus for severe COVID-19. We assessed numbers T cells expressing the chemokine receptor CXCR6 and plasma levels of CXCL16, in control and COVID-19 patients. Results demonstrated that circulating CD8+CXCR6+ T cells were significantly elevated with advancing age, yet virtually absent in patients with severe COVID-19. Peripheral levels of CXCL16 were significantly upregulated in severe COVID-19 patients compared to either mild COVID-19 patients or SARS-CoV-2 negative controls. This study supports a significant role of the CXCR6/CXCL16 axis in the immunopathogenesis of severe COVID-19.",Daniel J Payne; Surita Dalal; Richard Leach; Richard Parker; Stephen Griffin; Clive S McKimmie; Graham P Cook; Stephen J Richards; Peter Hillmen; Tal Munir; Kathryn Riley; Claire McKinley; Sandra Place; Richard L Baretto; Darren J Newton,https://biorxiv.org/cgi/content/short/2021.01.25.428125,https://biorxiv.org/cgi/content/short/2021.01.25.428125,2021-01-25,2021-01-25,,False
322,Tool for estimating the probability of having COVID-19 with one or more negative RT-PCR results,"Early case detection and isolation of infected individuals are critical to controlling COVID-19. RT-PCR is considered the diagnosis gold standard, but false-negatives occur. Based on previous work, we built a user-friendly online tool to estimate the probability of having COVID-19 with negative RT-PCR results and thus avoid preventable SARS-CoV-2 transmission.",Alejandro Jara; Eduardo A Undurraga; Rafael Araos,https://medrxiv.org/cgi/content/short/2021.01.16.21249939,https://medrxiv.org/cgi/content/short/2021.01.16.21249939,2021-01-24,2021-01-24,,True
323,CD8+ T cell epitope variations suggest a potential antigen presentation deficiency for spike protein of SARS-CoV-2,"COVID-19 is caused by a newly identified coronavirus, SARS-CoV-2, and has become a pandemic around the world. The illustration of the immune responses against SARS-CoV-2 is urgently needed for understanding the pathogenesis of the disease and its vaccine development. CD8+ T cells are critical for virus clearance and induce long lasting protection in the host. Here we identified specific HLA-A2 restricted T cell epitopes in the spike protein of SARS-CoV-2. Seven epitope peptides (n-Sp1, 2, 6, 7, 11, 13, 14) were confirmed to bind with HLA-A2 and potentially be presented by antigen presenting cells to induce host immune responses. Tetramers containing these peptides could interact with specific CD8+ T cells from convalescent COVID-19 patients, and one dominant epitope (n-Sp1) was defined. In addition, these epitopes could activate and generate epitope-specific T cells in vitro, and those activated T cells showed cytotoxicity to target cells. Meanwhile, all these epitopes exhibited high frequency of variations. Among them, n-Sp1 epitope variation 5L>F significantly decreased the proportion of specific T cell activation; n-Sp1 epitope 8L>V variant showed significantly reduced binding to HLA-A2 and decreased the proportion of n-Sp1-specific CD8+ T cell, which potentially contributes to the immune escape of SAR-CoV-2.",Congling Qiu; Chanchan Xiao; Zhigang Wang; Xiongfei Chen; Lijuan Gao; Jieping Den; Jun Su; Huanxin Su; Evandro Fei Fang; ZhangJing Zhang; Jikai Zhang; Oscar Junhong Luo; Pengchen Wang; Guobing Chen,https://biorxiv.org/cgi/content/short/2021.01.22.427863,https://biorxiv.org/cgi/content/short/2021.01.22.427863,2021-01-24,2021-01-24,,False
324,Artificial Intelligence for Emotion-Semantic Trending and People Emotion Detection During COVID-19 Social Isolation,"Taking advantage of social media platforms, such as Twitter, this paper provides an effective framework for emotion detection among those who are quarantined. Early detection of emotional feelings and their trends help implement timely intervention strategies. Given the limitations of medical diagnosis of early emotional change signs during the quarantine period, artificial intelligence models provide effective mechanisms in uncovering early signs, symptoms and escalating trends. Novelty of the approach presented herein is a multitask methodological framework of text data processing, implemented as a pipeline for meaningful emotion detection and analysis, based on the Plutchik/Ekman approach to emotion detection and trend detection. We present an evaluation of the framework and a pilot system. Results of confirm the effectiveness of the proposed framework for topic trends and emotion detection of COVID-19 tweets. Our findings revealed Stay-At-Home restrictions result in people expressing on twitter both negative and positive emotional semantics (feelings), where negatives are ""Anger"" (8.5% of tweets), followed by ""Fear"" (5.2%), ""Anticipation"" (53.6%) and positive emotional semantics are ""Joy"" (14.7%) and ""Trust"" (11.7%). Semantic trends of safety issues related to staying at home rapidly decreased within the 28 days and also negative feelings related to friends dying and quarantined life increased in some days. These findings have potential to impact public health policy decisions through monitoring trends of emotional feelings of those who are quarantined. The framework presented here has potential to assist in such monitoring by using as an online emotion detection tool kit.",Hamed Jelodar; Rita Orji; Stan Matwin; Swarna Weerasinghe; Oladapo Oyebode; Yongli Wang,https://medrxiv.org/cgi/content/short/2021.01.16.21249943,https://medrxiv.org/cgi/content/short/2021.01.16.21249943,2021-01-24,2021-01-24,,True
325,In silico investigation of the new UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 variants with a focus at the ACE2-Spike RBD interface,"SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as a receptor to invade cells. It has been reported that the UK and South African strains may have higher transmission capabilities, eventually due to amino acid substitutions on the SARS-CoV-2 Spike protein. The pathogenicity seems modified but is still under investigation. Here we used the experimental structure of the Spike RBD domain co-crystallized with part of the ACE2 receptor and several in silico methods to analyze the possible impacts of three amino acid replacements (Spike K417N, E484K, N501Y) with regard to ACE2 binding. We found that the N501Y replacement in this region of the interface (present in both UK and South African strains) should be favorable for the interaction with ACE2 while the K417N and E484K substitutions (South African) would seem unfavorable. It is unclear if the N501Y substitution in the South African strain could counterbalance the predicted less favorable (regarding binding) K417N and E484K Spike replacements. Our finding suggests that, if indeed the South African strain has a high transmission level, this could be due to the N501Y replacement and/or to substitutions in regions outside the direct Spike-ACE2 interface.

HihglightsO_LITransmission of the UK and possibly South African SARS-CoV-2 strains appears substantially increased compared to other variants
C_LIO_LIThis could be due, in part, to increased affinity between the variant Spike proteins and ACE2
C_LIO_LIWe investigated in silico the 3D structure of the Spike-ACE2 complex with a focus on Spike K417N, E484K and N501Y
C_LIO_LIThe N501Y substitution is predicted to increase the affinity toward ACE2 (UK strain) with subsequent enhanced transmissibility and possibly pathogenicity
C_LIO_LIAdditional substitutions at positions 417 and 484 (South African strain) may pertub the interaction with ACE2 raising questions about transmissibility and pathogenicity
C_LI",Bruno Villoutreix; Vincent Calvez; Anne-Genevieve Marcelin; Abdel-Majid Khatib,https://biorxiv.org/cgi/content/short/2021.01.24.427939,https://biorxiv.org/cgi/content/short/2021.01.24.427939,2021-01-24,2021-01-24,,False
326,Variation analysis of SARS-CoV-2 complete sequences from Iran,"The SARS-CoV-2 is a new emerging coronavirus initially reported in China at the late December 2019 and rapidly spread to the whole of the world. To date, 1261903 total case and 55830 deaths are reported from Iran as 8 January. In this study, we investigated all the complete sequences of SARS-CoV-2 that publicly reported from Iran. Twenty-four sequences between March to September 2020 were analyzed to identify genome variations and phylogenetic relationships. Furthermore, we assessed the amino acid changes related to the spike glycoprotein as an important viral factor associated with the entry to the host cells and as a vaccine target. Most of the variations are occurred in the ORF1ab, S, N, intergenic and ORF7 regions. The analysis of spike protein mutations demonstrated that D614G mutation could be detected from the May and beyond. Phylogenetic analysis showed that most of the circulated viruses in Iran are belong to the B.4 lineage. Although, we found a limited number of variants associated to the B.1 lineage carrying D614G mutation. Furthermore, we detected a variant characterize as the B.1.36 lineage with sixteen mutations in the spike protein region. This study showed the frequency of the viral populations in Iran as September, therefore, there is an emergent need to genomic surveillance to track viral lineage shift in the country beyond the September. These data would help to predict future situation and apply better strategy to control of the pandemic.",Jale Moradi; Mohsen Moghoofei; Amir Houshang Alvandi; Ramin Abiri,https://biorxiv.org/cgi/content/short/2021.01.23.427885,https://biorxiv.org/cgi/content/short/2021.01.23.427885,2021-01-24,2021-01-24,,False
327,Meta-analysis reveals consistent immune response patterns in COVID-19 infected patients at single-cell resolution,"A number of single-cell RNA studies looking at the human immune response to the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been recently published. However, the number of samples used in each individual study typically is small, moreover the technologies and protocols used in different studies vary, thus somewhat restricting the range of conclusions that can be made with high confidence. To better capture the cellular gene expression changes upon SARS-CoV-2 infection at different levels and stages of disease severity and to minimise the effect of technical artefacts, we performed meta-analysis of data from 9 previously published studies, together comprising 143 human samples, and a set of 16 healthy control samples (10X). In particular, we used generally accepted immune cell markers to discern specific cell subtypes and to look at the changes of the cell proportion over different disease stages and their consistency across the studies. While half of the observations reported in the individual studies can be confirmed across multiple studies, half of the results seem to be less conclusive. In particular, we show that the differentially expressed genes consistently point to upregulation of type I Interferon signal pathway and downregulation of the mitochondrial genes, alongside several other reproducibly consistent changes. We also confirm the presence of expanded B-cell clones in COVID-19 patients, however, no consistent trend in T-cell clonal expansion was observed.",Manik Garg; Xu Li; Pablo Andres Moreno Cortez; Irene Papatheodorou; Yuelong Shu; Alvis Brazma; Zhichao Miao,https://biorxiv.org/cgi/content/short/2021.01.24.427089,https://biorxiv.org/cgi/content/short/2021.01.24.427089,2021-01-24,2021-01-24,,False
328,An Autoantigen Atlas from Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19,"COVID-19 is accompanied by a myriad of both transient and long-lasting autoimmune responses. Dermatan sulfate (DS), a glycosaminoglycan crucial for wound healing, has unique affinity for autoantigens (autoAgs) from apoptotic cells. DS-autoAg complexes are capable of stimulating autoreactive B cells and autoantibody production. Using DS affinity, we identified an autoantigenome of 408 proteins from human fetal lung fibroblast HFL11 cells, at least 231 of which are known autoAgs. Comparing with available COVID data, 352 proteins of the autoantigenome have thus far been found to be altered at protein or RNA levels in SARS-Cov-2 infection, 210 of which are known autoAgs. The COVID-altered proteins are significantly associated with RNA metabolism, translation, vesicles and vesicle transport, cell death, supramolecular fibrils, cytoskeleton, extracellular matrix, and interleukin signaling. They offer clues to neurological problems, fibrosis, smooth muscle dysfunction, and thrombosis. In particular, 150 altered proteins are related to the nervous system, including axon, myelin sheath, neuron projection, neuronal cell body, and olfactory bulb. An association with the melanosome is also identified. The findings from our study illustrate a strong connection between viral infection and autoimmunity. The vast number of COVID-altered proteins with propensity to become autoAgs offers an explanation for the diverse autoimmune complications in COVID patients. The variety of autoAgs related to mRNA metabolism, translation, and vesicles raises concerns about potential adverse effects of mRNA vaccines. The COVID autoantigen atlas we are establishing provides a detailed molecular map for further investigation of autoimmune sequelae of the pandemic.

Summary sentenceAn autoantigenome by dermatan sulfate affinity from human lung HFL1 cells may explain neurological and autoimmune manifestations of COVID-19",Julia Y. Wang; Wei Zhang; Michael W. Roehrl; Victor B. Roehrl; Michael H. Roehrl,https://biorxiv.org/cgi/content/short/2021.01.24.427965,https://biorxiv.org/cgi/content/short/2021.01.24.427965,2021-01-24,2021-01-24,,False
329,"Six-month Neurological and Psychiatric Outcomes in 236,379 Survivors of COVID-19","BackgroundNeurological and psychiatric sequelae of COVID-19 have been reported, but there are limited data on incidence rates and relative risks.

MethodsUsing retrospective cohort studies and time-to-event analysis, we estimated the incidence of ICD-10 diagnoses in the 6 months after a confirmed diagnosis of COVID-19: intracranial haemorrhage; ischaemic stroke; Parkinsonism; Guillain-Barre syndrome; nerve/nerve root/plexus disorders; myoneural/muscle disease; encephalitis; dementia; mood, anxiety, and psychotic disorders; substance misuse; and insomnia. Data were obtained from the TriNetX electronic health records network (over 81 million patients). We compared incidences with those in propensity score-matched cohorts of patients with influenza or other respiratory infections using a Cox model. We investigated the effect on incidence estimates of COVID-19 severity, as proxied by hospitalization and encephalopathy (including delirium and related disorders).

Findings236,379 patients survived a confirmed diagnosis of COVID-19. Among them, the estimated incidence of neurological or psychiatric sequelae at 6 months was 33.6%, with 12.8% receiving their first such diagnosis. Most diagnostic categories were commoner after COVID-19 than after influenza or other respiratory infections (hazard ratios from 1.21 to 5.28), including stroke, intracranial haemorrhage, dementia, and psychotic disorders. Findings were equivocal for Parkinsonism and Guillain-Barre syndrome. Amongst COVID-19 cases, incidences and hazard ratios for most disorders were higher in patients who had been hospitalized, and markedly so in those who had experienced encephalopathy. Results were robust to sensitivity analyses, including comparisons against an additional four index health events.

InterpretationThe study provides evidence for substantial neurological and psychiatric morbidity following COVID-19 infection. Risks were greatest in, but not limited to, those who had severe COVID-19. The information can help in service planning and identification of research priorities.

FundingNational Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre.",Maxime Taquet; John R Geddes; Masud Husain; Sierra Luciano; Paul J Harrison,https://medrxiv.org/cgi/content/short/2021.01.16.21249950,https://medrxiv.org/cgi/content/short/2021.01.16.21249950,2021-01-24,2021-01-24,,True
330,Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant,"Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide and massive societal and economic burden. Recently, a new variant of SARS-CoV-2, known as B.1.1.7, was first detected in the United Kingdom and is spreading in several other countries, heightening public health concern and raising questions as to the resulting effectiveness of vaccines and therapeutic interventions. We and others previously identified host-directed therapies with antiviral efficacy against SARS-CoV-2 infection. Less prone to the development of therapy resistance, host-directed drugs represent promising therapeutic options to combat emerging viral variants as host genes possess a lower propensity to mutate compared to viral genes. Here, in the first study of the full-length B.1.1.7 variant virus, we find two host-directed drugs, plitidepsin (aplidin; inhibits translation elongation factor eEF1A) and ralimetinib (inhibits p38 MAP kinase cascade), as well as remdesivir, to possess similar antiviral activity against both the early-lineage SARS-CoV-2 and the B.1.1.7 variant, evaluated in both human gastrointestinal and lung epithelial cell lines. We find that plitidepsin is over an order of magnitude more potent than remdesivir against both viruses. These results highlight the importance of continued development of host-directed therapeutics to combat current and future coronavirus variant outbreaks.",Ann-Kathrin Reuschl; Lucy Thorne; Lorena Zuliani Alvarez; Mehdi Bouhaddou; Kirsten Obernier; Margaret Soucheray; Jane Turner; Jacqueline Fabius; Gina T. Nguyen; Danielle Swaney; Romel Rosales; Kris M. White; Pablo Aviles; Ilsa T Kirby; James E Melnyk; Ying Shi; Ziyang Zhang; Kevan Shokat; Adolfo Garcia-Sastre; Clare Jolly; Gregory J Towers; Nevan J Krogan,https://biorxiv.org/cgi/content/short/2021.01.24.427991,https://biorxiv.org/cgi/content/short/2021.01.24.427991,2021-01-24,2021-01-24,,False
331,"The psychosocial impact of the COVID-19 pandemic on 4,378 UK healthcare workers and ancillary staff: initial baseline data from a cohort study collected during the first wave of the pandemic.","ObjectivesThis study reports preliminary findings on the prevalence of, and factors associated with, mental health and wellbeing outcomes of healthcare workers during the early months (April-June) of the COVID-19 pandemic in the UK.

MethodsPreliminary cross-sectional data were analysed from a cohort study (n=4,378). Clinical and non-clinical staff of three London-based NHS Trusts (UK), including acute and mental health Trusts, took part in an online baseline survey. The primary outcome measure used is the presence of probable common mental disorders (CMDs), measured by the General Health Questionnaire (GHQ-12). Secondary outcomes are probable anxiety (GAD-7), depression (PHQ-9), Post-Traumatic Stress Disorder (PTSD) (PCL-6), suicidal ideation (CIS-R), and alcohol use (AUDIT). Moral injury is measured using the Moray Injury Event Scale (MIES).

ResultsAnalyses showed substantial levels of CMDs (58.9%, 95%CI 58.1 to 60.8), and of PTSD (30.2%, 95%CI 28.1 to 32.5) with lower levels of depression (27.3%, 95%CI 25.3 to 29.4), anxiety (23.2%, 95%CI 21.3 to 25.3), and alcohol misuse (10.5%, 95%CI, 9.2 to 11.9). Women, younger staff, and nurses tended to have poorer outcomes than other staff, except for alcohol misuse. Higher reported exposure to moral injury (distress resulting from violation of ones moral code) was strongly associated with increased levels of CMDs, anxiety, depression, PTSD symptoms, and alcohol misuse.

ConclusionsOur findings suggest that mental health support for healthcare workers should consider those demographics and occupations at highest risk. Rigorous longitudinal data are needed in order to respond to the potential long-term mental health impacts of the pandemic.

HighlightsO_ST_ABSWhat is already known about this subject?C_ST_ABSO_LILarge-scale population studies report increased prevalence of depression, anxiety, and psychological distress during the COVID-19 pandemic.
C_LIO_LIEvidence from previous epidemics indicates a high and persistent burden of adverse mental health outcomes among healthcare workers.
C_LI

What are the new findings?O_LISubstantial levels of probable common mental disorders and post-traumatic stress disorder were found among healthcare workers.
C_LIO_LIGroups at increased risk of adverse mental health outcomes included women, nurses, and younger staff, as well as those who reported higher levels of moral injury.
C_LI

How might this impact on policy or clinical practice in the foreseeable future?O_LIThe mental health offering to healthcare workers must consider the interplay of demographic, social, and occupational factors.
C_LIO_LIAdditional longitudinal research that emphasises methodological rigor, namely with use of standardised diagnostic interviews to establish mental health diagnoses, is necessary to better understand the mental health burden, identify those most at risk, and provide appropriate support without pathologizing ordinary distress responses.
C_LI",Danielle Lamb; Sam Gnanapragasam; Neil Greenberg; Rupa Bhundia; Ewan Carr; Matthew Hotopf; Reza Razavi; Rosalind Raine; Sean Cross; Amy Dewar; Mary Docherty; Sarah Dorrington; Stephani Hatch; Charlotte Wilson-Jones; Daniel Leightley; Ira Madan; Sally Marlow; Isabel McMullen; Anne Marie Rafferty; Martin Parsons; Catherine Polling; Danai Serfioti; Helen Gaunt; Peter Aitken; Joanna Morris-Bone; Chloe Simela; Veronica French; Rachel Harris; Sharon A.M. Stevelink; Simon Wessely,https://medrxiv.org/cgi/content/short/2021.01.21.20240887,https://medrxiv.org/cgi/content/short/2021.01.21.20240887,2021-01-22,2021-01-22,,True
332,Symptoms of anxiety and depression in relation to work patterns during the first wave of the COVID-19 epidemic in Philadelphia PA: a cross-sectional survey,"ObjectiveWe investigated whether patterns of work during COVID-19 pandemic altered by effort to contain the outbreak affected anxiety and depression.

MethodsWe conducted a cross-sectional online survey of 911 residents of Philadelphia, inquiring about their working lives during early months of the epidemic, symptoms of anxiety and depression, plus demographics, perceived sources of support, and general health.

ResultsOccupational contact with suspected COVID-19 cases was associated with anxiety. Concerns about return to work, childcare, lack of sick leave, and loss/reduction in work correlated with anxiety and depression, even when there was no evidence of occupational contact with infected persons; patterns differed by gender.

ConclusionsHeightened anxiety and depression during COVID-19 pandemic can be due to widespread disruption of working lives, especially in ""non-essential"" low-income industries, on par with experience in healthcare.

The significance to clinical practice of the information being presented: Anxiety and depression symptoms that emerged during COVID-19 pandemic may be related to disruption of working lives even among people who are not the ""essential"" workers with one-one-one contact with infected persons. Clinicians may find this evidence of occupational correlates and articulated specific worries useful in treating such patients.",Igor Burstyn; Tran Huynh,https://medrxiv.org/cgi/content/short/2021.01.21.21250117,https://medrxiv.org/cgi/content/short/2021.01.21.21250117,2021-01-22,2021-01-22,,True
333,Exploring support needs of people living with diabetes during the coronavirus COVID-19 pandemic: insights from a UK survey.,"BackgroundThe coronavirus COVID-19 pandemic has radically compromised healthcare for people living with chronic conditions such as diabetes. Government-imposed restrictions to contain the spread of the virus has forced people to suddenly adjust their lifestyle. This study aimed to capture the impact of the pandemic on people living with diabetes and the views of these individuals on ways in which the information, advice and support they are receiving could be improved.

Research design and methodsAn online anonymous survey was distributed across the UK during the first lockdown and initial easing. The survey comprised questions about confidence in diabetes self-management, resources used to obtain information, advice and support, and opinions on how these could be improved. Open-ended captured subjective experiences.

ResultsThe survey was completed by 773 adults living with diabetes (69.2% type 1, 28.5% type 2). There was notable variability in the impact of the pandemic on confidence in self-management, with confidence having deteriorated most commonly in the ability to take care of own mental wellbeing (37.0% respondents) and improved most commonly in maintaining a healthy weight (21.1% respondents). 41.2% of respondents living alone reported not receiving any outside support. The quality of information, advice and support received from the healthcare team was rated poorly by 37.2%. Respondents sought greater communication and tailored advice from their care team, clear and consistent information from the government and news channels, and improved understanding of diabetes and its challenges from their personal networks and employers.

ConclusionAdjusting to the COVID-19 pandemic has strained the mental health and wellbeing of people living with diabetes. Diabetes care teams must receive assistance to support these individuals without risking further inequalities in access to healthcare. Equipping personal networks and employers with knowledge on diabetes and skills to support self-management may reduce the burden on the NHS.

O_TEXTBOXSignificance of this study

O_LIWhat is already known about this subject?
O_LIThe COVID-19 pandemic has posed multiple challenges to the everyday life of people across the world.
C_LIO_LIPeople living with diabetes mellitus, particularly those with poor blood glucose are more vulnerable to developing the severe outcomes of COVID-19.
C_LIO_LINHS prioritisation of COVID-19 has disrupted the availability of care for patients with chronic health conditions, including diabetes mellitus.
C_LI
C_LIO_LIWhat are the new findings?
O_LIThe pandemic generated a decrease in confidence in diabetes self-management, particularly regarding mental wellbeing (37.0%) and adhering to physical activity recommendations (32.0%) and a healthy eating pattern (29.6%). Greater access to the healthcare team and services, strategies to adjust self-care (with greater focus on mental health) and more external support are deemed as important to reinstate diabetes self-management.
C_LIO_LICancellation of appointments reduced patients access to knowledge on their glucose control and their confidence in diabetes self-management, it generated difficulties in switching between treatments and resulted in impoverished mental health and motivation to self-manage.
C_LIO_LI41.2% of respondents living alone report not receiving support from outside their household.
C_LIO_LIQuality of information, advice and support received from the government and healthcare teams were perceived most poorly (% of respondents giving a rating of poor or very poor: 39.0% and 37.2% respectively). There is a request for greater transparency, higher quality information, improved contact, and an increased understanding of the condition by others.
C_LI
C_LIO_LIHow might these results change the focus of research or clinical practice?
O_LIThere is a need to ensure equitable contact between healthcare teams and their patients, both for diabetes self-management and overall wellbeing.
C_LIO_LIA shift to remote consultations should include training practitioners to detect emotional distress in patients and the ability to refer patients to NHS or community-led mental health support.
C_LIO_LIA collective effort is needed to produce more stratified and consistent guidance, with clear messaging to minimise uncertainty and distress.
C_LIO_LIFurther research and policy are needed to help patients identify a support network outside their direct care team and equip them with the knowledge and skills to provide adequate support.
C_LIO_LIGreater understanding on how some individuals were able to adjust their self-management successfully could assist care teams, relevant charities and policy makers to provide better support for those individuals who are struggling.
C_LI
C_LI

C_TEXTBOX",Sarah Sauchelli; Julia Bradley; Clare England; Aidan Searle; Alex Whitmarsh,https://medrxiv.org/cgi/content/short/2021.01.20.21249888,https://medrxiv.org/cgi/content/short/2021.01.20.21249888,2021-01-22,2021-01-22,,True
334,Early detection of SARS-CoV-2 infection cases or outbreaks at nursing homes by targeted wastewater tracking,"ObjectivesNear-source tracking of SARS-CoV-2 RNA in the sewage drains serving particular buildings may allow rapid identification of SARS-CoV-2 infection cases or local outbreaks. In this pilot study, we investigated whether this was the case for nursing homes (NH).

MethodsThe study involved five NH (from A to E) affiliated to the Clinico-Malvarrosa Health Department, Valencia (Spain). These were nursing or mixed nursing/care homes of different sizes, altogether providing care for 472 residents attended by a staff of 309. Near-source sewage samples were screened for presence of SARS-CoV-2 RNA by RT-qPCR at least 5 days per week during the study period. SARS-CoV-2 RNA testing in nasopharyngeal swabs from residents and staff was performed with the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Massachusetts, USA).

ResultsSARS-CoV-2 RNA was detected in wastewater samples from four of the five NH. SARS-CoV-2 infection cases were documented in three of these four NH. Of the two NH without SARS-CoV-2 infection cases, no SARS-CoV-2 RNA was detected in sewer samples from one facility, while it was repeatedly detected in samples from the other. Presence of SARS-CoV-2 RNA in sewage preceded identification of isolated cases among residents or staff or outbreak declaration in two NH, with lag times ranging from 5 to 19 days.

ConclusionOur study demonstrated that intermittent or persistent detection of SARS-CoV-2 RNA in NH sewers can provide an early warning of subsequent individual cases or outbreaks in these facilities.",Laura Davo; Raimundo Segui; Pilar Botija; Maria Jose Beltran; Eliseo Albert; Ignacio Torres; Pablo Angel Lopez-Fernandez; Rafael Orti; Juan Francisco Maestre; Gloria Sanchez; David Navarro,https://medrxiv.org/cgi/content/short/2021.01.21.21249640,https://medrxiv.org/cgi/content/short/2021.01.21.21249640,2021-01-22,2021-01-22,,True
335,REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England,"BackgroundHigh prevalence of SARS-CoV-2 virus in many northern hemisphere populations is causing extreme pressure on healthcare services and leading to high numbers of fatalities. Even though safe and effective vaccines are being deployed in many populations, the majority of those most at-risk of severe COVID-19 will not be protected until late spring, even in countries already at a more advanced stage of vaccine deployment.

MethodsThe REal-time Assessment of Community Transmission study-1 (REACT-1) obtains throat and nose swabs from between 120,000 and 180,000 people in the community in England at approximately monthly intervals. Round 8a of REACT-1 mainly covers a period from 6th January 2021 to 15th January 2021. Swabs are tested for SARS-CoV-2 virus and patterns of swab-positivity are described over time, space and with respect to individual characteristics. We compare swab-positivity prevalence from REACT-1 with mobility data based on the GPS locations of individuals using the Facebook mobile phone app. We also compare results from round 8a with those from round 7 in which swabs were collected from 13th November to 24th November (round 7a) and 25th November to 3rd December 2020 (round 7b).

ResultsIn round 8a, we found 1,962 positives from 142,909 swabs giving a weighted prevalence of 1.58% (95% CI, 1.49%, 1.68%). Using a constant growth model, we found no strong evidence for either growth or decay averaged across the period; rather, based on data from a limited number of days, prevalence may have started to rise at the end of round 8a. Facebook mobility data showed a marked decrease in activity at the end of December 2020, followed by a rise at the start of the working year in January 2021. Between round 7b and round 8a, prevalence increased in all adult age groups, more than doubling to 0.94% (0.83%, 1.07%) in those aged 65 and over. Large household size, living in a deprived neighbourhood, and Black and Asian ethnicity were all associated with increased prevalence. Both healthcare and care home workers, and other key workers, had increased odds of swab-positivity compared to other workers.

ConclusionDuring the initial 10 days of the third COVID-19 lockdown in England in January 2021, prevalence of SARS-CoV-2 was very high with no evidence of decline. Until prevalence in the community is reduced substantially, health services will remain under extreme pressure and the cumulative number of lives lost during this pandemic will continue to increase rapidly.",Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E. Walters; Haowei Wang; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,https://medrxiv.org/cgi/content/short/2021.01.20.21250158,https://medrxiv.org/cgi/content/short/2021.01.20.21250158,2021-01-22,2021-01-22,,True
336,Redeployment and training of healthcare professionals to Intensive Care during COVID-19: a systemic review,"BackgroundA rapid influx of patients to intensive care and infection control measures during the COVID-19 pandemic required the rapid development of innovative redeployment and training strategies.

MethodsWe conducted a systematic search of 9 databases including key terms related to intensive care AND training AND redeployment AND healthcare workers. Analysis consisted of a narrative synthesis of quantitative study outputs, and a framework-based thematic analysis of qualitative study outputs and grey literature. These results were then combined applying an interpretative synthesis.

ResultsTwenty papers were analysed. These took place primarily in the UK (N=8, 40%) and USA (N=5, 25%). Themes included in the results are Redeployment: Implementation strategies and learnings; Redeployed staff experience and strategies to address their needs; Redeployed staff learning needs; Training formats offered and training evaluations; and Future redeployment and training concerns.

Some of the redeployment implementation and training strategies documented in this review are: Skills-based redeployment, buddy support systems, and agreeing on locally-specific principles, rather than strict procedures.

ConclusionThe COVID-19 pandemic presented unique challenges to deliver training promptly while following infection control recommendations and develop flexible redeployment strategies. This study synthesises original approaches to tackle these challenges which are relevant to inform the development of targeted and adaptative training and redeployment plans.",Norha Vera San Juan; Matthew Camilleri; John Paul Jeans; Alexandra Monkhouse; Georgia Chisnall; Cecilia Vindrola-Padros,https://medrxiv.org/cgi/content/short/2021.01.21.21250230,https://medrxiv.org/cgi/content/short/2021.01.21.21250230,2021-01-22,2021-01-22,,True
337,Clinical prediction rule for SARS-CoV-2 infection from 116 U.S. emergency departments,"ObjectivesAccurate and reliable criteria to rapidly estimate the probability of infection with the novel coronavirus-2 that causes the severe acute respiratory syndrome (SARS-CoV-2) and associated disease (COVID-19) remain an urgent unmet need, especially in emergency care. The objective was to derive and validate a clinical prediction rule for SARS-CoV-2 infection that uses simple criteria widely available at the point of care.

MethodsData came from the Registry data from the national REgistry of suspected COVID-19 in EmeRgency care (RECOVER network) comprising 116 hospitals from 25 states in the US. Clinical predictors and 30-day outcomes were abstracted from medical records of 19,850 emergency department (ED) patients tested for SARS-CoV-2. The criterion standard for diagnosis of SARS-CoV-2 required a positive molecular test from a swabbed sample or positive antibody testing within 30 days. The prediction rule was derived from a 50% random sample (n=9,925) using unadjusted analysis of 107 candidate variables as a screening step, followed by stepwise forward logistic regression on 72 variables.

ResultsMultivariable regression yielded a 13-variable score, which was simplified to 13-point rule: +1 point each for age>50 years, measured temperature>37.5{degrees}C, oxygen saturation<95%, Black race, Hispanic or Latino ethnicity, household contact with known or suspected COVID-19, patient reported history of dry cough, anosmia/dysgeusia, myalgias or fever; and -1 point each for White race, no direct contact with infected person, or smoking. In the validation sample (n=9,975), the score produced an area under the receiver operating character curve of 0.80 (95% CI: 0.79-0.81), and this level of accuracy was retained across patients enrolled from the early spring to summer of 2020. In the simplified rule, a score of zero produced a sensitivity of 95.6% (94.8-96.3%), specificity of 20.0% (19.0-21.0%), likelihood ratio negative of 0.22 (0.19-0.26). Increasing points on the simplified rule predicted higher probability of infection (e.g., >75% probability with +5 or more points).

ConclusionCriteria that are available at the point of care can accurately predict the probability of SARS-CoV-2 infection. These criteria could assist with decision about isolation and testing at high throughput checkpoints.

Key pointsO_ST_ABSQuestionC_ST_ABSCan clinical criteria, derived solely from interview and vital signs accurately estimate the probability of infection from the novel coronavirus (SARS-CoV-2) that causes COVID-19?

FindingsFrom derivation sample (n=9,925), we derived a set of 13 clinical criteria that produced an area under the receiver operating characteristic curve of 0.80 (0.79-0.81) in a validation sample (n=9,925). At a score of zero, the simplified version of the criteria produced sensitivity of 95.6% (94.8 to 96.3%), and specificity of 20.0% (19.0 to 21.0%).

MeaningClinical criteria can estimate the probability of SARS-CoV-2 infection.",Jeffrey Kline; - RECOVER Network,https://medrxiv.org/cgi/content/short/2021.01.20.21249656,https://medrxiv.org/cgi/content/short/2021.01.20.21249656,2021-01-22,2021-01-22,,True
338,Clinical effectiveness of convalescent plasma in hospitalized patients with COVID-19: a systematic review and meta-analysis,"Given the variability of previously reported results, this systematic review aims to determine the clinical effectiveness of convalescent plasma employed in the treatment of hospitalized patients with diagnosis of COVID-19.

We conducted a systematic review of controlled clinical trials assessing treatment with convalescent plasma for hospitalized patients with a diagnosis of SARS-CoV-2 infection. The outcomes were mortality, clinical improvement, and ventilation requirement.

A total of 50 studies were retrieved from the databases. Four articles were finally included in the data extraction, qualitative and quantitative synthesis of results. The meta-analysis suggests that there is no benefit of convalescent plasma compared to standard care or placebo in the reduction of the overall mortality and in the ventilation requirement; but there could be a benefit for the clinical improvement in patients treated with plasma.

We can conclude that the convalescent plasma transfusion cannot reduce the mortality or ventilation requirement in hospitalized patients diagnosed with SARS-CoV-2 infection. More controlled clinical trials conducted with methodologies that ensure a low risk of bias are still needed.",Roberto Ariel Abeldano Zuniga; Ruth Ana Maria Gonzalez Villoria; Maria Vanesa Elizondo; Anel Yaneli Nicolas Osorio; Silvia Mercedes Coca,https://medrxiv.org/cgi/content/short/2021.01.16.21249956,https://medrxiv.org/cgi/content/short/2021.01.16.21249956,2021-01-22,2021-01-22,,True
339,Longitudinal trends and risk factors for depressed mood among Canadian adults during the first wave of COVID-19,"AO_SCPLOWBSTRACTC_SCPLOWO_ST_ABSBO_SCPLOWACKGROUNDC_SCPLOWC_ST_ABSThe COVID-19 pandemic has raised serious concerns about the mental health impact of people directed and indirectly affected by the virus. Because this is a rapidly evolving situation, our goal was to explore potential risk factors and trends in feelings of anxiety and depression among the general population in Canada over the first five months of the pandemic.

MO_SCPLOWETHODSC_SCPLOWWe completed on-line surveys of 3,127 unique individuals representative of the Canadian general population at 4 discreet periods every 6 weeks from April 15th to July 28th 2020. We assessed feelings of anxiety, depression and loss of interest with the interRAI self-reported mood scale using a multivariable generalized estimating equation model to examine factors associated with having a 5+ score on the scale (indicating potentially depressed mood). We also investigated potential longitudinal trends to examine temporal changes in mood scores.

RO_SCPLOWESULTSC_SCPLOWMore than 30% of participants felt highly anxious, depressed, and disinterested in everyday activities in the first survey (April), but this number decreased to about 20% over 4 months. Feeling lonely, younger age, feeling overwhelmed by ones health needs, having financial concerns, and living outside of Quebec were significantly associated with depressed mood.

IO_SCPLOWNTERPRETATIONC_SCPLOWThe prevalence of depressed mood during the pandemic was between 2 and 3 times the pre-pandemic rate (especially among young people), but it can change rapidly in response to social changes. Thus, monitoring of psychological distress among vulnerable groups that may benefit from additional supports should be a priority.",Gustavo Betini; John Hirdes; Rheda Adekpedjou; Chris Perlman; Nathan Huculak; Paul Hebert,https://medrxiv.org/cgi/content/short/2021.01.21.20245795,https://medrxiv.org/cgi/content/short/2021.01.21.20245795,2021-01-22,2021-01-22,,True
340,A cross-sectional analysis of demographic and behavioral risk factors of SARS-CoV-2 antibody positivity among a sample of U.S. college students,"BackgroundColleges and universities across the United States are developing and implementing data-driven prevention and containment measures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Identifying risk factors for SARS-CoV-2 seropositivity could help to direct these efforts.

ObjectiveTo estimate the associations between demographic factors and social behaviors and SARS-CoV-2 seropositivity and self-reported positive SARS-CoV-2 diagnostic test.

MethodsIn September 2020, we randomly sampled Indiana University Bloomington (IUB) undergraduate students. Participants completed a cross-sectional, online survey about demographics, SARS-CoV-2 testing history, relationship status, and risk behaviors. Additionally, during a subsequent appointment, participants were tested for SARS-CoV-2 antibodies using a fingerstick procedure and SARS-CoV-2 IgM/IgG rapid assay kit. We used unadjusted modified Poisson regression models to evaluate the associations between predictors of both SARS-CoV-2 seropositivity and self-reported positive SARS-CoV-2 infection history.

ResultsOverall, 1,076 students were included in the serological testing analysis, and 1,239 students were included in the SARS-CoV-2 infection history analysis. Current seroprevalence of SARS-CoV-2 was 4.6% (95% CI: 3.3%, 5.8%). Prevalence of self-reported SARS-CoV-2 infection history was 10.3% (95% CI: 8.6%, 12.0%). Greek membership, having multiple romantic partners, knowing someone in ones immediate environment with SARS-CoV-2 infection, drinking alcohol more than 1 day per week, and hanging out with more than 4 people when drinking alcohol increased both the likelihood of seropositivity and SARS-CoV-2 infection history.

ConclusionOur findings have implications for American colleges and universities and could be used to inform SARS-C0V-2 prevention and control strategies on such campuses.",Sina Kianersi; Christina Ludema; Jonathan T. Macy; Edlin Garcia; Chen Chen; Maya Luetke; Mason H. Lown; Molly Rosenberg,https://medrxiv.org/cgi/content/short/2021.01.20.21249905,https://medrxiv.org/cgi/content/short/2021.01.20.21249905,2021-01-22,2021-01-22,,True
341,Simulating the impact of different vaccination policies on the COVID-19 pandemic in New York City,"PurposeTo analyze potential COVID-19 epidemic outcomes in New York City under different SARS-CoV-2 virus circulation scenarios and vaccine rollout policies from early Jan 2021 to end of June 2021.

Key findingsIn anticipation of the potential arrival and dominance of the more infectious SARS-CoV-2 variant:

O_LIMass-vaccination would be critical to mitigating epidemic severity (26-52% reduction in infections, hospitalizations, and deaths, compared to no vaccination, provided the new UK variant supplants currently circulating variants).
C_LIO_LIPrioritizing key risk groups for earlier vaccination would lead to greater reductions in hospitalizations and deaths than infections. Thus, in general this would be a good strategy.
C_LIO_LICurrent vaccination prioritization policy is suboptimal. To avert more hospitalizations and deaths, mass-vaccination of all individuals 65 years or older should be done as soon as possible. For groups listed in the same phase, 65+ year-olds should be given first priority ahead of others.
C_LIO_LIAvailable vaccine doses should be given to the next priority groups as soon as possible without awaiting hesitant up-stream groups.
C_LIO_LIWhile efficacy of vaccination off-protocol is unknown, provided immune response following a first vaccine dose persists, delaying the 2nd vaccine dose by [~]1 month (i.e. administer the two doses 8 weeks apart) can substantially reduce infections, hospitalizations, and deaths compared to the 3-week apart regimen. Across all scenarios tested here, delaying the 2nd vaccine dose leads to the largest reduction in severe epidemic outcomes (e.g. hospitalizations and deaths). Therefore, to protect as many people as possible, this strategy should be considered if rapid increases in infections, hospitalization or deaths and/or shortages in vaccines were to occur.
C_LI",Wan Yang; Sasikiran Kandula; Jeffrey Shaman,https://medrxiv.org/cgi/content/short/2021.01.21.21250228,https://medrxiv.org/cgi/content/short/2021.01.21.21250228,2021-01-22,2021-01-22,,True
342,"Excess mortality associated with the COVID-19 pandemic among Californians 18-65 years of age, by occupational sector and occupation: March through October 2020","BackgroundThough SARS-CoV-2 outbreaks have been documented in occupational settings and though there is speculation that essential workers face heightened risks for COVID-19, occupational differences in excess mortality have, to date, not been examined. Such information could point to opportunities for intervention, such as workplace modifications and prioritization of vaccine distribution.

Methods and findingsUsing death records from the California Department of Public Health, we estimated excess mortality among Californians 18-65 years of age by occupational sector and occupation, with additional stratification of the sector analysis by race/ethnicity. During the COVID-19 pandemic, working age adults experienced a 22% increase in mortality compared to historical periods. Relative excess mortality was highest in food/agriculture workers (39% increase), transportation/logistics workers (28% increase), facilities (27%) and manufacturing workers (23% increase). Latino Californians experienced a 36% increase in mortality, with a 59% increase among Latino food/agriculture workers. Black Californians experienced a 28% increase in mortality, with a 36% increase for Black retail workers. Asian Californians experienced an 18% increase, with a 40% increase among Asian healthcare workers. Excess mortality among White working-age Californians increased by 6%, with a 16% increase among White food/agriculture workers.

ConclusionsCertain occupational sectors have been associated with high excess mortality during the pandemic, particularly among racial and ethnic groups also disproportionately affected by COVID-19. In-person essential work is a likely venue of transmission of coronavirus infection and must be addressed through strict enforcement of health orders in workplace settings and protection of in-person workers. Vaccine distribution prioritizing in-person essential workers will be important for reducing excess COVID mortality.",Yea-Hung Chen; Maria Glymour; Alicia Riley; John Balmes; Kate Duchowny; Robert Harrison; Ellicott Matthay; Kirsten Bibbins-Domingo,https://medrxiv.org/cgi/content/short/2021.01.21.21250266,https://medrxiv.org/cgi/content/short/2021.01.21.21250266,2021-01-22,2021-01-22,,True
343,Potential contribution of climate conditions on COVID-19 pandemic transmission over West and North African countries,"The COVID-19 disease, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is a very contagious disease that has killed many people around the world. According to the World Health Organization (WHO) data, the spread of the disease appears to be slower in Africa. Although a number of studies have been published on the relationship between meteorological parameters and COVID-19 transmission, the effects of climate conditions on COVID-19 remain largely unexplored and without consensus following the main research finding over Africa (often based on a single country or city). Here, using available epidemiological data over 275 days (i.e., from March 1 to November 30, 2020) taken from the European Center for Disease Prevention and Control of the European Union database and daily data of surface air temperature and humidity from the National Center for Environmental Prediction (NCEP), this paper investigates the potential contributions of climate conditions on COVID-19 transmission over 16 countries selected from three bioclimatic regions of Africa (i.e., Sahel, Maghreb and Gulf of Guinea). On average, our main findings highlight statistically significant inverse correlations between COVID-19 cases and temperature over the Maghreb and the Gulf of Guinea regions, whereas positive correlations are found in the Sahel, especially over the central part including Niger and Mali. Correlations with specific humidity and water vapor parameters display significant and positive values over the Sahelian and the Gulf of Guinean countries and negative values over the Maghreb countries. In other word, results imply that the COVID-19 pandemic transmission is influenced differently across the three bioclimatic regions: i) cold and dry environmental conditions over the Maghreb; ii) warm and humid conditions over the Sahel iii) cold and humid conditions over the Gulf of Guinea. These findings could be useful for decision-makers who plan public health and control measures in affected African countries and would have substantial implications for directing respiratory disease surveillance activities.",Ibrahima Diouf; Souleymane Sy; Habib Senghor; Papa Fall; Diarra Diouf; Moussa Diakhate; Wassila M. Thiaw; Amadou T. Gaye,https://medrxiv.org/cgi/content/short/2021.01.21.21250231,https://medrxiv.org/cgi/content/short/2021.01.21.21250231,2021-01-22,2021-01-22,,True
344,Problems with Evidence Assessment in COVID-19 Health Policy Impact Evaluation (PEACHPIE): A systematic strength of methods review,"IntroductionThe impact of policies on COVID-19 outcomes is one of the most important questions of our time. Unfortunately, there are substantial concerns about the strength and quality of the literature examining policy impacts. This study systematically assessed the currently published COVID-19 policy impact literature for a checklist of study design elements and methodological issues.

MethodsWe included studies that were primarily designed to estimate the quantitative impact of one or more implemented COVID-19 policies on direct SARS-CoV-2 and COVID-19 outcomes. After searching PubMed for peer-reviewed articles published on November 26 or earlier and screening, all studies were reviewed by three reviewers independently and in consensus. The review tool was based on review guidance for assessing COVID-19 health policy impact evaluation analyses, including first identifying the assumptions behind the methods used, followed by assessing graphical display of outcomes data, functional form for the outcomes, timing between policy and impact, concurrent changes to the outcomes, and an overall rating.

ResultsAfter 102 articles were identified as potentially meeting inclusion criteria, we identified 36 published articles that evaluated the quantitative impact of COVID-19 policies on direct COVID-19 outcomes. The majority (n=23/36) of studies in our sample examined the impact of stay-at-home requirements. Nine studies were set aside due to inappropriate study design (n=8 pre/post; n=1 cross-section), and 27 articles were given a full consensus assessment. 20/27 met criteria for graphical display of data, 5/27 for functional form, 19/27 for timing between policy implementation and impact, and only 3/27 for concurrent changes to the outcomes. Only 1/27 studies passed all of the above checks, and 4/27 were rated as overall appropriate. Including the 9 studies set aside, we found that only four (or by a stricter standard, only one) of the 36 identified published and peer-reviewed health policy impact evaluation studies passed a set of key design checks for identifying the causal impact of policies on COVID-19 outcomes.

DiscussionThe current literature directly evaluating the impact of COVID-19 policies largely fails to meet key design criteria for useful inference. This may be partially due to the circumstances for evaluation being particularly difficult, as well as a context with desire for rapid publication, the importance of the topic, and weak peer review processes. Importantly, weak evidence is non-informative and does not indicate how effective these policies were on COVID-19 outcomes.",Noah A Haber; Emma Clarke-Deelder; Avi Feller; Emily R Smith; Joshua Salomon; Benjamin MacCormack-Gelles; Elizabeth M Stone; Clara Bolster-Foucault; Jamie R Daw; Laura A Hatfield; Carrie E Fry; Christopher B Boyer; Eli Ben-Michael; Caroline M Joyce; Beth S Linas; Ian Schmid; Eric H Au; Sarah E Wieten; Brooke A Jarrett; Cathrine Axfors; Van Thu Nguyen; Beth Ann Griffin; Alyssa Bilinski; Elizabeth A Stuart,https://medrxiv.org/cgi/content/short/2021.01.21.21250243,https://medrxiv.org/cgi/content/short/2021.01.21.21250243,2021-01-22,2021-01-22,,True
345,Assessing the efficacy of interventions to control indoor SARS-Cov-2 transmission: an agent-based modeling approach,"Intervention strategies for minimizing indoor SARS-CoV-2 transmission are often based on anecdotal evidence because there is little evidence-based research to support them. We developed a spatially-explicit agent-based model for simulating indoor respiratory pathogen transmission, and used it to compare effects of four interventions on reducing individual-level SARS-CoV-2 transmission risk by simulating a well-known case study. We found that imposing movement restrictions and efficacious mask usage appear to have the greatest effects on reducing infection risk, but multiple concurrent interventions are required to minimize the proportion of susceptible individuals infected. Social distancing had little effect on reducing transmission if individuals move during the gathering. Furthermore, our results suggest that there is potential for ventilation airflow to expose susceptible people to aerosolized pathogens even if they are relatively far from infectious individuals. Maximizing rates of aerosol removal is the key to successful transmission-risk reduction when using ventilation systems as intervention tools.

Article Summary LineImposing mask usage requirements, group size restrictions, duration limits, and social distancing policies can have additive, and in some cases multiplicative protective effects on SARS-CoV-2 infection risk during indoor events.",Trevor S Farthing; Cristina Lanzas,https://medrxiv.org/cgi/content/short/2021.01.21.21250240,https://medrxiv.org/cgi/content/short/2021.01.21.21250240,2021-01-22,2021-01-22,,True
346,Do Pandemics Obey the Elliott Wave Principle of Financial Markets?,"The Elliott Wave principle is a time-honored, oft-used method for predicting variations in the financial markets. It is based on the notion that human emotions drive financial decisions. In the fight against COVID-19, human emotions are similarly decisive, for instance in that they determine ones willingness to be vaccinated, and/or to follow preventive measures including the wearing of masks, the application of social distancing protocols, and frequent handwashing. On this basis, we postulated that the Elliott Wave Principle may similarly be used to predict the future evolution of the COVID-19 pandemic. We demonstrated that this method reproduces the data pattern especially well for USA (daily new cases). Potential scenarios were then extrapolated, from the best-case corresponding to a rapid, full vaccination of the population, to the utterly disastrous case of slow vaccination, and poor adherence to preventive protocols.",Prashant Dogra; Eugene J. Koay; Zhihui Wang; Farhaan Vahidy; Mauro Ferrari; Renata Pasqualini; Wadih Arap; Marc L. Boom; H. Dirk Sostman; Vittorio Cristini,https://medrxiv.org/cgi/content/short/2021.01.21.21250273,https://medrxiv.org/cgi/content/short/2021.01.21.21250273,2021-01-22,2021-01-22,,True
347,Personalized Virus Load Curves of SARS-CoV-2 Infection,"We introduce an explicit function that describes virus-load curves on a patient-specific level. This function is based on simple and intuitive model parameters. It allows virus load analysis without solving a full virus load dynamic model. We validate our model on data from influenza A as well as SARS-CoV-2 infection data for Macaque monkeys and humans. Further, we compare the virus load function to an established target model of virus dynamics, which shows an excellent fit. Our virus-load function offers a new way to analyse patient virus load data, and it can be used as input to higher level models for the physiological effects of a virus infection, for models of tissue damage, and to estimate patient risks.",Thomas Hillen; Carlos Contreras; Jay M Newby,https://medrxiv.org/cgi/content/short/2021.01.21.21250268,https://medrxiv.org/cgi/content/short/2021.01.21.21250268,2021-01-22,2021-01-22,,True
348,Development and validation of a predictive model for critical illness in adult patients requiring hospitalization for COVID-19,"BackgroundIdentifying factors that can predict severe disease in patients needing hospitalization for COVID-19 is crucial for early recognition of patients at greatest risk.

Objective1) Identify factors predicting intensive care unit (ICU) transfer and (2) develop a simple calculator for clinicians managing patients hospitalized with COVID-19.

MethodsA total of 2,685 patients with laboratory-confirmed COVID-19 admitted to a large metropolitan health system in Georgia, USA between March and July 2020 were included in the study. Seventy-five percent of patients were included in the training dataset (admitted March 1 to July 10). Through multivariable logistic regression, we developed a prediction model (probability score) for ICU transfer. Then, we validated the model by estimating its performance accuracy (area under the curve [AUC]) using data from the remaining 25% of patients (admitted July 11 to July 31).

ResultsWe included 2,014 and 671 patients in the training and validation datasets, respectively. Diabetes mellitus, coronary artery disease, chronic kidney disease, serum C-reactive protein, and serum lactate dehydrogenase were identified as significant risk factors for ICU transfer, and a prediction model was developed. The AUC was 0.752 for the training dataset and 0.769 for the validation dataset. We developed a free, web-based calculator to facilitate use of the prediction model (https://icucovid19.shinyapps.io/ICUCOVID19/).

ConclusionOur validated, simple, and accessible prediction model and web-based calculator for ICU transfer may be useful in assisting healthcare providers in identifying hospitalized patients with COVID-19, who are at high risk for clinical deterioration.

Triage of such patients for early aggressive treatment can impact clinical outcomes for this potentially deadly disease.",Neha Paranjape; Lauren Staples; Christina Stradwick; Herman Ray; Ian Saldanha,https://medrxiv.org/cgi/content/short/2021.01.22.21250289,https://medrxiv.org/cgi/content/short/2021.01.22.21250289,2021-01-22,2021-01-22,,True
349,Using body temperature and variables commonly available in the EHR to predict acute infection: A proof-of-concept study showing improved pretest probability estimates for acute COVID-19 infection among discharged emergency department patients,"ObjectivesObtaining body temperature is a quick and easy method to screen for acute infection such as COVID-19. Currently, the predictive value of body temperature for acute infection is inhibited by failure to account for other readily available variables that affect temperature values. In this proof-of-concept study, we sought to improve COVID-19 pretest probability estimation by incorporating covariates known to be associated with body temperature, including patient age, sex, comorbidities, month, time of day.

MethodsFor patients discharged from an academic hospital emergency department after testing for COVID-19 in March and April of 2020, we abstracted clinical data. We reviewed physician documentation to retrospectively generate estimates of pretest probability for COVID-19. Using patients COVID-19 PCR test results as a gold standard, we compared AUCs of logistic regression models predicting COVID-19 positivity that used: 1) body temperature alone; 2) body temperature and pretest probability; 3) body temperature, pretest probability, and body temperature-relevant covariates. Calibration plots and bootstrap validation were used to assess predictive performance for model #3.

ResultsData from 117 patients were included. The models AUCs were: 1) 0.69 2) 0.72, and 3) 0.76, respectively. The absolute difference in AUC was 0.029 (95%CI -0.057 to 0.114, p=0.25) between model 2 and 1 and 0.038 (95%CI -0.021 to 0.097, p=0.10) between model 3 and 2.

ConclusionsBy incorporating covariates known to affect body temperature, we demonstrated improved pretest probability estimates of acute COVID-19 infection. Future work should be undertaken to further develop and validate our model in a larger, multi-institutional sample.",Carl T Berdahl; An T Nguyen; Marcio A Diniz; Andrew J Henreid; Teryl K Nuckols; Christopher P Libby; Joshua M Pevnick,https://medrxiv.org/cgi/content/short/2021.01.21.21250261,https://medrxiv.org/cgi/content/short/2021.01.21.21250261,2021-01-22,2021-01-22,,True
350,Abrupt increase in the UK coronavirus death-case ratio in December 2020,"1Objectiveto determine the statistical relationship between reported deaths and infections in the UK coronavirus outbreak

DesignPublicly available UK government data is used to determine a relationship between reported cases and deaths, taking into account various UK regions, age profiles and prevalence of the variant of concern (VOC) B.1.1.7.

Main Outcome MeasuresEstablishing a simple statistical relationship between detected cases and subsequent mortality.

ResultsThroughout October and November 2020, deaths in England are well described as 1/55th of detected cases from 12 days previously. After that, the relationship no longer holds and deaths are significantly higher. This is especially true in regions affected by the VOC B.1.1.7

ConclusionsIn early December, some new factor emerged to increase the case-fatality rate in the UK.

Summary BoxO_ST_ABSWhat is already known on this topicC_ST_ABSThe infection-mortality ratio enables one to predict future deaths based on current infections. Incomplete monitoring of infection may be sufficient to predict future trends.

What the study addsFor the specific case of the second wave of coronavirus infection in the UK, we show a clear mathematical relationship between detected infections (positive tests) and subsequent deaths. This relationship begins to fail in December, with unexpectedly high death rates. This may be correlated in time and region with the emergence of the Variant of Concern B 1.1.7.",David J Wallace; Graeme J Ackland,https://medrxiv.org/cgi/content/short/2021.01.21.21250264,https://medrxiv.org/cgi/content/short/2021.01.21.21250264,2021-01-22,2021-01-22,,True
351,Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines,"Observational studies of the effectiveness of vaccines to prevent COVID-19 are needed to inform real-world use. These are now in planning amid the ongoing rollout of SARS-CoV-2 vaccines globally. While traditional case-control (TCC) and test-negative design (TND) studies feature prominently among strategies used to assess vaccine effectiveness, such studies may encounter important threats to validity. Here we review the theoretical basis for estimation of vaccine direct effects under TCC and TND frameworks, addressing specific natural history parameters of SARS-CoV-2 infection and COVID-19 relevant to these designs. Bias may be introduced by misclassification of cases and controls, particularly when clinical case criteria include common, non-specific indicators of COVID-19. When using diagnostic assays with high analytical sensitivity for SARS-CoV-2 detection, individuals testing positive may be counted as cases even if their symptoms are due to other causes. The TCC may be particularly prone to confounding due to associations of vaccination with healthcare-seeking behavior or risk of infection. The TND reduces but may not eliminate this confounding, for instance if individuals who receive vaccination seek care or testing for less-severe infection. These circumstances indicate the two study designs cannot be applied naively to datasets gathered through public health surveillance or administrative sources. We suggest practical strategies to reduce bias in vaccine effectiveness estimates at the study design and analysis stages.",Joseph A Lewnard; Manish M Patel; Nicholas P Jewell; Jennifer R Verani; Miwako Kobayashi; Mark Tenforde; Natalie E Dean; Benjamin J Cowling; Benjamin A Lopman,https://medrxiv.org/cgi/content/short/2021.01.21.21250258,https://medrxiv.org/cgi/content/short/2021.01.21.21250258,2021-01-22,2021-01-22,,True
352,Agent-Based Simulation of Covid-19 Vaccination Policies in CovidSIMVL,"An agent-based infectious disease modeling tool (CovidSIMVL) is employed in this paper to explore outcomes associated with MRNA two-dose vaccination regimens set out in Emergency Use Authorization (EUA) documents submitted by Pfizer and Moderna to the US Department of Health & Human Services. As well, the paper explores outcomes associated with a third ""Hybrid"" policy that reflects ranges of expected levels of protection according to Pfizer and Moderna EUAs, but entails a 35 day separation between first and second dose, which exceeds the 21 days set out in Pfizer documentation or the 28 days in Moderna documentation.

Four CovidSIMVL parameters are varied in the course of 75 simulated clinical trials. Two relate directly to the vaccines and their impacts (duration between doses; degree of expected protection conferred by different vaccines following first or second dose). Two relate to the simulation contexts to which the vaccines are applied (degree of infectivity; duration of infectivity). The simulated trials demonstrate expected effects for timing of second dose, and for degree of protection associated with first and second dose of Pfizer and Moderna vaccines, and the effects are consistent with an assumed value of 75% for degree of protection after first and second doses for the Hybrid vaccine. However, the simulated trials suggest a more complex interaction between expected level of protection following first dose, timing of second dose and degree of infectivity. These results suggest that policy options should not be considered independent of the transmission dynamics that are manifested in the contexts in which the policies could be applied.

CovidSIMVL embodies stochasticity in the mechanisms that govern viral transmission, and it treats the basic reproduction number (R0)as an emergent characteristic of transmission dynamics, not as a pre-set value that determines those dynamics. As such, results reported in this paper reflect outcomes that could happen, but do not necessarily reflect what is more or less likely to happen, given different configurations of parameters. The discussion section goes into some measure of detail regarding next steps that could be pursued to enhance the potential for agent-based models such as CovidSIMVL to inform exploration of possible vaccination policies, and to project outcomes that are possible or likely in local contexts, where stochasticity and heterogeneity of transmission must be featured in models that are intended to reflect local realism.",Ernie Chang; Kenneth Andrew Moselle,https://medrxiv.org/cgi/content/short/2021.01.21.21250237,https://medrxiv.org/cgi/content/short/2021.01.21.21250237,2021-01-22,2021-01-22,,True
353,Negative Excess Mortality in Pneumonia Death caused by COVID-19 in Japan,"BackgroundSince the emergence of COVID-19, cases of excess mortality from all causes have been very few in Japan.

ObjectTo evaluate COVID-19 effects precisely, we specifically examine deaths caused by pneumonia and examine excess mortality attributable to pneumonia in Japan.

MethodWe applied the NIID model to pneumonia deaths from 2005 up through August, 2020 for the whole of Japan. Introduction of routine pneumococcal vaccination for elderly people and revision in ICD10 were incorporated into the estimation model. Results: No excess mortality was found for 2020. However, negative excess mortality was observed as 178 in May, 314 in June, and 75 in July.

Discussion and ConclusionSignificantly negative excess mortality might reflect precautions taken by people including wearing masks, washing hands with alcohol, and maintaining social distance. They reduced the infection risk not only of for COVID-19 but also of other infectious diseases causing pneumonia.",Junko Kurita; Tamie Sugawara; Yoshiyuki Sugishita; Yasushi Ohkusa,https://medrxiv.org/cgi/content/short/2021.01.22.21250283,https://medrxiv.org/cgi/content/short/2021.01.22.21250283,2021-01-22,2021-01-22,,True
354,Improving Fabric Face Masks: Impact of Design Features on the Protection Offered by Fabric Face Masks,"ObjectiveWith much of the public around the world depending on fabric face masks to protect themselves and others, it is essential to understand how the protective ability of fabric masks can be enhanced. This study evaluated the protection offered by eighteen fabric masks designs. In addition, it assessed the benefit of including three design features: insert filters, surgical mask underlayers, and nose wires.

MethodsQuantitative fit tests were conducted on different masks and with some additional design features. An array of fabric masks were tested on a single participant to account for variability in face shapes. The effects of insert filters, surgical mask underlayers and nose wires were also assessed.

ResultsAs expected, the fabric masks offered low degrees of protection; however, alterations in design showed significant increase in their protective ability. The most effective designs were multi-layered masks that fit tightly to the face and lacked dead space between the user and mask. Also, low air-resistance insert filters and surgical mask underlays provided the greatest increase in protection.

ConclusionsOur findings indicate substantial heterogeneity in the protection offered by various fabric face masks. We also note some design features which may enhance the protection these masks offer.",Eugenia O'Kelly; Anmol Arora; Sophia Pirog; James Ward; P John Clarkson,https://medrxiv.org/cgi/content/short/2021.01.21.20228569,https://medrxiv.org/cgi/content/short/2021.01.21.20228569,2021-01-22,2021-01-22,,True
355,Effects of Diabetes and Blood Glucose on COVID-19 Mortality: A Retrospective Observational Study,"OBJECTIVETo investigate the association of diabetes and blood glucose on mortality of patients with Coronavirus Disease 2019 (COVID-19).

RESEARCH DESIGN AND METHODSThis was a retrospective observational study of all patients with COVID-19 admitted to Huo-Shen-Shan Hospital, Wuhan, China. The hospital was built only for treating COVID-19 and opened on February 5, 2020. The primary endpoint was all-cause mortality during hospitalization.

RESULTSAmong 2877 hospitalized patients, 13.5% (387/2877) had a history of diabetes and 1.9% (56/2877) died in hospital. After adjustment for confounders, patients with diabetes had a 2-fold increase in the hazard of mortality as compared to patients without diabetes (adjusted HR 2.11, 95%CI: 1.16-3.83, P=0.014). The on-admission glucose (per mmol/L[&ge;]4mmol/L) was significantly associated with subsequent mortality on COVID-19 (adjusted HR 1.17, 95%CI: 1.10-1.24, P<0.001).

CONCLUSIONSDiabetes and on-admission glucose (per mmol/L[&ge;]4mmol/L) are associated with increased mortality in patients with COVID-19. These data support that blood glucose should be properly controlled for possibly better survival outcome in patients with COVID-19.",Fei Li; Yue Cai; Chao Gao; Lei Zhou; Renjuan Chen; Kan Zhang; Weiqin Li; Ruining Zhang; Xijing Zhang; Duolao Wang; Yi Liu; Ling Tao,https://medrxiv.org/cgi/content/short/2021.01.21.20202119,https://medrxiv.org/cgi/content/short/2021.01.21.20202119,2021-01-22,2021-01-22,,True
356,Insights from Genomes and Genetic Epidemiology of SARS-CoV-2 isolates from the state of Andhra Pradesh,"Coronavirus disease (COVID-19) emerged from a city in China and has now spread as a global pandemic affecting millions of individuals. The causative agent, SARS-CoV-2 is being extensively studied in terms of its genetic epidemiology using genomic approaches. Andhra Pradesh is one of the major states of India with the third-largest number of COVID-19 cases with limited understanding of its genetic epidemiology. In this study, we have sequenced 293 SARS-CoV-2 genome isolates from Andhra Pradesh with a mean coverage of 13,324X. We identified 564 high-quality SARS-CoV-2 variants, out of which 15 are novel. A total of 18 variants mapped to RT-PCR primer/probe sites, and 4 variants are known to be associated with an increase in infectivity. Phylogenetic analysis of the genomes revealed the circulating SARS-CoV-2 in Andhra Pradesh majorly clustered under the clade A2a (94%), while 6% fall under the I/A3i clade, a clade previously defined to be present in large numbers in India. To the best of our knowledge, this is the most comprehensive genetic epidemiological analysis performed for the state of Andhra Pradesh.",Pallavali Roja Rani; Mohamed Imran; J. Vijaya Lakshmi; Bani Jolly; S. Afsar; Abhinav Jain; Mohit Kumar Divakar; Panyam Suresh; Disha Sharma; Nambi Rajesh; Rahul C Bhoyar; Dasari Ankaiah; Sanaga Shanthi Kumari; Gyan Ranjan; Valluri Anitha Lavanya; Mercy Rophina; S. Umadevi; Paras Sehgal; Avula Renuka Devi; A. Surekha; Pulala Chandra; Rajamadugu Hymavathy; P R Vanaja; Vinod Scaria; Sridhar Sivasubbu,https://biorxiv.org/cgi/content/short/2021.01.22.427775,https://biorxiv.org/cgi/content/short/2021.01.22.427775,2021-01-22,2021-01-22,,False
357,DINC-COVID: A webserver for ensemble docking with flexible SARS-CoV-2 proteins,"MotivationRecent efforts to computationally identify inhibitors for SARS-CoV-2 proteins have largely ignored the issue of receptor flexibility. We have implemented a computational tool for ensemble docking with the SARS-CoV-2 proteins, including the main protease (Mpro), papain-like protease (PLpro) and RNA-dependent RNA polymerase (RdRp).

ResultsEnsembles of other SARS-CoV-2 proteins are being prepared and made available through a user-friendly docking interface. Plausible binding modes between conformations of a selected ensemble and an uploaded ligand are generated by DINC, our parallelized meta-docking tool. Binding modes are scored with three scoring functions, and account for the flexibility of both the ligand and receptor. Additional details on our methods are provided in the supplementary material.

Availabilitydinc-covid.kavrakilab.org

Supplementary informationDetails on methods for ensemble generation and docking are provided as supplementary data online.

Contactgeancarlo.zanatta@ufc.br, kavraki@rice.edu",Sarah Hall-Swan; Dinler A Antunes; Didier Devaurs; Mauricio M Rigo; Lydia E Kavraki; Geancarlo Zanatta,https://biorxiv.org/cgi/content/short/2021.01.21.427315,https://biorxiv.org/cgi/content/short/2021.01.21.427315,2021-01-22,2021-01-22,,False
358,Human embryonic stem cell-derived cardiomyocytes express SARS-CoV-2 host entry proteins: screen to identify inhibitors of infection,"Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection.",Thomas L Williams; Maria T Colzani; Robyn GC Macrae; Emma L Robinson; Stuart Bloor; Edward JD Greenwood; Jun Ru Zhan; Gregory Strachan; Rhoda E Kuc; Duuamene Nyimanu; Janet J Maguire; Paul J Lehner; Sanjay Sinha; Anthony P Davenport,https://biorxiv.org/cgi/content/short/2021.01.22.427737,https://biorxiv.org/cgi/content/short/2021.01.22.427737,2021-01-22,2021-01-22,,False
359,Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease,"Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, completely prevents S binding to Angiotensin-Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 recognizes a broad panel of RBD variants and neutralizes SARS-CoV-2 and the escape mutants generated by the single monoclonals at sub-nanomolar concentrations. In a novel model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining into a single molecule the advantages of antibody cocktails.",Not available,https://biorxiv.org/cgi/content/short/2021.01.22.427567,https://biorxiv.org/cgi/content/short/2021.01.22.427567,2021-01-22,2021-01-22,,False
360,Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation,"Virus propagation methods generally use transformed cell lines to grow viruses from clinical specimens, which may force viruses to rapidly adapt to cell culture conditions, a process facilitated by high viral mutation rates. Upon propagation in VeroE6 cells, SARS-CoV-2 may mutate or delete the multibasic cleavage site (MBCS) in the spike protein that facilitates serine protease-mediated entry into human airway cells. We report that propagating SARS-CoV-2 on the human airway cell line Calu-3 - that expresses serine proteases - prevents MBCS mutations. Similar results were obtained using a human airway organoid-based culture system for SARS-CoV-2 propagation. Thus, in-depth knowledge on the biology of a virus can be used to establish methods to prevent cell culture adaptation.",Mart Matthias Lamers; Anna Z Mykytyn; Tim Immanuel Breugem; Yiquan Wang; Douglas C Wu; Samra Riesebosch; Petra B van den Doel; Debby Schipper; Theo Bestebroer; Nicholas C Wu; Bart L Haagmans,https://biorxiv.org/cgi/content/short/2021.01.22.427802,https://biorxiv.org/cgi/content/short/2021.01.22.427802,2021-01-22,2021-01-22,,False
361,Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies,"SARS-CoV-2 Spike-specific antibodies contribute the majority of the neutralizing activity in most convalescent human sera. Two SARS-CoV-2 variants, N501Y.V1 (also known as B.1.1.7 lineage or VOC-202012/01) and N501Y.V2 (B.1.351 lineage), reported from the United Kingdom and South Africa, contain several mutations in the receptor binding domain of Spike and are of particular concern. To address the infectivity and neutralization escape phenotypes potentially caused by these mutations, we used SARS-CoV-2 pseudovirus system to compare the viral infectivity, as well as the neutralization activities of convalescent sera and monoclonal antibodies (mAbs) against SARS-CoV-2 variants. Our results showed that N501Y Variant 1 and Variant 2 increase viral infectivity compared to the reference strain (wild-type, WT) in vitro. At 8 months after symptom onset, 17 serum samples of 20 participants (85%) retaining titers of ID50 >40 against WT pseudovirus, whereas the NAb titers of 8 samples (40%) and 18 samples (90%) decreased below the threshold against N501Y.V1 and N501Y.V2, respectively. In addition, both N501Y Variant 1 and Variant 2 reduced neutralization sensitivity to most (6/8) mAbs tested, while N501Y.V2 even abrogated neutralizing activity of two mAbs. Taken together the results suggest that N501Y.V1 and N501Y.V2 reduce neutralization sensitivity to some convalescent sera and mAbs.",Jie Hu; Pai Peng; Kai Wang; Bei-zhong Liu; Liang Fang; Fei-yang Luo; Ai-shun Jin; Ni Tang; Ailong Huang,https://biorxiv.org/cgi/content/short/2021.01.22.427749,https://biorxiv.org/cgi/content/short/2021.01.22.427749,2021-01-22,2021-01-22,,False
362,CCR1 regulatory variants linked to pulmonary macrophage recruitment in severe COVID-19,"Genome-wide association studies have identified 3p21.31 as the main risk locus for severe symptoms and hospitalization in COVID-19 patients. To elucidate the mechanistic basis of this genetic association, we performed a comprehensive epigenomic dissection of the 3p21.31 locus. Our analyses pinpoint activating variants in regulatory regions of the chemokine receptor-encoding CCR1 gene as potentially pathogenic by enhancing infiltration of monocytes and macrophages into the lungs of patients with severe COVID-19.",Bernard Stikker; Gregoire Stik; Rudi W. Hendriks; Ralph Stadhouders,https://biorxiv.org/cgi/content/short/2021.01.22.427813,https://biorxiv.org/cgi/content/short/2021.01.22.427813,2021-01-22,2021-01-22,,False
363,Exploring the natural origins of SARS-CoV-2,"The lack of an identifiable intermediate host species for the proximal animal ancestor of SARS-CoV-2 and the distance (~1500 km) from Wuhan to Yunnan province, where the closest evolutionary related coronaviruses circulating in horseshoe bats have been identified, is fueling speculation on the natural origins of SARS-CoV-2. Here we analyse SARS-CoV-2s related bat and pangolin Sarbecoviruses and confirm horseshoe bats, Rhinolophus, are the likely true reservoir species as their host ranges extend across Central and Southern China, and into Southeast Asia. This would explain the bat Sarbecovirus recombinants in the West and East China, trafficked pangolin infections and bat Sarbecovirus recombinants linked to Southern China, and the recently reported bat Sarbecovirses in Cambodia and Thailand. Some horseshoe bat species, such as R. affinis seem to play a more significant role in virus spread as they have larger ranges. Recent ecological disturbances as a result of changes in meat sources could explain SARS-CoV-2 transmission to humans through direct or indirect contact with infected wildlife, and subsequent emergence towards Hubei in Central China. The only way, however, of finding the animal progenitor of SARS-CoV-2 as well as the whereabouts of its close relatives, very likely capable of posing a similar threat of emergence in the human population and other animals, will be by (carefully) increasing the intensity of our sampling.",Spyros Lytras; Joseph Hughes; Wei Xia; David L Robertson,https://biorxiv.org/cgi/content/short/2021.01.22.427830,https://biorxiv.org/cgi/content/short/2021.01.22.427830,2021-01-22,2021-01-22,,False
364,"Changes in healthcare workers' knowledge, attitudes, practices, and stress during the COVID-19 pandemic","IntroductionCoronavirus disease 2019 (COVID-19) has caused an unprecedented health crisis around the world, not least because of its heterogeneous clinical presentation and course. The new information on the pandemic emerging daily has made it challenging for healthcare workers (HCWs) to stay current with the latest knowledge, which could influence their attitudes and practices during patient care.

MethodsThis study is a follow-up evaluation of changes in HCWs knowledge, attitudes, and practices as well as anxiety levels regarding COVID-19 since the beginning of the pandemic. Data were collected through an anonymous, predesigned, self-administered questionnaire that was sent online to HCWs in Saudi Arabia.

ResultsThe questionnaire was sent to 1500 HCWs, with a 63.8% response rate (N=957). The majority of respondents were female (83%), and the most common age group was 31-40 years (52.2%). Nurses constituted 86.3% of the respondents. HCWs reported higher anxiety during the COVID-19 pandemic which increased from 4.91{+/-}2.84 to 8.6{+/-}2.27 on an 11-point Likert scale compared to other viral outbreaks. HCWs believed that their own preparedness as well as that of their hospitals intensive care unit (ICU) or emergency room (ER) was higher during the COVID-19 pandemic than during the Middle East respiratory syndrome coronavirus pandemic (2012-2015). About 58% of HCWs attended one or more simulations concerning the management of COVID-19 patients in their ICU/ER, and nearly all had undergone N95 mask fit testing. The mean score of HCWs knowledge of COVID-19 was 9.89/12. For most respondents (94.6%), the perception of being at increased risk of infection was the main cause of anxiety related to COVID-19; the mean score of anxiety over COVID-19 increased from 4.91{+/-}2.84 before to 8.6{+/-}2.27 during the pandemic in Saudi Arabia.

ConclusionsHCWs anxiety levels regarding COVID-19 have increased since a pandemic was declared. It is vital that healthcare facilities provide more emotional and psychological support for all HCWs.",Mohamad-Hani Temsah; Abdullah N Alhuzaimi; Abdulkarim Alrabiaah; Nurah Alamro; Fahad Alsohime; Ayman Al-Eyadhy; Khalid Alhasan; Jameela Kari; Ali Alhaboob; Amro Al Salmi; Wejdan Almuhanna; Ibrahim Almaghlouth; Fadi Aljamaan; Rabih Halwani; Mazin Barry; Fahad Alzamil; Ahmad Alhadi; Sarah Al-Subaie; Amr Jamal; Ali M Somily,https://medrxiv.org/cgi/content/short/2021.01.19.21250126,https://medrxiv.org/cgi/content/short/2021.01.19.21250126,2021-01-21,2021-01-21,,True
365,SARS-CoV-2 B.1.1.7 lineage-related perceptions and travel worry among healthcare workers,"BackgroundHealthcare workers (HCWs) travel-related anxiety needs to be assessed in light of the emergence of SARS-CoV-2 mutations.

MethodsAn online, cross-sectional questionnaire among HCWs between December 21, 2020 to January 7, 2021. The outcome variables were HCWs knowledge and awareness of the SARS-CoV-2 B.1.1.7 lineage, and its associated travel worry and Generalized Anxiety Disorder (GAD-7) score.

ResultsA total of 1,058 HCWs completed the survey; 66.5% were female, 59.0% were nurses. 9.0% indicated they had been previously diagnosed with COVID-19 themselves. Regarding the B.1.1.7 lineage, almost all (97.3%) were aware of its emergence, 73.8% were aware that it is more infectious, 78.0% thought it causes more severe disease, and only 50.0% knew that current COVID-19 vaccines are effective in preventing it. Despite this, 66.7% of HCWs were not registered to receive the vaccine. HCWs most common source of information about the new variant was social media platforms (67%), and this subgroup was significantly more worried about travelling. Nurses were more worried than physicians (P=0.001); additionally, those who had not travelled in the previous 3 months and those who had not received or registered for the COVID-19 vaccine were also significantly more worried (P = 0.037 and P < 0.001, respectively).

ConclusionsMost HCWs were aware of the emergence of SARS-CoV-2 B.1.1.7 variant and expressed substantial travel worries. Increased worry levels were found among HCWs who used social media as their main source of information, those with lower levels of COVID-19 vaccine uptake, and those with higher GAD-7 scores. Utilization of official social media platforms could improve accurate information dissemination among HCWs regarding the pandemics evolving mutations. Targeted vaccine campaigns are warranted to assure HCWs about the efficacy of COVID-19 vaccines toward SARS-CoV-2 variants.",Mohamad-Hani Temsah; Mazin Barry; Fadi Aljamaan; Abdullah N Alhuzaimi; Ayman Al-Eyadhy; Basema Saddik; Fahad Alsohime; Ali Alhaboob; Khalid Alhasan; Ali Alaraj; Rabih Halwani; Amr Jamal; Nurah Alamro; Reem Temsah; Shelaweeh Alanazi; Fahad Alzamil; Ali Alsomaily; Jafar A. Al-Tawfiq,https://medrxiv.org/cgi/content/short/2021.01.19.21250111,https://medrxiv.org/cgi/content/short/2021.01.19.21250111,2021-01-21,2021-01-21,,True
366,"Association between COVID-19 Outcomes and Mask Mandates, Adherence, and Attitudes","AbstractUsing publicly available data, we quantify the impact of mask adherence and mask mandates on COVID-19 outcomes. We show that mask mandates are associated with a statistically significant decrease in daily new cases (-3.24 per 100K), deaths (-0.19 per 100K), and the proportion of hospital admissions (-2.47%) due to COVID-19 between February 1 and September 27, 2020. These effects are large, corresponding to 13% of the highest recorded number of cases, 20% of deaths, and 7% of admission proportion. We also find that mask mandates are linked to a 23.4 percentage point increase in mask adherence in four diverse states, and that mask adherence is associated with improved COVID-19 outcomes. Lastly, using a large novel survey in 68 countries, we find that community mask adherence and attitudes towards masks are associated with a reduction in COVID-19 cases and deaths. Our results have relevant policy implications, indicating the need to maintain and encourage mask-wearing.",Dhaval Adjodah; Karthik Dinakar; Matteo Chinazzi; Samuel P. Fraiberger; Alex Pentland; Samantha Bates; Kyle Staller; Alessandro Vespignani; Deepak L. Bhatt,https://medrxiv.org/cgi/content/short/2021.01.19.21250132,https://medrxiv.org/cgi/content/short/2021.01.19.21250132,2021-01-21,2021-01-21,,True
367,Evaluating the Long-Term Efficacy of COVID-19 Vaccines,"AbstractLarge-scale deployment of safe and durably effective vaccines can halt the COVID-19 pandemic.1-3 However, the high vaccine efficacy reported by ongoing phase 3 placebo-controlled clinical trials is based on a median follow-up time of only about two months4-5 and thus does not pertain to long-term efficacy. To evaluate the duration of protection while allowing trial participants timely access to efficacious vaccine, investigators can sequentially cross placebo recipients to the vaccine arm according to priority groups. Here, we show how to estimate potentially time-varying placebo-controlled vaccine efficacy in this type of staggered vaccination of placebo recipients. In addition, we compare the performance of blinded and unblinded crossover designs in estimating long-term vaccine efficacy.

SummaryWe show how to estimate potentially waning long-term efficacy of COVID-19 vaccines in randomized, placebo-controlled clinical trials with staggered enrollment of participants and sequential crossover of placebo recipients.",Danyu Lin; Donglin Zeng; Peter Gilbert,https://medrxiv.org/cgi/content/short/2021.01.13.21249779,https://medrxiv.org/cgi/content/short/2021.01.13.21249779,2021-01-21,2021-01-21,,True
368,Evidence of ongoing recombination in SARS-CoV-2 through genealogical reconstruction,"AO_SCPLOWBSTRACTC_SCPLOWThe evolutionary process of genetic recombination has the potential to rapidly change the properties of a viral pathogen, and its presence is a crucial factor to consider in the development of treatments and vaccines. It can also significantly affect the results of phylogenetic analyses and the inference of evolutionary rates. The detection of recombination from samples of sequencing data is a very challenging problem, and is further complicated for SARS-CoV-2 by its relatively slow accumulation of genetic diversity. The extent to which recombination is ongoing for SARS-CoV-2 is not yet resolved. To address this, we use a parsimony-based method to reconstruct possible genealogical histories for samples of SARS-CoV-2 sequences, which enables the analysis of recombination events that could have generated the data. We propose a framework for disentangling the effects of recurrent mutation from recombination in the history of a sample, and hence provide a way of estimating the probability that ongoing recombination is present. We apply this to samples of sequencing data collected in England and in South Africa, and find evidence of ongoing recombination.",Anastasia Ignatieva; Jotun Hein; Paul A Jenkins,https://biorxiv.org/cgi/content/short/2021.01.21.427579,https://biorxiv.org/cgi/content/short/2021.01.21.427579,2021-01-21,2021-01-21,,False
369,Evolving Insights from SARS-CoV-2 Genome from 200K COVID-19 Patients,"We present an updated version of our automated computational pipeline, Infection Pathogen Detector IPD 2.0 with a SARS-CoV-2 module, to perform genomic analysis to understand the pathogenesis and virulence of the virus. Analysing the currently available 208911 SARS-CoV2 genome sequences (as accessed on 28 Dec 2020), we generate an extensive database of sample- wise variants and clade annotation, which forms the core of the SARS-CoV-2 analysis module of the analysis pipeline. A comparative account of lineage-specific mutations in the newer SARS-CoV-2 strains emerging in the UK, South Africa and Brazil along with data reported from India identify overlapping and lineages specific acquired mutations suggesting a repetitive convergent and adaptive evolution. Thus, the persistence of pandemic may lead to the emergence of newer regional strains with improved fitness. IPD 2.0 also adopts the recent dynamic clade nomenclature and shows improvement in accuracy of clade assignment, processing time and portability, to its predecessor and thus could be a vital tool to help facilitate genomic surveillance in a population to identify variants involved in breakthrough infections.",Sanket Shashikant Desai; Aishwarya Rane; Asim Joshi; Amit Dutt,https://biorxiv.org/cgi/content/short/2021.01.21.427574,https://biorxiv.org/cgi/content/short/2021.01.21.427574,2021-01-21,2021-01-21,,False
370,In vitro infection of human lung tissue with SARS-CoV-2: Heterogeneity in host defense and therapeutic response,"Cell lines are the mainstay in understanding the biology of COVID-19 infection, but do not recapitulate many of the complexities of human infection. The use of human lung tissue is one solution for the study of such novel respiratory pathogens. We hypothesized that a cryopreserved bank of human lung tissue allows for the in vitro study of the inter-individual heterogeneity of host response to SARS-CoV-2 infection, thus providing a bridge between studies with cell lines and studies in animal models. We generated a cryobank of tissues from 16 donors, most of whom had risk factors for severe illness from COVID-19. Cryopreserved tissues preserved 90% of cell viability and contained heterogeneous populations of metabolically active epithelial, endothelial, and immune cell subsets of the human lung. Samples were readily infectible with HCoV-OC43 and SARS-CoV-2 coronavirus strains, and demonstrated comparable susceptibility to infection. In contrast, we observed a marked donor-dependent heterogeneity in the expression of IL-6, CXCL8 and IFN{beta} in response to SARS-CoV-2 infection. Treatment of tissues with dexamethasone and the experimental drug, N-hydroxycytidine, suppressed viral growth in all samples, whereas chloroquine and remdesivir had no detectable effect. Metformin and sirolimus, molecules with predicted antiviral activity, suppressed viral replication in tissues from a subset of donors. In summary, we developed a novel system for the in vitro study of human SARS-CoV-2 infection using primary human lung tissue from a library of donor tissues. This model may be useful for drug screening and for understanding basic mechanisms of COVID-19 pathogenesis.

ImportanceThe current biological systems for the study of COVID-19 are in vitro systems that differ from the human lung in many respects, and animal hosts to which the virus is not adapted. We developed another alternative for studying pathogenesis and drug susceptibility of SARS-CoV-2 in a cryopreserved bank of human lung tissues. We consider the importance of this work to relate to the practical use of this culture system as a repeatable and scalable approach that allows for the study of an important infection in relevant tissues.

The tissue bank highlights the heterogeneous response to SARS-CoV-2 infection and treatment, which allows researchers to investigate why treatments work in some donors but not others.",Matthew A Schaller; Yamini Sharma; Zadia Dupee; Duy T Nguyen; Juan M Uruena; Ryan A Smolcheck; Julia C. Loeb; Tiago N Machuca; John A Lednicky; David Odde; Robert F Campbell; W. Gregory Sawyer; Borna Mehrad,https://biorxiv.org/cgi/content/short/2021.01.20.427541,https://biorxiv.org/cgi/content/short/2021.01.20.427541,2021-01-21,2021-01-21,,False
371,"High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.","SARS-CoV-2 has caused a global pandemic, and has taken over 1.7 million lives as of mid-December, 2020. Although great progress has been made in the development of effective countermeasures, with several pharmaceutical companies approved or poised to deliver vaccines to market, there is still an unmet need of essential antiviral drugs with therapeutic impact for the treatment of moderate-to-severe COVID-19. Towards this goal, a high-throughput assay was used to screen SARS-CoV-2 nsp15 uracil-dependent endonuclease (endoU) function against 13 thousand compounds from drug and lead repurposing compound libraries. While over 80% of initial hit compounds were pan-assay inhibitory compounds, three hits were confirmed as nsp15 endoU inhibitors in the 1-20 M range in vitro. Furthermore, Exebryl-1, a {beta}-amyloid anti-aggregation molecule for Alzheimers therapy, was shown to have antiviral activity between 10 to 66 M, in VERO, Caco-2, and Calu-3 cells. Although the inhibitory concentrations determined for Exebryl-1 exceed those recommended for therapeutic intervention, our findings show great promise for further optimization of Exebryl-1 as an nsp15 endoU inhibitor and as a SARS-CoV-2 antiviral.

Author summaryDrugs to treat COVID-19 are urgently needed. To address this, we searched libraries of drugs and drug-like molecules for inhibitors of an essential enzyme of the virus that causes COVID-19, SARS-CoV-2 nonstructural protein (nsp)15. We found several molecules that inhibited the nsp15 enzyme function and one was shown to be active in inhibiting the SARS-CoV-2 virus. This demonstrates that searching for SARS-CoV-2 nsp15 inhibitors can lead inhibitors of SARS-CoV-2, and thus therapeutics for COVID-19. We are currently working to see if these inhibitors could be turned into a drug to treat COVID-19.",Ryan Choi; Mowei Zhou; Roger Shek; Jesse W Wilson; Logan Tillery; Justin K Craig; Indraneel A Salukhe; Sarah E Hickson; Neeraj Kumar; Rhema M James; Garry W Buchko; Ruilian Wu; Sydney Huff; Tu-Trinh Nguyen; Brett L Hurst; Sara Cherry; Lynn K Barrett; Wesley C Van Voorhis,https://biorxiv.org/cgi/content/short/2021.01.21.427657,https://biorxiv.org/cgi/content/short/2021.01.21.427657,2021-01-21,2021-01-21,,False
372,"Design of Specific Primer Sets for the Detection of B.1.1.7, B.1.351 and P.1 SARS-CoV-2 Variants using Deep Learning","As the COVID-19 pandemic persists, new SARS-CoV-2 variants with potentially dangerous features have been identified by the scientific community. Variant B.1.1.7 lineage clade GR from Global Initiative on Sharing All Influenza Data (GISAID) was first detected in the UK, and it appears to possess an increased transmissibility. At the same time, South African authorities reported variant B.1.351, that shares several mutations with B.1.1.7, and might also present high transmissibility. Even more recently, a variant labeled P.1 with 17 non-synonymous mutations was detected in Brazil. In such a situation, it is paramount to rapidly develop specific molecular tests to uniquely identify, contain, and study new variants. Using a completely automated pipeline built around deep learning techniques, we design primer sets specific to variant B.1.1.7, B.1.351, and P.1, respectively. Starting from sequences openly available in the GISAID repository, our pipeline was able to deliver the primer sets in just under 16 hours for each case study. In-silico tests show that the sequences in the primer sets present high accuracy and do not appear in samples from different viruses, nor in other coronaviruses or SARS-CoV-2 variants. The presented methodology can be exploited to swiftly obtain primer sets for each independent new variant, that can later be a part of a multiplexed approach for the initial diagnosis of COVID-19 patients. Furthermore, since our approach delivers primers able to differentiate between variants, it can be used as a second step of a diagnosis in cases already positive to COVID-19, to identify individuals carrying variants with potentially threatening features.",Alejandro Lopez-Rincon; Carmina Perez-Romero; Alberto Tonda; Lucero Mendoza-Maldonado; Eric Claassen; Johan Garssen; Aletta D Kraneveld,https://biorxiv.org/cgi/content/short/2021.01.20.427043,https://biorxiv.org/cgi/content/short/2021.01.20.427043,2021-01-21,2021-01-21,,False
373,Personalized Virus Load Curves of SARS-CoV-2 Infection,"We introduce an explicit function that describes virus-load curves on a patient-specific level. This function is based on simple and intuitive model parameters. It allows virus load analysis without solving a full virus load dynamic model. We validate our model on data from influenza A as well as SARS-CoV-2 infection data for Macaque monkeys and humans. Further, we compare the virus load function to an established target model of virus dynamics, which shows an excellent fit. Our virus-load function offers a new way to analyse patient virus load data, and it can be used as input to higher level models for the physiological effects of a virus infection, for models of tissue damage, and to estimate patient risks.",Thomas Hillen; Carlos Contreras; Jay Newby,https://biorxiv.org/cgi/content/short/2021.01.21.427676,https://biorxiv.org/cgi/content/short/2021.01.21.427676,2021-01-21,2021-01-21,,False
374,Survey of peridomestic mammal susceptibility to SARS-CoV-2 infection,"Wild animals have been implicated as the origin of SARS-CoV-2, but it is largely unknown how the virus affects most wildlife species and if wildlife could ultimately serve as a reservoir for maintaining the virus outside the human population. Here we show that several common peridomestic species, including deer mice, bushy-tailed woodrats, and striped skunks, are susceptible to infection and can shed the virus in respiratory secretions. In contrast, we demonstrate that cottontail rabbits, fox squirrels, Wyoming ground squirrels, black-tailed prairie dogs, house mice, and racoons are not susceptible to SARS-CoV-2 infection. Our work expands upon the existing knowledge base of susceptible species and provides evidence that human-wildlife interactions could result in continued transmission of SARS-CoV-2.",Angela Bosco-Lauth; J Jeffrey Root; Stephanie Porter; Audrey Walker; Lauren Guilbert; Daphne Hawvermale; Aimee Pepper; Rachel Maison; Airn Hartwig; Paul Gordy; Helle Bielefeldt-Ohmann; Richard A Bowen,https://biorxiv.org/cgi/content/short/2021.01.21.427629,https://biorxiv.org/cgi/content/short/2021.01.21.427629,2021-01-21,2021-01-21,,False
375,Human Pre-Implantation Embryos Are Permissive to SARS-CoV-2 Entry,"Vertical transmission of SARS-CoV-2, the virus responsible for COVID-19, from parents to early embryos during conception could be catastrophic, but is contingent on the susceptibility of cells of the embryo to infection. Because presence of the SARS-CoV-2 virus has been reported in the human reproductive system, we assessed whether pre-implantation embryos are permissive to SARS-CoV-2 entry. RNA-seq and immunostaining studies revealed presence of two key entry factors in the trophectoderm of blastocyst-stage embryos, the ACE2 receptor and the TMPRSS2 protease. Exposure of blastocysts to fluorescent reporter virions pseudotyped with the SARS-CoV-2 Spike (S) glycoprotein revealed S-ACE2 dependent entry and fusion. These results indicate that human pre-implantation embryos can be infected by SARS-CoV-2, a finding pertinent to natural human conceptions and assisted reproductive technologies during and after the COVID-19 pandemic.",Mauricio Montano; Andrea R Victor; Darren K Griffin; Tommy Duong; Nathalie Bolduc; Andrew Farmer; Vidur Garg; Anna-Katerina Hadjantonakis; Frank L Barnes; Christo G Zouves; Warner C Greene; Manuel Viotti,https://biorxiv.org/cgi/content/short/2021.01.21.427501,https://biorxiv.org/cgi/content/short/2021.01.21.427501,2021-01-21,2021-01-21,,False
376,Publication practices during the COVID-19 pandemic: Biomedical preprints and peer-reviewed literature,"The coronavirus pandemic introduced many changes to our society, and deeply affected the established in biomedical sciences publication practices. In this article, we present a comprehensive study of the changes in scholarly publication landscape for biomedical sciences during the COVID-19 pandemic, with special emphasis on preprints posted on bioRxiv and medRxiv servers. We observe the emergence of a new category of preprint authors working in the fields of immunology, microbiology, infectious diseases, and epidemiology, who extensively used preprint platforms during the pandemic for sharing their immediate findings. The majority of these findings were works-in-progress unfitting for a prompt acceptance by refereed journals. The COVID-19 preprints that became peer-reviewed journal articles were often submitted to journals concurrently with the posting on a preprint server, and the entire publication cycle, from preprint to the online journal article, took on average 63 days. This included an expedited peer-review process of 43 days and journals production stage of 15 days, however there was a wide variation in publication delays between journals. Only one third of COVID-19 preprints posted during the first nine months of the pandemic appeared as peer-reviewed journal articles. These journal articles display high Altmetric Attention Scores further emphasizing a significance of COVID-19 research during 2020. This article will be relevant to editors, publishers, open science enthusiasts, and anyone interested in changes that the 2020 crisis transpired to publication practices and a culture of preprints in life sciences.",Yulia Sevryugina; Andrew  J Dicks,https://biorxiv.org/cgi/content/short/2021.01.21.427563,https://biorxiv.org/cgi/content/short/2021.01.21.427563,2021-01-21,2021-01-21,,False
377,Regression Tree Modelling to Predict Total Average Extra Costs in Household Spending During COVID-19 Pandemic,"BackgroundPrevention of coronavirus (COVID-19) regarding households has many aspects, such as buying masks, hand sanitizer, face shield, and many others. As a result of buying the previous items, the household spending per month will be increase during the COVID-19 pandemic period.

AimsTo calculate the average costs of each extra item involved in households spending during COVID-19 pandemic and to predict the total average extra costs spending by households.

MethodsA cross-sectional study was conducted at High Institute of Public Health (HIPH), University Alexandria. Exponential snowball sampling was used to recruit students at HIPH and their friends. Trimming costs was done to remove extreme low and high values. A regression tree modelling was implemented to predict the total extra costs spending during COVID-19 pandemic.

ResultsMost of the respondents were female (81%) and aged between 30 and 40 (56.3%). About 63.1% of families had the same monthly income while 35.4% had a decrease in monthly income. A significant reduction in days of leaving home before and after COVID-19 pandemic was observed (before; mean= 5.86, after; mean = 4.66, P=0.000). The extra spending in grocery was the dominated item compared to other items (mean = 707.2, SD = 530.7). Regarding regression tree, the maximum average extra costs due to COVID-19 pandemic was 1386 L.E/month (around 88.23$/month) while the minimum average extra costs was 217 L.E/month (around 13.81$/month).

ConclusionsThe effect of COVID-19 pandemic in households spending varies largely between households, it depends on what they do to prevent COVID-19.

*Hint: Convert form L.E to dollar performed according to price of dollar at 18-12-2020",Nesma Lotfy,https://medrxiv.org/cgi/content/short/2021.01.15.21249732,https://medrxiv.org/cgi/content/short/2021.01.15.21249732,2021-01-20,2021-01-20,,True
378,Estimating the effects of non-pharmaceutical interventions on the number of new infections with COVID-19 during the first epidemic wave,"The novel coronavirus (SARS-CoV-2) has rapidly developed into a global epidemic. To control its spread, countries have implemented non-pharmaceutical interventions (NPIs), such as school closures, gathering bans, or even stay-at-home orders. Here we study the effectiveness of seven NPIs in reducing the number of new infections, which was inferred from the reported cases of COVID-19 using a semi-mechanistic Bayesian hierarchical model. Based on data from the first epidemic wave of n = 20 countries (i.e., the United States, Canada, Australia, the EU-15 countries, Norway, and Switzerland), we estimate the relative reduction in the number of new infections attributed to each NPI. Among the NPIs considered, event bans were most effective, followed by venue and school closures, whereas stay-at-home orders and work bans were least effective. With this retrospective cross-country analysis, we provide estimates regarding the effectiveness of different NPIs during the first epidemic wave.",Nicolas Banholzer; Eva van Weenen; Adrian Lison; Alberto Cenedese; Arne Seeliger; Bernhard Kratzwald; Daniel Tschernutter; Joan Puig Salles; Pierluigi Bottrighi; Sonja Lehtinen; Stefan Feuerriegel; Werner Vach,https://medrxiv.org/cgi/content/short/2021.01.15.21249884,https://medrxiv.org/cgi/content/short/2021.01.15.21249884,2021-01-20,2021-01-20,,True
379,COVID-19 propagation by diffusion - a two-dimensional approach for Germany,"Diffusion comes anytime and everywhere. If there is a gradient or a potential difference of a quantity a diffusion process happens and this ends if an equilibrium is reached only. The concentration of a species maybe such quantity, or the voltage. An electric currant will be driven by a voltage difference for example.

In this COVID-19 pandemic one observes both regions with low incidence and other ones with high incidence. The local different people density could be a reason for that. In populous areas like big cities or congested urban areas higher COVID-19 incidences could be observed than in rural regions.

The aim of this paper consists in the application of a diffusion concept to describe one possible issue of the the COVID-19 propagation.

This will be discussed for the German situation based on the quite different incidence data for the different federal states of Germany.

With this ansatz some phenomenoms of the actual development of the pandemic could be confirmed. The model gives a possibility to investigate certain scenarios like border-crossings or local spreading events and their influence on the COVID-19 propagation as well.",Guenter K.F. Baerwolff,https://medrxiv.org/cgi/content/short/2021.01.15.21249893,https://medrxiv.org/cgi/content/short/2021.01.15.21249893,2021-01-20,2021-01-20,,True
380,Physician Perceptions of Catching COVID-19,"BackgroundRisk perception, influenced and biased by multiple factors, can affect behavior.

ObjectiveTo assess the variability of physician perceptions of catching COVID-19.

DesignCross sectional, random stratified sample of physicians registered with Sermo, a global networking platform open to verified and licensed physicians.

Main outcome measuresThe survey asked: ""What is your likelihood of catching COVID-19 in the next three months?"" The physicians were asked to give their best estimate as an exact percentage.

ResultsThe survey was completed by 1004 physicians (40 countries, 67 specialties, 49% frontline [e.g. ER, infectious disease, internal medicine]) with a mean (SD) age of 49.14 (12) years. Mean (SD) self-risk estimate was 32.3% {+/-} 26% with a range from 0% to 100% (Figure 1a). Risk estimates were higher in younger (<50 years) doctors and in non-US doctors versus their older and US counterparts (p<0.05 for all) (Figure 1b). Risk estimates were higher among front line versus non-frontline doctors (p<0.05). Risk estimates were higher for women than men (p<0.05) among respondents (60%) reporting gender.

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=122 SRC=""FIGDIR/small/20249089v2_fig1A.gif"" ALT=""Figure 1A"">
View larger version (17K):
org.highwire.dtl.DTLVardef@7dd844org.highwire.dtl.DTLVardef@17241org.highwire.dtl.DTLVardef@f43cb2org.highwire.dtl.DTLVardef@bcd7f1_HPS_FORMAT_FIGEXP  M_FIG O_FLOATNOFigure 1A.C_FLOATNO Distribution of risk prediction for overall sample (N=1004). Upper panel is a line box whisker and bottom panel shows the frequency distribution.

C_FIG O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=151 SRC=""FIGDIR/small/20249089v2_fig1B.gif"" ALT=""Figure 1B"">
View larger version (21K):
org.highwire.dtl.DTLVardef@51be7org.highwire.dtl.DTLVardef@16ae5fcorg.highwire.dtl.DTLVardef@12118a2org.highwire.dtl.DTLVardef@1d848c6_HPS_FORMAT_FIGEXP  M_FIG O_FLOATNOFigure1B.C_FLOATNO Mean (SD) risk estimates by age, frontline status, and geographic region.

C_FIG ConclusionsTo our knowledge, this is the first global study to document physician risk perceptions for catching COVID-19 and how it is impacted by age, gender, practice specialty and geography. Accurate calibration of risk perception is vital since both over- and underestimation of risk could impact physician behavior and have implications for public health.",P. Murali Doraiswamy; Mohan Chilukuri; Dan Ariely; Alexandra Rose Linares,https://medrxiv.org/cgi/content/short/2021.01.15.20249089,https://medrxiv.org/cgi/content/short/2021.01.15.20249089,2021-01-20,2021-01-20,,True
381,Electronic Computer-Based Model of Combined Ventilation Using a New Medical Device,"IntroductionThe increased demand for mechanical ventilation caused by SARS-CoV-2 could generate a critical situation where patients may lose access to mechanical ventilators. Combined ventilation, in which two patients are connected to a single ventilator has been proposed as a bridge while waiting for new ventilators availability. DuplicAR is a new device that allows individualization of ventilatory parameters in combined ventilation models.

Materials and MethodsWith an electronic circuit simulator applet, an electrical model of combined ventilation was created using resistor-capacitor circuits. The DuplicAR system electrical analog was added to the model. Through computational simulation, the model is tested in different scenarios with the aim of achieving adequate ventilation of two subjects under different circumstances: 1) two identical subjects; 2) two subjects with the same size but different lung compliance; and 3) two subjects with different size and compliance. The goal is to achieve the established load per unit of size on each capacitor under different levels of end-expiratory voltage (analog of end-expiratory pressure). Data collected included capacitor load and voltage, and load normalized to the weight of the simulated patient.

ResultsIn the three simulated stages, it is possible to provide the proper load to each capacitor under different circumstances. If the pair of connected capacitors have different capacitances, adjustments must be made to the source voltage and/or the resistance of the DuplicAR system to provide the appropriate load for each capacitor under initial conditions. In pressure control simulation, increasing the end-expiratory voltage on one capacitor requires increasing the source voltage and the resistance on the other capacitor. On the other hand, in the volume control simulation, it is only required to intervene in the resistance.

ConclusionsUnder simulated conditions, the electrical model of the DuplicAR system allows individualization of combined mechanical ventilation.",Matias Ramos Sr.; Roberto Orofino Sr.; Diego Riva Sr.; Maria Fernanda Biancolini Sr.; Ignacio Lugones Sr.,https://medrxiv.org/cgi/content/short/2021.01.17.21249912,https://medrxiv.org/cgi/content/short/2021.01.17.21249912,2021-01-20,2021-01-20,,True
382,Modelling the Long-Term Effects of Covid-19 Cancer Services Disruption on Patient Outcome in Scotland,"BackgroundModelling the long-term effects of disruption of cancer services and minimising any excess cancer mortality due to the Covid-19 pandemic is of great importance. Here we adapted a stage-shift model to inform service planning decisions within NHS Scotland for the   Detect Cancer Early tumours, breast, colorectal and lung cancer which represent 46% of all cancers diagnosed in Scotland.

Methods & DataLung, colorectal and breast cancer incidence data for years 2017-18 were obtained from Public Health Scotland Cancer Quality Performance Indicators (QPI), to define a baseline scenario. The most current stage-specific 5-year survival data came from 2009-2014 national cancer registry and South East Scotland Cancer Network (SCAN) QPI audit datasets. The Degeling et al., inverse stage-shift model was adapted to estimate changes in stage at diagnosis, excess mortality and life-years lost from delays to diagnosis and treatment due to Covid-19-related health services disruption. Three and 6-month periods of disruption were simulated to demonstrate the model predictions.

ResultsApproximately, 1-9% reductions in stage I/II presentations leading up to 2-10% increases in stage III/IV presentations are estimated across the three cancer types. A 6-month period of service disruption is predicted to lead to excess deaths at 5 years of 32.5 (31.1, 33.9) per 1000 cases for lung cancer, 16.5 (7.9, 24.3) for colorectal cancer and 31.6 (28.5, 34.4) for breast cancer.

ConclusionsDisruption of cancer diagnostic services can lead to significant excess deaths in following years. Increasing diagnostic and capacity for cancer services to deal with the backlog of care are needed. Real time monitoring of incidence and referral patterns over the disruption and post-disruption period to reduce excess deaths including more rapid incidence data by stage and other key tumour/clinical characteristics at presentation for key cancer cases (on a quarterly basis). Real time monitoring in cancer care and referral patterns should help inform what type of interventions are needed to reduce excess mortality and whether different population subgroups require public health messaging campaigns. Specific mitigation measures can be the subject of additional modelling analysis to assess the benefits and inform service planning decision making.",Jonine Figueroa; Ewan Gray; Yasuko Maeda; Peter S Hall; Melanie Mackean; Kenneth Elder; Farhat Din; Malcolm G Dunlop; David Weller,https://medrxiv.org/cgi/content/short/2021.01.17.21249993,https://medrxiv.org/cgi/content/short/2021.01.17.21249993,2021-01-20,2021-01-20,,True
383,Population-based seroprevalence of SARS-CoV-2 antibodies in a high-altitude setting in Peru,"BackgroundLittle evidence exists about the prevalence of COVID-19 infection at high altitude. We aimed to estimate the population-based seroprevalence of COVID-19 in Cusco at the end of the first wave.

MethodsA population-based survey was conducted in September 2020 in three settings in Cusco: (1) Cusco city at 3300 meters above the sea level (m.a.s.l.), (2) the periphery of Cusco (Santiago, San Jeronimo, San Sebastian, and Wanchaq) at 3300 m.a.s.l., and (3) Quillabamba city, located at 1050 m.a.s.l. People aged [&ge;]18 years within a family unit were included. The diagnosis of COVID-19 infection was based on identifying total antibodies (IgM and IgG) anti-SARS-CoV-2 in serum using the Elecsys Anti-SARS-CoV-2 chemiluminescence test.

FindingsWe enrolled 1924 participants from 712 families. Of the total, 637 participants were COVID-19 seropositive. Seroprevalence was 38{middle dot}8% (95%CI: 33{middle dot}4%-44{middle dot}9%) in Cusco city, 34{middle dot}9% (95%CI: 30{middle dot}4%-40{middle dot}1%) in the periphery of Cusco, and 20{middle dot}3% (95%CI: 16{middle dot}2%-25{middle dot}6%) in Quillabamba. In 141 families (19{middle dot}8%; 95%CI: 17{middle dot}0%-22{middle dot}8%) the whole members were positive to the test. Living with more than three persons in the same house, a positive COVID-19 case at home, and a member who died in the last five months were factors associated with COVID-19 positivity. The smell/taste alteration was the symptom most associated with seropositivity (aOR= 14{middle dot}27, 95% CI: 8{middle dot}24-24{middle dot}70); whereas always wearing a face shield (aOR= 0{middle dot}62; 95% CI: 0{middle dot}46-0{middle dot}84) or a facial mask (aOR= 0{middle dot}65, 95% CI: 0{middle dot}47-0{middle dot}88) reduced that probability.

InterpretationSeroprevalence of COVID-19 in Cusco was high, with significant differences between settings. Wearing masks and face shields were associated with lower rate of infection; however, efforts must be made to sustain them over time since there is still a high proportion of susceptible people.

FundingFondo Nacional de Desarrollo Cientifico, Tecnologico y de Innovacion Tecnologica (FONDECYT - Peru) and Universidad Andina del Cusco.",CHARLES HUAMANI; Lucio Velasquez; Sonia Montes; Ana Mayanga Herrera; Antonio Bernabe-Ortiz,https://medrxiv.org/cgi/content/short/2021.01.17.21249990,https://medrxiv.org/cgi/content/short/2021.01.17.21249990,2021-01-20,2021-01-20,,True
384,Sword of Damocles or choosing well. Population genetics sheds light into the future of the COVID-19 pandemic and SARS-CoV-2 new mutant strains.,"An immense scientific effort has been made worldwide due to Covid-19s pandemic magnitude. It has made possible to identify almost 300,000 SARS-CoV-2 different genetic variants, connecting them with clinical and epidemiological findings. Among this immense data collection, that constitutes the biggest evolutionary experiment in history, is buried the answer to what will happen in the future. Will new strains, more contagious than the current ones or resistant to the vaccines, arise by mutation? Although theoretic population genetics is, by far, the most powerful tool we have to do an accurate prediction, it has been barely used for the study of SARS-CoV-2 due to its conceptual difficulty. Having in mind that the size of the SARS-CoV-2 population is astronomical we can apply a discrete treatment, based on the branching process method, Fokker-Plank equations and Kolmogoroffs forward equations, to calculate the survival likelihood through time, to elucidate the likelihood to become dominant genotypes and how long will this take, for new SARS-CoV-2 mutants depending on their selective advantage. Results show that most of the new mutants that will arise in the SARS-CoV-2 meta-population will stay at very low frequencies. However, some few new mutants, significantly more infectious than current ones, will still emerge and become dominant in the population favoured by a great selective advantage. Far from showing a ""mutational meltdown"", SARS-CoV-2 meta-population will increase its fitness becoming more infective. There is a probability, small but finite, that new mutants arise resistant to some vaccines. High infected numbers and slow vaccination programs will significantly increase this likelihood.",Javier Garcia Garcia de AlcaÃ±iz; Victoria Lopez-Rodas; Eduardo Costas Sr.,https://medrxiv.org/cgi/content/short/2021.01.16.21249924,https://medrxiv.org/cgi/content/short/2021.01.16.21249924,2021-01-20,2021-01-20,,True
385,"Estimating Effect-sizes to Infer if COVID-19 transmission rates were low because of Masks, Heat or High because of Air-conditioners, Tests","How does one interpret the observed increase or decrease in COVID-19 case rates? Did the compliance to the non-pharmaceutical interventions, seasonal changes in the temperature influence the transmission rates or are they purely an artefact of the number of tests? To answer these questions, we estimate the effect-sizes from these different factors on the reproduction ratios (Rt) from the different states of the USA during March 9 to August 9. Ideally Rt should be less than 1 to keep the pandemic under control and our model predicts many of these factors contributed significantly to the Rts: Post-lockdown opening of the restaurants and nightclubs contributed 0.04 (CI 0.04-0.04) and 0.11 (CI. 0.11-0.11) to Rt. The mask mandates helped reduce Rt by 0.28 (CI 0.28-0.29)), whereas the testing rates which may have influenced the number of infections observed, did not influence Rt beyond 10,000 daily tests 0.07 (CI -0.57-0.42). In our attempt to understand the role of temperature, the contribution to the Rt was found to increase on both sides of 55 F, which we infer as a reflection of the climatization needs. A further analysis using the cooling and heating needs showed contributions of 0.24 (CI 0.18-0.31) and 0.31 (CI 0.28-0.33) respectively. The work thus illustrates a data-driven approach for estimating the effect-sizes on the graded policies, and the possibility of prioritizing the interventions, if necessary by weighing the economic costs and ease of acceptance with them.",C. K. Sruthi; Malay Ranjan Biswal; Brijesh Saraswat; Himanshu Joshi; Meher K Prakash,https://medrxiv.org/cgi/content/short/2021.01.15.21249896,https://medrxiv.org/cgi/content/short/2021.01.15.21249896,2021-01-20,2021-01-20,,True
386,Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients,"Structured AbstractO_ST_ABSImportanceC_ST_ABSRisk calculators can facilitate shared medical decision-making1. Demographics, comorbidities, medication use, geographic region, and other factors may increase the risk for COVID-19-related complications among patients with IBD2,3.

ObjectivesDevelop an individualized prognostic risk prediction tool for predicting the probability of adverse COVID-19 outcomes in patients with IBD.

Design, Setting, and ParticipantsThis study developed and validated prognostic penalized logistic regression models4 using reports to Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) from March-October 2020. Model development was done using a training data set (85% of cases reported March 13 - September 15, 2020), and model validation was conducted using a test data set (the remaining 15% of cases plus all cases reported September 16-October 20, 2020).

Main Outcomes and MeasuresCOVID-19 related:

O_LIHospitalization+: composite outcome of hospitalization, ICU admission, mechanical ventilation, or death
C_LIO_LIICU+: composite outcome of ICU admission, mechanical ventilation, or death
C_LIO_LIDeath
C_LI

We assessed the resulting models discrimination using the area under the curve (AUC) of the receiver-operator characteristic (ROC) curves and reported the corresponding 95% confidence intervals (CIs).

ResultsWe included 2709 cases from 59 countries (mean age 41.2 years [s.d. 18], 50.2% male). A total of 633 (24%) were hospitalized, 137 (5%) were admitted to the ICU or intubated, and 69 (3%) died. 2009 patients comprised the training set and 700 the test set.

The models demonstrated excellent discrimination, with a test set AUC (95% CI) of 0.79 (0.75, 0.83) for Hospitalization+, 0.88 (0.82, 0.95) for ICU+, and 0.94 (0.89, 0.99) for Death. Age, comorbidities, corticosteroid use, and male gender were associated with higher risk of death, while use of biologic therapies was associated with a lower risk.

Conclusions and RelevancePrognostic models can effectively predict who is at higher risk for COVID-19-related adverse outcomes in a population of IBD patients. A free online risk calculator (https://covidibd.org/covid-19-risk-calculator/) is available for healthcare providers to facilitate discussion of risks due to COVID-19 with IBD patients. The tool numerically and visually summarizes the patients probabilities of adverse outcomes and associated CIs. Helping physicians identify their highest-risk patients will be important in the coming months as cases rise in the US and worldwide. This tool can also serve as a model for risk stratification in other chronic diseases.

Key PointsO_ST_ABSQuestionC_ST_ABSHow well can a multivariable risk model predict the risk of hospitalization, intensive care unit (ICU) stay, or death due to COVID-19 in patients with inflammatory bowel disease (IBD)?

FindingsMultivariable prediction models developed using data from an international voluntary registry of IBD patients and available for use online (https://covidibd.org/) have very good discrimination for predicting hospitalization (Test set AUC 0.79) and excellent discrimination for ICU admission (Test set AUC 0.88) and death (Test set AUC 0.94). The models were developed with a training sample of 2009 cases and validated in an independent test sample of 700 cases comprised of a random sub-sample of cases and all cases entered in the registry during a one-month period after model development.

MeaningThis risk prediction model may serve as an effective tool for healthcare providers to facilitate conversations about COVID-19-related risks with IBD patients.",John Sperger; Kushal S. Shah; Minxin Lu; Xian Zhang; Ryan C. Ungaro; Erica J. Brenner; Manasi Agrawal; Jean-Frederic Colombel; Michael D. Kappelman; Michael R. Kosorok,https://medrxiv.org/cgi/content/short/2021.01.15.21249889,https://medrxiv.org/cgi/content/short/2021.01.15.21249889,2021-01-20,2021-01-20,,True
387,Population-scale patient safety data reveal inequalities in adverse events before and during COVID-19 pandemic,"Adverse patient safety events were associated with 110 thousand deaths in the U.S. alone in 2019. The COVID-19 pandemic has further challenged the ability of healthcare systems to ensure medication safety, and its effects on patient safety remain unknown. Here, we investigate negative outcomes associated with medication use before and during the pandemic. Using a dataset of 10,443,476 reports involving 3,624 drugs and 19,193 adverse events, we develop an algorithmic approach to analyze the pandemics impact on incidence of drug safety events by evaluating disproportional reporting relative to the pre-pandemic time, quantifying unexpected trends in clinical outcomes, and adjusting for drug interference. Among 64 adverse events identified by our analyses, we find 54 have increased incidence rates during the pandemic, even though reporting of adverse events has decreased by 4.4% overall. We find clinically relevant differences in drug safety outcomes between demographic groups. Comparing to male patients, women report 47.0% more distinct adverse events whose occurrence significantly increased during the pandemic relative to pre-pandemic levels. Out of 53 adverse events with the pre-pandemic gender gap, 33 have increased gap during the pandemic more than would have been expected had the pandemic not occurred. While musculoskeletal and metabolic side effects are disproportionately enriched in women during the pandemic, immune-related adverse events are enriched only in men. We also find the number of adverse events with a higher reporting ratio during the pandemic in adults is higher (16.8%) than in older patients (adjusted for population size). Our findings have implications for safe medication use and public health policy and highlight the role of variation in adverse events for improving patient safety during a public health emergency.",Xiang Zhang; Marissa Sumathipala; Marinka Zitnik,https://medrxiv.org/cgi/content/short/2021.01.17.21249988,https://medrxiv.org/cgi/content/short/2021.01.17.21249988,2021-01-20,2021-01-20,,True
388,The Socioeconomic Impact of COVID-19 in Urban Informal Settlements,"The COVID-19 pandemic has reached almost every corner of the world. Without a pharmaceutical solution, governments have been forced to implement regulations and public policies to control social behavior and prevent the spread of the virus. There is dramatic evidence of the social and economic effects of these measures and their disparate impact on vulnerable communities. Individuals living in urban informal settlements are in a structurally disadvantaged position to cope with a health crisis such as the COVID-19 pandemic. This paper examines the socioeconomic impact of the crisis brought by the pandemic in informal settlements in Chile. We use a three-wave panel study to compare the situation in informal settlements before and during the health crisis. We show that households living in informal settlements are paying a high toll. Their employment loss is dramatic, substantially larger than the loss reported in the general population, and has particularly affected the inmigrant population. We also find that the pandemic has triggered neighborhood cooperation within the settlements. Targeted government assistance programs have reached these communities; however, this groups coverage is not enough to counteract the magnitude of the crisis. Our results suggest that governments, the non-profit sector, and the community need to urgently provide economic support and protections to individuals living in informal settlements and consider this opportunity for long-term improvements in these marginalized communities.

HighlightsO_LIGovernments have implemented large-scale non-pharmaceutical interventions to control the spread of the COVID-19 pandemic
C_LIO_LIThese measures have had dramatic social and economic effects on the population, particularly affecting vulnerable communities
C_LIO_LIIndividuals living in urban informal settlements are in a structurally disadvantaged position to cope with this crisis
C_LIO_LIUsing panel data, we document a dramatic employment loss among informal settlements dwellers, substantially larger than the general population
C_LIO_LIThe pandemic has also triggered neighborhood cooperation within the settlements as well as targeted government assistance, but not enough to counteract the magnitude of the economic loss
C_LI",Diego Gil; Patricio Dominguez; Eduardo A Undurraga; Eduardo Valenzuela,https://medrxiv.org/cgi/content/short/2021.01.16.21249935,https://medrxiv.org/cgi/content/short/2021.01.16.21249935,2021-01-20,2021-01-20,,True
389,COVID-19 in 823 Transplant patients: A Systematic Scoping Review,"BackgroundManagement of COVID-19 in transplant patients is a big challenge. Data on immunosuppression management, clinical picture, and outcomes are lacking.

ObjectivesTo summarize the current literature on COVID-19 in transplant patients especially the data regarding the immunosuppression protocols, clinical presentation, and outcomes.

Search strategyA systematic search of MEDLINE, EBSCO, CENTRAL, CINAHL, LitCovid, Web of Science, and Scopus electronic databases. The references of the relevant studies were also searched. The search was last updated on June 3, 2020.

Selection CriteriaPrimary reports of solid organ transplant patients who developed COVID-19. An overlap of cases in different reports was checked.

Data collection and analysisA descriptive summary of immunosuppression therapy (before and after COVID-19), clinical presentation (symptoms, imaging, laboratory, and disease severity), management (oxygen therapy, antiviral, and antibacterial), major outcomes (Intensive care admission, invasive mechanical ventilation, acute kidney injury), and mortality.

Main resultsWe identified 74 studies reporting 823 cases of solid organ transplantation with COVID-19. Among 372 patients, 114 (30.6%) were mild COVID-19, 101 (27.2%) moderate, and 157 (42.2%) severe or critical.

Major outcomes included intensive care unit admission, invasive ventilation, and acute kidney injury, which occurred in 121 (14.7%), 97 (11.8%), and 63 (7.7%) of patients, respectively. Mortality was reported in 160 (19.4%) patients. Missing individual data hindered making clinical correlations.

ConclusionCOVID-19 in solid organ transplant patients probably has a more disease severity, worse major outcomes (Intensive care admission, invasive ventilation, acute kidney injury), and higher mortality than in non-transplant patients.",Moataz Maher Emara; Mahmoud Elsedeiq; Mohamed Elmorshedi; Hamed Neamatallah; Mostafa Abdelkhalek; Amr Yassen; Ashraf Nabhan,https://medrxiv.org/cgi/content/short/2021.01.18.21250025,https://medrxiv.org/cgi/content/short/2021.01.18.21250025,2021-01-20,2021-01-20,,True
390,Analysis of communities of countries with similar dynamics of the COVID-19 pandemic evolution,"This work addresses the spread of the coronavirus through a non-parametric approach, with the aim of identifying communities of countries based on how similar their evolution of the disease is. The analysis focuses on the number of daily new COVID-19 cases per ten thousand people during a period covering at least 250 days after the confirmation of the tenth case. Dynamic analysis is performed by constructing Minimal Spanning Trees (MST) and identifying groups of similarity in contagions evolution in 95 time windows of a 150-day amplitude that moves one day at a time. The number of times countries belonged to a similar performance group in constructed time windows was the intensity measure considered. Groups composition is not stable, indicating that the COVID-19 evolution needs to be treated as a dynamic problem in the context of complex systems. Three communities were identified by applying the Louvain algorithm. Identified communities analysis according to each countrys socioeconomic characteristics and variables related to the disease sheds light on whether there is any suggested course of action. Even when strong testing and tracing cases policies may be related with a more stable dynamic of the disease, results indicate that communities are conformed by countries with diverse characteristics. The best option to counteract the harmful effects of a pandemic may be having strong health systems in place,with contingent capacity to deal with unforeseen events and available resources capable of a rapid expansion of its capacity.",Emiliano Alvarez; Juan Gabriel Brida; Erick Limas; Lucia Rosich,https://medrxiv.org/cgi/content/short/2021.01.18.21250050,https://medrxiv.org/cgi/content/short/2021.01.18.21250050,2021-01-20,2021-01-20,,True
391,"State-of-the-Art Risk Models for Diabetes, Hypertension, Visual Diminution, and COVID-19 Severity in Mexico","BACKGROUNDDiabetes and hypertension are among top public health priorities, particularly in low and middle-income countries where their health and socioeconomic impact is exacerbated by the quality and accessibility of health care. Moreover, their connection with severe or deadly COVID-19 illness has further increased their societal relevance. Tools for early detection of these chronic diseases enable interventions to prevent high-impact complications, such as loss of sight and kidney failure. Similarly, prognostic tools for COVID-19 help stratify the population to prioritize protection and vaccination of high-risk groups, optimize medical resources and tests, and raise public awareness.

METHODSWe developed and validated state-of-the-art risk models for the presence of undiagnosed diabetes, hypertension, visual complications associated with diabetes and hypertension, and the risk of severe COVID-19 illness (if infected). The models were estimated using modern methods from the field of statistical learning (e.g., gradient boosting trees), and were trained on publicly available data containing health and socioeconomic information representative of the Mexican population. Lastly, we assembled a short integrated questionnaire and deployed a free online tool for massifying access to risk assessment.

RESULTSOur results show substantial improvements in accuracy and algorithmic equity (balance of accuracy across population subgroups), compared to established benchmarks. In particular, the models: i) reached state-of-the-art sensitivity and specificity rates of 90% and 56% (0.83 AUC) for diabetes, 80% and 64% (0.79 AUC) for hypertension, 90% and 56% (0.84 AUC) for visual diminution as a complication, and 90% and 60% (0.84 AUC) for development of severe COVID disease; and ii) achieved substantially higher equity in sensitivity across gender, indigenous/non-indigenous, and regional populations. In addition, the most relevant features used by the models were in line with risk factors commonly identified by previous studies. Finally, the online platform was deployed and made accessible to the public on a massive scale.

CONCLUSIONSThe use of large databases representative of the Mexican population, coupled with modern statistical learning methods, allowed the development of risk models with state-of-the-art accuracy and equity for two of the most relevant chronic diseases, their eye complications, and COVID-19 severity. These tools can have a meaningful impact on democratizing early detection, enabling large-scale preventive strategies in low-resource health systems, increasing public awareness, and ultimately raising social well-being.",Heladio Amaya; Jennifer Enciso; Daniela Meizner; Alex Pentland; Alejandro Noriega,https://medrxiv.org/cgi/content/short/2021.01.18.21250034,https://medrxiv.org/cgi/content/short/2021.01.18.21250034,2021-01-20,2021-01-20,,True
392,Impact of Public Health Education Program on the Novel Coronavirus Outbreak in the United States,"The coronavirus outbreak in the United States continues to pose a serious threat to human lives. Public health measures to slow down the spread of the virus involve using a face mask, social-distancing, and frequent hand washing. Since the beginning of the pandemic, there has been a global campaign on the use of non-pharmaceutical interventions (NPIs) to curtail the spread of the virus. However, the number of cases, mortality, and hospitalization continue to rise globally, including in the United States. We developed a mathematical model to assess the impact of a public health education program on the coronavirus outbreak in the US. Our simulation showed the prospect of an effective public health education program in reducing both the cumulative and daily mortality of the novel coronavirus. Finally, our result suggests the need to obey public health measures as loss of willingness would increase the cumulative and daily mortality in the US.",Enahoro A Iboi; Ariana Richardson; Rachel Ruffin; DeAndrea Ingram; Jailyn Clark; Jala Hawkins; Maati McKinney; Nianza Horne; Reyla Ponder; Zoe Denton; Folashade B Agusto; Bismark Oduro; Lanre Akinyemi,https://medrxiv.org/cgi/content/short/2021.01.18.21250047,https://medrxiv.org/cgi/content/short/2021.01.18.21250047,2021-01-20,2021-01-20,,True
393,Hidden Parameters impacting resurgence of SARS-CoV-2 Pandemic,"The spread of the COVID-19 virus has had an enormous impact on the worlds health and socioeconomic system. While lockdowns, which severely limit the movement of the population, have been implemented in March 2020 and again recently, the psychological and economic cost are severe. Removal of these restrictions occurred with varying degrees of success.

To study the resurgence of the virus in some communities we consider an epidemiological model, SIR-SD-L, that incorporates introduction of new population due to the removal of lockdown and identify parameters that impact the spread of the virus. This compartmental model of the epidemic incorporates a social distance metric based on progression of the infections; it models the dynamic propensity of infection spread based on the current infections relative to the susceptible population. The model is validated using data on growth of infections, hospitalizations and death, considering 24 counties in multiple US states and a categorization of the lockdown removal policies after the first lockdown. Model parameters, which include a compartment for the isolated population, are used to determine the rate at which the susceptible population increases to fit the rate of infections. Along with social distancing mandates, we identify active infections and the susceptible population as important factors in the resurgence of infections. We measure the efficacy of the lockdown removal policy via a ratio, PIR, which evaluates to less than 1 for counties where social distancing measures were mandated and which delayed complete re-opening of closed spaces like bars and restaurants. For other counties this ratio is greater than 1.

We also studied infection growth in the 24 US counties with respect to a release policy derived from CDC guidelines and compared against strategies that delay the removal of lockdown.

Our results illustrate that guidelines for deciding when lockdown rules are to be relaxed should consider the current state of the infectious population and the remaining susceptible population, hidden parameters that are deducible from models such as SIR-SD-L, and not limit policy considerations to the rate of new infections alone. This is especially true for counties where the growth rate of the virus is initially slow and misleading. Emphasis on social distancing is critical.",Yi Zhang; Sanjiv Kapoor,https://medrxiv.org/cgi/content/short/2021.01.15.20248217,https://medrxiv.org/cgi/content/short/2021.01.15.20248217,2021-01-20,2021-01-20,,True
394,Optimizing SARS-CoV-2 vaccination strategies in France: Results from a stochastic agent-based model,"The COVID-19 pandemic is a major global societal, economic and health threat. The availability of COVID-19 vaccines has raised hopes for a decline in the pandemic. We built upon a stochastic agent-based microsimulation model of the COVID-19 epidemic in France. We examined the potential impact of different vaccination strategies, defined according to the age, medical conditions, and expected vaccination acceptance of the target non-immunized adult population, on disease cumulative incidence, mortality, and number of hospital admissions. Specifically, we examined whether these vaccination strategies would allow to lift all non-pharmacological interventions (NPIs), based on a sufficiently low cumulative mortality and number of hospital admissions. While vaccinating the full adult non-immunized population, if performed immediately, would be highly effective in reducing incidence, mortality and hospital-bed occupancy, and would allow discontinuing all NPIs, this strategy would require a large number of vaccine doses. Vaccinating only adults at higher risk for severe SARS-CoV-2 infection, i.e. those aged over 65 years or with medical conditions, would be insufficient to lift NPIs. Immediately vaccinating only adults aged over 45 years, or only adults aged over 55 years with mandatory vaccination of those aged over 65 years, would enable lifting all NPIs with a substantially lower number of vaccine doses, particularly with the latter vaccination strategy. Benefits of these strategies would be markedly reduced if the vaccination was delayed, was less effective than expected on virus transmission or in preventing COVID-19 among older adults, or was not widely accepted.",Nicolas Hoertel; Martin Blachier; Frederic Limosin; Marina Sanchez-Rico; Carlos Blanco; Mark Olfson; Stephane Luchini; Michael Schwarzinger; Henri Leleu,https://medrxiv.org/cgi/content/short/2021.01.17.21249970,https://medrxiv.org/cgi/content/short/2021.01.17.21249970,2021-01-20,2021-01-20,,True
395,Issues of Random Sampling with Rapid Antigen Tests for COVID-19 Diagnosis: A Special Reference to Kalmunai RDHS Division,"Random sampling from the community and performing the rapid antigen test has become a debatable issue during this COVID-19 pandemic. This writing analyzes the concerns using the data from Kalmunai RDHS Division, Sri Lanka, related to COVID-19 and shows the issues of random sampling in a community wherein the incident rate is small. Therefore, suitable sampling protocol is to be developed for performing rapid antigen test for COVID-19 diagnosis.",Razmy Athambawa Mohamed; Sainulabdeen Mohamed Junaideen,https://medrxiv.org/cgi/content/short/2021.01.11.21249636,https://medrxiv.org/cgi/content/short/2021.01.11.21249636,2021-01-20,2021-01-20,,True
396,City Reduced Probability of Infection (CityRPI) for Indoor Airborne Transmission of SARS-CoV-2 and Urban Building Energy Impacts,"Airborne transmission of aerosols produced by asymptomatic individuals is a large portion of the SARS-CoV-2 spread indoors. Outdoor air ventilation rate, air filtration, room occupancy, exposure time, and mask-wearing are among the key parameters that affect its airborne transmission in indoor spaces. In this work, we developed a new web-based platform, City Reduced Probability of Infection - CityRPI, to calculate the indoor airborne transmission of COVID-19 in various buildings of a city scale. An archetype library of twenty-nine building types is developed based on several standards and references. Among the mitigation strategies recommended to reduce infection risk, some could result in significant energy impacts on buildings. To study the combined effects of energy consumption and reduced infection probability, we integrated CityRPI with City Building Energy Model. We applied the integrated model to Montreal City and studied the impact of six mitigation measures on the infection risk and peak energy demand in winter. It shows that the same strategy could perform quite differently, depending on building types and properties. In the winter season, increasing the outdoor air ventilation rate may cause massive building energy consumption. All strategies are shown to reduce the infection risk but wearing a mask and reducing exposure time are the most effective strategies in many buildings, with around 60% reduction. Doubling the outdoor air ventilation rate is not as effective as other strategies to reduce the risk with less than 35% reduction. It also significantly increases building peak heating demand with 10-60%.",Ali Katal; Maher Albettar; Liangzhu (Leon) Wang,https://medrxiv.org/cgi/content/short/2021.01.19.21250046,https://medrxiv.org/cgi/content/short/2021.01.19.21250046,2021-01-20,2021-01-20,,True
397,"Emergence of a novel SARS-CoV-2 strain in Southern California, USA","Since October 2020, novel strains of SARS-CoV-2 including B.1.1.7, have been identified to be of global significance from an infection and surveillance perspective. While this strain (B.1.1.7) may play an important role in increased COVID rates in the UK, there are still no reported strains to account for the spike of cases in Los Angeles (LA) and California as a whole, which currently has some of the highest absolute and per-capita COVID transmission rates in the country. From the early days of the pandemic when LA only had a single viral genome uploaded onto GISAID we have been at the forefront of generating and analyzing the SARS-CoV-2 sequencing data from the LA region. We report a novel strain emerging in Southern California. Most current cases in the catchment population in LA fall into two distinct subclades: 1) 20G (24% of total) is the predominant subclade currently in the United States 2) a relatively novel strain in clade 20C, CAL.20C strain ([~]36% of total) is defined by five concurrent mutations. After an analysis of all of the publicly available data and a comparison to our recent sequences, we see a dramatic growth in the relative percentage of the CAL.20C strain beginning in November of 2020. The predominance of this strain coincides with the increased positivity rate seen in this region. Unlike 20G, this novel strain CAL.20C is defined by multiple mutations in the S protein, a characteristic it shares with both the UK and South African strains, both of which are of significant clinical and scientific interest",Wenjuan Zhang; Brian Davis; Stephanie S Chen; Jorge Sincuir Martinez; Jasmine T Plummer; Eric Vail,https://medrxiv.org/cgi/content/short/2021.01.18.21249786,https://medrxiv.org/cgi/content/short/2021.01.18.21249786,2021-01-20,2021-01-20,,True
398,"Clinical utility of Corona Virus Disease-19 serum IgG, IgM, and neutralizing antibodies and inflammatory markers","Most deaths from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection occur in older subjects. We assessed age effects and clinical utility of serum SARS-CoV-2 immunoglobulin G (IgG), immunoglobulin M (IgM), and neutralizing antibodies and serum inflammatory markers. Serum IgG, IgM, and neutralizing antibody levels were measured using chemiluminescence assays from Diazyme (Poway, CA), while serum interleukin-6 (IL-6), C reactive protein (CRP), and ferritin were measured with immunoassays obtained from Roche (Indianapolis, IN). In 79,005 subjects, IgG and IgM levels were positive ([&ge;]1.0 arbitrary units [AU]/mL) in 5.29% and 3.25% of subjects, respectively. In antibody positive subjects, median IgG levels were 3.93 AU/mL if <45 years of age, 10.18 AU/mL if 45-64 years of age, and 10.85 AU/mL if [&ge;]65 years of age (p<0.0001). In SARS-CoV-2 RNA positive cases, family members and exposed subjects (n=1,111), antibody testing was found to be valuable for case finding, and persistent IgM levels were associated with chronic symptoms. In non-hospitalized and hospitalized subjects assessed for SARS-CoV-2 RNA (n=278), median IgG levels in AU/mL were 0.05 in negative subjects (n=100), 14.83 in positive outpatients (n=129), and 30.61 in positive hospitalized patients (n=49, p<0.0001). Neutralizing antibody levels correlated significantly with IgG (r=0.875; p<0.0001). Two or more of the criteria of IL-6 [&ge;]10 pg/mL, CRP [&ge;]10 mg/L, and/or IgM >1.0 AU/mL occurred in 97.7% of inpatients versus 1.8% of outpatients (>50-fold relative risk, C statistic 0.986, p<0.0001). Our data indicate that: 1) IgG levels are significantly higher in positive older subjects, possibly to compensate for decreased cellular immunity with aging; 2) IgG levels are important for case finding in family clusters; 3) IgG levels are significantly correlated with neutralizing antibody levels; 4) persistently elevated IgM levels are associated with chronic disease; and 5) markedly elevated IL-6, hs-CRP, and/or positive IgM accurately identify SARS-CoV-2 RNA positive subjects requiring hospitalization.",Ernst J Schaefer; Florence Comite; Latha Dulipsingh; Maxine Lang; Jessica Jimison; Martin M Grajower; Nathan E Lebowitz; Andrew S Geller; Margaret R Diffenderfer; Lihong He; Gary Breton; Michael L Dansinger; Ben Saida; Chong Yuan,https://medrxiv.org/cgi/content/short/2021.01.19.21249604,https://medrxiv.org/cgi/content/short/2021.01.19.21249604,2021-01-20,2021-01-20,,True
399,The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma,"Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at enrollment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients.",Tengfei Ma; Chad C. Wiggins; Breanna M. Kornatowski; Ra'ed S. Hailat; Andrew C. Clayburn; Winston Guo; Patrick W. Johnson; Jonathon W. Senefeld; Stephen A. Klassen; Sarah E. Baker; Katelyn A. Bruno; DeLisa Fairweather; R. Scott Wright; Rickey E. Carter; Chenxi Li; Michael J. Joyner; Nigel Paneth,https://medrxiv.org/cgi/content/short/2021.01.19.21249678,https://medrxiv.org/cgi/content/short/2021.01.19.21249678,2021-01-20,2021-01-20,,True
400,NEWS2 and laboratory predictors correlated with clinical deterioration in hospitalised patients with COVID-19,"BackgroundWe aimed to determine prognostic values of NEWS2 and laboratory parameters during the first week of COVID-19.

MethodsAll adult patients who were hospitalized for a confirmed COVID-19 between the 11th of March and the 11th of May 2020 were retrospectively included. To evaluate the factors in prognosis which are admission to intensive care unit (ICU) and in-hospital death, univariate logistic regression analysis was performed at admission (D0), at day-3 (D3), day-5 (D5), and day-7 (D7). Additionally, receiver operating characteristic (ROC) analyses were performed.

ResultsOverall, 611 patients were included. Clinical deterioration was observed in 79 (12.9%) patients during hospitalisation, 36 (5.9%) during the first three days, 54 (8.8%) during the first five days, and 62 (10.1%) during the first week of hospitalisation. Our results showed that NEWS2, procalcitonin, neutrophil/lymphocyte ratio (NLR), and albumin were the best predictors for clinical deterioration at D0, D3, D5, and D7. Procalcitonin had the highest odds ratio for clinical deterioration on all days in univariate analysis. ROC analyses showed that NEWS2 at D7, procalcitonin at D5, albumin at D7, and NLR at D5 had highest AUC values. Additionally, we detected a strong correlation between NEWS2 and laboratory parameters including neutrophil, lymphocyte, NLR, platelet/lymphocyte ratio, CRP, procalcitonin, ferritin, and urea on all days.

ConclusionThis study provides a list of several laboratory parameters correlated with NEWS2 and potential predictors for ICU admission or in-hospital death during the clinical course of COVID-19. Dynamic monitoring of NEWS2 and laboratory parameters is vital for improving clinical outcomes.",Gulsah Tuncer; Serkan Surme; Osman Faruk Bayramlar; Hatice Kubra Karanalbant; Betul Copur; Meltem Yazla; Esra Zerdali; Inci Yilmaz-Nakir; Ayse Ruhkar Kurt-Cinar; Ahmet Buyukyazgan; Hatice Balli; Yesim Kurekci; Serap Simsek-Yavuz; Mehmet Mesut Sonmez; Gonul Sengoz; Filiz Pehlivanoglu,https://medrxiv.org/cgi/content/short/2021.01.17.21249878,https://medrxiv.org/cgi/content/short/2021.01.17.21249878,2021-01-20,2021-01-20,,True
401,Endothelial cell-activating antibodies in COVID-19,"Patients with coronavirus disease 19 (COVID-19) are at high risk for fibrin-based occlusion of vascular beds of all sizes. Although endothelial cell activation has regularly been described as part of the COVID-19 thrombo-inflammatory storm, the upstream mediators of this activation have yet to be fully elucidated. Here, we began by pursuing the hypothesis that circulating factors such as neutrophil extracellular trap (NET) remnants, D-dimer, or C-reactive protein might predict the COVID-19 serum samples (n=118) that most robustly activated cultured endothelial cells. Indeed, we found modest correlations between serum NET remnants (cell-free DNA, myeloperoxidase-DNA complexes, citrullinated histone H3) and upregulation of surface E-selectin, VCAM-1, and ICAM-1 on endothelial cells. However, a more robust predictor of the ability of COVID-19 serum to activate endothelial cells was the presence of circulating antiphospholipid antibodies, specifically anticardiolipin IgG and IgM and anti-phosphatidlyserine/prothrombin (anti-PS/PT) IgG and IgM. Depletion of total IgG from anticardiolipin-high and anti-PS/PT-high samples markedly restrained upregulation of E-selectin, VCAM-1, and ICAM-1. At the same time, supplementation of control serum with patient IgG was sufficient to trigger endothelial cell activation. These data are the first to reveal that patient antibodies are a driver of endothelial cell activation and add important context regarding thrombo-inflammatory effects of COVID-19 autoantibodies in severe COVID-19.",Hui Shi; Yu Zuo; Alex A. Gandhi; Gautam Sule; Srilakshmi Yalavarthi; Kelsey Gockman; Jacqueline A. Madison; Melanie Zuo; Yue Shi; Jason S. Knight; Yogendra Kanthi,https://medrxiv.org/cgi/content/short/2021.01.18.21250041,https://medrxiv.org/cgi/content/short/2021.01.18.21250041,2021-01-20,2021-01-20,,True
402,Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV 2 infection,"We hypothesised that host-response biomarkers of viral infections may contribute to early identification of SARS-CoV-2 infected individuals, critical to breaking chains of transmission. We identified 20 candidate blood transcriptomic signatures of viral infection by systematic review and evaluated their ability to detect SARS-CoV-2 infection, compared to the gold-standard of virus PCR tests, among a prospective cohort of 400 hospital staff subjected to weekly testing when fit to attend work. The transcriptional signatures had limited overlap, but were mostly co-correlated as components of type 1 interferon responses. We reconstructed each signature score in blood RNA sequencing data from 41 individuals over sequential weeks spanning a first positive SARS-CoV-2 PCR, and after 6-month convalescence. A single blood transcript for IFI27 provided the highest accuracy for discriminating individuals at the time of their first positive viral PCR result from uninfected controls, with area under the receiver operating characteristic curve (AUROC) of 0.95 (95% confidence interval 0.91-0.99), sensitivity 0.84 (0.7-0.93) and specificity 0.95 (0.85-0.98) at a predefined test threshold. The test performed equally well in individuals with and without symptoms, correlated with viral load, and identified incident infections one week before the first positive viral PCR with sensitivity 0.4 (0.17-0.69) and specificity 0.95 (0.85-0.98). Our findings strongly support further urgent evaluation and development of blood IFI27 transcripts as a biomarker for early phase SARS-CoV-2 infection, for screening individuals such as contacts of index cases, in order to facilitate early case isolation and early antiviral treatments as they emerge.",Rishi K Gupta; Joshua Rosenheim; Lucy C K Bell; Aneesh Chandran; Jose Afonso Guerra-Assuncao; Gabriele Pollara; Matthew Whelan; Jessica Artico; George Joy; Hibba Kurdi; Daniel M Altmann; Rosemary Boyton; Mala Maini; Aine McKnight; Jonathan Lambourne; Teresa Cutino-moguel; Charlotte Manisty; Thomas Alexander Treibel; James Moon; Benjamin Chain; Mahdad Noursadeghi; - The COVIDsortium Investigators,https://medrxiv.org/cgi/content/short/2021.01.18.21250044,https://medrxiv.org/cgi/content/short/2021.01.18.21250044,2021-01-20,2021-01-20,,True
403,Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,"BackgroundMortality from COVID-19 shows a strong relationship with age and pre-existing medical conditions, as does mortality from other causes. However it is unclear how specific factors are differentially associated with COVID-19 mortality as compared to mortality from other causes.

MethodsWorking on behalf of NHS England, we carried out a cohort study within the OpenSAFELY platform. Primary care data from England were linked to national death registrations. We included all adults (aged [&ge;]18 years) in the database on 1st February 2020 and with >1 year of continuous prior registration, the cut-off date for deaths was 9th November 2020. Associations between individual-level characteristics and COVID-19 and non-COVID deaths were estimated by fitting age- and sex-adjusted logistic models for these two outcomes.

Results17,456,515 individuals were included. 17,063 died from COVID-19 and 134,316 from other causes. Most factors associated with COVID-19 death were similarly associated with non-COVID death, but the magnitudes of association differed. Older age was more strongly associated with COVID-19 death than non-COVID death (e.g. ORs 40.7 [95% CI 37.7-43.8] and 29.6 [28.9-30.3] respectively for [&ge;]80 vs 50-59 years), as was male sex, deprivation, obesity, and some comorbidities. Smoking, history of cancer and chronic liver disease had stronger associations with non-COVID than COVID-19 death. All non-white ethnic groups had higher odds than white of COVID-19 death (OR for Black: 2.20 [1.96-2.47], South Asian: 2.33 [2.16-2.52]), but lower odds than white of non-COVID death (Black: 0.88 [0.83-0.94], South Asian: 0.78 [0.75-0.81]).

InterpretationSimilar associations of most individual-level factors with COVID-19 and non-COVID death suggest that COVID-19 largely multiplies existing risks faced by patients, with some notable exceptions. Identifying the unique factors contributing to the excess COVID-19 mortality risk among non-white groups is a priority to inform efforts to reduce deaths from COVID-19.

FundingWellcome, Royal Society, National Institute for Health Research, National Institute for Health Research Oxford Biomedical Research Centre, UK Medical Research Council, Health Data Research UK.",Krishnan Bhaskaran; Sebastian CJ Bacon; Stephen JW Evans; Chris J Bates; Christopher T Rentsch; MacKenna Brian; Laurie Tomlinson; Alex J Walker; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,https://medrxiv.org/cgi/content/short/2021.01.15.21249756,https://medrxiv.org/cgi/content/short/2021.01.15.21249756,2021-01-20,2021-01-20,,True
404,Viral dispersion in open air,"The SARS-CoV-2 pandemic has revived the debate about the routes of virus transmission and their likelihoods. It is of utmost importance to assess the risks of contamination of susceptible people by infectious individuals and to evaluate the level of viral transmission in the community. Most countries have imposed non-pharmaceutical measures to contain SARS-CoV-2 transmission, including social distancing and mask wearing. Here we evaluated the spreading of viruses in open air using harmless Escherichia coli bacteriophages as a surrogate. Phages were sprayed towards Petri dishes seeded with bacteria at different lengths and angles. Median droplets size was 127 {micro}m, similar to those produced by sneeze. Our results showed that the transmission rate decreased exponentially with distance. The highest recorded transmission rate was 9 x 10-6 PFU/plate when phages were sprayed from a 1 m distance, suggesting that the probability of transmission of a single virus at a 1 m distance is 1:100,000. These results agree with the WHO recommendation that face mask protection in an uncrowded well-ventilated space is not required.",Gabriella Trombini Machado; Claudia Ramos de Carvalho Pinto; Luisa Andrea Villanueva da Fonseca; Taissa Cristina dos Santos Ramos; Tuanny Fernanda Pereira Paggi; Beny Spira,https://medrxiv.org/cgi/content/short/2021.01.18.21249463,https://medrxiv.org/cgi/content/short/2021.01.18.21249463,2021-01-20,2021-01-20,,True
405,Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic,"BackgroundAccurate detection of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is necessary to mitigate the coronavirus disease-19 (COVID-19) pandemic. However, the test reagents and assay platforms are varied and may not be sufficiently robust to diagnose COVID-19.

MethodsWe reviewed 85 studies (21,530 patients), published from five regions of the world, to highlight issues involved in the diagnosis of COVID-19 in the early phase of the pandemic, following the standards outlined in the PRISMA statement. All relevant articles, published up to May 31, 2020, in PubMed, BioRiXv, MedRiXv, and Google Scholar, were included. We evaluated the qualitative (9749 patients) and quantitative (10,355 patients) performance of RT-PCR and serologic diagnostic tests for real-world samples, and assessed the concordance (5,538 patients) between methods in meta-analyses.

ResultsThe RT-PCR tests exhibited heterogeneity in the primers and reagents used. Of 1,957 positive RT-PCR COVID-19 participants, 1,585 had positive serum antibody (IgM +/- IgG) tests (sensitivity 0.81, 95%CI 0.66-.90). While 3,509 of 3581 participants RT-PCR negative for COVID-19 were found negative by serology testing (specificity 0.98, 95%CI 0.94-0.99). The chemiluminescent immunoassay exhibited the highest sensitivity, followed by ELISA and lateral flow immunoassays. Serology tests had higher sensitivity and specificity for laboratory-approval than for real-world reporting data.

ConclusionsThe robustness of the assays/platforms is influenced by variability in sampling and reagents. Serological testing complements and may minimize false negative RT-PCR results. Lack of standardized assay protocols in the early phase of pandemic might have contributed to the spread of COVID-19.",Chandrakumar Shanmugam; Michael Behring; Vishwas Luthra; Sixto M. Leal Jr.; Sooryanarayana Varambally; George J. Netto; Upender Manne,https://medrxiv.org/cgi/content/short/2021.01.16.21249937,https://medrxiv.org/cgi/content/short/2021.01.16.21249937,2021-01-20,2021-01-20,,True
406,Inactivation of SARS-CoV-2 virus in saliva using a guanidium based transport medium suitable for RT-PCR diagnostic assays,"BackgroundUpper respiratory samples used to test for SARS-CoV-2 virus may be infectious and present a hazard during transport and testing. A buffer with the ability to inactivate SARS-CoV-2 at the time of sample collection could simplify and expand testing for COVID-19 to non-conventional settings.

MethodsWe evaluated a guanidium thiocyanate-based buffer, eNAT (Copan) as a possible transport and inactivation medium for downstream RT-PCR testing to detect SARS-CoV-2. Inactivation of SARS-CoV-2 USA-WA1/2020 in eNAT and in diluted saliva was studied at different incubation times. The stability of viral RNA in eNAT was also evaluated for up to 7 days at room temperature (28{degrees}C), refrigerated conditions (4{degrees}C) and at 35{degrees}C.

ResultsSARS-COV-2 virus spiked directly in eNAT could be inactivated at >5.6 log10 PFU/ml within a minute of incubation. When saliva was diluted 1:1 in eNAT, no cytopathic effect (CPE) on vero-E6 cell lines was observed, although SARS-CoV-2 RNA could be detected even after 30 min incubation and after two cell culture passages. A 1:2 (saliva:eNAT) dilution abrogated both CPE and detectable viral RNA after as little as 5 min incubation in eNAT. SARS-CoV-2 RNA from virus spiked at 5X the limit of detection remained positive up to 7 days of incubation in all tested conditions.

ConclusioneNAT and similar guanidinium thiocyanate-based media may be of value for transport, preservation, and processing of clinical samples for RT-PCR based SARS-CoV-2 detection.",Sukalyani Banik; Kaheerman Saibire; Shraddha Suryavanshi; Glenn Johns; Soumitesh Chakravorty; Robert Kwiatkawoski; David Alland; Padmapriya P. Banada,https://medrxiv.org/cgi/content/short/2021.01.15.21249891,https://medrxiv.org/cgi/content/short/2021.01.15.21249891,2021-01-20,2021-01-20,,True
407,The Impact of U.S. County-Level Factors on COVID-19 Morbidity and Mortality,"BackgroundThe effect of socioeconomic factors, ethnicity, and other variables, on the frequency of COVID-19 cases [morbidity] and induced deaths [mortality] at sub-population, rather than at individual levels, is only partially understood.

ObjectiveTo determine which county-level features best predict COVID-19 morbidity and mortality for a given county in the U.S.

DesignA Machine-Learning model that predicts COVID-19 mortality and morbidity using county-level features, followed by a SHAP-values-based importance analysis of the predictive features.

SettingPublicly available data from various American government and news websites.

Participants3,071 U.S. counties, from which 53 county-level features, as well as morbidity and mortality numbers, were collected.

MeasurementsFor each county: Ethnicity, socioeconomic factors, educational attainment, mask usage, population density, age distribution, COVID-19 morbidity and mortality, air quality indicators, presidential election results, ICU beds.

ResultsA Random Forest classifier produced an AUROC of 0.863 for morbidity prediction and an AUROC of 0.812 for mortality prediction. A SHAP-values-based analysis indicated that poverty rate, obesity rate, mean commute time to work, and proportion of people that wear masks significantly affected morbidity rates, while ethnicity, median income, poverty rate, and education levels, heavily influenced mortality rates. The correlation between several of these factors and COVID-19 morbidity and mortality, from 4/2020 to 11/2020 shifted, probably due to COVID-19 being initially associated with more urbanized areas, then with less urbanized ones.

LimitationsData are still coming in.

ConclusionsEthnicity, education, and economic disparity measures are major factors in predicting the COVID-19 mortality rate in a county. Between-counties low-variance factors (e.g., age), are not meaningful predictors.

Differing correlations can be explained by the COVID-19 spread from metropolitan to less metropolitan areas.

Primary Funding SourceNone.",Nevo Itzhak; Tomer Shahar; Robert Moskovitch; Yuval Shahar,https://medrxiv.org/cgi/content/short/2021.01.19.21250092,https://medrxiv.org/cgi/content/short/2021.01.19.21250092,2021-01-20,2021-01-20,,True
408,Forecasting the Spread of the COVID-19 Epidemic in Lombardy: A Dynamic Model Averaging Approach,"Forecasting with accuracy the evolution of COVID-19 daily incidence curves is one of the most important exercises in the field of epidemic modeling. We examine the forecastability of daily COVID-19 cases in the Italian region of Lombardy using Dynamic Model Averaging and Dynamic Model Selection methods. To investigate the predictive accuracy of this approach, we compute forecast performance metrics of sequential out-of-sample real-time forecasts in a back-testing exercise ranging from March 1 to December 10 of 2020. We find that (i) Dynamic Model Averaging leads to a consistent and substantial predictive improvements over alternative epidemiological models and machine learning approaches when producing short-run forecasts. Using estimated posterior inclusion probabilities we also provide evidence on which set of predictors are relevant for forecasting in each period. Our findings also suggest that (ii) future incidences can be forecasted by exploiting information on the epidemic dynamics of neighboring regions, human mobility patterns, pollution and temperatures levels.",Lisa Gianmoena; Vicente Rios,https://medrxiv.org/cgi/content/short/2021.01.18.21250053,https://medrxiv.org/cgi/content/short/2021.01.18.21250053,2021-01-20,2021-01-20,,True
409,Modelling the COVID-19 Fatality Rate in England and its Regions,"A model to account for the fatality rate in England and its regions is proposed. It follows the clear observation that, rather than two connected waves, there have been many waves of infections and fatalities in the regions of England of various magnitudes, usually overlapping. The waves are self-limiting, in that clear peaks are seen, particularly in reported positive test rates. The present model considers fatalities as the data reported are more reliable than positive test rates, particularly so during the first wave when so little testing was done.

The model considers the observed waves are essentially similar in form and can be modelled using a single wave form whose final state is only dependent on its peak height and the start date of the particular wave. The basic wave form was modelled using the observed fatality rates for London, which unlike the other regions, exhibited almost completely as a single wave in the ""first wave"". Its form matches rather well with the ""Do Nothing"" model reported by Imperial College on 16th March 2020, but reduced substantially from its expected peak.

There are, essentially, only two adjustable parameters used in the model, the start date of the relevant wave and its height. The modelled fatalities for each wave are summated per day and a cumulative curve is matched to that reported. The minimal number of adjustable parameters, alongside the fact that the waves invariably overlap, provides highly stringent conditions on the fitting process.

Results are presented for each region for both the ""first"" and ""second waves. High levels of accuracy are obtained with R2 values approaching 100% against the ideal fit for both waves. It can also be seen there are fundamental differences between the underlying behaviour of the ""first"" and ""second"" waves.",Nigel Saunders,https://medrxiv.org/cgi/content/short/2021.01.19.21249816,https://medrxiv.org/cgi/content/short/2021.01.19.21249816,2021-01-20,2021-01-20,,True
410,Studying the course of Covid-19 by a recursive delay approach,"AO_SCPLOWBSTRACTC_SCPLOWIn an earlier paper we proposed a recursive model for epidemics; in the present paper we generalize this model to include the asymptomatic or unrecorded symptomatic people, which we call dark people (dark sector). We call this the SEPARd-model. A delay differential equation version of the model is added; it allows a better comparison to other models. We carry this out by a comparison with the classical SIR model and indicate why we believe that the SEPARd model may work better for Covid-19 than other approaches.

In the second part of the paper we explain how to deal with the data provided by the JHU, in particular we explain how to derive central model parameters from the data. Other parameters, like the size of the dark sector, are less accessible and have to be estimated more roughly, at best by results of representative serological studies which are accessible, however, only for a few countries. We start our country studies with Switzerland where such data are available. Then we apply the model to a collection of other countries, three European ones (Germany, France, Sweden), the three most stricken countries from three other continents (USA, Brazil, India). Finally we show that even the aggregated world data can be well represented by our approach.

At the end of the paper we discuss the use of the model. Perhaps the most striking application is that it allows a quantitative analysis of the influence of the time until people are sent to quarantine or hospital. This suggests that imposing means to shorten this time is a powerful tool to flatten the curves.",Erhard Scholz; Matthias Kreck,https://medrxiv.org/cgi/content/short/2021.01.18.21250012,https://medrxiv.org/cgi/content/short/2021.01.18.21250012,2021-01-20,2021-01-20,,True
411,The Association between Early Country-level Testing Capacity and Later COVID-19 Mortality Outcomes,"BackgroundThe COVID-19 pandemic has overrun hospital systems while exacerbating economic hardship and food insecurity on a global scale. In an effort to understand how early action to find and control the virus is associated with cumulative outcomes, we explored how country-level testing capacity affects later COVID-19 mortality.

MethodsWe used the Our World in Data database to explore testing and mortality records in 27 countries from December 31, 2019 to September 30, 2020; we applied ordinary-least squares regression with clustering on country to determine the association between early COVID-19 testing capacity (cumulative tests per case) and later COVID-19 mortality (time to specified mortality thresholds), adjusting for country-level confounders, including median age, GDP, hospital bed capacity, population density, and non-pharmaceutical interventions.

ResultsHigher early testing implementation, as indicated by more cumulative tests per case when mortality was still low, was associated with longer accrual time for higher per capita deaths. For instance, a higher cumulative number of tests administered per case at the time of 6 deaths per million persons was positively predictive of a longer time to reach 15 deaths per million, after adjustment for all confounders ({beta}=0.659; P=0.001).

ConclusionsCountries that developed stronger COVID-19 testing capacity at early timepoints, as measured by tests administered per case identified, experienced a slower increase of deaths per capita. Thus, this study operationalizes the value of testing and provides empirical evidence that stronger testing capacity at early timepoints is associated with reduced mortality and better pandemic control.",Sneha Kannoth; Sasikiran Kandula; Jeffrey Shaman,https://medrxiv.org/cgi/content/short/2021.01.18.21249998,https://medrxiv.org/cgi/content/short/2021.01.18.21249998,2021-01-20,2021-01-20,,True
412,Modeling and Simulation: A study on predicting the outbreak of COVID- 19 in Saudi Arabia,"The novel coronavirus (Covid-19) infection has resulted in an ongoing pandemic affecting health system and economy of more than 200 countries around the world. Mathematical models are used to predict the biological and epidemiological trends of an epidemic and develop methods for controlling it. In this work, we use mathematical model perspective to study the role of behavior change in slowing the spread of the COVID-19 disease in Saudi Arabia. The real-time updated data from 1st May 2020 to 8th January 2021 is collected from Saudi Ministry of Health, aiming to provide dynamic behaviors of the pandemic in Saudi Arabia. During this period, it has infected 297,205 people, resulting in 6124 deaths with the mortality rate 2.06 %. There is weak positive relationship between the spread of the infection and mortality (R2 =0.412). We use Susceptible-Exposed-Infection-Recovered (SEIR) mode, the logistic growth model and with special focus on the exposed, infection and recovery individuals to simulate the final phase of the outbreak. The results indicate that social distancing, good hygienic conditions, and travel limitation are the crucial measures to prevent further spreading of the epidemic.",Ahmed Hussein Msmali; Zico Meetei Mutum; Idir Mechai; Abdullah A Ahmadini,https://medrxiv.org/cgi/content/short/2021.01.17.21249837,https://medrxiv.org/cgi/content/short/2021.01.17.21249837,2021-01-20,2021-01-20,,True
413,"The impacts of COVID-19 vaccine timing, number of doses, and risk prioritization on mortality in the US","As COVID-19 vaccination begins worldwide, policymakers face critical trade-offs. Using a mathematical model of COVID-19 transmission, we find that timing of the rollout is expected to have a substantially greater impact on mortality than risk-based prioritization and adherence and that prioritizing first doses over second doses may be life saving.",Xutong Wang; Zhanwei Du; Kaitlyn Johnson; Spencer Fox; Michael Lachmann; Jason S McLellan; Lauren Ancel Meyers,https://medrxiv.org/cgi/content/short/2021.01.18.21250071,https://medrxiv.org/cgi/content/short/2021.01.18.21250071,2021-01-20,2021-01-20,,True
414,"Remote care for mental health: qualitative study with service users, carers and staff during the COVID-19 pandemic","ObjectivesTo explore the experiences of service users, carers and staff seeking or providing secondary mental health services during the COVID-19 pandemic.

DesignQualitative interview study, co-designed with mental health service users and carers.

MethodsWe conducted semi-structured, telephone or online interviews with a purposively constructed sample; a peer researcher with lived experience conducted and analysed interviews with service users. Analysis was based on the constant comparison method.

SettingNHS secondary mental health services in England between June and August 2020.

ParticipantsOf 65 participants, 20 had either accessed or needed to access English secondary mental healthcare during the pandemic; 10 were carers of people with mental health difficulties; 35 were members of staff working in NHS secondary mental health services during the pandemic.

ResultsExperiences of remote care were mixed. Some service users valued the convenience of remote methods in the context of maintaining contact with familiar clinicians. Most participants commented that a lack of non-verbal cues and the loss of a therapeutic  safe space challenged therapeutic relationship building, assessments, and identification of deteriorating mental wellbeing. Some carers felt excluded from remote meetings and concerned that assessments were incomplete without their input. Like service users, remote methods posed challenges for clinicians who reported uncertainty about technical options and a lack of training. All groups expressed concern about intersectionality exacerbating inequalities and the exclusion of some service user groups if alternatives to remote care are lost.

ConclusionsWhilst remote mental healthcare is likely to become increasingly widespread in secondary mental health services, our findings highlight the continued importance of a tailored, personal approach to decisions about remote mental healthcare. Further research should focus on which types of consultations best suit face-to-face interaction, and for whom and why, and which can be provided remotely and by which medium.

ARTICLE SUMMARYO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIStrengths include its qualitative approach in speaking to a large sample of participants with varied mental health difficulties, carers, and a diverse range of mental healthcare staff.
C_LIO_LIIts novelty lies in a deep exploration of the views and experiences of remote mental healthcare during a pandemic.
C_LIO_LIThe methods are strengthened by the involvement of experts-by-experience and the use of peer research methods.
C_LIO_LIWe did not adopt a narrative method; the interviews were one-off conversations so we could not explore change as the pandemic progressed and people may have become accustomed to remote care.
C_LIO_LIThe study used remote methods to comply with UK lockdown regulations; this will have excluded some groups without the ability to engage remotely.
C_LI",Elisa Liberati; Natalie Richards; Jennie Parker; Janet Willars; David Scott; Nicola Boydell; Vanessa Pinfold; Graham Martin; Mary Dixon-Woods; Peter B Jones,https://medrxiv.org/cgi/content/short/2021.01.18.21250032,https://medrxiv.org/cgi/content/short/2021.01.18.21250032,2021-01-20,2021-01-20,,True
415,Sleeping under the waves: a longitudinal study across the contagion peaks of COVID-19 pandemic in Italy,"After the March-April 2020 COVID-19 outbreak, a second contagion wave afflicted Europe in autumn. This study aimed to evaluate sleep health/patterns of Italians during this further challenging situation.

A total of 2013 Italians longitudinally participated in a web-based survey during the two contagion peaks of the COVID-19 outbreak. We investigated the risk factors for sleep disturbances during the second wave, and we compared sleep quality and psychological well-being between the two assessments (March-April and November-December 2020). Female gender, low education, evening chronotype, being at high-risk for COVID-19 infection, reporting negative social or economic impact, and evening smartphone overuse predicted a higher risk of poor sleep and insomnia symptoms during the second wave. Advanced age, living with high-risk subjects for COVID-19 infection, and having a relative/friend infected with COVID-19 before the prior two weeks were risk categories for poor sleep quality. Living with children, having contracted COVID-19 before the prior two weeks, being pessimistic on the vaccine, and working in healthcare were risk factors for insomnia symptoms. The follow-up assessment highlighted reduced insomnia symptoms and anxiety. Nevertheless, we showed reduced sleep duration, higher daytime dysfunction and sleep medication use, and advanced sleep phase, confirming the alarming prevalence of poor sleepers ([~]60%) and severe depression ([~]20%) in a context of increased perceived stress.

This study demonstrated a persistent impact of the COVID-19 pandemic on sleep and mental health. Large-scale interventions to counteract the chronicity and exacerbation of sleep and psychological disturbances are necessary, especially for the risk categories.",Federico Salfi; Aurora D'Atri; Daniela Tempesta; Michele Ferrara,https://medrxiv.org/cgi/content/short/2021.01.17.21249947,https://medrxiv.org/cgi/content/short/2021.01.17.21249947,2021-01-20,2021-01-20,,True
416,Examining the effect of information channel on COVID-19 vaccine acceptance,"Hesitancy towards the COVID-19 vaccine remains high among the US population. Now that the vaccine is available to priority populations, it is critical to convince those that are hesitant to take the vaccine. Public health communication about the vaccine as well as misinformation on the vaccine occurs through a variety of different information channels. Some channels of information are more commonly found to spread misinformation. Given the expansive information environment, we sought to characterize the use of different media channels for COVID-19 vaccine information and determine the relationship between information channel and vaccine acceptance. We conducted a convenience sample of vaccine priority groups (N=2,650) between December 13 and 23, 2020 and conducted bivariate chi-squared tests and multivariable multinomial logistic regression analyses to determine the relative impact of channels of information on vaccine acceptance. We found traditional channels of information, especially National TV, National newspapers, and local newspapers increased the relative risk of vaccine acceptance. Individuals who received information from traditional media compared to social media or both traditional and social media were most likely to accept the vaccine. The implications of this study suggest social media channels have a role to play in educating the hesitant to accept the vaccine, while traditional media channels should continue to promote data-driven and informed vaccine content to their viewers.",Rachael Piltch-Loeb; Elena Savoia; Beth Goldberg; Brian Hughes; Tanner Verhey; Juliette Kayyem; Cynthia Miller-Idriss; Marcia Testa,https://medrxiv.org/cgi/content/short/2021.01.18.21250049,https://medrxiv.org/cgi/content/short/2021.01.18.21250049,2021-01-20,2021-01-20,,True
417,Improved screening of COVID-19 cases through a Bayesian network symptoms model and psychophysical olfactory test,"The infectiousness and presymptomatic transmission of COVID-19 hinder pandemic control efforts worldwide. Therefore, the frequency of testing, accessibility, and immediate results are critical for reopening societies until an effective vaccine becomes available for a substantial proportion of the population. The loss of sense of smell is among the earliest, most discriminant, and prevalent symptoms of COVID-19, with 75-98% prevalence when clinical olfactory tests are used. Frequent screening for olfactory dysfunction could substantially reduce viral spread. However, olfactory dysfunction is generally self-reported and not measured, which is specially problematic as partial olfactory impairment is broadly unrecognized. To address this limitation, we developed a rapid psychophysical olfactory test (KOR) deployed on a web platform for automated reporting and traceability based on a low-cost, six-odor olfactory identification kit. Based on test results, we defined an anosmia score -a classifier for olfactory impairment-, and a Bayesian Network (BN) model that incorporates other symptoms for detecting COVID-19 cases. We trained and validated the BN model on two samples: suspected COVID-19 cases in five healthcare centers (n = 926; 32% COVID-19 prevalence) and healthy (asymptomatic) mining workers (n = 1, 365; 1.1% COVID-19 prevalence). All participants had COVID-19 assessment by RT-PCR assay. Using the BN model, we predicted COVID-19 status with 76% accuracy (AUC=0.79 [0.75 - 0.82]) in the healthcare sample and 84% accuracy (AUC=0.71 [0.63 - 0.79]) among miners. The KOR test and BN model enabled the detection of COVID-19 cases that otherwise appeared asymptomatic. Our results confirmed that olfactory dysfunction is the most discriminant symptom to predict COVID-19 status when based on olfactory function measurements. Overall, this work highlights the potential for low-cost, frequent, accessible, routine testing for COVID-19 surveillance to aid societys reopening.",Susana Eyheramendy Prof.; Pedro Andres Saa Prof.; Eduardo A Undurraga Prof.; Carlos Valencia Mr.; Carolina Lopez Mrs.; Luis Mendez Dr.; Javier Pizarro-Berdichevsky Dr.; Andres Finkelstein-Kulka Dr.; Sandra Solari Dr.; Nicolas Salas Mr.; Pedro Bahamondes Mr.; Martin Ugarte Dr.; Pablo Barcelo Prof.; Marcelo Arenas Prof.; Eduardo Agosin Prof.,https://medrxiv.org/cgi/content/short/2021.01.18.21249821,https://medrxiv.org/cgi/content/short/2021.01.18.21249821,2021-01-20,2021-01-20,,True
418,The COVID-19 Infodemic: The complex task of elevating signal and eliminating noise.,"In Situation Report #3 and 39 days before declaring COVID-19 a pandemic, the WHO declared a -19 infodemic. The volume of coronavirus tweets was far too great for one to find accurate or reliable information. Healthcare workers were flooded with which drowned the of valuable COVID-19 information. To combat the infodemic, physicians created healthcare-specific micro-communities to share scientific information with other providers. We analyzed the content of eight physician-created communities and categorized each message in one of five domains. We coded 1) an application programming interface to download tweets and their metadata in JavaScript Object Notation and 2) a reading algorithm using visual basic application in Excel to categorize the content. We superimposed the publication date of each tweet into a timeline of key pandemic events. Finally, we created NephTwitterArchive.com to help healthcare workers find COVID-19-related signal tweets when treating patients. We collected 21071 tweets from the eight hashtags studied. Only 9051 tweets were considered signal: tweets categorized into both a domain and subdomain. There was a trend towards fewer signal tweets as the pandemic progressed, with a daily median of 22% (IQR 0-42%. The most popular subdomain in Prevention was PPE (2448 signal tweets). In Therapeutics, Hydroxychloroquine/chloroquine wwo Azithromycin and Mechanical Ventilation were the most popular subdomains. During the active Infodemic phase (Days 0 to 49), a total of 2021 searches were completed in NephTwitterArchive.com, which was a 26% increase from the same time period before the pandemic was declared (Days -50 to -1). The COVID-19 Infodemic indicates that future endeavors must be undertaken to eliminate noise and elevate signal in all aspects of scientific discourse on Twitter. In the absence of any algorithm-based strategy, healthcare providers will be left with the nearly impossible task of manually finding high-quality tweets from amongst a tidal wave of noise.",TEJAS DESAI; Arvind Conjeevaram,https://medrxiv.org/cgi/content/short/2021.01.19.21249936,https://medrxiv.org/cgi/content/short/2021.01.19.21249936,2021-01-20,2021-01-20,,True
419,Temporal Trends in COVID-19 associated AKI from March to December 2020 in New York City,"Acute Kidney Injury (AKI) is among the most common complications of Coronavirus Disease 2019 (COVID-19). Throughout 2020 pandemic, the clinical approach to COVID-19 has progressively improved, but it is unknown how these changes have affected AKI incidence and severity. In this retrospective analysis, we report the trend over time of COVID-19 associated AKI and need of renal replacement therapy in a large health system in New York City, the first COVID-19 epicenter in United States.",Sergio Dellepiane; Akhil Vaid; Suraj K Jaladanki; Ishan Paranjpe; Stevn Coca; Zahi Fayad; Alexander Charney; Erwin P Bottinger; John Cijiang He; Benjamin S Glicksberg; Lili Chan; Girish Nadkarni,https://medrxiv.org/cgi/content/short/2021.01.18.21249414,https://medrxiv.org/cgi/content/short/2021.01.18.21249414,2021-01-20,2021-01-20,,True
420,Covid-19 respiratory protection: the filtration efficiency assessment of decontaminated FFP2 masks responding to associated shortages,"During the Covid-19 pandemic, healthcare workers were extremely vulnerable to infection with the virus and needed continuous protection. One of the most effective and widely used means of protection was the FFP2 respirator. Unfortunately, this crisis created a shortage of these masks, prompting hospitals to explore opportunities to reuse them after decontamination.

An approach for assessing the filtration efficiency of decontaminated FFP2 masks has been proposed and applied to evaluate the possibilities of their safe reuse. The decontamination processes adopted are those based on moist heat or hydrogen peroxide. The approach introduces efficiency measures that define the filtration and protection capacity of the masks, which characterize both chemical and structural changes, and encompasses many techniques including scanning electron microscopy (SEM), Fourier transforms infrared spectroscopy (FTIR), and thermogravimetric analysis (TGA). The test protocol was applied to mask samples that had endured different decontamination cycles and the results of their efficiency measures were compared to brand-new masks performances.

The main result was that chemical and structural characterization of the decontaminated masks have shown no substantial change or deformation of their filter media structures. Indeed, the respiratory resistance test has shown that the results of both the FFP2 masks that have undergone a hydrogen peroxide disinfection cycle or a steam autoclave cycle remained constant with a small variation of 10 Pa from the EN149 standard. The chemical characterization, on the other hand, has shown that the filter media of the decontaminated masks remains unchanged, with no detectable chemical derivatives in its constituents.",benboubker moussa; Bouchra Omokhtar; Fouzia hmami; Khalil El mabrouk; Leena El alami; Btissam Arhoune; Mohammed Faouzi Belahcen; Ahmed Aboutajeddine,https://medrxiv.org/cgi/content/short/2021.01.18.21249976,https://medrxiv.org/cgi/content/short/2021.01.18.21249976,2021-01-20,2021-01-20,,True
421,The burden of nosocomial covid-19: results from the Wales multi-centre retrospective observational study of 2518 hospitalised adults.,"ObjectivesTo define the burden of nosocomial (hospital-acquired) novel pandemic coronavirus (covid-19) infection among adults hospitalised across Wales.

DesignRetrospective observational study of adult patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection between 1st March - 1st July 2020 with a recorded hospital admission within the subsequent 31 days. Outcomes were collected up to 20th November using a standardised online data collection tool.

SettingService evaluation performed across 18 secondary or tertiary care hospitals.

Participants4112 admissions with a positive SARS-CoV-2 PCR result between 1st March to 1st July 2020 were screened. Anonymised data from 2518 participants were returned, representing over 60% of adults hospitalised across the nation of Wales.

Main outcome measuresThe prevalence and outcomes (death, discharge) for nosocomial covid-19, assessed across of a range of possible case definitions.

ResultsInpatient mortality rates for nosocomial covid-19 ranged from 38% to 42% and remained consistently higher than participants with community-acquired infection (31% to 35%) across a range of case definitions. Participants with nosocomial-acquired infection were an older, frailer, and multi-morbid population than those with community-acquired infection. Based on the Public Health Wales case definition, 50% of participants had been admitted for 30 days prior to diagnostic testing.

ConclusionsThis represents the largest assessment of clinical outcomes for patients with nosocomial covid-19 in the UK to date. These findings suggest that inpatient mortality rates from nosocomial-infection are likely higher than previously reported, emphasizing the importance of infection control measures, and supports prioritisation of vaccination for covid-19 negative admissions and trials of post-exposure prophylaxis in inpatient cohorts.

Trial registrationThis project was approved and sponsored by the Welsh Government, as part of a national audit and quality improvement scheme for patients hospitalised covid-19 across Wales.

Key MessagesO_ST_ABSWhat is already known on this topicC_ST_ABSWe searched PubMed and ISI Web of Science up until 31-December-2020 for studies reporting on patient outcomes following hospital-acquired infection due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We identified a range of case-definitions for hospital-acquired infection, based on timing of diagnostic testing 5 to 15 days following admission. The largest and only multi-centre study concluded individuals with nosocomial infection are at a lower risk of death from SARS-CoV-2 than those infected in the community, however, was performed early in the pandemic and utilised a conservative definition of nosocomial infection.

What this study addsOur multi-centre observational study represents the largest assessment of clinical outcomes for patients with nosocomial covid-19 in the UK to date, and suggests the burden of nosocomial SARS-CoV-2 infection has been underestimated. Nosocomial-infection occurred in older, frailer, and multi-morbid individuals, and was consistently associated with greater inpatient mortality than amongst those who were infected in the community across a spectrum of case-definitions. Our findings support implementation of enhanced infection control measures to reduce this burden during future waves, especially given the recent emergence of novel viral variants with enhanced transmissibility. Furthermore, roughly half of the patients meeting the Public Health Wales definition of definite nosocomial SARS-CoV-2 infection had been admitted for 30 days prior to diagnosis, highlighting a potential window of opportunity for inpatient pre-exposure and/or post-exposure prophylaxis.",Mark J Ponsford; Rhys Jefferies; Chris Davies; Daniel Farewell; Ian R Humphreys; Stephen Jolles; Sara Fairbairn; Keir Lewis; Daniel Menzies; Amit Benjamin; Favas Thaivalappil; Simon M Barry,https://medrxiv.org/cgi/content/short/2021.01.18.21249433,https://medrxiv.org/cgi/content/short/2021.01.18.21249433,2021-01-20,2021-01-20,,True
422,Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2,"SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 mutations found in the B.1.1.7 Spike protein. The vaccine sera exhibited a broad range of neutralizing titres against the wild-type pseudoviruses (<1:4 to 3449) that were reduced against B.1.1.7 variant by 3.85 fold (IQR 2.68-5.28). This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralization was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 outof 29), but not in neutralizing mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background led to a further loss of neutralizing activity by vaccine-elicited antibodies over that conferred by the B.1.1.7 mutations alone. Further work is needed to establish the impact of these observations on protective vaccine efficacy in the context of the evolving B.1.1.7 lineage that will likely acquire E484K.",Dami Collier; Anna De Marco; Isabella Ferreira; Bo Meng; Rawlings Datir; Alexandra C. Walls; Steven A. Kemp S; Jessica Bassi; Dora Pinto; Chiara Silacci Fregni; Siro Bianchi; M. Alejandra Tortorici; John Bowen; Katja Culap; Stefano Jaconi; Elisabetta Cameroni; Gyorgy Snell; Matteo S. Pizzuto; Alessandra Franzetti Pellanda; Christian Garzoni; Agostino Riva; - The CITIID-NIHR BioResource COVID-19 Collaboration; Anne Elmer; Nathalie Kingston; Barbara Graves; Laura McCoy; Ken Smith; John Bradley; James Thaventhiran J; Ceron Ceron-Gutierrez L; Gabriela Barcenas-Morales; Herbert W. Virgin; Antonio Lanzavecchia; Luca Piccoli; Rainer Doffinger; Mark Wills; David Veesler; Davide Corti; Ravindra Gupta,https://medrxiv.org/cgi/content/short/2021.01.19.21249840,https://medrxiv.org/cgi/content/short/2021.01.19.21249840,2021-01-20,2021-01-20,,True
423,"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study","BackgroundEffective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein vaccine produced in a baculovirus expression system. We present interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM vaccine with two different adjuvant formulations.

MethodsThis Phase I/II, randomised, double-blind study (NCT04537208) is being conducted in healthy, SARS-CoV-2-seronegative adults in the USA. Participants were stratified by age (18-49 and [&ge;]50 years) and randomised to receive one (on Day[D]1) or two doses (D1, D22) of placebo or candidate vaccine, containing: low-dose (LD, effective dose 1.3 {micro}g) or high-dose (HD, 2.6 {micro}g) antigen with adjuvant AF03 (Sanofi Pasteur) or AS03 (GlaxoSmithKline); or unadjuvanted HD (18-49 years only). Safety was assessed up to D43. SARS-CoV-2 neutralising and binding antibody profiles were assessed in D1, D22 and D36 serum samples.

FindingsThe interim safety analyses included 439/441 randomised participants. There were no related unsolicited immediate AEs, serious AEs, medically attended AEs classified as severe, or AE of special interest. More grade 3 solicited reactions were reported than expected after the second dose in the adjuvanted vaccine groups. Neutralising and binding antibody responses after two vaccine doses were higher in adjuvanted versus unadjuvanted groups, in AS03-versus AF03-adjuvanted groups, in HD versus LD groups, and in younger versus older age strata.

InterpretationThe lower than expected immune responses, especially in the older age stratum, and the higher than anticipated reactogenicity post dose 2 were likely due to a higher than anticipated host cell protein content and lower than planned antigen dose in the clinical material. Further development of the AS03-adjuvanted candidate vaccine will focus on identifying the optimal antigen formulation and dose.",Paul A Goepfert; Bo Fu; Anne-Laure Chabanon; Matthew I Bonaparte; Matthew G Davis; Brandon J Essink; Ian Frank; Owen Haney; Helene Janosczyk; Michael C Keefer; Marguerite Koutsoukos; Murray A Kimmel; Roger Masotti; Stephen J Savarino; Lode Schuerman; Howard Schwartz; Lawrence D Sher; Jon Smith; Fernanda Tavares-Da-Silva; Sanjay Gurunathan; Carlos A DiazGranados; Guy DeBruyn,https://medrxiv.org/cgi/content/short/2021.01.19.20248611,https://medrxiv.org/cgi/content/short/2021.01.19.20248611,2021-01-20,2021-01-20,,True
424,"A comprehensive antigen production and characterization study for easy-to-implement, highly specific and quantitative SARS-CoV-2 antibody assays","Antibody tests are essential tools to investigate humoral immunity following SARS-CoV-2 infection. While first-generation antibody tests have primarily provided qualitative results with low specificity, accurate seroprevalence studies and tracking of antibody levels over time require highly specific, sensitive and quantitative test setups. Here, we describe two quantitative ELISA antibody tests based on the SARS-CoV-2 spike receptor-binding domain and the nucleocapsid protein. Comparative expression in bacterial, insect, mammalian and plant-based platforms enabled the identification of new antigen designs with superior quality and high suitability as diagnostic reagents. Both tests scored excellently in clinical validations with multi-centric specificity and sensitivity cohorts and showed unprecedented correlation with SARS-CoV-2 neutralization titers. Orthogonal testing increased assay specificity to 99.8%, thereby enabling robust serodiagnosis in low-prevalence settings. The inclusion of a calibrator permits accurate quantitative monitoring of antibody concentrations in samples collected at different time points during the acute and convalescent phase of COVID-19.",Miriam Klausberger; Mark Duerkop; Helmuth Haslacher; Gordana Wozniak-Knopp; Monika Cserjan-Puschmann; Thomas Perkmann; Nico Lingg; Patricia Pereira Aguilar; Elisabeth Laurent; Jelle De Vos; Manuela Hofer; Barbara Holzer; Maria Stadler; Gabriele Manhart; Klemens Vierlinger; Margot Egger; Lisa Milchram; Elisabeth Gludovacz; Nicolas Marx; Christoph Koeppl; Christopher Tauer; Juergen Beck; Daniel Maresch; Clemens Gruenwald-Gruber; Florian Strobl; Peter Satzer; Gerhard Stadlmayr; Ulrike Vavra; Jasmin Huber; Markus Wahrmann; Farsad Eskandary; Marie-Kathrin Breyer; Daniela Sieghart; Peter Quehenberger; Gerda Leitner; Robert Strassl; Alexander E Egger; Christian Irsara; Andrea Griesmacher; Gregor Hoermann; Guenter Weiss; Rosa Bellmann-Weiler; Judith Loeffler-Ragg; Nicole Borth; Richard Strasser; Alois Jungbauer; Rainer Hahn; Juergen Mairhofer; Boris Hartmann; Nikolaus B Binder; Gerald Striedner; Lukas Mach; Andreas Weinhaeusl; Benjamin Dieplinger; Florian Grebien; Wilhelm Gerner; Christoph J Binder; Reingard Grabherr,https://medrxiv.org/cgi/content/short/2021.01.19.21249921,https://medrxiv.org/cgi/content/short/2021.01.19.21249921,2021-01-20,2021-01-20,,True
425,Diagnosis of SARS-Cov-2 infection using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis,"BackgroundThe rapid and accurate testing of SARS-CoV-2 infection is still crucial to mitigate, and eventually halt, the spread of this disease. Currently, nasopharyngeal swab (NPS) and oropharyngeal swab (OPS) are the recommended standard sampling, yet, with some limitations. Several specimens that are easier to collect are being tested as alternatives to nasal/throat swabs in nucleic acid assays for SARS-CoV-2 detection. This study aims to critically appraise and compare the clinical performance of RT-PCR tests using oral saliva, deep-throat saliva/ posterior oropharyngeal saliva (DTS/POS), sputum, urine, feces, and tears/conjunctival swab [CS]) against standard specimens (NPS, OPS, or a combination of both).

MethodsIn this systematic review and meta-analysis, five databases (PubMed, Scopus, Web of Science, ClinicalTrial.gov and NIPH Clinical Trial) were searched up to the 30th of December 2020. Case-control and cohort studies on the detection of SARS-CoV-2 were included. Methodological quality was assessed through the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS 2).

FindingsWe identified 3022 entries, 33 of which (1.1%) met all required criteria and were included for the quantitative data analysis. Saliva presented the higher accuracy, 92.1% (95% CI: 70.0-98.3), with an estimated sensitivity of 83.9% (95% CI: 77.4-88.8) and specificity of 96.4% (95% CI: 89.5-98.8). DTS/POS samples had an overall accuracy of 79.7% (95% CI: 43.3-95.3), with an estimated sensitivity of 90.1% (95% CI: 83.3-96.9) and specificity of 63.1% (95% CI: 36.8-89.3). Remaining index specimens presented uncertainty given the lack of studies available.

InterpretationOur meta-analysis shows that saliva samples from oral region provide a high sensitivity and specificity, being the best candidate as an alternative specimen to NPS/OPS for COVID-19 detection, with suitable protocols for swab-free sample collection to be determined and validated in the future. The distinction between oral and extra-oral salivary samples will be crucial since DTS/POS samples may induce a higher rate of false positives. Urine, feces, tears/CS and sputum seem unreliable for diagnosis. Saliva testing may increase testing capacity, ultimately promoting the implementation of truly deployable COVID-19 tests, which could either work at the point-of-care (e.g. hospitals, clinics) or outbreak control spots (e.g. schools, airports, and nursing homes).

FundingNothing to declare.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSThe lack of systematized data on the accuracy performance of alternative specimens for the detection of SARS-CoV-2 (against the standard NPS/OPS). The ever-growing number of studies available, made this updated systematic review timely and of the utmost importance

Added value of this studyOur meta-analysis shows that saliva samples from the oral region provide a high sensitivity and specificity, being the best candidate as an alternative specimen to NPS/OPS for COVID-19 detection, with suitable protocols for swab-free sample collection to be determined and validated in the future. The distinction between oral and extra-oral salivary samples will be crucial since DTS/POS samples may induce a higher rate of false positives.

Implications of all the available evidenceSaliva samples simply taken from the oral cavity are promising alternatives to the currently used nasal/throat swabs. Saliva specimens can be self-collected, mitigate the discomfort caused by sampling, reduce the transmission risk and increase testing capacity. Therefore, the validation of this alternative specimen will promote the implementation of truly deployable rapid tests for SARS-CoV-2 detection at the point-of-care or outbreak spots.",Vania M. Moreira; Paulo Mascarenhas; Vanessa Machado; Joao Botelho; Jose Joao Mendes; Nuno Taveira; Maria Gabriela Almeida,https://medrxiv.org/cgi/content/short/2021.01.19.21250094,https://medrxiv.org/cgi/content/short/2021.01.19.21250094,2021-01-20,2021-01-20,,True
426,"Immunisation, asymptomatic infection, herd immunity and the new variants of COVID-19","ObjectivesIs ""herd immunity"" to COVID-19 a realistic outcome of any immunisation programme with the two main vaccines currently licenced in the UK (Pfizer vaccine BNT162b2 and Astra Zeneca/Oxford vaccine ChAdOx1-S)? More formally, can these vaccines achieve a sufficient level of population immunity to reduce R, the reproduction number of the infection, to below one in the absence of any non-pharmaceutical interventions?

DesignThe study uses simple mathematical models of the transmission of COVID-19 infection from primary to secondary cases parameterised using data on virus transmission and vaccine efficacy from the literature and the regulatory approval process for the vaccines.

ResultsIn the regulatory approval documents, the efficacy of the Pfizer vaccine is estimated at 0.948 (that for the Moderna vaccine is similar). Efficacy for the Oxford vaccine against primary symptomatic illness is estimated as 0.704, based on pooling of data from two dose regimes. For values of R0 similar to those reported during the first months of the pandemic, the simplest analysis implies that reducing the value of R below 1 would require 69% and 93% of the population to be vaccinated with the Pfizer and Oxford vaccine respectively (or achieve a comparable level of immunity through natural infection). However, the new variant of COVID-19 (Lineage B.1.1.7, named Variant of Concern VOC-202012/01) is reported to have an R-value 1.56 (0.92 to 2.28) times higher than the original strain. Vaccinating the entire population with the Oxford vaccine would only reduce the R value to 1.325 while the Pfizer vaccine would require 82% of the population to be vaccinated to control the spread of the new variant.

The Oxford vaccine reduces the incidence of serious illness to a greater extent than it reduces symptomatic illness. But its efficacy against the incidence of asymptomatic infections is lower, reducing its efficacy against all infection from 0.704 to 0.525 for the pooled data. Although asymptomatics are less infectious, including them in our calculations still raises R values by 20% or more, from 1.33 to 1.6 for the new variant with 100% vaccination. Neither vaccine is licenced for use in children, and when this is taken into account, this R value rises by a further 37% to 2.2 if the whole adult population is vaccinated. Even the more effective mRNA vaccines may allow the pandemic to persist via transmission amongst children, as current authorisations only allow their use on adults. In the absence of vaccination, R will reduce to 1 when 89% of the population has acquired immunity as a result of previous infection with COVID-19.

ConclusionsAll currently licensed vaccines provide substantial protection against serious illness to vaccinated individuals themselves. But the Oxford vaccine appears to have relatively low efficacy against asymptomatic infections. Although no comparable data from human trials are available for the mRNA vaccines, non-human primate studies suggest they are better at preventing nasal shedding and so transmission. Herd immunity to COVID-19 will be very difficult to achieve, especially so for the less effective vaccine. The possibility of transmission from vaccinated but infected individuals to vulnerable unvaccinated individuals is of serious concern. There is a strong case for preferring the more effective mRNA vaccines for health and social care workers and those who have contact with large numbers of vulnerable others.",Alastair Grant; Paul R Hunter,https://medrxiv.org/cgi/content/short/2021.01.16.21249946,https://medrxiv.org/cgi/content/short/2021.01.16.21249946,2021-01-20,2021-01-20,,True
427,"Seroepidemiological Study of Novel Corona Virus (CoVID-19) in Tehran, Iran","A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread to all countries of the world, including Iran. Although new anti-coronavirus antibodies in patients may be identified by immunological methods with sufficient sensitivity and specificity, the conclusive diagnosis of the disease is by the molecular RT-PCR process. We used a population-based seroepidemiological survey to quantify the proportion of the exposed population with SARS-CoV-2 antibodies and evaluated whether the antibodies are a marker of total or partial immunity to the proportion of the population that remains susceptible to the virus. This cross-sectional study was conducted to investigate the seroprevalence of CoVID-19 in Tehran, the capital of Iran, between April and end of October 2020. Specimens of clotted and heparinized blood (2ml) were collected from the patients. The serum and plasma were separated and stored at - 80LJ{degrees}C until use. We examined serum anti-SARS-CoV-2 IgG and IgM antibodies from 1375 in-patients admitted to our hospitals using ELISA kits. In total, 1375 participants were enrolled in this study, and SARS-CoV-2 antibodies were detected using IgM-IgG antibody assay in 291 patients. Among the seropositive patients studied, 187 were men (64.3%), and 104 were women (35.7%) (P<0.05). The mean age of the patients was 49{+/-}8.4 years; the majority (27%) were in age group 31-40 years. Also, the lowest frequency of cases was reported in the age group of 1-10 years (P <0.05). We determined the seroprevalence of SARS-CoV-2 for IgM or IgG antibodies to be 21.2%. Diabetes mellitus was the most common underlying disease among SARS-CoV-2 patients [P=0.05; Odd Ratio=1.61(0.90-2.91)]. Conventional serological assays in SARS-CoV-2 cases, such as the enzyme-linked immunoassay (ELISA) for specific IgM and IgG antibodies, have a high-throughput advantage and minimize false-negative rates that occur with the RT-PCR method. This study determined the seroprevalence of SARS-CoV-2 antibodies to be 21%. Control of diabetes among other cases factors shall play important role in management and control of COVID-19.",Zeinab Tabanejad; Sorena Darvish; Zeinab Borjian Boroujeni; Seyed Saeed Asadi; Morteza Mesri; Omid Raiesi; Muhammad Ibrahim Getso; Mahdi Zareei,https://medrxiv.org/cgi/content/short/2021.01.18.20248911,https://medrxiv.org/cgi/content/short/2021.01.18.20248911,2021-01-20,2021-01-20,,True
428,"Factors associated with COVID-19 related hospitalisation, critical care admission and mortality using linked primary and secondary care data","BackgroundTo identify risk factors associated with increased risk of hospitalisation, intensive care unit (ICU) admission and mortality in inner North East London (NEL) during the first UK COVID-19 wave.

MethodsMultivariate logistic regression analysis on linked primary and secondary care data from people aged 16 or older with confirmed COVID-19 infection between 01/02/2020-30/06/2020 determined odds ratios (OR), 95% confidence intervals (CI) and p-values for the association between demographic, deprivation and clinical factors with COVID-19 hospitalisation, ICU admission and mortality.

ResultsOver the study period 1,781 people were diagnosed with COVID-19, of whom 1,195 (67%) were hospitalised, 152 (9%) admitted to ICU and 400 (23%) died. Results confirm previously identified risk factors: being male, or of Black or Asian ethnicity, or aged over 50. Obesity, type 2 diabetes and chronic kidney disease (CKD) increased the risk of hospitalisation. Obesity increased the risk of being admitted to ICU. Underlying CKD, stroke and dementia in-creased the risk of death. Having learning disabilities was strongly associated with increased risk of death (OR=4.75, 95%CI=(1.91,11.84), p=0.001). Having three or four co-morbidities increased the risk of hospitalisation (OR=2.34,95%CI=(1.55,3.54),p<0.001;OR=2.40, 95%CI=(1.55,3.73), p<0.001 respectively) and death (OR=2.61, 95%CI=(1.59,4.28), p<0.001;OR=4.07, 95% CI= (2.48,6.69), p<0.001 respectively).

ConclusionsWe confirm that age, sex, ethnicity, obesity, CKD and diabetes are important determinants of risk of COVID-19 hospitalisation or death. For the first time, we also identify people with learning disabilities and multi-morbidity as additional patient cohorts that need to be actively protected during COVID-19 waves.",Lisa Cummings; Irene Ebyarimpa; Nathan Cheetham; Victoria Tzortziou Brown; Katie Brennan; Jasmina Panovska-Griffiths,https://medrxiv.org/cgi/content/short/2021.01.19.20241844,https://medrxiv.org/cgi/content/short/2021.01.19.20241844,2021-01-20,2021-01-20,,True
429,Epidemic waves of COVID-19 in Scotland: a genomic perspective on the impact of the introduction and relaxation of lockdown on SARS-CoV-2,"The second SARS virus, SARS-CoV-2, emerged in December 2019, and within a month was globally distributed. It was first introduced into Scotland in February 2020 associated with returning travellers and visitors. By March it was circulating in communities across the UK, and to control COVID-19 cases, and prevent overwhelming of the National Health Service (NHS), a  lockdown was introduced on 23rd March 2020 with a restriction of peoples movements. To augment the public health efforts a large-scale genome epidemiology effort (as part of the COVID-19 Genomics UK (COG-UK) consortium) resulted in the sequencing of over 5000 SARS-CoV-2 genomes by 18th August 2020 from Scottish cases, about a quarter of the estimated number of cases at that time. Here we quantify the geographical origins of the first wave introductions into Scotland from abroad and other UK regions, the spread of these SARS-CoV-2 lineages to different regions within Scotland (defined at the level of NHS Health Board) and the effect of lockdown on virus  success. We estimate that approximately 300 introductions seeded lineages in Scotland, with around 25% of these lineages composed of more than five viruses, but by June circulating lineages were reduced to low levels, in line with low numbers of recorded positive cases. Lockdown was, thus, associated with a dramatic reduction in infection numbers and the extinguishing of most virus lineages. Unfortunately since the summer cases have been rising in Scotland in a second wave, with >1000 people testing positive on a daily basis, and hospitalisation of COVID-19 cases on the rise again. Examining the available Scottish genome data from the second wave, and comparing it to the first wave, we find that while some UK lineages have persisted through the summer, the majority of lineages responsible for the second wave are new introductions from outside of Scotland and many from outside of the UK. This indicates that, while lockdown in Scotland is directly linked with the first wave case numbers being brought under control, travel-associated imports (mostly from Europe or other parts of the UK) following the easing of lockdown are responsible for seeding the current epidemic population. This demonstrates that the impact of stringent public health measures can be compromised if following this, movements from regions of high to low prevalence are not minimised.",Samantha J Lycett; Joseph Hughes; Martin P McHugh; Ana Da Silva Filipe; Rebecca Dewar; Lu Lu; Thomas Doherty; Amy Shepherd; Rhys Inward; Gianluigi Rossi; Daniel Balaz; Rowland R Kao; Stefan Rooke; Seb Cotton; Michael D Gallagher; Carlos E Balcazar-Lopez; Aine O'Toole; Emily Scher; Verity Hill; John T McCrone; Rachel M Colquhoun; Ben Jackson; Thomas C Williams; Kathleen A Williamson; Natasha Johnson; Katherine Smollett; Daniel Mair; Stephen Carmichael; Lily Tong; Jenna Nichols; Kirstyn Brunker; James G Shepherd; Kathy Li; Elihu Aranday-Cortes; Yasmin A Parr; Alice Broos; Kyriaki Nomikou; Sarah E McDonald; Marc Niebel; Patawee Asamaphan; Igor Starinskij; Natasha Jesudason; Rajiv Shah; Vattipally B Sreenu; Tom Stanton; Sharif Shaaban; Alasdair MacLean; - The COVID-19 Genomics UK (COG-UK) consortium; Mark Woolhouse; Rory Gunson; Kate Templeton; Emma C Thomson; Andrew Rambaut; Matthew TG Holden; David L Robertson,https://medrxiv.org/cgi/content/short/2021.01.08.20248677,https://medrxiv.org/cgi/content/short/2021.01.08.20248677,2021-01-20,2021-01-20,,True
430,"Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru.","BackgroundDetection of SARS-CoV-2 antibodies among people at risk is critical for understanding both the prior transmission of COVID-19 and vulnerability of the population to the continuing transmission and, when done serially, the intensity of ongoing transmission over an interval in a community. In this study, we estimated the seroprevalence of COVID-19 in a representative population-based cohort of Iquitos, one of the regions with the highest mortality rates from COVID-19 in Peru, where a devastating number of cases occurred in March 2020.

MethodsWe conducted a population-based study of transmission tested each participant using the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech and used survey analysis methods to estimate seroprevalence accounting for the sampling design effect and test performance characteristics. Here we report results from the baseline (13 to 18 July 2020) and the first month of follow-up (13 to 18 August 2020) study.

FindingsWe enrolled a total of 716 participants and estimated seroprevalence of 70.0% (95% CI: 67.0%-73.4%), a test-re-test positivity of 65% (95% CI: 61.0%-68.3%), and an incidence of new exposures of 1.8% (95% CI: 0.9%-3.2%) data that suggest that transmission is ongoing but is occurring at low levels. We observed significant differences in the seroprevalence between age groups, with participants 18 to 29 years of age having lower seroprevalence than children <12 years of age (Prevalence ratio =0.85 [PR]; 95% CI: 0.73 - 0.98), suggesting that children were not refractory to infection in this setting.

InterpretationIquitos demonstrates one of the highest rates of seroprevalence of COVID-19 worldwide. Current data shows a limited case burden in Iquitos for the past seven months and suggests that these levels are sufficient to provide significant but incomplete herd immunity.

FundingDireccion Regional de Salud de Loreto, DIRESA, Loreto, Peru",Carlos Alvarez-Antonio; Graciela Meza-Sanchez; Carlos Calampa; Wilma Casanova; Cristiam Carey; Freddy Alava; Hugo Rodriguez-Ferrucci; Antonio Marty Quispe,https://medrxiv.org/cgi/content/short/2021.01.17.21249913,https://medrxiv.org/cgi/content/short/2021.01.17.21249913,2021-01-20,2021-01-20,,True
431,Incidence and Relative Risk of infection with SARS-CoV-2 virus (Covid-19) in European Soccer Players.,The purpose of the present study was to investigate the incidence and relative risk of infection Covid-virus in soccer players. Data from five leagues was used and compared to data from the normal population in each country. Our results revealed that the relative risk was higher in soccer players in three countries when correcting for the estimated true number of infected people in the populations. We discuss that the reason for the higher incidence in soccer players is caused by the virus entering a group of players that work closely together.,Thomas Bull Andersen; Andreas Busk Dahl; Jeppe Bjerregaard Carstensen,https://medrxiv.org/cgi/content/short/2021.01.19.21250085,https://medrxiv.org/cgi/content/short/2021.01.19.21250085,2021-01-20,2021-01-20,,True
432,Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.",Drishya Kurup; Delphine C Malherbe; Christoph Wirblich; Rachael Lambert; Adam Ronk; Leila Zabihi Diba; Alexander Bukreyev; Matthias J. Schnell,https://biorxiv.org/cgi/content/short/2021.01.19.427373,https://biorxiv.org/cgi/content/short/2021.01.19.427373,2021-01-20,2021-01-20,,False
433,Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts,"Analysis of SARS-CoV-2 genetic diversity within infected hosts can provide insight into the generation and spread of new viral variants and may enable high resolution inference of transmission chains. However, little is known about temporal aspects of SARS-CoV-2 intrahost diversity and the extent to which shared diversity reflects convergent evolution as opposed to transmission linkage. Here we use high depth of coverage sequencing to identify within-host genetic variants in 325 specimens from hospitalized COVID-19 patients and infected employees at a single medical center. We validated our variant calling by sequencing defined RNA mixtures and identified a viral load threshold that minimizes false positives. By leveraging clinical metadata, we found that intrahost diversity is low and does not vary by time from symptom onset. This suggests that variants will only rarely rise to appreciable frequency prior to transmission. Although there was generally little shared variation across the sequenced cohort, we identified intrahost variants shared across individuals who were unlikely to be related by transmission. These variants did not precede a rise in frequency in global consensus genomes, suggesting that intrahost variants may have limited utility for predicting future lineages. These results provide important context for sequence-based inference in SARS-CoV-2 evolution and epidemiology.",Andrew L. Valesano; Kalee E. Rumfelt; Derek E. Dimcheff; Christopher N. Blair; William J. Fitzsimmons; Joshua G. Petrie; Emily Toth Martin; Adam S. Lauring,https://biorxiv.org/cgi/content/short/2021.01.19.427330,https://biorxiv.org/cgi/content/short/2021.01.19.427330,2021-01-20,2021-01-20,,False
434,COVID-19: making the best out of a forced transition to online medical teaching. A mixed methods study,"Introductionthe COVID-19 pandemic resulted in a decreed confinement in our country from March until the end of term in June 2020. This forced a transition exclusively to distance learning. The aim of this study was to broaden the understanding of fully online distance learning from the experiences of undergraduate medical students and faculty members during confinement, and identify its key elements.

MethodsA convergent mixed methods study analyzing: (a) an online teaching follow- up program, (b) two focus groups and a nominal group with students and faculty, respectively, and (c) a survey with students from 1st to 5th year.

ResultsThirteen strongly interconnected categories were identified. Four played an organizational role: course planning, coordination, communication and pedagogical coherence. The remaining nine categories were: learning outcomes, teaching methodology, online resources, evaluation, time management, workload, student motivation, participation, and teacher-student relationship. Among the key aspects of learning were those that promoted rapport between faculty and students, such as synchronous sessions, especially those based on clinical cases.

Conclusionthe experiences from confinement allowed us to gain insight into some of the key aspects of online medical teaching. Promoting student motivation and participation at all levels was essential to distance learning in Medicine.",Montserrat Virumbrales; Marta Elorduy; Mariona Graell; Pau Mezquita; Pedro Brotons; Albert Balaguer,https://medrxiv.org/cgi/content/short/2021.01.19.21249790,https://medrxiv.org/cgi/content/short/2021.01.19.21249790,2021-01-20,2021-01-20,,True
435,Modelling pooling strategies for SARS-CoV-2 testing in a university setting,"Pre-symptomatic and asymptomatic transmission of SARS-CoV-2 are important elements in the Covid-19 pandemic, and until vaccines are made widely available there remains a reliance on testing to manage the spread of the disease, alongside non-pharmaceutical interventions such as measures to reduce close social interactions. In the UK, many universities opened for blended learning for the 2020-2021 academic year, with a mixture of face to face and online teaching. In this study we present a simulation framework to evaluate the effectiveness of different asymptomatic testing strategies within a university setting, across a range of transmission scenarios. We show that when positive cases are clustered by known social structures, such as student households, the pooling of samples by these social structures can substantially reduce the total cost of conducting RT-qPCR tests. We also note that routine recording of quantitative RT-qPCR results would facilitate future modelling studies.",Gibran Hemani; Amy C Thomas; Josephine G Walker; Adam Trickey; Emily Nixon; David Ellis; Rachel Kwiatkowska; Caroline Relton; Leon Danon; Hannah Christensen; Ellen Brooks-Pollock,https://medrxiv.org/cgi/content/short/2021.01.19.20248560,https://medrxiv.org/cgi/content/short/2021.01.19.20248560,2021-01-20,2021-01-20,,True
436,"Coevolutionary Analysis and Perturbation-Based Network Modeling of the SARS-CoV-2 Spike Protein Complexes with Antibodies: Binding-Induced Control of Dynamics, Allosteric Interactions and Signaling","The structural and biochemical studies of the SARS-CoV-2 spike glycoproteins and complexes with highly potent antibodies have revealed multiple conformation-dependent epitopes highlighting the link between conformational plasticity of spike proteins and capacity for eliciting specific binding and broad neutralization responses. In this study, we used coevolutionary analysis, molecular simulations, and perturbation-based hierarchical network modeling of the SARS-CoV-2 S complexes with H014, S309, S2M11 and S2E12 antibodies targeting distinct epitopes to explore molecular mechanisms underlying binding-induced modulation of dynamics, stability and allosteric signaling in the spike protein trimers. The results of this study revealed key regulatory centers that can govern allosteric interactions and communications in the SARS-CoV-2 spike proteins. Through coevolutionary analysis of the SARS-CoV-2 spike proteins, we identified highly coevolving hotspots and functional clusters forming coevolutionary networks. The results revealed significant coevolutionary couplings between functional regions separated by the medium-range distances which may help to facilitate a functional cross-talk between distant allosteric regions in the SARS-CoV-2 spike complexes with antibodies. We also discovered a potential mechanism by which antibody-specific targeting of coevolutionary centers can allow for efficient modulation of allosteric interactions and signal propagation between remote functional regions. Using a hierarchical network modeling and perturbation-response scanning analysis, we demonstrated that binding of antibodies could leverage direct contacts with coevolutionary hotspots to allosterically restore and enhance couplings between spatially separated functional regions, thereby protecting the spike apparatus from membrane fusion. The results of this study also suggested that antibody binding can induce a switch from a moderately cooperative population-shift mechanism, governing structural changes of the ligand-free SARS-CoV-2 spike protein, to antibody-induced highly cooperative mechanism that can better withstand mutations in the functional regions without significant deleterious consequences for protein function. This study provides a novel insight into allosteric regulatory mechanisms of SARS-CoV-2 S proteins, showing that antibodies can modulate allosteric interactions and signaling of spike proteins, providing a plausible strategy for therapeutic intervention by targeting specific hotspots of allosteric interactions in the SARS-CoV-2 proteins.",Gennady Verkhivker; Luisa Di Paola,https://biorxiv.org/cgi/content/short/2021.01.19.427320,https://biorxiv.org/cgi/content/short/2021.01.19.427320,2021-01-20,2021-01-20,,False
437,Estimating dates of origin and end of COVID-19 epidemics,"Estimating the date at which an epidemic started in a country and the date at which it can end depending on interventions intensity are important to guide public health responses. Both are potentially shaped by similar factors including stochasticity (due to small population sizes), super-spreading events, and memory effects. Focusing on COVID-19 epidemics, we develop and analyse mathematical models to explore how these three factors may affect early and final epidemic dynamics. Regarding the date of origin, we find limited effects on the mean estimates, but strong effects on their variances. Regarding the date of extinction following lock-down onset, mean values decrease with stochasticity or with the presence of superspreading events. These results underline the importance of accounting for heterogeneity in infection history and transmission patterns to make accurate predictions regarding epidemic temporal estimates.",Thomas Beneteau; Baptiste Elie; Mircea T Sofonea; Samuel Alizon,https://medrxiv.org/cgi/content/short/2021.01.19.21250080,https://medrxiv.org/cgi/content/short/2021.01.19.21250080,2021-01-20,2021-01-20,,True
438,Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein,"Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike (S) protein receptor-binding domain and block virus interactions with the cellular receptor angiotensin-converting enzyme 2. We describe a panel of human mAbs binding to diverse epitopes on the N-terminal domain (NTD) of S protein from SARS-CoV-2 convalescent donors and found a minority of these possessed neutralizing activity. Two mAbs (COV2-2676 and COV2-2489) inhibited infection of authentic SARS-CoV-2 and recombinant VSV/SARS-CoV-2 viruses. We mapped their binding epitopes by alanine-scanning mutagenesis and selection of functional SARS-CoV-2 S neutralization escape variants. Mechanistic studies showed that these antibodies neutralize in part by inhibiting a post-attachment step in the infection cycle. COV2-2676 and COV2-2489 offered protection either as prophylaxis or therapy, and Fc effector functions were required for optimal protection. Thus, natural infection induces a subset of potent NTD-specific mAbs that leverage neutralizing and Fc-mediated activities to protect against SARS-CoV-2 infection using multiple functional attributes.",Naveenchandra Suryadevara; Swathi Shrihari; Pavlo Gilchuk; Laura VanBlargan; Elad Binshtein; Seth Zost; Rachel Nargi; Rachel Sutton; Emma S Winkler; Elaine C Chen; Mallorie E. Fouch; Edgar Davidson; Benjamin Doranz; Robert H Carnahan Jr.; Larissa Thackray; Michael D Diamond; James E. Crowe,https://biorxiv.org/cgi/content/short/2021.01.19.427324,https://biorxiv.org/cgi/content/short/2021.01.19.427324,2021-01-20,2021-01-20,,False
439,A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering,"A ""universal"" vaccine design platform that can rapidly generate multiplex vaccine candidates is critically needed to control future pandemics. Here, using SARS-CoV-2 pandemic virus as a model, we have developed such a platform by CRISPR engineering of bacteriophage T4. A pipeline of vaccine candidates were engineered by incorporating various viral components into appropriate compartments of phage nanoparticle structure. These include: expressible spike genes in genome, spike and envelope epitopes as surface decorations, and nucleocapsid proteins in packaged core. Phage decorated with spike trimers is found to be the most potent vaccine candidate in mouse and rabbit models. Without any adjuvant, this vaccine stimulated robust immune responses, both TH1 and TH2 IgG subclasses, blocked virus-receptor interactions, neutralized viral infection, and conferred complete protection against viral challenge. This new type of nanovaccine design framework might allow rapid deployment of effective phage-based vaccines against any emerging pathogen in the future.",Not available,https://biorxiv.org/cgi/content/short/2021.01.19.427310,https://biorxiv.org/cgi/content/short/2021.01.19.427310,2021-01-20,2021-01-20,,False
440,Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible SARS-CoV-2 variants' spike protein,"Two SARS-CoV-2 variants showing increased transmissibility relative to the Wuhan virus have recently been identified. Although neither variant causes more severe illness or increased risk of death, the faster spread of the virus is a major threat. Using computational tools, we found that the new SARS-CoV-2 variants may acquire an increased transmissibility by increasing the propensity of its spike protein to expose the receptor binding domain. This information leads to the identification of potential treatments to avert the imminent threat of these more transmittable SARS-CoV-2 variants.

TeaserThe more infective SARS-CoV-2 variants may expose its Achilles Heel - an opportunity to reduce their spreading.",Benjamin R Kraemer; Daria Mochly-Rosen; Suman Pokhrel; Lucia Lee; Kate Samardzic,https://biorxiv.org/cgi/content/short/2021.01.19.427355,https://biorxiv.org/cgi/content/short/2021.01.19.427355,2021-01-20,2021-01-20,,False
441,Evaluation of the effects of SARS-CoV-2 genetic mutations on diagnostic RT-PCR assays,"Several mutant strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are emerging. Mismatch(es) in primer/probe binding regions would decrease the detection sensitivity of the PCR test, thereby affecting the results of clinical testing. In this study, we conducted an in silico survey on SARS-CoV-2 sequence variability within the binding regions of primer/probe published by the Japan National Institute of Infectious Diseases (NIID) and Centers for Disease Control and Prevention (CDC). In silico analysis revealed the presence of mutations in the primer/probe binding regions. We performed RT-PCR assays using synthetic RNAs containing the mutations and showed that some mutations significantly decreased the detection sensitivity of the RT-PCR assays.

Our results highlight the importance of genomic monitoring of SARS-CoV-2 and evaluating the effects of mismatches on PCR testing sensitivity.",Takeru Nakabayashi; Yuki Kawasaki; Koichiro Murashima; Kazuya Omi; Satoshi Yuhara,https://biorxiv.org/cgi/content/short/2021.01.19.426622,https://biorxiv.org/cgi/content/short/2021.01.19.426622,2021-01-20,2021-01-20,,False
442,Use Of Canine Olfactory Detection For COVID-19 Testing Study On U.A.E. Trained Detection Dog Sensitivity,"This study aimed to evaluate the sensitivity of 21 dogs belonging to different United Arab Emirates (UAE) Ministry of Interior (MOI), trained for COVID-19 olfactory detection.

The study involved 17 explosives detection dogs, two cadaver detection dogs and two dogs with no previous detection training. Training lasted two weeks before starting the validation protocol. Sequential five and seven-cone line-ups were used with axillary sweat samples from symptomatic COVID-19 individuals (SARS-CoV-2 PCR positive) and from asymptomatic COVID-19 negative individuals (SARS-CoV-2 PCR negative). A total of 1368 trials were performed during validation, including 151 positive and 110 negative samples. Each line-up had one positive sample and at least one negative sample. The dog had to mark the positive sample, randomly positioned behind one of the cones. The dog, handler and data recorder were blinded to the positive sample location.

The calculated overall sensitivities were between 71% and 79% for three dogs, between83% and 87% for three other dogs, and equal to or higher than 90% for the remaining 15 dogs (more than two thirds of the 21 dogs).

After calculating the overall sensitivity for each dog using all line-ups, ""matched"" sensitivities were calculated only including line-ups containing COVID-19 positive and negative samples strictly comparable on confounding factors such as diabetes, anosmia, asthma, fever, body pain, diarrhoea, sex, hospital, method of sweat collection and sampling duration. Most of the time, the sensitivities increased after matching.

Pandemic conditions in the U.A.E., associated with the desire to use dogs as an efficient mass-pretesting tool has already led to the operational deployment of the study dogs.

Future studies will focus on comparatives fields-test results including the impact of the main COVID-19 comorbidities and other respiratory tract infections.",Dana H Al Marzooqi; Clothilde Lecoq-Julien; Hamad K Al Hammadi; Guillaume Alvergnat; Kalthoom M Al Blooshi; Salah K Al Mazrooei; Mohammed S Alhmoudi; Faisal M Al Ahbabi; Yasser S Mohammed; Nasser M Al Falasi; Noor M Almheiri; Sumaya M Al Blooshi; Quentin Muzzin; Loic Desquilbet,https://biorxiv.org/cgi/content/short/2021.01.20.427105,https://biorxiv.org/cgi/content/short/2021.01.20.427105,2021-01-20,2021-01-20,,False
443,GRP78 binds SARS-CoV-2 Spike protein and ACE2 and GRP78 depleting antibody blocks viral entry and infection in vitro,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the current COVID-19 global pandemic, utilizes the host receptor angiotensin-converting enzyme 2 (ACE2) for viral entry. However, other host factors may also play major roles in viral infection. Here we report that the stress-inducible molecular chaperone GRP78 can form a complex with the SARS-CoV-2 Spike protein and ACE2 intracellularly and on the cell surface, and that the substrate binding domain of GRP78 is critical for this function. Knock-down of GRP78 by siRNA dramatically reduced cell surface ACE2 expression. Treatment of lung epithelial cells with a humanized monoclonal antibody (hMAb159), selected for its ability to cause GRP78 endocytosis and its safe clinical profile in preclinical models, reduces cell surface ACE2 expression, SARS-CoV-2 Spike-driven viral entry, and significantly inhibits SARS-CoV-2 infection in vitro. Our data suggest that GRP78 is an important host auxiliary factor for SARS-CoV-2 entry and infection and a potential target to combat this novel pathogen and other viruses that utilize GRP78.",Anthony J Carlos; Dat P Ha; Da-Wei Yeh; Richard Van Krieken; Parkash Gill; Keigo Machida; Amy Lee,https://biorxiv.org/cgi/content/short/2021.01.20.427368,https://biorxiv.org/cgi/content/short/2021.01.20.427368,2021-01-20,2021-01-20,,False
444,Exploring overcrowding trends in an inner city emergence department in the UK before and during COVID-19 epidemic,"BackgroundWe compared impact of three pre-COVID-19 interventions and of the COVID-19 UK-epidemic and the first UK national lockdown on overcrowding within University College London Hospital Emergency Department (UCLH ED). The three interventions: target the influx of patients at ED (A), reduce the pressure on in-patients beds (B) and improve ED processes to improve the flow of patents out from ED (C).

MethodsWe analysed the change in overcrowding metrics (daily attendances, the proportion of people leaving within four hours of arrival (four-hours target) and the reduction in overall waiting time) across three analysis. The first analysis used data 01/04/2017-31/12-2019 to calculate changes over a period of six months before and after the start of interventions A-C. The second and third analyses focused on evaluating the impact of the COVID-19 epidemic, comparing the first 10 months in 2020 and 2019, and of the first national lockdown (23/03/2020-31/05/2020).

ResultsPre-COVID-19 all interventions led to small reductions in waiting time (17%, p<0.001 for A and C;9%, p=0.322 for B) but also to a small decrease in the number of patients leaving within four hours of arrival (6.6%,7.4%,6.2% respectively A-C,p<0.001).

In presence of the COVID-19 pandemic, attendance and waiting time were reduced (40% and 8%;p<0.001), and the number of people leaving within four hours of arrival was increased (6%,p<0.001). During the first lockdown, there was 65% reduction in attendance, 22% reduction in waiting time and 8% increase in number of people leaving within 4 hours of arrival (p<0.001). Crucially, when the lockdown was lifted, there was an increase (6.5%,p<0.001) in the percentage of people leaving within four hours, together with a larger (12.5%,p<0.001) decrease in waiting time. This occurred despite the increase of 49.6%(p<0.001) in attendance after lockdown ended.

ConclusionsThe mixed results pre-COVID-19 (significant improvements in waiting time with some interventions but not improvement in the four-hours target), may be due to a  spill-over effect where clogging up one part of the ED system affects other parts. Hence multifaceted interventions and a system-wide approach to improve the pathway of flow through the ED system is necessary.

During 2020 and in presence of the COVID-19 epidemic, a shift in public behaviour with anxiety over attending hospitals and higher use of virtual consultations, led to notable drop in UCLH ED attendance and consequential curbing of overcrowding.

Importantly, once the lockdown was lifted, although there was an increase in arrivals at UCLH ED, overcrowding metrics were reduced. Thus, the combination of shifted public behaviour and the restructuring changes during COVID-19 epidemic, maybe be able to curb future ED overcrowding, but longer timeframe analysis is required to confirm this.",Jasmina Panovska-Griffiths; Jack Ross; Samer Elkhodair; Christopher Baxter-Derrington; Chris Laing; Rosalind Raine,https://medrxiv.org/cgi/content/short/2021.01.20.21250150,https://medrxiv.org/cgi/content/short/2021.01.20.21250150,2021-01-20,2021-01-20,,True
445,Sleep in Frontline Healthcare Workers on Social Media During the COVID-19 Pandemic,"ImportanceDuring the pandemic, healthcare workers on social media are sharing their challenges, including sleep disturbances.

ObjectiveTo assess sleep using validated measures among frontline healthcare workers on social media

DesignA self-selection survey was distributed on Facebook, Twitter, and Instagram for 16 days (August 31-September 15, 2020) targeting healthcare workers (HCW) who were clinically active during the pandemic. Study participants completed the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), and reported demographic/career information. Poor sleep quality was defined as PSQI>5. Moderate-to-severe insomnia was defined as an ISI>14. The mini-Z was used to measure burnout. Multivariate logistic regression tested associations between demographics, career characteristics, and sleep outcomes.

SettingOnline self-selection survey on social media

Participants963 surveys were completed. Participants were predominantly White (92.8%), female (73.4%), aged 30-49 (71.9%), and physicians (64.4%). Mean sleep duration was 6.1 (SD 1.2) hours. Nearly 90% reported poor sleep (PSQI). One third (33.0%) reported moderate or severe insomnia. Many (60%) experienced sleep disruptions due to device usage or had bad dreams at least once per week (45%). Over 50% reported burnout. In multivariable logistic regressions, non-physician (OR 2.4; CI: 1.7, 3.4), caring for COVID-19 patients (OR 1.8; CI 1.2, 2.8), Hispanic ethnicity (OR 2.2; CI: 1.4, 3.5), being female (OR 1.6; CI 1.1, 2.4), and having a sleep disorder (OR 4.3; CI 2.7,6.9) were associated with increased odds of insomnia. In open-ended comments (n=310), poor sleep mapped to four categories: children and family, work demands, personal health, and pandemic-related sleep disturbances.

ConclusionDuring the COVID-19 pandemic, 90% of frontline healthcare workers surveyed on social media reported poor sleep, over one-third reported insomnia, and over half reported burnout. Many also reported sleep disruptions due to device usage and nightmares. Sleep interventions for frontline healthcare workers are urgently needed.

Key pointsO_ST_ABSQuestionC_ST_ABSHow are frontline healthcare workers on social media sleeping during the pandemic?

FindingsDuring the COVID-19 pandemic, 90% of frontline healthcare workers on social media are reporting poor sleep, and one third are reporting insomnia. Those who report sleep disturbances were more likely to report burnout.

MeaningInterventions aimed at improving the sleep of frontline healthcare workers are warranted.",Nancy H Stewart; Anya L Koza; Serena Dhaon; Christiana Shoushtari; Maylyn Martinez; Vineet M Arora,https://medrxiv.org/cgi/content/short/2021.01.19.21250128,https://medrxiv.org/cgi/content/short/2021.01.19.21250128,2021-01-20,2021-01-20,,True
446,Deficient hand washing facilities in public toilets in the time of the COVID-19 pandemic: A survey in one high-income country,"AimsTo identify the extent of the provision of water and soap for hand washing in public toilets at the time of the COVID-19 pandemic. To also make comparisons with a pre-pandemic survey that included a sample of the same facilities.

MethodsWe collected data from 400 toilets that were open to the public; all those in three contiguous city council territories (228) and a further convenience sample of 172 around the rest of New Zealand. Comparisons were made with the data on the same facilities included in a 2012/2013 survey.

ResultsFor all the toilets in this survey, 2.5% had no water for hand washing and 14.8% had no soap. There was COVID-19 related health messaging signage in 19.5% of toilets, with posters of the COVID-19 QR code used to facilitate contact tracing in 12.3%, and generic hand washing signage in 1.8%. The hand washing water had ""no touch"" activation at 28.0% of toilets and at 18.5% for toilet bowl flushing. Toilet bowl lids were not present at 32.8%, and 2.3% of toilets had damage which would impair their functionality (eg, broken toilet seats). For the 128 sites that had also been examined in the previous survey, this new survey found significantly increased provision of soap (risk ratio = 1.47; 95%CI: 1.25 to 1.72), but no increased provision of water.

ConclusionsDespite the serious threat of the COVID-19 pandemic, the majority of hand washing facilities in public toilets sampled required tap touching, and did not have health messaging. Nevertheless there has been some modest improvements in soap (but not water) provision since the previous survey eight years before.",Nick Wilson; George Thomson,https://medrxiv.org/cgi/content/short/2021.01.19.21250124,https://medrxiv.org/cgi/content/short/2021.01.19.21250124,2021-01-20,2021-01-20,,True
447,Head-to-head comparison of direct-input RT-PCR and RT-LAMP against RTqPCR on extracted RNA for rapid SARS-CoV-2 diagnostics,"Viral pandemics, such as Covid-19, pose serious threats to human societies. To control the spread of highly contagious viruses such as SARS-CoV-2, effective test-trace-isolate strategies require population-wide, systematic testing. Currently, RT-qPCR on extracted RNA is the only broadly accepted test for SARS-CoV-2 diagnostics, which bears the risk of supply chain bottlenecks, often exaggerated by dependencies on proprietary reagents. Here, we directly compare the performance of gold standard diagnostic RT-qPCR on extracted RNA to direct input RT-PCR, RT-LAMP and bead-LAMP on 384 primary patient samples collected from individuals with suspected Covid-19 infection. With a simple five minute crude sample inactivation step and one hour of total reaction time, we achieve assay sensitivities of 98% (direct RT-PCR), 93% (bead-LAMP) and 82% (RT-LAMP) for clinically relevant samples (diagnostic RT-qPCR Ct <35) and a specificity of >98%. For direct RT-PCR, our data further demonstrate a perfect agreement between real-time and end-point measurements, which allow a simple binary classification similar to the powerful visual readout of colorimetric LAMP assays. Our study provides highly sensitive and specific, easy to implement, rapid and cost-effective alternatives to diagnostic RT-qPCR tests.",Max J Kellner; Martin Matl; Julian J Ross; Jakob Schnabl; Dominik Handler; Robert Heinen; Justine Schaeffer; Peter Hufnagl; Alexander Indra; Marcus Dekens; Robert Fritsche-Polanz; Manuela Foedinger; Johannes Zuber; Franz Allerberger; Andrea Pauli; Julius Brennecke,https://medrxiv.org/cgi/content/short/2021.01.19.21250079,https://medrxiv.org/cgi/content/short/2021.01.19.21250079,2021-01-20,2021-01-20,,True
448,The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera,"The current COVID-19 (coronavirus disease 19) pandemic, caused by SARS-CoV-2, disproportionally affects the elderly and people with comorbidities like obesity and associated type 2 diabetes mellitus. Small animal models are crucial for the successful development and validation of antiviral vaccines, therapies and to study the role that comorbidities have on the outcome of viral infections. The initially available SARS-CoV-2 isolates require adaptation in order to use the mouse angiotensin converting enzyme 2 (mACE-2) entry receptor and to productively infect the cells of the murine respiratory tract. We have ""mouse-adapted"" SARS-CoV-2 by serial passaging a clinical virus isolate in the lungs of mice. We then used low doses of this virus in mouse models for advanced age, diabetes and obesity. Similar to SARS-CoV-2 infection in humans, the outcome of infection with mouse-adapted SARS-CoV-2 resulted in enhanced morbidity in aged and diabetic obese mice. Mutations associated with mouse adaptation occurred in the S, M, N and ORF8 genes. Interestingly, one mutation in the receptor binding domain of the S protein results in the change of an asparagine to tyrosine residue at position 501 (N501Y). This mutation is also present in the newly emerging SARS-CoV-2 variant viruses reported in the U.K. (20B/501Y.V1, B1.1.7 lineage) that is epidemiologically associated with high human to human transmission. We show that human convalescent and post vaccination sera can neutralize the newly emerging N501Y virus variant with similar efficiency as that of the reference USA-WA1/2020 virus, suggesting that current SARS-CoV-2 vaccines will protect against the 20B/501Y.V1 strain.",Raveen Rathnasinghe; Sonia Jangra; Anastasija Cupic; Carles Martinez-Romero; Lubbertus C.F. Mulder; Thomas Kehrer; Soner Yildiz; Angela Choi; Ignacio Mena; Jana De Vrieze; Sadaf Aslam; Daniel Stadlbauer; David A. Meekins; Chester D. McDowell; Velmurugan Balaraman; Juergen A. Richt; Bruno G. De Geest; Lisa Miorin; - Personalized Virology Initiative; Florian Krammer; Viviana Simon; Adolfo Garcia-Sastre; Michael Schotsaert,https://medrxiv.org/cgi/content/short/2021.01.19.21249592,https://medrxiv.org/cgi/content/short/2021.01.19.21249592,2021-01-20,2021-01-20,,True
449,Excessive matrix metalloproteinase-1 and hyperactivation of endothelial cells occurred in COVID-19 patients and were associated with the severity of COVID-19,"COVID-19 starts as a respiratory disease that can progress to pneumonia, severe acute respiratory syndrome (SARS), and multi-organ failure. Growing evidence suggests that COVID-19 is a systemic illness that primarily injures the vascular endothelium, yet the underlying mechanisms remain unknown. SARS-CoV-2 infection is believed to trigger a cytokine storm that plays a critical role in the pathogenesis of endothelialitis and vascular injury, eventually leading to respiratory and multi-organ failure in COVID-19 patients. We used a multiplex immunoassay to systematically profile and compare 65 inflammatory cytokines/chemokines/growth factors in plasma samples from 24 hospitalized (severe/critical) COVID-19 patients, 14 mild/moderate cases, and 13 healthy controls (HCs). Patients with severe/critical and mild/moderate COVID-19 had significantly higher plasma levels of 20 analytes than HCs. Surprisingly, only one cytokine (MIF) was among these altered analytes, while the rest were chemokines and growth factors. In addition, only MMP-1 and VEGF-A were significantly elevated in hospitalized COVID-19 patients when compared to mild/moderate cases. Given that excessive MMP-1 plays a central role in tissue destruction in a wide variety of vascular diseases and that elevated VEGF-A, an EC activation marker, increases vascular permeability, we further studied MMP-1 enzymatic activity and other EC activation markers such as soluble forms of CD146, ICAM-1, and VCAM-1. We found that plasma MMP-1 enzymatic activity and plasma levels of MMP-1 and EC activation markers were highly dysregulated in COVID-19 patients. Some dysregulations were associated with patients age or gender, but not with race. Our results demonstrate that COVID-19 patients have distinct inflammatory profiles that are distinguished from the cytokine storms in other human diseases. Excessive MMP-1 and hyperactivation of ECs occur in COVID-19 patients and are associated with the severity of COVID-19.",Fahim Syed; Wei Li; Ryan F Relich; Patrick M Russell; Shanxiang Zhang; Michelle K Zimmerman; Qigui Yu,https://medrxiv.org/cgi/content/short/2021.01.19.21250115,https://medrxiv.org/cgi/content/short/2021.01.19.21250115,2021-01-20,2021-01-20,,True
450,Overcrowding and Exposure to Secondhand Smoke Increase Risk for COVID-19 Infection Among Latinx Families in Greater San Francisco Bay Area,"BackgroundThe novel coronavirus (COVID-19) has disproportionately impacted the Latinx community in the United States. Environmental risk factors, including community level pollution burden and exposure to smoking and secondhand smoke, have not been evaluated in relation to risk for infection with COVID-19.

MethodsWe evaluated self-reported infection rates of COVID-19 in three, preexisting, longitudinal, Latinx family cohorts in the San Francisco Bay Area from May through September 2020 (N=383 households, 1,875 people). All households were previously recruited during pregnancy and postpartum at Zuckerberg San Francisco General Hospital (ZSFG) and UCSF Benioff before the pandemic. For the COVID-19 sub-study, participants responded to a 15-minute telephonic interview where we assessed food consumption patterns, housing and employment status, and history of COVID-19 infection based on community and hospital-based testing. We also evaluated secondhand smoke exposure based on previously collected self-reported data. Environmental pollution exposure was determined from census tract residence using Californias EnviroScreen 2.0 data. Non-parametric tests and multiple logistic regression were used to assess possible associations and independent predictors of COVID-19 infection.

ResultsIn the combined Latinx, Eating and Diabetes Cohort (LEAD) and Hispanic, Eating and Nutrition (HEN) cohorts there was a 7.6% household infection rate (14/183) with a lower rate of 3.5% (7/200) in the Telomeres at Birth (TAB) cohort. Larger household size increased risk for infection (OR, 1.43 (95%CI 1.10-1.87)) in the combined LEAD/HEN cohorts and increasing number of children trended towards significance in the TAB cohort (OR 1.82, 95% CI 0.98-3.37). Any exposure to secondhand smoke in the household also trended towards increasing risk after adjusting for household size and other exposures (OR 3.20, 95%CI 0.80-12.73) and (OR 4.37, 95% CI 0.80-23.70). We did not find any associations between neighborhood pollution level based on census track location and risk of infection. Furthermore, we found weak evidence between dietary exposure and risk of COVID-19 infection after adjusting for possible confounders.

ConclusionCrowding as indicated by household size increases risk for COVID-19 infection in Latinx families. Exposure to secondhand smoke may also increase risk for COVID-19 through increased coughing, respiratory impairment and increased travel of virus on smoke particles. Public policy and health interventions need to ensure that multiunit residential complexes prevent any exposure to secondhand smoke.",Andrea DeCastro Mendez; Milagro Escobar; Maria Romero Encinas; Janet Wojcicki,https://medrxiv.org/cgi/content/short/2021.01.19.21250139,https://medrxiv.org/cgi/content/short/2021.01.19.21250139,2021-01-20,2021-01-20,,True
451,A Label-Free SARS-CoV-2 Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients,"BackgroundThe laboratory-based methods to measure the SARS-CoV-2 humoral response include virus neutralization tests (VNTs) to determine antibody neutralization potency. For ease of use and universal applicability, surrogate virus neutralization tests (sVNTs) based on antibody-mediated blockage of molecular interactions have been proposed.

MethodsA surrogate virus neutralization test established on a label-free immunoassay platform (LF-sVNT). The LF-sVNT analyzes the binding ability of RBD to ACE2 after neutralizing RBD with antibodies in serum.

ResultsThe LF-sVNT neutralizing antibody titers (IC50) were determined from serum samples (n=246) from COVID-19 patients (n=113), as well as the IgG concentrations and the IgG avidity indices. Although there is variability in the kinetics of the IgG concentrations and neutralizing antibody titers between individuals, there is an initial rise, plateau and then in some cases a gradual decline at later timepoints after 40 days post-symptom onset. The IgG avidity indices, in the same cases, plateau after the initial rise and did not show a decline.

ConclusionsThe LF-sVNT can be a valuable tool in clinical laboratories for the assessment of the presence of neutralizing antibodies to COVID-19. This study is the first to provide longitudinal neutralizing antibody titers beyond 200 days post-symptom onset. Despite the decline of IgG concentration and neutralizing antibody titer, IgG avidity index increases, reaches a plateau and then remains constant up to 8 months post-infection. The decline of antibody neutralization potency can be attributed to the reduction in antibody quantity rather than the deterioration of antibody avidity, a measure of antibody quality.

SummaryA surrogate virus neutralization test established on a label-free immunoassay platform (LF-sVNT). Using the LF-sVNT and other assays, 246 serum samples from 113 COVID-19 patients were measured. We observed the time course of antibody characteristics beyond 200 days post-symptom onset.",Yiqi Ruben Luo; Cassandra Yun; Indrani Chakraborty; Alan H.B. Wu; Kara Lake Lynch,https://medrxiv.org/cgi/content/short/2021.01.19.21250137,https://medrxiv.org/cgi/content/short/2021.01.19.21250137,2021-01-20,2021-01-20,,True
452,Modeling the population effects of epitope specific escape mutations in SARS-CoV-2 to guide vaccination strategies,"Escape mutations (EM) to SARS-Cov-2 have been detected and are spreading. Vaccines may need adjustment to respond to these or future mutations. We designed a population level model integrating both waning immunity and EM. We also designed a set of criteria for elaborating and fitting this model to cross-neutralization and other data in a manner that minimizes vaccine decision errors. We formulated four model variations. These define criteria for which prior infections provide immunity that can be escaped. They also specify different sequences where one EM follows another. At all reasonable parameter values, these model variations led to patterns where: 1) EM were rare in the first epidemic, 2) rebound epidemics after the first epidemic were accelerated more by increasing drifting than by increasing waning (with some exceptions), 3) the long term endemic level of infection was determined mostly by waning rates with small effects of the drifting parameter, 4) EM caused loss of vaccine effectiveness and under some conditions, vaccines induced EM that caused higher levels of infection with vaccines than without them. The differences and similarities across the four models suggest paths for developing models specifying the epitopes where EM act. This model is a base on which to construct epitope specific evolutionary models using new high-throughput assay data from population samples to guide vaccine decisions.

HighlightsO_LIThis model is the first to integrate both antigenic drifting from escape mutations and immunity waning in continuous time.
C_LIO_LITiny amounts of only waning or only escape mutation drifting have small or no effects. Together, they have large effects.
C_LIO_LIThere are no or few escape mutations during the first epidemic peak and no effect of drifting parameters on the size of that wave.
C_LIO_LIAfter the first epidemic peak, escape mutations accumulate rapidly. They increase with increases in waning rates and with increases in the drifting rate. Escape mutations then amplify other escape mutations since these raise the frequency of reinfections.
C_LIO_LIEscape mutations can completely negate the effects of vaccines and even lead to more infections with vaccination than without, especially at very low waning rates.
C_LIO_LIThe model generates population level cross-neutralization patterns that enable the model to be fitted to population level serological data.
C_LIO_LIThe model can be modified to use laboratory data that determine the epitope specific effects of mutations on ACE2 attachment strength or escape from antibody effects.
C_LIO_LIThe model, although currently unable to predict the effects of escape mutations in the real world, opens up a path that can guide model incorporation of molecularly studied escape mutations and improve predictive value. We describe that path.
C_LIO_LIModel analysis indicates that vaccine trials and serological surveys are needed now to detect the effects of epitope specific escape mutations that could cause the loss of vaccine efficacy.
C_LI",James S Koopman; Carl P Simon; Wayne M Getz; Richard Salter,https://medrxiv.org/cgi/content/short/2021.01.19.21250114,https://medrxiv.org/cgi/content/short/2021.01.19.21250114,2021-01-20,2021-01-20,,True
453,"Spatio-temporal analysis between the incidence of COVID-19 and human development in Mato Grosso do Sul, Brazil.","ObjetiveTo analyze the spatial distribution of the Covid-19 incidence and its correlation with the municipal human development index (IDHM) in the state of Mato Grosso do Sul (MS), Brazil.

MethodsThis is an ecological, exploratory and analytical study whose units of analysis were the 79 municipalities that make up the state of MS. Covid-19 incidence coefficients, death numbers, lethality rate, mortality rate and Human Development Index for municipalities (IDHM) in the period from March 2020 to December 31, 2020 were used. spatial correlations between the variables mentioned above.

ResultsThe incidence of Covid-19 has spatial dependence with moderate positive correlation and formation of clusters located in the Metropolitan Region of Campo Grande (RMCG) and municipalities in the region.

ConclusionThe uneven mapping of Covid-19 and its relationship with IDHM in the Ministry of Health can contribute to actions to address the regional pandemic.",Amaury Souza Sr.; Marcel Carvalho Abreu Sr.; Jose Francisco de Oliveira Junior Sr.,https://medrxiv.org/cgi/content/short/2021.01.19.21250106,https://medrxiv.org/cgi/content/short/2021.01.19.21250106,2021-01-20,2021-01-20,,True
454,"Hyperinflammatory conditions, gender differences and mortality in Indian COVID-19 patients","PurposeEvidence suggests that COVID-19 induces hyperinflammatory conditions and causes relatively more deaths in males than females. The purpose of this study was to analyze gender differences associated with various hyperinflammatory conditions (HIC) and mortality in the Indian COVID-19 patients

MethodsThis study was conducted at the Eras Lucknow Medical College and Hospital (ELMCH), ERA University, which is located in the northern part of India. Starting from July 4, 2020 till December 3, 2020 a total of 2997 patients were treated at ELMCH. We randomly collected blood samples from 150 severe COVID-19 patients (required oxygen) between August 10 and September 15, 2020 for analyzing the following HIC and associated laboratory markers: hyperferritinaemia (serum ferritin), hematological dysfunctions (lymphocytopenia and neutrophil to lymphocyte ratio), cytokinaemia (C-reactive protein), coagulopathy (D-dimer), liver inflammation (aspartate aminotransferase), renal inflammation (blood urea and creatinine), and hyperglycemia (random blood glucose). The threshold values/cut off limits of these laboratory markers used for analyzing the risk of mortality in male and female COVID-19 patients were set according to the scale validated recently by Webb et al, (2020).

ResultsIn the above cohort of consecutively admitted COVID-19 patients, analysis of various HIC revealed hyperferritinaemia (odd ratio: 2.9, 95% CI 1.4-6.0), hematological dysfunctions (odd ratio: 2.10, 95% CI 1.0-4.2), hepatic inflammation (odd ratio: 2.0, 95% CI 0.52-7.40), and coagulopathy (odd ratio: 1.5, 95% CI 1.50, 95% CI 0.50-4.60) were more prevalent and sever in male COVID-19 patients. Approximately 86% male to 64% female COVID-19 patients developed lymphocytopenia. Regarding mortality, while hyperferritinaemia (odd ratio: 1.70, 95% CI 0.37-7.43) and cytokinaemia (odd ratio: 1.60, 95% CI 0.37 -7.30) were strongly associated with mortality in male COVID-19 patients, coagulopathy (odd ratio: 3.30, 95% CI 0.31-35), and hematological dysfunctions (odd ratio: 1.70, 95% CI 0.27-10) were more commonly associated with mortality in female COVID-19 patients. Nearly 80% male and female COVID-19 patients, who died had developed [&ge;]2 criteria of HIS criteria. Chronic renal disease was associated with more deaths in female than male COVID-19 patients (odd ratio: 2.0, 95% CI 0.54 - 7.4). While the mortality proportion was slightly higher in male (6.3%) than female (4.5%) COVID-19 patients, survival curves of the two genders were not different (hazard ratio: 1.02, 95% CI 0.71-1.40, P = 0. 953).

ConclusionDistinct HIC were associated with the severity, and mortality in male and female COVID-19 patients. Coagulopathy and renal injury were detrimental, specifically, for female COVID-19 patients. The overall mortality proportion was around 5.3%. The above results suggest that gender differences associated with COVID-19 severity and mortality arise due to differences in various HIC. These results may help in developing personalized or gender based treatments for COVID-19 patients.",Fouzia Shoeb; Imran Hussain; Gazala Afrin; Shagufta T Mufti; Syed T Raza; Farzana Mahdi,https://medrxiv.org/cgi/content/short/2021.01.19.21250134,https://medrxiv.org/cgi/content/short/2021.01.19.21250134,2021-01-20,2021-01-20,,True
455,Impact of immediate and preferential relaxation of social and travel restrictions for vaccinated people on the spreading dynamics of COVID-19 : a model-based analysis,"BackgroundFour COVID-19 vaccine candidates developed by Pfizer, Moderna, University of Oxford/ Astra Zeneca (also Oxford/ Serum Institute of India) and ICMR/ Bharat Biotech have been granted emergency use authorization in the democratic world following established clinical trial procedures in their respective countries. Vaccination of the general public is expected to begin in several weeks. We consider the question of whether people who have received the vaccine can be selectively and immediately cleared to return to normal activities, including hassle-free travel.

MethodsWe use a delay differential equation model developed previously by our group to calculate the effects of vaccinee ""immunity passports"" on the spreading trajectories of the disease. We consider default virus strains as well as high-transmissibility variants such as B1.1.7 in our analysis.

ResultsWe find that with high vaccine efficacy of 80 percent or greater, vaccinees may be immediately cleared for normal life with no significant increase in case counts. Free travel of such vaccinees between two regions should not jeopardize the infection control performance of either. At current vaccine administration rates, it may be eight months or more before COVID-19 transmission is significantly reduced or eliminated. With lower vaccine efficacy of approximately 60 percent however, social as well as travel restrictions for vaccinees may need to remain in place until transmission of the disease is eliminated.

ConclusionsDesigning high-efficacy vaccines with easily scalable manufacturing and distribution capacity should remain on the priority list in academic as well as industrial circles. Performance of all vaccines should continue to be monitored in real time during vaccination drive with a view to analysing socio-demographic determinants if any of efficacy, and optimizing distribution accordingly. A speedy and efficacious vaccination drive will provide the smoothest path out of the pandemic with the least additional caseloads, death toll and socioeconomic cost.",B Shayak; Mohit Manoj Sharma; Anand Kumar Mishra,https://medrxiv.org/cgi/content/short/2021.01.19.21250100,https://medrxiv.org/cgi/content/short/2021.01.19.21250100,2021-01-20,2021-01-20,,True
456,The Association of COVID-19 Incidence with Sport and Face Mask Use in United States High School Athletes,"PurposeTo evaluate the influence of sport characteristics and face mask use on COVID-19 incidence among high school athletes.

MethodsSurveys were distributed to high school athletic directors throughout the United States regarding sport re-initiation, COVID-19 cases, and risk reduction procedures in fall 2020.

Separate mixed effects Poisson regression models were developed to evaluate the associations between reported COVID-19 incidence and 1) sport characteristics (contact/non-contact, individual/team, indoor/outdoor) and 2) face mask use while playing (yes/no).

Results991 schools had restarted fall sports, representing 152,484 athletes on 5,854 teams. 2,565 cases of COVID-19 were reported, representing a case rate of 1,682 cases per 100,000 athletes and an incidence rate of 24.6 cases per 100,000 player-days. COVID-19 incidence was lower among outdoor versus indoor sports (incidence rate ratio [IRR]=0.54, 95% CI=0.49-0.60, p<0.001) and non-contact versus contact sports (IRR=0.78 [0.70-0.87], p<0.001), but not team versus individual sports (IRR=0.96 [0.84-1.1], p=0.49). Face mask use was associated with a decreased incidence in girls volleyball (IRR=0.53 [0.37-0.73], p<0.001), boys basketball (IRR=0.53 [0.33-0.83], p=0.008) and girls basketball (IRR=0.36 [0.19-0.63], p<0.001), and approached statistical significance in football (IRR=0.79 [0.59-1.04], p=0.10) and cheer/dance (IRR=0.75 [0.53-1.03], p=0.081).

ConclusionsIn this nationwide survey of US high school athletic directors representing 152,484 athletes, lower COVID-19 incidence was independently associated with participation in outdoor versus indoor and non-contact versus contact sports, but not team versus individual sports. Face mask use was associated with decreased COVID-19 incidence among indoor sports, and may be protective among outdoor sports with prolonged close contact between participants.",Andrew Watson; Kristin Haraldsdottir; Kevin Biese; Leslie Goodavish; Bethany Stevens; Timothy McGuine,https://medrxiv.org/cgi/content/short/2021.01.19.21250116,https://medrxiv.org/cgi/content/short/2021.01.19.21250116,2021-01-20,2021-01-20,,True
457,Invasive Mould Disease in Fatal COVID-1 19: A Systematic Review of Autopsies,"BackgroundInvasive mould disease (IMD) - most commonly pulmonary aspergillosis - is reported to affect up to a third of critically ill COVID-19 patients. Most reported cases are diagnosed with probable/putative COVID-19 associated pulmonary aspergillosis (CAPA) based on a combination of non-specific clinical, radiographic, and mycological findings, but the clinical significance - and whether these cases represent true invasive disease - is unresolved.

MethodsWe performed a systematic review of autopsy series of decedents with COVID-19 for evidence of IMD. We searched PubMed, Web of Science, OVID (Embase) and MedRxiv for English- or French-language case series published between January 1, 2019 to September 26, 2020. We included series describing lung histology of [&ge;]3 decedents, and authors were contacted for missing information as necessary.

FindingsWe identified 51 case series describing autopsies of 702 decedents. Individual-level data was available for 430 decedents. The median age was 72 (IQR 61 to 80) years. Diabetes mellitus, pre-existing lung disease, and immunocompromising conditions were reported for 129 (32%), 95 (22%), and 25 (6%) decedents, respectively. The median hospitalization length was 10 (IQR 5-22) days. 51.6% of decedents had received mechanical ventilation for a median of nine (IQR 5-20) days. Treatment included immunomodulation in 60 (most often steroids or tocilizumab) and antifungals in 41 decedents. Eleven decedents (1{middle dot}6%) had autopsy-confirmed IMD (6 with CAPA, 4 with invasive pulmonary mycosis not specified and 1 with disseminated mucormycosis). Among 173 decedents who received mechanical ventilation, 5 had IMD (2{middle dot}9%).

InterpretationAutopsy-proven IMD, including CAPA, is uncommon in fatal COVID-19.

FundingThis study is unfunded

CategoryReview",Brittany Kula; Cornelius J Clancy; Minh Hong Nguyen; Ilan S. Schwartz,https://medrxiv.org/cgi/content/short/2021.01.13.21249761,https://medrxiv.org/cgi/content/short/2021.01.13.21249761,2021-01-20,2021-01-20,,True
458,SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma,"SARS-CoV-2 501Y.V2, a novel lineage of the coronavirus causing COVID-19, contains multiple mutations within two immunodominant domains of the spike protein. Here we show that this lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies. Furthermore 501Y.V2 shows substantial or complete escape from neutralizing antibodies in COVID-19 convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and may foreshadow reduced efficacy of current spike-based vaccines.",Constantinos Kurt Wibmer; Frances Ayres; Tandile Hermanus; Mashudu Madzivhandila; Prudence Kgagudi; Bronwen E Lambson; Marion Vermeulen; Karin van den Berg; Theresa Rossouw; Michael Boswell; Veronica Ueckermann; Susan Meiring; Anne von Gottberg; Cheryl Cohen; Lynn Morris; Jinal N Bhiman; Penny L Moore,https://biorxiv.org/cgi/content/short/2021.01.18.427166,https://biorxiv.org/cgi/content/short/2021.01.18.427166,2021-01-19,2021-01-19,,False
459,Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera,"Recently, a new SARS-CoV-2 lineage called B.1.1.7 has emerged in the United Kingdom that was reported to spread more efficiently than other strains. This variant has an unusually large number of mutations with 10 amino acid changes in the spike protein, raising concerns that its recognition by neutralizing antibodies may be affected. Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2. The immune sera had equivalent neutralizing titers to both variants. These data, together with the combined immunity involving humoral and cellular effectors induced by this vaccine, make it unlikely that the B.1.1.7 lineage will escape BNT162b2-mediated protection.",Alexander Muik; Ann-Kathrin Wallisch; Bianca Saenger; Kena A Swanson; Julia Muehl; Wei Chen; Hui Cai; Ritu Sarkar; Oezlem Tuereci; Philip R Dormitzer; Ugur Sahin,https://biorxiv.org/cgi/content/short/2021.01.18.426984,https://biorxiv.org/cgi/content/short/2021.01.18.426984,2021-01-19,2021-01-19,,False
460,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants,"To date severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 100 million individuals resulting in over two million deaths. Many vaccines are being deployed to prevent coronavirus disease 2019 (COVID-19) including two novel mRNA-based vaccines1,2. These vaccines elicit neutralizing antibodies and appear to be safe and effective, but the precise nature of the elicited antibodies is not known3-6. Here we report on the antibody and memory B cell responses in a cohort of 20 volunteers who received either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines. Consistent with prior reports, 8 weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers3,5,6. Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection7,8. However, activity against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin. Consistent with these findings, vaccine-elicited monoclonal antibodies (mAbs) potently neutralize SARS-CoV-2, targeting a number of different RBD epitopes in common with mAbs isolated from infected donors. Structural analyses of mAbs complexed with S trimer suggest that vaccine- and virus-encoded S adopts similar conformations to induce equivalent anti-RBD antibodies. However, neutralization by 14 of the 17 most potent mAbs tested was reduced or abolished by either K417N, or E484K, or N501Y mutations. Notably, the same mutations were selected when recombinant vesicular stomatitis virus (rVSV)/SARS-CoV-2 S was cultured in the presence of the vaccine elicited mAbs. Taken together the results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid potential loss of clinical efficacy.",Zijun Wang; Fabian Schmidt; Yiska Weisblum; Frauke Muecksch; Christopher O Barnes; Shlomo Finkin; Dennis Schaefer-Babajew; Melissa Cipolla; Christian Gaebler; Jenna A Lieberman; Thiago Y Oliveira; Zhi Yang; Morgan E Abernathy; Kathryn E Huey-Tubman; Arlene Hurley; Martina Turroja; Kamille A West; Kristie Gordon; Katrina G Millard; Victor Ramos; Justin Da Silva; Jianliang Xu; Robert A Colbert; Roshni Patel; Juan P Dizon; Irina Shimeliovich; Anna Gazumyan; Marina Caskey; Pamela J Bjorkman; Rafael Casellas; Theodora Hatziioannou; Paul D Bieniasz; Michel C Nussenzweig,https://biorxiv.org/cgi/content/short/2021.01.15.426911,https://biorxiv.org/cgi/content/short/2021.01.15.426911,2021-01-19,2021-01-19,,False
461,Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine,"The ongoing pandemic of Coronavirus disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single dose, fast-acting vesicular stomatitis virus-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (IM) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (IN) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to control animals. While IM and IN vaccination both induced neutralizing antibody titers, only IM vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of IM-vaccinated animals only. Overall, the data demonstrates that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study.

One sentence summaryVSV vaccine protects NHPs from COVID-19 in 10 days",Wakako Furuyama; Kyle Shifflett; Amanda N Pinksi; Amanda J Griffin; Friederike Feldmann; Atsushi Okumura; Tylisha Gourdine; Allen Jankeel; Jamie Lovaglio; Patrick W Hanley; Tina Thomas; Chad S Clancy; Ilhem Messaoudi; Andrea Marzi,https://biorxiv.org/cgi/content/short/2021.01.19.426885,https://biorxiv.org/cgi/content/short/2021.01.19.426885,2021-01-19,2021-01-19,,False
462,Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine,"Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirms the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.",Yasunori Watanabe; Luiza MendonÃ§a; Elizabeth R. Allen; Andrew Howe; Mercede Lee; Joel D Allen; Himanshi Chawla; David Pulido; Francesca Donnellan; Hannah Davies; Marta Ulaszewska; Sandra Belij-Rammerstorfer; Susan Morris; Wanwisa Dejnirattisai; Juthathip Mongkolsapaya; Piyada Supasa; Gavin R. Screaton; Catherine M. Green; Teresa Lambe; Peijun Zhang; Sarah C Gilbert; Max Crispin,https://biorxiv.org/cgi/content/short/2021.01.15.426463,https://biorxiv.org/cgi/content/short/2021.01.15.426463,2021-01-19,2021-01-19,,False
463,Comprehensive mapping of SARS-CoV-2 interactions in vivo reveals functional virus-host interactions,"SARS-CoV-2 has emerged as a major threat to global public health, resulting in global societal and economic disruptions. Here, we investigate the intramolecular and intermolecular RNA interactions of wildtype (WT) and a mutant ({Delta}382) SARS-CoV-2 virus in cells using high throughput structure probing on Illumina and Nanopore platforms. We identified twelve potentially functional structural elements within the SARS-CoV-2 genome, observed that identical sequences can fold into divergent structures on different subgenomic RNAs, and that WT and {Delta}382 virus genomes can fold differently. Proximity ligation sequencing experiments identified hundreds of intramolecular and intermolecular pair-wise interactions within the virus genome and between virus and host RNAs. SARS-CoV-2 binds strongly to mitochondrial and small nucleolar RNAs and is extensively 2-O-methylated. 2-O-methylation sites in the virus genome are enriched in the untranslated regions and are associated with increased pair-wise interactions. SARS-CoV-2 infection results in a global decrease of 2-O-methylation sites on host mRNAs, suggesting that binding to snoRNAs could be a pro-viral mechanism to sequester methylation machinery from host RNAs towards the virus genome. Collectively, these studies deepen our understanding of the molecular basis of SARS-CoV-2 pathogenicity, cellular factors important during infection and provide a platform for targeted therapy.",Yue Wan; Siwy Ling Yang; Louis DeFalco; Danielle E Anderson; Yu Zhang; Ashley J Aw; Su Ying Lim; Xin Ni Lim; Kiat Yee Tan; Tong Zhang; Tanu Chawla; Yan Su; Alexander Lezhava; Paola de Sessions; Andres Merits; Lin-Fa Wang; Roland G Huber,https://biorxiv.org/cgi/content/short/2021.01.17.427000,https://biorxiv.org/cgi/content/short/2021.01.17.427000,2021-01-19,2021-01-19,,False
464,Interferon-regulated genetic programs and JAK/STAT pathway activate the intronic promoter of the short ACE2 isoform in renal proximal tubules,"Recently, a short, interferon-inducible isoform of Angiotensin-Converting Enzyme 2 (ACE2), dACE2 was identified. ACE2 is a SARS-Cov-2 receptor and changes in its renal expression have been linked to several human nephropathies. These changes were never analyzed in context of dACE2, as its expression was not investigated in the kidney. We used Human Primary Proximal Tubule (HPPT) cells to show genome-wide gene expression patterns after cytokine stimulation, with emphasis on the ACE2/dACE2 locus. Putative regulatory elements controlling dACE2 expression were identified using ChIP-seq and RNA-seq. qRT-PCR differentiating between ACE2 and dACE2 revealed 300- and 600-fold upregulation of dACE2 by IFN and IFN{beta}, respectively, while full length ACE2 expression was almost unchanged. JAK inhibitor ruxolitinib ablated STAT1 and dACE2 expression after interferon treatment. Finally, with RNA-seq, we identified a set of genes, largely immune-related, induced by cytokine treatment. These gene expression profiles provide new insights into cytokine response of proximal tubule cells.",Not available,https://biorxiv.org/cgi/content/short/2021.01.15.426908,https://biorxiv.org/cgi/content/short/2021.01.15.426908,2021-01-19,2021-01-19,,False
465,An all-solid-state heterojunction oxide transistor for the rapid detection of biomolecules and SARS-CoV-2 spike S1 protein,"Solid-state transistor sensors that can detect biomolecules in real time are highly attractive for emerging bioanalytical applications. However, combining cost-effective manufacturing with high sensitivity, specificity and fast sensing response, remains challenging. Here we develop low-temperature solution-processed In2O3/ZnO heterojunction transistors featuring a geometrically engineered tri-channel architecture for rapid real-time detection of different biomolecules. The sensor combines a high electron mobility channel, attributed to the quasi-two-dimensional electron gas (q2DEG) at the buried In2O3/ZnO heterointerface, in close proximity to a sensing surface featuring tethered analyte receptors. The unusual tri-channel design enables strong coupling between the buried q2DEG and the minute electronic perturbations occurring during receptor-analyte interactions allowing for robust, real-time detection of biomolecules down to attomolar (aM) concentrations. By functionalizing the tri-channel surface with SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) antibody receptors, we demonstrate real-time detection of the SARS-CoV-2 spike S1 protein down to attomolar concentrations in under two minutes.",Yen-Hung Lin; Yang Han; Abhinav Sharma; Wejdan S. AlGhamdi; Chien-Hao Liu; Tzu-Hsuan Chang; Xi-Wen Xiao; Akmaral Seitkhan; Alexander D. Mottram; Pichaya Pattanasattayavong; Hendrik Faber; Martin Heeney; Thomas D. Anthopoulos,https://biorxiv.org/cgi/content/short/2021.01.19.427256,https://biorxiv.org/cgi/content/short/2021.01.19.427256,2021-01-19,2021-01-19,,False
466,The impact of Spike mutations on SARS-CoV-2 neutralization,"Multiple SARS-CoV-2 vaccines have shown protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, Spike. Antibodies from SARS-CoV-2 infection neutralize the virus by focused targeting of Spike and there is limited serum cross-neutralization of the closely-related SARS-CoV. As new SARS-CoV-2 variants are rapidly emerging, exemplified by the B.1.1.7, 501Y.V2 and P.1 lineages, it is critical to understand if antibody responses induced by infection with the original SARS-CoV-2 virus or the current vaccines will remain effective against virus variants. In this study we evaluate neutralization of a series of mutated Spike pseudotypes including a B.1.1.7 Spike pseudotype. The analyses of a panel of Spike-specific monoclonal antibodies revealed that the neutralizing activity of some antibodies was dramatically reduced by Spike mutations. In contrast, polyclonal antibodies in the serum of patients infected in early 2020 remained active against most mutated Spike pseudotypes. The majority of serum samples were equally able to neutralize the B.1.1.7 Spike pseudotype, however potency was reduced in a small number of samples (3 of 36) by 5-10-fold. This work highlights that changes in the SARS-CoV-2 Spike can alter neutralization sensitivity and underlines the need for effective real-time monitoring of emerging mutations and their impact on vaccine efficacy.",Chloe Rees-Spear; Luke Muir; Sarah A Griffith; Judith Heaney; Yoann Aldon; Jonne Snitselaar; Peter Thomas; Carl Graham; Jeffrey Seow; Nayung Lee; Annachiara Rosa; Chloe Roustan; Catherine F Houlihan; Rogier W Sanders; Ravindra K Gupta; Peter Cherepanov; Hans Stauss; Eleni Nastouli; Katie J Doores; Marit J van Gils; Laura E McCoy,https://biorxiv.org/cgi/content/short/2021.01.15.426849,https://biorxiv.org/cgi/content/short/2021.01.15.426849,2021-01-19,2021-01-19,,False
467,Experimental re-infected cats do not transmit SARS-CoV-2,"SARS-CoV-2 is the causative agent of COVID-19 and responsible for the current global pandemic. We and others have previously demonstrated that cats are susceptible to SARS-CoV-2 infection and can efficiently transmit the virus to naive cats. Here, we address whether cats previously exposed to SARS-CoV-2 can be re-infected with SARS-CoV-2. In two independent studies, SARS-CoV-2-infected cats were re-challenged with SARS-CoV-2 at 21 days post primary challenge (DPC) and necropsies performed at 4, 7 and 14 days post-secondary challenge (DP2C). Sentinels were co-mingled with the re-challenged cats at 1 DP2C. Clinical signs were recorded, and nasal, oropharyngeal, and rectal swabs, blood, and serum were collected and tissues examined for histologic lesions. Viral RNA was transiently shed via the nasal, oropharyngeal and rectal cavities of the re-challenged cats. Viral RNA was detected in various tissues of re-challenged cats euthanized at 4 DP2C, mainly in the upper respiratory tract and lymphoid tissues, but less frequently and at lower levels in the lower respiratory tract when compared to primary SARS-CoV-2 challenged cats at 4 DPC. Histologic lesions that characterized primary SARS-CoV-2 infected cats at 4 DPC were absent in the re-challenged cats. Naive sentinels co-housed with the re-challenged cats did not shed virus or seroconvert. Together, our results indicate that cats previously infected with SARS-CoV-2 can be experimentally re-infected with SARS-CoV-2; however, the levels of virus shed was insufficient for transmission to co-housed naive sentinels. We conclude that SARS-CoV-2 infection in cats induces immune responses that provide partial, non-sterilizing immune protection against reinfection.",Natasha N Gaudreault; Mariano Carossino; Igor Morozov; Jessie D Trujillo; David A Meekins; Daniel W Madden; Konner Cool; Bianca Libanori Artiaga; Chester McDowell; Dashzeveg Bold; Velmurugan Balaraman; Taeyong Kwon; Wenjun Ma; Jamie Henningson; Dennis W Wilson; William C Wilson; Udeni BR Balasuriya; Adolfo Garcia-Sastre; Juergen A Richt,https://biorxiv.org/cgi/content/short/2021.01.18.427182,https://biorxiv.org/cgi/content/short/2021.01.18.427182,2021-01-19,2021-01-19,,False
468,A trans-complementation system for SARS-CoV-2,"The biosafety level-3 (BSL-3) requirement to culture severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a bottleneck for research and countermeasure development. Here we report a trans-complementation system that produces single-round infectious SARS-CoV-2 that recapitulates authentic viral replication. We demonstrate that the single-round infectious SARS-CoV-2 can be used at BSL-2 laboratories for high-throughput neutralization and antiviral testing. The trans-complementation system consists of two components: a genomic viral RNA containing a deletion of ORF3 and envelope gene, and a producer cell line expressing the two deleted genes. Trans-complementation of the two components generates virions that can infect naive cells for only one round, but does not produce wild-type SARS-CoV-2. Hamsters and K18-hACE2 transgenic mice inoculated with the complementation-derived virions exhibited no detectable disease, even after intracranial inoculation with the highest possible dose. The results suggest that the trans-complementation platform can be safely used at BSL-2 laboratories for research and countermeasure development.",Xianwen Zhang; Yang Liu; Jianying Liu; Adam L Bailey; Kenneth S Plante; Jessica A Plante; Jing Zou; Hongjie Xia; Nathen E Bopp; Patricia V Aguilar; Ping Ren; Vineet D Menachery; Michael S Diamond; Scott C Weaver; Xuping Xie; Pei-Yong Shi,https://biorxiv.org/cgi/content/short/2021.01.16.426970,https://biorxiv.org/cgi/content/short/2021.01.16.426970,2021-01-19,2021-01-19,,False
469,Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IÎºBÎ±-Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry,"Large-scale efforts have been persistently undertaken for medical prophylaxis and treatment of COVID-19 disasters worldwide. A variety of novel viral spike protein-targeted vaccine preparations have recently been clinically distributed based on accelerated approval. We revisited the early but inconclusive clinical interest in the combination of azithromycin and zinc sulfate repurposing with safety advantages. In vitro proof of concept was provided for rapid and synergistic suppression of ACE2 expression following treatments in human airway cells, Calu-3 and H322M. The two representative ACE2-expressing human airway cells indicate the upper and lower respiratory tracts. Prophylactic and early therapeutic roles of azithromycin combined with zinc are proposed for virus cellular entry prevention potential bridging to effective antibody production.",Yin-Kai Chen; Tsung-Tao Huang; Chia-Wei Chang; Ming-Cheng Lee; Bor-Ru Lin; Yen-Pei Lu; Yih-Jen Hsu; Chun-Yu Chuang,https://biorxiv.org/cgi/content/short/2021.01.19.427206,https://biorxiv.org/cgi/content/short/2021.01.19.427206,2021-01-19,2021-01-19,,False
470,BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2,"SARS-CoV-2 infection of human cells is initiated by the binding of the viral Spike protein to its cell-surface receptor ACE2. We conducted an unbiased CRISPRi screen to uncover druggable pathways controlling Spike protein binding to human cells. We found that the protein BRD2 is an essential node in the cellular response to SARS-CoV-2 infection. BRD2 is required for ACE2 transcription in human lung epithelial cells and cardiomyocytes, and BRD2 inhibitors currently evaluated in clinical trials potently block endogenous ACE2 expression and SARS-CoV-2 infection of human cells. BRD2 also controls transcription of several other genes induced upon SARS-CoV-2 infection, including the interferon response, which in turn regulates ACE2 levels. It is possible that the previously reported interaction between the viral E protein and BRD2 evolved to manipulate the transcriptional host response during SARS-CoV-2 infection. Together, our results pinpoint BRD2 as a potent and essential regulator of the host response to SARS-CoV-2 infection and highlight the potential of BRD2 as a novel therapeutic target for COVID-19.",Ruilin Tian; Avi J Samelson; Veronica V Rezelj; Merissa Chen; Gokul N Ramadoss; Xiaoyan Guo; Alice Mac Kain; Quang Dinh Tran; Shion A Lim; Irene Lui; James Nunez; Sarah J Rockwood; Na Liu; Jared Carlson-Stevermer; Jennifer Oki; Travis Maures; Kevin Holden; Jonathan S Weissman; James A Wells; Bruce Conklin; Marco Vignuzzi; Martin Kampmann,https://biorxiv.org/cgi/content/short/2021.01.19.427194,https://biorxiv.org/cgi/content/short/2021.01.19.427194,2021-01-19,2021-01-19,,False
471,Sterically-Confined Rearrangements of SARS-CoV-2 Spike Protein Control Cell Invasion,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly contagious, and transmission involves a series of processes that may be targeted by vaccines and therapeutics. During transmission, host cell invasion is controlled by a large-scale conformational change of the Spike protein. This conformational rearrangement leads to membrane fusion, which creates transmembrane pores through which the viral genome is passed to the host. During Spike-protein-mediated fusion, the fusion peptides must be released from the core of the protein and associate with the host membrane. Interestingly, the Spike protein possesses many post-translational modifications, in the form of branched glycans that flank the surface of the assembly. Despite the large number of glycosylation sites, until now, the specific role of glycans during cell invasion has been unclear. Here, we propose that glycosylation is needed to provide sufficient time for the fusion peptides to reach the host membrane, otherwise the viral particle would fail to enter the host. To understand this process, an all-atom model with simplified energetics was used to perform thousands of simulations in which the protein transitions between the prefusion and postfusion conformations. These simulations indicate that the steric composition of the glycans induces a pause during the Spike protein conformational change. We additionally show that this glycan-induced delay provides a critical opportunity for the fusion peptides to capture the host cell. This previously-unrecognized role of glycans reveals how the glycosylation state can regulate infectivity of this pervasive pathogen.",Esteban Dodero Rojas; Jose Nelson Onuchic; Paul Whitford,https://biorxiv.org/cgi/content/short/2021.01.18.427189,https://biorxiv.org/cgi/content/short/2021.01.18.427189,2021-01-19,2021-01-19,,False
472,SARS-CoV-2 infection of circulating immune cells is not responsible for virus dissemination in severe COVID-19 patients,"In late 2019 a novel coronavirus (SARS-CoV-2) emerged, and has since caused a global pandemic. Understanding the pathogenesis of COVID-19 disease is necessary to inform development of therapeutics, and management of infected patients. Using scRNAseq of blood drawn from SARS-CoV-2 patients, we asked whether SARS-CoV-2 may exploit immune cells as a  Trojan Horse to disseminate and access multiple organ systems. Our data suggests that circulating cells are not actively infected with SARS-CoV-2, and do not appear to be a source of viral dissemination.",Nicole L Rosin; Arzina Jaffer; Sarthak Sinha; Rory P Mulloy; Carolyn Robinson; Elodie Labit; Luiz G Almeida; Antoine Dufour; Jennifer A Corcoran; Bryan Yipp; Jeff Biernaskie,https://biorxiv.org/cgi/content/short/2021.01.19.427282,https://biorxiv.org/cgi/content/short/2021.01.19.427282,2021-01-19,2021-01-19,,False
473,"COVID-19 Knowledge, Attitudes, and Practices of United Arab Emirates Medical and Health Sciences Students: A Cross Sectional Study","COVID-19 pandemic is the largest unprecedented viral pandemic of the 21st century. We aimed to study the COVID-19 knowledge, attitudes, and practices (KAP) among medical and health sciences students in the United Arab Emirates (UAE). We performed a cross-sectional study between 2nd June and 19th August 2020. The survey was developed using online Survey Monkey. The link was distributed via UAE University to all students and via WhatsApp(C) groups. The self-administered questionnaire was conducted in English and comprised of two parts: socio-demographic characteristics and KAP towards COVID-19. A total of 712 responses to the questionnaire were collected. 90% (n=695) were under-graduate, while 10% (n=81) were post-graduate students. Majority (87%, n=647) stated that they obtained COVID-19 information from multiple reliable sources. They were highly knowledgeable about COVID-19 pandemic but 76% (n=539) did not recognize its routes of transmission. 63% (n=431) were worried of getting COVID-19, while 92% (n=633)) were worried that a family member could get infected with the virus. 97% (n=655) took precautions when accepting home deliveries, 94% (n=637) had been washing their hands more frequently, and 95% (n=643) had been wearing face masks. In conclusion, participants showed high levels of knowledge and awareness about COVID-19. They were worried about getting infected themselves or their family members, and had good practices against COVID-19.",Noura Baniyas; Mohamud  M Sheek-Hussein; Nouf Al Kaabi; Maitha Al Shamsi; Maitha  M Al Neyadi; Rauda Al Khoori; Suad Ajab; Muhammad Abid; Michael Grivna; Fikri  M Abu Zidan,https://biorxiv.org/cgi/content/short/2021.01.19.427250,https://biorxiv.org/cgi/content/short/2021.01.19.427250,2021-01-19,2021-01-19,,False
474,Acute Endotheliitis (Type 3 Hypersensitivity Vasculitis) in Ten COVID-19 Autopsy Brains,"Central nervous system (CNS) involvement in COVID-19 may occur through direct SARS-CoV-2 invasion through peripheral or cranial nerves or through vascular endothelial cell infection. The renin-angiotensin system may play a major part in CNS morbidity. Effects of hypoxia have also been implicated in CNS lesions in COVID-19. This communication reports on ten consecutive autopsies of individuals with death due to COVID-19 with decedent survival ranging from 30 minutes to 84 days after admission. All ten brains examined had neutrophilic microvascular endotheliitis present in variable amounts and variably distributed. Importantly, this acute stage of type 3 hypersensitivity vasculitis can be followed by fibrinoid necrosis and inner vascular wall sclerosis, but these later stages were not found. These results suggest that a vasculitis with autoimmune features occurred in all ten patients. It is possible that viral antigen in or on microvascular walls or other antigen-antibody complexes occurred in all ten patients proximate to death as a form of autoimmune vasculitis.",Roy H Rhodes; Gordon L Love; Fernanda Da Silve Lameira; Maryam Sadough Shahmirzadi; Sharon E Fox; Richard S Vander Heide,https://medrxiv.org/cgi/content/short/2021.01.16.21249632,https://medrxiv.org/cgi/content/short/2021.01.16.21249632,2021-01-18,2021-01-18,,True
475,Correlates of and changes in aerobic physical activity and strength training before and after the onset of COVID-19 pandemic in the UK. Findings from the HEBECO study.,"ObjectivesUnderstanding changes in moderate to vigorous aerobic physical activity (MVPA) and strength training (MSA) from before to after (pre-/post-) the onset of the Covid-19 pandemic in the UK (first lockdown) and their correlates can inform interventions.

MethodsCross-sectional analysis of retrospective and concurrent data on MVPA/MSA pre- and post-Covid-19 (until 14th June 2020) among 2,657 UK adults. The associations between socio-demographic and health characteristics, MVPA/MSA pre-Covid-19, living and exercise conditions and meeting WHO recommended levels for MVPA/MSA/both (vs meeting neither), and changes in MVPA/MSA from pre-to post-Covid-19 following stratification for pre-Covid-19 MVPA/MSA levels were evaluated.

ResultsA third of adults maintained (30.4%), decreased (36.2%) or increased (33.4%) their MVPA levels post-Covid-19. For MSA, the percentages were 61.6%, 18.2%, and 20.2%, respectively. MVPA increased or decreased by an average of 150min/week, and MSA by 2 days/week. Meeting both MSA+MVPA recommendations during lockdown (vs. meeting neither) was positively associated with meeting MVPA+MSA pre-lockdown (aOR=16.11,95%CI=11.24-23.07), and post-16-years of age education (aOR=1.57,1.14-2.17), and negatively associated with being obese (aOR=0.49,0.33-0.73), older age (65+ vs [&le;]34; aOR=.53.32-.87), and annual household income <50.000GBP (vs [&ge;]50.000GBP; aOR=0.65,0.46-0.91). The odds for decreasing MVPA were significantly lower for white ethnicity, post-16-years of age education, access to garden/balcony, and higher for those who were in total isolation. The odds for decreasing MSA were significantly higher for those who were overweight or obese.

ConclusionAerobic and strength training were differently impacted during the first UK lockdown, with poorer outcomes associated with older age, lower education, and higher body mass index.

O_TEXTBOXWhat are the new findingsO_LIAt the start of the Covid-19 pandemic, a third of UK adults decreased and a third increased moderate-to-vigorous physical activity; the corresponding proportions for muscle strength training were 18% and 20%.
C_LIO_LIOlder adults were more likely to maintain inactivity from before to start of the pandemic.
C_LIO_LIAdults with higher body mass index were at risk of not meeting WHO recommendations for weekly levels of strength and aerobic training, and at decreasing muscle strength training in this period.
C_LIO_LIThose with lower incomes, no post-16-years of age education, ethnic minority background and living in total isolation had poorer physical activity outcomes.
C_LI

C_TEXTBOX",Aleksandra Herbec; Verena Schneider; Abi Fisher; Dimitra Kale; Lion Shahab; Phillippa Lally,https://medrxiv.org/cgi/content/short/2021.01.16.21249925,https://medrxiv.org/cgi/content/short/2021.01.16.21249925,2021-01-18,2021-01-18,,True
476,Fluorescent Glycan Fingerprinting of SARS2 Spike Proteins,"Glycosylation is the most common post-translational modification and has myriad biological functions. However, glycan analysis and research has always been a challenge. Here, we would like to present new techniques of glycan fingerprinting based on enzymatic fluorescent labeling and gel electrophoresis. The method is illustrated on SARS-2 spike (S) glycoproteins. SARS-2, a novel coronavirus and the causative agent of COVID-19 pandemic, has devastated the world since the end of 2019. To obtain the N-glycan fingerprint of a S protein, glycans released from the protein are first labeled through enzymatic incorporation of fluorophore-conjugated sialic acid or fucose, and then separated on acrylamide gel through electrophoresis, and finally visualized with a fluorescent imager. To identify the labeled glycans of a fingerprint, glycan standards and glycan ladders that are enzymatically generated are run alongside the samples as references. By comparing the mobility of a labeled glycan to that of a glycan standard, the identity of glycans maybe determined. Due to lack of enzyme for broad O-glycans releasing, O-glycans on the RBD protein are labeled with fluorescent sialic acid and digested with trypsin to obtain labeled glycan peptides that are then separated on gel. Glycan fingerprinting could serve as a quick way for global assessment of the glycosylation of a glycoprotein.",Not available,https://biorxiv.org/cgi/content/short/2021.01.16.426965,https://biorxiv.org/cgi/content/short/2021.01.16.426965,2021-01-18,2021-01-18,,False
477,SARS-CoV-2 RECoVERY: a multi-platform open-source bioinformatic pipeline for the automatic construction and analysis of SARS-CoV-2 genomes from NGS sequencing data,"BackgroundSince its first appearance in December 2019, the novel Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2), spread worldwide causing an increasing number of cases and deaths (35,537,491 and 1,042,798, respectively at the time of writing, https://covid19.who.int). Similarly, the number of complete viral genome sequences produced by Next Generation Sequencing (NGS), increased exponentially. NGS enables a rapid accumulation of a large number of sequences. However, bioinformatics analyses are critical and require combined approaches for data analysis, which can be challenging for non-bioinformaticians.

ResultsA user-friendly and sequencing platform-independent bioinformatics pipeline, named SARS-CoV-2 RECoVERY (REconstruction of CoronaVirus gEnomes & Rapid analYsis) has been developed to build SARS-CoV-2 complete genomes from raw sequencing reads and to investigate variants. The genomes built by SARS-CoV-2 RECoVERY were compared with those obtained using other software available and revealed comparable or better performances of SARS-CoV2 RECoVERY. Depending on the number of reads, the complete genome reconstruction and variants analysis can be achieved in less than one hour. The pipeline was implemented in the multi-usage open-source Galaxy platform allowing an easy access to the software and providing computational and storage resources to the community.

ConclusionsSARS-CoV-2 RECoVERY is a piece of software destined to the scientific community working on SARS-CoV-2 phylogeny and molecular characterisation, providing a performant tool for the complete reconstruction and variants analysis of the viral genome. Additionally, the simple software interface and the ability to use it through a Galaxy instance without the need to implement computing and storage infrastructures, make SARS-CoV-2 RECoVERY a resource also for virologists with little or no bioinformatics skills.

Availability and implementationThe pipeline SARS-CoV-2 RECoVERY (REconstruction of COronaVirus gEnomes & Rapid analYsis) is implemented in the Galaxy instance ARIES (https://aries.iss.it).",Luca De Sabato; Gabriele Vaccari; Arnold Knijn; Giovanni Ianiro; Ilaria Di Bartolo; Stefano Morabito,https://biorxiv.org/cgi/content/short/2021.01.16.425365,https://biorxiv.org/cgi/content/short/2021.01.16.425365,2021-01-18,2021-01-18,,False
478,SARS-CoV-2 infection reduces KruÌˆppel-Like Factor 2 in human lung autopsy,"Acute respiratory distress syndrome (ARDS) occurred in ~12% of hospitalized COVID-19 patients in a recent New York City cohort. Pulmonary endothelial dysfunction, characterized by increased expression of inflammatory genes and increased monolayer permeability, is a major component of ARDS. Vascular leak results in parenchymal accumulation of leukocytes, protein, and extravascular water, leading to pulmonary edema, ischemia, and activation of coagulation associated with COVID-19. Endothelial inflammation further contributes to uncontrolled cytokine storm in ARDS. We have recently demonstrated that Kruppel-like factor 2 (KLF2), a transcription factor which promotes endothelial quiescence and monolayer integrity, is significantly reduced in experimental models of ARDS. Lung inflammation and high-tidal volume ventilation result in reduced KLF2, leading to pulmonary endothelial dysfunction and acute lung injury. Mechanistically, we found that KLF2 is a potent transcriptional activator of Rap guanine nucleotide exchange factor 3 (RAPGEF3) which orchestrates and maintains vascular integrity. Moreover, KLF2 regulates multiple genome-wide association study (GWAS)-implicated ARDS genes. Whether lung KLF2 is regulated by SARS-CoV-2 infection is unknown. Here we report that endothelial KLF2 is significantly reduced in human lung autopsies from COVID-19 patients, which supports that ARDS due to SARS-CoV-2 is a vascular phenotype possibly attributed to KLF2 down-regulation. We provide additional data demonstrating that KLF2 is down-regulated in SARS-CoV infection in mice.",Tzu-Han Lee; David Wu; Robert Guzy; Nathan Schoettler; Ayodeji Adegunsoye; Jeffrey Mueller; Aliya Hussein; Anne Sperling; Gokhan M Mutlu; Yun Fang,https://biorxiv.org/cgi/content/short/2021.01.15.426691,https://biorxiv.org/cgi/content/short/2021.01.15.426691,2021-01-18,2021-01-18,,False
479,Tropism of SARS-CoV-2 for Developing Human Cortical Astrocytes,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) readily infects a variety of cell types impacting the function of vital organ systems, with particularly severe impact on respiratory function. It proves fatal for one percent of those infected. Neurological symptoms, which range in severity, accompany a significant proportion of COVID-19 cases, indicating a potential vulnerability of neural cell types. To assess whether human cortical cells can be directly infected by SARS-CoV-2, we utilized primary human cortical tissue and stem cell-derived cortical organoids. We find significant and predominant infection in cortical astrocytes in both primary and organoid cultures, with minimal infection of other cortical populations. Infected astrocytes had a corresponding increase in reactivity characteristics, growth factor signaling, and cellular stress. Although human cortical cells, including astrocytes, have minimal ACE2 expression, we find high levels of alternative coronavirus receptors in infected astrocytes, including DPP4 and CD147. Inhibition of DPP4 reduced infection and decreased expression of the cell stress marker, ARCN1. We find tropism of SARS-CoV-2 for human astrocytes mediated by DPP4, resulting in reactive gliosis-type injury.",Madeline G Andrews; Tanzila Mukhtar; Ugomma C Eze; Camille R Simoneau; Yonatan Perez; Mohammed A Mostajo-Radji; Shaohui Wang; Dmitry Velmeshev; Jahan Salma; G. Renuka Kumar; Alex A Pollen; Elizabeth E Crouch; Melanie Ott; Arnold R Kriegstein,https://biorxiv.org/cgi/content/short/2021.01.17.427024,https://biorxiv.org/cgi/content/short/2021.01.17.427024,2021-01-18,2021-01-18,,False
480,"From COVID-19 to the Common Cold: Novel Host-Targeted, Pan-Respiratory Antiviral Small Molecule Therapeutics","Antiviral compounds displaying remarkable features have been identified by an unconventional drug screen and advanced through animal validation. Efficacy is observed against the six viral families causing most human respiratory viral disease, irrespective of strain, including both influenza (FLUV) and SARS-CoV-2, with cell culture EC50 at or below 100 nM. Survival benefit is demonstrated in pigs against another member of family Coronaviridae, porcine epidemic diarrhea virus (PEDV), and shown equally effective in mild and severe disease. Respiratory syncytial virus (RSV) titer is reduced by drug treatment in cotton rats. A substantial barrier to viral resistance is demonstrated for FLUV. Drug resin affinity chromatography (DRAC) reveals a novel drug target: a multi-protein complex (MPC) formed transiently, in an energy-dependent fashion, and composed of host proteins implicated in both viral lifecycles and manipulation of innate immunity. The protein composition of this host MPC is modified upon viral infection, with increase or decrease of some proteins and appearance or complete loss of others. Valosin-containing protein, also known as Transitional endoplasmatic reticulum ATPase (VCP/p97), is present in the target MPC of uninfected cells and significantly increased in both FLUV and CoV infection. SQSTM1/p62, a key regulator of the autophagy pathway of innate immunity whose dysfunction is implicated in cytokine storm, is i) found in the target MPC from uninfected cells, ii) diminished in DRAC eluates by infection, and iii) restored by drug treatment of infected cells. 14-3-3 is one of likely several proteins that comprise the drug-binding site. Advanced compounds with improved pharmacokinetic (PK) properties and lung exposure are approaching criteria for a Target Product Profile. We propose these novel drug targets to comprise a previously unappreciated molecular basis for homeostasis that is modified by viruses to allow exploitation for viral propagation and is restored by treatment with the therapeutic compounds presented. This discovery has transformative implications for treatment of respiratory viral-related disease, applicable to everything from seasonal FLUV to COVID-19 and future novel respiratory viruses, due to the pan-family nature of drug activity and barrier to resistance development.",Suganya Selvarajah; Anuradha F Lingappa; Maya Michon; Shao Feng Yu; Amanda Macieik; Suguna Mallesh; Umesh Appiah; Jackelyn Crabtree; Kiel Copeland; Jim Lin; Olayemi Akintunde; Christine Nichols; Emma Petrouski; A. Raquel Moreira; I-ting Jiang; Nicholas DeYarman; Sean Broce; Ian Brown; Sharon Lau; Ilana Segal; Danielle Goldsmith; Shi Hong; Vinod Asundi; Erica M Briggs; Ngwe Sin Phyo; Markus Froehlich; Robert J Hogan; Ralph A Tripp; Sanjeev Anand; Thomas W. Campi; Michael Ford; Jonathan C. Reed; Bruce Onisko; Kent Matlack; Debendranath Dey; Jaisri R Lingappa; M Dharma Prasad; Anatoliy Kitaygorodskyy; Dennis Solas; Kumar Paulvannan; Vishwanath R Lingappa,https://biorxiv.org/cgi/content/short/2021.01.17.426875,https://biorxiv.org/cgi/content/short/2021.01.17.426875,2021-01-18,2021-01-18,,False
481,Large scale genomic and evolutionary study reveals SARS-CoV-2 virus isolates from Bangladesh strongly correlate with European origin and not with China.,"RationaleThe global public health is in serious crisis due to emergence of SARS-CoV-2 virus. Studies are ongoing to reveal the genomic variants of the virus circulating in various parts of the world. However, data generated from low- and middle-income countries are scarce due to resource limitation. This study was focused to perform whole genome sequencing of 151 SARS-CoV-2 isolates from COVID-19 positive Bangladeshi patients. The goal of this study was to identify the genomic variants among the SARS-CoV-2 virus isolates in Bangladesh, to determine the molecular epidemiology and to develop a relationship between host clinical trait with the virus genomic variants.

MethodSuspected patients were tested for COVID-19 using one step commercial qPCR kit for SARS-CoV-2 Virus. Viral RNA was extracted from positive patients, converted to cDNA which was amplified using Ion AmpliSeq SARS-CoV-2 Research Panel. Massive parallel sequencing was carried out using Ion AmpliSeq Library Kit Plus. Assembly of raw data is done by aligning the reads to a pre-defined reference genome (NC_045512.2) while retaining the unique variations of the input raw data by creating a consensus genome. A random forest-based association analysis was carried out to correlate the viral genomic variants with the clinical traits present in the host.

ResultAmong the 151 viral isolates, we observed the 413 unique variants. Among these 8 variants occurred in more than 80 % of cases which include 241C to T, 1163A to T, 3037C to T,14408C to T, 23403A to G, 28881G to A, 28882 G to A, and finally the 28883G to C. Phylogenetic analysis revealed a predominance of variants belonging to GR clade, which have a strong geographical presence in Europe, indicating possible introduction of the SARS-CoV-2 virus into Bangladesh through a European channel. However, other possibilities like a route of entry from China cannot be ruled out as viral isolate belonging to L clade with a close relationship to Wuhan reference genome was also detected. We observed a total of 37 genomic variants to be strongly associated with clinical symptoms such as fever, sore throat, overall symptomatic status, etc. (Fishers Exact Test p-value<0.05). The most mention-worthy among those were the 3916CtoT (associated with causing sore throat, p-value 0.0005), the 14408C to T (associated with protection from developing cough, p-value= 0.027), and the 28881G to A, 28882G to A, and 28883G to C variant (associated with causing chest pain, p-value 0.025).

ConclusionTo our knowledge, this study is the first large scale phylogenomic studies of SARS-CoV-2 virus circulating in Bangladesh. The observed epidemiological and genomic features may inform future research platform for disease management, vaccine development and epidemiological study.",Mohammad Fazle Alam Rabbi; Md. Imran Khan; Saam Hasan; Mauricio Chalita; Kazi Nadim Hasan; Abu Sufian; Md. Bayejid Hosen; Mohammed Nafiz Imtiaz Polol; Jannatun Naima; Kihyun Lee; Yeong Ouk Kim; Mamudul Hasan Razu; Mala Khan; Md. Mizanur Rahman; Jongsik Chun; Md. Abdul Khaleque; Nur A Hasan; Rita R Colwell; Sharif Akhteruzzaman,https://biorxiv.org/cgi/content/short/2021.01.17.425424,https://biorxiv.org/cgi/content/short/2021.01.17.425424,2021-01-18,2021-01-18,,False
482,A national analysis of trends in COVID-19 infection and clinical management in Veterans Health Administration medical facilities,"OBJECTIVEWe explored longitudinal trends in sociodemographic characteristics, reported symptoms, laboratory findings, pharmacological and non-pharmacological treatment, comorbidities, and 30-day in-hospital mortality among hospitalized patients with coronavirus disease 2019 (COVID-19).

METHODSThis retrospective cohort study included 43,267 patients diagnosed with COVID-19 in the Veterans Health Administration between 03/01/20 and 08/31/20 and followed until 09/30/20. We focused our analysis on patients that were subsequently hospitalized, and categorized them into groups based on the month of hospitalization. We summarized our findings through descriptive statistics. We used a nonparametric rank-sum test for trend to examine any differences in the distribution of our study variables across the six months.

RESULTSDuring our study period, 8,240 patients were hospitalized, and 1,081 (13.1%) died within 30 days of admission. Hospitalizations increased over time, but the proportion of patients that died consistently declined from March (N=221/890, 24.8%) to August (N=111/1,396, 8.0%). Patients hospitalized in March compared to August were younger on average, mostly black, and symptomatic. They also had a higher frequency of baseline comorbidities, including hypertension and diabetes, and were more likely to present with abnormal laboratory findings including low lymphocyte counts and elevated creatinine. Lastly, receipt of mechanical ventilation and Hydroxychloroquine declined from March to August, while treatment with Dexamethasone and Remdesivir increased.

CONCLUSIONWe found evidence of declining COVID-19 severity and fatality over time within a national health care system.",Maya Aboumrad; Brian Shiner; Natalie Riblet; Hugh Huizenga; Nabin Neupane; Yinong Young-Xu,https://biorxiv.org/cgi/content/short/2021.01.18.427092,https://biorxiv.org/cgi/content/short/2021.01.18.427092,2021-01-18,2021-01-18,,False
483,SARS-CoV-2 viral load distribution in different patient populations and age groups reveals that viral loads increase with age.,"ObjectiveTo describe the SARS-CoV-2 viral load distribution in different patient groups and age categories.

MethodsAll SARS-CoV-2 RT-PCR results from nasopharyngeal (NP) and oropharyngeal (OP) swabs (first PCR from unique patients only) that were collected between January 1 and December 1, 2020, predominantly in the Public Health Services regions Kennemerland and Hollands Noorden, province of North Holland, the Netherlands were included in this study. Swabs were derived from patients with respiratory symptoms who were presented at the general practitioner (GP), hospital, or hospital health care workers (HCWs) of four regional hospitals, nursing home residents and HCWs of multiple nursing homes, and in majority (>75%) from Public Health testing facilities of the two Public Health Services. SARS-CoV-2 PCR crossing point (Cp) values were used to estimate viral loads (higher Cp-values indicate lower viral loads).

ResultsIn total, 278.455 unique patients were tested of whom 9{middle dot}1% (n=25.374) were SARS-CoV-2 positive. As there were differences in viral load distribution between tested populations, further analyses focused on PCRs performed by public health services (n=211.914) where sampling and inclusion were uniform. These data reveal a clear relation between age and SARS-CoV-2 viral load, with especially children aged<12 years showing lower viral loads than shown in adults ({beta}: -0{middle dot}03, 95CI% -0{middle dot}03 to -0{middle dot}02, p<0{middle dot}001), independent of sex and/or symptom duration. Interestingly, the median Cp-values between the oldest (>79 years) and youngest (<12 years) population differed by over 4 PCR cycles, suggesting approximately a 16-fold difference in viral load. In addition, the proportion of children aged <12 years with a low load (Cp-value >30) was significantly higher compared to the other patients (31{middle dot}1% vs. 17{middle dot}2%, p-value<0.001).

ConclusionWe observed that in patients tested by Public Health Services, SARS-CoV2 viral load increases significantly with age. Previous studies suggest that young children (<12 years) play a limited role in SARS-CoV-2 transmission. Currently, the relation between viral load and infectivity is not yet well understood, and further studies should elucidate whether the lower viral load in children is indeed related to their suggested limited role in SARS-CoV-2 transmission. Moreover, as rapid antigen tests are less sensitive than PCR, these results suggest that SARS-CoV-2 antigen tests could have lower sensitivity in children than in adults.",Sjoerd Euser; Sem Aronson; Irene Manders; Steven van Lelyveld; Bjorn Herpers; Jan Sinnige; Jayant Kalpoe; Claudia van Gemeren; Dominic Snijders; Ruud Jansen; Sophie Schuurmans Stekhoven; Marlies van Houten; Ivar Lede; James Cohen Stuart; Fred Slijkerman Megelink; Erik Kapteijns; Jeroen den Boer; Elisabeth Sanders; Alex Wagemakers; Dennis Souverein,https://medrxiv.org/cgi/content/short/2021.01.15.21249691,https://medrxiv.org/cgi/content/short/2021.01.15.21249691,2021-01-17,2021-01-17,,True
484,Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2,"BackgroundIndia has been amongst the most affected nations during the SARS-CoV2 pandemic, with sparse data on country-wide spread of asymptomatic infections and antibody persistence. This longitudinal cohort study was aimed to evaluate SARS-CoV2 sero-positivity rate as a marker of infection and evaluate temporal persistence of antibodies with neutralization capability and to infer possible risk factors for infection.

MethodsCouncil of Scientific and Industrial Research, India (CSIR) with its more than 40 laboratories and centers in urban and semi-urban settings spread across the country piloted the pan country surveillance. 10427 adult individuals working in CSIR laboratories and their family members based on voluntary participation were assessed for antibody presence and stability was analyzed over 6 months utilizing qualitative Elecsys SARS CoV2 specific antibody kit and GENScript cPass SARS-CoV2 Neutralization Antibody Detection Kit. Along with demographic information, possible risk factors were evaluated through self to be filled online forms with data acquired on blood group type, occupation type, addiction and habits including smoking and alcohol, diet preferences, medical history and transport type utilized. Symptom history and information on possible contact and compliance with COVID 19 universal precautions was also obtained.

Findings1058 individuals (10{middle dot}14%) had antibodies against SARS-CoV2. A follow-up on 346 sero-positive individuals after three months revealed stable to higher antibody levels against SARS-CoV2 but declining plasma activity for neutralizing SARS-CoV2 receptor binding domain and ACE2 interaction. A repeat sampling of 35 individuals, at six months, revealed declining antibody levels while the neutralizing activity remained stable compared to three months. Majority of sero-positive individuals (75%) did not recall even one of nine symptoms since March 2020. Fever was the most common symptom with one-fourth reporting loss of taste or smell. Significantly associated risks for sero-positivity (Odds Ratio, 95% CI, p value) were observed with usage of public transport (1{middle dot}79, 1{middle dot}43 - 2{middle dot}24, 2{middle dot}81561E-06), occupational responsibilities such as security, housekeeping personnel etc. (2{middle dot}23, 1{middle dot}92 - 2{middle dot}59, 6{middle dot}43969E-26), non-smokers (1{middle dot}52, 1{middle dot}16 - 1{middle dot}99, 0{middle dot}02) and non-vegetarianism (1{middle dot}67, 1{middle dot}41 - 1{middle dot}99, 3{middle dot}03821E-08). An iterative regression analysis was confirmatory and led to only modest changes to estimates. Predilections for sero-positivity was noted with specific ABO blood groups -O was associated with a lower risk.

InterpretationIn a first-of-its-kind study from India, we report the sero-positivity in a country-wide cohort and identify variable susceptible associations for contacting infection. Serology and Neutralizing Antibody response provides much-sought-for general insights on the immune response to the virus among Indians and will be an important resource for designing vaccination strategies.

FundingCouncil of Scientific and Industrial Research, India (CSIR)",Salwa Naushin; Viren Sardana; Rajat Ujjainiya; Nitin Bhatheja; Rintu Kutum; Akash Kumar Bhaskar; Shalini Pradhan; Satyartha Prakash; Raju Khan; Birendra Singh Rawat; Giriraj Ratan Chandak; Karthik Bharadwaj Tallapaka; Mahesh Anumalla; Amit Lahiri; Susanta Kar; Shrikant Ramesh Mulay; Madhav Nilakanth Mugale; Mrigank Srivastava; Shaziya Khan; Anjali Srivastava; Bhawna Tomar; Murugan Veerapandian; Ganesh Venkatachalam; Selvamani Raja Vijayakumar; Ajay Agarwal; Dinesh Gupta; Prakash M Halami; Muthukumar Serva Peddha; Gopinath M; Ravindra P Veeranna; Anirban Pal; Vinay Kumar Agarwal; Anil Ku Maurya; Ranvijay Kumar Singh; Ashok Kumar Raman; Suresh Kumar Anandasadagopan; Parimala Karupannan; Subramanian Venkatesan; Harish Kumar Sardana; Anamika Kothari; Rishabh Jain; Anupma Thakur; Devendra Singh Parihar; Anas Saifi; Jasleen Kaur; Virendra Kumar; Avinash Mishra; Iranna Gogeri; Geetha Vani Rayasam; Praveen Singh; Rahul Chakraborty; Gaura Chaturvedi; Pinreddy Karunakar; Rohit Yadav; Sunanda Singhmar; Dayanidhi Singh; Sharmistha Sarkar; Purbasha Bhattacharya; Sundaram Acharya; Vandana Singh; Shweta Verma; Drishti Soni; Surabhi Seth; Firdaus Fatima; Shakshi Vashisht; Sarita Thakran; Akash Pratap Singh; Akanksha Sharma; Babita Sharma; Manikandan Subramanian; Yogendra Padwad; Vipin Hallan; Vikram Patial; Damanpreet Singh; Narendra Vijay Tirpude; Partha Chakrabarti; Sujay Krishna Maity; Dipyaman Ganguly; Jit Sarkar; Sistla Ramakrishna; Balthu Narender Kumar; Kiran A Kumar; Sumit G. Gandhi; Piyush Singh Jamwal; Rekha Chouhan; Vijay Lakshmi Jamwal; Nitika Kapoor; Debashish Ghosh; Ghanshyam Thakkar; Umakanta Subudhi; Pradip Sen; Saumya Raychaudhri; Amit Tuli; Pawan Gupta; Rashmi Kumar; Deepak Sharma; Rajesh P. Ringe; Amarnarayan D; Mahesh Kulkarni; Dhanasekaran Shanmugam; Mahesh Dharne; Syed G Dastager; Rakesh Joshi; Amita P. Patil; Sachin N Mahajan; Abu Junaid Khan; Vasudev Wagh; Rakeshkumar Yadav; Ajinkya Khilari; Mayuri Bhadange; Arvindkumar H. Chaurasiya; Shabda E Kulsange; Krishna khairnar; Shilpa Paranjape; Jatin Kalita; G.Narahari Sastry; Tridip Phukan; Prasenjit Manna; Wahengbam Romi; Pankaj Bharali; Dibyajyoti Ozah; Ravi Kumar Sahu; Elapaval VSSK Babu; Rajeev K Sukumaran; Aishwarya R Nair; Anoop Puthiyamadam; Prajeesh Kooloth Valappil; Adarsh Velayudhanpillai; Kalpana Chodankar; Samir Damare; Yennapu Madhavi; Ved Varun Agrawal; Sumit Dahiya; Anurag Agrawal; Debasis Dash; Shantanu Sengupta,https://medrxiv.org/cgi/content/short/2021.01.12.21249713,https://medrxiv.org/cgi/content/short/2021.01.12.21249713,2021-01-16,2021-01-16,,True
485,A Serology Strategy for Epidemiological Studies Based on the Comparison of the Performance of Seven Different Test Systems - The Representative COVID-19 Cohort Munich,"BackgroundSerosurveys are essential to understand SARS-CoV-2 exposure and enable population-level surveillance, but currently available tests need further in-depth evaluation. We aimed to identify testing-strategies by comparing seven seroassays in a population-based cohort.

MethodsWe analysed 6,658 samples consisting of true-positives (n=193), true-negatives (n=1,091), and specimens of unknown status (n=5,374). For primary testing, we used Euroimmun-Anti-SARS-CoV-2-ELISA-IgA/IgG and Roche-Elecsys-Anti-SARS-CoV-2; and virus-neutralisation, GeneScript(R)cPass, VIRAMED-SARS-CoV-2-ViraChip(R), and Mikrogen-recomLine-SARS-CoV-2-IgG, including common-cold CoVs, for confirmatory testing. Statistical modelling generated optimised assay cut-off-thresholds.

FindingsSensitivity of Euroimmun-anti-S1-IgA was 64.8%, specificity 93.3%; for Euroimmun-anti-S1-IgG, sensitivity was 77.2/79.8% (manufacturers/optimised cut-offs), specificity 98.0/97.8%; Roche-anti-N sensitivity was 85.5/88.6%, specificity 99.8/99.7%. In true-positives, mean and median titres remained stable for at least 90-120 days after RT-PCR-positivity. Of true-positives with positive RT-PCR (<30 days), 6.7% did not mount detectable seroresponses. Virus-neutralisation was 73.8% sensitive, 100.0% specific (1:10 dilution). Neutralisation surrogate tests (GeneScript(R)cPass, Mikrogen-recomLine-RBD) were >94.9% sensitive, >98.1% specific. Seasonality had limited effects; cross-reactivity with common-cold CoVs 229E and NL63 in SARS-CoV-2 true-positives was significant.

ConclusionOptimised cut-offs improved test performances of several tests. Non-reactive serology in true-positives was uncommon. For epidemiological purposes, confirmatory testing with virus-neutralisation may be replaced with GeneScript(R)cPass or recomLine-RBD. Head-to-head comparisons given here aim to contribute to the refinement of testing-strategies for individual and public health use.",Laura Olbrich; Noemi Castelletti; Yannik Schaelte; Merce Gari; Peter Puetz; Abhishek Bakuli; Michael Pritsch; Inge Kroidl; Elmar Saathoff; Jessica Michelle Guggenbuehl Noller; Volker Fingerle; Ronan Le Gleut; Leonard Gilberg; Isabel Brand; Philine Falk; Alisa Markgraf; Flora Deak; Friedrich Riess; Max Diefenbach; Tabea M Eser; Franz Weinauer; Silke Martin; Ernst-Markus Quenzel; Marc Becker; Juergen Durner; Philipp Girl; Katharina Mueller; Katja Radon; Christiane Fuchs; Roman Woelfel; Jan Hasenauer; Michael Hoelscher; Andreas Wieser,https://medrxiv.org/cgi/content/short/2021.01.13.21249735,https://medrxiv.org/cgi/content/short/2021.01.13.21249735,2021-01-16,2021-01-16,,True
486,Metabolic markers distinguish COVID-19 from other intensive care patients and show potential to stratify for disease risk,"Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus. there is increasing interest in metabolic and lipoprotein signatures of the disease and early analyses have demonstrated metabolic pattern typical for atherosclerotic and hepatic damage in COVID-19 patients. However, it remains unclear whether these are specific for COVID-19 or a general marker of critical illness. To answer this question, we have analyzed 276 serum samples from 92 individuals using NMR metabolomics, including longitudinally collected samples from 5 COVID-19 and 11 cardiogenic shock intensive care patients, 18 SARS-CoV-2 antibody-positive individuals, and 58 healthy controls.

COVID-19 patients showed a distinct metabolic serum profile, including changes typical for severe dyslipidemia and a deeply altered metabolic status compared to healthy controls. Specifically, VLDL parameters, IDL particles, large-sized LDL particles, and the ApoB100/ApoA1 ratio were significantly increased, whereas HDL fractions were decreased. Moreover, a similarly perturbed profile was apparent, even when compared to other ICU patients suffering from cardiogenic shock, highlighting the impact of COVID-19 especially on lipid metabolism and energy status. COVID-19 patients were separated with an AUROC of 1.0 when compared to both healthy controls and cardiogenic shock patients. Anti-SARS-CoV-2 antibody-positive individuals without acute COVID-19 did not show a significantly perturbed metabolic profile compared to age- and sex-matched healthy controls, but SARS-CoV-2 antibody-titers correlated significantly with metabolic parameters, including levels of glycine, ApoA2, and small-sized LDL and HDL subfractions. Our data suggest that NMR metabolic profiles are suitable for COVID-19 patient stratification and post-treatment monitoring.",Franziska Schmelter; Bandik Foeh; Alvaro Mallagray; Johann Rahmoeller; Marc Ehlers; Selina Lehrian; Vera von Kopylow; Inga Kuensting; Anne Sophie Lixenfeld; Emily Martin; Mohab Ragab; Max Borsche; Alexander Balck; Eva Juliane Vollstedt; Roza Meyer-Saraei; Fabian Kreutzmann; Ingo Eitel Eitel; Stefan Taube Taube; Christine Klein Klein; Alexander Katalinic Katalinic; Jan Rupp Rupp; Eckard Jantzen Jantzen; Tobias Graf; Christian Sina; Ulrich L Guenther,https://medrxiv.org/cgi/content/short/2021.01.13.21249645,https://medrxiv.org/cgi/content/short/2021.01.13.21249645,2021-01-16,2021-01-16,,True
487,SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy,"Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. To gauge the effectiveness of these measures at the University of Pennsylvania, we conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between 5/21/2020 and 10/8/2020. Participants completed questionnaires and had up to five serial blood collections. Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95%CI 0.0-4.1%) over 14.8 person-years of follow up, with a median of 13 healthcare visits per patient. These results suggest that cancer patients receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.",Lova Sun; Sanjna Surya; Noah G.; Anh N. Le; Gregory Kelly; Olutosin Owoyemi; Heena Desai; Cathy Zheng; Shannon DeLuca; Madeline L. Good; Jasmin Hussain; Seth D. Jeffries; Yolanda R. Kry; Emily M. Kugler; Maikel Mansour; John Ndicu; AnnaClaire Osei-Akoto; Timothy Prior; Stacy L. Pundock; Lisa A. Varughese; JoEllen Weaver; Abigail Doucette; Scott Dudek; Shefali Setia Verma; Sigrid Gouma; Madison E. Weirick; Christopher M. McAllister; Erin Bange; Peter Gabriel; Marylyn Ritchie; Daniel J. Rader; Robert H. Vonderheide; Lynn M Schuchter; Anurag Verma; Ivan Maillard; Ronac Mamtani; Scott E. Hensley; Robert Gross; E. Paul Wileyto; Alexander C. Huang; Kara N. Maxwell; Angela DeMichele,https://medrxiv.org/cgi/content/short/2021.01.15.21249810,https://medrxiv.org/cgi/content/short/2021.01.15.21249810,2021-01-16,2021-01-16,,True
488,Reduction in transfer of micro-organisms between patients and staff using short-sleeved gowns and hand/arm hygiene in Intensive Care during the Covid pandemic: a simulation-based randomised trial.,"BackgroundCurrent PPE practices in UK intensive care units involve ""sessional"" gown use. This protects staff, but puts patients at risk of nosocomial infection via PPE gowns. Anecdotal reports of such infections in ITUs during Covid are frequent. We therefore explored the use of short-sleeved gowns with hand and arm hygiene as an alternative to sessional gowns.

MethodsITU Staff were invited for simulation suite training in Covid intubation and proning. They were trained in a specific hand and arm washing technique before performing simulated tasks using both standard and modified (short sleeved) PPE. Fluorescent powder was used to simulate micro-organisms, and detected using standardised photos under U/V light. Teams of staff were randomised to use standard or modified PPE first. Individuals were questioned about their feeling of personal safety, comfort and the patients safety at 4 intervals.

Results68 staff and 17 proning volunteers were studied in 17 sessions. Modified PPE completely prevented staff contamination during Covid intubation, which occurred in 30/67 staff wearing standard PPE (p = 0.0029, McNemar). Conversely, proning volunteers were contaminated by staff in 15/17 sessions with standard PPE and in 1/17 with modified PPE (P = 0.0227 McNemar). Impressions of staff comfort were superior with modified PPE (p< 0.001, t-test); personal safety scored higher with standard PPE, but the difference decreased during the session (p<0.001 start, 0.068 end). Impressions of patient safety were initially similar (p=0.87) but finished strongly in favour of modified PPE (p<0.001).

ConclusionsModified PPE using short sleeves and hand/arm cleansing appears superior to standard PPE with sessional gowns in preventing transfer of contamination between staff and patients. A clinical trial of this strategy is merited.",Laura Vincent; Mudathir Ibrahim; Joanne Kitchin; Claire Pickering; Enrico Sorrentino; Claudia Salvagno; Laurie Earl; Louise Ma; Kathryn Simpson; Rose Baker; Peter McCulloch,https://medrxiv.org/cgi/content/short/2021.01.16.21249221,https://medrxiv.org/cgi/content/short/2021.01.16.21249221,2021-01-16,2021-01-16,,True
489,Modeling the impact of racial and ethnic disparities on COVID-19 epidemic dynamics,"The impact of variable infection risk by race and ethnicity on the dynamics of SARS-CoV-2 spread is largely unknown. Here, we fit structured compartmental models to seroprevalence data from New York State and analyze how herd immunity thresholds (HITs), final sizes, and epidemic risk changes across racial and ethnic groups. A proportionate mixing model reduced the overall HIT, but more realistic levels of assortative mixing increased the threshold. Across all models, the burden of infection fell disproportionately on minority populations: in an assortative mixing model fit to Long Island census data, 80% of Hispanics or Latinos were infected when the HIT is reached compared to 33% of non-Hispanic whites. Our findings, which are meant to be illustrative and not best estimates, demonstrate how racial and ethnic disparities can impact epidemic trajectories and result in a dis-proportionate distribution of the burden of SARS-CoV-2 infection.",Kevin C Ma; Tigist Menkir; Stephen Kissler; Yonatan Grad; Marc Lipsitch,https://medrxiv.org/cgi/content/short/2021.01.15.21249881,https://medrxiv.org/cgi/content/short/2021.01.15.21249881,2021-01-15,2021-01-15,,True
490,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,"In the midst of a pandemic, serologic studies are a valuable tool to understand the course of the outbreak and guide public health and general pandemic management. However, given significant safety constraints including social distancing and stay-at-home orders, sample collection becomes more difficult given traditional phlebotomy protocols. For such studies, a representative sample of the underlying population is paramount to elicit meaningful insights that capture the spread of the infection, particularly when different sub-populations face varying disease burden. We aimed to address these challenges by conducting a fully remote study to investigate the seroprevalence of SARS-CoV-2 in the state of Massachusetts. Leveraging electronic study engagement and at-home self-collection of finger-prick samples, we enrolled 2,066 participants representative of the ethnic and racial composition of Massachusetts. SARS-CoV-2 total IgG seropositivity was 3.15%, and follow-up measurements at days 7, 15, 45, and 90 indicate a generally durable antibody response. A higher risk of infection was observed for healthcare workers and their cohabitants and those with comorbidities, as well as lower-income, less educated, Hispanic, and those in the age groups of 18-29 and 50-59-years-old. High engagement and positive feedback from the participants and quality of self-collected specimens point to the usefulness of this design for future population-level serological studies that more effectively and safely reach a broad representative cohort, thus yielding more comprehensive insights into the burden of infection and disease in populations.

Key pointsO_ST_ABSQuestionC_ST_ABSWe aimed to implement a fully remote seroprevalence study for SARS-CoV-2, leveraging electronic methods and at-home self-collection of specimens to engage a representative study population.

FindingsThe population enrolled reflected the ethnic and racial composition of Massachusetts, revealing a SARS-CoV-2 seroprevalence of 3.15% and higher risk of previous infection associated with healthcare workers/their cohabitants, those with comorbidities, lower-income, less educated, Hispanic, and those in age groups 18-29 and 50-59 years old.

MeaningHigh engagement and positive feedback from participants as well as quality of self-collected specimens point to the usefulness of this design for future population-level serological studies.",Aishani V Aatresh; Kate Cummings; Hilary Gerstein; Christopher S Knight; Andreas Limberopolous; Megan A Stasi; Alice Bedugnis; Kenneth A Somberg; Camila T Franca; Michael J Mina,https://medrxiv.org/cgi/content/short/2021.01.14.21249824,https://medrxiv.org/cgi/content/short/2021.01.14.21249824,2021-01-15,2021-01-15,,True
491,Importance of patient bed pathways and length of stay differences in predicting COVID-19 bed occupancy in England,"ObjectivesPredicting bed occupancy for hospitalised patients with COVID-19 requires understanding of length of stay (LoS) in particular bed types. LoS can vary depending on the patients ""bed pathway"" - the sequence of transfers between bed types during a hospital stay. In this study, we characterise these pathways, and their impact on predicted hospital bed occupancy.

DesignWe obtained data from University College Hospital (UCH) and the ISARIC4C COVID-19 Clinical Information Network (CO-CIN) on hospitalised patients with COVID-19 who required care in general ward or critical care (CC) beds to determine possible bed pathways and LoS. We developed a discrete-time model to examine the implications of using either bed pathways or only average LoS by bed type to forecast bed occupancy. We compared model-predicted bed occupancy to publicly available bed occupancy data on COVID-19 in England between March and August 2020.

ResultsIn both the UCH and CO-CIN datasets, 82% of hospitalised patients with COVID-19 only received care in general ward beds. We identified four other bed pathways, present in both datasets: ""Ward, CC, Ward"", ""Ward, CC"", ""CC"" and ""CC, Ward"". Mean LoS varied by bed type, pathway, and dataset, between 1.78 and 13.53 days.

For UCH, we found that using bed pathways improved the accuracy of bed occupancy predictions, while only using an average LoS for each bed type underestimated true bed occupancy. However, using the CO-CIN LoS dataset we were not able to replicate past data on bed occupancy in England, suggesting regional LoS heterogeneities.

ConclusionsWe identified five bed pathways, with substantial variation in LoS by bed type, pathway, and geography. This might be caused by local differences in patient characteristics, clinical care strategies, or resource availability, and suggests that national LoS averages may not be appropriate for local forecasts of bed occupancy for COVID-19.",Quentin J Leclerc; Naomi M Fuller; Ruth H Keogh; Karla Diaz-Ordaz; Richard Sekula; Malcolm G Semple; - ISARIC4C Investigators; - CMMID COVID-19 Working Group; Katherine E Atkins; Simon R Procter; Gwenan M Knight,https://medrxiv.org/cgi/content/short/2021.01.14.21249791,https://medrxiv.org/cgi/content/short/2021.01.14.21249791,2021-01-15,2021-01-15,,True
492,"Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020","BackgroundThere is an urgent need to better understand whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection.

MethodsA large multi-centre prospective cohort was recruited from publicly funded hospital staff in the UK. Participants attended regular SARS-CoV-2 PCR and antibody testing (every 2-4 weeks) and completed fortnightly questionnaires on symptoms and exposures. At enrolment, participants were assigned to either the positive cohort (antibody positive or prior PCR/antibody test positive) or negative cohort (antibody negative, not previously known to be PCR/antibody positive). Potential reinfections were clinically reviewed and classified according to case definitions (confirmed, probable, possible (subdivided by symptom-status)) depending on hierarchy of evidence. Individuals in the primary infection were excluded from this analysis if infection was confirmed by antibody only. Reinfection rates in the positive cohort were compared against new PCR positives in the negative cohort using a mixed effective multivariable logistic regression analysis.

FindingsBetween 18 June and 09 November 2020, 44 reinfections (2 probable, 42 possible) were detected in the baseline positive cohort of 6,614 participants, collectively contributing 1,339,078 days of follow-up. This compares with 318 new PCR positive infections and 94 antibody seroconversions in the negative cohort of 14,173 participants, contributing 1,868,646 days of follow-up. The incidence density per 100,000 person days between June and November 2020 was 3.3 reinfections in the positive cohort, compared with 22.4 new PCR confirmed infections in the negative cohort. The adjusted odds ratio was 0.17 for all reinfections (95% CI 0.13-0.24) compared to PCR confirmed primary infections. The median interval between primary infection and reinfection was over 160 days.

InterpretationA prior history of SARS-CoV-2 infection was associated with an 83% lower risk of infection, with median protective effect observed five months following primary infection. This is the minimum likely effect as seroconversions were not included.

FundingDepartment of Health and Social Care and Public Health England, with contributions from the Scottish, Welsh and Northern Irish governments.",Victoria Jane Hall; Sarah Foulkes; Andre Charlett; Ana Atti; Edward JM Monk; Ruth Simmons; Edgar Wellington; Michelle J Cole; Ayoub Saei; Blanche Oguti; Katie Munro; Sarah Wallace; Peter D Kirwan; Madhumita Shrotri; Amoolya Vusirikala; Sakib Rokadiya; Meaghan Kall; Maria Zambon; Mary Ramsay; Tim Brooks; - SIREN Sudy Group; Colin S Brown; Meera A Chand; Susan Hopkins,https://medrxiv.org/cgi/content/short/2021.01.13.21249642,https://medrxiv.org/cgi/content/short/2021.01.13.21249642,2021-01-15,2021-01-15,,True
493,Direct Simulation of the CoVid-19 epidemic,"AO_SCPLOWBSTRACTC_SCPLOWWe introduce an agent-based model to simulate the epidemiological dynamics of COVID-19. Most computational models proposed to study this epidemic do no take into account human mobility. We present a direct simulation model where mobility plays a key role and propose as well four quarantine strategies. The results show that the no-quarantine strategy does lead to a high peak of contagions with no rebound. Quarantined strategies, for their part, show a re-emergence of the epidemic with smaller and softer peaks.",Augusto Cabrera-Becerril; Raul Peralta; Pedro Miramontes,https://medrxiv.org/cgi/content/short/2021.01.14.21249829,https://medrxiv.org/cgi/content/short/2021.01.14.21249829,2021-01-15,2021-01-15,,True
494,Epidemiological Investigation of New SARS-CoV-2 Variant of Concern 202012/01 in England,"Lighthouse Labs network tests for the presence of RNA of SARS-CoV-2, the causative agent of COVID-19. The Thermofisher TaqPath assay targets three regions of SARS-CoV-2; ORF1ab, N and S-genes. The assay identified a drop in S-gene target detection among positive samples due to the circulation of a new SARS-CoV-2 Variant of Concern (VOC) designated as 202012/01. By end of December 2020, 60% of daily positive test results at Alderley Park Lighthouse Labs, were linked to the new Variant of Concern. This timeline view identifies the rapid spread of the variant across the country.",Alfredo Maria Gravagnuolo; Layla Faqih; Cara Cronshaw; Jackie Wynn; Lewis Burglin; Paul Klapper; Mark Wigglesworth,https://medrxiv.org/cgi/content/short/2021.01.14.21249386,https://medrxiv.org/cgi/content/short/2021.01.14.21249386,2021-01-15,2021-01-15,,True
495,"Modelling the Spreading of the SARS-CoV-2 in Presence of the Lockdown and Quarantine Measures by a ""Kinetic-Type Reactions"" Approach","We propose a realistic model for the evolution of the COVID-19 pandemic subject to the lockdown and quarantine measures, which takes into account the time-delay for recovery or death processes. The dynamic equations for the entire process are derived by adopting a kinetic-type reactions approach. More specifically, the lockdown and the quarantine measures are modelled by some kind of inhibitor reactions where susceptible and infected individuals can be trapped into inactive states. The dynamics for the recovered people is obtained by accounting people who are only traced back to hospitalised infected people. To get the evolution equation we take inspiration from the Michaelis-Mentens enzyme-substrate reaction model (the so-called MM reaction) where the enzyme is associated to the available hospital beds, the substrate to the infected people, and the product to the recovered people, respectively. In other words, everything happens as if the hospitals beds act as a catalyzer in the hospital recovery process. Of course, in our case the reverse MM reactions has no sense in our case and, consequently, the kinetic constant is equal to zero. Finally, the O.D.E.s for people tested positive to COVID-19 is simply modelled by the following kinetic scheme S + I {Rightarrow} 2I with I {Rightarrow} R or I {Rightarrow} D, with S, I, R, and D denoting the compartments Susceptible, Infected, Recovered, and Deceased people, respectively. The resulting kinetic-type equations provide the O.D.E.s, for elementary reaction steps, describing the number of the infected people, the total number of the recovered people previously hospitalised, subject to the lockdown and the quarantine measure, and the total number of deaths. The model foresees also the second wave of Infection by Coronavirus. The tests carried out on real data for Belgium, France and Germany confirmed the correctness of our model.",Giorgio SONNINO; Philippe PEETERS; Pasquale NARDONE,https://medrxiv.org/cgi/content/short/2021.01.14.21249797,https://medrxiv.org/cgi/content/short/2021.01.14.21249797,2021-01-15,2021-01-15,,True
496,Optimal piecewise constant vaccination and lockdown policies for COVID-19,"We formulate a controlled system of ordinary differential equations, with vaccination and lockdown interventions as controls, to simulate the mitigation of COVID-19. The performance of the controls is measured through a cost functional involving vaccination and lockdown costs as well as the burden of COVID19 quantified in DALYs. We calibrate parameters with data from Mexico City and Valle de Mexico. By using differential evolution, we minimize the cost functional subject to the controlled system and find optimal policies that are constant in time intervals of a given size. The main advantage of these policies relies on its practical implementation since the health authority has to make only a finite number of different decisions. Our methodology to find optimal policies is relatively general, allowing changes in the dynamics, the cost functional, or the frequency the policymaker changes actions.",Gabriel Adrian Salcedo-Varea; Francisco Penunuri; David Gonzalez-Sanchez; Saul Diaz-Infante,https://medrxiv.org/cgi/content/short/2021.01.13.21249773,https://medrxiv.org/cgi/content/short/2021.01.13.21249773,2021-01-15,2021-01-15,,True
497,Optimal SARS-CoV-2 vaccine allocation using real-time seroprevalence estimates in Rhode Island and Massachusetts,"As three SARS-CoV-2 vaccines come to market in Europe and North America in the winter of 2020-2021, distribution networks will be in a race against a major epidemiological wave of SARS-CoV-2 that began in autumn 2020. Rapid and optimized vaccine allocation is critical during this time. With 95% efficacy reported for two of the vaccines, near-term public health needs require that distribution is prioritized to the elderly, health-care workers, teachers, essential workers, and individuals with co-morbidities putting them at risk of severe clinical progression. Here, we evaluate various age-based vaccine distributions using a validated mathematical model based on current epidemic trends in Rhode Island and Massachusetts. We allow for varying waning efficacy of vaccine-induced immunity, as this has not yet been measured. We account for the fact that known COVID-positive cases may not be included in the first round of vaccination. And, we account for current age-specific immune patterns in both states. We find that allocating a substantial proportion (> 75%) of vaccine supply to individuals over the age of 70 is optimal in terms of reducing total cumulative deaths through mid-2021. As we do not explicitly model other high mortality groups, this result on vaccine allocation applies to all groups at high risk of mortality if infected. Our analysis confirms that for an easily transmissible respiratory virus, allocating a large majority of vaccinations to groups with the highest mortality risk is optimal. Our analysis assumes that health systems during winter 2020-2021 have equal staffing and capacity to previous phases of the SARS-CoV-2 epidemic; we do not consider the effects of understaffed hospitals or unvaccinated medical staff. Vaccinating only seronegative individuals avoids redundancy in vaccine use on individuals that may already be immune, and will result in 1% to 2% reductions in cumulative hospitalizations and deaths by mid-2021. Assuming high vaccination coverage (> 28%) and no major relaxations in distancing, masking, gathering size, or hygiene guidelines between now and spring 2021, our model predicts that a combination of vaccination and population immunity will lead to low or near-zero transmission levels by the second quarter of 2021.",Thu Nguyen-Anh Tran; Nathan Wikle; Joseph Albert; Haider Inam; Emily R Strong; Karel Brinda; Scott M Leighow; Fuhan Yang; Sajid Hossain; Justin R Pritchard; Philip Chan; William P Hanage; Ephraim M Hanks; Maciej F Boni,https://medrxiv.org/cgi/content/short/2021.01.12.21249694,https://medrxiv.org/cgi/content/short/2021.01.12.21249694,2021-01-15,2021-01-15,,True
498,"Socioeconomic status determines COVID-19 incidence and related mortality in Santiago, Chile","The current coronavirus disease 2019 (COVID-19) pandemic has impacted dense urban populations particularly hard. Here, we provide an in-depth characterization of disease incidence and mortality patterns, and their dependence on demographic and socioeconomic strata in Santiago, a highly segregated city and the capital of Chile. We find that among all age groups, there is a strong association between socioeconomic status and both mortality -measured either by direct COVID-19 attributed deaths or excess deaths- and public health capacity. Specifically, we show that behavioral factors like human mobility, as well as health system factors such as testing volumes, testing delays, and test positivity rates are associated with disease outcomes. These robust patterns suggest multiple possibly interacting pathways that can explain the observed disease burden and mortality differentials: (i) in lower socioeconomic status municipalities, human mobility was not reduced as much as in more affluent municipalities; (ii) testing volumes in these locations were insufficient early in the pandemic and public health interventions were applied too late to be effective; (iii) test positivity and testing delays were much higher in less affluent municipalities, indicating an impaired capacity of the health-care system to contain the spread of the epidemic; and (iv) infection fatality rates appear much higher in the lower end of the socioeconomic spectrum. Together, these findings highlight the exacerbated consequences of health-care inequalities in a large city of the developing world, and provide practical methodological approaches useful for characterizing COVID-19 burden and mortality in other segregated urban centers.",Gonzalo E Mena; Pamela P Martinez; Ayesha Mahmud; Pablo Marquet; Caroline Buckee; Mauricio Santillana,https://medrxiv.org/cgi/content/short/2021.01.12.21249682,https://medrxiv.org/cgi/content/short/2021.01.12.21249682,2021-01-15,2021-01-15,,True
499,Predicting Emerging Themes in Rapidly Expanding COVID-19 Literature with Dynamic Word Embedding Networks and Machine Learning,"BackgroundCOVID-19 knowledge has been changing rapidly with the fast pace of information that accompanied the pandemic. Since peer-reviewed research is a trusted source of evidence, capturing and predicting the emerging themes in COVID-19 literature are crucial for guiding research and policy. Machine learning, natural language processing and dynamical networks have the potential to enable rapid distillation and prediction of actionable insights for ending the pandemic.

ObjectiveWe hypothesized that emerging COVID-19 research trends can be captured and predicted from networks constructed upon language features. Further, we aimed to detect communities in these networks and used centrality measures to track and predict emerging network modules as dominant themes in a given time period. The goal of our study was to make our findings publicly available as an explainable AI dashboard for researchers and policymakers.

MethodsAbstracts from more than 95,000 peer-reviewed articles from the WHO curated COVID-19 database were used to construct word embedding models. Named entity recognition was used to refine the terms. Cosine similarity between the terms was then used to construct dynamical networks in order to understand the temporal trend of emerging associations over months and visualized as alluvial diagrams. Finally, temporal link prediction between diseases for the subsequent month based on their trends of occurrence in the previous six months was carried out to predict the emergence and disappearance of associations in the rapidly changing pandemic scenario.

ResultsCommunity detection upon dynamical networks clearly demonstrated the emergence of thromboembolic complications as a cluster and dominant theme between March and August, 2020. Forecasting of top-K influential entities further allowed prediction of future trends, such as the emergence of psychiatry theme as a central node by February 2021. XGBoost modeling in our proposed temporal link prediction framework achieved an AUC-ROC score of 0.855 for predicting new dis(associations) one month in advance. Visualization of the underlying word-embedding models allowed interactive querying to choose novel keywords and extractive models summarized the research relevant to the keyword, allowing faster knowledge distillation.

ConclusionWe provide an explainable AI approach for querying, tracking and predicting novel insights in COVID-19 peer reviewed literature. The EvidenceFlow web-application is publicly available and emerging trends are updated on a monthly basis. Such approaches will be crucial to understand and pre-empt actionable research such as vaccine strategies in the ongoing pandemic.",Ridam Pal; Harshita Chopra; Raghav Awasthi; Harsh Bandhey; Aditya Nagori; Amogh Gulati; Ponnurangam Kumaraguru; Tavpritesh Sethi,https://medrxiv.org/cgi/content/short/2021.01.14.21249855,https://medrxiv.org/cgi/content/short/2021.01.14.21249855,2021-01-15,2021-01-15,,True
500,Impact of training modules on physicians perspective of COVID-19: An online survey,"BackgroundThe outbreak of COVID-19 has remained a massive challenge for healthcare workers specially physicians. Effective professional training has a crucial role in preparing doctors for responding to pandemics.

ObjectiveTo assess the effectiveness of existing training modules on enhancing knowledge, ensuring safe practice, and improving behavior on COVID-19 among physicians.

MethodsThis is a descriptive, cross-sectional, online survey; where a virtual questionnaire was used to collect data through online professional platforms. A pre-tested survey tool was employed to assess the impact of professional training on infection prevention and control.

ResultsTotal 161 physicians participated in this survey from 15 different countries. Most of the respondents (72%) received training from various sources like the workplace (60%) and international agencies (21%), through the in-person or online format. Knowledge assessment revealed advanced (43%) and competent (40%) understanding by the participants. Improving knowledge progression was displayed by the cohort who received professional training (p<0.00). Physicians positive behavior and good practices were observed with the training modules.

ConclusionIt became evident from this study, that professional training is effective in enhancing knowledge, improving behavior, and ensuring safe practices. Hence, designing such training modules for the physicians is warranted to tackle ongoing and future pandemics.",Badar Uddin Umar; Nazmun Nahar Alam; Tanbira Alam; Mahmudul Mannan; S M Niazur Rahman,https://medrxiv.org/cgi/content/short/2021.01.13.21249689,https://medrxiv.org/cgi/content/short/2021.01.13.21249689,2021-01-15,2021-01-15,,True
501,Implementing Essential Coaching for Every Mother during COVID-19: A Pilot Pre-Post Intervention Study,"ObjectivesThe primary objective was to evaluate the preliminary impact of Essential Coaching for Every Mother on self-efficacy, social support, postpartum anxiety and postpartum depression. The second objective was to explore the acceptability of the Essential Coaching for Every Mother program provided during the COVID-19 pandemic.

MethodsA prospective pre-post study was conducted with first time mothers in Nova Scotia, Canada between July 15th and September 19th, 2020. Participants completed a self-report survey at enrolment (after birth) and six-weeks postpartum. Variety of standardized measures were used and qualitative feedback on the program was also collected. Paired t-tests were carried out to determine changes from baseline to follow-up on psychosocial outcomes and qualitative feedback was analysed through thematic analysis.

ResultsA total of 88 women enrolled. Self-efficacy increased between baseline (B) and follow-up (F) (B:33.33; F:37.11, p=0.000) while anxiety (STAI) declined (B:38.49; F:34.79; p=0.004). No other significant changes were found. In terms of acceptability, 89% of participants felt that the number of messages were just right, 84.5% felt the messages contained all the information they needed relative to caring for a newborn and 98.8% indicated they would recommend this program to other new mothers.

ConclusionEssential Coaching for Every Mother may play a role increasing maternal self-efficacy and decreasing anxiety, although future work with a control group is important to delineate the true effects of the program. Overall, mothers were satisfied with the Essential Coaching for Every Mother program and would recommend it for other mothers, during COVID-19 and beyond.",Justine Dol; Megan Aston; Amy Grant; Douglas McMillan; Gail Tomblin Murphy; Marsha Campbell-Yeo,https://medrxiv.org/cgi/content/short/2021.01.13.21249598,https://medrxiv.org/cgi/content/short/2021.01.13.21249598,2021-01-15,2021-01-15,,True
502,Sterilization of disposable face masks with respect to COVID-19 shortages; a nationwide field study including 19 sterilisation departments,"ObjectiveFace masks also referred to as half masks are essential to protect healthcare professionals, working in close contact with patients having Covid-19 related symptoms. During the threating deficit, healthcare institutions sought an approach to re-use face masks or to acquire imported masks. The objective of this study is to assess the quality of sterilised and imported FFP2/KN95 face mask materials.

Designprospective, bench-to-bedside

SettingGeneral healthcare including 19 hospitals in the Netherlands

InterventionsFace masks were reprocessed using a medical autoclave at 121{degrees}C.

MethodsA 48 minutes steam sterilization process of single-use face masks with 15 min holding time at a 121 {degrees}C was developed, validated and implemented in 19 different hospitals. Steam and H2O2 plasma sterilized as well as new, imported masks are tested in a custom-made, non-standard EN-149, test set-up that measures Particle Filtration Efficiency (PFE) and pressure drops.

ResultsPFE validation data of 84 masks indicated differences of 2.3{+/-}2 % (mean{+/-}SD) between the custom build test set-up and a continues flow according to the EN-149. Test data showed the mean PFE values of 444 sterilised FFP2 face masks from 19 CSSD were 90{+/-}11% (mean{+/-}SD) and of 474 imported KN95/FFP2 face masks 83{+/-}16% (mean{+/-}SD). Differences in PFE between sterilisation departments were found.

ConclusionFace masks can be reprocessed with 121 0 C steam or H2O2 plasma sterilization with minimum reduction of PFE. PFE comparison between sterilised mask and new, imported mask filter material indicates that most reprocessed masks of high quality brands outperform new imported face masks of unknown brands. Although the PFE of tested face mask material from different sterilisation departments remained efficient, different types of sterilisation equipment can result in different PFE outcomes.

Strengths and limitations of this study- Reprocessing face masks at 121 {degrees}C steam Sterilization, a simple method to be used by hospitals in times of shortages
- Laboratory findings to evaluate the safety and quality of face mask material
- The study is limited and restricted to selected FFP-2 face masks
- This study is a first of its kind in quality and safety check of the vast growing face masks, entering our markets
- The study focusses on testing environmental dry particles in a rapid test setup",Bart van Straten; Daniel Robertson; Harry Oussoren; Sue Ellen Pereira Espindola; Elmira Ghanbari; Jenny Dankelman; Stephen Picken; Tim Horeman,https://medrxiv.org/cgi/content/short/2021.01.15.21249843,https://medrxiv.org/cgi/content/short/2021.01.15.21249843,2021-01-15,2021-01-15,,True
503,SARS-CoV-2 infection control implementation based on sources of infection showing directions for three age groups in Japan,"BackgroundSome aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in children and adults remain unclear. This report describes different SARS-CoV-2 transmission patterns by age group in Japan.

Methods and findingsThis retrospective observational case series study analyzed transmission patterns of real-time polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infections found by local health authorities and commercial laboratories during January 14 through July 31, 2020 in Japan. After ascertaining the infection source for every symptomatic case as clusters at households, daycare facilities, schools, hospitals and workplaces etc., their associated transmission patterns were analyzed. Identified cases were divided into three groups: underage, < 20; adults, 20-59; and elderly people 60 years old and older. The reproductive number (R)s of respective transmission directions found for the respective age groups were compared.

Of 26,986 total cases, 23,746 unknown cases were found, leaving 3,240 ascertained sources of infection (12.0%) comprising 125 (3.9%) underage, 2350 (72.5%) adult, and 765 (23.6%) elderly people. The respective Rs of underage infection sources directed to underage, adult, and elderly people were estimated respectively as 0.0415 (95% CI, 0.0138-0.0691), 1.11 (95% CI, 0.9171-1.3226), and 0.2811 (95% CI, 0.2074-0.3687). The respective Rs of adult infection source directed to underage, adult, and elderly people were estimated respectively as 0.0140 (95% CI, 0.0120-0.0162), 0.5392 (95% CI, 0.5236-0.5550), and 0.1135 (95% CI, 0.1074-0.1197). The respective Rs of elderly infection source directed to underage, adult, and elderly people were estimated as 0.065 (95% CI, 0.0039-0.0091), 0.3264 (95% CI, 0.3059-0.3474), and 0.3991 (95% CI, 0.3757-0.4229).

ConclusionsThe main sources of SARS-CoV-2 infection were adults and elderly people. The R of underage people directed to adults was greater than 1 because of close familial contact but they were unlikely to become carriers transmitting SARS-CoV-2 because they accounted for a minority for transmissions. Apparently, SARS-CoV-2 was transmitted among adults and elderly people, suggesting that infection control of SARS-CoV-2 should be managed specifically by generation.",Atsuko Hata; Junko Kurita; Eri Muso; Toshiro Katayama; Takahide Hata; Yasushi Ohkusa,https://medrxiv.org/cgi/content/short/2021.01.14.21249637,https://medrxiv.org/cgi/content/short/2021.01.14.21249637,2021-01-15,2021-01-15,,True
504,How to best test suspected cases of COVID-19: an analysis of the diagnostic performance of RT-PCR and alternative molecular methods for the detection of SARS-CoV-2,"As COVID-19 testing is rolled out increasingly widely, the use of a range of alternative testing methods will be beneficial in ensuring testing systems are resilient and adaptable to different clinical and public health scenarios. Here, we compare and discuss the diagnostic performance of a range of different molecular assays designed to detect the presence of SARS-CoV-2 infection in people with suspected COVID-19. Using findings from a systematic review of 103 studies, we categorised COVID-19 molecular assays into 12 different test classes, covering point-of-care tests, various alternative RT-PCR protocols, and alternative methods such as isothermal amplification. We carried out meta-analyses to estimate the diagnostic accuracy and clinical utility of each test class. We also estimated the positive and negative predictive values of all diagnostic test classes across a range of prevalence rates. Using previously validated RT-PCR assays as a reference standard, 11 out of 12 classes showed a summary sensitivity estimate of at least 92% and a specificity estimate of at least 99%. Several diagnostic test classes were estimated to have positive predictive values of 100% throughout the investigated prevalence spectrum, whilst estimated negative predictive values were more variable and sensitive to disease prevalence. We also report the results of clinical utility models that can be used to determine the information gained from a positive and negative test result in each class, and whether each test is more suitable for confirmation or exclusion of disease. Our analysis suggests that several tests exist that are suitable alternatives to standard RT-PCR and we discuss scenarios in which these could be most beneficial, such as where time to test result is critical or, where resources are constrained. However, we also highlight methodological concerns with the design and conduct of many included studies, and also the existence of likely publication bias for some test classes. Our results should be interpreted with these shortcomings in mind. Furthermore, our conclusions on test performance are limited to their use in symptomatic populations: we did not identify sufficient suitable data to allow analysis of testing in asymptomatic populations.",Adrian Mironas; David Jarrom; Evan Campbell; Jennifer Washington; Sabine Ettinger; Ingrid Wilbacher; Gottfried Endel; Hrvoje Vrazic; Susan Myles; Matthew Prettyjohns,https://medrxiv.org/cgi/content/short/2021.01.15.21249863,https://medrxiv.org/cgi/content/short/2021.01.15.21249863,2021-01-15,2021-01-15,,True
505,Antibiotic Prescribing Patterns at COVID-19 Dedicated Wards in Bangladesh: A Single Center Point-Prevalence Survey,"There is a clear deficiency in antimicrobial usage data and ongoing stewardship programs both in government and private health care facilities in Bangladesh. As evidences are mounting regarding irrational and often unnecessary use of antibiotics during COVID-19 pandemic, a point prevalence survey (PPS) was conducted across COVID-19 dedicated wards in Dhaka Medical College and Hospital (DMCH). Antibiotic usage data were collected from 193 patients at different COVID-19 dedicated wards at DMCH between 21 May, 2020 and 10 June, 2020. Comparisons in antibiotic usage were made between different groups using Pearson chi-square and Fisher exact test. Factors associated with multiple antibiotic prescription were evaluated using binary logistic regression model.

On survey date all (100%) patients were receiving at least one antibiotic with 133 patients (68.91%) receiving multiple antibiotics. Overall, patients presenting with severe disease received more antibiotics on average. Third generation cephalosporin ceftriaxone (53.8%), meropenem (40.9%), moxifloxacin (29.5%) and doxycycline (25.4%) were the four most prescribed antibiotics among survey patients. Among comorbidities diabetes mellitus (DM) was independently associated with increased antibiotic prescribing. Abnormal C-reactive protein (CRP) and serum d-dimer were linked with higher odds of antibiotic prescribing among survey patients. Overall, prevalence of antibiotic prescribing in COVID-19 patients at DMCH was very high. This could be attributed to a lack of clear treatment protocol against COVID-19 till date as well as lack of modern laboratory facilities to support judicial antibiotic prescribing in Bangladesh. A well-functioning antibiotic stewardship program in Bangladesh is required to prevent an impending health crisis.",Md. Maruf Ahmed Molla; Mahmuda Yeasmin; Md. Khairul Islam; Md. Mohiuddin Sharif; Mohammad Robed Amin; Tasnim Nafisa; Asish Kumar Ghosh; Monira Parveen; Md. Masum Hossain Arif; Junaid Abdullah Jamiul Alam; Syed Jafar Raza Rizvi; KM Saif-Ur-Rahman; Arifa Akram; AKM Shamsuzzaman,https://medrxiv.org/cgi/content/short/2021.01.15.21249868,https://medrxiv.org/cgi/content/short/2021.01.15.21249868,2021-01-15,2021-01-15,,True
506,Factor V is an immune inhibitor that is expressed at increased levels in leukocytes of patients with severe Covid-19,"Severe Covid-19 is associated with elevated plasma Factor V (FV) and increased risk of thromboembolism. We report that neutrophils, T regulatory cells (Tregs), and monocytes from patients with severe Covid-19 express FV, and expression correlates with T cell lymphopenia. In vitro full length FV, but not FV activated by thrombin cleavage, suppresses T cell proliferation. Increased and prolonged FV expression by cells of the innate and adaptive immune systems may contribute to lymphopenia in severe Covid-19. Activation by thrombin destroys the immunosuppressive properties of FV. Anticoagulation in Covid-19 patients may have the unintended consequence of suppressing the adaptive immune system.",Jun Wang; Prasanti Kotagiri; Paul Lyons; Federica Mescia; Laura Bergamaschi; Lorinda Turner; Rafia Al-Lamki; Michael D Morgan; Fernando J Calero-Nieto; Karsten Bach; Nicole Mende; Nicola K Wilson; Emily R Watts; - Cambridge Institute of Therapeutic Immunology and Infectious Disease - NIHR Covid BioResource; Patrick Chinnery; Nathalie Kingston; Sofia Papadia; Kathleen Stirrups; Neil Walker; Ravindra K Gupta; Mark Toshner; Michael Weekes; James A Nathan; Sarah Walmsley; Willem Hendrik Ouwehand; Mary Kasanicki; Berthold Gottgens; John C Marioni; Smith GC Smith; Jordan S Pober; John R Bradley,https://medrxiv.org/cgi/content/short/2021.01.14.21249801,https://medrxiv.org/cgi/content/short/2021.01.14.21249801,2021-01-15,2021-01-15,,True
507,"Anticipating the curve: can online symptom-based data reflect COVID-19 case activity in Ontario, Canada?","BackgroundLimitations in laboratory diagnostic capacity and reporting delays have hampered efforts to mitigate and control the ongoing COVID-19 pandemic globally. Syndromic surveillance of COVID-19 is an important public health tool that can help detect outbreaks, mobilize a rapid response, and thereby reduce morbidity and mortality. The primary objective of this study was to determine whether syndromic surveillance through self-reported COVID-19 symptoms could be a timely proxy for laboratory-confirmed case trends in the Canadian province of Ontario.

MethodsWe retrospectively analyzed self-reported symptoms data collected using an online tool - Outbreaks Near Me (ONM) - from April 20th to Oct 11th, 2020 in Ontario, Canada. We estimated the correlation coefficient between the weekly proportion of respondents reporting a COVID-like illness (CLI) to both the weekly number of PCR-confirmed COVID-19 cases and the percent positivity in the same period for the same week and with a one-week lag.

ResultsThere were 314,686 responses from 188,783 unique respondents to the ONM symptom survey. Respondents were more likely to be female and be in the 40-59 age demographic compared to the Ontario general population. There was a strong positive correlation between the weekly number of reported cases in Ontario and the percent of respondents reporting CLI each week (r = 0.89, p <0.01) and with a one-week lag (r = 0.89, p <0.01).

InterpretationWe demonstrate a strong positive and significant correlation (r = 0.89, p <0.01) between percent of self-reported COVID-like illness and the subsequent weeks COVID-19 cases reported, highlighting that a rise in CLI may precede official statistics by at least 1 week. This demonstrates the utility of syndromic surveillance in predicting near-future disease activity. Digital surveillance systems are low-cost tools that may help measure the burden of COVID-19 in a community if there is under-detection of cases through conventional laboratory diagnostic testing. This additional information can be used to guide a healthcare response and policy decisions.",Arjuna S Maharaj; Jennifer Parker; Jessica P Hopkins; Effie Gournis; Isaac Bogoch; Benjamin Rader; Christina M Astley; Noah M Ivers; Jared B Hawkins; Liza Lee; Ashleigh Tuite; David N Fisman; John S Brownstein; Lauren Lapointe-Shaw,https://medrxiv.org/cgi/content/short/2021.01.15.21249879,https://medrxiv.org/cgi/content/short/2021.01.15.21249879,2021-01-15,2021-01-15,,True
508,A Vital Sign-based Prediction Algorithm for Differentiating COVID-19 Versus Seasonal Influenza in Hospitalized Patients,"Patients with influenza and SARS-CoV2/Coronavirus disease 2019 (COVID-19) infections have different clinical course and outcomes. We developed and validated a supervised machine learning pipeline to distinguish the two viral infections using the available vital signs and demographic dataset from the first hospital/emergency room encounters of 3,883 patients who had confirmed diagnoses of influenza A/B, COVID-19 or negative laboratory test results. The models were able to achieve an area under the receiver operating characteristic curve (ROC AUC) of at least 97% using our multiclass classifier. The predictive models were externally validated on 15,697 encounters in 3,125 patients available on TrinetX database that contains patient-level data from different healthcare organizations. The influenza vs. COVID-19-positive model had an AUC of 98%, and 92% on the internal and external test sets, respectively. Our study illustrates the potentials of machine-learning models for accurately distinguishing the two viral infections. The code is made available at https://github.com/ynaveena/COVID-19-vs-Influenza and may be have utility as a frontline diagnostic tool to aid healthcare workers in triaging patients once the two viral infections start cocirculating in the communities.",Naveena Yanamala; Nanda H. Krishna; Quincy A. Hathaway; Aditya Radhakrishnan; Srinidhi Sunkara; Heenaben Patel; Peter Farjo; Brijesh Patel; Partho P Sengupta,https://medrxiv.org/cgi/content/short/2021.01.13.21249540,https://medrxiv.org/cgi/content/short/2021.01.13.21249540,2021-01-15,2021-01-15,,True
509,Innate lymphoid cells and disease tolerance in SARS-CoV-2 infection,"BACKGROUNDRisk of severe coronavirus disease 2019 (COVID-19) increases with age, is greater in males, and is associated with decreased numbers of blood lymphoid cells. Though the reasons for these robust associations are unclear, effects of age and sex on innate and adaptive lymphoid subsets, including on homeostatic innate lymphoid cells (ILCs) implicated in disease tolerance, may underlie the effects of age and sex on COVID-19 morbidity and mortality.

METHODSFlow cytometry was used to quantitate subsets of blood lymphoid cells from people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comparing those hospitalized with severe COVID-19 (n=40) and those treated as outpatients for less severe disease (n=51). 86 healthy individuals served as controls. The relationship between abundance of specific blood lymphoid cell types, age, sex, hospitalization, duration of hospitalization, and elevation of blood markers for systemic inflammation, was determined using multiple regression.

RESULTSAfter accounting for effects of age and sex, hospitalization for COVID-19 was associated with 1.78-fold fewer ILCs (95%CI: 2.34-1.36; p = 4.55 x 10-5) and 2.31-fold fewer CD16+ natural killer (NK) cells (95%CI: 3.1-1.71; p = 1.04 x 10-7), when compared to uninfected controls. Among people infected with SARS-CoV-2, the odds ratio for hospitalization, adjusted for age, sex, and duration of symptoms, was 0.413 (95%CI: 0.197-0.724; p = 0.00691) for every 2-fold increase in ILCs. In addition, higher ILC abundance was associated with less time spent in the hospital and lower levels of blood markers associated with COVID-19 severity: each two-fold increase in ILC abundance was associated with a 9.38 day decrease in duration of hospital stay (95% CI: 15.76-3.01; p= 0.0054), and decrease in blood C-reactive protein (CRP) by 46.29 mg/L (95% CI: 71.34-21.24; p = 6.25 x 10-4), erythrocyte sedimentation rate (ESR) by 11.04 mm/h (95% CI: 21.94-0.13; p = 0.047), and the fibrin degradation product D-dimer by 1098.52 ng/mL (95% CI: 1932.84-264.19; p = 0.011).

CONCLUSIONSBoth ILCs and NK cells were depleted in the blood of people hospitalized for severe COVID-19, but, among lymphoid cell subsets, only ILC abundance was independently associated with the need for hospitalization, duration of hospital stay, and severity of inflammation. These results indicate that, by promoting disease tolerance, homeostatic ILCs protect against morbidity and mortality in SARS-CoV-2 infection, and suggest that reduction in the number of ILCs with age and in males accounts for the increased risk of severe COVID-19 in these demographic groups.",Noah J. Silverstein; Yetao Wang; Zachary Manickas-Hill; Claudia C. Carbone; Ann Dauphin; Jonathan Z. Li; Bruce D. Walker; Xu G. Yu; Jeremy Luban,https://medrxiv.org/cgi/content/short/2021.01.14.21249839,https://medrxiv.org/cgi/content/short/2021.01.14.21249839,2021-01-15,2021-01-15,,True
